"Gene","Plate number","Well number","Clone ID","ORF_length","Trans_mem_ref_acc","Other_acc","Definition","Accession","Protein","LocusLink ID","Unigene ID","Gene synonym","Ensembl","Gene description","Chromosome","Position","Protein class","Evidence","Antibody","Reliability (IH)","Reliability (Mouse Brain)","Reliability (IF)","Subcellular location","Prognostic p-value","RNA cancer category","RNA tissue category","RNA TS","RNA TS TPM","TPM max in non-specific","RNA cell line category","RNA CS","RNA CS TPM"
"A2M",72,"F12","IOH26170",4425,"0",NA,"alpha-2-macroglobulin, mRNA (cDNA clone MGC:47683 IMAGE:6056126), complete cds","BC040071.1","AAH40071.1",2,"Hs.212838","CPAMD5, FWP007, S863-7","ENSG00000175899","Alpha-2-macroglobulin","12","9067664-9116229","Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA002265, CAB017621","Supported",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"lung: 1920.7","Cell line enhanced",NA,"AF22: 726.1;ASC diff: 146.4;Hep G2: 419.1;SK-MEL-30: 170.2"
"AADACL2",93,"F7","IOH40762",1140,"0",NA,"arylacetamide deacetylase-like 2, mRNA (cDNA clone MGC:72001 IMAGE:6663150), complete cds","BC065724.1","AAH65724.1",344752,"Hs.144710","MGC72001","ENSG00000197953","Arylacetamide deacetylase like 2","3","151733916-151761339","Predicted secreted proteins","Evidence at transcript level",NA,NA,NA,NA,NA,NA,"Not detected","Tissue enriched",14,"skin: 31.1","breast: 2.3","Not detected",NA,NA
"ABAT",18,"H12","IOH13638",1503,"0",NA,"4-aminobutyrate aminotransferase (ABAT), nuclear gene encoding mitochondrial protein, transcript variant 2, mRNA.","NM_000663.4","NP_000654.2",18,"Hs.336768","GABAT","ENSG00000183044","4-aminobutyrate aminotransferase","16","8674565-8784575","Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA041528, HPA041690","Enhanced","Supported","Supported","Mitochondria","Renal cancer:5.44e-8 (favourable), Liver cancer:5.36e-5 (favourable), Lung cancer:5.93e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 164.5;kidney: 135.3;liver: 175.2","thyroid gland: 47.5","Cell line enhanced",NA,"Hep G2: 83.0;MCF7: 60.0;RH-30: 64.1;T-47d: 39.1"
"ABAT",54,"B12","IOH22724",1503,"0",NA,"4-aminobutyrate aminotransferase, mRNA (cDNA clone MGC:35480 IMAGE:5195212), complete cds","BC031413.1","AAH31413.1",18,"Hs.336768","GABAT","ENSG00000183044","4-aminobutyrate aminotransferase","16","8674565-8784575","Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA041528, HPA041690","Enhanced","Supported","Supported","Mitochondria","Renal cancer:5.44e-8 (favourable), Liver cancer:5.36e-5 (favourable), Lung cancer:5.93e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 164.5;kidney: 135.3;liver: 175.2","thyroid gland: 47.5","Cell line enhanced",NA,"Hep G2: 83.0;MCF7: 60.0;RH-30: 64.1;T-47d: 39.1"
"ABHD1",66,"A3","IOH28775",1218,"0",NA,"abhydrolase domain containing 1 (ABHD1), mRNA.","NM_032604.3","NP_115993.3",84696,"Hs.375791","FLJ36128, LABH1","ENSG00000143994","Abhydrolase domain containing 1","2","27123789-27130812","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA044390","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enriched",17,"testis: 30.0","liver: 1.7","Cell line enhanced",NA,"RPMI-8226: 1.1;T-47d: 3.0;U-266/70: 2.4;U-266/84: 1.9"
"ABHD10",55,"D4","IOH22907",921,"0",NA,"abhydrolase domain containing 10 (ABHD10), mRNA.","NM_018394.2","NP_060864.1",55347,"Hs.708240","FLJ11342","ENSG00000144827","Abhydrolase domain containing 10","3","111979010-111993363","Enzymes, Predicted secreted proteins","Evidence at protein level","HPA036991, HPA036992, HPA066081","Supported",NA,"Approved","Mitochondria","Renal cancer:4.72e-9 (favourable), Cervical cancer:7.57e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 62.1","Expressed in all",NA,NA
"ABI3BP",72,"C11","IOH27300",3228,"0",NA,"ABI family, member 3 (NESH) binding protein (ABI3BP), mRNA.","NM_015429.3","NP_056244.2",25890,"Hs.477015","DKFZP586L2024, NESHBP, TARSH","ENSG00000154175","ABI family member 3 binding protein","3","100749156-100993515","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA044127","Uncertain",NA,NA,NA,"Renal cancer:6.14e-4 (favourable)","Mixed","Mixed",NA,NA,"gallbladder: 158.4","Cell line enhanced",NA,"hTEC/SVTERT24-B: 841.3;hTERT-HME1: 650.5;TIME: 1525.7"
"ACAN",69,"C10","IOH22274",2166,"0",NA,"aggrecan, mRNA (cDNA clone IMAGE:4823544), complete cds.","BC036445.1","AAH36445.1",176,"Hs.2159","AGC1, CSPG1, CSPGCP, MSK16","ENSG00000157766","Aggrecan","15","88803443-88875354","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB016377, HPA038241, HPA038242","Enhanced",NA,NA,NA,"Renal cancer:1.47e-6 (unfavourable)","Mixed","Tissue enhanced",NA,"seminal vesicle: 5.0","testis: 3.3","Cell line enriched",5,"WM-115: 28.1"
"ACP2",92,"H9","IOH5120",1272,"NP_001601.1","AAH03160.1","acid phosphatase 2, lysosomal, mRNA (cDNA clone MGC:4215 IMAGE:2957907), complete cds","BC003160.1","AAH03160.1",53,"Hs.532492","LAP","ENSG00000134575","Acid phosphatase 2, lysosomal","11","47239302-47248906","Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Endometrial cancer:1.04e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"duodenum: 41.2","Expressed in all",NA,NA
"ACP5",2,"D10","IOH14225",978,"0",NA,"acid phosphatase 5, tartrate resistant (ACP5), transcript variant 4, mRNA.","NM_001611.3","NP_001602.1",54,"Hs.1211","HPAP, TRAP","ENSG00000102575","Acid phosphatase 5, tartrate resistant","19","11574660-11579008","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB002584, HPA057655, HPA059463","Enhanced",NA,"Approved","Cytosol",NA,"Expressed in all","Tissue enhanced",NA,"lung: 254.0","lymph node: 86.3","Cell line enhanced",NA,"BEWO: 36.2;SK-MEL-30: 85.3;U-138 MG: 97.5"
"ACRBP",68,"C9","IOH22257",1632,"0",NA,"acrosin binding protein (ACRBP), mRNA.","NM_032489.2","NP_115878.2",84519,"Hs.123239","CT23, OY-TES-1, SP32","ENSG00000111644","Acrosin binding protein","12","6638075-6647460","Predicted secreted proteins","Evidence at protein level","HPA039081, HPA039082","Enhanced",NA,"Approved","Nucleoplasm<br>Vesicles",NA,"Mixed","Tissue enriched",19,"testis: 432.5","thyroid gland: 22.6","Cell line enhanced",NA,"HMC-1: 5.8;U-266/70: 11.3;U-266/84: 7.3"
"ACRV1",18,"B6","IOH11009",798,"0",NA,"acrosomal vesicle protein 1 (ACRV1), transcript variant 1, mRNA.","NM_001612.4","NP_001603.1",56,"Hs.169222","D11S4365, SP-10, SPACA2","ENSG00000134940","Acrosomal vesicle protein 1","11","125671522-125681123","Predicted secreted proteins","Evidence at protein level","HPA038718, HPA038719","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enriched",40,"testis: 153.6","epididymis: 3.8","Mixed",NA,NA
"ACVR1",41,"G2","IOH21860",1530,"NP_001096.1","NP_001096.1","activin A receptor, type I (ACVR1), transcript variant 1, mRNA.","NM_001105.4","NP_001096.1",90,"Hs.470316","ACVR1A, ACVRLK2, ALK2, SKR1","ENSG00000115170","Activin A receptor type 1","2","157736444-157875862","Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA007505, HPA046514","Approved",NA,"Approved","Nucleoli<br>Cytosol","Urothelial cancer:5.17e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 74.2","Mixed",NA,NA
"ACVR1C",1,"B11","IOH10813",1482,"NP_660302.1","AAH22530.1","activin A receptor, type IC, mRNA (cDNA clone MGC:26673 IMAGE:4801219), complete cds","BC022530.1","AAH22530.1",130399,"Hs.562901","ACVRLK7, ALK7","ENSG00000123612","Activin A receptor type 1C","2","157526767-157629005","Enzymes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA007982, HPA011933","Approved",NA,NA,NA,NA,"Mixed","Tissue enriched",8,"adipose tissue: 34.1","ovary: 4.3","Cell line enhanced",NA,"ASC diff: 7.5;HDLM-2: 4.8"
"ACVRL1",40,"F4","IOH21048",1512,"0",NA,"activin A receptor type II-like 1 (ACVRL1), transcript variant 1, mRNA.","NM_000020.2","NP_000011.2",94,"Hs.591026","ACVRLK1, ALK1, HHT, HHT2, ORW2","ENSG00000139567","Activin A receptor like type 1","12","51906908-51923361","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA007041","Approved",NA,NA,NA,NA,"Expressed in all","Tissue enhanced",NA,"placenta: 126.4","lung: 76.4","Cell line enhanced",NA,"ASC diff: 42.2;EFO-21: 52.0;HUVEC TERT2: 171.4;TIME: 130.8"
"ACYP1",52,"B2","IOH27552",300,"0",NA,"acylphosphatase 1, erythrocyte (common) type (ACYP1), transcript variant 1, mRNA.","NM_001107.3","NP_001098.1",97,"Hs.18573",NA,"ENSG00000119640","Acylphosphatase 1","14","75053221-75069483","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA034944","Approved",NA,"Approved","Nucleus<br>Cytosol","Liver cancer:6.14e-7 (unfavourable), Breast cancer:1.17e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"adrenal gland: 46.4","Expressed in all",NA,NA
"ACYP1",107,"G12","IOH44619",168,"0",NA,"acylphosphatase 1, erythrocyte (common) type (ACYP1), transcript variant 2, mRNA.","NM_203488.1","NP_982355.1",97,"Hs.18573",NA,"ENSG00000119640","Acylphosphatase 1","14","75053221-75069483","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA034944","Approved",NA,"Approved","Nucleus<br>Cytosol","Liver cancer:6.14e-7 (unfavourable), Breast cancer:1.17e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"adrenal gland: 46.4","Expressed in all",NA,NA
"ADAM12",69,"E4","IOH29226",2214,"NP_003465.2","AAH60804.1","ADAM metallopeptidase domain 12, mRNA (cDNA clone MGC:71621 IMAGE:30348514), complete cds","BC060804.1","AAH60804.1",8038,"Hs.594537","MCMPMltna, MLTN","ENSG00000148848","ADAM metallopeptidase domain 12","10","126012381-126388455","Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA030866, HPA030867, HPA030868","Enhanced",NA,"Supported","Plasma membrane","Renal cancer:2.39e-14 (unfavourable)","Mixed","Tissue enriched",8,"placenta: 237.2","cervix, uterine: 29.7","Cell line enhanced",NA,"fHDF/TERT166: 119.5;hTEC/SVTERT24-B: 94.3;U-2197: 86.6;U-251 MG: 71.0"
"ADAM15",131,"H5","IOH46711",2319,"0",NA,"ADAM metallopeptidase domain 15 (ADAM15), transcript variant 1, mRNA.","NM_207191.1","NP_997074.1",8751,"Hs.312098","MDC15","ENSG00000143537","ADAM metallopeptidase domain 15","1","155050566-155062775","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA011633, HPA072878","Uncertain",NA,"Uncertain","Vesicles","Renal cancer:5.64e-9 (unfavourable), Glioma:3.49e-5 (unfavourable), Liver cancer:3.49e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"skin: 72.6","Cell line enhanced",NA,"PC-3: 305.3"
"ADAM15",91,"G11","IOH12766",2445,"NP_003806.2","AAH14566.1","ADAM metallopeptidase domain 15, mRNA (cDNA clone MGC:2122 IMAGE:2958341), complete cds","BC014566.2","AAH14566.1",8751,"Hs.312098","MDC15","ENSG00000143537","ADAM metallopeptidase domain 15","1","155050566-155062775","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA011633, HPA072878","Uncertain",NA,"Uncertain","Vesicles","Renal cancer:5.64e-9 (unfavourable), Glioma:3.49e-5 (unfavourable), Liver cancer:3.49e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"skin: 72.6","Cell line enhanced",NA,"PC-3: 305.3"
"ADAM22",55,"D7","IOH27232",1029,"NP_004185.1","AAH36029.1","ADAM metallopeptidase domain 22, mRNA (cDNA clone IMAGE:5278621), complete cds.","BC036029.1","AAH36029.1",53616,"Hs.592282","MDC2","ENSG00000008277","ADAM metallopeptidase domain 22","7","87934143-88202889","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA050325",NA,NA,"Approved","Cell Junctions",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 47.6","prostate: 18.2","Cell line enhanced",NA,"Karpas-707: 58.7;SH-SY5Y: 81.7"
"ADAM32",136,"B8","IOH56066",2364,"NP_659441.1","NP_659441.3","ADAM metallopeptidase domain 32 (ADAM32), mRNA.","NM_145004.5","NP_659441.3",203102,"Hs.521545",NA,"ENSG00000197140","ADAM metallopeptidase domain 32","8","39106990-39284911","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA044156, HPA062151","Enhanced",NA,"Approved","Nucleus<br>Vesicles",NA,"Not detected","Tissue enriched",35,"testis: 28.7","skin: 0.8","Cell line enhanced",NA,"U-2 OS: 1.1"
"ADAM33",93,"B6","IOH40734",258,"0",NA,"ADAM metallopeptidase domain 33, mRNA (cDNA clone IMAGE:30405083), complete cds.","BC062663.1","AAH62663.1",80332,"Hs.173716","C20orf153, dJ964F7.1, DKFZp434K0521","ENSG00000149451","ADAM metallopeptidase domain 33","20","3667965-3682246","Disease related genes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA067152, HPA071758","Approved",NA,"Uncertain","Nuclear speckles<br>Plasma membrane",NA,"Mixed","Mixed",NA,NA,"endometrium: 103.3","Cell line enhanced",NA,"ASC diff: 55.2;ASC TERT1: 72.4;BJ: 31.3;BJ hTERT+: 51.1;fHDF/TERT166: 29.6;U-2197: 46.1"
"ADAMTS1",82,"G10","IOH22476",2904,"0",NA,"ADAM metallopeptidase with thrombospondin type 1 motif, 1, mRNA (cDNA clone MGC:32979 IMAGE:5266513), complete cds","BC036515.2","AAH36515.1",9510,"Hs.643357","C3-C5, KIAA1346, METH1","ENSG00000154734","ADAM metallopeptidase with thrombospondin type 1 motif 1","21","26835747-26845409","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB016394","Uncertain",NA,NA,NA,"Head and neck cancer:5.13e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"ovary: 412.9","adipose tissue: 279.9","Cell line enhanced",NA,"BJ: 346.6;hTEC/SVTERT24-B: 277.6"
"ADAMTS12",67,"C3","IOH29490",690,"0",NA,"ADAM metallopeptidase with thrombospondin type 1 motif, 12, mRNA (cDNA clone IMAGE:6701691), complete cds.","BC058841.1","AAH58841.1",81792,"Hs.12680",NA,"ENSG00000151388","ADAM metallopeptidase with thrombospondin type 1 motif 12","5","33523535-33892192","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA035973, HPA075079","Uncertain",NA,"Approved","Nucleoli<br>Mitochondria","Urothelial cancer:6.78e-4 (unfavourable)","Mixed","Mixed",NA,NA,"adipose tissue: 9.8","Cell line enhanced",NA,"hTEC/SVTERT24-B: 48.2;U-2 OS: 38.4"
"ADAMTS18",93,"H12","IOH40422",3666,"0",NA,"ADAM metallopeptidase with thrombospondin type 1 motif, 18, mRNA (cDNA clone MGC:71557 IMAGE:30343625), complete cds","BC063283.1","AAH63283.1",170692,"Hs.188746","ADAMTS21","ENSG00000140873","ADAM metallopeptidase with thrombospondin type 1 motif 18","16","77247813-77435114","Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA044326","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enriched",16,"placenta: 29.1","cervix, uterine: 1.8","Group enriched",7,"HUVEC TERT2: 6.7;TIME: 2.0;U-87 MG: 4.7"
"ADAMTSL1",151,"B7","IOH63425",855,"0",NA,"ADAMTS-like 1, mRNA (cDNA clone IMAGE:40000502), complete cds.","BC100790.2","AAI00791.1",92949,"Hs.522019","ADAMTSR1, C9orf94, FLJ35283","ENSG00000178031","ADAMTS like 1","9","17906563-18910950","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA057437","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"endometrium: 24.1","smooth muscle: 18.7","Cell line enhanced",NA,"ASC TERT1: 81.0;hTEC/SVTERT24-B: 62.6;TIME: 164.0;U-138 MG: 93.4"
"ADAMTSL1",153,"C4","IOH63419",1404,"0",NA,"ADAMTS-like 1, mRNA (cDNA clone IMAGE:40000500), complete cds.","BC100788.2","AAI00789.1",92949,"Hs.522019","ADAMTSR1, C9orf94, FLJ35283","ENSG00000178031","ADAMTS like 1","9","17906563-18910950","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA057437","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"endometrium: 24.1","smooth muscle: 18.7","Cell line enhanced",NA,"ASC TERT1: 81.0;hTEC/SVTERT24-B: 62.6;TIME: 164.0;U-138 MG: 93.4"
"ADAMTSL1",80,"A4","IOH21525",1320,"0",NA,"ADAMTS-like 1, mRNA (cDNA clone MGC:40193 IMAGE:5201199), complete cds","BC030262.1","AAH30262.1",92949,"Hs.522019","ADAMTSR1, C9orf94, FLJ35283","ENSG00000178031","ADAMTS like 1","9","17906563-18910950","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA057437","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"endometrium: 24.1","smooth muscle: 18.7","Cell line enhanced",NA,"ASC TERT1: 81.0;hTEC/SVTERT24-B: 62.6;TIME: 164.0;U-138 MG: 93.4"
"ADCYAP1",150,"F6","IOH61996",531,"0",NA,"adenylate cyclase activating polypeptide 1 (pituitary) (ADCYAP1), transcript variant 1, mRNA.","NM_001099733.1","NP_001093203.1",116,"Hs.531719","PACAP","ENSG00000141433","Adenylate cyclase activating polypeptide 1","18","904943-912172","Predicted secreted proteins","Evidence at protein level","HPA065887",NA,"Approved",NA,NA,"Renal cancer:2.91e-6 (favourable)","Tissue enhanced","Tissue enhanced",NA,"appendix: 19.3;cerebral cortex: 16.0;gallbladder: 15.7","testis: 5.6","Cell line enriched",17,"SCLC-21H: 20.8"
"ADI1",26,"B6","IOH4030",540,"0",NA,"acireductone dioxygenase 1 (ADI1), mRNA.","NM_018269.2","NP_060739.2",55256,"Hs.502773","APL1, ARD, FLJ10913, HMFT1638, MTCBP-1, mtnD, SIPL","ENSG00000182551","Acireductone dioxygenase 1","2","3497361-3519736","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA035403, HPA035404","Approved",NA,"Supported","Nucleoplasm<br>Golgi apparatus",NA,"Expressed in all","Expressed in all",NA,NA,"liver: 228.3","Expressed in all",NA,NA
"ADIG",123,"D7","IOH57351",243,"0",NA,"adipogenin (ADIG), mRNA.","NM_001018082.1","NP_001018092.1",149685,"Hs.368028","MGC39724, RP5-1100H13.2, SMAF1","ENSG00000182035","Adipogenin","20","38581195-38588463","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at transcript level","HPA041124","Uncertain",NA,NA,NA,NA,"Tissue enhanced","Group enriched",10,"epididymis: 5.1;testis: 16.1;thyroid gland: 3.4","seminal vesicle: 0.8","Not detected",NA,NA
"ADM",16,"F2","IOH13846",558,"0",NA,"adrenomedullin (ADM), mRNA.","NM_001124.1","NP_001115.1",133,"Hs.441047","AM","ENSG00000148926","Adrenomedullin","11","10304680-10307397","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB016075","Approved",NA,NA,NA,"Renal cancer:6.33e-4 (unfavourable), Liver cancer:7.56e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 158.5","Cell line enhanced",NA,"ASC diff: 519.0;U-138 MG: 397.2"
"ADPGK",135,"C10","IOH56962",1494,"0",NA,"ADP-dependent glucokinase, mRNA (cDNA clone MGC:12975 IMAGE:3347312), complete cds","BC006112.1","AAH06112.1",83440,"Hs.654636","ADP-GK, DKFZp434B195","ENSG00000159322","ADP dependent glucokinase","15","72751369-72785846","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA045194, HPA058525","Approved",NA,"Approved","Centrosome","Renal cancer:4.52e-7 (unfavourable), Prostate cancer:2.22e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"lung: 25.1","Expressed in all",NA,NA
"AFM",100,"B4","IOH36008",1800,"0",NA,"afamin (AFM), mRNA.","NM_001133.2","NP_001124.1",173,"Hs.168718","ALB2, ALBA","ENSG00000079557","Afamin","4","73481683-73504001","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA017006, HPA052437","Enhanced",NA,NA,NA,"Liver cancer:1.80e-4 (favourable)","Tissue enriched","Tissue enriched",6,"liver: 468.3","kidney: 80.9","Cell line enriched",6,"CACO-2: 1.3"
"AFP",17,"F9","IOH11419",1830,"0",NA,"alpha-fetoprotein (AFP), mRNA.","NM_001134.1","NP_001125.1",174,"Hs.518808","FETA, HPAFP","ENSG00000081051","Alpha fetoprotein","4","73431138-73456174","Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA010607, HPA023600, CAB024283, CAB025339","Approved",NA,"Uncertain","Cytosol",NA,"Group enriched","Tissue enhanced",NA,"liver: 1.9","breast: 0.5","Cell line enriched",158,"Hep G2: 1466.5"
"AGA",12,"D3","IOH10474",1041,"0",NA,"aspartylglucosaminidase (AGA), mRNA.","NM_000027.2","NP_000018.1",175,"Hs.207776","ASRG","ENSG00000038002","Aspartylglucosaminidase","4","177430770-177442503","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA031415, HPA031417","Enhanced",NA,NA,NA,"Liver cancer:1.99e-4 (unfavourable), Head and neck cancer:8.61e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 35.3","Expressed in all",NA,NA
"AGER",7,"D8","IOH12890",1215,"NP_001127.1","NP_001127.1","advanced glycosylation end product-specific receptor (AGER), transcript variant 1, mRNA.","NM_001136.3","NP_001127.1",177,"Hs.534342","RAGE, SCARJ1","ENSG00000204305","Advanced glycosylation end-product specific receptor","6","32180968-32184324","Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB011682, HPA064436","Enhanced",NA,"Approved","Nucleoli fibrillar center<br>Plasma membrane<br>Cell Junctions","Renal cancer:9.01e-7 (unfavourable), Urothelial cancer:2.74e-6 (favourable), Pancreatic cancer:3.41e-4 (favourable)","Expressed in all","Tissue enriched",181,"lung: 889.2","thyroid gland: 4.9","Cell line enhanced",NA,"HEK 293: 2.5;U-266/70: 2.6"
"AGR2",49,"C2","IOH10438",528,"0",NA,"anterior gradient homolog 2 (Xenopus laevis) (AGR2), mRNA.","NM_006408.3","NP_006399.1",10551,"Hs.530009","AG2, HAG-2, PDIA17, XAG-2","ENSG00000106541","Anterior gradient 2, protein disulphide isomerase family member","7","16791811-16833433","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA007912","Enhanced",NA,"Approved","Cytosol","Renal cancer:8.79e-5 (unfavourable), Liver cancer:1.15e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"rectum: 1322.0;stomach: 1307.3","cervix, uterine: 939.5","Cell line enhanced",NA,"A549: 239.4;RPTEC TERT1: 465.3;RT4: 298.0;T-47d: 1243.5"
"AGR3",65,"C7","IOH29439",501,"0",NA,"anterior gradient homolog 3 (Xenopus laevis) (AGR3), mRNA.","NM_176813.3","NP_789783.1",155465,"Hs.100686","BCMP11, hAG-3, HAG3, PDIA18","ENSG00000173467","Anterior gradient 3, protein disulphide isomerase family member","7","16859405-16881987","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA053942","Enhanced",NA,"Supported","Endoplasmic reticulum<br>Vesicles",NA,"Tissue enhanced","Tissue enhanced",NA,"fallopian tube: 354.7;small intestine: 259.5","rectum: 233.8","Cell line enriched",52,"T-47d: 316.6"
"AGT",35,"C11","IOH9674",1458,"0",NA,"angiotensinogen (serpin peptidase inhibitor, clade A, member 8), mRNA (cDNA clone MGC:17092 IMAGE:4213559), complete cds","BC011519.1","AAH11519.1",183,"Hs.19383","SERPINA8","ENSG00000135744","Angiotensinogen","1","230702523-230714297","Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA001557, CAB025798","Supported",NA,NA,NA,NA,"Group enriched","Tissue enhanced",NA,"cerebral cortex: 226.5;liver: 649.6","gallbladder: 133.7","Cell line enhanced",NA,"CACO-2: 60.4;Hep G2: 401.1;THP-1: 150.6"
"AGTRAP",15,"C9","IOH14721",459,"NP_065083.2","NP_001035284.1","angiotensin II receptor-associated protein (AGTRAP), transcript variant 2, mRNA.","NM_001040194.1","NP_001035284.1",57085,"Hs.464438","ATRAP","ENSG00000177674","Angiotensin II receptor associated protein","1","11736084-11754802","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA044120","Approved",NA,"Supported","Vesicles","Liver cancer:6.57e-7 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"prostate: 92.6","Expressed in all",NA,NA
"AHCYL2",124,"A9","IOH11403",1836,"0",NA,"adenosylhomocysteinase-like 2 (AHCYL2), transcript variant 1, mRNA.","NM_015328.2","NP_056143.1",23382,"Hs.600789","KIAA0828","ENSG00000158467","Adenosylhomocysteinase like 2","7","129225023-129430211","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA053128","Uncertain",NA,"Approved","Nucleoplasm<br>Cytosol","Renal cancer:1.08e-7 (favourable), Head and neck cancer:4.17e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"rectum: 194.5","Cell line enriched",9,"HDLM-2: 218.4"
"AHSG",83,"G4","IOH2128",1104,"0",NA,"alpha-2-HS-glycoprotein, mRNA (cDNA clone MGC:52261 IMAGE:5798874), complete cds","BC048198.1","AAH48198.1",197,"Hs.324746","A2HS, FETUA, HSGA","ENSG00000145192","Alpha 2-HS glycoprotein","3","186612923-186621318","Cancer-related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA001524, HPA001525, CAB026209","Enhanced",NA,"Supported","Golgi apparatus",NA,"Tissue enriched","Tissue enriched",1903,"liver: 2823.4","testis: 1.4","Cell line enriched",64,"Hep G2: 1410.0"
"AIG1",15,"B1","IOH14045",717,"NP_057192.1","NP_057192.2","androgen-induced 1 (AIG1), mRNA.","NM_016108.2","NP_057192.2",51390,"Hs.567501","AIG-1, dJ95L4.1, FLJ10485","ENSG00000146416","Androgen induced 1","6","143060496-143340304","Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA060766","Approved",NA,"Approved","Golgi apparatus","Head and neck cancer:3.25e-7 (unfavourable), Cervical cancer:3.26e-6 (unfavourable), Endometrial cancer:3.06e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"liver: 153.1","Expressed in all",NA,NA
"AKAP10",1,"E10","IOH10972",1989,"0",NA,"A kinase (PRKA) anchor protein 10 (AKAP10), nuclear gene encoding mitochondrial protein, mRNA.","NM_007202.2","NP_009133.2",11216,"Hs.708043","D-AKAP2, MGC9414, PRKA10","ENSG00000108599","A-kinase anchoring protein 10","17","19904302-19978343","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA028901","Approved",NA,"Supported","Plasma membrane<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 26.2","Expressed in all",NA,NA
"ALB",61,"C3","IOH27981",1254,"0",NA,"albumin, mRNA (cDNA clone MGC:32888 IMAGE:4766983), complete cds","BC041789.1","AAH41789.1",213,"Hs.418167",NA,"ENSG00000163631","Albumin","4","73397114-73421412","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB006262, HPA031024, HPA031025","Supported",NA,"Enhanced","Endoplasmic reticulum<br>Golgi apparatus","Stomach cancer:7.87e-4 (unfavourable)","Tissue enriched","Tissue enriched",220,"liver: 105947.0","kidney: 482.5","Cell line enriched",33,"Hep G2: 3030.6"
"ALB",61,"B2","IOH27974",1191,"0",NA,"albumin, mRNA (cDNA clone MGC:32581 IMAGE:4714468), complete cds","BC035969.1","AAH35969.1",213,"Hs.418167",NA,"ENSG00000163631","Albumin","4","73397114-73421412","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB006262, HPA031024, HPA031025","Supported",NA,"Enhanced","Endoplasmic reticulum<br>Golgi apparatus","Stomach cancer:7.87e-4 (unfavourable)","Tissue enriched","Tissue enriched",220,"liver: 105947.0","kidney: 482.5","Cell line enriched",33,"Hep G2: 3030.6"
"ALB",39,"B12","IOH23065",1830,"0",NA,"albumin (ALB), mRNA.","NM_000477.5","NP_000468.1",213,"Hs.418167",NA,"ENSG00000163631","Albumin","4","73397114-73421412","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB006262, HPA031024, HPA031025","Supported",NA,"Enhanced","Endoplasmic reticulum<br>Golgi apparatus","Stomach cancer:7.87e-4 (unfavourable)","Tissue enriched","Tissue enriched",220,"liver: 105947.0","kidney: 482.5","Cell line enriched",33,"Hep G2: 3030.6"
"ALG1",131,"F4","IOH55307",1395,"0",NA,"asparagine-linked glycosylation 1, beta-1,4-mannosyltransferase homolog (S. cerevisiae) (ALG1), mRNA.","NM_019109.4","NP_061982.3",56052,"Hs.592086","CDG1K, HMAT1, HMT-1, Mat-1","ENSG00000033011","ALG1, chitobiosyldiphosphodolichol beta-mannosyltransferase","16","5033960-5087379","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA060392","Approved",NA,"Approved","Nucleoli fibrillar center<br>Endoplasmic reticulum","Colorectal cancer:5.79e-4 (favourable), Testis cancer:6.93e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 33.4","Expressed in all",NA,NA
"ALG1",54,"G9","IOH27228",1395,"0",NA,"asparagine-linked glycosylation 1, beta-1,4-mannosyltransferase homolog (S. cerevisiae), mRNA (cDNA clone MGC:33924 IMAGE:5276692), complete cds","BC031095.1","AAH31095.1",56052,"Hs.592086","CDG1K, HMAT1, HMT-1, Mat-1","ENSG00000033011","ALG1, chitobiosyldiphosphodolichol beta-mannosyltransferase","16","5033960-5087379","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA060392","Approved",NA,"Approved","Nucleoli fibrillar center<br>Endoplasmic reticulum","Colorectal cancer:5.79e-4 (favourable), Testis cancer:6.93e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 33.4","Expressed in all",NA,NA
"ALG9",8,"G5","IOH13444",1857,"0",NA,"asparagine-linked glycosylation 9, alpha-1,2-mannosyltransferase homolog (S. cerevisiae) (ALG9), transcript variant 1, mRNA.","NM_024740.2","NP_079016.2",79796,"Hs.503850","DIBD1","ENSG00000086848","ALG9, alpha-1,2-mannosyltransferase","11","111782195-111871581","Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA038575","Approved",NA,"Approved","Endoplasmic reticulum","Renal cancer:7.29e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 25.8","Expressed in all",NA,NA
"ALPL",2,"A11","IOH14614",1575,"0",NA,"alkaline phosphatase, liver/bone/kidney (ALPL), transcript variant 1, mRNA.","NM_000478.3","NP_000469.3",249,"Hs.75431","HOPS, TNSALP","ENSG00000162551","Alkaline phosphatase, liver/bone/kidney","1","21509372-21578412","Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA007105, HPA008765, CAB020829","Enhanced",NA,"Approved","Cytosol","Melanoma:7.08e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"lung: 78.8","kidney: 47.2","Group enriched",8,"HAP1: 31.9;HSkMC: 126.3;hTEC/SVTERT24-B: 139.0;LHCN-M2: 85.3;NTERA-2: 40.7;SCLC-21H: 103.8"
"ALPP",155,"H3","IOH62504",1608,"0",NA,"alkaline phosphatase, placental (Regan isozyme) (ALPP), mRNA.","NM_001632.3","NP_001623.3",250,"Hs.284255",NA,"ENSG00000163283","Alkaline phosphatase, placental","2","232378534-232382889","Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB026327, HPA038764, HPA038765, HPA051699","Enhanced",NA,"Approved","Plasma membrane","Pancreatic cancer:4.33e-4 (unfavourable)","Tissue enhanced","Group enriched",14,"cervix, uterine: 25.5;placenta: 45.5","fallopian tube: 2.5","Group enriched",6,"HaCaT: 311.4;SiHa: 103.4"
"ALPPL2",76,"C7","IOH12169",1599,"0",NA,"alkaline phosphatase, placental-like 2, mRNA (cDNA clone MGC:20678 IMAGE:4652865), complete cds","BC014139.2","AAH14139.1",251,"Hs.333509",NA,"ENSG00000163286","Alkaline phosphatase, placental like 2","2","232406843-232410714","Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB020698, HPA038764, HPA038765, HPA051699","Supported",NA,"Approved","Plasma membrane",NA,"Tissue enhanced","Tissue enhanced",NA,"fallopian tube: 1.5","lung: 0.7","Group enriched",29,"BEWO: 6.5;CAPAN-2: 29.9;HaCaT: 22.2"
"AMBN",101,"E5","IOH37726",1344,"0",NA,"ameloblastin (enamel matrix protein) (AMBN), mRNA.","NM_016519.4","NP_057603.1",258,"Hs.272396",NA,"ENSG00000178522","Ameloblastin","4","70592256-70607288","Disease related genes, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Group enriched","Not detected",NA,NA,"cerebral cortex: 0.3","Cell line enriched",9,"HEK 293: 6.2"
"AMBP",60,"G11","IOH28015",1059,"0",NA,"alpha-1-microglobulin/bikunin precursor (AMBP), mRNA.","NM_001633.3","NP_001624.1",259,"Hs.436911","EDC1, HCP, HI30, IATIL, ITI, ITIL, ITILC, UTI","ENSG00000106927","Alpha-1-microglobulin/bikunin precursor","9","114060127-114078472","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA001497, CAB069436","Approved",NA,NA,NA,"Endometrial cancer:1.20e-4 (favourable)","Tissue enriched","Tissue enriched",23,"liver: 5176.2","gallbladder: 230.0","Cell line enriched",113,"Hep G2: 861.2"
"AMELX",103,"E3","IOH35187",576,"0",NA,"amelogenin (amelogenesis imperfecta 1, X-linked) (AMELX), transcript variant 1, mRNA.","NM_001142.2","NP_001133.1",265,"Hs.654436","AIH1, AMG","ENSG00000125363","Amelogenin, X-linked","X","11293413-11300761","Disease related genes, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enhanced","Not detected",NA,NA,"epididymis: 0.4","Not detected",NA,NA
"AMTN",139,"A11","IOH59735",630,"0",NA,"amelotin (AMTN), mRNA.","NM_212557.2","NP_997722.1",401138,"Hs.453069","RSTI689, UNQ689","ENSG00000187689","Amelotin","4","70518540-70532742","Predicted secreted proteins","Evidence at protein level","HPA036136, HPA036137","Uncertain",NA,NA,NA,NA,"Group enriched","Tissue enhanced",NA,"stomach: 6.9;tonsil: 24.9","prostate: 3.3","Cell line enhanced",NA,"hTERT-HME1: 3.4;MCF7: 2.6"
"AMY1B",93,"F4","IOH40716",1536,"0",NA,"amylase, alpha 1B (salivary) (AMY1B), mRNA.","NM_001008218.1","NP_001008219.1",277,"Hs.599274","AMY1","ENSG00000174876","Amylase, alpha 1B (salivary)","1","103687415-103696680","Enzymes, Predicted secreted proteins","Evidence at protein level","HPA045394, HPA045399, HPA046980","Supported",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",15,"salivary gland: 1841.0","cervix, uterine: 126.4","Not detected",NA,NA
"AMY2A",73,"F1","IOH7158",1536,"0",NA,"amylase, alpha 2A (pancreatic) (AMY2A), mRNA.","NM_000699.2","NP_000690.1",279,"Hs.654437","AMY2","ENSG00000243480","Amylase, alpha 2A (pancreatic)","1","103616811-103625780","Enzymes, FDA approved drug targets, Predicted secreted proteins","Evidence at protein level","HPA045394, HPA045399, CAB045960, HPA046980","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",313,"pancreas: 31329.4","ovary: 99.9","Not detected",NA,NA
"AMY2B",46,"A4","IOH10274",1536,"0",NA,"amylase, alpha 2B (pancreatic) (AMY2B), mRNA.","NM_020978.3","NP_066188.1",280,"Hs.484588","AMY2","ENSG00000240038","Amylase, alpha 2B (pancreatic)","1","103553815-103579534","Enzymes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA045394, HPA045399, HPA046980","Supported",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",66,"pancreas: 6585.9","salivary gland: 99.6","Cell line enhanced",NA,"EFO-21: 9.6"
"ANG",65,"B6","IOH29453",444,"0",NA,"angiogenin, ribonuclease, RNase A family, 5 (ANG), transcript variant 1, mRNA.","NM_001145.4","NP_001136.1",283,"Hs.283749","RAA1, RNASE5","ENSG00000214274","Angiogenin","14","20684177-20698971","Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Liver cancer:7.83e-5 (favourable), Endometrial cancer:6.85e-4 (favourable)","Tissue enriched","Tissue enriched",27,"liver: 1565.4","stomach: 57.0","Cell line enriched",5,"Hep G2: 105.0"
"ANG",147,"G1","IOH62862",444,"0",NA,"angiogenin, ribonuclease, RNase A family, 5, mRNA (cDNA clone MGC:71966 IMAGE:4716820), complete cds","BC062698.1","AAH62698.1",283,"Hs.283749","RAA1, RNASE5","ENSG00000214274","Angiogenin","14","20684177-20698971","Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Liver cancer:7.83e-5 (favourable), Endometrial cancer:6.85e-4 (favourable)","Tissue enriched","Tissue enriched",27,"liver: 1565.4","stomach: 57.0","Cell line enriched",5,"Hep G2: 105.0"
"ANGPT1",137,"A4","IOH52109",1497,"0",NA,"angiopoietin 1 (ANGPT1), mRNA.","NM_001146.3","NP_001137.2",284,"Hs.369675","Ang1, KIAA0003","ENSG00000154188","Angiopoietin 1","8","107249482-107498055","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","CAB017815, HPA018793, HPA018816","Enhanced",NA,NA,NA,"Renal cancer:4.40e-4 (favourable)","Mixed","Tissue enhanced",NA,"seminal vesicle: 46.2","lung: 32.9","Cell line enhanced",NA,"ASC diff: 60.0;HEL: 46.9;HSkMC: 105.6;U-138 MG: 70.1;WM-115: 46.8"
"ANGPT1",86,"H11","IOH23195",444,"0",NA,"angiopoietin 1, mRNA (cDNA clone IMAGE:4805448), complete cds.","BC029406.1","AAH29406.1",284,"Hs.369675","Ang1, KIAA0003","ENSG00000154188","Angiopoietin 1","8","107249482-107498055","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","CAB017815, HPA018793, HPA018816","Enhanced",NA,NA,NA,"Renal cancer:4.40e-4 (favourable)","Mixed","Tissue enhanced",NA,"seminal vesicle: 46.2","lung: 32.9","Cell line enhanced",NA,"ASC diff: 60.0;HEL: 46.9;HSkMC: 105.6;U-138 MG: 70.1;WM-115: 46.8"
"ANGPTL2",68,"F6","IOH10555",1482,"0",NA,"angiopoietin-like 2 (ANGPTL2), mRNA.","NM_012098.2","NP_036230.1",23452,"Hs.653262","ARP2, HARP","ENSG00000136859","Angiopoietin like 2","9","127087332-127122883","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA040933, HPA041299","Approved",NA,"Approved","Golgi apparatus","Renal cancer:3.32e-5 (unfavourable)","Expressed in all","Mixed",NA,NA,"adipose tissue: 114.9","Cell line enhanced",NA,"ASC diff: 96.3;ASC TERT1: 66.5;BJ hTERT+: 165.9;HSkMC: 70.1"
"ANGPTL3",63,"B9","IOH29442",1383,"0",NA,"angiopoietin-like 3 (ANGPTL3), mRNA.","NM_014495.2","NP_055310.1",27329,"Hs.209153","ANGPT5","ENSG00000132855","Angiopoietin like 3","1","62597487-62606159","Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA038097","Approved",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",6,"liver: 356.4","kidney: 55.7","Not detected",NA,NA
"ANGPTL4",61,"D2","IOH27952",1221,"0",NA,"angiopoietin-like 4 (ANGPTL4), transcript variant 1, mRNA.","NM_139314.1","NP_647475.1",51129,"Hs.9613","ARP4, FIAF, HFARP, NL2, PGAR, pp1158","ENSG00000167772","Angiopoietin like 4","19","8363289-8374373","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA007879, CAB033770","Approved",NA,"Approved","Nucleoplasm<br>Vesicles","Renal cancer:1.34e-5 (unfavourable), Colorectal cancer:7.53e-4 (unfavourable), Lung cancer:9.50e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"adipose tissue: 78.7","liver: 43.2","Cell line enhanced",NA,"HBEC3-KT: 161.5;TIME: 92.8;U-138 MG: 64.0"
"ANGPTL5",56,"C10","IOH26886",1167,"0",NA,"angiopoietin-like 5, mRNA (cDNA clone MGC:57467 IMAGE:5285447), complete cds","BC049170.1","AAH49170.1",253935,"Hs.318370",NA,"ENSG00000187151","Angiopoietin like 5","11","101890674-101916522","Predicted secreted proteins","Evidence at protein level","HPA038516","Uncertain",NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"ovary: 27.1","breast: 7.2","Cell line enhanced",NA,"ASC diff: 1.8"
"ANGPTL7",53,"C10","IOH4956",1041,"0",NA,"angiopoietin-like 7 (ANGPTL7), mRNA.","NM_021146.2","NP_066969.1",10218,"Hs.146559","AngX, CDT6","ENSG00000171819","Angiopoietin like 7","1","11189341-11195981","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enriched","Tissue enhanced",NA,"seminal vesicle: 9.3","gallbladder: 5.8","Cell line enriched",434,"SCLC-21H: 48.4"
"ANK1",38,"B7","IOH23131",468,"0",NA,"ankyrin 1, erythrocytic, mRNA (cDNA clone IMAGE:4245014), complete cds.","BC030957.1","AAH30957.1",286,"Hs.654438","ANK, SPH1","ENSG00000029534","Ankyrin 1","8","41653220-41896762","Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA004842, HPA056953","Supported",NA,NA,NA,NA,"Mixed","Tissue enriched",5,"skeletal muscle: 348.3","heart muscle: 63.9","Group enriched",5,"HEL: 84.7;K-562: 96.3;RH-30: 157.8"
"ANKDD1A",152,"C3","IOH63557",1272,"0",NA,"ankyrin repeat and death domain containing 1A, mRNA (cDNA clone MGC:120306 IMAGE:40024168), complete cds","BC101274.1","AAI01275.1",348094,"Hs.207157","FLJ25870","ENSG00000166839","Ankyrin repeat and death domain containing 1A","15","64911902-64958700","Predicted intracellular proteins, Predicted secreted proteins","Evidence at transcript level","HPA040757","Approved",NA,"Approved","Nucleoplasm",NA,"Mixed","Mixed",NA,NA,"spleen: 15.0","Cell line enhanced",NA,"Karpas-707: 17.4;RT4: 14.8;U-266/84: 17.5"
"ANKDD1A",152,"B3","IOH63556",1200,"0",NA,"ankyrin repeat and death domain containing 1A, mRNA (cDNA clone MGC:120305 IMAGE:40024165), complete cds","BC101273.1","AAI01274.1",348094,"Hs.207157","FLJ25870","ENSG00000166839","Ankyrin repeat and death domain containing 1A","15","64911902-64958700","Predicted intracellular proteins, Predicted secreted proteins","Evidence at transcript level","HPA040757","Approved",NA,"Approved","Nucleoplasm",NA,"Mixed","Mixed",NA,NA,"spleen: 15.0","Cell line enhanced",NA,"Karpas-707: 17.4;RT4: 14.8;U-266/84: 17.5"
"ANKDD1A",152,"E3","IOH63562",1272,"0",NA,"ankyrin repeat and death domain containing 1A, mRNA (cDNA clone MGC:120307 IMAGE:40024170), complete cds","BC101275.1","AAI01276.1",348094,"Hs.207157","FLJ25870","ENSG00000166839","Ankyrin repeat and death domain containing 1A","15","64911902-64958700","Predicted intracellular proteins, Predicted secreted proteins","Evidence at transcript level","HPA040757","Approved",NA,"Approved","Nucleoplasm",NA,"Mixed","Mixed",NA,NA,"spleen: 15.0","Cell line enhanced",NA,"Karpas-707: 17.4;RT4: 14.8;U-266/84: 17.5"
"ANKRD54",116,"G12","IOH12507",903,"0",NA,"ankyrin repeat domain 54 (ANKRD54), mRNA.","NM_138797.1","NP_620152.1",129138,"Hs.135259","LIAR","ENSG00000100124","Ankyrin repeat domain 54","22","37830855-37849327","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA071287","Approved",NA,"Approved","Nucleoplasm<br>Microtubules<br>Midbody","Endometrial cancer:7.38e-5 (favourable), Cervical cancer:2.06e-4 (favourable), Pancreatic cancer:6.16e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"fallopian tube: 35.8","Expressed in all",NA,NA
"ANKRD54",148,"A1","IOH61483",903,"0",NA,"ankyrin repeat domain 54, mRNA (cDNA clone MGC:87097 IMAGE:4795922), complete cds","BC066909.1","AAH66909.1",129138,"Hs.135259","LIAR","ENSG00000100124","Ankyrin repeat domain 54","22","37830855-37849327","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA071287","Approved",NA,"Approved","Nucleoplasm<br>Microtubules<br>Midbody","Endometrial cancer:7.38e-5 (favourable), Cervical cancer:2.06e-4 (favourable), Pancreatic cancer:6.16e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"fallopian tube: 35.8","Expressed in all",NA,NA
"ANTXR1",8,"B8","IOH12656",1002,"NP_115584.1","NP_060623.2","anthrax toxin receptor 1 (ANTXR1), transcript variant 3, mRNA.","NM_018153.3","NP_060623.2",84168,"Hs.165859","ATR, FLJ10601, FLJ21776, TEM8","ENSG00000169604","Anthrax toxin receptor 1","2","69013178-69249327","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA054785",NA,NA,"Uncertain","Vesicles","Thyroid cancer:1.22e-5 (unfavourable), Cervical cancer:5.76e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"gallbladder: 180.5","Cell line enhanced",NA,"LHCN-M2: 286.7"
"ANTXR1",104,"F4","IOH42103",1107,"0",NA,"anthrax toxin receptor 1 (ANTXR1), transcript variant 2, mRNA.","NM_053034.2","NP_444262.1",84168,"Hs.165859","ATR, FLJ10601, FLJ21776, TEM8","ENSG00000169604","Anthrax toxin receptor 1","2","69013178-69249327","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA054785",NA,NA,"Uncertain","Vesicles","Thyroid cancer:1.22e-5 (unfavourable), Cervical cancer:5.76e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"gallbladder: 180.5","Cell line enhanced",NA,"LHCN-M2: 286.7"
"AOAH",9,"A5","IOH10670",1728,"0",NA,"acyloxyacyl hydrolase (neutrophil) (AOAH), mRNA.","NM_001637.2","NP_001628.1",313,"Hs.488007",NA,"ENSG00000136250","Acyloxyacyl hydrolase","7","36512949-36724549","Enzymes, Predicted secreted proteins","Evidence at protein level","HPA021666, HPA026716","Uncertain",NA,NA,NA,NA,"Expressed in all","Tissue enhanced",NA,"spleen: 88.9","appendix: 45.9","Group enriched",6,"HDLM-2: 3.4;NB-4: 16.7;THP-1: 13.5;U-937: 6.8"
"AOC2",149,"H11","IOH61100",2271,"0",NA,"amine oxidase, copper containing 2 (retina-specific) (AOC2), transcript variant 2, mRNA.","NM_009590.2","NP_033720.2",314,"Hs.143102","DAO2, RAO","ENSG00000131480","Amine oxidase, copper containing 2","17","42844600-42850707","Enzymes, Predicted secreted proteins","Evidence at protein level","HPA057779","Uncertain",NA,NA,NA,"Urothelial cancer:2.47e-4 (favourable)","Tissue enhanced","Group enriched",5,"adipose tissue: 6.2;testis: 5.8","spleen: 1.2","Cell line enhanced",NA,"ASC diff: 7.7"
"APCDD1",66,"D5","IOH29413",1545,"0",NA,"adenomatosis polyposis coli down-regulated 1 (APCDD1), mRNA.","NM_153000.4","NP_694545.1",147495,"Hs.293274","B7323","ENSG00000154856","APC down-regulated 1","18","10454628-10489948","Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Endometrial cancer:6.39e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"skin: 153.1","cerebral cortex: 60.6","Cell line enhanced",NA,"AF22: 31.6;BJ hTERT+: 56.8;HaCaT: 37.9;HSkMC: 28.6"
"APCS",21,"H1","IOH7176",672,"0",NA,"amyloid P component, serum (APCS), mRNA.","NM_001639.3","NP_001630.1",325,"Hs.507080","MGC88159, PTX2, SAP","ENSG00000132703","Amyloid P component, serum","1","159587825-159588865","Disease related genes, Plasma proteins, Potential drug targets, Predicted secreted proteins, Transporters","Evidence at protein level","CAB007817, HPA053294","Supported",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",25,"liver: 1851.8","gallbladder: 73.5","Cell line enhanced",NA,"RH-30: 1.1"
"APLN",92,"D12","IOH40655",234,"0",NA,"apelin (APLN), mRNA.","NM_017413.3","NP_059109.3",8862,"Hs.303084","apelin, XNPEP2","ENSG00000171388","Apelin","X","129645259-129654937","Predicted secreted proteins","Evidence at transcript level",NA,NA,NA,NA,NA,"Renal cancer:9.61e-5 (unfavourable), Cervical cancer:2.92e-4 (unfavourable), Lung cancer:6.09e-4 (unfavourable), Liver cancer:9.32e-4 (unfavourable)","Group enriched","Tissue enhanced",NA,"placenta: 79.6","lung: 20.8","Cell line enriched",6,"HUVEC TERT2: 421.2"
"APLN",33,"G8","IOH12605",369,"0",NA,"Apelin Precursor (APJ endogenous ligand) [Contains Apelin-36;Apelin-31;Apelin-28;Apelin-13] [Source:UniProtKB/Swiss-Prot;Acc:Q9ULZ1]","ENST00000429967","ENSP00000391800",8862,"Hs.303084","apelin, XNPEP2","ENSG00000171388","Apelin","X","129645259-129654937","Predicted secreted proteins","Evidence at transcript level",NA,NA,NA,NA,NA,"Renal cancer:9.61e-5 (unfavourable), Cervical cancer:2.92e-4 (unfavourable), Lung cancer:6.09e-4 (unfavourable), Liver cancer:9.32e-4 (unfavourable)","Group enriched","Tissue enhanced",NA,"placenta: 79.6","lung: 20.8","Cell line enriched",6,"HUVEC TERT2: 421.2"
"APLP2",43,"B6","IOH5604",1569,"NP_001633.1","AAH04371.1","amyloid beta (A4) precursor-like protein 2, mRNA (cDNA clone MGC:10449 IMAGE:3640033), complete cds","BC004371.1","AAH04371.1",334,"Hs.709184","APPH, APPL2","ENSG00000084234","Amyloid beta precursor like protein 2","11","130069837-130144811","Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA039319","Approved",NA,"Approved","Vesicles","Renal cancer:1.33e-9 (favourable), Thyroid cancer:2.90e-4 (favourable), Liver cancer:3.37e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 1056.8","Expressed in all",NA,NA
"APOA1",14,"C1","IOH7318",804,"0",NA,"apolipoprotein A-I (APOA1), mRNA.","NM_000039.1","NP_000030.1",335,"Hs.633003",NA,"ENSG00000118137","Apolipoprotein A1","11","116835751-116837950","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB016778, HPA046715","Supported",NA,"Approved","Vesicles<br>Cytosol","Renal cancer:1.67e-8 (unfavourable), Liver cancer:5.05e-4 (favourable)","Tissue enriched","Tissue enhanced",NA,"liver: 8458.6;small intestine: 4128.6","duodenum: 1609.4","Cell line enriched",15,"Hep G2: 1951.8"
"APOA2",77,"A4","IOH7290",303,"0",NA,"apolipoprotein A-II (APOA2), mRNA.","NM_001643.1","NP_001634.1",336,"Hs.237658",NA,"ENSG00000158874","Apolipoprotein A2","1","161222292-161223631","Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB025885","Supported",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",1068,"liver: 18325.0","bone marrow: 17.1","Cell line enriched",8,"Hep G2: 11388.0"
"APOA4",150,"D4","IOH61918",1191,"0",NA,"apolipoprotein A-IV, mRNA (cDNA clone MGC:103796 IMAGE:30915177), complete cds","BC074764.2","AAH74764.1",337,"Hs.591940",NA,"ENSG00000110244","Apolipoprotein A4","11","116820700-116823306","Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA001352, HPA002549, CAB068250, CAB068251, CAB068252","Enhanced",NA,"Approved","Vesicles",NA,"Tissue enriched","Group enriched",126,"duodenum: 2211.8;small intestine: 3441.1","liver: 22.3","Cell line enhanced",NA,"BEWO: 7.4;CACO-2: 6.6;Hep G2: 5.1;NB-4: 4.6;RPMI-8226: 8.2;SH-SY5Y: 11.1"
"APOA5",131,"H3","IOH55133",1101,"0",NA,"apolipoprotein A-V (APOA5), mRNA.","NM_052968.3","NP_443200.2",116519,"Hs.283923","APOA-V, RAP3","ENSG00000110243","Apolipoprotein A5","11","116789367-116792420","Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enriched","Tissue enriched",273,"liver: 259.2","testis: 0.9","Cell line enriched",54,"Hep G2: 40.9"
"APOC1",47,"C10","IOH9856",252,"0",NA,"apolipoprotein C-I (APOC1), mRNA.","NM_001645.3","NP_001636.1",341,"Hs.110675",NA,"ENSG00000130208","Apolipoprotein C1","19","44914247-44919349","Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA051518","Supported",NA,NA,NA,"Liver cancer:1.15e-7 (favourable)","Tissue enriched","Tissue enriched",7,"liver: 7257.2","adrenal gland: 1113.0","Cell line enhanced",NA,"Hep G2: 389.1;HSkMC: 242.1;SK-MEL-30: 203.2"
"APOC2",139,"H2","IOH54561",306,"0",NA,"apolipoprotein C-II (APOC2), mRNA.","NM_000483.3","NP_000474.2",344,"Hs.75615",NA,"ENSG00000234906","Apolipoprotein C2","19","44945982-44949565","Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA055877","Supported",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",59,"liver: 4214.4","small intestine: 71.0","Cell line enhanced",NA,"Hep G2: 463.1;HMC-1: 196.0;THP-1: 841.9"
"APOC2",76,"E5","IOH7233",306,"0",NA,"apolipoprotein C-II, mRNA (cDNA clone MGC:12445 IMAGE:3935036), complete cds","BC005348.2","AAH05348.3",344,"Hs.75615",NA,"ENSG00000234906","Apolipoprotein C2","19","44945982-44949565","Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA055877","Supported",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",59,"liver: 4214.4","small intestine: 71.0","Cell line enhanced",NA,"Hep G2: 463.1;HMC-1: 196.0;THP-1: 841.9"
"APOC4",32,"E12","IOH14363",384,"0",NA,"apolipoprotein C-IV (APOC4), mRNA.","NM_001646.1","NP_001637.1",346,"Hs.655423",NA,"ENSG00000267467","Apolipoprotein C4","19","44942238-44945496","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA062671","Approved",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",124,"liver: 347.3","testis: 2.8","Cell line enhanced",NA,"HEL: 1.5;SK-MEL-30: 2.0"
"APOD",29,"F4","IOH5861",570,"0",NA,"apolipoprotein D (APOD), mRNA.","NM_001647.3","NP_001638.1",347,"Hs.522555",NA,"ENSG00000189058","Apolipoprotein D","3","195568702-195584205","Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA040520","Enhanced",NA,"Approved","Plasma membrane","Thyroid cancer:4.12e-4 (unfavourable), Breast cancer:5.51e-4 (favourable), Stomach cancer:6.02e-4 (unfavourable)","Expressed in all","Tissue enriched",7,"breast: 4620.2","adipose tissue: 670.2","Cell line enhanced",NA,"ASC diff: 1866.1;ASC TERT1: 1018.4;WM-115: 301.1"
"APOE",122,"D12","IOH4456",954,"0",NA,"apolipoprotein E (APOE), mRNA.","NM_000041.2","NP_000032.1",348,"Hs.654439","AD2","ENSG00000130203","Apolipoprotein E","19","44905754-44909393","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB008363, HPA065539, HPA068768, CAB069921","Enhanced",NA,"Approved","Vesicles",NA,"Expressed in all","Expressed in all",NA,NA,"adrenal gland: 1801.1","Cell line enhanced",NA,"ASC diff: 1276.1;Hep G2: 626.6;HSkMC: 991.4;SK-MEL-30: 1417.0"
"APOF",18,"G2","IOH14362",981,"0",NA,"apolipoprotein F (APOF), mRNA.","NM_001638.2","NP_001629.1",319,"Hs.534302",NA,"ENSG00000175336","Apolipoprotein F","12","56360569-56362823","Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enriched","Tissue enriched",111,"liver: 220.1","prostate: 1.9","Cell line enriched",9,"Hep G2: 3.0"
"APOH",48,"D11","IOH14204",1038,"0",NA,"apolipoprotein H (beta-2-glycoprotein I) (APOH), mRNA.","NM_000042.2","NP_000033.2",350,"Hs.445358","B2G1, BG","ENSG00000091583","Apolipoprotein H","17","66212033-66256525","Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA001654, HPA003732, CAB022214","Enhanced",NA,"Supported","Golgi apparatus","Liver cancer:2.39e-7 (favourable), Renal cancer:1.10e-6 (unfavourable)","Tissue enriched","Tissue enriched",278,"liver: 9090.4","kidney: 32.7","Cell line enriched",17,"Hep G2: 846.7"
"APOL3",111,"B11","IOH42368",996,"0",NA,"apolipoprotein L, 3, mRNA (cDNA clone MGC:52206 IMAGE:5932779), complete cds","BC042918.1","AAH42918.1",80833,"Hs.474737","APOLIII, CG12-1","ENSG00000128284","Apolipoprotein L3","22","36140330-36166177","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA036228",NA,NA,"Approved","Nuclear bodies<br>Mitochondria","Renal cancer:1.23e-5 (unfavourable), Breast cancer:6.82e-4 (favourable)","Expressed in all","Mixed",NA,NA,"spleen: 64.0","Cell line enhanced",NA,"ASC TERT1: 38.5;Karpas-707: 42.5"
"APOL3",104,"E1","IOH44125",609,"0",NA,"apolipoprotein L, 3 (APOL3), transcript variant beta/a, mRNA.","NM_145641.2","NP_663616.1",80833,"Hs.474737","APOLIII, CG12-1","ENSG00000128284","Apolipoprotein L3","22","36140330-36166177","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA036228",NA,NA,"Approved","Nuclear bodies<br>Mitochondria","Renal cancer:1.23e-5 (unfavourable), Breast cancer:6.82e-4 (favourable)","Expressed in all","Mixed",NA,NA,"spleen: 64.0","Cell line enhanced",NA,"ASC TERT1: 38.5;Karpas-707: 42.5"
"APOM",49,"H3","IOH12125",567,"0",NA,"apolipoprotein M (APOM), mRNA.","NM_019101.2","NP_061974.2",55937,"Hs.534468","ApoM, G3a, NG20","ENSG00000204444","Apolipoprotein M","6","31652416-31658210","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB034086, HPA051006","Approved",NA,"Approved","Golgi apparatus",NA,"Tissue enriched","Mixed",NA,NA,"testis: 5.6","Mixed",NA,NA
"ARHGDIG",133,"C12","IOH53858",678,"0",NA,"Rho GDP dissociation inhibitor (GDI) gamma (ARHGDIG), mRNA.","NM_001176.3","NP_001167.2",398,"Hs.647388","RHOGDI-3","ENSG00000242173","Rho GDP dissociation inhibitor gamma","16","268727-283010","Predicted intracellular proteins","Evidence at protein level","HPA078260",NA,NA,"Approved","Plasma membrane<br>Cytosol",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 131.1;duodenum: 44.2","small intestine: 17.9","Cell line enhanced",NA,"HEK 293: 24.6;MCF7: 27.2;SCLC-21H: 14.0;SH-SY5Y: 15.7"
"ARMC5",128,"B12","IOH14691",2316,"0",NA,"armadillo repeat containing 5, mRNA (cDNA clone MGC:22948 IMAGE:4860377), complete cds","BC014945.1","AAH14945.1",79798,"Hs.121915","FLJ13063","ENSG00000140691","Armadillo repeat containing 5","16","31458080-31467166","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA041524, HPA063706","Approved",NA,"Approved","Nucleoplasm<br>Focal adhesion sites<br>Cytosol","Pancreatic cancer:1.97e-6 (favourable)","Expressed in all","Mixed",NA,NA,"bone marrow: 13.2","Cell line enhanced",NA,"NB-4: 37.4"
"ARSA",121,"C1","IOH46147",1524,"0",NA,"arylsulfatase A, mRNA (cDNA clone MGC:20637 IMAGE:4763974), complete cds","BC014210.2","AAH14210.2",410,"Hs.88251",NA,"ENSG00000100299","Arylsulfatase A","22","50622754-50628173","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA005554, CAB025183","Enhanced",NA,"Uncertain","Golgi apparatus<br>Cytosol","Endometrial cancer:2.96e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 37.4","Cell line enhanced",NA,"Karpas-707: 58.2"
"ARSK",107,"G11","IOH44578",1611,"0",NA,"arylsulfatase family, member K (ARSK), mRNA.","NM_198150.2","NP_937793.1",153642,"Hs.585051","DKFZp313G1735, TSULF","ENSG00000164291","Arylsulfatase family member K","5","95555074-95605064","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA042384","Approved",NA,"Approved","Nucleus<br>Vesicles","Liver cancer:2.59e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"parathyroid gland: 22.7","thyroid gland: 8.5","Expressed in all",NA,NA
"ART3",19,"F6","IOH14107",1137,"NP_001170.2","NP_001170.2","ADP-ribosyltransferase 3 (ART3), transcript variant 2, mRNA.","NM_001179.4","NP_001170.2",419,"Hs.24976",NA,"ENSG00000156219","ADP-ribosyltransferase 3","4","76011184-76112802","Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA011268","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"skeletal muscle: 77.0;testis: 174.4","heart muscle: 29.1","Group enriched",7,"NB-4: 3.4;NTERA-2: 14.0;SK-MEL-30: 4.9"
"ART3",20,"F9","IOH7386",1170,"0",NA,"ADP-ribosyltransferase 3, mRNA (cDNA clone MGC:14489 IMAGE:4244549), complete cds","BC008397.1","AAH08397.1",419,"Hs.24976",NA,"ENSG00000156219","ADP-ribosyltransferase 3","4","76011184-76112802","Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA011268","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"skeletal muscle: 77.0;testis: 174.4","heart muscle: 29.1","Group enriched",7,"NB-4: 3.4;NTERA-2: 14.0;SK-MEL-30: 4.9"
"ART4",114,"A7","IOH42492",945,"0",NA,"ADP-ribosyltransferase 4 (Dombrock blood group) (ART4), mRNA.","NM_021071.2","NP_066549.2",420,"Hs.591158","CD297, DO, DOK1","ENSG00000111339","ADP-ribosyltransferase 4 (Dombrock blood group)","12","14825569-14843495","Blood group antigen proteins, CD markers, Enzymes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA075664",NA,NA,"Approved","Rods & Rings",NA,"Tissue enhanced","Tissue enhanced",NA,"liver: 27.2;spleen: 26.9","gallbladder: 15.1","Cell line enhanced",NA,"AN3-CA: 5.6;HEL: 10.9;Hep G2: 4.9;HUVEC TERT2: 22.5"
"ART4",154,"A7","IOH62694",1560,"0",NA,"cDNA clone MGC:105008 IMAGE:3055541, complete cds.","BC089421.1","AAH89421.1",420,"Hs.591158","CD297, DO, DOK1","ENSG00000111339","ADP-ribosyltransferase 4 (Dombrock blood group)","12","14825569-14843495","Blood group antigen proteins, CD markers, Enzymes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA075664",NA,NA,"Approved","Rods & Rings",NA,"Tissue enhanced","Tissue enhanced",NA,"liver: 27.2;spleen: 26.9","gallbladder: 15.1","Cell line enhanced",NA,"AN3-CA: 5.6;HEL: 10.9;Hep G2: 4.9;HUVEC TERT2: 22.5"
"ART5",43,"H10","IOH12508",879,"0",NA,"ADP-ribosyltransferase 5, mRNA (cDNA clone MGC:22848 IMAGE:3934249), complete cds","BC014577.1","AAH14577.1",116969,"Hs.125680",NA,"ENSG00000167311","ADP-ribosyltransferase 5","11","3638503-3642316","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at transcript level","HPA041637, HPA044099","Uncertain",NA,NA,NA,"Renal cancer:1.85e-4 (favourable)","Tissue enhanced","Tissue enhanced",NA,"ovary: 10.2;testis: 22.6","endometrium: 5.1","Cell line enhanced",NA,"BEWO: 2.9;HEK 293: 1.9;U-2 OS: 2.1"
"ARTN",97,"H10","IOH40680",687,"0",NA,"artemin (ARTN), transcript variant 4, mRNA.","NM_057090.2","NP_476431.2",9048,"Hs.632404","ENOVIN, EVN, NBN","ENSG00000117407","Artemin","1","43933320-43937241","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Ovarian cancer:8.18e-4 (favourable)","Mixed","Tissue enhanced",NA,"parathyroid gland: 21.2","seminal vesicle: 12.2","Cell line enhanced",NA,"A-431: 60.4;HaCaT: 62.8;HBEC3-KT: 45.5"
"ASAH1",30,"C3","IOH23007",1170,"0",NA,"N-acylsphingosine amidohydrolase (acid ceramidase) 1, mRNA (cDNA clone MGC:24572 IMAGE:4109317), complete cds","BC016828.1","AAH16828.1",427,"Hs.527412","AC, ACDase, ASAH, FLJ21558, PHP32","ENSG00000104763","N-acylsphingosine amidohydrolase 1","8","18055992-18084998","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA005468","Supported",NA,NA,NA,"Renal cancer:3.08e-8 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 547.6","Expressed in all",NA,NA
"ASAH1",80,"G3","IOH21469",1188,"0",NA,"N-acylsphingosine amidohydrolase (acid ceramidase) 1, mRNA (cDNA clone MGC:9327 IMAGE:3923451), complete cds","BC016481.1","AAH16481.1",427,"Hs.527412","AC, ACDase, ASAH, FLJ21558, PHP32","ENSG00000104763","N-acylsphingosine amidohydrolase 1","8","18055992-18084998","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA005468","Supported",NA,NA,NA,"Renal cancer:3.08e-8 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 547.6","Expressed in all",NA,NA
"ASPN",118,"F1","IOH40733",1155,"0",NA,"asporin, mRNA (cDNA clone MGC:71931 IMAGE:30404602), complete cds","BC063114.1","AAH63114.1",54829,"Hs.435655","FLJ20129, PLAP1, SLRR1C","ENSG00000106819","Asporin","9","92456205-92482506","Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA008435, HPA024230","Approved",NA,"Uncertain","Nucleoplasm","Renal cancer:1.64e-7 (unfavourable)","Expressed in all","Tissue enhanced",NA,"endometrium: 115.6;smooth muscle: 161.0","gallbladder: 104.1","Cell line enhanced",NA,"ASC TERT1: 11.2;BJ hTERT+: 4.6;HHSteC: 19.2"
"ATG5",41,"E11","IOH5286",828,"0",NA,"ATG5 autophagy related 5 homolog (S. cerevisiae) (ATG5), mRNA.","NM_004849.2","NP_004840.1",9474,"Hs.486063","APG5, APG5L, ASP, hAPG5","ENSG00000057663","Autophagy related 5","6","106045423-106325791","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB034432, CAB037309, HPA042973","Enhanced",NA,"Approved","Centrosome","Renal cancer:8.73e-4 (unfavourable), Liver cancer:8.84e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 32.3","Expressed in all",NA,NA
"ATP6AP1",85,"D9","IOH4722",1413,"NP_001174.2","NP_001174.2","ATPase, H+ transporting, lysosomal accessory protein 1 (ATP6AP1), mRNA.","NM_001183.4","NP_001174.2",537,"Hs.6551","16A, Ac45, ATP6IP1, ATP6S1, CF2, ORF, VATPS1, XAP-3, XAP3","ENSG00000071553","ATPase H+ transporting accessory protein 1","X","154428632-154436516","Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB015218","Uncertain",NA,"Approved","Plasma membrane<br>Microtubules<br>Cytosol","Renal cancer:5.26e-8 (favourable), Breast cancer:2.40e-4 (unfavourable), Glioma:7.82e-4 (unfavourable), Pancreatic cancer:7.83e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 209.7","Expressed in all",NA,NA
"ATP6AP2",114,"E7","IOH42509",1053,"0",NA,"ATPase, H+ transporting, lysosomal accessory protein 2 (ATP6AP2), mRNA.","NM_005765.2","NP_005756.2",10159,"Hs.495960","APT6M8-9, ATP6IP2, ATP6M8-9, M8-9, PRR, RENR","ENSG00000182220","ATPase H+ transporting accessory protein 2","X","40579372-40606848","Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA003156","Approved",NA,NA,NA,"Renal cancer:2.01e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 893.4","Expressed in all",NA,NA
"ATP6AP2",16,"H11","IOH13836",300,"NP_005756.2","AAH10395.1","ATPase, H+ transporting, lysosomal accessory protein 2, mRNA (cDNA clone IMAGE:4275837), complete cds.","BC010395.1","AAH10395.1",10159,"Hs.495960","APT6M8-9, ATP6IP2, ATP6M8-9, M8-9, PRR, RENR","ENSG00000182220","ATPase H+ transporting accessory protein 2","X","40579372-40606848","Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA003156","Approved",NA,NA,NA,"Renal cancer:2.01e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 893.4","Expressed in all",NA,NA
"AZGP1",125,"A1","IOH21748",897,"0",NA,"alpha-2-glycoprotein 1, zinc-binding (AZGP1), mRNA.","NM_001185.2","NP_001176.1",563,"Hs.546239","ZA2G, ZAG","ENSG00000160862","Alpha-2-glycoprotein 1, zinc-binding","7","99966720-99976157","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA012582, CAB016087, CAB032276","Enhanced",NA,NA,NA,"Renal cancer:1.53e-4 (favourable), Liver cancer:2.90e-4 (favourable)","Group enriched","Tissue enhanced",NA,"breast: 1201.5;liver: 1272.1;prostate: 1490.2;salivary gland: 1423.5","kidney: 294.4","Cell line enhanced",NA,"Hep G2: 33.7;RPMI-8226: 79.5;T-47d: 35.0"
"AZU1",121,"E5","IOH29646",756,"0",NA,"azurocidin 1 (AZU1), mRNA.","NM_001700.3","NP_001691.1",566,"Hs.72885","AZAMP, AZU, CAP37, HBP, HUMAZUR, NAZC","ENSG00000172232","Azurocidin 1","19","825097-832018","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA055851","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enriched",525,"bone marrow: 1311.2","skin: 2.4","Cell line enriched",6,"THP-1: 722.4"
"B2M",63,"D10","IOH21955",360,"0",NA,"beta-2-microglobulin (B2M), mRNA.","NM_004048.2","NP_004039.1",567,"Hs.534255",NA,"ENSG00000166710","Beta-2-microglobulin","15","44711477-44718877","Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB002572, HPA006361","Enhanced",NA,"Enhanced","Golgi apparatus<br>Plasma membrane<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"lymph node: 5119.8","Expressed in all",NA,NA
"B3GALNT1",148,"F2","IOH62087",996,"0",NA,"beta-1,3-N-acetylgalactosaminyltransferase 1 (globoside blood group), mRNA (cDNA clone MGC:26035 IMAGE:4838965), complete cds","BC028571.1","AAH28571.1",8706,"Hs.418062","B3GALT3, beta3Gal-T3, galT3, GLOB, P1","ENSG00000169255","Beta-1,3-N-acetylgalactosaminyltransferase 1 (globoside blood group)","3","161083883-161105384","Blood group antigen proteins, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA041204",NA,NA,"Approved","Vesicles",NA,"Expressed in all","Mixed",NA,NA,"thyroid gland: 47.9","Cell line enhanced",NA,"RT4: 111.0"
"B3GALNT2",80,"A5","IOH21576",1503,"0",NA,"beta-1,3-N-acetylgalactosaminyltransferase 2 (B3GALNT2), mRNA.","NM_152490.2","NP_689703.1",148789,"Hs.716571","MGC39558","ENSG00000162885","Beta-1,3-N-acetylgalactosaminyltransferase 2","1","235449923-235504481","Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA012502, HPA050662","Approved",NA,"Approved","Nucleoplasm<br>Golgi apparatus",NA,"Expressed in all","Mixed",NA,NA,"smooth muscle: 15.9","Expressed in all",NA,NA
"B4GALNT1",50,"F6","IOH22807",987,"0",NA,"beta-1,4-N-acetyl-galactosaminyl transferase 1, mRNA (cDNA clone MGC:34476 IMAGE:5176204), complete cds","BC029828.1","AAH29828.1",2583,"Hs.591019","beta1-4GalNAc-T, GALGT, SPG26","ENSG00000135454","Beta-1,4-N-acetyl-galactosaminyltransferase 1","12","57623410-57633355","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA008968, HPA015128","Enhanced",NA,NA,NA,"Renal cancer:3.18e-14 (unfavourable)","Tissue enriched","Tissue enriched",6,"cerebral cortex: 26.2","seminal vesicle: 4.0","Cell line enhanced",NA,"EFO-21: 33.8;HDLM-2: 29.7"
"B4GALT4",50,"A11","IOH5188",1035,"0",NA,"UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 4, mRNA (cDNA clone MGC:3811 IMAGE:3531796), complete cds","BC004523.2","AAH04523.1",8702,"Hs.13225","beta4Gal-T4","ENSG00000121578","Beta-1,4-galactosyltransferase 4","3","119211732-119241103","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA046819, HPA063546","Approved",NA,"Supported","Golgi apparatus","Liver cancer:4.04e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 75.8","Expressed in all",NA,NA
"B9D1",24,"C3","IOH5726",462,"0",NA,"B9 protein domain 1, mRNA (cDNA clone MGC:11339 IMAGE:3953287), complete cds","BC002944.2","AAH02944.1",27077,"Hs.462445","B9, EPPB9, MKS9","ENSG00000108641","B9 domain containing 1","17","19337554-19378182","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA022957","Approved",NA,NA,NA,"Renal cancer:4.14e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"fallopian tube: 102.1","Mixed",NA,NA
"BACE2",86,"C5","IOH13508",1557,"NP_036237.2","NP_036237.2","beta-site APP-cleaving enzyme 2 (BACE2), transcript variant a, mRNA.","NM_012105.3","NP_036237.2",25825,"Hs.529408","AEPLC, ALP56, CEAP1, DRAP","ENSG00000182240","Beta-site APP-cleaving enzyme 2","21","41167801-41282518","Enzymes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA035416","Approved",NA,NA,NA,"Cervical cancer:1.11e-4 (unfavourable), Glioma:8.13e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"stomach: 30.5","Cell line enhanced",NA,"SK-BR-3: 43.8;WM-115: 41.2"
"BCAN",81,"E2","IOH10285",2736,"0",NA,"brevican, mRNA (cDNA clone MGC:18150 IMAGE:4154474), complete cds","BC009117.1","AAH09117.1",63827,"Hs.516904","BEHAB, CSPG7, MGC13038","ENSG00000132692","Brevican","1","156641390-156659532","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA007865, CAB025862","Enhanced","Supported",NA,NA,NA,"Group enriched","Tissue enriched",24,"cerebral cortex: 428.3","epididymis: 18.0","Cell line enhanced",NA,"HDLM-2: 67.3;K-562: 92.6;U-266/84: 84.7"
"BCAR1",135,"H4","IOH57307",2613,"0",NA,"breast cancer anti-estrogen resistance 1, mRNA (cDNA clone MGC:71216 IMAGE:6427808), complete cds","BC062556.1","AAH62556.1",9564,"Hs.479747","CAS, CASS1, Crkas, P130Cas","ENSG00000050820","BCAR1, Cas family scaffolding protein","16","75228187-75268053","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB000443, HPA042282","Approved","Supported","Approved","Plasma membrane<br>Cytosol","Renal cancer:4.55e-8 (favourable), Liver cancer:9.11e-5 (unfavourable), Lung cancer:1.24e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"spleen: 41.0","Mixed",NA,NA
"BCKDHB",72,"F6","IOH26206",1179,"0",NA,"branched chain keto acid dehydrogenase E1, beta polypeptide (BCKDHB), nuclear gene encoding mitochondrial protein, transcript variant 2, mRNA.","NM_000056.3","NP_000047.1",594,"Hs.654441",NA,"ENSG00000083123","Branched chain keto acid dehydrogenase E1 subunit beta","6","80106647-80346270","Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins","Evidence at protein level","HPA031580","Approved",NA,NA,NA,"Renal cancer:5.54e-9 (favourable)","Expressed in all","Expressed in all",NA,NA,"liver: 39.9","Expressed in all",NA,NA
"BCKDHB",149,"F4","IOH62054",657,"0",NA,"branched chain keto acid dehydrogenase E1, beta polypeptide, mRNA (cDNA clone MGC:26350 IMAGE:4824846), complete cds","BC034481.1","AAH34481.1",594,"Hs.654441",NA,"ENSG00000083123","Branched chain keto acid dehydrogenase E1 subunit beta","6","80106647-80346270","Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins","Evidence at protein level","HPA031580","Approved",NA,NA,NA,"Renal cancer:5.54e-9 (favourable)","Expressed in all","Expressed in all",NA,NA,"liver: 39.9","Expressed in all",NA,NA
"BDNF",82,"F12","IOH34694",744,"0",NA,"brain-derived neurotrophic factor (BDNF), transcript variant 4, mRNA.","NM_001709.4","NP_001700.2",627,"Hs.502182",NA,"ENSG00000176697","Brain derived neurotrophic factor","11","27654893-27722058","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB009564, HPA031440, HPA056104","Enhanced",NA,"Supported","Nuclear speckles<br>Mitochondria",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 11.9","epididymis: 4.9","Cell line enhanced",NA,"BJ: 37.3;BJ hTERT+ SV40 Large T+: 30.7;HBF TERT88: 30.4;U-138 MG: 45.3"
"BDNF",133,"H9","IOH53872",768,"0",NA,"brain-derived neurotrophic factor (BDNF), transcript variant 3, mRNA.","NM_170731.4","NP_733927.1",627,"Hs.502182",NA,"ENSG00000176697","Brain derived neurotrophic factor","11","27654893-27722058","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB009564, HPA031440, HPA056104","Enhanced",NA,"Supported","Nuclear speckles<br>Mitochondria",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 11.9","epididymis: 4.9","Cell line enhanced",NA,"BJ: 37.3;BJ hTERT+ SV40 Large T+: 30.7;HBF TERT88: 30.4;U-138 MG: 45.3"
"BDNF",36,"C10","IOH22708",744,"0",NA,"brain-derived neurotrophic factor, mRNA (cDNA clone MGC:34632 IMAGE:5193877), complete cds","BC029795.1","AAH29795.1",627,"Hs.502182",NA,"ENSG00000176697","Brain derived neurotrophic factor","11","27654893-27722058","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB009564, HPA031440, HPA056104","Enhanced",NA,"Supported","Nuclear speckles<br>Mitochondria",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 11.9","epididymis: 4.9","Cell line enhanced",NA,"BJ: 37.3;BJ hTERT+ SV40 Large T+: 30.7;HBF TERT88: 30.4;U-138 MG: 45.3"
"BGLAP",138,"G2","IOH58586",303,"0",NA,"bone gamma-carboxyglutamate (gla) protein (BGLAP), mRNA.","NM_199173.3","NP_954642.1",632,"Hs.654541","OCN","ENSG00000242252","Bone gamma-carboxyglutamate protein","1","156241962-156243321","FDA approved drug targets, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Mixed","Mixed",NA,NA,"skin: 2.1","Cell line enhanced",NA,"U-87 MG: 2.8"
"BGN",89,"D8","IOH5449",1107,"0",NA,"biglycan (BGN), mRNA.","NM_001711.3","NP_001702.1",633,"Hs.821","DSPG1, SLRR1A","ENSG00000182492","Biglycan","X","153494939-153509554","Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA003157, CAB003678","Enhanced",NA,"Approved","Endoplasmic reticulum<br>Golgi apparatus","Renal cancer:6.00e-8 (unfavourable)","Expressed in all","Mixed",NA,NA,"gallbladder: 501.3","Cell line enhanced",NA,"BJ: 258.4;BJ hTERT+: 318.9;fHDF/TERT166: 430.9;hTEC/SVTERT24-B: 230.0;HUVEC TERT2: 458.3;U-138 MG: 240.7"
"BMP1",101,"C5","IOH36655",1869,"0",NA,"Bone morphogenetic protein 1 Precursor (BMP-1)(EC 3.4.24.19)(Procollagen C-proteinase)(PCP)(Mammalian tolloid protein)(mTld) [Source:UniProtKB/Swiss-Prot;Acc:P13497]","ENST00000397814","ENSP00000380915",649,"Hs.1274","PCOLC","ENSG00000168487","Bone morphogenetic protein 1","8","22164736-22212326","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins","Evidence at protein level","HPA014572","Enhanced",NA,NA,NA,"Renal cancer:3.37e-9 (unfavourable)","Expressed in all","Tissue enhanced",NA,"placenta: 21.1","smooth muscle: 10.5","Mixed",NA,NA
"BMP10",131,"G9","IOH46456",1275,"0",NA,"bone morphogenetic protein 10 (BMP10), mRNA.","NM_014482.1","NP_055297.1",27302,"Hs.158317",NA,"ENSG00000163217","Bone morphogenetic protein 10","2","68865481-68871517","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Not detected","Tissue enriched",91,"heart muscle: 327.8","liver: 3.5","Not detected",NA,NA
"BMP3",132,"B1","IOH46503",1419,"0",NA,"bone morphogenetic protein 3, mRNA (cDNA clone MGC:116937 IMAGE:40006306), complete cds","BC117514.1","AAI17515.1",651,"Hs.387411",NA,"ENSG00000152785","Bone morphogenetic protein 3","4","81030965-81057531","Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"urinary bladder: 20.6","lung: 8.7","Cell line enhanced",NA,"AF22: 10.7;Daudi: 12.2;RT4: 11.3;SK-BR-3: 4.6"
"BMP4",9,"G10","IOH11166",1227,"0",NA,"bone morphogenetic protein 4, mRNA (cDNA clone MGC:21303 IMAGE:4399276), complete cds","BC020546.2","AAH20546.1",652,"Hs.68879","BMP2B","ENSG00000125378","Bone morphogenetic protein 4","14","53949736-53958761","Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB006863, HPA066235","Enhanced",NA,NA,NA,NA,"Expressed in all","Mixed",NA,NA,"placenta: 64.1","Cell line enhanced",NA,"CACO-2: 100.3;CAPAN-2: 262.8;Hep G2: 222.2;U-2 OS: 93.4"
"BMP8A",149,"H3","IOH61985",351,"0",NA,"bone morphogenetic protein 8a, mRNA (cDNA clone IMAGE:7939588), complete cds.","BC093743.1","AAH93743.1",353500,"Hs.472497",NA,"ENSG00000183682","Bone morphogenetic protein 8a","1","39491646-39525935","Predicted secreted proteins","Evidence at transcript level",NA,NA,NA,NA,NA,NA,"Mixed","Tissue enriched",19,"thyroid gland: 82.0","testis: 4.4","Cell line enhanced",NA,"U-2197: 12.8;U-266/70: 5.4;U-266/84: 4.6"
"BMPER",100,"D10","IOH29213",2058,"0",NA,"BMP binding endothelial regulator, mRNA (cDNA clone MGC:71818 IMAGE:30345290), complete cds","BC060868.1","AAH60868.1",168667,"Hs.660998","CRIM3, Cv2","ENSG00000164619","BMP binding endothelial regulator","7","33904911-34155872","Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA018083",NA,"Supported",NA,NA,NA,"Tissue enhanced","Mixed",NA,NA,"placenta: 9.5","Cell line enhanced",NA,"fHDF/TERT166: 17.5;HBF TERT88: 23.1;hTEC/SVTERT24-B: 16.0;U-138 MG: 24.5"
"BMPER",137,"E10","IOH55622",2058,"0",NA,"BMP binding endothelial regulator (BMPER), mRNA.","NM_133468.3","NP_597725.1",168667,"Hs.660998","CRIM3, Cv2","ENSG00000164619","BMP binding endothelial regulator","7","33904911-34155872","Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA018083",NA,"Supported",NA,NA,NA,"Tissue enhanced","Mixed",NA,NA,"placenta: 9.5","Cell line enhanced",NA,"fHDF/TERT166: 17.5;HBF TERT88: 23.1;hTEC/SVTERT24-B: 16.0;U-138 MG: 24.5"
"BOLA1",97,"D4","IOH39867",414,"0",NA,"bolA homolog 1 (E. coli) (BOLA1), mRNA.","NM_016074.3","NP_057158.1",51027,"Hs.13880","CGI-143","ENSG00000178096","BolA family member 1","1","149887890-149900798","Predicted secreted proteins","Evidence at protein level","HPA007005","Approved",NA,NA,NA,"Liver cancer:5.88e-4 (unfavourable), Ovarian cancer:6.41e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"duodenum: 15.6","Cell line enhanced",NA,"MCF7: 42.0"
"BPI",57,"D4","IOH26197",1464,"0",NA,"bactericidal/permeability-increasing protein, mRNA (cDNA clone MGC:48884 IMAGE:5218655), complete cds","BC040955.1","AAH40955.1",671,"Hs.529019","BPIFD1","ENSG00000101425","Bactericidal/permeability-increasing protein","20","38260149-38337505","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA061284","Enhanced",NA,NA,NA,NA,"Not detected","Tissue enriched",37,"bone marrow: 961.6","testis: 25.9","Group enriched",5,"AF22: 2.3;ASC diff: 1.1;ASC TERT1: 3.1;BJ: 2.1;BJ hTERT+: 2.1;HL-60: 1.1"
"BSG",41,"C10","IOH3378",810,"NP_001719.1","NP_940991.1","basigin (Ok blood group) (BSG), transcript variant 2, mRNA.","NM_198589.1","NP_940991.1",682,"Hs.501293","CD147, EMMPRIN, OK","ENSG00000172270","Basigin (Ok blood group)","19","571277-583493","Blood group antigen proteins, CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","CAB002427, HPA036048, HPA074870","Enhanced",NA,"Approved","Vesicles","Renal cancer:1.95e-6 (favourable), Liver cancer:5.48e-6 (unfavourable), Endometrial cancer:2.59e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"heart muscle: 593.5","Expressed in all",NA,NA
"BST1",122,"D7","IOH13147",957,"0",NA,"bone marrow stromal cell antigen 1 (BST1), mRNA.","NM_004334.2","NP_004325.2",683,"Hs.399980","CD157","ENSG00000109743","Bone marrow stromal cell antigen 1","4","15702950-15738313","CD markers, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA050121","Uncertain",NA,NA,NA,NA,"Expressed in all","Tissue enhanced",NA,"bone marrow: 105.5","duodenum: 54.8","Cell line enhanced",NA,"THP-1: 60.3;TIME: 39.6;U-937: 45.8;WM-115: 51.6"
"BTD",77,"A10","IOH13161",1632,"0",NA,"biotinidase (BTD), mRNA.","NM_000060.2","NP_000051.1",686,"Hs.517830",NA,"ENSG00000169814","Biotinidase","3","15601341-15645822","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA052275","Uncertain",NA,NA,NA,"Renal cancer:2.60e-9 (favourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 53.0","Mixed",NA,NA
"BTN2A2",108,"B1","IOH44638",1224,"0",NA,"butyrophilin, subfamily 2, member A2 (BTN2A2), transcript variant 2, mRNA.","NM_181531.1","NP_853509.1",10385,"Hs.373938","BT2.2, BTF2, BTN2.2","ENSG00000124508","Butyrophilin subfamily 2 member A2","6","26383096-26394874","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA051504","Uncertain",NA,"Supported","Mitochondria","Breast cancer:1.01e-4 (favourable)","Expressed in all","Mixed",NA,NA,"lymph node: 37.6","Mixed",NA,NA
"BTN2A2",4,"G1","IOH14772",1572,"0",NA,"butyrophilin, subfamily 2, member A2 (BTN2A2), transcript variant 1, mRNA.","NM_006995.3","NP_008926.2",10385,"Hs.373938","BT2.2, BTF2, BTN2.2","ENSG00000124508","Butyrophilin subfamily 2 member A2","6","26383096-26394874","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA051504","Uncertain",NA,"Supported","Mitochondria","Breast cancer:1.01e-4 (favourable)","Expressed in all","Mixed",NA,NA,"lymph node: 37.6","Mixed",NA,NA
"BTN2A2",76,"H9","IOH14419",1011,"NP_008926.2","AAH17497.1","butyrophilin, subfamily 2, member A2, mRNA (cDNA clone MGC:20007 IMAGE:4648935), complete cds","BC017497.1","AAH17497.1",10385,"Hs.373938","BT2.2, BTF2, BTN2.2","ENSG00000124508","Butyrophilin subfamily 2 member A2","6","26383096-26394874","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA051504","Uncertain",NA,"Supported","Mitochondria","Breast cancer:1.01e-4 (favourable)","Expressed in all","Mixed",NA,NA,"lymph node: 37.6","Mixed",NA,NA
"BTN3A2",25,"H1","IOH5425",1005,"0",NA,"butyrophilin, subfamily 3, member A2 (BTN3A2), mRNA.","NM_007047.3","NP_008978.2",11118,"Hs.376046","BTN3.2","ENSG00000186470","Butyrophilin subfamily 3 member A2","6","26365159-26378320","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB019392","Uncertain",NA,NA,NA,"Renal cancer:4.24e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 129.4","Mixed",NA,NA
"BTN3A3",134,"H8","IOH57141",1755,"0",NA,"butyrophilin, subfamily 3, member A3 (BTN3A3), transcript variant 1, mRNA.","NM_006994.3","NP_008925.1",10384,"Hs.167741","BTF3, BTN3.3","ENSG00000111801","Butyrophilin subfamily 3 member A3","6","26440472-26453415","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA007904, HPA011871","Enhanced",NA,NA,NA,"Renal cancer:2.42e-5 (unfavourable), Ovarian cancer:1.80e-4 (favourable)","Expressed in all","Mixed",NA,NA,"spleen: 64.0","Cell line enhanced",NA,"ASC TERT1: 43.5;BJ hTERT+ SV40 Large T+ RasG12V: 41.9"
"BTN3A3",112,"E12","IOH45792",1629,"0",NA,"butyrophilin, subfamily 3, member A3 (BTN3A3), transcript variant 2, mRNA.","NM_197974.1","NP_932078.1",10384,"Hs.167741","BTF3, BTN3.3","ENSG00000111801","Butyrophilin subfamily 3 member A3","6","26440472-26453415","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA007904, HPA011871","Enhanced",NA,NA,NA,"Renal cancer:2.42e-5 (unfavourable), Ovarian cancer:1.80e-4 (favourable)","Expressed in all","Mixed",NA,NA,"spleen: 64.0","Cell line enhanced",NA,"ASC TERT1: 43.5;BJ hTERT+ SV40 Large T+ RasG12V: 41.9"
"C10orf99",120,"A5","IOH50140",246,"0",NA,"chromosome 10 open reading frame 99 (C10orf99), mRNA.","NM_207373.2","NP_997256.1",387695,"Hs.298713","AP-57, CSBF, FLJ21763, RLLV1833, UNQ1833","ENSG00000188373","Chromosome 10 open reading frame 99","10","84173738-84185294","Predicted secreted proteins","Evidence at protein level","HPA050920","Enhanced",NA,NA,NA,"Renal cancer:1.20e-5 (unfavourable)","Mixed","Group enriched",11,"colon: 239.2;esophagus: 185.4;rectum: 264.2","urinary bladder: 20.8","Cell line enriched",6,"RT4: 37.2"
"C11orf1",7,"F4","IOH12100",453,"0",NA,"chromosome 11 open reading frame 1 (C11orf1), mRNA.","NM_022761.2","NP_073598.1",64776,"Hs.17546","FLJ23499","ENSG00000137720","Chromosome 11 open reading frame 1","11","111878935-111885975","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA038410, HPA057519","Uncertain",NA,"Enhanced","Nucleoplasm","Renal cancer:1.39e-4 (favourable), Endometrial cancer:9.32e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 104.9","Expressed in all",NA,NA
"C11orf24",50,"B2","IOH12453",1350,"NP_071733.1","AAH11765.1","chromosome 11 open reading frame 24, mRNA (cDNA clone MGC:19741 IMAGE:3614861), complete cds","BC011765.2","AAH11765.1",53838,"Hs.303025","DM4E3","ENSG00000171067","Chromosome 11 open reading frame 24","11","68261335-68272001","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA012748","Uncertain",NA,"Uncertain","Nucleoplasm<br>Vesicles","Renal cancer:1.60e-9 (unfavourable), Lung cancer:6.05e-4 (unfavourable), Glioma:9.83e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"small intestine: 65.9","Expressed in all",NA,NA
"C12orf10",120,"C1","IOH28884",1131,"0",NA,"chromosome 12 open reading frame 10, mRNA (cDNA clone MGC:60246 IMAGE:5170816), complete cds","BC051871.1","AAH51871.1",60314,"Hs.655988","Gamm1, MYG, MYG1","ENSG00000139637","Chromosome 12 open reading frame 10","12","53299686-53307177","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA038626, HPA038627","Approved","Supported","Supported","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 114.3","Expressed in all",NA,NA
"C12orf10",37,"D12","IOH22187",666,"0",NA,"chromosome 12 open reading frame 10, mRNA (cDNA clone MGC:25015 IMAGE:4454943), complete cds","BC028904.1","AAH28904.1",60314,"Hs.655988","Gamm1, MYG, MYG1","ENSG00000139637","Chromosome 12 open reading frame 10","12","53299686-53307177","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA038626, HPA038627","Approved","Supported","Supported","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 114.3","Expressed in all",NA,NA
"C14orf80",90,"F10","IOH9994",747,"0",NA,"chromosome 14 open reading frame 80, mRNA (cDNA clone MGC:16771 IMAGE:3907551), complete cds","BC016028.1","AAH16028.1",283643,"Hs.70327",NA,"ENSG00000185347","Chromosome 14 open reading frame 80","14","105489855-105499575","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA039049, HPA039050","Uncertain",NA,"Approved","Nucleoplasm<br>Golgi apparatus<br>Cytosol","Liver cancer:3.54e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"appendix,skin: 6.6","Mixed",NA,NA
"C15orf41",49,"C3","IOH6336",552,"0",NA,"chromosome 15 open reading frame 41 (C15orf41), transcript variant 2, mRNA.","NM_032499.4","NP_115888.1",84529,"Hs.48348","FLJ22851, HH114, MGC11326","ENSG00000186073","Chromosome 15 open reading frame 41","15","36579611-36810248","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA061023","Uncertain",NA,"Approved","Nucleoplasm",NA,"Mixed","Tissue enhanced",NA,"heart muscle: 63.4","smooth muscle: 14.3","Expressed in all",NA,NA
"C16orf89",42,"D5","IOH21850",1200,"0",NA,"chromosome 16 open reading frame 89, mRNA (cDNA clone MGC:45438 IMAGE:5190553), complete cds","BC033681.1","AAH33681.1",146556,"Hs.11782","MGC45438","ENSG00000153446","Chromosome 16 open reading frame 89","16","5044122-5066110","Predicted secreted proteins","Evidence at protein level","HPA013613, HPA016934","Enhanced",NA,NA,NA,NA,"Group enriched","Tissue enhanced",NA,"lung: 145.4;thyroid gland: 352.5","epididymis: 94.3","Cell line enhanced",NA,"ASC diff: 1.4;Hep G2: 1.7;NTERA-2: 1.5;U-2197: 2.0"
"C17orf58",125,"B8","IOH50196",294,"0",NA,"chromosome 17 open reading frame 58, mRNA (cDNA clone MGC:46703 IMAGE:5587712), complete cds","BC036760.1","AAH36760.1",284018,"Hs.90790",NA,"ENSG00000186665","Chromosome 17 open reading frame 58","17","67991101-67996431","Predicted intracellular proteins, Predicted secreted proteins","Evidence at transcript level","HPA023036","Uncertain",NA,"Approved","Plasma membrane<br>Cytosol","Renal cancer:1.31e-10 (unfavourable), Liver cancer:8.99e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"placenta: 50.5","cervix, uterine: 42.4","Expressed in all",NA,NA
"C17orf67",105,"D10","IOH43359",273,"0",NA,"chromosome 17 open reading frame 67, mRNA (cDNA clone MGC:120940 IMAGE:7939750), complete cds","BC093905.1","AAH93905.1",339210,"Hs.658949",NA,"ENSG00000214226","Chromosome 17 open reading frame 67","17","56791913-56838773","Predicted secreted proteins","Evidence at protein level","HPA043479","Uncertain","Approved",NA,NA,NA,"Mixed","Mixed",NA,NA,"spleen: 3.7","Cell line enhanced",NA,"MOLT-4: 11.9"
"C17orf75",63,"F6","IOH29309",1191,"0",NA,"chromosome 17 open reading frame 75 (C17orf75), mRNA.","NM_022344.2","NP_071739.2",64149,"Hs.655257","NJMU-R1, SRI2","ENSG00000108666","Chromosome 17 open reading frame 75","17","32324565-32350023","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA004061","Approved","Approved","Approved","Golgi apparatus<br>Cytosol","Renal cancer:1.33e-4 (favourable), Ovarian cancer:3.13e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 39.6","Expressed in all",NA,NA
"C19orf47",17,"G7","IOH11549",1068,"0",NA,"chromosome 19 open reading frame 47 (C19orf47), mRNA.","NM_178830.2","NP_849152.1",126526,"Hs.631557","FLJ36888","ENSG00000160392","Chromosome 19 open reading frame 47","19","40319536-40348527","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA041843, HPA046309","Uncertain",NA,"Enhanced","Nucleoplasm","Endometrial cancer:7.10e-5 (unfavourable), Liver cancer:1.41e-4 (unfavourable), Breast cancer:6.50e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"skeletal muscle: 63.7","Expressed in all",NA,NA
"C19orf47",100,"F11","IOH29337",846,"0",NA,"chromosome 19 open reading frame 47, mRNA (cDNA clone MGC:23442 IMAGE:4662735), complete cds","BC023623.2","AAH23623.1",126526,"Hs.631557","FLJ36888","ENSG00000160392","Chromosome 19 open reading frame 47","19","40319536-40348527","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA041843, HPA046309","Uncertain",NA,"Enhanced","Nucleoplasm","Endometrial cancer:7.10e-5 (unfavourable), Liver cancer:1.41e-4 (unfavourable), Breast cancer:6.50e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"skeletal muscle: 63.7","Expressed in all",NA,NA
"C19orf70",129,"G3","IOH53736",357,"0",NA,"chromosome 19 open reading frame 70 (C19orf70), mRNA.","NM_205767.1","NP_991330.1",125988,"Hs.356626","MIC13, P117, QIL1","ENSG00000174917","Chromosome 19 open reading frame 70","19","5678421-5680896","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA042672","Approved",NA,"Supported","Nucleoplasm<br>Mitochondria","Renal cancer:7.60e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"heart muscle: 79.9","Expressed in all",NA,NA
"C19orf70",58,"E10","IOH26892",357,"0",NA,"chromosome 19 open reading frame 70, mRNA (cDNA clone MGC:57483 IMAGE:5288954), complete cds","BC042386.1","AAH42386.1",125988,"Hs.356626","MIC13, P117, QIL1","ENSG00000174917","Chromosome 19 open reading frame 70","19","5678421-5680896","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA042672","Approved",NA,"Supported","Nucleoplasm<br>Mitochondria","Renal cancer:7.60e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"heart muscle: 79.9","Expressed in all",NA,NA
"C1orf159",91,"A4","IOH6237",558,"0",NA,"chromosome 1 open reading frame 159, mRNA (cDNA clone MGC:3446 IMAGE:3627081), complete cds","BC008788.2","AAH08788.1",54991,"Hs.235095","FLJ20584","ENSG00000131591","Chromosome 1 open reading frame 159","1","1081818-1116361","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA010019","Approved",NA,"Approved","Nucleoli fibrillar center<br>Cytosol","Renal cancer:1.77e-6 (unfavourable), Liver cancer:9.58e-6 (unfavourable), Urothelial cancer:1.62e-4 (favourable)","Expressed in all","Mixed",NA,NA,"skin: 15.3","Expressed in all",NA,NA
"C1orf159",139,"D11","IOH59824",765,"NP_060361.1","ENSP00000253892","Uncharacterized protein C1orf159 Precursor  [Source:UniProtKB/Swiss-Prot;Acc:Q96HA4]","ENST00000253892","ENSP00000253892",54991,"Hs.235095","FLJ20584","ENSG00000131591","Chromosome 1 open reading frame 159","1","1081818-1116361","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA010019","Approved",NA,"Approved","Nucleoli fibrillar center<br>Cytosol","Renal cancer:1.77e-6 (unfavourable), Liver cancer:9.58e-6 (unfavourable), Urothelial cancer:1.62e-4 (favourable)","Expressed in all","Mixed",NA,NA,"skin: 15.3","Expressed in all",NA,NA
"C1QA",36,"H9","IOH23091",738,"0",NA,"complement component 1, q subcomponent, A chain (C1QA), mRNA.","NM_015991.2","NP_057075.1",712,"Hs.632379",NA,"ENSG00000173372","Complement C1q A chain","1","22636506-22639608","Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA002350, CAB009823","Supported",NA,"Uncertain","Golgi apparatus<br>Cytosol","Renal cancer:1.58e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 1166.4","Cell line enhanced",NA,"HMC-1: 2.0;RPMI-8226: 4.9;SCLC-21H: 3.5"
"C1QB",77,"G9","IOH3324",762,"0",NA,"complement component 1, q subcomponent, B chain (C1QB), mRNA.","NM_000491.3","NP_000482.3",713,"Hs.8986",NA,"ENSG00000173369","Complement C1q B chain","1","22652762-22661538","Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA052116","Approved",NA,NA,NA,"Renal cancer:9.58e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 1435.2","Not detected",NA,NA
"C1QC",5,"F5","IOH3326",738,"0",NA,"complement component 1, q subcomponent, C chain (C1QC), transcript variant 2, mRNA.","NM_172369.3","NP_758957.2",714,"Hs.467753","C1QG","ENSG00000159189","Complement C1q C chain","1","22643630-22648110","Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA001471, CAB009828","Supported",NA,"Uncertain","Vesicles","Renal cancer:1.17e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 1285.6","Cell line enhanced",NA,"RPMI-8226: 1.7"
"C1QL1",100,"A6","IOH6218",777,"0",NA,"complement component 1, q subcomponent-like 1 (C1QL1), mRNA.","NM_006688.3","NP_006679.1",10882,"Hs.134012","C1QRF, C1QTNF14, CRF","ENSG00000131094","Complement C1q like 1","17","44959693-44968071","Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:1.31e-8 (unfavourable)","Tissue enriched","Tissue enriched",14,"cerebral cortex: 38.4","prostate: 2.6","Cell line enhanced",NA,"SCLC-21H: 49.2;SH-SY5Y: 31.5;U-2 OS: 108.2;U-87 MG: 32.8"
"C1QTNF1",5,"A11","IOH13365",846,"0",NA,"C1q and tumor necrosis factor related protein 1 (C1QTNF1), transcript variant 1, mRNA.","NM_030968.2","NP_112230.1",114897,"Hs.201398","CTRP1, FLJ90694, GIP, ZSIG37","ENSG00000173918","C1q and tumor necrosis factor related protein 1","17","79022814-79049788","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB025429","Approved",NA,NA,NA,"Renal cancer:9.09e-9 (unfavourable), Cervical cancer:2.95e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"adipose tissue: 155.0","seminal vesicle: 65.5","Cell line enhanced",NA,"ASC diff: 229.1;BJ hTERT+: 66.0;HHSteC: 105.8;U-87 MG: 78.1"
"C1QTNF3",143,"H3","IOH59781",741,"0",NA,"C1q and tumor necrosis factor related protein 3 (C1QTNF3), transcript variant 1, mRNA.","NM_030945.2","NP_112207.1",114899,"Hs.171929","2310005P21Rik, Corcs, Cors, Cors-26, CTRP3","ENSG00000082196","C1q and tumor necrosis factor related protein 3","5","34019448-34043832","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA064996, HPA066011","Uncertain",NA,"Approved","Golgi apparatus","Renal cancer:6.29e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"esophagus: 38.8","smooth muscle: 33.0","Cell line enriched",195,"U-266/84: 563.8"
"C1QTNF7",33,"D2","IOH10940",870,"0",NA,"C1q and tumor necrosis factor related protein 7 (C1QTNF7), transcript variant 3, mRNA.","NM_031911.4","NP_114117.1",114905,"Hs.153714","CTRP7","ENSG00000163145","C1q and tumor necrosis factor related protein 7","4","15339818-15446166","Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB007055, HPA051797, HPA055392","Uncertain",NA,"Approved","Vesicles",NA,"Mixed","Mixed",NA,NA,"cervix, uterine: 36.4","Cell line enhanced",NA,"ASC diff: 3.0;ASC TERT1: 2.1;HSkMC: 1.2"
"C1QTNF9",58,"H3","IOH26200",1002,"0",NA,"C1q and tumor necrosis factor related protein 9, mRNA (cDNA clone MGC:48915 IMAGE:5227612), complete cds","BC040438.1","AAH40438.1",338872,"Hs.362854","AQL1, C1QTNF9A, CTRP9, MGC48915","ENSG00000240654","C1q and tumor necrosis factor related protein 9","13","24307166-24322535","Predicted secreted proteins","Evidence at protein level","HPA056632","Uncertain",NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"skeletal muscle: 2.9","adipose tissue: 2.1","Not detected",NA,NA
"C1R",78,"B4","IOH26787",2118,"0",NA,"complement component 1, r subcomponent (C1R), mRNA.","NM_001733.4","NP_001724.3",715,"Hs.524224",NA,"ENSG00000159403","Complement C1r","12","7080209-7092607","Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA001251, HPA001551","Uncertain",NA,"Uncertain","Nucleoplasm<br>Cytosol","Renal cancer:1.94e-14 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"liver: 1226.4","Cell line enhanced",NA,"ASC diff: 1273.8;ASC TERT1: 658.4;BJ hTERT+: 685.9;BJ hTERT+ SV40 Large T+ RasG12V: 496.0;HSkMC: 797.4"
"C1S",117,"F5","IOH29122",2067,"0",NA,"complement component 1, s subcomponent (C1S), transcript variant 2, mRNA.","NM_001734.3","NP_001725.1",716,"Hs.458355",NA,"ENSG00000182326","Complement C1s","12","6988259-7071032","Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB016722, HPA018852","Supported",NA,"Approved","Nucleus<br>Cytosol","Renal cancer:7.44e-15 (unfavourable), Liver cancer:7.73e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"liver: 1326.7","Cell line enhanced",NA,"ASC diff: 521.6;ASC TERT1: 703.0;BJ hTERT+: 271.2;HSkMC: 390.5"
"C2",30,"G8","IOH22649",987,"0",NA,"complement component 2, mRNA (cDNA clone IMAGE:5183067), complete cds.","BC029781.1","AAH29781.1",717,"Hs.69771",NA,"ENSG00000166278","Complement C2","6","31897785-31945672","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB016775","Supported",NA,NA,NA,"Renal cancer:2.64e-7 (unfavourable)","Tissue enriched","Tissue enhanced",NA,"liver: 86.3;lung: 42.6","placenta: 21.9","Group enriched",5,"Hep G2: 30.0;Karpas-707: 94.7"
"C2",100,"H10","IOH26384",2259,"0",NA,"complement component 2 (C2), transcript variant 1, mRNA.","NM_000063.4","NP_000054.2",717,"Hs.69771",NA,"ENSG00000166278","Complement C2","6","31897785-31945672","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB016775","Supported",NA,NA,NA,"Renal cancer:2.64e-7 (unfavourable)","Tissue enriched","Tissue enhanced",NA,"liver: 86.3;lung: 42.6","placenta: 21.9","Group enriched",5,"Hep G2: 30.0;Karpas-707: 94.7"
"C21orf33",14,"B1","IOH5054",807,"0",NA,"chromosome 21 open reading frame 33, mRNA (cDNA clone MGC:3859 IMAGE:2822714), complete cds","BC003587.1","AAH03587.1",8209,"Hs.413482","D21S2048E, ES1, GT335, HES1, KNP-I, KNP-Ia, KNPH, KNPI","ENSG00000160221","Chromosome 21 open reading frame 33","21","44133605-44145723","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA018517","Supported",NA,"Approved","Centrosome<br>Mitochondria",NA,"Mixed","Expressed in all",NA,NA,"kidney: 35.4","Cell line enhanced",NA,"Daudi: 101.9"
"C2orf40",38,"D9","IOH10634",447,"0",NA,"chromosome 2 open reading frame 40 (C2orf40), mRNA.","NM_032411.2","NP_115787.1",84417,"Hs.43125","augurin, ECRG4","ENSG00000119147","Chromosome 2 open reading frame 40","2","106063246-106078159","Predicted intracellular proteins, Predicted secreted proteins","Evidence at transcript level","HPA008546","Uncertain",NA,NA,NA,"Breast cancer:4.58e-4 (favourable)","Tissue enriched","Tissue enhanced",NA,"seminal vesicle: 116.4;thyroid gland: 128.1","prostate: 61.6","Not detected",NA,NA
"C2orf66",138,"D9","IOH58653",354,"0",NA,"chromosome 2 open reading frame 66 (C2orf66), mRNA.","NM_213608.1","NP_998773.1",401027,"Hs.372069","UNQ6411","ENSG00000187944","Chromosome 2 open reading frame 66","2","196805002-196810276","Predicted secreted proteins","Evidence at transcript level","HPA020869","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"adipose tissue: 2.8;adrenal gland: 1.7;testis: 1.7","skin: 1.1","Cell line enhanced",NA,"HEL: 4.0;RT4: 1.3;TIME: 1.5"
"C2orf69",63,"E11","IOH22421",810,"0",NA,"chromosome 2 open reading frame 69, mRNA (cDNA clone MGC:33409 IMAGE:4825616), complete cds","BC036456.1","AAH36456.1",205327,"Hs.471040","FLJ38973","ENSG00000178074","Chromosome 2 open reading frame 69","2","199911256-199955935","Predicted secreted proteins","Evidence at protein level","HPA045225","Uncertain",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"testis: 26.6","Expressed in all",NA,NA
"C3orf33",98,"H2","IOH39949",885,"0",NA,"chromosome 3 open reading frame 33, mRNA (cDNA clone MGC:70365 IMAGE:6008321), complete cds","BC064898.1","AAH64898.1",285315,"Hs.350846","AC3-33, FLJ31139","ENSG00000174928","Chromosome 3 open reading frame 33","3","155762617-155806351","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA037663","Uncertain",NA,"Approved","Nucleoplasm<br>Cytosol","Renal cancer:6.48e-7 (favourable)","Expressed in all","Mixed",NA,NA,"thyroid gland: 14.4","Mixed",NA,NA
"C4BPB",89,"C11","IOH7320",756,"0",NA,"complement component 4 binding protein, beta (C4BPB), transcript variant 2, mRNA.","NM_001017364.1","NP_001017364.1",725,"Hs.99886","C4BP","ENSG00000123843","Complement component 4 binding protein beta","1","207088842-207099993","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA051620","Approved",NA,NA,NA,NA,"Tissue enriched","Group enriched",16,"liver: 241.3;ovary: 52.0","placenta: 8.9","Group enriched",15,"CACO-2: 94.2;HeLa: 31.3;Hep G2: 101.7"
"C4BPB",143,"G4","IOH59815",759,"0",NA,"complement component 4 binding protein, beta (C4BPB), transcript variant 5, mRNA.","NM_001017367.1","NP_001017367.1",725,"Hs.99886","C4BP","ENSG00000123843","Complement component 4 binding protein beta","1","207088842-207099993","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA051620","Approved",NA,NA,NA,NA,"Tissue enriched","Group enriched",16,"liver: 241.3;ovary: 52.0","placenta: 8.9","Group enriched",15,"CACO-2: 94.2;HeLa: 31.3;Hep G2: 101.7"
"C4orf26",107,"F12","IOH44607",393,"0",NA,"chromosome 4 open reading frame 26 (C4orf26), mRNA.","NM_178497.2","NP_848592.1",152816,"Hs.24510","AI2A4, FLJ23657","ENSG00000174792","Chromosome 4 open reading frame 26","4","75556048-75565885","Disease related genes, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",12,"placenta: 5.9","cerebral cortex: 0.5","Cell line enriched",7,"HDLM-2: 40.8"
"C5orf46",33,"A11","IOH12084",219,"0",NA,"chromosome 5 open reading frame 46, mRNA (cDNA clone MGC:23985 IMAGE:3931172), complete cds","BC021680.1","AAH21680.1",389336,"Hs.660038","MGC23985, SSSP1","ENSG00000178776","Chromosome 5 open reading frame 46","5","147880726-147906538","Predicted secreted proteins","Evidence at transcript level","HPA058999",NA,NA,"Approved","Nuclear speckles<br>Mitochondria","Renal cancer:1.75e-9 (unfavourable), Cervical cancer:3.98e-4 (unfavourable)","Tissue enhanced","Group enriched",8,"breast: 17.6;salivary gland: 77.2;skin: 62.4;testis: 19.9","heart muscle: 5.8","Cell line enhanced",NA,"PC-3: 83.2;SiHa: 21.5;U-2 OS: 59.9;U-251 MG: 19.3"
"C6orf58",120,"B12","IOH46114",993,"0",NA,"chromosome 6 open reading frame 58 (C6orf58), mRNA.","NM_001010905.1","NP_001010905.1",352999,"Hs.226268","LEG1","ENSG00000184530","Chromosome 6 open reading frame 58","6","127519455-127591817","Predicted secreted proteins","Evidence at protein level","HPA036263, HPA041449","Enhanced",NA,NA,NA,NA,"Group enriched","Group enriched",21,"duodenum: 603.5;salivary gland: 163.4;stomach: 314.9","esophagus: 17.1","Cell line enhanced",NA,"RPMI-8226: 1.8;WM-115: 1.8"
"C7",94,"B3","IOH40503",2532,"0",NA,"complement component 7 (C7), mRNA.","NM_000587.2","NP_000578.2",730,"Hs.78065",NA,"ENSG00000112936","Complement C7","5","40909252-40982939","Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA001465","Approved",NA,NA,NA,"Liver cancer:5.89e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"adrenal gland: 1115.3","placenta: 718.4","Group enriched",11,"ASC diff: 115.0;HHSteC: 185.4;HSkMC: 221.4;SH-SY5Y: 223.2"
"C8A",108,"E5","IOH44369",1755,"0",NA,"complement component 8, alpha polypeptide (C8A), mRNA.","NM_000562.2","NP_000553.1",731,"Hs.93210",NA,"ENSG00000157131","Complement C8 alpha chain","1","56854806-56918221","Disease related genes, Plasma proteins, Potential drug targets, Predicted secreted proteins, Transporters","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enriched","Tissue enriched",63,"liver: 328.8","gallbladder: 5.2","Not detected",NA,NA
"C8G",108,"D4","IOH44341",609,"0",NA,"complement component 8, gamma polypeptide, mRNA (cDNA clone MGC:142184 IMAGE:8322676), complete cds","BC113624.1","AAI13625.1",733,"Hs.1285",NA,"ENSG00000176919","Complement C8 gamma chain","9","136945246-136946974","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA046269","Approved",NA,"Uncertain","Endoplasmic reticulum","Colorectal cancer:2.99e-4 (unfavourable)","Tissue enriched","Group enriched",6,"duodenum: 49.8;liver: 106.5;small intestine: 34.5","gallbladder: 9.8","Cell line enriched",16,"HMC-1: 139.2"
"C9",7,"G9","IOH12924",1680,"0",NA,"complement component 9 (C9), mRNA.","NM_001737.3","NP_001728.1",735,"Hs.654443",NA,"ENSG00000113600","Complement C9","5","39284262-39424868","Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB002151, HPA029577","Uncertain",NA,"Uncertain","Plasma membrane<br>Cytosol",NA,"Tissue enriched","Tissue enriched",120,"liver: 728.9","epididymis: 6.0","Cell line enhanced",NA,"U-698: 1.4"
"C9orf47",141,"E8","IOH59697",609,"0",NA,"chromosome 9 open reading frame 47 (C9orf47), transcript variant 1, mRNA.","NM_001001938.3","NP_001001938.1",286223,"Hs.585118","bA791O21.3, C9orf108, FLJ37523","ENSG00000186354","Chromosome 9 open reading frame 47","9","88990863-88996140","Predicted secreted proteins","Evidence at transcript level","CAB009902","Approved",NA,NA,NA,NA,"Not detected","Mixed",NA,NA,"adrenal gland: 2.1","Cell line enhanced",NA,"AF22: 2.7;HeLa: 1.6"
"CA10",69,"H11","IOH21439",987,"0",NA,"carbonic anhydrase X (CA10), transcript variant 2, mRNA.","NM_020178.4","NP_064563.1",56934,"Hs.463466","CA-RPX, CARPX, HUCEP-15","ENSG00000154975","Carbonic anhydrase 10","17","51630313-52160017","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA054825, HPA057837","Supported",NA,"Approved","Vesicles",NA,"Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 56.7;cervix, uterine: 32.1","testis: 10.7","Cell line enhanced",NA,"RT4: 1.6;SCLC-21H: 7.3"
"CA11",91,"F3","IOH5293",987,"0",NA,"carbonic anhydrase XI (CA11), mRNA.","NM_001217.3","NP_001208.2",770,"Hs.428446","CARP2, CARPX1","ENSG00000063180","Carbonic anhydrase 11","19","48637942-48646312","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA041778",NA,NA,"Approved","Vesicles<br>Microtubules","Lung cancer:2.11e-5 (favourable), Pancreatic cancer:8.60e-5 (favourable), Cervical cancer:4.33e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 244.1","ovary: 49.5","Cell line enhanced",NA,"AN3-CA: 39.9;SCLC-21H: 35.8"
"CA6",141,"A5","IOH59066",927,"0",NA,"carbonic anhydrase VI (CA6), mRNA.","NM_001215.2","NP_001206.2",765,"Hs.100322",NA,"ENSG00000131686","Carbonic anhydrase 6","1","8945867-8975092","Enzymes, Predicted secreted proteins","Evidence at protein level","HPA028550, HPA028692","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enriched",154,"salivary gland: 3805.4","breast: 24.7","Mixed",NA,NA
"CA6",37,"C3","IOH22153",540,"0",NA,"carbonic anhydrase VI, mRNA (cDNA clone MGC:21256 IMAGE:4746599), complete cds","BC034350.1","AAH34350.1",765,"Hs.100322",NA,"ENSG00000131686","Carbonic anhydrase 6","1","8945867-8975092","Enzymes, Predicted secreted proteins","Evidence at protein level","HPA028550, HPA028692","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enriched",154,"salivary gland: 3805.4","breast: 24.7","Mixed",NA,NA
"CA9",32,"F10","IOH14740",1380,"NP_001207.1","AAH14950.1","carbonic anhydrase IX, mRNA (cDNA clone MGC:22967 IMAGE:4865275), complete cds","BC014950.1","AAH14950.1",768,"Hs.63287","CAIX, MN","ENSG00000107159","Carbonic anhydrase 9","9","35673856-35681159","Enzymes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB005100, CAB017107, HPA055207","Enhanced",NA,"Enhanced","Plasma membrane<br>Cytosol","Renal cancer:2.22e-7 (unfavourable), Liver cancer:1.71e-5 (unfavourable), Testis cancer:9.50e-4 (favourable)","Mixed","Tissue enhanced",NA,"gallbladder: 36.0;stomach: 93.6","small intestine: 14.5","Group enriched",11,"A-431: 152.1;HDLM-2: 84.3;U-87 MG: 337.9"
"CADM3",42,"B5","IOH21870",1197,"NP_067012.1","NP_001120645.1","cell adhesion molecule 3 (CADM3), transcript variant 2, mRNA.","NM_001127173.1","NP_001120645.1",57863,"Hs.365689","BIgR, FLJ10698, IGSF4B, Necl-1, NECL1, SynCAM3, TSLL1","ENSG00000162706","Cell adhesion molecule 3","1","159171609-159203313","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA002981, CAB025746","Enhanced",NA,NA,NA,"Renal cancer:1.03e-5 (unfavourable), Urothelial cancer:5.75e-4 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 278.5;placenta: 113.9","cervix, uterine: 44.7","Group enriched",7,"HHSteC: 54.6;HSkMC: 158.9;hTERT-HME1: 91.2;U-2 OS: 34.5;WM-115: 59.5"
"CALCA",93,"C11","IOH40367",426,"0",NA,"calcitonin-related polypeptide alpha (CALCA), transcript variant 1, mRNA.","NM_001741.2","NP_001732.1",796,"Hs.37058","CALC1","ENSG00000110680","Calcitonin related polypeptide alpha","11","14966668-14972354","Cancer-related genes, Plasma proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA059886",NA,"Supported",NA,NA,"Endometrial cancer:4.49e-5 (unfavourable)","Tissue enriched","Group enriched",78,"parathyroid gland: 849.6;thyroid gland: 183.4","kidney: 6.6","Not detected",NA,NA
"CALCR",99,"D6","IOH40322",1425,"NP_001733.1","NP_001733.1","calcitonin receptor (CALCR), mRNA.","NM_001742.2","NP_001733.1",799,"Hs.489127","CTR","ENSG00000004948","Calcitonin receptor","7","93424487-93574730","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA028962, HPA061428","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enhanced",NA,"kidney: 2.1;testis: 1.4","placenta: 1.0","Cell line enhanced",NA,"RPTEC TERT1: 1.5;T-47d: 3.6"
"CALCRL",101,"A5","IOH36648",1386,"NP_005786.1","NP_005786.1","calcitonin receptor-like (CALCRL), mRNA.","NM_005795.4","NP_005786.1",10203,"Hs.470882","CGRPR, CRLR","ENSG00000064989","Calcitonin receptor like receptor","2","187343129-187448460","G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA008070, HPA046515","Uncertain",NA,"Supported","Plasma membrane",NA,"Expressed in all","Tissue enhanced",NA,"lung: 114.3","adipose tissue: 76.8","Cell line enhanced",NA,"HUVEC TERT2: 145.5;RPTEC TERT1: 30.7;TIME: 20.7"
"CALR",21,"G5","IOH6741",1254,"0",NA,"calreticulin (CALR), mRNA.","NM_004343.3","NP_004334.1",811,"Hs.515162","cC1qR, CRT, FLJ26680, RO, SSA","ENSG00000179218","Calreticulin","19","12938578-12944489","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB001513, HPA002242, CAB019952","Enhanced",NA,NA,NA,"Renal cancer:1.11e-16 (unfavourable), Ovarian cancer:1.10e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 1652.0","Expressed in all",NA,NA
"CALR3",92,"G10","IOH10728",1155,"0",NA,"calreticulin 3, mRNA (cDNA clone MGC:26577 IMAGE:4822010), complete cds","BC014595.2","AAH14595.1",125972,"Hs.304020","CRT2, CT93, FLJ25355, MGC26577","ENSG00000269058","Calreticulin 3","19","16479057-16496192","Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB025749, HPA043355, HPA048460","Enhanced",NA,NA,NA,NA,"Not detected","Tissue enriched",93,"testis: 98.8","epididymis: 1.0","Not detected",NA,NA
"CALU",76,"F12","IOH14786",948,"0",NA,"calumenin (CALU), transcript variant 1, mRNA.","NM_001219.3","NP_001210.1",813,"Hs.7753",NA,"ENSG00000128595","Calumenin","7","128739292-128771807","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA006018","Supported",NA,"Supported","Endoplasmic reticulum","Renal cancer:1.30e-11 (unfavourable), Urothelial cancer:4.60e-5 (unfavourable), Liver cancer:1.80e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"smooth muscle: 444.9","Expressed in all",NA,NA
"CANX",78,"E11","IOH4977",1779,"NP_001737.1","NP_001737.1","calnexin (CANX), transcript variant 1, mRNA.","NM_001746.3","NP_001737.1",821,"Hs.699155","CNX, IP90, P90","ENSG00000127022","Calnexin","5","179678628-179730925","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB004738, HPA009433, HPA009696","Enhanced",NA,"Enhanced","Endoplasmic reticulum","Colorectal cancer:1.38e-4 (favourable), Thyroid cancer:3.17e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 294.4","Expressed in all",NA,NA
"CARTPT",41,"F6","IOH22771",351,"0",NA,"CART prepropeptide (CARTPT), mRNA.","NM_004291.2","NP_004282.1",9607,"Hs.1707","CART","ENSG00000164326","CART prepropeptide","5","71719163-71721048","FDA approved drug targets, Predicted secreted proteins","Evidence at protein level","CAB025515, HPA046278","Enhanced",NA,NA,NA,"Stomach cancer:4.36e-4 (unfavourable)","Tissue enriched","Tissue enriched",8,"adrenal gland: 132.5","cerebral cortex: 17.4","Not detected",NA,NA
"CASQ1",135,"B2","IOH57242",1173,"0",NA,"calsequestrin 1 (fast-twitch, skeletal muscle), mRNA (cDNA clone MGC:22462 IMAGE:4338020), complete cds","BC022289.1","AAH22289.1",844,"Hs.632476","CASQ, PDIB1","ENSG00000143318","Calsequestrin 1","1","160190556-160201886","Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA007845, CAB015170, HPA026823","Enhanced",NA,"Uncertain","Nucleoplasm<br>Mitochondria","Urothelial cancer:8.93e-5 (favourable)","Mixed","Tissue enriched",33,"skeletal muscle: 1514.0","esophagus: 45.3","Group enriched",9,"BEWO: 18.6;HDLM-2: 35.6;RT4: 53.5"
"CASQ2",42,"F7","IOH12278",1200,"0",NA,"calsequestrin 2 (cardiac muscle) (CASQ2), mRNA.","NM_001232.3","NP_001223.2",845,"Hs.57975","PDIB2","ENSG00000118729","Calsequestrin 2","1","115700007-115768781","Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA027285, HPA055298","Enhanced",NA,NA,NA,"Urothelial cancer:2.25e-5 (unfavourable), Head and neck cancer:2.30e-4 (unfavourable)","Mixed","Tissue enriched",11,"heart muscle: 679.4","skeletal muscle: 62.3","Cell line enriched",14,"HSkMC: 9.6"
"CBLN4",126,"B2","IOH40259",606,"0",NA,"cerebellin 4 precursor (CBLN4), mRNA.","NM_080617.4","NP_542184.1",140689,"Hs.126141","CBLNL1, dJ885A10.1","ENSG00000054803","Cerebellin 4 precursor","20","55997440-56005472","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA051496, HPA074497",NA,"Supported","Approved","Midbody ring",NA,"Mixed","Tissue enhanced",NA,"adrenal gland: 24.5;cerebral cortex: 15.6;epididymis: 11.2","fallopian tube: 6.8","Cell line enriched",51,"SH-SY5Y: 10.2"
"CCBE1",71,"E11","IOH26386",648,"0",NA,"collagen and calcium binding EGF domains 1, mRNA (cDNA clone MGC:50861 IMAGE:5766933), complete cds","BC046645.1","AAH46645.1",147372,"Hs.34333","FLJ30681, KIAA1983","ENSG00000183287","Collagen and calcium binding EGF domains 1","18","59430940-59697380","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA041361, HPA041374","Uncertain",NA,"Enhanced","Plasma membrane<br>Cytosol",NA,"Mixed","Tissue enhanced",NA,"ovary: 40.6","cervix, uterine: 16.0","Cell line enhanced",NA,"BJ hTERT+ SV40 Large T+ RasG12V: 91.8;HBF TERT88: 109.2;hTERT-HME1: 117.8;LHCN-M2: 146.3"
"CCDC112",51,"F3","IOH21586",1341,"0",NA,"coiled-coil domain containing 112, mRNA (cDNA clone MGC:39633 IMAGE:5265792), complete cds","BC031242.1","AAH31242.1",153733,"Hs.436121","MGC39633","ENSG00000164221","Coiled-coil domain containing 112","5","115267188-115296831","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA045120, HPA050621","Uncertain",NA,"Supported","Nucleoplasm<br>Plasma membrane<br>Cytosol","Renal cancer:1.51e-6 (unfavourable)","Expressed in all","Tissue enriched",6,"testis: 73.7","cerebral cortex: 13.1","Expressed in all",NA,NA
"CCDC134",9,"B11","IOH10944",690,"0",NA,"coiled-coil domain containing 134 (CCDC134), mRNA.","NM_024821.2","NP_079097.1",79879,"Hs.474991","FLJ22349","ENSG00000100147","Coiled-coil domain containing 134","22","41800679-41826299","Predicted secreted proteins","Evidence at protein level","HPA003936","Approved",NA,NA,NA,"Liver cancer:7.42e-7 (unfavourable), Renal cancer:1.36e-5 (favourable), Endometrial cancer:4.09e-4 (favourable)","Expressed in all","Mixed",NA,NA,"parathyroid gland: 14.1","Mixed",NA,NA
"CCDC149",96,"G6","IOH40060",261,"0",NA,"coiled-coil domain containing 149, mRNA (cDNA clone IMAGE:4792861), complete cds.","BC067735.1","AAH67735.1",91050,"Hs.106432","DKFZp761B107","ENSG00000181982","Coiled-coil domain containing 149","4","24806117-24980204","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA044158, HPA047913","Uncertain",NA,"Approved","Nucleoli","Endometrial cancer:6.63e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 24.1","Cell line enhanced",NA,"U-87 MG: 30.1"
"CCDC80",128,"A9","IOH26312",258,"0",NA,"coiled-coil domain containing 80, mRNA (cDNA clone IMAGE:5164985), complete cds.","BC042105.1","AAH42105.1",151887,"Hs.477128","DRO1, SSG1, URB","ENSG00000091986","Coiled-coil domain containing 80","3","112596794-112649530","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA002266","Approved",NA,NA,NA,"Renal cancer:2.86e-5 (unfavourable), Urothelial cancer:1.26e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"smooth muscle: 526.0","Cell line enhanced",NA,"fHDF/TERT166: 992.9"
"CCK",28,"A4","IOH6245",348,"0",NA,"cholecystokinin (CCK), mRNA.","NM_000729.3","NP_000720.1",885,"Hs.458426",NA,"ENSG00000187094","Cholecystokinin","3","42257825-42266207","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA045039, HPA069515","Enhanced","Supported",NA,NA,NA,"Group enriched","Group enriched",5,"cerebral cortex: 133.7;duodenum: 116.2;prostate: 31.6","small intestine: 17.7","Group enriched",6,"CAPAN-2: 8.5;RPTEC TERT1: 18.9"
"CCL1",151,"F1","IOH34715",291,"0",NA,"chemokine (C-C motif) ligand 1 (CCL1), mRNA.","NM_002981.1","NP_002972.1",6346,"Hs.72918","I-309, P500, SCYA1, SISe, TCA3","ENSG00000108702","C-C motif chemokine ligand 1","17","34360328-34363231","Predicted secreted proteins","Evidence at protein level","HPA049861","Uncertain",NA,NA,NA,NA,"Not detected","Tissue enriched",5,"rectum: 2.6","cerebral cortex,testis: 0.4","Cell line enriched",50,"HMC-1: 622.2"
"CCL11",39,"C4","IOH13029",294,"0",NA,"chemokine (C-C motif) ligand 11 (CCL11), mRNA.","NM_002986.2","NP_002977.1",6356,"Hs.54460","eotaxin, MGC22554, SCYA11","ENSG00000172156","C-C motif chemokine ligand 11","17","34285668-34288334","Cancer-related genes, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Head and neck cancer:1.99e-4 (favourable), Colorectal cancer:8.70e-4 (favourable)","Mixed","Tissue enhanced",NA,"appendix: 39.3;small intestine: 37.3","duodenum: 30.8","Cell line enriched",18,"BJ hTERT+: 7.2"
"CCL13",73,"H9","IOH3315",297,"0",NA,"chemokine (C-C motif) ligand 13 (CCL13), mRNA.","NM_005408.2","NP_005399.1",6357,"Hs.414629","CKb10, MCP-4, MGC17134, NCC-1, SCYA13, SCYL1","ENSG00000181374","C-C motif chemokine ligand 13","17","34356452-34358610","Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Mixed","Mixed",NA,NA,"lung: 31.6","Cell line enhanced",NA,"ASC diff: 1.2;BJ hTERT+: 1.3;BJ hTERT+ SV40 Large T+ RasG12V: 1.0;HMC-1: 1.1;HSkMC: 1.1"
"CCL14",58,"G8","IOH26595",282,"0",NA,"chemokine (C-C motif) ligand 14 (CCL14), transcript variant 3, mRNA.","NM_032963.3","NP_116739.1",6358,"Hs.272493","CKb1, HCC-1, HCC-3, MCIF, NCC-2, SCYA14, SCYL2","ENSG00000276409","C-C motif chemokine ligand 14","17","35983291-35987004","Cancer-related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB004423, HPA030268","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"spleen: 271.8","adipose tissue: 123.7","Cell line enriched",53,"HUVEC TERT2: 46.6"
"CCL15",109,"A4","IOH41002",342,"0",NA,"chemokine (C-C motif) ligand 15 (CCL15), mRNA.","NM_032965.3","NP_116741.1",6359,"Hs.272493","HCC-2, HMRP-2B, Lkn-1, MIP-1d, MIP-5, NCC-3, SCYA15, SCYL3","ENSG00000275718","C-C motif chemokine ligand 15","17","35996440-36002038","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA058608",NA,NA,"Approved","Golgi apparatus<br>Vesicles","Urothelial cancer:3.02e-4 (favourable)","Tissue enhanced","Tissue enhanced",NA,"duodenum: 21.5;rectum: 30.6;small intestine: 26.6","colon: 18.9","Cell line enriched",12,"Hep G2: 22.7"
"CCL17",77,"C5","IOH39735",285,"0",NA,"chemokine (C-C motif) ligand 17 (CCL17), mRNA.","NM_002987.2","NP_002978.1",6361,"Hs.546294","ABCD-2, SCYA17, TARC","ENSG00000102970","C-C motif chemokine ligand 17","16","57404767-57416062","Predicted secreted proteins","Evidence at protein level","CAB002583","Approved",NA,NA,NA,"Cervical cancer:1.91e-5 (favourable), Urothelial cancer:5.80e-4 (favourable)","Mixed","Tissue enhanced",NA,"appendix: 11.1;lymph node: 9.9","tonsil: 5.4","Cell line enriched",725,"HDLM-2: 2231.6"
"CCL18",139,"F8","IOH58934",270,"0",NA,"chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated) (CCL18), mRNA.","NM_002988.2","NP_002979.1",6362,"Hs.143961","AMAC-1, CKb7, DC-CK1, DCCK1, MIP-4, PARC, SCYA18","ENSG00000275385","C-C motif chemokine ligand 18","17","36064280-36072032","Cancer-related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Expressed in all","Tissue enhanced",NA,"adipose tissue: 20.9;lung: 13.0;tonsil: 10.5","lymph node: 6.2","Not detected",NA,NA
"CCL19",31,"F12","IOH11962",297,"0",NA,"chemokine (C-C motif) ligand 19 (CCL19), mRNA.","NM_006274.2","NP_006265.1",6363,"Hs.50002","CKb11, ELC, exodus-3, MIP-3b, SCYA19","ENSG00000172724","C-C motif chemokine ligand 19","9","34689567-34691277","Cancer-related genes, Predicted secreted proteins","Evidence at protein level","HPA067758","Enhanced",NA,NA,NA,"Renal cancer:8.63e-7 (unfavourable), Cervical cancer:9.91e-6 (favourable), Breast cancer:2.88e-5 (favourable)","Expressed in all","Group enriched",5,"adipose tissue: 173.8;appendix: 771.8;lymph node: 703.2;tonsil: 556.0","gallbladder: 107.9","Cell line enhanced",NA,"HDLM-2: 2.9;TIME: 1.2"
"CCL2",1,"B9","IOH9954",300,"0",NA,"chemokine (C-C motif) ligand 2 (CCL2), mRNA.","NM_002982.3","NP_002973.1",6347,"Hs.303649","GDCF-2, HC11, MCAF, MCP-1, MCP1, MGC9434, SCYA2, SMC-CF","ENSG00000108691","C-C motif chemokine ligand 2","17","34255218-34257203","Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB013676, HPA019163","Approved",NA,"Approved","Golgi apparatus<br>Vesicles","Renal cancer:4.51e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"gallbladder: 411.3","Group enriched",5,"BJ hTERT+: 1539.3;BJ hTERT+ SV40 Large T+ RasG12V: 503.9;HMC-1: 2137.8"
"CCL20",125,"C9","IOH50190",291,"0",NA,"chemokine (C-C motif) ligand 20 (CCL20), transcript variant 1, mRNA.","NM_004591.2","NP_004582.1",6364,"Hs.75498","CKb4, exodus-1, LARC, MIP-3a, SCYA20, ST38","ENSG00000115009","C-C motif chemokine ligand 20","2","227813842-227817564","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:9.19e-8 (unfavourable), Pancreatic cancer:2.73e-4 (unfavourable), Liver cancer:9.29e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"gallbladder: 269.7;tonsil: 155.2","urinary bladder: 83.4","Cell line enhanced",NA,"Hep G2: 23.9;NB-4: 12.7;RT4: 12.0"
"CCL20",7,"H7","IOH12246",288,"0",NA,"chemokine (C-C motif) ligand 20 (CCL20), transcript variant 2, mRNA.","NM_001130046.1","NP_001123518.1",6364,"Hs.75498","CKb4, exodus-1, LARC, MIP-3a, SCYA20, ST38","ENSG00000115009","C-C motif chemokine ligand 20","2","227813842-227817564","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:9.19e-8 (unfavourable), Pancreatic cancer:2.73e-4 (unfavourable), Liver cancer:9.29e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"gallbladder: 269.7;tonsil: 155.2","urinary bladder: 83.4","Cell line enhanced",NA,"Hep G2: 23.9;NB-4: 12.7;RT4: 12.0"
"CCL21",38,"F6","IOH11392",405,"0",NA,"chemokine (C-C motif) ligand 21 (CCL21), mRNA.","NM_002989.2","NP_002980.1",6366,"Hs.57907","6Ckine, CKb9, ECL, exodus-2, SCYA21, SLC, TCA4","ENSG00000137077","C-C motif chemokine ligand 21","9","34709005-34710124","Cancer-related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB005067, HPA051210","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"lymph node: 3155.9","tonsil: 946.7","Cell line enhanced",NA,"K-562: 1.0"
"CCL22",125,"D8","IOH50179",282,"0",NA,"chemokine (C-C motif) ligand 22 (CCL22), mRNA.","NM_002990.3","NP_002981.2",6367,"Hs.534347","A-152E5.1, ABCD-1, DC/B-CK, MDC, MGC34554, SCYA22, STCP-1","ENSG00000102962","C-C motif chemokine ligand 22","16","57358772-57366190","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Endometrial cancer:2.23e-6 (favourable), Head and neck cancer:9.17e-5 (favourable), Colorectal cancer:2.98e-4 (favourable)","Mixed","Tissue enhanced",NA,"appendix: 18.6;tonsil: 13.5","skin: 7.9","Cell line enriched",21,"HDLM-2: 45.9"
"CCL22",33,"C5","IOH11389",282,"0",NA,"chemokine (C-C motif) ligand 22, mRNA (cDNA clone MGC:34554 IMAGE:5220453), complete cds","BC027952.1","AAH27952.1",6367,"Hs.534347","A-152E5.1, ABCD-1, DC/B-CK, MDC, MGC34554, SCYA22, STCP-1","ENSG00000102962","C-C motif chemokine ligand 22","16","57358772-57366190","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Endometrial cancer:2.23e-6 (favourable), Head and neck cancer:9.17e-5 (favourable), Colorectal cancer:2.98e-4 (favourable)","Mixed","Tissue enhanced",NA,"appendix: 18.6;tonsil: 13.5","skin: 7.9","Cell line enriched",21,"HDLM-2: 45.9"
"CCL23",133,"E2","IOH46195",414,"0",NA,"chemokine (C-C motif) ligand 23 (CCL23), transcript variant CKbeta8-1, mRNA.","NM_005064.3","NP_005055.2",6368,"Hs.169191","Ckb-8, CKb8, MIP-3, MPIF-1, SCYA23","ENSG00000274736","C-C motif chemokine ligand 23","17","36013056-36017968","Cancer-related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA042015","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"smooth muscle: 15.4","lung: 11.1","Group enriched",5,"HEL: 15.9;THP-1: 25.4;U-937: 5.1"
"CCL23",149,"B3","IOH62015",363,"0",NA,"chemokine (C-C motif) ligand 23, mRNA (cDNA clone MGC:121005 IMAGE:7939815), complete cds","BC093970.1","AAH93970.1",6368,"Hs.169191","Ckb-8, CKb8, MIP-3, MPIF-1, SCYA23","ENSG00000274736","C-C motif chemokine ligand 23","17","36013056-36017968","Cancer-related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA042015","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"smooth muscle: 15.4","lung: 11.1","Group enriched",5,"HEL: 15.9;THP-1: 25.4;U-937: 5.1"
"CCL24",110,"G11","IOH34716",360,"0",NA,"chemokine (C-C motif) ligand 24 (CCL24), mRNA.","NM_002991.2","NP_002982.2",6369,"Hs.247838","Ckb-6, eotaxin-2, MPIF-2, MPIF2, SCYA24","ENSG00000106178","C-C motif chemokine ligand 24","7","75811665-75823356","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Colorectal cancer:5.41e-4 (favourable)","Tissue enhanced","Tissue enhanced",NA,"rectum: 111.7;small intestine: 96.2","urinary bladder: 51.4","Cell line enhanced",NA,"CAPAN-2: 4.8;RH-30: 2.0;U-2 OS: 5.9"
"CCL26",101,"D10","IOH40395",285,"0",NA,"chemokine (C-C motif) ligand 26 (CCL26), mRNA.","NM_006072.4","NP_006063.1",10344,"Hs.131342","eotaxin-3, IMAC, MIP-4a, MIP-4alpha, SCYA26, TSC-1","ENSG00000006606","C-C motif chemokine ligand 26","7","75769533-75789896","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"ovary: 12.0","rectum: 7.6","Cell line enhanced",NA,"hTEC/SVTERT24-B: 15.8;PC-3: 42.0;U-2 OS: 13.1"
"CCL27",110,"F11","IOH34759",339,"0",NA,"chemokine (C-C motif) ligand 27 (CCL27), mRNA.","NM_006664.2","NP_006655.1",10850,"Hs.648124","ALP, CTACK, CTAK, ESkine, ILC, PESKY, SCYA27, skinkine","ENSG00000213927","C-C motif chemokine ligand 27","9","34661880-34664048","Predicted secreted proteins","Evidence at protein level","HPA073848","Enhanced",NA,NA,NA,NA,"Not detected","Tissue enriched",16,"skin: 504.4","breast: 32.2","Cell line enhanced",NA,"AN3-CA: 2.0"
"CCL28",97,"F11","IOH40714",384,"0",NA,"chemokine (C-C motif) ligand 28 (CCL28), mRNA.","NM_148672.2","NP_683513.1",56477,"Hs.656904","CCK1, MEC, SCYA28","ENSG00000151882","C-C motif chemokine ligand 28","5","43376645-43412391","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA077434","Supported",NA,NA,NA,"Pancreatic cancer:1.43e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"breast: 71.1;salivary gland: 126.0","thyroid gland: 38.0","Cell line enhanced",NA,"EFO-21: 12.1;SiHa: 31.8;SK-MEL-30: 12.9;T-47d: 37.8"
"CCL3",70,"C12","IOH29648",279,"0",NA,"chemokine (C-C motif) ligand 3 (CCL3), mRNA.","NM_002983.2","NP_002974.1",6348,"Hs.514107","G0S19-1, LD78ALPHA, MIP-1-alpha, SCYA3","ENSG00000277632","C-C motif chemokine ligand 3","17","36088256-36090169","Cancer-related genes, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Expressed in all","Tissue enhanced",NA,"bone marrow: 50.2","adipose tissue: 12.5","Group enriched",14,"Karpas-707: 110.0;U-266/70: 198.4;U-266/84: 494.6"
"CCL3L3",14,"E5","IOH6518",282,"0",NA,"chemokine (C-C motif) ligand 3-like 3, mRNA (cDNA clone MGC:12815 IMAGE:4308472), complete cds","BC007783.2","AAH07783.1",414062,"Hs.512304","CCL3L1, D17S1718, G0S19-2, LD78BETA, MGC12815, SCYA3L, SCYA3L1","ENSG00000276085","C-C motif chemokine ligand 3 like 3","17","36194869-36196758","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Expressed in all","Group enriched",8,"bone marrow: 7.4;gallbladder: 1.5","lymph node,urinary bladder: 0.5","Group enriched",33,"U-266/70: 37.7;U-266/84: 73.6"
"CCL4",150,"B12","IOH63629",279,"0",NA,"chemokine (C-C motif) ligand 4, mRNA (cDNA clone MGC:126025 IMAGE:40032168), complete cds","BC104226.1","AAI04227.1",6351,"Hs.75703","Act-2, AT744.1, LAG1, MIP-1-beta, SCYA4","ENSG00000275302","C-C motif chemokine ligand 4","17","36103590-36105621","Cancer-related genes, Predicted secreted proteins","Evidence at protein level","CAB007805","Approved",NA,NA,NA,"Endometrial cancer:1.97e-5 (favourable), Renal cancer:1.68e-4 (unfavourable), Colorectal cancer:3.54e-4 (favourable), Melanoma:3.97e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"spleen: 24.8","lymph node: 17.6","Group enriched",22,"Karpas-707: 2.2;U-266/70: 5.1;U-266/84: 2.4"
"CCL5",5,"E5","IOH3320",276,"0",NA,"chemokine (C-C motif) ligand 5 (CCL5), mRNA.","NM_002985.2","NP_002976.2",6352,"Hs.514821","D17S136E, MGC17164, RANTES, SCYA5, SISd, TCP228","ENSG00000271503","C-C motif chemokine ligand 5","17","35871491-35880793","Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:3.61e-7 (unfavourable), Endometrial cancer:1.34e-5 (favourable), Melanoma:2.42e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"spleen: 80.5","lymph node: 68.5","Group enriched",7,"HL-60: 31.8;NB-4: 158.3;THP-1: 39.1;U-937: 41.8"
"CCL7",106,"F7","IOH42935",300,"0",NA,"chemokine (C-C motif) ligand 7 (CCL7), mRNA.","NM_006273.2","NP_006264.2",6354,"Hs.251526","FIC, MARC, MCP-3, MCP3, NC28, SCYA6, SCYA7","ENSG00000108688","C-C motif chemokine ligand 7","17","34270221-34272242","Cancer-related genes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Mixed","Group enriched",8,"appendix: 3.6;bone marrow: 15.2","gallbladder,rectum: 1.1","Cell line enhanced",NA,"BJ hTERT+: 9.3;BJ hTERT+ SV40 Large T+: 2.2;BJ hTERT+ SV40 Large T+ RasG12V: 2.8;HSkMC: 2.4"
"CCL8",70,"E12","IOH29653",300,"0",NA,"chemokine (C-C motif) ligand 8 (CCL8), mRNA.","NM_005623.2","NP_005614.2",6355,"Hs.271387","HC14, MCP-2, SCYA8","ENSG00000108700","C-C motif chemokine ligand 8","17","34319036-34321402","Cancer-related genes, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:1.05e-7 (unfavourable)","Mixed","Mixed",NA,NA,"adipose tissue: 13.1","Cell line enhanced",NA,"EFO-21: 1.3;HSkMC: 1.4"
"CCNB1IP1",27,"C2","IOH3409",834,"0",NA,"cyclin B1 interacting protein 1 (CCNB1IP1), transcript variant 2, mRNA.","NM_182849.1","NP_878269.1",57820,"Hs.107003","C14orf18, HEI10","ENSG00000100814","Cyclin B1 interacting protein 1","14","20311368-20333312","Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:5.18e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"ovary: 120.9","Expressed in all",NA,NA
"CD14",145,"A11","IOH63178",570,"0",NA,"cDNA clone MGC:104455 IMAGE:30352955, complete cds.","BC092455.1","AAH92455.1",929,"Hs.163867",NA,"ENSG00000170458","CD14 molecule","5","140631728-140633701","Cancer-related genes, CD markers, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA001887, HPA002127, CAB033631, CAB072865, CAB072866","Enhanced",NA,"Supported","Vesicles","Renal cancer:6.80e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"appendix: 267.3","Cell line enhanced",NA,"A549: 8.6;CACO-2: 12.0;SiHa: 18.3"
"CD14",11,"A8","IOH10265",1128,"0",NA,"CD14 molecule (CD14), transcript variant 1, mRNA.","NM_000591.2","NP_000582.1",929,"Hs.163867",NA,"ENSG00000170458","CD14 molecule","5","140631728-140633701","Cancer-related genes, CD markers, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA001887, HPA002127, CAB033631, CAB072865, CAB072866","Enhanced",NA,"Supported","Vesicles","Renal cancer:6.80e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"appendix: 267.3","Cell line enhanced",NA,"A549: 8.6;CACO-2: 12.0;SiHa: 18.3"
"CD160",19,"H9","IOH12216",546,"0",NA,"CD160 molecule (CD160), mRNA.","NM_007053.2","NP_008984.1",11126,"Hs.488237","BY55, NK1, NK28","ENSG00000117281","CD160 molecule","1","145719471-145739288","CD markers, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"spleen: 19.6","small intestine: 5.1","Mixed",NA,NA
"CD164",28,"A8","IOH9709",594,"NP_006007.2","NP_006007.2","CD164 molecule, sialomucin (CD164), transcript variant 1, mRNA.","NM_006016.4","NP_006007.2",8763,"Hs.520313","DFNA66, MGC-24, MUC-24","ENSG00000135535","CD164 molecule","6","109366514-109382457","CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA010636","Uncertain",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"thyroid gland: 613.1","Expressed in all",NA,NA
"CD177",30,"H8","IOH22650",1314,"0",NA,"CD177 molecule, mRNA (cDNA clone MGC:34257 IMAGE:5182826), complete cds","BC029167.1","AAH29167.1",57126,"Hs.232165","HNA2A, NB1, PRV1","ENSG00000204936","CD177 molecule","19","43353659-43363172","Predicted secreted proteins","Evidence at protein level","HPA041820, HPA046601","Enhanced",NA,NA,NA,"Cervical cancer:3.66e-4 (favourable)","Tissue enhanced","Group enriched",16,"bone marrow: 193.1;colon: 155.7;prostate: 105.4;rectum: 181.9","appendix: 9.7","Cell line enriched",23,"RPMI-8226: 65.6"
"CD2",92,"E10","IOH22609",1056,"NP_001758.1","AAH33583.1","CD2 molecule, mRNA (cDNA clone MGC:34621 IMAGE:5227138), complete cds","BC033583.1","AAH33583.1",914,"Hs.523500","SRBC","ENSG00000116824","CD2 molecule","1","116754385-116769228","CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB002430, HPA003883","Enhanced",NA,NA,NA,"Renal cancer:4.82e-6 (unfavourable), Endometrial cancer:1.69e-5 (favourable), Melanoma:3.97e-5 (favourable), Head and neck cancer:7.46e-5 (favourable), Cervical cancer:1.47e-4 (favourable), Breast cancer:4.36e-4 (favourable), Ovarian cancer:7.72e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"lymph node: 131.1","tonsil: 70.8","Group enriched",27,"HDLM-2: 201.2;MOLT-4: 129.2"
"CD200",6,"B5","IOH10755",810,"NP_005935.3","AAH31103.1","CD200 molecule, mRNA (cDNA clone MGC:33959 IMAGE:5301702), complete cds","BC031103.1","AAH31103.1",4345,"Hs.79015","MOX1, MOX2, MRC, OX-2","ENSG00000091972","CD200 molecule","3","112332347-112362812","CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA031149","Approved",NA,NA,NA,NA,"Expressed in all","Mixed",NA,NA,"cerebral cortex: 78.6","Cell line enhanced",NA,"AF22: 74.9;NTERA-2: 47.6;REH: 38.6;WM-115: 82.4"
"CD200R1",99,"G6","IOH40362",1047,"NP_620161.1","NP_620161.1","CD200 receptor 1 (CD200R1), transcript variant 1, mRNA.","NM_138806.3","NP_620161.1",131450,"Hs.309158","CD200R, HCRTR2, MOX2R, OX2R","ENSG00000163606","CD200 receptor 1","3","112921209-112975122","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA068512",NA,NA,"Supported","Plasma membrane",NA,"Mixed","Tissue enhanced",NA,"spleen: 14.5","placenta: 10.2","Cell line enriched",8,"HEL: 26.4"
"CD24",47,"F9","IOH5911",243,"XP_212340.1","NP_037362.1","CD24 molecule (CD24), mRNA.","NM_013230.2","NP_037362.1",100133941,"Hs.644105","CD24A","ENSG00000272398","CD24 molecule","6","106969831-106975627","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA045879, CAB078471",NA,NA,"Supported","Vesicles","Breast cancer:2.44e-5 (unfavourable), Colorectal cancer:3.29e-4 (favourable), Liver cancer:7.58e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"thyroid gland: 2706.1","esophagus: 1402.0","Cell line enhanced",NA,"NTERA-2: 984.0;RPTEC TERT1: 3501.8;SK-BR-3: 1014.5"
"CD300A",49,"F12","IOH21716",900,"0",NA,"CD300a molecule (CD300A), mRNA.","NM_007261.2","NP_009192.2",11314,"Hs.9688","CMRF-35-H9, CMRF35H, IGSF12, IRC1, IRC2, Irp60","ENSG00000167851","CD300a molecule","17","74466416-74484796","CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA011645","Approved",NA,NA,NA,"Renal cancer:1.91e-5 (unfavourable)","Expressed in all","Tissue enhanced",NA,"spleen: 85.8","appendix: 40.0","Cell line enhanced",NA,"HMC-1: 88.9;NB-4: 27.4;RPMI-8226: 57.9"
"CD300LB",20,"F2","IOH11440",717,"0",NA,"CD300 molecule-like family member b, mRNA (cDNA clone MGC:40124 IMAGE:5219239), complete cds","BC028091.1","AAH28091.1",124599,"Hs.313343","CLM7, TREM5","ENSG00000178789","CD300 molecule like family member b","17","74521174-74531474","CD markers, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"appendix: 11.4","spleen: 5.2","Cell line enhanced",NA,"HL-60: 1.5;NB-4: 1.5;THP-1: 1.3"
"CD300LF",20,"G1","IOH11414",585,"NP_620587.1","AAH28199.1","CD300 molecule-like family member f, mRNA (cDNA clone MGC:40116 IMAGE:5207520), complete cds","BC028199.1","AAH28199.1",146722,"Hs.567706","CD300f, CLM1, IGSF13, IREM1, NKIR","ENSG00000186074","CD300 molecule like family member f","17","74694311-74712978","CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA013712","Supported",NA,NA,NA,NA,"Expressed in all","Tissue enhanced",NA,"lung: 25.6;spleen: 28.0","appendix: 18.2","Group enriched",7,"THP-1: 16.6;U-937: 37.2"
"CD300LG",18,"F7","IOH10923",999,"NP_660316.1","NP_660316.1","CD300 molecule-like family member g (CD300LG), mRNA.","NM_145273.2","NP_660316.1",146894,"Hs.657365","CLM9, Trem4","ENSG00000161649","CD300 molecule like family member g","17","43847148-43863629","CD markers, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Mixed","Group enriched",5,"adipose tissue: 143.0;placenta: 86.4;testis: 33.9","lung: 17.3","Not detected",NA,NA
"CD3D",91,"D12","IOH40817",516,"0",NA,"CD3d molecule, delta (CD3-TCR complex) (CD3D), transcript variant 1, mRNA.","NM_000732.4","NP_000723.1",915,"Hs.504048","T3D","ENSG00000167286","CD3d molecule","11","118338954-118342744","CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB013055","Enhanced",NA,NA,NA,"Endometrial cancer:1.73e-7 (favourable), Renal cancer:3.07e-5 (unfavourable), Cervical cancer:8.46e-5 (favourable), Head and neck cancer:1.70e-4 (favourable), Breast cancer:3.00e-4 (favourable), Urothelial cancer:6.16e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"lymph node: 199.3;tonsil: 119.1","appendix: 86.9","Cell line enriched",7,"MOLT-4: 903.0"
"CD3D",13,"A2","IOH10177",711,"0",NA,"cDNA clone MGC:17259 IMAGE:4149333, complete cds.","BC012876.2","AAH12876.1",915,"Hs.504048","T3D","ENSG00000167286","CD3d molecule","11","118338954-118342744","CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB013055","Enhanced",NA,NA,NA,"Endometrial cancer:1.73e-7 (favourable), Renal cancer:3.07e-5 (unfavourable), Cervical cancer:8.46e-5 (favourable), Head and neck cancer:1.70e-4 (favourable), Breast cancer:3.00e-4 (favourable), Urothelial cancer:6.16e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"lymph node: 199.3;tonsil: 119.1","appendix: 86.9","Cell line enriched",7,"MOLT-4: 903.0"
"CD3D",18,"D4","IOH14840",708,"0",NA,"cDNA clone MGC:27152 IMAGE:4691630, complete cds.","BC015833.1","AAH15833.1",915,"Hs.504048","T3D","ENSG00000167286","CD3d molecule","11","118338954-118342744","CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB013055","Enhanced",NA,NA,NA,"Endometrial cancer:1.73e-7 (favourable), Renal cancer:3.07e-5 (unfavourable), Cervical cancer:8.46e-5 (favourable), Head and neck cancer:1.70e-4 (favourable), Breast cancer:3.00e-4 (favourable), Urothelial cancer:6.16e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"lymph node: 199.3;tonsil: 119.1","appendix: 86.9","Cell line enriched",7,"MOLT-4: 903.0"
"CD4",68,"G11","IOH11860",1377,"NP_000607.1","NP_000607.1","CD4 molecule (CD4), mRNA.","NM_000616.3","NP_000607.1",920,"Hs.631659",NA,"ENSG00000010610","CD4 molecule","12","6786858-6820808","CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB000011, HPA004252, HPA004472, CAB068180","Enhanced",NA,"Supported","Plasma membrane","Endometrial cancer:2.16e-4 (favourable), Renal cancer:7.45e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"parathyroid gland: 549.0","spleen: 220.5","Group enriched",5,"HEL: 90.7;HL-60: 32.7;NB-4: 37.0;THP-1: 77.1;U-937: 84.2"
"CD40",12,"C2","IOH10427",834,"NP_001241.1","NP_001241.1","CD40 molecule, TNF receptor superfamily member 5 (CD40), transcript variant 1, mRNA.","NM_001250.4","NP_001241.1",958,"Hs.472860","Bp50, p50, TNFRSF5","ENSG00000101017","CD40 molecule","20","46118272-46129863","Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB002495, HPA031567, HPA031568, CAB072868","Enhanced",NA,NA,NA,"Renal cancer:4.48e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 64.7","Cell line enhanced",NA,"CAPAN-2: 63.4;EFO-21: 116.6"
"CD40",101,"B12","IOH39887",456,"0",NA,"CD40 molecule, TNF receptor superfamily member 5, mRNA (cDNA clone MGC:74540 IMAGE:5227115), complete cds","BC064518.1","AAH64518.1",958,"Hs.472860","Bp50, p50, TNFRSF5","ENSG00000101017","CD40 molecule","20","46118272-46129863","Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB002495, HPA031567, HPA031568, CAB072868","Enhanced",NA,NA,NA,"Renal cancer:4.48e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 64.7","Cell line enhanced",NA,"CAPAN-2: 63.4;EFO-21: 116.6"
"CD44",140,"G6","IOH53593",1086,"NP_000601.2","NP_001001391.1","CD44 molecule (Indian blood group) (CD44), transcript variant 4, mRNA.","NM_001001391.1","NP_001001391.1",960,"Hs.502328","CD44R, CSPG8, HCELL, IN, MC56, MDU2, MDU3, MIC4, Pgp1","ENSG00000026508","CD44 molecule (Indian blood group)","11","35138870-35232402","Blood group antigen proteins, Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB000112, CAB000316, HPA005785","Enhanced",NA,"Enhanced","Golgi apparatus<br>Plasma membrane","Renal cancer:1.78e-8 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"skin: 530.1","Mixed",NA,NA
"CD44",24,"C4","IOH5581",2100,"0",NA,"CD44 molecule (Indian blood group), mRNA (cDNA clone MGC:10468 IMAGE:3638681), complete cds","BC004372.1","AAH04372.1",960,"Hs.502328","CD44R, CSPG8, HCELL, IN, MC56, MDU2, MDU3, MIC4, Pgp1","ENSG00000026508","CD44 molecule (Indian blood group)","11","35138870-35232402","Blood group antigen proteins, Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB000112, CAB000316, HPA005785","Enhanced",NA,"Enhanced","Golgi apparatus<br>Plasma membrane","Renal cancer:1.78e-8 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"skin: 530.1","Mixed",NA,NA
"CD48",125,"C2","IOH22606",510,"0",NA,"CD48 molecule, mRNA (cDNA clone MGC:34616 IMAGE:5223308), complete cds","BC030224.1","AAH30224.1",962,"Hs.243564","BCM1, BLAST, hCD48, mCD48, SLAMF2","ENSG00000117091","CD48 molecule","1","160678746-160711851","CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB002497, HPA055146","Enhanced",NA,"Supported","Nucleoli fibrillar center<br>Plasma membrane<br>Cytosol","Renal cancer:3.36e-4 (unfavourable), Breast cancer:3.91e-4 (favourable), Colorectal cancer:4.17e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"lymph node: 311.4;spleen: 213.1;tonsil: 226.0","appendix: 148.5","Cell line enhanced",NA,"Daudi: 153.4;HMC-1: 202.6;U-266/70: 372.1;U-266/84: 244.7"
"CD48",34,"E2","IOH13424",732,"NP_001769.2","NP_001769.2","CD48 molecule (CD48), mRNA.","NM_001778.2","NP_001769.2",962,"Hs.243564","BCM1, BLAST, hCD48, mCD48, SLAMF2","ENSG00000117091","CD48 molecule","1","160678746-160711851","CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB002497, HPA055146","Enhanced",NA,"Supported","Nucleoli fibrillar center<br>Plasma membrane<br>Cytosol","Renal cancer:3.36e-4 (unfavourable), Breast cancer:3.91e-4 (favourable), Colorectal cancer:4.17e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"lymph node: 311.4;spleen: 213.1;tonsil: 226.0","appendix: 148.5","Cell line enhanced",NA,"Daudi: 153.4;HMC-1: 202.6;U-266/70: 372.1;U-266/84: 244.7"
"CD55",90,"G12","IOH3209",1146,"0",NA,"CD55 molecule, decay accelerating factor for complement (Cromer blood group) (CD55), transcript variant 1, mRNA.","NM_000574.3","NP_000565.1",1604,"Hs.126517","CR, CROM, DAF, TC","ENSG00000196352","CD55 molecule (Cromer blood group)","1","207321508-207386804","Blood group antigen proteins, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA002190, CAB010454, HPA024386","Enhanced",NA,"Uncertain","Vesicles<br>Midbody ring","Renal cancer:9.36e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"lung: 324.4","Cell line enhanced",NA,"HMC-1: 495.0;U-2197: 364.6"
"CD59",17,"H12","IOH14390",387,"0",NA,"CD59 molecule, complement regulatory protein (CD59), transcript variant 2, mRNA.","NM_000611.5","NP_000602.1",966,"Hs.278573","16.3A5, EJ16, EJ30, EL32, G344, MIC11, MIN1, MIN2, MIN3, MSK21, p18-20","ENSG00000085063","CD59 molecule","11","33698261-33736445","Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB001448, HPA026494","Supported",NA,"Approved","Golgi apparatus<br>Vesicles","Renal cancer:1.39e-10 (favourable), Pancreatic cancer:2.92e-5 (unfavourable), Head and neck cancer:3.10e-5 (unfavourable), Cervical cancer:3.81e-5 (unfavourable), Stomach cancer:9.03e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 923.3","Cell line enhanced",NA,"TIME: 2367.1;U-2197: 2401.2"
"CD5L",146,"A11","IOH62858",711,"0",NA,"cDNA clone MGC:72002 IMAGE:30350364, complete cds.","BC062711.1","AAH62711.1",922,"Hs.134035","API6, Spalpha","ENSG00000073754","CD5 molecule like","1","157830914-157898256","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA065686, HPA068384","Enhanced",NA,NA,NA,"Liver cancer:8.88e-5 (favourable)","Tissue enriched","Tissue enriched",14,"spleen: 787.1","liver: 54.4","Not detected",NA,NA
"CD5L",30,"C6","IOH22613",1044,"0",NA,"CD5 molecule-like (CD5L), mRNA.","NM_005894.2","NP_005885.1",922,"Hs.134035","API6, Spalpha","ENSG00000073754","CD5 molecule like","1","157830914-157898256","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA065686, HPA068384","Enhanced",NA,NA,NA,"Liver cancer:8.88e-5 (favourable)","Tissue enriched","Tissue enriched",14,"spleen: 787.1","liver: 54.4","Not detected",NA,NA
"CD6",59,"C12","IOH21877",1920,"NP_006716.1","AAH33755.1","CD6 molecule, mRNA (cDNA clone MGC:45196 IMAGE:5213263), complete cds","BC033755.1","AAH33755.1",923,"Hs.643167","Tp120","ENSG00000013725","CD6 molecule","11","60971680-61020377","CD markers, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB002489, CAB016252","Enhanced",NA,NA,NA,"Head and neck cancer:5.10e-6 (favourable), Cervical cancer:1.57e-5 (favourable), Renal cancer:1.82e-4 (unfavourable), Breast cancer:1.95e-4 (favourable), Endometrial cancer:2.41e-4 (favourable)","Mixed","Tissue enhanced",NA,"appendix: 28.5;lymph node: 49.2","tonsil: 26.8","Cell line enriched",17,"MOLT-4: 31.3"
"CD68",53,"C11","IOH14423",1065,"NP_001242.1","NP_001242.2","CD68 molecule (CD68), transcript variant 1, mRNA.","NM_001251.2","NP_001242.2",968,"Hs.647419","DKFZp686M18236, GP110, LAMP4, macrosialin, SCARD1","ENSG00000129226","CD68 molecule","17","7579467-7582113","CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB000051, CAB000066, HPA048982, CAB072861, CAB072862","Enhanced",NA,"Supported","Golgi apparatus<br>Vesicles","Renal cancer:1.14e-5 (unfavourable)","Mixed","Expressed in all",NA,NA,"lung: 532.4","Expressed in all",NA,NA
"CD7",16,"B4","IOH14100",723,"NP_006128.1","NP_006128.1","CD7 molecule (CD7), mRNA.","NM_006137.6","NP_006128.1",924,"Hs.36972","GP40, LEU-9, Tp40, TP41","ENSG00000173762","CD7 molecule","17","82314868-82317602","CD markers, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB002594, HPA039079","Enhanced",NA,NA,NA,"Renal cancer:7.75e-11 (unfavourable), Endometrial cancer:2.03e-5 (favourable), Melanoma:2.69e-4 (favourable), Cervical cancer:5.51e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"appendix: 43.1;lymph node: 41.5;spleen: 43.1","small intestine: 17.0","Group enriched",5,"Hep G2: 35.2;MOLT-4: 95.7"
"CD79A",107,"A11","IOH44544",681,"NP_001774.1","NP_001774.1","CD79a molecule, immunoglobulin-associated alpha (CD79A), transcript variant 1, mRNA.","NM_001783.3","NP_001774.1",973,"Hs.631567","IGA, MB-1","ENSG00000105369","CD79a molecule","19","41877120-41881372","Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB000019","Enhanced",NA,NA,NA,"Head and neck cancer:1.18e-5 (favourable), Renal cancer:2.15e-5 (unfavourable), Breast cancer:8.45e-5 (favourable)","Mixed","Group enriched",6,"appendix: 263.8;lymph node: 515.1;spleen: 317.9;tonsil: 423.1","stomach: 63.3","Group enriched",23,"Daudi: 1084.6;REH: 432.6;U-698: 905.8"
"CD79A",18,"E2","IOH14191",720,"0",NA,"cDNA clone MGC:23888 IMAGE:4704496, complete cds.","BC022362.1","AAH22362.1",973,"Hs.631567","IGA, MB-1","ENSG00000105369","CD79a molecule","19","41877120-41881372","Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB000019","Enhanced",NA,NA,NA,"Head and neck cancer:1.18e-5 (favourable), Renal cancer:2.15e-5 (unfavourable), Breast cancer:8.45e-5 (favourable)","Mixed","Group enriched",6,"appendix: 263.8;lymph node: 515.1;spleen: 317.9;tonsil: 423.1","stomach: 63.3","Group enriched",23,"Daudi: 1084.6;REH: 432.6;U-698: 905.8"
"CD80",72,"F3","IOH27312",867,"NP_005182.1","NP_005182.1","CD80 molecule (CD80), mRNA.","NM_005191.3","NP_005182.1",941,"Hs.838","B7-1, B7.1, CD28LG, CD28LG1","ENSG00000121594","CD80 molecule","3","119524293-119559602","CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB025368, HPA050092","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"appendix: 7.2;lymph node: 6.7;tonsil: 6.3","spleen: 4.7","Cell line enhanced",NA,"Daudi: 8.5;HDLM-2: 39.3;Karpas-707: 12.2;U-266/70: 5.5"
"CD86",55,"G5","IOH27390",990,"NP_008820.1","AAH40261.1","CD86 molecule, mRNA (cDNA clone MGC:34413 IMAGE:5173789), complete cds","BC040261.1","AAH40261.1",942,"Hs.171182","B7-2, B7.2, CD28LG2","ENSG00000114013","CD86 molecule","3","122055366-122121139","CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB004319","Uncertain",NA,NA,NA,"Renal cancer:9.83e-5 (unfavourable)","Expressed in all","Mixed",NA,NA,"appendix: 47.8","Cell line enriched",10,"HDLM-2: 275.8"
"CD86",133,"G11","IOH53922",990,"0",NA,"T-lymphocyte activation antigen CD86.","P42081","P42081",942,"Hs.171182","B7-2, B7.2, CD28LG2","ENSG00000114013","CD86 molecule","3","122055366-122121139","CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB004319","Uncertain",NA,NA,NA,"Renal cancer:9.83e-5 (unfavourable)","Expressed in all","Mixed",NA,NA,"appendix: 47.8","Cell line enriched",10,"HDLM-2: 275.8"
"CD8A",125,"G6","IOH10625",708,"NP_001759.3","AAH25715.1","CD8a molecule, mRNA (cDNA clone MGC:34614 IMAGE:5227906), complete cds","BC025715.1","AAH25715.1",925,"Hs.85258","CD8","ENSG00000153563","CD8a molecule","2","86784610-86808396","CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB000012, HPA037756, CAB075722","Enhanced",NA,NA,NA,"Endometrial cancer:6.15e-6 (favourable), Renal cancer:1.91e-5 (unfavourable), Cervical cancer:4.54e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"spleen: 161.9","lymph node: 46.9","Cell line enriched",5,"MOLT-4: 11.7"
"CD8B",151,"G11","IOH63435",732,"0",NA,"CD8b molecule, mRNA (cDNA clone MGC:119117 IMAGE:40003725), complete cds","BC100914.1","AAI00915.1",926,"Hs.405667","CD8B1","ENSG00000172116","CD8b molecule","2","86815339-86861924","CD markers, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB004353, HPA029164","Enhanced",NA,"Supported","Plasma membrane","Endometrial cancer:7.88e-7 (favourable), Renal cancer:7.11e-6 (unfavourable)","Mixed","Tissue enhanced",NA,"cervix, uterine: 60.8;lymph node: 39.6","parathyroid gland: 22.7","Cell line enriched",50,"RPMI-8226: 837.8"
"CD8B",141,"B9","IOH59739",633,"0",NA,"CD8b molecule (CD8B), transcript variant 5, mRNA.","NM_004931.3","NP_004922.1",926,"Hs.405667","CD8B1","ENSG00000172116","CD8b molecule","2","86815339-86861924","CD markers, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB004353, HPA029164","Enhanced",NA,"Supported","Plasma membrane","Endometrial cancer:7.88e-7 (favourable), Renal cancer:7.11e-6 (unfavourable)","Mixed","Tissue enhanced",NA,"cervix, uterine: 60.8;lymph node: 39.6","parathyroid gland: 22.7","Cell line enriched",50,"RPMI-8226: 837.8"
"CD8B",108,"F10","IOH35341",732,"NP_757362.1","NP_757362.1","CD8b molecule (CD8B), transcript variant 2, mRNA.","NM_172213.2","NP_757362.1",926,"Hs.405667","CD8B1","ENSG00000172116","CD8b molecule","2","86815339-86861924","CD markers, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB004353, HPA029164","Enhanced",NA,"Supported","Plasma membrane","Endometrial cancer:7.88e-7 (favourable), Renal cancer:7.11e-6 (unfavourable)","Mixed","Tissue enhanced",NA,"cervix, uterine: 60.8;lymph node: 39.6","parathyroid gland: 22.7","Cell line enriched",50,"RPMI-8226: 837.8"
"CD8B",103,"H6","IOH35301",666,"NP_004922.1","NP_742099.1","CD8b molecule (CD8B), transcript variant 3, mRNA.","NM_172101.2","NP_742099.1",926,"Hs.405667","CD8B1","ENSG00000172116","CD8b molecule","2","86815339-86861924","CD markers, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB004353, HPA029164","Enhanced",NA,"Supported","Plasma membrane","Endometrial cancer:7.88e-7 (favourable), Renal cancer:7.11e-6 (unfavourable)","Mixed","Tissue enhanced",NA,"cervix, uterine: 60.8;lymph node: 39.6","parathyroid gland: 22.7","Cell line enriched",50,"RPMI-8226: 837.8"
"CD99",88,"C11","IOH5089",558,"NP_002405.1","NP_002405.1","CD99 molecule (CD99), transcript variant 1, mRNA.","NM_002414.3","NP_002405.1",4267,"Hs.654354","MIC2","ENSG00000002586","CD99 molecule","X","2691179-2741309","CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB000020, HPA035304","Supported",NA,"Approved","Golgi apparatus","Renal cancer:5.87e-7 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"gallbladder: 375.1","Mixed",NA,NA
"CDCP1",5,"H10","IOH12521",1032,"NP_073753.2","NP_835488.1","CUB domain containing protein 1 (CDCP1), transcript variant 2, mRNA.","NM_178181.1","NP_835488.1",64866,"Hs.476093","CD318, SIMA135","ENSG00000163814","CUB domain containing protein 1","3","45082278-45146422","CD markers, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA010978, HPA010979, CAB025637","Enhanced",NA,NA,NA,"Lung cancer:1.41e-5 (unfavourable), Pancreatic cancer:1.48e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"skin: 27.7","Cell line enhanced",NA,"hTEC/SVTERT24-B: 263.4;hTERT-HME1: 135.9"
"CDH1",132,"E3","IOH46767",2649,"NP_004351.1","NP_004351.1","cadherin 1, type 1, E-cadherin (epithelial) (CDH1), mRNA.","NM_004360.3","NP_004351.1",999,"Hs.461086","CD324, UVO, uvomorulin","ENSG00000039068","Cadherin 1","16","68737225-68835548","Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB000087, HPA004812, CAB028364, CAB072855, CAB072856, CAB072857","Enhanced",NA,"Supported","Golgi apparatus<br>Plasma membrane<br>Cell Junctions","Renal cancer:2.06e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"parathyroid gland: 475.1","thyroid gland: 266.2","Cell line enhanced",NA,"BEWO: 645.6;CAPAN-2: 281.0;HaCaT: 273.9"
"CDH11",35,"A11","IOH9642",2391,"0",NA,"cadherin 11, type 2, OB-cadherin (osteoblast), mRNA (cDNA clone MGC:17193 IMAGE:4183901), complete cds","BC013609.1","AAH13609.1",1009,"Hs.116471","CAD11, OB","ENSG00000140937","Cadherin 11","16","64943753-65126112","Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB013072","Enhanced",NA,NA,NA,"Renal cancer:2.48e-9 (unfavourable)","Expressed in all","Tissue enhanced",NA,"ovary: 223.4","placenta: 173.7","Cell line enhanced",NA,"BJ: 205.7;fHDF/TERT166: 259.6;HSkMC: 159.5;PC-3: 262.9;U-2197: 178.5"
"CDH13",127,"H5","IOH27416",483,"0",NA,"HSPC047 protein, mRNA (cDNA clone MGC:34358 IMAGE:5178752), complete cds.","BC035371.1","AAH35371.1",1012,"Hs.654386","CDHH","ENSG00000140945","Cadherin 13","16","82626803-83800640","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA001380, CAB025863","Enhanced",NA,"Supported","Plasma membrane","Renal cancer:1.73e-6 (unfavourable)","Expressed in all","Tissue enhanced",NA,"endometrium: 70.0","cervix, uterine: 66.4","Cell line enhanced",NA,"LHCN-M2: 185.2;U-138 MG: 276.1;U-87 MG: 239.0"
"CDH13",144,"A11","IOH54116",2142,"0",NA,"cadherin 13, H-cadherin (heart) (CDH13), mRNA.","NM_001257.3","NP_001248.1",1012,"Hs.654386","CDHH","ENSG00000140945","Cadherin 13","16","82626803-83800640","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA001380, CAB025863","Enhanced",NA,"Supported","Plasma membrane","Renal cancer:1.73e-6 (unfavourable)","Expressed in all","Tissue enhanced",NA,"endometrium: 70.0","cervix, uterine: 66.4","Cell line enhanced",NA,"LHCN-M2: 185.2;U-138 MG: 276.1;U-87 MG: 239.0"
"CDH19",131,"F2","IOH46710",2319,"0",NA,"cadherin 19, type 2 (CDH19), mRNA.","NM_021153.2","NP_066976.1",28513,"Hs.42771","CDH7","ENSG00000071991","Cadherin 19","18","66501083-66604138","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA056332","Uncertain",NA,NA,NA,NA,"Tissue enriched","Mixed",NA,NA,"heart muscle: 8.4","Group enriched",15,"SK-MEL-30: 28.3;WM-115: 63.0"
"CDH19",7,"H12","IOH13013",1173,"NP_066976.1","AAH15877.1","cadherin 19, type 2, mRNA (cDNA clone MGC:27490 IMAGE:4716394), complete cds","BC015877.1","AAH15877.1",28513,"Hs.42771","CDH7","ENSG00000071991","Cadherin 19","18","66501083-66604138","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA056332","Uncertain",NA,NA,NA,NA,"Tissue enriched","Mixed",NA,NA,"heart muscle: 8.4","Group enriched",15,"SK-MEL-30: 28.3;WM-115: 63.0"
"CDNF",148,"B10","IOH62293",258,"0",NA,"arginine-rich, mutated in early stage tumors-like 1, mRNA (cDNA clone IMAGE:5273319), complete cds.","BC037872.1","AAH37872.1",441549,"Hs.559067","ARMETL1","ENSG00000185267","Cerebral dopamine neurotrophic factor","10","14819250-14838575","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA044587","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"testis: 20.1","skeletal muscle: 12.5","Cell line enhanced",NA,"RPMI-8226: 8.5"
"CDON",154,"D5","IOH62671",3864,"0",NA,"Cdon homolog (mouse), mRNA (cDNA clone MGC:111524 IMAGE:30528009), complete cds","BC098583.1","AAH98583.1",50937,"Hs.38034","CDO, CDON1, ORCAM","ENSG00000064309","Cell adhesion associated, oncogene regulated","11","125955796-126063335","Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB012422, HPA017377","Uncertain",NA,NA,NA,"Renal cancer:1.78e-7 (unfavourable), Breast cancer:1.35e-4 (favourable)","Mixed","Tissue enhanced",NA,"thyroid gland: 75.5","ovary: 53.5","Cell line enhanced",NA,"AF22: 55.0;ASC diff: 47.4;RH-30: 93.1"
"CEACAM19",154,"G7","IOH62726",900,"0",NA,"carcinoembryonic antigen-related cell adhesion molecule 19 (CEACAM19), transcript variant 1, mRNA.","NM_001127893.1","NP_001121365.1",56971,"Hs.416925","CEAL1","ENSG00000186567","Carcinoembryonic antigen related cell adhesion molecule 19","19","44662278-44684359","Predicted membrane proteins, Predicted secreted proteins","Evidence at transcript level","HPA014462, HPA052865","Uncertain",NA,"Approved","Nucleus<br>Nucleoli<br>Mitochondria",NA,"Expressed in all","Mixed",NA,NA,"skin: 12.7","Cell line enhanced",NA,"RPTEC TERT1: 11.9;TIME: 16.9"
"CEACAM5",39,"C8","IOH22663",2109,"0",NA,"carcinoembryonic antigen-related cell adhesion molecule 5, mRNA (cDNA clone MGC:34212 IMAGE:5184800), complete cds","BC034671.1","AAH34671.1",1048,"Hs.709196","CD66e, CEA","ENSG00000105388","Carcinoembryonic antigen related cell adhesion molecule 5","19","41708585-41729798","Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB000021, CAB000022, HPA011041, HPA019758","Enhanced",NA,"Supported","Plasma membrane",NA,"Tissue enhanced","Tissue enhanced",NA,"colon: 1012.7;rectum: 1086.0","appendix: 257.7","Cell line enriched",6,"HaCaT: 11.8"
"CEACAM5",137,"F9","IOH55634",2109,"0",NA,"Carcinoembryonic antigen-related cell adhesion molecule 5.","P06731","P06731",1048,"Hs.709196","CD66e, CEA","ENSG00000105388","Carcinoembryonic antigen related cell adhesion molecule 5","19","41708585-41729798","Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB000021, CAB000022, HPA011041, HPA019758","Enhanced",NA,"Supported","Plasma membrane",NA,"Tissue enhanced","Tissue enhanced",NA,"colon: 1012.7;rectum: 1086.0","appendix: 257.7","Cell line enriched",6,"HaCaT: 11.8"
"CECR1",104,"A3","IOH40959",813,"0",NA,"cat eye syndrome chromosome region, candidate 1 (CECR1), transcript variant 2, mRNA.","NM_177405.1","NP_803124.1",51816,"Hs.170310","ADGF, IDGFL","ENSG00000093072","Cat eye syndrome chromosome region, candidate 1","22","17178790-17221989","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA007888","Approved",NA,NA,NA,"Pancreatic cancer:8.91e-4 (favourable), Ovarian cancer:9.26e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 161.4","Cell line enhanced",NA,"CAPAN-2: 22.2;Karpas-707: 30.5;MOLT-4: 33.3;U-937: 32.1"
"CECR1",66,"C5","IOH28837",1536,"0",NA,"cat eye syndrome chromosome region, candidate 1, mRNA (cDNA clone MGC:51862 IMAGE:5753141), complete cds","BC051755.1","AAH51755.1",51816,"Hs.170310","ADGF, IDGFL","ENSG00000093072","Cat eye syndrome chromosome region, candidate 1","22","17178790-17221989","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA007888","Approved",NA,NA,NA,"Pancreatic cancer:8.91e-4 (favourable), Ovarian cancer:9.26e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 161.4","Cell line enhanced",NA,"CAPAN-2: 22.2;Karpas-707: 30.5;MOLT-4: 33.3;U-937: 32.1"
"CELA2A",156,"E1","IOH61872",810,"0",NA,"elastase 2A, mRNA (cDNA clone MGC:97041 IMAGE:7262251), complete cds","BC069331.1","AAH69331.1",63036,"Hs.631866","ELA2A","ENSG00000142615","Chymotrypsin like elastase family member 2A","1","15456728-15472091","Enzymes, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enriched","Tissue enriched",371,"pancreas: 34335.1","ovary: 92.5","Cell line enhanced",NA,"HMC-1: 1.1"
"CELA2A",22,"F5","IOH7156",810,"0",NA,"chymotrypsin-like elastase family, member 2A (CELA2A), mRNA.","NM_033440.2","NP_254275.1",63036,"Hs.631866","ELA2A","ENSG00000142615","Chymotrypsin like elastase family member 2A","1","15456728-15472091","Enzymes, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enriched","Tissue enriched",371,"pancreas: 34335.1","ovary: 92.5","Cell line enhanced",NA,"HMC-1: 1.1"
"CELA2A",150,"G3","IOH61876",810,"0",NA,"elastase 2A, mRNA (cDNA clone MGC:97063 IMAGE:7262275), complete cds","BC069432.1","AAH69432.1",63036,"Hs.631866","ELA2A","ENSG00000142615","Chymotrypsin like elastase family member 2A","1","15456728-15472091","Enzymes, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enriched","Tissue enriched",371,"pancreas: 34335.1","ovary: 92.5","Cell line enhanced",NA,"HMC-1: 1.1"
"CELA2B",98,"D3","IOH40271",810,"0",NA,"chymotrypsin-like elastase family, member 2B (CELA2B), mRNA.","NM_015849.2","NP_056933.2",51032,"Hs.631871","ELA2B, RP11-265F14.2","ENSG00000215704","Chymotrypsin like elastase family member 2B","1","15465909-15491400","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enriched","Tissue enriched",262,"pancreas: 4261.7","ovary: 16.2","Cell line enriched",5,"U-138 MG: 3.8"
"CELA2B",124,"B11","IOH40305",810,"0",NA,"elastase 2B, mRNA (cDNA clone MGC:97052 IMAGE:7262263), complete cds","BC069412.1","AAH69412.1",51032,"Hs.631871","ELA2B, RP11-265F14.2","ENSG00000215704","Chymotrypsin like elastase family member 2B","1","15465909-15491400","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enriched","Tissue enriched",262,"pancreas: 4261.7","ovary: 16.2","Cell line enriched",5,"U-138 MG: 3.8"
"CELA3A",84,"D5","IOH7227",813,"0",NA,"elastase 3A, pancreatic, mRNA (cDNA clone MGC:12505 IMAGE:3949901), complete cds","BC008383.1","AAH08383.1",10136,"Hs.654349","ELA3, ELA3A","ENSG00000142789","Chymotrypsin like elastase family member 3A","1","22001656-22012539","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA028086, HPA045650","Supported",NA,"Approved","Cytosol",NA,"Tissue enriched","Tissue enriched",352,"pancreas: 56987.6","ovary: 161.9","Cell line enriched",24,"MOLT-4: 20.6"
"CELA3A",22,"E5","IOH7155",813,"0",NA,"elastase 3A, pancreatic, mRNA (cDNA clone MGC:12383 IMAGE:3950453), complete cds","BC007028.1","AAH07028.1",10136,"Hs.654349","ELA3, ELA3A","ENSG00000142789","Chymotrypsin like elastase family member 3A","1","22001656-22012539","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA028086, HPA045650","Supported",NA,"Approved","Cytosol",NA,"Tissue enriched","Tissue enriched",352,"pancreas: 56987.6","ovary: 161.9","Cell line enriched",24,"MOLT-4: 20.6"
"CELA3A",14,"F1","IOH7440",813,"0",NA,"elastase 3A, pancreatic, mRNA (cDNA clone MGC:14514 IMAGE:4295129), complete cds","BC005918.1","AAH05918.1",10136,"Hs.654349","ELA3, ELA3A","ENSG00000142789","Chymotrypsin like elastase family member 3A","1","22001656-22012539","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA028086, HPA045650","Supported",NA,"Approved","Cytosol",NA,"Tissue enriched","Tissue enriched",352,"pancreas: 56987.6","ovary: 161.9","Cell line enriched",24,"MOLT-4: 20.6"
"CELA3B",20,"G5","IOH7266",813,"0",NA,"elastase 3B, pancreatic, mRNA (cDNA clone MGC:12233 IMAGE:3949903), complete cds","BC005216.1","AAH05216.1",23436,"Hs.181289","CBPP, ELA3B","ENSG00000219073","Chymotrypsin like elastase family member 3B","1","21977021-21998642","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA028086, HPA045650","Supported",NA,"Approved","Cytosol",NA,"Tissue enriched","Tissue enriched",296,"pancreas: 10568.2","ovary: 35.6","Mixed",NA,NA
"CER1",95,"F6","IOH40249",804,"0",NA,"cerberus 1, cysteine knot superfamily, homolog (Xenopus laevis), mRNA (cDNA clone MGC:96939 IMAGE:7262148), complete cds","BC069491.1","AAH69491.1",9350,"Hs.248204","DAND4","ENSG00000147869","Cerberus 1, DAN family BMP antagonist","9","14719724-14722717","Predicted secreted proteins","Evidence at protein level","HPA019917","Uncertain",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",6,"epididymis: 1.3","endometrium: 0.2","Group enriched",10,"HEL: 3.6;NTERA-2: 7.1;SCLC-21H: 3.2"
"CERCAM",104,"E6","IOH42094",1554,"0",NA,"cerebral endothelial cell adhesion molecule, mRNA (cDNA clone MGC:104846 IMAGE:6672104), complete cds","BC098432.1","AAH98432.2",51148,"Hs.495230","CEECAM1, CerCAM, GLT25D3","ENSG00000167123","Cerebral endothelial cell adhesion molecule","9","128411751-128437351","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA021657, HPA051595","Uncertain",NA,"Approved","Nucleus<br>Nucleoli<br>Cell Junctions","Renal cancer:3.33e-16 (unfavourable), Urothelial cancer:3.30e-5 (unfavourable), Ovarian cancer:5.22e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 155.6","Mixed",NA,NA
"CES1",53,"E1","IOH11665",1701,"0",NA,"carboxylesterase 1 (monocyte/macrophage serine esterase 1), mRNA (cDNA clone MGC:9220 IMAGE:3879691), complete cds","BC012418.1","AAH12418.1",1066,"Hs.558865","CEH, CES1A1, CES1A2, CES2, HMSE, HMSE1, SES1","ENSG00000198848","Carboxylesterase 1","16","55802851-55833337","Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA012023, HPA046717","Enhanced",NA,"Enhanced","Endoplasmic reticulum","Urothelial cancer:9.92e-4 (unfavourable)","Tissue enriched","Group enriched",7,"gallbladder: 399.2;liver: 1099.9;lung: 229.9","adipose tissue: 79.7","Group enriched",5,"Hep G2: 414.0;THP-1: 439.1;U-937: 102.6"
"CES3",70,"B8","IOH29013",1707,"0",NA,"carboxylesterase 3, mRNA (cDNA clone MGC:61567 IMAGE:6145696), complete cds.","BC053670.1","AAH53670.1",23491,"Hs.268700","ES31, FLJ21736","ENSG00000172828","Carboxylesterase 3","16","66961237-66975148","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA041008, HPA041307","Approved",NA,"Approved","Nuclear membrane<br>Endoplasmic reticulum","Liver cancer:7.26e-5 (favourable)","Mixed","Tissue enhanced",NA,"colon: 37.2;duodenum: 30.5;rectum: 34.1","small intestine: 26.6","Cell line enhanced",NA,"AN3-CA: 7.1"
"CETP",17,"F8","IOH11986",1482,"0",NA,"cholesteryl ester transfer protein, plasma, mRNA (cDNA clone MGC:34512 IMAGE:5223614), complete cds","BC025739.1","AAH25739.1",1071,"Hs.89538","BPIFF","ENSG00000087237","Cholesteryl ester transfer protein","16","56961850-56983845","Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Mixed","Group enriched",6,"adipose tissue: 36.9;liver: 21.7;lymph node: 46.3;placenta: 50.4;spleen: 77.7","thyroid gland: 8.4","Cell line enhanced",NA,"HEL: 2.4;HUVEC TERT2: 3.6;TIME: 2.1"
"CFB",22,"B12","IOH6091",2295,"0",NA,"complement factor B, mRNA (cDNA clone MGC:4445 IMAGE:2959706), complete cds","BC007990.2","AAH07990.1",629,"Hs.69771","BF, BFD, H2-Bf","ENSG00000243649","Complement factor B","6","31945650-31952084","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA000951, HPA001817, HPA001832, CAB016381","Supported",NA,"Approved","Endoplasmic reticulum<br>Vesicles<br>Cell Junctions","Renal cancer:1.53e-5 (unfavourable), Breast cancer:2.76e-5 (favourable)","Expressed in all","Tissue enriched",21,"liver: 285.9","stomach: 13.8","Cell line enhanced",NA,"CAPAN-2: 6.6;fHDF/TERT166: 9.6;HSkMC: 14.1"
"CFC1",98,"D6","IOH40270",672,"0",NA,"cripto, FRL-1, cryptic family 1 (CFC1), mRNA.","NM_032545.2","NP_115934.1",55997,"Hs.567542","CRYPTIC, HTX2","ENSG00000136698","Cripto, FRL-1, cryptic family 1","2","130592168-130599575","Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA041773","Uncertain",NA,NA,NA,NA,"Tissue enriched","Tissue enhanced",NA,"pancreas: 4.1;prostate: 10.4;stomach: 8.0","fallopian tube: 1.6","Group enriched",18,"RPMI-8226: 13.6;SCLC-21H: 12.6"
"CFD",118,"D7","IOH29270",762,"0",NA,"complement factor D (adipsin) (CFD), mRNA.","NM_001928.2","NP_001919.2",1675,"Hs.155597","ADN, DF, PFD","ENSG00000197766","Complement factor D","19","859643-863630","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins","Evidence at protein level","HPA052799",NA,NA,"Uncertain","Plasma membrane","Pancreatic cancer:1.77e-4 (favourable), Renal cancer:7.09e-4 (unfavourable)","Expressed in all","Tissue enriched",7,"adipose tissue: 378.5","breast: 52.5","Group enriched",6,"ASC diff: 82.6;THP-1: 121.6"
"CFH",131,"E4","IOH55284",1350,"0",NA,"complement factor H (CFH), transcript variant 2, mRNA.","NM_001014975.2","NP_001014975.1",3075,"Hs.363396","ARMD4, ARMS1, FHL1, HF, HF1, HF2, HUS","ENSG00000000971","Complement factor H","1","196651878-196747504","Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB016385, CAB016769, HPA038922, HPA049176, HPA053326","Supported",NA,"Approved","Vesicles","Renal cancer:1.92e-6 (unfavourable)","Tissue enriched","Tissue enhanced",NA,"liver: 839.5","gallbladder: 205.3","Cell line enhanced",NA,"HHSteC: 100.0;RT4: 176.9"
"CFH",75,"E7","IOH27156",1350,"0",NA,"complement factor H, mRNA (cDNA clone IMAGE:5267249), complete cds.","BC037285.2","AAH37285.1",3075,"Hs.363396","ARMD4, ARMS1, FHL1, HF, HF1, HF2, HUS","ENSG00000000971","Complement factor H","1","196651878-196747504","Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB016385, CAB016769, HPA038922, HPA049176, HPA053326","Supported",NA,"Approved","Vesicles","Renal cancer:1.92e-6 (unfavourable)","Tissue enriched","Tissue enhanced",NA,"liver: 839.5","gallbladder: 205.3","Cell line enhanced",NA,"HHSteC: 100.0;RT4: 176.9"
"CFHR1",10,"C1","IOH12873",993,"0",NA,"complement factor H-related 1 (CFHR1), mRNA.","NM_002113.2","NP_002104.2",3078,"Hs.575869","CFHL, CFHL1, CFHL1P, CFHR1P, FHR1, H36-1, H36-2, HFL1, HFL2","ENSG00000244414","Complement factor H related 1","1","196819757-196832189","Cancer-related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA038915, HPA038922, HPA040726","Supported",NA,"Approved","Vesicles","Liver cancer:8.71e-6 (favourable)","Tissue enriched","Tissue enriched",147,"liver: 1057.6","lymph node: 7.1","Cell line enhanced",NA,"HL-60: 1.5;U-266/70: 1.9"
"CFHR2",51,"B7","IOH13657",813,"0",NA,"complement factor H-related 2 (CFHR2), mRNA.","NM_005666.2","NP_005657.1",3080,"Hs.632450","CFHL2, FHR2, HFL3","ENSG00000080910","Complement factor H related 2","1","196943772-196959226","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA038915, HPA040726, HPA049813","Supported",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",4661,"liver: 466.1","all non-specific tissues: 0.0","Not detected",NA,NA
"CFHR3",49,"D4","IOH13605",588,"0",NA,"complement factor H-related 3, mRNA (cDNA clone IMAGE:4734101), complete cds.","BC020687.1","AAH20687.1",10878,"Hs.575869","CFHL3, DOWN16, FHR-3, FHR3, HLF4","ENSG00000116785","Complement factor H related 3","1","196774795-196795406","Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Liver cancer:2.86e-5 (favourable)","Tissue enriched","Tissue enriched",244,"liver: 314.2","adipose tissue: 1.2","Cell line enhanced",NA,"NTERA-2: 2.1;T-47d: 4.2;U-266/70: 6.1"
"CFHR5",113,"B8","IOH44612",1710,"0",NA,"complement factor H-related 5 (CFHR5), mRNA.","NM_030787.3","NP_110414.1",81494,"Hs.282594","CFHL5, FHR-5, FHR5","ENSG00000134389","Complement factor H related 5","1","196977556-197009674","Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA038915, HPA040726","Supported",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",500,"liver: 88.0","testis: 0.1","Not detected",NA,NA
"CFI",46,"E11","IOH14320",1134,"0",NA,"complement factor I, mRNA (cDNA clone MGC:22501 IMAGE:4716122), complete cds","BC020718.1","AAH20718.1",3426,"Hs.312485","C3b-INA, FI, IF, KAF","ENSG00000205403","Complement factor I","4","109740694-109802179","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins","Evidence at protein level","HPA001143, CAB016777, HPA024061","Supported",NA,NA,NA,"Urothelial cancer:6.06e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"liver: 524.7","kidney: 221.8","Cell line enhanced",NA,"CAPAN-2: 112.1;Hep G2: 117.9;HSkMC: 48.7;RPTEC TERT1: 139.4"
"CFP",34,"D2","IOH12225",1410,"0",NA,"complement factor properdin (CFP), transcript variant 1, mRNA.","NM_002621.2","NP_002612.1",5199,"Hs.53155","PFC","ENSG00000126759","Complement factor properdin","X","47623172-47630305","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"bone marrow: 58.1;spleen: 76.6","appendix: 29.9","Cell line enhanced",NA,"EFO-21: 21.2;HEL: 4.6;HMC-1: 4.9;NB-4: 7.2;U-937: 6.1"
"CGA",45,"G3","IOH12272",351,"0",NA,"glycoprotein hormones, alpha polypeptide, mRNA (cDNA clone MGC:13639 IMAGE:4043527), complete cds","BC010957.1","AAH10957.1",1081,"Hs.119689","FSHA, GPHa, GPHA1, HCG, LHA, TSHA","ENSG00000135346","Glycoprotein hormones, alpha polypeptide","6","87085498-87095406","Cancer-related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB023350, HPA029698","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",22,"placenta: 654.5","stomach: 29.1","Cell line enriched",26,"BEWO: 481.2"
"CGA",87,"G10","IOH14636",351,"0",NA,"glycoprotein hormones, alpha polypeptide (CGA), mRNA.","NM_000735.2","NP_000726.1",1081,"Hs.119689","FSHA, GPHa, GPHA1, HCG, LHA, TSHA","ENSG00000135346","Glycoprotein hormones, alpha polypeptide","6","87085498-87095406","Cancer-related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB023350, HPA029698","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",22,"placenta: 654.5","stomach: 29.1","Cell line enriched",26,"BEWO: 481.2"
"CGB5",37,"E4","IOH6333",498,"0",NA,"chorionic gonadotropin, beta polypeptide 5 (CGB5), mRNA.","NM_033043.1","NP_149032.1",93659,"Hs.590955","HCG","ENSG00000189052","Chorionic gonadotropin beta subunit 5","19","49043884-49045311","Predicted secreted proteins","Evidence at protein level","HPA038925, HPA038934","Supported",NA,"Approved","Cytosol","Stomach cancer:1.18e-5 (unfavourable), Urothelial cancer:9.47e-4 (unfavourable)","Tissue enhanced","Tissue enriched",68,"placenta: 31.7","pancreas,skin,testis: 0.4","Group enriched",24,"BEWO: 99.4;U-251 MG: 40.1"
"CGREF1",30,"C9","IOH22656",906,"0",NA,"cell growth regulator with EF-hand domain 1 (CGREF1), mRNA.","NM_006569.4","NP_006560.2",10669,"Hs.159525","CGR11","ENSG00000138028","Cell growth regulator with EF-hand domain 1","2","27098889-27119115","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA008241","Uncertain",NA,NA,NA,"Endometrial cancer:3.18e-4 (unfavourable), Liver cancer:7.57e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 44.7","stomach: 11.5","Cell line enhanced",NA,"SK-BR-3: 58.9"
"CHGA",85,"E9","IOH4766",1374,"0",NA,"chromogranin A (parathyroid secretory protein 1) (CHGA), mRNA.","NM_001275.3","NP_001266.1",1113,"Hs.150793",NA,"ENSG00000100604","Chromogranin A","14","92923080-92935293","Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB000023, HPA017369, CAB040544, CAB055506, CAB058688","Enhanced",NA,"Supported","Vesicles","Breast cancer:7.85e-5 (favourable), Liver cancer:2.40e-4 (unfavourable), Urothelial cancer:3.99e-4 (unfavourable), Pancreatic cancer:4.07e-4 (favourable)","Tissue enhanced","Tissue enriched",9,"parathyroid gland: 7061.6","adrenal gland: 818.1","Group enriched",156,"SCLC-21H: 285.4;SH-SY5Y: 700.4"
"CHGB",39,"C12","IOH3444",2034,"0",NA,"chromogranin B (secretogranin 1), mRNA (cDNA clone MGC:8377 IMAGE:2820258), complete cds","BC000375.2","AAH00375.1",1114,"Hs.516874","SCG1, SgI","ENSG00000089199","Chromogranin B","20","5911430-5925361","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA008759, CAB009403, HPA012602","Enhanced","Supported","Enhanced","Vesicles","Head and neck cancer:1.89e-4 (unfavourable), Pancreatic cancer:9.96e-4 (favourable)","Tissue enriched","Tissue enriched",26,"adrenal gland: 4382.4","cerebral cortex: 168.3","Group enriched",25,"SCLC-21H: 405.5;SH-SY5Y: 559.4"
"CHI3L1",55,"B12","IOH25737",1152,"0",NA,"chitinase 3-like 1 (cartilage glycoprotein-39), mRNA (cDNA clone MGC:17199 IMAGE:4212419), complete cds","BC038354.1","AAH38354.1",1116,"Hs.382202","GP39, YKL40","ENSG00000133048","Chitinase 3 like 1","1","203178931-203186749","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enriched","Tissue enhanced",NA,"appendix: 186.7;cerebral cortex: 267.1;urinary bladder: 179.4","bone marrow: 146.9","Group enriched",7,"ASC diff: 215.1;ASC TERT1: 484.9;HSkMC: 450.3;THP-1: 704.0;U-138 MG: 292.3;U-87 MG: 289.1"
"CHI3L1",5,"G5","IOH3327",1152,"0",NA,"chitinase 3-like 1 (cartilage glycoprotein-39) (CHI3L1), mRNA.","NM_001276.2","NP_001267.2",1116,"Hs.382202","GP39, YKL40","ENSG00000133048","Chitinase 3 like 1","1","203178931-203186749","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enriched","Tissue enhanced",NA,"appendix: 186.7;cerebral cortex: 267.1;urinary bladder: 179.4","bone marrow: 146.9","Group enriched",7,"ASC diff: 215.1;ASC TERT1: 484.9;HSkMC: 450.3;THP-1: 704.0;U-138 MG: 292.3;U-87 MG: 289.1"
"CHI3L2",35,"D11","IOH9675",1173,"0",NA,"chitinase 3-like 2, mRNA (cDNA clone MGC:17183 IMAGE:4214121), complete cds","BC011460.1","AAH11460.1",1117,"Hs.514840","YKL-39, YKL39","ENSG00000064886","Chitinase 3 like 2","1","111200771-111243440","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA005443","Uncertain",NA,NA,NA,"Renal cancer:8.59e-7 (unfavourable), Glioma:1.55e-4 (unfavourable), Head and neck cancer:2.19e-4 (favourable)","Tissue enriched","Tissue enhanced",NA,"appendix: 152.3","tonsil: 103.1","Cell line enhanced",NA,"ASC diff: 62.1;MOLT-4: 277.3;U-698: 51.9"
"CHIA",130,"F4","IOH57647",1107,"0",NA,"chitinase, acidic (CHIA), transcript variant 2, mRNA.","NM_021797.2","NP_068569.2",27159,"Hs.128814","AMCase, CHIT2, TSA1902","ENSG00000134216","Chitinase, acidic","1","111290862-111320566","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA059193","Approved",NA,NA,NA,NA,"Tissue enhanced","Group enriched",11,"lung: 15.6;stomach: 8.2","endometrium: 1.1","Cell line enhanced",NA,"ASC diff: 1.1"
"CHID1",34,"H12","IOH4593",1182,"0",NA,"chitinase domain containing 1 (CHID1), transcript variant 1, mRNA.","NM_001142675.1","NP_001136147.1",66005,"Hs.144468","FLJ42707, MGC3234","ENSG00000177830","Chitinase domain containing 1","11","867860-915058","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA039374","Uncertain",NA,"Uncertain","Nucleoplasm<br>Intermediate filaments","Endometrial cancer:6.76e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 109.0","Expressed in all",NA,NA
"CHID1",154,"D3","IOH62644",1182,"0",NA,"chitinase domain containing 1, mRNA (cDNA clone MGC:110905 IMAGE:30333427), complete cds","BC095409.1","AAH95409.1",66005,"Hs.144468","FLJ42707, MGC3234","ENSG00000177830","Chitinase domain containing 1","11","867860-915058","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA039374","Uncertain",NA,"Uncertain","Nucleoplasm<br>Intermediate filaments","Endometrial cancer:6.76e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 109.0","Expressed in all",NA,NA
"CHIT1",150,"B10","IOH63601",1401,"0",NA,"chitinase 1 (chitotriosidase), mRNA (cDNA clone MGC:125322 IMAGE:40005693), complete cds","BC103695.1","AAI03696.1",1118,"Hs.201688","CHI3, CHIT","ENSG00000133063","Chitinase 1","1","203212827-203273641","Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA010575","Approved",NA,NA,NA,"Cervical cancer:2.02e-4 (favourable)","Tissue enhanced","Group enriched",14,"bone marrow: 31.3;breast: 10.9;cervix, uterine: 13.5;lung: 53.2;lymph node: 21.0","prostate,thyroid gland: 1.8","Not detected",NA,NA
"CHN1",69,"F11","IOH9774",1380,"0",NA,"chimerin (chimaerin) 1 (CHN1), transcript variant 1, mRNA.","NM_001822.4","NP_001813.1",1123,"Hs.654534","ARHGAP2, CHN, DURS2, n-chimerin, RhoGAP2","ENSG00000128656","Chimerin 1","2","174799363-175005369","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA036111",NA,NA,"Approved","Cytosol","Renal cancer:5.07e-4 (unfavourable)","Expressed in all","Group enriched",7,"cerebral cortex: 639.0;parathyroid gland: 133.3","placenta: 56.0","Cell line enhanced",NA,"BJ hTERT+: 172.5"
"CHPF2",146,"A3","IOH62979",2001,"0",NA,"chondroitin sulfate glucuronyltransferase, mRNA (cDNA clone MGC:71339 IMAGE:6423613), complete cds","BC064509.1","AAH64509.1",54480,"Hs.647084","ChSy-3, CSGlcA-T, KIAA1402","ENSG00000033100","Chondroitin polymerizing factor 2","7","151232489-151238827","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA020992","Approved",NA,"Approved","Nucleoplasm<br>Cytosol","Pancreatic cancer:2.51e-4 (favourable), Liver cancer:9.47e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"gallbladder,spleen: 23.5","Expressed in all",NA,NA
"CHPF2",144,"F9","IOH52785",2319,"0",NA,"chondroitin polymerizing factor 2 (CHPF2), mRNA.","NM_019015.1","NP_061888.1",54480,"Hs.647084","ChSy-3, CSGlcA-T, KIAA1402","ENSG00000033100","Chondroitin polymerizing factor 2","7","151232489-151238827","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA020992","Approved",NA,"Approved","Nucleoplasm<br>Cytosol","Pancreatic cancer:2.51e-4 (favourable), Liver cancer:9.47e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"gallbladder,spleen: 23.5","Expressed in all",NA,NA
"CHRDL1",24,"F2","IOH5714",1353,"0",NA,"Chordin-like protein 1 Precursor (Neuralin-1)(Ventroptin)(Neurogenesin-1) [Source:UniProtKB/Swiss-Prot;Acc:Q9BU40]","ENST00000372045","ENSP00000361115",91851,"Hs.496587","CHL, MGC1, NRLN1","ENSG00000101938","Chordin like 1","X","110673856-110795819","Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA000226, HPA000250","Approved",NA,NA,NA,"Urothelial cancer:2.23e-4 (unfavourable), Renal cancer:2.36e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"seminal vesicle: 386.7","parathyroid gland: 315.6","Group enriched",8,"ASC diff: 446.8;ASC TERT1: 622.4"
"CHRNA5",87,"C7","IOH21951",1407,"NP_000736.1","NP_000736.2","cholinergic receptor, nicotinic, alpha 5 (CHRNA5), mRNA.","NM_000745.2","NP_000736.2",1138,"Hs.1614",NA,"ENSG00000169684","Cholinergic receptor nicotinic alpha 5 subunit","15","78565520-78595269","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA054381","Approved",NA,"Approved","Plasma membrane<br>Focal adhesion sites","Lung cancer:3.64e-5 (unfavourable)","Mixed","Mixed",NA,NA,"gallbladder: 6.9","Mixed",NA,NA
"CHRNB1",65,"E2","IOH27836",1506,"NP_000738.1","AAH23553.1","cholinergic receptor, nicotinic, beta 1 (muscle), mRNA (cDNA clone MGC:19706 IMAGE:3531876), complete cds","BC023553.2","AAH23553.1",1140,"Hs.330386","CHRNB","ENSG00000170175","Cholinergic receptor nicotinic beta 1 subunit","17","7445061-7457707","Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA005822, CAB011200","Approved",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"skeletal muscle: 21.9","Cell line enhanced",NA,"LHCN-M2: 28.7;RH-30: 68.7"
"CHRNB1",41,"E4","IOH9801",1506,"0",NA,"cholinergic receptor, nicotinic, beta 1 (muscle) (CHRNB1), mRNA.","NM_000747.2","NP_000738.2",1140,"Hs.330386","CHRNB","ENSG00000170175","Cholinergic receptor nicotinic beta 1 subunit","17","7445061-7457707","Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA005822, CAB011200","Approved",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"skeletal muscle: 21.9","Cell line enhanced",NA,"LHCN-M2: 28.7;RH-30: 68.7"
"CHRND",131,"F12","IOH46556",1554,"NP_000742.1","NP_000742.1","cholinergic receptor, nicotinic, delta (CHRND), mRNA.","NM_000751.1","NP_000742.1",1144,"Hs.156289","ACHRD","ENSG00000135902","Cholinergic receptor nicotinic delta subunit","2","232525993-232536667","Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA056404, HPA065404",NA,NA,"Supported","Nucleoplasm<br>Plasma membrane<br>Cytosol",NA,"Tissue enriched","Tissue enriched",12,"skeletal muscle: 9.6","prostate: 0.8","Cell line enriched",76,"RH-30: 79.9"
"CHST13",151,"H10","IOH63441",678,"0",NA,"carbohydrate (chondroitin 4) sulfotransferase 13, mRNA (cDNA clone MGC:119279 IMAGE:40005101), complete cds","BC103896.1","AAI03897.1",166012,"Hs.292375","C4ST3","ENSG00000180767","Carbohydrate sulfotransferase 13","3","126524283-126543291","Enzymes, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"liver: 5.9;testis: 6.3","spleen: 2.9","Group enriched",6,"CACO-2: 13.9;Hep G2: 20.6;NB-4: 12.8;THP-1: 7.9"
"CHST13",151,"G7","IOH63440",1026,"0",NA,"carbohydrate (chondroitin 4) sulfotransferase 13, mRNA (cDNA clone MGC:119278 IMAGE:40005100), complete cds","BC103895.1","AAI03896.1",166012,"Hs.292375","C4ST3","ENSG00000180767","Carbohydrate sulfotransferase 13","3","126524283-126543291","Enzymes, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"liver: 5.9;testis: 6.3","spleen: 2.9","Group enriched",6,"CACO-2: 13.9;Hep G2: 20.6;NB-4: 12.8;THP-1: 7.9"
"CLCF1",9,"H12","IOH11263",678,"0",NA,"cardiotrophin-like cytokine factor 1 (CLCF1), mRNA.","NM_013246.2","NP_037378.1",23529,"Hs.502977","BSF-3, BSF3, CISS2, CLC, NNT-1, NNT1, NR6","ENSG00000175505","Cardiotrophin-like cytokine factor 1","11","67364168-67374177","Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA042444","Uncertain",NA,"Approved","Nuclear bodies<br>Vesicles",NA,"Expressed in all","Tissue enhanced",NA,"gallbladder: 26.3","endometrium: 21.4","Cell line enhanced",NA,"SiHa: 56.8"
"CLDN7",49,"E6","IOH4602",636,"NP_001298.2","AAH01055.1","claudin 7, mRNA (cDNA clone MGC:1858 IMAGE:3504311), complete cds","BC001055.2","AAH01055.1",1366,"Hs.513915","CEPTRL2, CPETRL2, Hs.84359","ENSG00000181885","Claudin 7","17","7259903-7263983","Cancer-related genes, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","CAB013063, HPA014703, HPA073662","Enhanced",NA,"Approved","Vesicles<br>Cell Junctions","Renal cancer:8.96e-11 (favourable), Thyroid cancer:1.85e-4 (favourable), Stomach cancer:4.09e-4 (favourable)","Expressed in all","Mixed",NA,NA,"small intestine: 350.1","Cell line enhanced",NA,"BEWO: 162.4;CAPAN-2: 304.6;HaCaT: 644.4;MCF7: 198.9;SK-BR-3: 225.1"
"CLDN7",145,"G4","IOH63093",636,"0",NA,"claudin 7 (CLDN7), mRNA.","NM_001307.4","NP_001298.3",1366,"Hs.513915","CEPTRL2, CPETRL2, Hs.84359","ENSG00000181885","Claudin 7","17","7259903-7263983","Cancer-related genes, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","CAB013063, HPA014703, HPA073662","Enhanced",NA,"Approved","Vesicles<br>Cell Junctions","Renal cancer:8.96e-11 (favourable), Thyroid cancer:1.85e-4 (favourable), Stomach cancer:4.09e-4 (favourable)","Expressed in all","Mixed",NA,NA,"small intestine: 350.1","Cell line enhanced",NA,"BEWO: 162.4;CAPAN-2: 304.6;HaCaT: 644.4;MCF7: 198.9;SK-BR-3: 225.1"
"CLEC18C",55,"F3","IOH27329",906,"0",NA,"C-type lectin domain family 18, member C, mRNA (cDNA clone MGC:34761 IMAGE:5188643), complete cds","BC039068.1","AAH39068.1",283971,"Hs.556045","MGC34761","ENSG00000157335","C-type lectin domain family 18 member C","16","70173322-70187361","Predicted secreted proteins","Evidence at transcript level","HPA048976","Uncertain",NA,NA,NA,NA,"Tissue enriched","Group enriched",23,"kidney: 11.4;testis: 3.6","duodenum: 0.3","Not detected",NA,NA
"CLEC3A",150,"C9","IOH63583",594,"0",NA,"C-type lectin domain family 3, member A, mRNA (cDNA clone MGC:129558 IMAGE:40003144), complete cds","BC104414.2","AAI04415.1",10143,"Hs.177936","CLECSF1","ENSG00000166509","C-type lectin domain family 3 member A","16","78022515-78066761","Predicted secreted proteins","Evidence at protein level","HPA051511","Uncertain",NA,NA,NA,"Breast cancer:1.61e-4 (unfavourable)","Tissue enriched","Tissue enhanced",NA,"breast: 12.4;urinary bladder: 8.3","prostate: 3.3","Cell line enhanced",NA,"MCF7: 2.5;SK-BR-3: 5.5;T-47d: 19.7"
"CLEC3B",44,"G6","IOH14450",609,"0",NA,"C-type lectin domain family 3, member B, mRNA (cDNA clone MGC:13592 IMAGE:4042921), complete cds","BC011024.1","AAH11024.1",7123,"Hs.476092","TN, TNA","ENSG00000163815","C-type lectin domain family 3 member B","3","45001548-45036071","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB002582, HPA034794","Approved",NA,NA,NA,"Liver cancer:9.99e-9 (favourable), Head and neck cancer:1.53e-4 (favourable), Pancreatic cancer:5.68e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"spleen: 303.3","adipose tissue: 203.9","Cell line enhanced",NA,"ASC diff: 169.4;ASC TERT1: 341.9;U-2197: 94.5"
"CLGN",18,"H9","IOH11926",1833,"NP_004353.1","NP_004353.1","calmegin (CLGN), transcript variant 1, mRNA.","NM_004362.2","NP_004353.1",1047,"Hs.86368",NA,"ENSG00000153132","Calmegin","4","140388455-140427968","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB020709, HPA048761, HPA058627","Enhanced",NA,"Enhanced","Endoplasmic reticulum",NA,"Tissue enhanced","Tissue enriched",5,"testis: 186.4","heart muscle: 35.6","Cell line enhanced",NA,"U-251 MG: 54.9"
"CLPS",38,"C2","IOH7303",339,"0",NA,"colipase, pancreatic (CLPS), mRNA.","NM_001832.2","NP_001823.1",1208,"Hs.1340",NA,"ENSG00000137392","Colipase","6","35794982-35797344","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA010512","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",264,"pancreas: 56632.1","ovary: 214.3","Not detected",NA,NA
"CLSTN3",91,"A1","IOH27403",870,"0",NA,"calsyntenin 3, mRNA (cDNA clone IMAGE:5175809), complete cds.","BC039075.1","AAH39075.1",9746,"Hs.535378","CDHR14, CSTN3, KIAA0726","ENSG00000139182","Calsyntenin 3","12","7129698-7158945","Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Pancreatic cancer:1.19e-5 (favourable), Renal cancer:4.49e-5 (unfavourable), Breast cancer:5.08e-4 (favourable), Urothelial cancer:8.07e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 126.6","parathyroid gland: 40.3","Mixed",NA,NA
"CLUL1",83,"G9","IOH11005",1401,"0",NA,"clusterin-like 1 (retinal) (CLUL1), transcript variant 1, mRNA.","NM_014410.4","NP_055225.1",27098,"Hs.632357",NA,"ENSG00000079101","Clusterin like 1","18","596988-650334","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB025264, HPA075240","Supported",NA,"Approved","Endoplasmic reticulum<br>Plasma membrane",NA,"Mixed","Tissue enhanced",NA,"prostate: 13.9","thyroid gland: 11.5","Cell line enhanced",NA,"Hep G2: 23.4"
"CMA1",150,"D9","IOH63586",411,"0",NA,"chymase 1, mast cell, mRNA (cDNA clone MGC:119890 IMAGE:40015325), complete cds","BC103974.1","AAI03975.1",1215,"Hs.135626",NA,"ENSG00000092009","Chymase 1","14","24505353-24508265","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB000363, HPA052634","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"breast: 23.8","esophagus: 11.4","Not detected",NA,NA
"CMPK1",2,"H1","IOH14868",687,"0",NA,"cytidine monophosphate (UMP-CMP) kinase 1, cytosolic, mRNA (cDNA clone MGC:23020 IMAGE:4901714), complete cds","BC014961.1","AAH14961.1",51727,"Hs.714325","CMPK, UMP-CMPK","ENSG00000162368","Cytidine/uridine monophosphate kinase 1","1","47333797-47378839","Enzymes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA053730, HPA058604","Approved",NA,"Supported","Nucleus","Glioma:8.67e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"small intestine: 169.1","Expressed in all",NA,NA
"CNDP1",108,"H7","IOH42043",1524,"0",NA,"carnosine dipeptidase 1 (metallopeptidase M20 family) (CNDP1), mRNA.","NM_032649.5","NP_116038.4",84735,"Hs.400613","CN1, CPGL2, HsT2308, MGC10825","ENSG00000150656","Carnosine dipeptidase 1","18","74534440-74587212","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA008933","Enhanced",NA,NA,NA,NA,"Group enriched","Group enriched",12,"cerebral cortex: 101.7;liver: 23.0","duodenum: 5.1","Cell line enriched",68,"U-266/84: 57.1"
"CNGA4",151,"G4","IOH60270",1728,"XP_290552.1","NP_001032406.1","cyclic nucleotide gated channel alpha 4 (CNGA4), mRNA.","NM_001037329.2","NP_001032406.1",1262,"Hs.434618","CNCA2, CNG5, CNGB2, OCNC2, OCNCb","ENSG00000132259","Cyclic nucleotide gated channel alpha 4","11","6234765-6244429","Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels","Evidence at protein level",NA,NA,NA,NA,NA,"Endometrial cancer:1.48e-4 (favourable)","Tissue enriched","Group enriched",9,"fallopian tube: 27.9;testis: 10.5","lung: 2.1","Not detected",NA,NA
"CNPY2",110,"E10","IOH45647",549,"0",NA,"canopy 2 homolog (zebrafish) (CNPY2), mRNA.","NM_014255.4","NP_055070.1",10330,"Hs.8752","Cnpy2, HP10390, TMEM4, ZSIG9","ENSG00000257727","Canopy FGF signaling regulator 2","12","56309842-56316336","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA038465, HPA038466","Supported",NA,"Supported","Cytosol","Renal cancer:2.32e-8 (unfavourable), Pancreatic cancer:8.37e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 87.4","Expressed in all",NA,NA
"CNPY2",4,"B11","IOH4215",255,"0",NA,"canopy 2 homolog (zebrafish), mRNA (cDNA clone IMAGE:3344788), complete cds.","BC001027.2","AAH01027.1",10330,"Hs.8752","Cnpy2, HP10390, TMEM4, ZSIG9","ENSG00000257727","Canopy FGF signaling regulator 2","12","56309842-56316336","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA038465, HPA038466","Supported",NA,"Supported","Cytosol","Renal cancer:2.32e-8 (unfavourable), Pancreatic cancer:8.37e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 87.4","Expressed in all",NA,NA
"CNPY3",85,"C11","IOH5802",837,"0",NA,"canopy 3 homolog (zebrafish) (CNPY3), mRNA.","NM_006586.3","NP_006577.2",10695,"Hs.414099","CAG4A, TNRC5","ENSG00000137161","Canopy FGF signaling regulator 3","6","42929192-42939287","Predicted secreted proteins","Evidence at protein level","HPA016560","Uncertain",NA,NA,NA,"Renal cancer:9.85e-6 (unfavourable), Colorectal cancer:3.03e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 103.1","Expressed in all",NA,NA
"CNPY3",120,"F5","IOH50088",165,"0",NA,"Protein canopy homolog 3 Precursor (Trinucleotide repeat-containing gene 5 protein)(CTG repeat protein 4a)(Expanded repeat-domain protein CAG/CTG 5) [Source:UniProtKB/Swiss-Prot;Acc:Q9BT09]","ENST00000394142","ENSP00000377698",10695,"Hs.414099","CAG4A, TNRC5","ENSG00000137161","Canopy FGF signaling regulator 3","6","42929192-42939287","Predicted secreted proteins","Evidence at protein level","HPA016560","Uncertain",NA,NA,NA,"Renal cancer:9.85e-6 (unfavourable), Colorectal cancer:3.03e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 103.1","Expressed in all",NA,NA
"CNTFR",16,"H6","IOH14561",1119,"0",NA,"ciliary neurotrophic factor receptor (CNTFR), transcript variant 2, mRNA.","NM_001842.3","NP_001833.1",1271,"Hs.129966",NA,"ENSG00000122756","Ciliary neurotrophic factor receptor","9","34551432-34590140","Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB025310","Approved",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"adipose tissue: 62.6;cerebral cortex: 53.4","spleen: 27.5","Group enriched",9,"AF22: 107.8;SH-SY5Y: 55.3"
"CNTN4",128,"E3","IOH11930",2094,"0",NA,"contactin 4, mRNA (cDNA clone MGC:33615 IMAGE:4826091), complete cds","BC026119.1","AAH26119.1",152330,"Hs.298705","BIG-2","ENSG00000144619","Contactin 4","3","2098813-3057956","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:1.00e-4 (favourable)","Mixed","Tissue enhanced",NA,"parathyroid gland: 48.7","testis: 24.3","Group enriched",6,"BEWO: 8.1;CACO-2: 7.6;HEK 293: 5.1;SH-SY5Y: 18.0;WM-115: 5.6"
"CNTNAP2",124,"F6","IOH53659",3996,"NP_054860.1","NP_054860.1","contactin associated protein-like 2 (CNTNAP2), mRNA.","NM_014141.4","NP_054860.1",26047,"Hs.655684","Caspr2, KIAA0868, NRXN4","ENSG00000174469","Contactin associated protein-like 2","7","146116002-148420998","Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA002739","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Group enriched",11,"cerebral cortex: 17.9;prostate: 6.0","fallopian tube: 1.0","Cell line enhanced",NA,"AF22: 7.9;CACO-2: 5.7;NTERA-2: 11.9;SCLC-21H: 28.5"
"COASY",78,"G8","IOH6429",678,"0",NA,"Coenzyme A synthase, mRNA (cDNA clone IMAGE:4123850), complete cds.","BC006354.1","AAH06354.1",80347,"Hs.709231","CoASY, DPCK, NBP, PPAT","ENSG00000068120","Coenzyme A synthase","17","42561467-42566277","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA022875, HPA022912, HPA023273","Approved",NA,"Approved","Nucleoplasm<br>Cytosol","Liver cancer:7.54e-5 (unfavourable), Endometrial cancer:2.15e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 60.1","Expressed in all",NA,NA
"COASY",109,"C6","IOH40019",1695,"0",NA,"Coenzyme A synthase, mRNA (cDNA clone MGC:74579 IMAGE:6502943), complete cds","BC067254.1","AAH67254.1",80347,"Hs.709231","CoASY, DPCK, NBP, PPAT","ENSG00000068120","Coenzyme A synthase","17","42561467-42566277","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA022875, HPA022912, HPA023273","Approved",NA,"Approved","Nucleoplasm<br>Cytosol","Liver cancer:7.54e-5 (unfavourable), Endometrial cancer:2.15e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 60.1","Expressed in all",NA,NA
"COASY",32,"A6","IOH21447",810,"0",NA,"Coenzyme A synthase (COASY), nuclear gene encoding mitochondrial protein, transcript variant 5, mRNA.","NM_001042531.1","NP_001035996.1",80347,"Hs.709231","CoASY, DPCK, NBP, PPAT","ENSG00000068120","Coenzyme A synthase","17","42561467-42566277","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA022875, HPA022912, HPA023273","Approved",NA,"Approved","Nucleoplasm<br>Cytosol","Liver cancer:7.54e-5 (unfavourable), Endometrial cancer:2.15e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 60.1","Expressed in all",NA,NA
"COCH",41,"D3","IOH6799",1485,"0",NA,"coagulation factor C homolog, cochlin (Limulus polyphemus), mRNA (cDNA clone MGC:15268 IMAGE:2824361), complete cds","BC007230.1","AAH07230.1",1690,"Hs.21016","COCH-5B2, DFNA31, DFNA9","ENSG00000100473","Cochlin","14","30874514-30895065","Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA065086",NA,NA,"Approved","Vesicles",NA,"Mixed","Group enriched",6,"pancreas: 94.8;prostate: 79.0;seminal vesicle: 99.1","cervix, uterine: 15.4","Cell line enhanced",NA,"HEK 293: 92.9;K-562: 114.9;NB-4: 71.8;SCLC-21H: 130.1"
"COL21A1",105,"A4","IOH43848",2874,"0",NA,"collagen, type XXI, alpha 1 (COL21A1), mRNA.","NM_030820.3","NP_110447.2",81578,"Hs.47629",NA,"ENSG00000124749","Collagen type XXI alpha 1 chain","6","56056590-56394094","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA031212",NA,NA,"Supported","Cytosol",NA,"Mixed","Tissue enhanced",NA,"cervix, uterine: 36.7;placenta: 39.0","endometrium: 19.6","Cell line enhanced",NA,"ASC TERT1: 15.7;BEWO: 7.2;HSkMC: 16.7"
"COL2A1",22,"G1","IOH6830",807,"0",NA,"collagen, type II, alpha 1, mRNA (cDNA clone IMAGE:3010564), complete cds.","BC007252.1","AAH07252.1",1280,"Hs.408182","AOM, SEDC, STL1","ENSG00000139219","Collagen type II alpha 1 chain","12","47972965-48004486","Cancer-related genes, Disease related genes, Predicted secreted proteins","Evidence at protein level","CAB002214, HPA055753","Supported",NA,"Approved","Nucleoplasm",NA,"Mixed","Group enriched",9,"epididymis: 23.0;stomach: 6.2","prostate: 1.6","Group enriched",23,"AF22: 154.1;HAP1: 101.9;HEK 293: 33.7"
"COL3A1",84,"A3","IOH11545",3492,"0",NA,"collagen, type III, alpha 1, mRNA (cDNA clone MGC:39848 IMAGE:5405119), complete cds","BC028178.1","AAH28178.1",1281,"Hs.443625","EDS4A","ENSG00000168542","Collagen type III alpha 1 chain","2","188974320-189012746","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA007583, CAB016766, CAB059993","Approved",NA,NA,NA,"Renal cancer:3.59e-10 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cervix, uterine: 3796.7;gallbladder: 3334.2;smooth muscle: 3029.8","placenta: 2768.0","Cell line enhanced",NA,"AF22: 1344.2;ASC diff: 1690.4;ASC TERT1: 2979.5;fHDF/TERT166: 1406.5;HHSteC: 1419.6;HSkMC: 2318.4"
"COL4A5",98,"D10","IOH36464",5076,"0",NA,"collagen, type IV, alpha 5 (COL4A5), transcript variant 2, mRNA.","NM_033380.1","NP_203699.1",1287,"Hs.369089","ASLN, ATS","ENSG00000188153","Collagen type IV alpha 5 chain","X","108439844-108697545","Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA065449",NA,NA,"Uncertain","Lipid droplets","Renal cancer:2.41e-5 (unfavourable)","Expressed in all","Mixed",NA,NA,"endometrium: 76.4","Cell line enhanced",NA,"HHSteC: 80.3;HUVEC TERT2: 76.9;SiHa: 73.2;TIME: 73.5"
"COL4A6",93,"C9","IOH40798",219,"0",NA,"collagen, type IV, alpha 6, mRNA (cDNA clone IMAGE:4274195), complete cds.","BC070203.1","AAH70203.1",1288,"Hs.145586",NA,"ENSG00000197565","Collagen type IV alpha 6 chain","X","108155607-108439497","Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA065393",NA,NA,"Approved","Endoplasmic reticulum",NA,"Mixed","Mixed",NA,NA,"smooth muscle: 36.9","Cell line enhanced",NA,"HBEC3-KT: 32.9;HHSteC: 49.7;hTERT-HME1: 33.8;HUVEC TERT2: 34.7;TIME: 76.5"
"COL4A6",77,"D4","IOH7363",222,"0",NA,"collagen, type IV, alpha 6, mRNA (cDNA clone IMAGE:3951220), complete cds.","BC005305.1","AAH05305.1",1288,"Hs.145586",NA,"ENSG00000197565","Collagen type IV alpha 6 chain","X","108155607-108439497","Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA065393",NA,NA,"Approved","Endoplasmic reticulum",NA,"Mixed","Mixed",NA,NA,"smooth muscle: 36.9","Cell line enhanced",NA,"HBEC3-KT: 32.9;HHSteC: 49.7;hTERT-HME1: 33.8;HUVEC TERT2: 34.7;TIME: 76.5"
"COL5A2",154,"B8","IOH62731",3420,"0",NA,"collagen, type V, alpha 2, mRNA (cDNA clone MGC:105115 IMAGE:30708812), complete cds","BC086874.1","AAH86874.1",1290,"Hs.445827",NA,"ENSG00000204262","Collagen type V alpha 2 chain","2","189031896-189179879","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:1.53e-10 (unfavourable), Urothelial cancer:3.58e-4 (unfavourable), Lung cancer:5.37e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"placenta: 154.0","Cell line enhanced",NA,"BJ hTERT+ SV40 Large T+: 407.0;BJ hTERT+ SV40 Large T+ RasG12V: 363.2;fHDF/TERT166: 325.7"
"COL6A2",26,"F9","IOH4285",1278,"0",NA,"collagen, type VI, alpha 2, mRNA (cDNA clone IMAGE:3347413), complete cds.","BC002484.2","AAH02484.1",1292,"Hs.420269",NA,"ENSG00000142173","Collagen type VI alpha 2 chain","21","46098097-46132849","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA007029, HPA030920, HPA038799","Enhanced",NA,"Approved","Plasma membrane<br>Cytosol","Renal cancer:8.72e-14 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 472.0","Cell line enhanced",NA,"ASC TERT1: 1480.1;BJ: 903.2;HHSteC: 946.3;HSkMC: 1105.7;U-138 MG: 1108.3"
"COL8A2",152,"B9","IOH63247",1284,"0",NA,"collagen, type VIII, alpha 2, mRNA (cDNA clone MGC:116972 IMAGE:40007335), complete cds","BC096296.3","AAH96296.1",1296,"Hs.353001","FECD, FECD1, PPCD, PPCD2","ENSG00000171812","Collagen type VIII alpha 2 chain","1","36095236-36125220","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA049788","Uncertain",NA,"Uncertain","Golgi apparatus","Renal cancer:9.35e-5 (unfavourable), Ovarian cancer:7.26e-4 (unfavourable), Head and neck cancer:9.44e-4 (favourable)","Expressed in all","Mixed",NA,NA,"placenta: 18.2","Cell line enhanced",NA,"BJ: 4.9;fHDF/TERT166: 3.3;HHSteC: 11.8"
"COL9A1",11,"H5","IOH10948",987,"0",NA,"collagen, type IX, alpha 1, mRNA (cDNA clone IMAGE:4392252), complete cds.","BC015409.1","AAH15409.1",1297,"Hs.590892",NA,"ENSG00000112280","Collagen type IX alpha 1 chain","6","70215061-70303083","Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA074749","Supported",NA,NA,NA,NA,"Mixed","Tissue enriched",6,"prostate: 31.4","testis: 5.1","Group enriched",6,"AF22: 27.0;NTERA-2: 9.9"
"COL9A3",85,"B1","IOH12425",2055,"0",NA,"collagen, type IX, alpha 3 (COL9A3), mRNA.","NM_001853.3","NP_001844.3",1299,"Hs.716639","DJ885L7.4.1, EDM3, FLJ90759, IDD, MED","ENSG00000092758","Collagen type IX alpha 3 chain","20","62816244-62841159","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA040125, HPA058323","Supported",NA,"Approved","Nucleoplasm<br>Intermediate filaments",NA,"Mixed","Group enriched",6,"cerebral cortex: 7.5;salivary gland: 10.5;testis: 6.3;thyroid gland: 19.1","seminal vesicle: 1.8","Group enriched",6,"BEWO: 139.2;Hep G2: 40.1;SK-MEL-30: 37.9;WM-115: 57.3"
"COLEC10",114,"G6","IOH42479",834,"0",NA,"collectin sub-family member 10 (C-type lectin), mRNA (cDNA clone MGC:118794 IMAGE:40000432), complete cds","BC103815.1","AAI03816.1",10584,"Hs.176615","CL-L1","ENSG00000184374","Collectin subfamily member 10","8","118995452-119106582","Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Liver cancer:5.79e-4 (favourable)","Mixed","Group enriched",8,"liver: 51.2;placenta: 26.0","thyroid gland: 5.0","Group enriched",6,"BJ hTERT+: 5.2;HHSteC: 2.1;SK-BR-3: 8.4"
"COLEC11",22,"D8","IOH4726",816,"0",NA,"collectin sub-family member 11 (COLEC11), transcript variant 1, mRNA.","NM_024027.3","NP_076932.1",78989,"Hs.32603","CL-K1, MGC3279","ENSG00000118004","Collectin subfamily member 11","2","3594832-3644644","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA035241","Approved",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"gallbladder: 102.0","adrenal gland: 36.2","Group enriched",8,"HHSteC: 135.6;SH-SY5Y: 158.1"
"CORT",106,"A8","IOH42947",468,"0",NA,"cortistatin (CORT), mRNA.","NM_001302.3","NP_001293.2",1325,"Hs.412311","MGC32686","ENSG00000241563","Cortistatin","1","10449719-10451902","Predicted secreted proteins","Evidence at transcript level",NA,NA,NA,NA,NA,NA,"Mixed","Tissue enriched",24,"cerebral cortex: 24.8","placenta: 1.0","Mixed",NA,NA
"CPA1",20,"B9","IOH7369",1260,"0",NA,"carboxypeptidase A1 (pancreatic), mRNA (cDNA clone MGC:12328 IMAGE:3949850), complete cds","BC005279.1","AAH05279.1",1357,"Hs.2879","CPA","ENSG00000091704","Carboxypeptidase A1","7","130380339-130388114","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA021836, CAB025197, HPA052215","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",367,"pancreas: 48856.8","ovary: 133.1","Cell line enhanced",NA,"AN3-CA: 10.9;SCLC-21H: 2.5;U-2 OS: 1.7"
"CPA1",134,"G3","IOH53980",1260,"0",NA,"carboxypeptidase A1 (pancreatic) (CPA1), mRNA.","NM_001868.2","NP_001859.1",1357,"Hs.2879","CPA","ENSG00000091704","Carboxypeptidase A1","7","130380339-130388114","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA021836, CAB025197, HPA052215","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",367,"pancreas: 48856.8","ovary: 133.1","Cell line enhanced",NA,"AN3-CA: 10.9;SCLC-21H: 2.5;U-2 OS: 1.7"
"CPA2",61,"B3","IOH27872",1254,"0",NA,"carboxypeptidase A2 (pancreatic), mRNA (cDNA clone MGC:22698 IMAGE:3950117), complete cds","BC014571.1","AAH14571.1",1358,"Hs.490038",NA,"ENSG00000158516","Carboxypeptidase A2","7","130266827-130289798","Enzymes, Predicted secreted proteins","Evidence at protein level","HPA020342, HPA021317","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",104,"pancreas: 9283.9","stomach: 89.6","Cell line enhanced",NA,"AN3-CA: 2.0;CACO-2: 3.0;RH-30: 2.8;SCLC-21H: 1.9"
"CPA2",21,"G2","IOH7191",1254,"0",NA,"carboxypeptidase A2 (pancreatic), mRNA (cDNA clone MGC:12327 IMAGE:3949984), complete cds","BC007009.1","AAH07009.1",1358,"Hs.490038",NA,"ENSG00000158516","Carboxypeptidase A2","7","130266827-130289798","Enzymes, Predicted secreted proteins","Evidence at protein level","HPA020342, HPA021317","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",104,"pancreas: 9283.9","stomach: 89.6","Cell line enhanced",NA,"AN3-CA: 2.0;CACO-2: 3.0;RH-30: 2.8;SCLC-21H: 1.9"
"CPA3",17,"G1","IOH13721",1254,"0",NA,"carboxypeptidase A3 (mast cell), mRNA (cDNA clone MGC:13637 IMAGE:4104766), complete cds","BC012613.1","AAH12613.1",1359,"Hs.646",NA,"ENSG00000163751","Carboxypeptidase A3","3","148865256-148897196","Enzymes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA006479, HPA008689, CAB020712","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"gallbladder: 173.9","lung: 126.9","Cell line enriched",46,"HEL: 265.9"
"CPA3",134,"A2","IOH53977",1254,"0",NA,"Mast cell carboxypeptidase A.","P15088","P15088",1359,"Hs.646",NA,"ENSG00000163751","Carboxypeptidase A3","3","148865256-148897196","Enzymes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA006479, HPA008689, CAB020712","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"gallbladder: 173.9","lung: 126.9","Cell line enriched",46,"HEL: 265.9"
"CPA4",127,"F11","IOH28090",1266,"0",NA,"carboxypeptidase A4 (CPA4), transcript variant 1, mRNA.","NM_016352.3","NP_057436.2",51200,"Hs.93764","CPA3","ENSG00000128510","Carboxypeptidase A4","7","130293134-130324180","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA021030","Uncertain",NA,"Approved","Nucleoplasm<br>Centrosome<br>Cytosol","Urothelial cancer:1.31e-4 (unfavourable)","Tissue enhanced","Tissue enriched",7,"skin: 67.8","esophagus: 10.0","Cell line enhanced",NA,"LHCN-M2: 238.0;U-2 OS: 159.5;U-87 MG: 268.2"
"CPA6",128,"F6","IOH21853",1314,"0",NA,"carboxypeptidase A6, mRNA (cDNA clone MGC:45032 IMAGE:5193403), complete cds","BC033684.1","AAH33684.1",57094,"Hs.658850","CPAH","ENSG00000165078","Carboxypeptidase A6","8","67422038-67746385","Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"prostate: 4.9;rectum: 2.9","colon: 1.7","Cell line enhanced",NA,"CACO-2: 2.9;EFO-21: 1.8;Hep G2: 3.6"
"CPB1",80,"B2","IOH11321",1254,"0",NA,"carboxypeptidase B1 (tissue) (CPB1), mRNA.","NM_001871.2","NP_001862.2",1360,"Hs.477891",NA,"ENSG00000153002","Carboxypeptidase B1","3","148791102-148860187","Enzymes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB026158, HPA038069, HPA046340","Enhanced",NA,NA,NA,NA,"Group enriched","Tissue enriched",312,"pancreas: 47292.1","ovary: 151.6","Cell line enhanced",NA,"HDLM-2: 1.0;U-2 OS: 1.7"
"CPB2",134,"D6","IOH57046",1272,"0",NA,"carboxypeptidase B2 (plasma) (CPB2), transcript variant 1, mRNA.","NM_001872.3","NP_001863.2",1361,"Hs.512937","CPU, PCPB, TAFI","ENSG00000080618","Carboxypeptidase B2","13","46053186-46105076","Enzymes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA004146","Approved",NA,NA,NA,"Liver cancer:2.06e-4 (favourable)","Tissue enriched","Tissue enriched",28,"liver: 755.5","lung: 26.5","Cell line enriched",66,"Hep G2: 117.8"
"CPE",87,"H6","IOH21845",1431,"0",NA,"carboxypeptidase E (CPE), mRNA.","NM_001873.2","NP_001864.1",1363,"Hs.75360",NA,"ENSG00000109472","Carboxypeptidase E","4","165361194-165498320","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA003819, CAB024907","Supported",NA,"Approved","Nucleoplasm<br>Vesicles<br>Centrosome","Urothelial cancer:2.12e-4 (unfavourable), Renal cancer:2.60e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 1560.8","Group enriched",5,"Hep G2: 211.8;SCLC-21H: 493.5;SH-SY5Y: 147.0;SiHa: 668.1"
"CPM",86,"C7","IOH12912",1332,"0",NA,"carboxypeptidase M (CPM), transcript variant 3, mRNA.","NM_001005502.2","NP_001005502.1",1368,"Hs.654387",NA,"ENSG00000135678","Carboxypeptidase M","12","68842197-68971570","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA002657, HPA077243","Uncertain",NA,"Uncertain","Vesicles","Endometrial cancer:1.00e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"adipose tissue: 164.0","placenta: 101.2","Cell line enhanced",NA,"ASC diff: 48.8;ASC TERT1: 35.1;HSkMC: 66.3;SiHa: 73.7"
"CPN1",54,"H3","IOH11355",1377,"0",NA,"carboxypeptidase N, polypeptide 1 (CPN1), mRNA.","NM_001308.2","NP_001299.1",1369,"Hs.2246",NA,"ENSG00000120054","Carboxypeptidase N subunit 1","10","100042193-100081877","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA040323",NA,NA,"Approved","Nucleus<br>Nucleoli",NA,"Group enriched","Tissue enriched",22,"liver: 37.1","testis: 1.7","Cell line enriched",16,"SK-MEL-30: 110.4"
"CPVL",29,"G10","IOH10663",1431,"0",NA,"carboxypeptidase, vitellogenic-like, mRNA (cDNA clone MGC:10029 IMAGE:3888647), complete cds","BC016838.2","AAH16838.1",54504,"Hs.233389",NA,"ENSG00000106066","Carboxypeptidase, vitellogenic like","7","28995231-29195451","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB003697, HPA045715, HPA056466","Enhanced",NA,"Supported","Endoplasmic reticulum","Endometrial cancer:8.56e-6 (unfavourable), Urothelial cancer:4.99e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 301.8","Cell line enhanced",NA,"BEWO: 183.9;RPTEC TERT1: 604.1"
"CPXM1",157,"H12","IOH61540",2205,"0",NA,"carboxypeptidase X (M14 family), member 1, mRNA (cDNA clone MGC:74418 IMAGE:5239864), complete cds","BC063430.1","AAH63430.1",56265,"Hs.659346","CPX-1, CPX1, CPXM","ENSG00000088882","Carboxypeptidase X, M14 family member 1","20","2794069-2800637","Enzymes, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:4.62e-10 (unfavourable)","Expressed in all","Tissue enhanced",NA,"endometrium: 130.4;gallbladder: 132.2","urinary bladder: 75.0","Group enriched",5,"AF22: 158.5;HSkMC: 62.0;NB-4: 92.9;NTERA-2: 34.2;REH: 136.3;SH-SY5Y: 113.9"
"CRELD1",130,"F6","IOH57815",1263,"NP_056328.2","NP_056328.2","cysteine-rich with EGF-like domains 1 (CRELD1), transcript variant 2, mRNA.","NM_015513.3","NP_056328.2",78987,"Hs.9383","AVSD2","ENSG00000163703","Cysteine rich with EGF like domains 1","3","9933822-9945413","Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA026964","Uncertain",NA,"Approved","Nucleoli<br>Cytosol","Glioma:6.05e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 65.6","Expressed in all",NA,NA
"CRELD1",29,"C1","IOH6530",1269,"0",NA,"cysteine-rich with EGF-like domains 1 (CRELD1), transcript variant 1, mRNA.","NM_001031717.2","NP_001026887.1",78987,"Hs.9383","AVSD2","ENSG00000163703","Cysteine rich with EGF like domains 1","3","9933822-9945413","Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA026964","Uncertain",NA,"Approved","Nucleoli<br>Cytosol","Glioma:6.05e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 65.6","Expressed in all",NA,NA
"CRELD2",126,"E9","IOH5701",966,"0",NA,"cysteine-rich with EGF-like domains 2, mRNA (cDNA clone MGC:11256 IMAGE:3941590), complete cds","BC002894.1","AAH02894.1",79174,"Hs.211282","MGC11256","ENSG00000184164","Cysteine rich with EGF like domains 2","22","49918167-49927540","Predicted secreted proteins","Evidence at protein level","HPA000603, CAB025604","Approved",NA,NA,NA,"Renal cancer:1.34e-9 (unfavourable), Endometrial cancer:2.42e-7 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 94.2","Expressed in all",NA,NA
"CRH",37,"D11","IOH4131",591,"0",NA,"corticotropin releasing hormone (CRH), mRNA.","NM_000756.1","NP_000747.1",1392,"Hs.75294","CRF, CRH1","ENSG00000147571","Corticotropin releasing hormone","8","66176382-66178725","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA046846, HPA062111","Uncertain","Supported",NA,NA,NA,"Tissue enriched","Tissue enhanced",NA,"cerebral cortex: 2.1;placenta: 8.0","adipose tissue: 1.2","Not detected",NA,NA
"CRHBP",87,"G5","IOH11163",969,"0",NA,"corticotropin releasing hormone binding protein (CRHBP), mRNA.","NM_001882.3","NP_001873.2",1393,"Hs.115617","CRF-BP, CRFBP","ENSG00000145708","Corticotropin releasing hormone binding protein","5","76952713-76981158","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA046120","Approved",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"liver: 69.9;spleen: 42.2","kidney: 30.2","Cell line enhanced",NA,"BJ hTERT+ SV40 Large T+: 3.2;BJ hTERT+ SV40 Large T+ RasG12V: 3.3;HBF TERT88: 6.0;U-698: 4.8;U-87 MG: 3.6;WM-115: 3.2"
"CRHR1",77,"H6","IOH39398",1248,"NP_004373.2","NP_004373.2","corticotropin releasing hormone receptor 1 (CRHR1), transcript variant 2, mRNA.","NM_004382.4","NP_004373.2",1394,"Hs.417628","CRF-R, CRF1, CRHR","ENSG00000120088","Corticotropin releasing hormone receptor 1","17","45784280-45835828","FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","CAB025251","Approved",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 4.0","endometrium: 0.8","Cell line enhanced",NA,"RT4: 2.7;SH-SY5Y: 2.2"
"CRHR2",102,"D5","IOH29569",1236,"0",NA,"corticotropin releasing hormone receptor 2 (CRHR2), mRNA.","NM_001883.3","NP_001874.2",1395,"Hs.546246","CRF-RB, CRF2, HM-CRF","ENSG00000106113","Corticotropin releasing hormone receptor 2","7","30651943-30700129","G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA046683","Uncertain",NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"seminal vesicle: 1.7","cerebral cortex: 1.2","Not detected",NA,NA
"CRISP1",139,"C11","IOH59798",750,"0",NA,"cysteine-rich secretory protein 1 (CRISP1), transcript variant 1, mRNA.","NM_001131.2","NP_001122.2",167,"Hs.109620","AEGL1, ARP, CRISP-1, HSCRISP1D, HSCRISP1G, HUMARP","ENSG00000124812","Cysteine rich secretory protein 1","6","49834257-49877096","Predicted secreted proteins","Evidence at protein level","HPA028445, HPA030534","Enhanced",NA,NA,NA,NA,"Not detected","Tissue enriched",20,"epididymis: 1915.6","seminal vesicle: 96.7","Cell line enhanced",NA,"NB-4: 1.7"
"CRISPLD2",45,"H4","IOH6278",363,"0",NA,"cysteine-rich secretory protein LCCL domain containing 2, mRNA (cDNA clone IMAGE:3953885), complete cds.","BC007689.2","AAH07689.1",83716,"Hs.513779","DKFZP434B044, LCRISP2, LGL1","ENSG00000103196","Cysteine rich secretory protein LCCL domain containing 2","16","84819984-84920768","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA030054, HPA030055","Approved",NA,"Approved","Nucleus<br>Nucleoli","Renal cancer:1.97e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 174.3","Cell line enhanced",NA,"BEWO: 66.9;HHSteC: 135.7;HSkMC: 49.5"
"CRISPLD2",157,"C9","IOH61545",1350,"0",NA,"cysteine-rich secretory protein LCCL domain containing 2, mRNA (cDNA clone MGC:74865 IMAGE:5217820), complete cds","BC063012.1","AAH63012.1",83716,"Hs.513779","DKFZP434B044, LCRISP2, LGL1","ENSG00000103196","Cysteine rich secretory protein LCCL domain containing 2","16","84819984-84920768","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA030054, HPA030055","Approved",NA,"Approved","Nucleus<br>Nucleoli","Renal cancer:1.97e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 174.3","Cell line enhanced",NA,"BEWO: 66.9;HHSteC: 135.7;HSkMC: 49.5"
"CRLF1",133,"F8","IOH57263",1269,"0",NA,"cytokine receptor-like factor 1 (CRLF1), mRNA.","NM_004750.3","NP_004741.1",9244,"Hs.114948","CISS, CISS1, CLF, CLF-1","ENSG00000006016","Cytokine receptor like factor 1","19","18572220-18607741","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA041493, HPA041793","Approved",NA,NA,NA,"Renal cancer:3.96e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 17.2;placenta: 16.8","adipose tissue: 10.1","Group enriched",8,"ASC diff: 706.3;Hep G2: 309.6"
"CRTAC1",32,"E4","IOH21411",1356,"0",NA,"cartilage acidic protein 1, mRNA (cDNA clone MGC:16989 IMAGE:4178363), complete cds","BC034245.1","AAH34245.1",55118,"Hs.500736","ASPIC1, CEP-68, FLJ10320","ENSG00000095713","Cartilage acidic protein 1","10","97865000-98030828","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA008175","Enhanced",NA,NA,NA,"Endometrial cancer:5.01e-6 (unfavourable), Urothelial cancer:1.51e-4 (favourable), Renal cancer:1.85e-4 (favourable)","Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 51.0;fallopian tube: 63.6;lung: 76.3;seminal vesicle: 48.1","urinary bladder: 12.8","Cell line enhanced",NA,"HUVEC TERT2: 6.0;SCLC-21H: 5.6;SK-MEL-30: 6.3;TIME: 8.0"
"CRY2",74,"D3","IOH27709",1782,"0",NA,"cryptochrome 2 (photolyase-like), mRNA (cDNA clone MGC:43402 IMAGE:5266781), complete cds","BC041814.1","AAH41814.1",1408,"Hs.532491",NA,"ENSG00000121671","Cryptochrome circadian clock 2","11","45847118-45883248","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA037577","Supported",NA,"Supported","Nuclear speckles<br>Cytosol","Renal cancer:6.44e-15 (favourable), Liver cancer:6.82e-5 (favourable), Colorectal cancer:1.67e-4 (unfavourable), Pancreatic cancer:4.39e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 56.2","Expressed in all",NA,NA
"CRY2",147,"G5","IOH62260",1386,"0",NA,"cryptochrome 2 (photolyase-like), mRNA (cDNA clone MGC:43304 IMAGE:5265444), complete cds","BC035161.1","AAH35161.1",1408,"Hs.532491",NA,"ENSG00000121671","Cryptochrome circadian clock 2","11","45847118-45883248","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA037577","Supported",NA,"Supported","Nuclear speckles<br>Cytosol","Renal cancer:6.44e-15 (favourable), Liver cancer:6.82e-5 (favourable), Colorectal cancer:1.67e-4 (unfavourable), Pancreatic cancer:4.39e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 56.2","Expressed in all",NA,NA
"CSF1",105,"D1","IOH43696",771,"0",NA,"colony stimulating factor 1 (macrophage) (CSF1), transcript variant 3, mRNA.","NM_172211.2","NP_757350.1",1435,"Hs.591402","M-CSF, MCSF, MGC31930","ENSG00000184371","Colony stimulating factor 1","1","109910242-109930992","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:1.00e-11 (unfavourable), Liver cancer:4.25e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"adipose tissue: 66.6","Cell line enhanced",NA,"ASC diff: 146.1;HHSteC: 271.2;HSkMC: 150.5"
"CSF1",83,"F5","IOH13347",1665,"NP_757349.1","NP_000748.3","colony stimulating factor 1 (macrophage) (CSF1), transcript variant 1, mRNA.","NM_000757.4","NP_000748.3",1435,"Hs.591402","M-CSF, MCSF, MGC31930","ENSG00000184371","Colony stimulating factor 1","1","109910242-109930992","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:1.00e-11 (unfavourable), Liver cancer:4.25e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"adipose tissue: 66.6","Cell line enhanced",NA,"ASC diff: 146.1;HHSteC: 271.2;HSkMC: 150.5"
"CSF2",151,"C2","IOH44352",435,"0",NA,"colony stimulating factor 2 (granulocyte-macrophage) (CSF2), mRNA.","NM_000758.2","NP_000749.2",1437,"Hs.1349","GM-CSF, GMCSF","ENSG00000164400","Colony stimulating factor 2","5","132073790-132076170","Cancer-related genes, Predicted secreted proteins","Evidence at protein level","HPA057404, HPA062006",NA,NA,"Enhanced","Vesicles",NA,"Mixed","Tissue enhanced",NA,"lung: 3.0","urinary bladder: 0.9","Cell line enhanced",NA,"BJ hTERT+: 74.1;hTEC/SVTERT24-B: 20.9"
"CSF2RA",42,"H7","IOH5253",1203,"0",NA,"colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage) (CSF2RA), transcript variant 1, mRNA.","NM_006140.4","NP_006131.2",1438,"Hs.520937","CD116, CSF2R","ENSG00000198223","Colony stimulating factor 2 receptor alpha subunit","X","1268800-1310381","Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB016148","Uncertain",NA,NA,NA,"Cervical cancer:2.38e-5 (favourable), Head and neck cancer:2.81e-4 (favourable), Testis cancer:5.53e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"placenta: 93.3","appendix: 34.6","Group enriched",8,"BEWO: 187.1;HMC-1: 51.2;SK-MEL-30: 109.5"
"CSF3",139,"B12","IOH59727",624,"0",NA,"colony stimulating factor 3 (granulocyte) (CSF3), transcript variant 1, mRNA.","NM_000759.2","NP_000750.1",1440,"Hs.2233","C17orf33, G-CSF, GCSF, MGC45931","ENSG00000108342","Colony stimulating factor 3","17","40015361-40017813","Cancer-related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Endometrial cancer:8.45e-4 (favourable)","Mixed","Tissue enhanced",NA,"appendix: 19.1;cervix, uterine: 38.2","adipose tissue: 10.3","Cell line enhanced",NA,"BJ hTERT+: 57.2;hTEC/SVTERT24-B: 34.2;U-87 MG: 265.0"
"CSH1",49,"E7","IOH5369",654,"0",NA,"chorionic somatomammotropin hormone 1 (placental lactogen) (CSH1), transcript variant 1, mRNA.","NM_001317.3","NP_001308.1",1442,"Hs.654390","CSA, CSMT, FLJ75407, hCS-A, PL","ENSG00000136488","Chorionic somatomammotropin hormone 1","17","63894909-63896661","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB026374, HPA043715","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",211,"placenta: 13487.0","smooth muscle: 63.9","Cell line enriched",6,"BEWO: 11.1"
"CSH1",139,"C6","IOH58682",369,"0",NA,"chorionic somatomammotropin hormone 1 (placental lactogen) (CSH1), transcript variant 3, mRNA.","NM_022641.2","NP_072167.1",1442,"Hs.654390","CSA, CSMT, FLJ75407, hCS-A, PL","ENSG00000136488","Chorionic somatomammotropin hormone 1","17","63894909-63896661","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB026374, HPA043715","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",211,"placenta: 13487.0","smooth muscle: 63.9","Cell line enriched",6,"BEWO: 11.1"
"CSH1",118,"H5","IOH29152",654,"0",NA,"chorionic somatomammotropin hormone 1 (placental lactogen), mRNA (cDNA clone MGC:71529 IMAGE:30337725), complete cds","BC057768.1","AAH57768.1",1442,"Hs.654390","CSA, CSMT, FLJ75407, hCS-A, PL","ENSG00000136488","Chorionic somatomammotropin hormone 1","17","63894909-63896661","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB026374, HPA043715","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",211,"placenta: 13487.0","smooth muscle: 63.9","Cell line enriched",6,"BEWO: 11.1"
"CSH2",60,"G5","IOH27937",654,"0",NA,"chorionic somatomammotropin hormone 2 (CSH2), transcript variant 1, mRNA.","NM_020991.3","NP_066271.1",1443,"Hs.654390","CS-2, CSB, hCS-B","ENSG00000213218","Chorionic somatomammotropin hormone 2","17","63872012-63873766","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA043715","Supported",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",193,"placenta: 3932.3","smooth muscle: 20.4","Cell line enriched",27,"BEWO: 7.7"
"CSHL1",86,"E10","IOH23169",387,"0",NA,"chorionic somatomammotropin hormone-like 1 (CSHL1), transcript variant 3, mRNA.","NM_001318.2","NP_001309.3",1444,"Hs.655225","CS-5, CSHP1, CSL, hCS-L, MGC149868","ENSG00000204414","Chorionic somatomammotropin hormone like 1","17","63909597-63918838","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB025646, HPA043715","Enhanced",NA,NA,NA,NA,"Not detected","Tissue enriched",352,"placenta: 216.7","smooth muscle: 0.6","Not detected",NA,NA
"CSN1S1",108,"D6","IOH44412",558,"0",NA,"casein alpha s1 (CSN1S1), transcript variant 1, mRNA.","NM_001890.1","NP_001881.1",1446,"Hs.3155","CASA, CSN1","ENSG00000126545","Casein alpha s1","4","69931081-69946574","Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA035659, HPA057031","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",85,"breast: 1600.9","adipose tissue: 18.9","Not detected",NA,NA
"CSN3",10,"H4","IOH12932",549,"0",NA,"casein kappa, mRNA (cDNA clone MGC:13553 IMAGE:4279903), complete cds","BC010935.1","AAH10935.1",1448,"Hs.54415","CSN10","ENSG00000171209","Casein kappa","4","70242588-70251428","Predicted secreted proteins","Evidence at protein level","HPA035953, HPA035954","Enhanced",NA,NA,NA,NA,"Group enriched","Tissue enriched",13,"breast: 428.0","salivary gland: 32.0","Not detected",NA,NA
"CST1",16,"D9","IOH14329",426,"0",NA,"cystatin SN (CST1), mRNA.","NM_001898.2","NP_001889.2",1469,"Hs.123114",NA,"ENSG00000170373","Cystatin SN","20","23747553-23751268","Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB026769, HPA043706, HPA044763","Enhanced",NA,NA,NA,"Breast cancer:4.00e-4 (favourable)","Mixed","Tissue enriched",27,"salivary gland: 9590.6","gallbladder: 352.0","Cell line enhanced",NA,"CACO-2: 139.8;RT4: 891.2;TIME: 178.3"
"CST2",93,"E5","IOH40727",426,"0",NA,"cystatin SA (CST2), mRNA.","NM_001322.2","NP_001313.1",1470,"Hs.669305",NA,"ENSG00000170369","Cystatin SA","20","23823769-23826731","Predicted secreted proteins","Evidence at protein level","CAB024963, HPA043706, HPA044763","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enriched",281,"salivary gland: 2052.3","gallbladder: 7.3","Cell line enriched",13,"RT4: 53.8"
"CST3",83,"D12","IOH10287",441,"0",NA,"cystatin C (CST3), mRNA.","NM_000099.2","NP_000090.1",1471,"Hs.304682",NA,"ENSG00000101439","Cystatin C","20","23626706-23638473","Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB000118, HPA013143","Enhanced",NA,"Supported","Golgi apparatus<br>Vesicles","Endometrial cancer:1.83e-4 (favourable), Urothelial cancer:8.77e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 1265.8","Cell line enhanced",NA,"ASC diff: 1105.8"
"CST4",93,"H4","IOH40718",426,"0",NA,"cystatin S (CST4), mRNA.","NM_001899.2","NP_001890.1",1472,"Hs.654549",NA,"ENSG00000101441","Cystatin S","20","23685640-23689040","Predicted secreted proteins","Evidence at protein level","HPA043706, HPA044763","Supported",NA,NA,NA,"Ovarian cancer:4.98e-5 (unfavourable), Urothelial cancer:2.88e-4 (favourable)","Mixed","Tissue enriched",113,"salivary gland: 9926.9","gallbladder: 87.6","Cell line enhanced",NA,"CACO-2: 4.5;hTEC/SVTERT24-B: 2.1;RT4: 10.7;TIME: 1.8"
"CST5",97,"B12","IOH40728",429,"0",NA,"cystatin D (CST5), mRNA.","NM_001900.4","NP_001891.2",1473,"Hs.121489",NA,"ENSG00000170367","Cystatin D","20","23875935-23879750","Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB024944, HPA061449","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",363,"salivary gland: 756.2","lung,smooth muscle: 2.0","Not detected",NA,NA
"CST6",116,"B12","IOH23279",450,"0",NA,"cystatin E/M (CST6), mRNA.","NM_001323.2","NP_001314.1",1474,"Hs.139389",NA,"ENSG00000175315","Cystatin E/M","11","66011841-66013505","Cancer-related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB019316, HPA044963","Enhanced",NA,"Approved","Plasma membrane<br>Cytosol",NA,"Tissue enhanced","Tissue enriched",9,"skin: 213.2","breast: 24.9","Group enriched",6,"A-431: 83.9;CAPAN-2: 228.1"
"CST7",49,"D1","IOH9888",504,"0",NA,"cystatin F (leukocystatin) (CST7), mRNA.","NM_003650.2","NP_003641.2",8530,"Hs.143212",NA,"ENSG00000077984","Cystatin F","20","24949230-24959928","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA040442","Enhanced",NA,NA,NA,"Renal cancer:4.37e-6 (unfavourable), Endometrial cancer:9.17e-6 (favourable), Head and neck cancer:5.85e-5 (favourable), Breast cancer:6.55e-4 (favourable), Cervical cancer:7.90e-4 (favourable)","Expressed in all","Tissue enriched",9,"bone marrow: 642.9","spleen: 74.1","Group enriched",19,"HL-60: 58.5;HMC-1: 170.9;NB-4: 126.6;U-937: 278.1"
"CST9L",52,"C4","IOH22863",444,"0",NA,"cystatin 9-like (CST9L), mRNA.","NM_080610.2","NP_542177.1",128821,"Hs.121554","bA218C14.1, CTES7B","ENSG00000101435","Cystatin 9-like","20","23564732-23568749","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",6,"testis: 108.4","epididymis: 19.6","Cell line enriched",13,"HEL: 1.2"
"CTBS",106,"F2","IOH41275",1158,"0",NA,"chitobiase, di-N-acetyl- (CTBS), mRNA.","NM_004388.2","NP_004379.1",1486,"Hs.513557","CTB","ENSG00000117151","Chitobiase","1","84549606-84574480","Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB017043, HPA023594, HPA048810","Approved",NA,"Uncertain","Cytosol",NA,"Expressed in all","Mixed",NA,NA,"epididymis: 3.8","Mixed",NA,NA
"CTHRC1",36,"F12","IOH14338",732,"0",NA,"collagen triple helix repeat containing 1 (CTHRC1), mRNA.","NM_138455.2","NP_612464.1",115908,"Hs.405614",NA,"ENSG00000164932","Collagen triple helix repeat containing 1","8","103371515-103382997","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA059806, HPA061896","Approved",NA,"Approved","Nucleoplasm","Renal cancer:1.22e-14 (unfavourable), Liver cancer:1.67e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"gallbladder: 137.8;placenta: 125.5;urinary bladder: 100.0","breast: 49.2","Cell line enhanced",NA,"ASC TERT1: 202.9;HHSteC: 162.6;HSkMC: 291.0;WM-115: 375.8"
"CTNS",131,"D9","IOH57640",1104,"0",NA,"Cystinosin.","O60931","O60931",1497,"Hs.187667","CTNS-LSB, PQLC4","ENSG00000040531","Cystinosin, lysosomal cystine transporter","17","3636468-3661542","Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA046947",NA,NA,"Supported","Vesicles<br>Intermediate filaments","Pancreatic cancer:6.39e-5 (favourable), Head and neck cancer:7.33e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 42.6","Expressed in all",NA,NA
"CTNS",79,"A12","IOH27166",1203,"NP_004928.1","AAH32850.1","cystinosis, nephropathic, mRNA (cDNA clone MGC:33097 IMAGE:5268683), complete cds","BC032850.2","AAH32850.1",1497,"Hs.187667","CTNS-LSB, PQLC4","ENSG00000040531","Cystinosin, lysosomal cystine transporter","17","3636468-3661542","Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA046947",NA,NA,"Supported","Vesicles<br>Intermediate filaments","Pancreatic cancer:6.39e-5 (favourable), Head and neck cancer:7.33e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 42.6","Expressed in all",NA,NA
"CTRB1",21,"A5","IOH7194",792,"0",NA,"chymotrypsinogen B1, mRNA (cDNA clone MGC:12508 IMAGE:3950220), complete cds","BC005385.1","AAH05385.1",1504,"Hs.610926","CTRB","ENSG00000168925","Chymotrypsinogen B1","16","75219000-75224924","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at transcript level",NA,NA,NA,NA,NA,NA,"Tissue enriched","Tissue enriched",376,"pancreas: 48923.8","ovary: 130.0","Cell line enhanced",NA,"EFO-21: 2.9;HDLM-2: 2.3;U-2 OS: 2.4;U-266/84: 1.0"
"CTRC",45,"B2","IOH12105",807,"0",NA,"chymotrypsin C (caldecrin) (CTRC), mRNA.","NM_007272.2","NP_009203.2",11330,"Hs.631869","CLCR, ELA4","ENSG00000162438","Chymotrypsin C","1","15438439-15449242","Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins","Evidence at protein level","HPA046920","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",361,"pancreas: 18186.4","ovary: 50.3","Not detected",NA,NA
"CTSA",70,"D5","IOH29615",1443,"0",NA,"cathepsin A (CTSA), transcript variant 2, mRNA.","NM_001127695.1","NP_001121167.1",5476,"Hs.609336","GSL, PPGB","ENSG00000064601","Cathepsin A","20","45890144-45898820","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB024930, HPA031068","Enhanced",NA,"Enhanced","Vesicles","Liver cancer:1.95e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"adrenal gland: 243.4","Expressed in all",NA,NA
"CTSA",127,"G1","IOH4244",1440,"0",NA,"cathepsin A, mRNA (cDNA clone MGC:1994 IMAGE:3346150), complete cds","BC000597.2","AAH00597.1",5476,"Hs.609336","GSL, PPGB","ENSG00000064601","Cathepsin A","20","45890144-45898820","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB024930, HPA031068","Enhanced",NA,"Enhanced","Vesicles","Liver cancer:1.95e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"adrenal gland: 243.4","Expressed in all",NA,NA
"CTSB",11,"A7","IOH10210",1020,"0",NA,"cathepsin B, mRNA (cDNA clone MGC:17266 IMAGE:4154307), complete cds","BC010240.1","AAH10240.1",1508,"Hs.520898",NA,"ENSG00000164733","Cathepsin B","8","11842524-11869448","Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB000457, HPA018156","Uncertain",NA,"Supported","Nucleoli<br>Vesicles","Thyroid cancer:5.76e-4 (favourable), Urothelial cancer:9.02e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 2894.5","Expressed in all",NA,NA
"CTSB",129,"C6","IOH53785",1020,"0",NA,"cathepsin B (CTSB), transcript variant 1, mRNA.","NM_001908.3","NP_001899.1",1508,"Hs.520898",NA,"ENSG00000164733","Cathepsin B","8","11842524-11869448","Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB000457, HPA018156","Uncertain",NA,"Supported","Nucleoli<br>Vesicles","Thyroid cancer:5.76e-4 (favourable), Urothelial cancer:9.02e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 2894.5","Expressed in all",NA,NA
"CTSC",70,"G4","IOH29634",1392,"0",NA,"cathepsin C (CTSC), transcript variant 1, mRNA.","NM_001814.4","NP_001805.3",1075,"Hs.128065","DPP1, PALS, PLS","ENSG00000109861","Cathepsin C","11","88293592-88337787","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB025364, HPA066610, HPA068434","Enhanced",NA,"Supported","Vesicles","Liver cancer:9.30e-5 (unfavourable), Renal cancer:4.80e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"lung: 390.4","Expressed in all",NA,NA
"CTSC",107,"A10","IOH41180",414,"0",NA,"cathepsin C (CTSC), transcript variant 2, mRNA.","NM_148170.3","NP_680475.1",1075,"Hs.128065","DPP1, PALS, PLS","ENSG00000109861","Cathepsin C","11","88293592-88337787","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB025364, HPA066610, HPA068434","Enhanced",NA,"Supported","Vesicles","Liver cancer:9.30e-5 (unfavourable), Renal cancer:4.80e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"lung: 390.4","Expressed in all",NA,NA
"CTSD",51,"B2","IOH14300",1239,"0",NA,"cathepsin D (CTSD), mRNA.","NM_001909.3","NP_001900.1",1509,"Hs.121575","CLN10, CPSD","ENSG00000117984","Cathepsin D","11","1752752-1764573","Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB000109, HPA003001","Enhanced",NA,NA,NA,"Renal cancer:4.93e-5 (favourable), Colorectal cancer:2.46e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"lung: 1026.9","Expressed in all",NA,NA
"CTSE",131,"D1","IOH55345",1449,"0",NA,"Synthetic construct Homo sapiens clone IMAGE:100016336, MGC:184278 Unknown (protein for MGC:184278) (LOC283874) mRNA, encodes complete protein.","BC153046.1","AAI53047.1",1510,"Hs.644082",NA,"ENSG00000196188","Cathepsin E","1","206009264-206023909","Enzymes, Predicted secreted proteins","Evidence at protein level","HPA012940, CAB032687","Enhanced",NA,NA,NA,"Urothelial cancer:5.26e-5 (favourable)","Group enriched","Group enriched",9,"duodenum: 229.1;stomach: 1121.8","lung: 74.6","Group enriched",7,"BEWO: 20.3;RT4: 32.6"
"CTSE",75,"F4","IOH27398",1191,"0",NA,"cathepsin E (CTSE), transcript variant 1, mRNA.","NM_001910.2","NP_001901.1",1510,"Hs.644082",NA,"ENSG00000196188","Cathepsin E","1","206009264-206023909","Enzymes, Predicted secreted proteins","Evidence at protein level","HPA012940, CAB032687","Enhanced",NA,NA,NA,"Urothelial cancer:5.26e-5 (favourable)","Group enriched","Group enriched",9,"duodenum: 229.1;stomach: 1121.8","lung: 74.6","Group enriched",7,"BEWO: 20.3;RT4: 32.6"
"CTSF",81,"G8","IOH13840",1455,"0",NA,"cathepsin F (CTSF), mRNA.","NM_003793.3","NP_003784.2",8722,"Hs.11590","CATSF, CLN13","ENSG00000174080","Cathepsin F","11","66563463-66568841","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB002141, HPA031431, HPA055610","Approved",NA,"Approved","Vesicles<br>Plasma membrane<br>Cytosol","Renal cancer:8.92e-7 (favourable)","Expressed in all","Expressed in all",NA,NA,"ovary: 140.6","Cell line enhanced",NA,"SK-MEL-30: 123.6"
"CTSG",19,"G1","IOH13616",768,"0",NA,"cathepsin G (CTSG), mRNA.","NM_001911.2","NP_001902.1",1511,"Hs.421724","CG","ENSG00000100448","Cathepsin G","14","24573522-24576260","Enzymes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB000110, HPA047737","Enhanced",NA,NA,NA,"Head and neck cancer:1.57e-4 (favourable), Urothelial cancer:8.91e-4 (unfavourable)","Mixed","Tissue enriched",84,"bone marrow: 3457.0","gallbladder: 41.2","Cell line enriched",6,"THP-1: 6055.4"
"CTSH",132,"G4","IOH29767",1008,"0",NA,"cathepsin H (CTSH), transcript variant 1, mRNA.","NM_004390.3","NP_004381.2",1512,"Hs.148641","ACC-4, ACC-5, ACC4, ACC5, CPSB","ENSG00000103811","Cathepsin H","15","78921058-78949574","Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB000458, HPA003524","Enhanced",NA,"Supported","Vesicles<br>Cytosol<br>Cytoplasmic bodies","Endometrial cancer:6.90e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"lung: 570.6","Cell line enhanced",NA,"CAPAN-2: 219.5;HaCaT: 161.7;RT4: 558.6"
"CTSK",19,"H1","IOH14212",990,"0",NA,"cathepsin K (CTSK), mRNA.","NM_000396.2","NP_000387.1",1513,"Hs.632466","CTSO, CTSO2, PKND, PYCD","ENSG00000143387","Cathepsin K","1","150796208-150808323","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA050346",NA,NA,"Supported","Vesicles","Renal cancer:7.12e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cervix, uterine: 575.0","Group enriched",6,"ASC diff: 1592.3;ASC TERT1: 590.6;BJ hTERT+: 1576.7"
"CTSS",133,"C10","IOH53925",996,"0",NA,"cathepsin S (CTSS), mRNA.","NM_004079.3","NP_004070.3",1520,"Hs.181301",NA,"ENSG00000163131","Cathepsin S","1","150730196-150765957","Enzymes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB000460, HPA002988","Supported",NA,"Approved","Vesicles",NA,"Expressed in all","Expressed in all",NA,NA,"spleen: 374.8","Cell line enhanced",NA,"HMC-1: 238.0;U-698: 410.8"
"CTSS",88,"A5","IOH5299",996,"0",NA,"cathepsin S, mRNA (cDNA clone MGC:3886 IMAGE:3610589), complete cds","BC002642.2","AAH02642.1",1520,"Hs.181301",NA,"ENSG00000163131","Cathepsin S","1","150730196-150765957","Enzymes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB000460, HPA002988","Supported",NA,"Approved","Vesicles",NA,"Expressed in all","Expressed in all",NA,NA,"spleen: 374.8","Cell line enhanced",NA,"HMC-1: 238.0;U-698: 410.8"
"CTSZ",117,"F9","IOH28012",912,"0",NA,"cathepsin Z (CTSZ), mRNA.","NM_001336.3","NP_001327.2",1522,"Hs.252549","CTSX","ENSG00000101160","Cathepsin Z","20","58995185-59007247","Enzymes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB025114, HPA049876, HPA053504","Supported",NA,"Supported","Vesicles","Renal cancer:5.72e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"lung: 476.8","Cell line enhanced",NA,"fHDF/TERT166: 693.2"
"CX3CL1",73,"C5","IOH4580",1194,"NP_002987.1","NP_002987.1","chemokine (C-X3-C motif) ligand 1 (CX3CL1), mRNA.","NM_002996.3","NP_002987.1",6376,"Hs.531668","ABCD-3, C3Xkine, CXC3, CXC3C, fractalkine, neurotactin, NTN, SCYD1","ENSG00000006210","C-X3-C motif chemokine ligand 1","16","57372458-57385048","Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB026192, HPA040361","Approved",NA,"Supported","Plasma membrane","Renal cancer:8.52e-7 (favourable), Cervical cancer:9.46e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 100.1","lung: 69.3","Cell line enhanced",NA,"EFO-21: 28.0;HDLM-2: 78.9;Hep G2: 42.9;RPTEC TERT1: 27.3"
"CXADR",11,"H6","IOH10207",1098,"NP_001329.1","NP_001329.1","coxsackie virus and adenovirus receptor (CXADR), mRNA.","NM_001338.3","NP_001329.1",1525,"Hs.634837","CAR","ENSG00000154639","Coxsackie virus and adenovirus receptor","21","17512382-17593579","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA003342, CAB005103, HPA030411, HPA030412","Enhanced",NA,"Enhanced","Plasma membrane<br>Cell Junctions","Head and neck cancer:3.50e-4 (favourable)","Expressed in all","Mixed",NA,NA,"skin: 59.1","Cell line enhanced",NA,"CACO-2: 77.2;NTERA-2: 105.2;RT4: 82.7"
"CXCL1",47,"D11","IOH10429",324,"0",NA,"chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) (CXCL1), mRNA.","NM_001511.1","NP_001502.1",2919,"Hs.789","FSP, GRO1, GROa, MGSA, MGSA-a, NAP-3, SCYB1","ENSG00000163739","C-X-C motif chemokine ligand 1","4","73869393-73871242","Cancer-related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:1.60e-4 (unfavourable), Liver cancer:2.91e-4 (unfavourable), Cervical cancer:7.23e-4 (unfavourable), Breast cancer:7.83e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"cervix, uterine: 178.6;spleen: 112.8","urinary bladder: 92.0","Group enriched",7,"BJ hTERT+: 658.8;EFO-21: 1914.4;RPTEC TERT1: 559.0"
"CXCL10",2,"F2","IOH13677",297,"0",NA,"chemokine (C-X-C motif) ligand 10 (CXCL10), mRNA.","NM_001565.2","NP_001556.2",3627,"Hs.632586","C7, crg-2, gIP-10, IFI10, INP10, IP-10, mob-1, SCYB10","ENSG00000169245","C-X-C motif chemokine ligand 10","4","76021117-76023497","Cancer-related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:1.16e-6 (unfavourable), Ovarian cancer:1.12e-5 (favourable), Pancreatic cancer:4.61e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"appendix: 129.4","lymph node: 72.5","Cell line enhanced",NA,"BJ hTERT+: 4.9;BJ hTERT+ SV40 Large T+: 2.0;BJ hTERT+ SV40 Large T+ RasG12V: 2.1;RPMI-8226: 2.9;THP-1: 2.0"
"CXCL11",77,"H3","IOH7289",285,"0",NA,"chemokine (C-X-C motif) ligand 11 (CXCL11), mRNA.","NM_005409.3","NP_005400.1",6373,"Hs.632592","b-R1, H174, I-TAC, IP-9, SCYB11, SCYB9B","ENSG00000169248","C-X-C motif chemokine ligand 11","4","76033682-76041415","Predicted secreted proteins","Evidence at protein level","CAB009921","Uncertain",NA,NA,NA,"Ovarian cancer:4.31e-7 (favourable), Renal cancer:3.29e-6 (unfavourable), Pancreatic cancer:8.18e-5 (unfavourable)","Expressed in all","Tissue enhanced",NA,"appendix: 13.5","lymph node: 11.5","Group enriched",6,"BJ hTERT+: 2.4;BJ hTERT+ SV40 Large T+: 4.3;BJ hTERT+ SV40 Large T+ RasG12V: 4.7"
"CXCL12",104,"H2","IOH40945",282,"0",NA,"chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) (CXCL12), transcript variant 2, mRNA.","NM_000609.4","NP_000600.1",6387,"Hs.522891","PBSF, SCYB12, SDF-1a, SDF-1b, SDF1, SDF1A, SDF1B, TLSF-a, TLSF-b, TPAR1","ENSG00000107562","C-X-C motif chemokine ligand 12","10","44370165-44386493","Predicted secreted proteins","Evidence at protein level","CAB017564","Approved",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"endometrium: 618.3","Cell line enhanced",NA,"ASC diff: 349.6;BJ hTERT+ SV40 Large T+ RasG12V: 429.9;fHDF/TERT166: 388.7;HSkMC: 941.2"
"CXCL13",45,"B3","IOH14282",330,"0",NA,"chemokine (C-X-C motif) ligand 13 (CXCL13), mRNA.","NM_006419.2","NP_006410.1",10563,"Hs.100431","ANGIE, ANGIE2, BCA-1, BLC, BLR1L, SCYB13","ENSG00000156234","C-X-C motif chemokine ligand 13","4","77511753-77611834","Cancer-related genes, Predicted secreted proteins","Evidence at protein level","HPA052613","Uncertain",NA,NA,NA,"Renal cancer:1.16e-10 (unfavourable), Ovarian cancer:5.41e-4 (favourable), Endometrial cancer:5.52e-4 (favourable), Colorectal cancer:9.12e-4 (favourable)","Expressed in all","Group enriched",7,"appendix: 163.3;lymph node: 599.9;spleen: 423.8;tonsil: 395.7","urinary bladder: 57.9","Cell line enhanced",NA,"U-266/70: 1.0"
"CXCL14",35,"A6","IOH5492",336,"0",NA,"chemokine (C-X-C motif) ligand 14 (CXCL14), mRNA.","NM_004887.4","NP_004878.2",9547,"Hs.483444","BMAC, bolekine, BRAK, Kec, KS1, MIP-2g, NJAC, SCYB14","ENSG00000145824","C-X-C motif chemokine ligand 14","5","135570679-135579279","Predicted secreted proteins","Evidence at protein level","CAB029996","Uncertain",NA,NA,NA,"Cervical cancer:1.71e-4 (favourable), Colorectal cancer:4.52e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"skin: 874.5","kidney: 335.8","Group enriched",12,"HAP1: 60.3;hTCEpi: 55.4;RPTEC TERT1: 157.5;U-2 OS: 88.6"
"CXCL17",105,"H9","IOH43349",360,"0",NA,"chemokine (C-X-C motif) ligand 17 (CXCL17), mRNA.","NM_198477.1","NP_940879.1",284340,"Hs.445586","Dcip1, DMC, UNQ473, VCC1","ENSG00000189377","C-X-C motif chemokine ligand 17","19","42428288-42443048","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Lung cancer:4.92e-5 (favourable), Pancreatic cancer:4.63e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"lung: 193.5;stomach: 289.7","esophagus: 83.1","Cell line enhanced",NA,"RT4: 1.8"
"CXCL2",90,"B4","IOH13606",324,"0",NA,"chemokine (C-X-C motif) ligand 2 (CXCL2), mRNA.","NM_002089.3","NP_002080.1",2920,"Hs.75765","CINC-2a, GRO2, GROb, MGSA-b, MIP-2a, SCYB2","ENSG00000081041","C-X-C motif chemokine ligand 2","4","74097035-74099293","Cancer-related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:2.07e-6 (unfavourable), Breast cancer:5.93e-5 (favourable), Cervical cancer:1.41e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"liver: 110.2","lung: 95.2","Cell line enhanced",NA,"BJ hTERT+: 38.3;HHSteC: 26.8;hTCEpi: 24.9;hTEC/SVTERT24-B: 24.7;hTERT-HME1: 25.6;U-87 MG: 27.5"
"CXCL3",19,"B9","IOH12905",324,"0",NA,"chemokine (C-X-C motif) ligand 3 (CXCL3), mRNA.","NM_002090.2","NP_002081.2",2921,"Hs.89690","CINC-2b, GRO3, GROg, MIP-2b, SCYB3","ENSG00000163734","C-X-C motif chemokine ligand 3","4","74036589-74038807","Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Cervical cancer:2.33e-4 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"adipose tissue: 26.9;cervix, uterine: 33.6","appendix: 20.3","Cell line enhanced",NA,"BJ hTERT+: 39.2;hTEC/SVTERT24-B: 75.0;RPTEC TERT1: 32.7"
"CXCL5",41,"G6","IOH7295",345,"0",NA,"chemokine (C-X-C motif) ligand 5 (CXCL5), mRNA.","NM_002994.3","NP_002985.1",6374,"Hs.89714","ENA-78, SCYB5","ENSG00000163735","C-X-C motif chemokine ligand 5","4","73995642-73998779","Cancer-related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA065474","Approved",NA,NA,NA,"Renal cancer:2.45e-5 (unfavourable), Liver cancer:1.39e-4 (unfavourable), Pancreatic cancer:2.23e-4 (unfavourable), Cervical cancer:3.43e-4 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"appendix: 47.7","urinary bladder: 15.5","Cell line enhanced",NA,"A549: 165.3;EFO-21: 141.1;HSkMC: 77.3;hTEC/SVTERT24-B: 78.0;RPTEC TERT1: 436.4"
"CXCL6",33,"B9","IOH10758",345,"0",NA,"chemokine (C-X-C motif) ligand 6 (granulocyte chemotactic protein 2) (CXCL6), mRNA.","NM_002993.3","NP_002984.1",6372,"Hs.164021","CKA-3, GCP-2, SCYB6","ENSG00000124875","C-X-C motif chemokine ligand 6","4","73836497-73849064","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:4.82e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"gallbladder: 50.3;spleen: 112.9","urinary bladder: 32.4","Group enriched",6,"BJ hTERT+: 36.7;EFO-21: 100.3;hTEC/SVTERT24-B: 22.6;HUVEC TERT2: 59.0;RPTEC TERT1: 62.9"
"CXCL9",138,"H12","IOH57247",378,"0",NA,"chemokine (C-X-C motif) ligand 9 (CXCL9), mRNA.","NM_002416.1","NP_002407.1",4283,"Hs.77367","CMK, crg-10, Humig, MIG, SCYB9","ENSG00000138755","C-X-C motif chemokine ligand 9","4","76001275-76007488","Cancer-related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:5.15e-6 (unfavourable), Endometrial cancer:2.07e-4 (favourable), Breast cancer:6.36e-4 (favourable), Ovarian cancer:8.06e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"lymph node: 327.4","appendix: 86.2","Not detected",NA,NA
"CYHR1",126,"D8","IOH6572",579,"NP_116076.1","NP_116076.1","cysteine/histidine-rich 1 (CYHR1), transcript variant 2, mRNA.","NM_032687.3","NP_116076.1",50626,"Hs.459379","CHRP, KIAA0496, MGC13010","ENSG00000187954","Cysteine and histidine rich 1","8","144449582-144465677","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA053653, HPA059543","Approved",NA,"Enhanced","Nucleoplasm","Colorectal cancer:1.05e-4 (unfavourable), Liver cancer:3.90e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 51.4","Expressed in all",NA,NA
"CYP17A1",109,"A6","IOH39857",1527,"0",NA,"cytochrome P450, family 17, subfamily A, polypeptide 1 (CYP17A1), mRNA.","NM_000102.3","NP_000093.1",1586,"Hs.438016","CPT7, CYP17, P450C17, S17AH","ENSG00000148795","Cytochrome P450 family 17 subfamily A member 1","10","102830531-102837533","Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA048533","Enhanced",NA,NA,NA,"Renal cancer:5.43e-7 (favourable)","Tissue enriched","Tissue enriched",25,"adrenal gland: 3751.4","testis: 152.4","Cell line enhanced",NA,"HMC-1: 2.6;SCLC-21H: 1.3"
"CYP20A1",43,"F4","IOH21873",1389,"0",NA,"cytochrome P450, family 20, subfamily A, polypeptide 1, mRNA (cDNA clone MGC:45025 IMAGE:5211537), complete cds","BC033752.1","AAH33752.1",57404,"Hs.446065","CYP-M","ENSG00000119004","Cytochrome P450 family 20 subfamily A member 1","2","203238940-203305611","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA055872, HPA058461","Uncertain",NA,"Approved","Plasma membrane<br>Cell Junctions<br>Actin filaments",NA,"Expressed in all","Mixed",NA,NA,"thyroid gland: 16.4","Mixed",NA,NA
"CYP20A1",78,"E7","IOH27932",1389,"0",NA,"cytochrome P450, family 20, subfamily A, polypeptide 1, mRNA (cDNA clone MGC:22229 IMAGE:4689065), complete cds","BC020616.1","AAH20616.1",57404,"Hs.446065","CYP-M","ENSG00000119004","Cytochrome P450 family 20 subfamily A member 1","2","203238940-203305611","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA055872, HPA058461","Uncertain",NA,"Approved","Plasma membrane<br>Cell Junctions<br>Actin filaments",NA,"Expressed in all","Mixed",NA,NA,"thyroid gland: 16.4","Mixed",NA,NA
"CYP2A6",152,"G6","IOH63274",1485,"0",NA,"cytochrome P450, family 2, subfamily A, polypeptide 6, mRNA (cDNA clone MGC:116920 IMAGE:40006064), complete cds","BC096255.1","AAH96255.1",1548,"Hs.250615","CPA6, CYP2A, CYP2A3","ENSG00000255974","Cytochrome P450 family 2 subfamily A member 6","19","40843538-40850447","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA046713, HPA047262","Supported",NA,NA,NA,"Liver cancer:5.38e-5 (favourable)","Tissue enriched","Tissue enriched",67,"liver: 839.4","breast: 12.4","Cell line enhanced",NA,"RH-30: 1.1"
"CYP2A7",77,"H7","IOH39393",1485,"0",NA,"cytochrome P450, family 2, subfamily A, polypeptide 7 (CYP2A7), transcript variant 1, mRNA.","NM_000764.2","NP_000755.2",1549,"Hs.250615","CYP2A","ENSG00000198077","Cytochrome P450 family 2 subfamily A member 7","19","40875439-40882752","Enzymes, Predicted secreted proteins","Evidence at protein level","CAB033510, HPA046713, HPA047262","Enhanced",NA,NA,NA,NA,"Group enriched","Tissue enriched",123,"liver: 60.9","breast: 0.4","Not detected",NA,NA
"CYP2B6",155,"C1","IOH62527",1476,"0",NA,"cytochrome P450, family 2, subfamily B, polypeptide 6, mRNA (cDNA clone MGC:79256 IMAGE:7002137), complete cds","BC067430.1","AAH67430.1",1555,"Hs.1360","CPB6, CYP2B, CYPIIB6","ENSG00000197408","Cytochrome P450 family 2 subfamily B member 6","19","40991299-41018398","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB033866, HPA048124, HPA062973","Supported",NA,"Approved","Nucleoplasm<br>Nuclear membrane<br>Cytosol",NA,"Tissue enhanced","Tissue enriched",18,"liver: 283.3","kidney: 15.7","Cell line enhanced",NA,"HaCaT: 2.3"
"CYP2B6",154,"H12","IOH62524",1476,"0",NA,"cytochrome P450, family 2, subfamily B, polypeptide 6, mRNA (cDNA clone MGC:79257 IMAGE:7002142), complete cds","BC067431.1","AAH67431.1",1555,"Hs.1360","CPB6, CYP2B, CYPIIB6","ENSG00000197408","Cytochrome P450 family 2 subfamily B member 6","19","40991299-41018398","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB033866, HPA048124, HPA062973","Supported",NA,"Approved","Nucleoplasm<br>Nuclear membrane<br>Cytosol",NA,"Tissue enhanced","Tissue enriched",18,"liver: 283.3","kidney: 15.7","Cell line enhanced",NA,"HaCaT: 2.3"
"CYP2C18",109,"F6","IOH40368",1473,"0",NA,"cytochrome P450, family 2, subfamily C, polypeptide 18 (CYP2C18), transcript variant 1, mRNA.","NM_000772.2","NP_000763.1",1562,"Hs.511872","CPCI, CYP2C, CYP2C17, P450IIC17","ENSG00000108242","Cytochrome P450 family 2 subfamily C member 18","10","94683621-94736190","Enzymes, Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enhanced","Group enriched",11,"duodenum: 103.1;esophagus: 24.6;gallbladder: 24.5;liver: 97.8;small intestine: 88.1;stomach: 62.2","tonsil: 6.2","Cell line enhanced",NA,"BEWO: 3.0"
"CYP2C18",152,"E9","IOH63284",1296,"0",NA,"cytochrome P450, family 2, subfamily C, polypeptide 18 (CYP2C18), transcript variant 2, mRNA.","NM_001128925.1","NP_001122397.1",1562,"Hs.511872","CPCI, CYP2C, CYP2C17, P450IIC17","ENSG00000108242","Cytochrome P450 family 2 subfamily C member 18","10","94683621-94736190","Enzymes, Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enhanced","Group enriched",11,"duodenum: 103.1;esophagus: 24.6;gallbladder: 24.5;liver: 97.8;small intestine: 88.1;stomach: 62.2","tonsil: 6.2","Cell line enhanced",NA,"BEWO: 3.0"
"CYP2C8",7,"E10","IOH12740",1473,"0",NA,"cytochrome P450, family 2, subfamily C, polypeptide 8, mRNA (cDNA clone MGC:22146 IMAGE:4767198), complete cds","BC020596.1","AAH20596.1",1558,"Hs.709188","CPC8","ENSG00000138115","Cytochrome P450 family 2 subfamily C member 8","10","95036772-95069497","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA013547, HPA013970, HPA015066","Enhanced",NA,NA,NA,"Pancreatic cancer:9.82e-4 (favourable)","Tissue enriched","Tissue enriched",154,"liver: 1124.1","gallbladder: 7.3","Not detected",NA,NA
"CYP2C9",48,"G12","IOH13730",489,"0",NA,"cytochrome P450, family 2, subfamily C, polypeptide 9, mRNA (cDNA clone IMAGE:4766890), complete cds.","BC020754.1","AAH20754.1",1559,"Hs.282624","CYP2C10, P450IIC9","ENSG00000138109","Cytochrome P450 family 2 subfamily C member 9","10","94938658-94989390","Enzymes, Predicted secreted proteins","Evidence at protein level","HPA015066, CAB016123","Enhanced",NA,NA,NA,"Liver cancer:2.83e-6 (favourable)","Tissue enriched","Tissue enriched",7,"liver: 963.1","duodenum: 136.8","Not detected",NA,NA
"CYP2E1",155,"A3","IOH62535",1482,"0",NA,"cytochrome P450, family 2, subfamily E, polypeptide 1, mRNA (cDNA clone MGC:79262 IMAGE:7002164), complete cds","BC067435.1","AAH67435.1",1571,"Hs.12907","CYP2E","ENSG00000130649","Cytochrome P450 family 2 subfamily E member 1","10","133520406-133561220","Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA009128, HPA029564","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",177,"liver: 5332.2","tonsil: 30.1","Cell line enhanced",NA,"HaCaT: 9.7;NB-4: 15.1"
"CYP2E1",70,"G5","IOH29616",1482,"0",NA,"cytochrome P450, family 2, subfamily E, polypeptide 1 (CYP2E1), mRNA.","NM_000773.3","NP_000764.1",1571,"Hs.12907","CYP2E","ENSG00000130649","Cytochrome P450 family 2 subfamily E member 1","10","133520406-133561220","Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA009128, HPA029564","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",177,"liver: 5332.2","tonsil: 30.1","Cell line enhanced",NA,"HaCaT: 9.7;NB-4: 15.1"
"CYP2E1",155,"G1","IOH62534",1482,"0",NA,"cytochrome P450, family 2, subfamily E, polypeptide 1, mRNA (cDNA clone MGC:79260 IMAGE:7002160), complete cds","BC067433.1","AAH67433.1",1571,"Hs.12907","CYP2E","ENSG00000130649","Cytochrome P450 family 2 subfamily E member 1","10","133520406-133561220","Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA009128, HPA029564","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",177,"liver: 5332.2","tonsil: 30.1","Cell line enhanced",NA,"HaCaT: 9.7;NB-4: 15.1"
"CYP46A1",9,"A3","IOH10707",1503,"0",NA,"cytochrome P450, family 46, subfamily A, polypeptide 1 (CYP46A1), mRNA.","NM_006668.1","NP_006659.1",10858,"Hs.25121","CYP46","ENSG00000036530","Cytochrome P450 family 46 subfamily A member 1","14","99684304-99727301","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA040702","Uncertain",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",21,"cerebral cortex: 64.1","heart muscle: 3.0","Group enriched",5,"AF22: 2.4;U-937: 5.4"
"CYP4F11",83,"H12","IOH10348",1575,"0",NA,"cytochrome P450, family 4, subfamily F, polypeptide 11, mRNA (cDNA clone MGC:16892 IMAGE:3846027), complete cds","BC016853.1","AAH16853.1",57834,"Hs.187393",NA,"ENSG00000171903","Cytochrome P450 family 4 subfamily F member 11","19","15912367-15934867","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA017265, CAB033648, HPA058960","Enhanced",NA,NA,NA,"Breast cancer:4.05e-4 (favourable), Pancreatic cancer:9.28e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"gallbladder: 29.5;liver: 32.7;small intestine: 26.3","epididymis: 20.0","Cell line enhanced",NA,"A-431: 11.4;CAPAN-2: 44.2;EFO-21: 17.4;Hep G2: 17.0;RT4: 12.1"
"CYR61",35,"E6","IOH3109",1146,"0",NA,"cysteine-rich, angiogenic inducer, 61 (CYR61), mRNA.","NM_001554.4","NP_001545.2",3491,"Hs.8867","CCN1, GIG1, IGFBP10","ENSG00000142871","Cysteine rich angiogenic inducer 61","1","85580761-85583962","Predicted secreted proteins","Evidence at protein level","HPA029853","Uncertain",NA,NA,NA,"Renal cancer:1.39e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"cervix, uterine: 1095.9","Mixed",NA,NA
"CYTL1",30,"B11","IOH22679",411,"0",NA,"cytokine-like 1 (CYTL1), mRNA.","NM_018659.2","NP_061129.1",54360,"Hs.13872","C17, C4orf4","ENSG00000170891","Cytokine like 1","4","5014586-5019472","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA067201",NA,NA,"Supported","Nuclear membrane<br>Endoplasmic reticulum","Stomach cancer:3.00e-5 (unfavourable), Urothelial cancer:1.25e-4 (unfavourable), Renal cancer:7.43e-4 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"placenta: 64.9","seminal vesicle: 19.1","Cell line enhanced",NA,"HEL: 171.3;HUVEC TERT2: 124.6;NB-4: 237.3;WM-115: 86.9"
"D2HGDH",154,"G11","IOH62479",924,"0",NA,"D-2-hydroxyglutarate dehydrogenase, mRNA (cDNA clone MGC:87530 IMAGE:30334929), complete cds","BC071598.1","AAH71598.1",728294,"Hs.516813","D2HGD, FLJ42195, MGC25181","ENSG00000180902","D-2-hydroxyglutarate dehydrogenase","2","241734579-241768816","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA056216, HPA060548","Uncertain",NA,"Approved","Mitochondria","Head and neck cancer:9.11e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"skin: 46.5","Expressed in all",NA,NA
"DAG1",8,"E5","IOH12528",2688,"NP_004384.1","NP_004384.2","dystroglycan 1 (dystrophin-associated glycoprotein 1) (DAG1), mRNA.","NM_004393.2","NP_004384.2",1605,"Hs.76111","156DAG, A3a, AGRNR, DAG","ENSG00000173402","Dystroglycan 1","3","49468703-49535618","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB001960, CAB016353","Enhanced",NA,"Supported","Vesicles","Renal cancer:2.59e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 109.3","Expressed in all",NA,NA
"DCD",93,"C5","IOH40723",333,"0",NA,"dermcidin (DCD), mRNA.","NM_053283.2","NP_444513.1",117159,"Hs.350570","AIDD, DCD-1, DSEP, HCAP, PIF","ENSG00000161634","Dermcidin","12","54644591-54648493","Plasma proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA063967","Supported",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",96,"breast: 336.4","skeletal muscle: 3.5","Not detected",NA,NA
"DCN",136,"B3","IOH57041",1080,"0",NA,"decorin (DCN), transcript variant A1, mRNA.","NM_001920.3","NP_001911.1",1634,"Hs.718429","DSPG2, SLRR1B","ENSG00000011465","Decorin","12","91140484-91183123","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA003315, CAB017118, HPA064736, CAB068930","Enhanced",NA,NA,NA,"Renal cancer:1.46e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"ovary: 3807.0","Cell line enhanced",NA,"ASC diff: 2514.0;ASC TERT1: 1962.9;BJ hTERT+: 2379.1;HSkMC: 1868.4"
"DDOST",4,"F8","IOH4125",1371,"NP_005207.2","NP_005207.2","dolichyl-diphosphooligosaccharide-protein glycosyltransferase (DDOST), mRNA.","NM_005216.4","NP_005207.2",1650,"Hs.523145","KIAA0115, OST, OST48, WBP1","ENSG00000244038","Dolichyl-diphosphooligosaccharide--protein glycosyltransferase non-catalytic subunit","1","20651767-20661544","Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB009746, HPA046841, HPA052867","Supported",NA,"Supported","Endoplasmic reticulum","Renal cancer:9.05e-7 (unfavourable), Liver cancer:2.64e-5 (unfavourable), Head and neck cancer:4.88e-4 (unfavourable), Endometrial cancer:5.99e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 308.3","Expressed in all",NA,NA
"DDR1",65,"F4","IOH5763",2631,"NP_001945.2","NP_001945.3","discoidin domain receptor tyrosine kinase 1 (DDR1), transcript variant 2, mRNA.","NM_001954.4","NP_001945.3",780,"Hs.631988","CAK, CD167, EDDR1, NEP, NTRK4, PTK3A, RTK6","ENSG00000204580","Discoidin domain receptor tyrosine kinase 1","6","30876421-30900156","CD markers, Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB010162, CAB025656, HPA057194","Approved",NA,"Approved","Nucleoplasm<br>Cell Junctions","Renal cancer:3.31e-10 (favourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 51.6","Cell line enhanced",NA,"HaCaT: 80.3;RT4: 74.6;T-47d: 96.8"
"DDR2",140,"G10","IOH28909",2568,"NP_006173.1","NP_001014796.1","discoidin domain receptor tyrosine kinase 2 (DDR2), transcript variant 1, mRNA.","NM_001014796.1","NP_001014796.1",4921,"Hs.275757","NTRKR3, TKT, TYRO10","ENSG00000162733","Discoidin domain receptor tyrosine kinase 2","1","162631373-162787400","Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA070112",NA,NA,"Supported","Plasma membrane<br>Actin filaments","Renal cancer:1.73e-7 (unfavourable)","Expressed in all","Mixed",NA,NA,"adrenal gland: 93.5","Cell line enhanced",NA,"ASC diff: 203.0;ASC TERT1: 203.2;BJ hTERT+: 181.9"
"DDT",132,"F11","IOH7446",357,"0",NA,"D-dopachrome tautomerase (DDT), transcript variant 1, mRNA.","NM_001355.3","NP_001346.1",1652,"Hs.656723","DDCT","ENSG00000099977","D-dopachrome tautomerase","22","23971365-23980469","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA049871","Approved",NA,"Approved","Mitochondria",NA,"Expressed in all","Expressed in all",NA,NA,"liver: 109.9","Expressed in all",NA,NA
"DDX17",6,"D9","IOH1750",552,"0",NA,"DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 (DDX17), transcript variant 2, mRNA.","NM_030881.3","NP_112020.1",10521,"Hs.528305","P72","ENSG00000100201","DEAD-box helicase 17","22","38483440-38507660","Enzymes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB024908, HPA063142","Enhanced",NA,"Enhanced","Nuclear speckles","Lung cancer:6.06e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 336.0","Expressed in all",NA,NA
"DDX20",74,"C10","IOH27218",2475,"0",NA,"DEAD (Asp-Glu-Ala-Asp) box polypeptide 20, mRNA (cDNA clone MGC:33313 IMAGE:5273709), complete cds","BC031062.1","AAH31062.1",11218,"Hs.591405","DP103, GEMIN3","ENSG00000064703","DEAD-box helicase 20","1","111755245-111768016","Enzymes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA005516, CAB015427","Enhanced",NA,"Supported","Nucleoplasm<br>Nuclear bodies<br>Cytosol","Liver cancer:6.35e-6 (unfavourable), Colorectal cancer:9.85e-5 (favourable)","Expressed in all","Tissue enriched",10,"testis: 130.7","parathyroid gland: 12.6","Expressed in all",NA,NA
"DDX20",67,"G11","IOH26834",2475,"0",NA,"DEAD (Asp-Glu-Ala-Asp) box polypeptide 20, mRNA (cDNA clone MGC:26212 IMAGE:4824324), complete cds","BC034953.2","AAH34953.1",11218,"Hs.591405","DP103, GEMIN3","ENSG00000064703","DEAD-box helicase 20","1","111755245-111768016","Enzymes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA005516, CAB015427","Enhanced",NA,"Supported","Nucleoplasm<br>Nuclear bodies<br>Cytosol","Liver cancer:6.35e-6 (unfavourable), Colorectal cancer:9.85e-5 (favourable)","Expressed in all","Tissue enriched",10,"testis: 130.7","parathyroid gland: 12.6","Expressed in all",NA,NA
"DDX20",85,"C2","IOH13000",2475,"0",NA,"DEAD (Asp-Glu-Ala-Asp) box polypeptide 20, mRNA (cDNA clone MGC:20004 IMAGE:4651697), complete cds","BC011556.1","AAH11556.1",11218,"Hs.591405","DP103, GEMIN3","ENSG00000064703","DEAD-box helicase 20","1","111755245-111768016","Enzymes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA005516, CAB015427","Enhanced",NA,"Supported","Nucleoplasm<br>Nuclear bodies<br>Cytosol","Liver cancer:6.35e-6 (unfavourable), Colorectal cancer:9.85e-5 (favourable)","Expressed in all","Tissue enriched",10,"testis: 130.7","parathyroid gland: 12.6","Expressed in all",NA,NA
"DDX28",59,"B7","IOH23202",1623,"0",NA,"DEAD (Asp-Glu-Ala-Asp) box polypeptide 28 (DDX28), nuclear gene encoding mitochondrial protein, mRNA.","NM_018380.2","NP_060850.1",55794,"Hs.458313","FLJ11282, MDDX28","ENSG00000182810","DEAD-box helicase 28","16","68021274-68023442","Enzymes, Predicted secreted proteins","Evidence at protein level","HPA041911, HPA053585","Approved",NA,"Supported","Nucleoli<br>Mitochondria<br>Cytosol","Renal cancer:2.07e-10 (favourable)","Expressed in all","Expressed in all",NA,NA,"bone marrow: 11.2","Expressed in all",NA,NA
"DEFA3",33,"F5","IOH11891",285,"0",NA,"defensin, alpha 3, neutrophil-specific (DEFA3), mRNA.","NM_005217.2","NP_005208.1",1668,"Hs.654448","DEF3, HNP-3","ENSG00000239839","Defensin alpha 3","8","7015869-7018301","Cancer-related genes, Predicted secreted proteins","Evidence at protein level","HPA052517","Supported",NA,NA,NA,NA,"Not detected","Tissue enriched",246,"bone marrow: 23273.5","spleen: 94.7","Not detected",NA,NA
"DEFA4",108,"H3","IOH44329",294,"0",NA,"defensin, alpha 4, corticostatin (DEFA4), mRNA.","NM_001925.1","NP_001916.1",1669,"Hs.591391","DEF4, HP-4","ENSG00000164821","Defensin alpha 4","8","6935822-6938338","Predicted secreted proteins","Evidence at protein level","HPA051266","Enhanced",NA,NA,NA,NA,"Not detected","Tissue enriched",640,"bone marrow: 3105.2","spleen: 4.8","Cell line enriched",8,"THP-1: 8.6"
"DEFA5",93,"H10","IOH40358",285,"0",NA,"defensin, alpha 5, Paneth cell-specific (DEFA5), mRNA.","NM_021010.1","NP_066290.1",1670,"Hs.655233","DEF5, HD-5","ENSG00000164816","Defensin alpha 5","8","7055304-7056734","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA015775, CAB069919","Enhanced",NA,NA,NA,"Colorectal cancer:9.44e-5 (favourable)","Tissue enhanced","Group enriched",480,"duodenum: 10677.9;small intestine: 19102.0","appendix: 31.0","Group enriched",6,"BEWO: 55.6;NB-4: 31.4;RPMI-8226: 35.9;SH-SY5Y: 42.9;U-2197: 16.2"
"DEFA6",99,"F6","IOH40361",303,"0",NA,"defensin, alpha 6, Paneth cell-specific (DEFA6), mRNA.","NM_001926.2","NP_001917.1",1671,"Hs.711","DEF6, HD-6","ENSG00000164822","Defensin alpha 6","8","6924693-6926076","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA019462","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Group enriched",525,"duodenum: 5743.0;small intestine: 10524.2","colon: 15.4","Group enriched",9,"BEWO: 28.1;NB-4: 20.0;RPMI-8226: 25.8;SH-SY5Y: 26.0;U-2197: 10.6"
"DEFB1",58,"A8","IOH26662",207,"0",NA,"defensin, beta 1 (DEFB1), mRNA.","NM_005218.3","NP_005209.1",1672,"Hs.32949","BD1, DEFB-1, DEFB101, HBD-1, HBD1, MGC51822","ENSG00000164825","Defensin beta 1","8","6870575-6878022","Predicted secreted proteins, Transporters","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:1.90e-5 (favourable), Lung cancer:5.62e-4 (unfavourable), Pancreatic cancer:5.94e-4 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"cervix, uterine: 618.9;kidney: 1500.2","salivary gland: 232.3","Cell line enhanced",NA,"NB-4: 34.9;SCLC-21H: 45.7;THP-1: 129.4"
"DEFB103A",101,"D2","IOH34916",204,"0",NA,"defensin, beta 103A (DEFB103A), mRNA.","NM_018661.3","NP_061131.1",55894,"Hs.283082","DEFB-3, DEFB103, DEFB3, HBD-3, HBD3, HBP-3, HBP3","ENSG00000176797","Defensin beta 103A","8","7881204-7882664","Predicted secreted proteins, Transporters","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"tonsil: 2.1","skin: 0.8","Not detected",NA,NA
"DEFB108B",120,"B4","IOH50119",222,"0",NA,"defensin, beta 108B (DEFB108B), mRNA.","NM_001002035.1","NP_001002035.1",245911,"Hs.555032",NA,"ENSG00000184276","Defensin beta 108B","11","71833200-71837710","Predicted secreted proteins","Evidence at transcript level","HPA042588","Uncertain",NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"all non-specific tissues: 0.0","Not detected",NA,NA
"DEFB119",123,"G7","IOH57357",267,"0",NA,"defensin, beta 119 (DEFB119), transcript variant 3, mRNA.","NM_153323.3","NP_697018.1",245932,"Hs.516998","DEFB-19, DEFB-20, DEFB120","ENSG00000180483","Defensin beta 119","20","31377164-31390603","Predicted secreted proteins","Evidence at protein level","HPA043059","Supported",NA,NA,NA,NA,"Tissue enriched","Group enriched",3499,"epididymis: 2335.6;testis: 472.8","duodenum: 0.4","Not detected",NA,NA
"DEFB119",102,"C1","IOH40759",255,"0",NA,"defensin, beta 119 (DEFB119), transcript variant 1, mRNA.","NM_153289.2","NP_695021.2",245932,"Hs.516998","DEFB-19, DEFB-20, DEFB120","ENSG00000180483","Defensin beta 119","20","31377164-31390603","Predicted secreted proteins","Evidence at protein level","HPA043059","Supported",NA,NA,NA,NA,"Tissue enriched","Group enriched",3499,"epididymis: 2335.6;testis: 472.8","duodenum: 0.4","Not detected",NA,NA
"DEFB121",123,"C7","IOH57346",231,"0",NA,"defensin, beta 121 (DEFB121), mRNA.","NM_001011878.1","NP_001011878.1",245934,"Hs.272294","DEFB-21","ENSG00000204548","Defensin beta 121","20","31404845-31412838","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Not detected","Tissue enriched",6458,"epididymis: 2005.4","testis: 0.3","Cell line enriched",19,"NB-4: 1.8"
"DEFB132",125,"G8","IOH50188",288,"0",NA,"defensin, beta 132 (DEFB132), mRNA.","NM_207469.2","NP_997352.1",400830,"Hs.516819","DEFB32, RP5-1103G7.6","ENSG00000186458","Defensin beta 132","20","257736-261096","Predicted secreted proteins","Evidence at transcript level","HPA046399","Approved",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",11,"epididymis: 332.3","seminal vesicle: 29.0","Not detected",NA,NA
"DFNA5",114,"A10","IOH41276",1491,"0",NA,"deafness, autosomal dominant 5 (DFNA5), transcript variant 1, mRNA.","NM_004403.2","NP_004394.1",1687,"Hs.520708","ICERE-1","ENSG00000105928","DFNA5, deafness associated tumor suppressor","7","24698353-24758113","Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA011326, CAB019306","Approved",NA,"Enhanced","Cytosol","Liver cancer:2.49e-5 (unfavourable)","Mixed","Mixed",NA,NA,"placenta: 58.7","Mixed",NA,NA
"DHH",128,"C5","IOH27366",1191,"0",NA,"desert hedgehog homolog (Drosophila) (DHH), mRNA.","NM_021044.2","NP_066382.1",50846,"Hs.524382","HHG-3, MGC35145","ENSG00000139549","Desert hedgehog","12","49089421-49094819","Disease related genes, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Mixed","Tissue enriched",21,"testis: 20.7","appendix,placenta: 0.9","Group enriched",8,"AN3-CA: 2.1;EFO-21: 4.6;HUVEC TERT2: 1.7;K-562: 7.8;TIME: 3.7"
"DHRS7",73,"G4","IOH4195",1020,"0",NA,"dehydrogenase/reductase (SDR family) member 7 (DHRS7), mRNA.","NM_016029.2","NP_057113.1",51635,"Hs.59719","retDSR4, SDR34C1","ENSG00000100612","Dehydrogenase/reductase 7","14","60144120-60169856","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA031121","Approved",NA,"Approved","Nucleoplasm<br>Mitochondria","Renal cancer:1.92e-10 (favourable), Head and neck cancer:2.51e-4 (unfavourable), Breast cancer:6.42e-4 (favourable), Ovarian cancer:7.99e-4 (unfavourable)","Tissue enriched","Expressed in all",NA,NA,"prostate: 650.0","Expressed in all",NA,NA
"DHRS9",64,"H9","IOH29062",960,"0",NA,"dehydrogenase/reductase (SDR family) member 9 (DHRS9), transcript variant 1, mRNA.","NM_005771.4","NP_005762.2",10170,"Hs.179608","3alpha-HSD, RDH15, RDHL, RETSDR8, SDR9C4","ENSG00000073737","Dehydrogenase/reductase 9","2","169064789-169096167","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA036491, HPA036667","Approved",NA,NA,NA,"Pancreatic cancer:2.73e-4 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"colon: 66.5;rectum: 48.1","esophagus: 30.1","Cell line enhanced",NA,"NB-4: 21.6;THP-1: 66.4;TIME: 35.4;U-2197: 29.3"
"DKK1",134,"A8","IOH57116",801,"0",NA,"dickkopf homolog 1 (Xenopus laevis) (DKK1), mRNA.","NM_012242.2","NP_036374.1",22943,"Hs.40499","DKK-1, SK","ENSG00000107984","Dickkopf WNT signaling pathway inhibitor 1","10","52314296-52318042","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Head and neck cancer:4.35e-8 (unfavourable), Lung cancer:7.80e-6 (unfavourable), Pancreatic cancer:1.27e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"cervix, uterine: 56.5;placenta: 71.9","urinary bladder: 14.5","Cell line enhanced",NA,"BJ: 975.2;CACO-2: 841.6;fHDF/TERT166: 1247.0"
"DKK3",88,"B6","IOH5946",1053,"0",NA,"dickkopf homolog 3 (Xenopus laevis), mRNA (cDNA clone MGC:1123 IMAGE:3347453), complete cds","BC007660.2","AAH07660.1",27122,"Hs.292156","REIC, RIG","ENSG00000050165","Dickkopf WNT signaling pathway inhibitor 3","11","11963106-12009769","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA011868, CAB024949","Approved",NA,"Approved","Vesicles","Renal cancer:6.31e-5 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 373.5;heart muscle: 805.5","cervix, uterine: 138.8","Cell line enhanced",NA,"BJ: 355.1;BJ hTERT+: 524.6;fHDF/TERT166: 475.8;TIME: 285.3"
"DKK4",103,"B7","IOH35309",675,"0",NA,"dickkopf homolog 4 (Xenopus laevis) (DKK4), mRNA.","NM_014420.2","NP_055235.1",27121,"Hs.159311",NA,"ENSG00000104371","Dickkopf WNT signaling pathway inhibitor 4","8","42374068-42377232","Predicted secreted proteins","Evidence at protein level","HPA052916","Approved",NA,NA,NA,NA,"Tissue enriched","Tissue enhanced",NA,"duodenum: 2.4;esophagus: 5.4;testis: 2.7","urinary bladder: 1.4","Cell line enriched",9,"Hep G2: 1.4"
"DKKL1",31,"A8","IOH22346",729,"0",NA,"dickkopf-like 1 (soggy) (DKKL1), mRNA.","NM_014419.3","NP_055234.1",27120,"Hs.515855","CT34, SGY-1","ENSG00000104901","Dickkopf like acrosomal protein 1","19","49361783-49375116","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB025410, HPA047194","Enhanced",NA,"Approved","Vesicles",NA,"Tissue enhanced","Tissue enriched",149,"testis: 265.5","endometrium,fallopian tube: 1.7","Cell line enhanced",NA,"AF22: 5.0;AN3-CA: 8.9"
"DLG4",117,"E2","IOH36584",2304,"0",NA,"discs, large homolog 4 (Drosophila) (DLG4), transcript variant 1, mRNA.","NM_001365.3","NP_001356.1",1742,"Hs.463928","PSD-95, PSD95, SAP-90, SAP90","ENSG00000132535","Discs large MAGUK scaffold protein 4","17","7189890-7219702","Predicted intracellular proteins, Predicted secreted proteins, Transporters","Evidence at protein level","CAB001999, CAB002000, HPA010122","Enhanced",NA,"Approved","Vesicles","Pancreatic cancer:8.82e-6 (favourable), Renal cancer:1.70e-4 (unfavourable)","Expressed in all","Tissue enriched",6,"cerebral cortex: 178.6","endometrium: 28.9","Cell line enhanced",NA,"HMC-1: 57.4"
"DLK1",42,"A6","IOH6430",1152,"NP_003827.2","AAH07741.1","delta-like 1 homolog (Drosophila), mRNA (cDNA clone MGC:12806 IMAGE:4128269), complete cds","BC007741.2","AAH07741.1",8788,"Hs.533717","Delta1, FA1, pG2, Pref-1, ZOG","ENSG00000185559","Delta like non-canonical Notch ligand 1","14","100725705-100738224","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB005872, HPA053879, HPA062262","Supported",NA,"Approved","Golgi apparatus","Endometrial cancer:2.31e-4 (unfavourable)","Tissue enhanced","Group enriched",20,"adrenal gland: 1591.0;placenta: 2331.6","ovary: 100.3","Group enriched",6,"AF22: 118.4;Hep G2: 282.9;SH-SY5Y: 501.8"
"DMKN",15,"F6","IOH14207",414,"0",NA,"dermokine (DMKN), transcript variant 7, mRNA.","NM_001126061.1","NP_001119533.1",93099,"Hs.417795","ZD52F10","ENSG00000161249","Dermokine","19","35497220-35513658","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA029406","Enhanced",NA,"Approved","Nucleoplasm<br>Cytosol","Renal cancer:5.37e-6 (favourable)","Mixed","Tissue enriched",15,"skin: 3991.5","breast: 259.8","Cell line enhanced",NA,"CACO-2: 150.9;HBEC3-KT: 169.4;RPTEC TERT1: 173.1"
"DNAJB11",23,"A7","IOH4824",1077,"0",NA,"DnaJ (Hsp40) homolog, subfamily B, member 11 (DNAJB11), mRNA.","NM_016306.4","NP_057390.1",51726,"Hs.317192","EDJ, ERdj3, HEDJ","ENSG00000090520","DnaJ heat shock protein family (Hsp40) member B11","3","186567403-186585800","Predicted secreted proteins","Evidence at protein level","HPA010814, HPA017051","Supported",NA,"Supported","Endoplasmic reticulum","Renal cancer:3.44e-9 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 88.4","Expressed in all",NA,NA
"DNAJB9",32,"C9","IOH22212",672,"0",NA,"DnaJ (Hsp40) homolog, subfamily B, member 9 (DNAJB9), mRNA.","NM_012328.1","NP_036460.1",4189,"Hs.6790","MDG1","ENSG00000128590","DnaJ heat shock protein family (Hsp40) member B9","7","108569568-108574850","Predicted secreted proteins","Evidence at protein level","HPA040967, HPA041553","Supported",NA,"Approved","Endoplasmic reticulum<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"thyroid gland: 113.5","Expressed in all",NA,NA
"DNASE1",116,"A10","IOH23149",849,"0",NA,"deoxyribonuclease I (DNASE1), mRNA.","NM_005223.3","NP_005214.2",1773,"Hs.629638","DNL1","ENSG00000213918","Deoxyribonuclease 1","16","3611728-3680143","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA010703","Enhanced",NA,"Supported","Vesicles","Urothelial cancer:1.14e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"small intestine: 37.8","duodenum: 29.9","Mixed",NA,NA
"DNASE1L1",50,"G5","IOH11824",909,"0",NA,"deoxyribonuclease I-like 1 (DNASE1L1), transcript variant 2, mRNA.","NM_001009932.1","NP_001009932.1",1774,"Hs.401929","DNAS1L1, DNASEX, DNL1L, XIB","ENSG00000013563","Deoxyribonuclease 1 like 1","X","154401238-154412112","Predicted secreted proteins","Evidence at protein level","HPA072635","Approved",NA,NA,NA,"Renal cancer:2.19e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"skeletal muscle: 56.6","Expressed in all",NA,NA
"DNASE1L3",15,"F7","IOH14823",918,"0",NA,"deoxyribonuclease I-like 3 (DNASE1L3), mRNA.","NM_004944.2","NP_004935.1",1776,"Hs.476453","DNAS1L3, LSD","ENSG00000163687","Deoxyribonuclease 1 like 3","3","58192257-58214697","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA019955","Approved",NA,NA,NA,"Renal cancer:1.06e-7 (favourable), Liver cancer:1.20e-6 (favourable)","Mixed","Tissue enhanced",NA,"liver: 136.7;spleen: 316.5","tonsil: 51.2","Cell line enhanced",NA,"BEWO: 1.8;RPMI-8226: 1.4"
"DNASE2",53,"H11","IOH14142",1083,"0",NA,"deoxyribonuclease II, lysosomal (DNASE2), mRNA.","NM_001375.2","NP_001366.1",1777,"Hs.118243","DNL, DNL2","ENSG00000105612","Deoxyribonuclease 2, lysosomal","19","12875211-12881468","Enzymes, Predicted secreted proteins","Evidence at protein level","HPA066185","Enhanced",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"thyroid gland: 59.0","Expressed in all",NA,NA
"DNASE2B",108,"C3","IOH44707",462,"0",NA,"deoxyribonuclease II beta (DNASE2B), transcript variant 2, mRNA.","NM_058248.1","NP_490649.1",58511,"Hs.129142","DLAD","ENSG00000137976","Deoxyribonuclease 2 beta","1","84398532-84415018","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at transcript level",NA,NA,NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",7,"salivary gland: 73.0","prostate: 10.5","Not detected",NA,NA
"DPEP2",7,"C12","IOH12764",1200,"0",NA,"dipeptidase 2, mRNA (cDNA clone MGC:27249 IMAGE:4616323), complete cds","BC024021.1","AAH24021.1",64174,"Hs.372633",NA,"ENSG00000167261","Dipeptidase 2","16","67987394-68000586","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA035644","Approved",NA,NA,NA,"Testis cancer:8.47e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"spleen: 38.7","lung: 27.9","Cell line enhanced",NA,"HEL: 3.7;HMC-1: 16.1;U-937: 4.9"
"DPP7",83,"G12","IOH10330",1479,"0",NA,"dipeptidyl-peptidase 7, mRNA (cDNA clone MGC:21556 IMAGE:4157582), complete cds","BC016961.1","AAH16961.1",29952,"Hs.37916","DPP2, DPPII","ENSG00000176978","Dipeptidyl peptidase 7","9","137110542-137115177","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA021282, CAB025541, HPA059381","Supported",NA,"Enhanced","Golgi apparatus<br>Vesicles","Colorectal cancer:6.07e-6 (unfavourable), Pancreatic cancer:8.31e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"adrenal gland: 70.7","Mixed",NA,NA
"DPT",133,"B11","IOH53854",606,"0",NA,"dermatopontin (DPT), mRNA.","NM_001937.3","NP_001928.2",1805,"Hs.80552",NA,"ENSG00000143196","Dermatopontin","1","168695459-168729264","Predicted secreted proteins","Evidence at protein level","HPA065548",NA,NA,"Approved","Vesicles","Renal cancer:4.74e-5 (unfavourable)","Expressed in all","Mixed",NA,NA,"adipose tissue: 330.3","Group enriched",10,"ASC diff: 94.1;fHDF/TERT166: 44.4"
"DPT",37,"E8","IOH21824",606,"0",NA,"dermatopontin, mRNA (cDNA clone MGC:45278 IMAGE:5176855), complete cds","BC033736.1","AAH33736.1",1805,"Hs.80552",NA,"ENSG00000143196","Dermatopontin","1","168695459-168729264","Predicted secreted proteins","Evidence at protein level","HPA065548",NA,NA,"Approved","Vesicles","Renal cancer:4.74e-5 (unfavourable)","Expressed in all","Mixed",NA,NA,"adipose tissue: 330.3","Group enriched",10,"ASC diff: 94.1;fHDF/TERT166: 44.4"
"DSE",74,"C12","IOH27207",2877,"NP_037484.1","NP_037484.1","dermatan sulfate epimerase (DSE), transcript variant 1, mRNA.","NM_013352.2","NP_037484.1",29940,"Hs.486292","DSEPI, SART2","ENSG00000111817","Dermatan sulfate epimerase","6","116254173-116444860","Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA014764, HPA052151","Uncertain",NA,"Supported","Nucleoplasm<br>Cytosol","Renal cancer:1.50e-4 (unfavourable), Cervical cancer:3.36e-4 (unfavourable), Ovarian cancer:6.34e-4 (unfavourable)","Mixed","Mixed",NA,NA,"appendix: 36.2","Mixed",NA,NA
"DYNLT3",5,"H2","IOH3006",351,"0",NA,"dynein, light chain, Tctex-type 3 (DYNLT3), mRNA.","NM_006520.2","NP_006511.1",6990,"Hs.446392","TCTE1L, TCTEX1L","ENSG00000165169","Dynein light chain Tctex-type 3","X","37836757-37847637","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA003938","Approved",NA,NA,NA,"Glioma:4.22e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"adrenal gland: 77.2","Mixed",NA,NA
"EBAG9",20,"D8","IOH7355",642,"0",NA,"estrogen receptor binding site associated, antigen, 9, mRNA (cDNA clone MGC:12283 IMAGE:3930583), complete cds","BC005249.1","AAH05249.1",9166,"Hs.409368","EB9, RCAS1","ENSG00000147654","Estrogen receptor binding site associated, antigen, 9","8","109539711-109565996","Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA021153, HPA021154, CAB072810, CAB072811, CAB072812","Enhanced",NA,"Enhanced","Golgi apparatus",NA,"Expressed in all","Expressed in all",NA,NA,"thyroid gland: 96.5","Expressed in all",NA,NA
"EBAG9",11,"E10","IOH10322",642,"0",NA,"estrogen receptor binding site associated, antigen, 9 (EBAG9), transcript variant 1, mRNA.","NM_004215.3","NP_004206.1",9166,"Hs.409368","EB9, RCAS1","ENSG00000147654","Estrogen receptor binding site associated, antigen, 9","8","109539711-109565996","Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA021153, HPA021154, CAB072810, CAB072811, CAB072812","Enhanced",NA,"Enhanced","Golgi apparatus",NA,"Expressed in all","Expressed in all",NA,NA,"thyroid gland: 96.5","Expressed in all",NA,NA
"EBF4",120,"B2","IOH28965",267,"0",NA,"early B-cell factor 4, mRNA (cDNA clone IMAGE:5502800), complete cds.","BC054347.1","AAH54347.1",57593,"Hs.471955","COE4, KIAA1442, O/E-4, RP5-860F19.3","ENSG00000088881","Early B-cell factor 4","20","2692878-2760108","Predicted intracellular proteins, Transcription factors","Evidence at transcript level",NA,NA,NA,NA,NA,"Pancreatic cancer:2.47e-5 (favourable), Colorectal cancer:6.59e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"parathyroid gland: 23.7","Cell line enhanced",NA,"SH-SY5Y: 15.8"
"EBI3",29,"H10","IOH11371",690,"0",NA,"Epstein-Barr virus induced 3 (EBI3), mRNA.","NM_005755.2","NP_005746.2",10148,"Hs.501452","IL27B, IL35B","ENSG00000105246","Epstein-Barr virus induced 3","19","4229498-4237531","Predicted secreted proteins","Evidence at protein level","HPA046635","Enhanced",NA,NA,NA,"Renal cancer:1.04e-8 (unfavourable)","Expressed in all","Tissue enriched",8,"placenta: 209.2","spleen: 26.1","Cell line enriched",13,"HDLM-2: 197.3"
"ECM1",68,"D2","IOH27780",1623,"0",NA,"extracellular matrix protein 1, mRNA (cDNA clone MGC:3614 IMAGE:3614195), complete cds","BC023505.2","AAH23505.1",1893,"Hs.81071",NA,"ENSG00000143369","Extracellular matrix protein 1","1","150508062-150513789","Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA027241","Enhanced",NA,"Approved","Nucleoplasm<br>Cytosol","Renal cancer:1.51e-9 (unfavourable), Urothelial cancer:1.20e-5 (unfavourable), Pancreatic cancer:3.55e-4 (unfavourable)","Expressed in all","Group enriched",6,"epididymis: 581.9;esophagus: 989.7","tonsil: 122.7","Cell line enhanced",NA,"ASC TERT1: 277.2;BJ hTERT+: 233.5;fHDF/TERT166: 213.1;hTEC/SVTERT24-B: 192.3"
"ECSIT",25,"C3","IOH4404",1296,"0",NA,"ECSIT homolog (Drosophila) (ECSIT), transcript variant 1, mRNA.","NM_016581.3","NP_057665.2",51295,"Hs.515146","SITPEC","ENSG00000130159","ECSIT signalling integrator","19","11505916-11529174","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA042979","Approved",NA,"Supported","Nucleoplasm<br>Cytosol","Renal cancer:1.48e-9 (favourable)","Expressed in all","Expressed in all",NA,NA,"heart muscle: 54.2","Expressed in all",NA,NA
"ECSIT",23,"A1","IOH6244",891,"0",NA,"ECSIT homolog (Drosophila) (ECSIT), transcript variant 2, mRNA.","NM_001142464.1","NP_001135936.1",51295,"Hs.515146","SITPEC","ENSG00000130159","ECSIT signalling integrator","19","11505916-11529174","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA042979","Approved",NA,"Supported","Nucleoplasm<br>Cytosol","Renal cancer:1.48e-9 (favourable)","Expressed in all","Expressed in all",NA,NA,"heart muscle: 54.2","Expressed in all",NA,NA
"EDEM2",84,"C6","IOH3977",1737,"0",NA,"ER degradation enhancer, mannosidase alpha-like 2, mRNA (cDNA clone MGC:935 IMAGE:3051376), complete cds","BC001371.2","AAH01371.1",55741,"Hs.356273","bA4204.1, C20orf31, C20orf49, FLJ10783","ENSG00000088298","ER degradation enhancing alpha-mannosidase like protein 2","20","35115357-35147364","Predicted secreted proteins","Evidence at protein level","CAB037238, HPA048353","Approved",NA,NA,NA,"Renal cancer:4.76e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 54.7","Expressed in all",NA,NA
"EDIL3",134,"D2","IOH54017",1443,"0",NA,"EGF-like repeats and discoidin I-like domains 3 (EDIL3), mRNA.","NM_005711.3","NP_005702.3",10085,"Hs.482730","DEL1","ENSG00000164176","EGF like repeats and discoidin domains 3","5","83940554-84384793","Predicted secreted proteins","Evidence at protein level","HPA020415","Approved",NA,NA,NA,NA,"Expressed in all","Tissue enhanced",NA,"cerebral cortex: 131.5","epididymis: 54.6","Cell line enhanced",NA,"LHCN-M2: 141.8;TIME: 165.9;U-2 OS: 174.3;U-87 MG: 110.4"
"EDIL3",66,"G3","IOH28981",1413,"0",NA,"EGF-like repeats and discoidin I-like domains 3, mRNA (cDNA clone MGC:61588 IMAGE:5753154), complete cds","BC053656.1","AAH53656.1",10085,"Hs.482730","DEL1","ENSG00000164176","EGF like repeats and discoidin domains 3","5","83940554-84384793","Predicted secreted proteins","Evidence at protein level","HPA020415","Approved",NA,NA,NA,NA,"Expressed in all","Tissue enhanced",NA,"cerebral cortex: 131.5","epididymis: 54.6","Cell line enhanced",NA,"LHCN-M2: 141.8;TIME: 165.9;U-2 OS: 174.3;U-87 MG: 110.4"
"EDIL3",31,"B3","IOH22214",1443,"0",NA,"EGF-like repeats and discoidin I-like domains 3, mRNA (cDNA clone MGC:26287 IMAGE:4791845), complete cds","BC030828.1","AAH30828.1",10085,"Hs.482730","DEL1","ENSG00000164176","EGF like repeats and discoidin domains 3","5","83940554-84384793","Predicted secreted proteins","Evidence at protein level","HPA020415","Approved",NA,NA,NA,NA,"Expressed in all","Tissue enhanced",NA,"cerebral cortex: 131.5","epididymis: 54.6","Cell line enhanced",NA,"LHCN-M2: 141.8;TIME: 165.9;U-2 OS: 174.3;U-87 MG: 110.4"
"EDN1",13,"H8","IOH9950",639,"0",NA,"endothelin 1, mRNA (cDNA clone MGC:9513 IMAGE:3900704), complete cds","BC009720.1","AAH09720.1",1906,"Hs.511899","ET1","ENSG00000078401","Endothelin 1","6","12290363-12297194","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA031976, CAB032500, CAB037291","Approved",NA,"Approved","Nucleus<br>Nucleoli<br>Golgi apparatus",NA,"Expressed in all","Mixed",NA,NA,"lung: 43.5","Group enriched",6,"EFO-21: 622.7;HUVEC TERT2: 372.8;T-47d: 129.1;TIME: 272.4"
"EDN2",30,"A11","IOH22678",537,"0",NA,"endothelin 2 (EDN2), mRNA.","NM_001956.3","NP_001947.1",1907,"Hs.1407","ET2","ENSG00000127129","Endothelin 2","1","41478775-41484673","Predicted secreted proteins","Evidence at protein level","HPA028459","Uncertain",NA,"Approved","Cytosol","Endometrial cancer:2.85e-4 (unfavourable), Pancreatic cancer:5.81e-4 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"esophagus: 10.6;small intestine: 18.1","epididymis: 5.5","Cell line enhanced",NA,"CAPAN-2: 12.3;EFO-21: 32.7;SCLC-21H: 19.7;SK-BR-3: 31.2;U-2 OS: 16.7"
"EDN3",134,"B6","IOH57032",717,"0",NA,"endothelin 3 (EDN3), transcript variant 1, mRNA.","NM_000114.2","NP_000105.1",1908,"Hs.1408","ET3","ENSG00000124205","Endothelin 3","20","59300427-59325992","Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA036618",NA,"Supported",NA,NA,"Glioma:2.38e-4 (favourable)","Mixed","Tissue enhanced",NA,"small intestine: 39.3","duodenum: 38.3","Not detected",NA,NA
"EDN3",64,"H1","IOH28947",660,"0",NA,"endothelin 3 (EDN3), transcript variant 2, mRNA.","NM_207032.1","NP_996915.1",1908,"Hs.1408","ET3","ENSG00000124205","Endothelin 3","20","59300427-59325992","Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA036618",NA,"Supported",NA,NA,"Glioma:2.38e-4 (favourable)","Mixed","Tissue enhanced",NA,"small intestine: 39.3","duodenum: 38.3","Not detected",NA,NA
"EDNRB",3,"C6","IOH14234",1329,"NP_000106.1","NP_000106.1","endothelin receptor type B (EDNRB), transcript variant 1, mRNA.","NM_000115.2","NP_000106.1",1910,"Hs.82002","ETB, HSCR, HSCR2","ENSG00000136160","Endothelin receptor type B","13","77895481-77919768","Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB017842, HPA027546","Approved",NA,"Supported","Plasma membrane<br>Cytosol","Renal cancer:7.20e-5 (favourable)","Group enriched","Tissue enhanced",NA,"placenta: 180.2","cerebral cortex: 88.8","Cell line enhanced",NA,"AF22: 59.4;ASC diff: 35.4;SK-MEL-30: 42.0;U-266/70: 29.1;WM-115: 122.9"
"EFEMP1",9,"F6","IOH12494",1482,"0",NA,"EGF-containing fibulin-like extracellular matrix protein 1 (EFEMP1), transcript variant 1, mRNA.","NM_004105.3","NP_004096.2",2202,"Hs.76224","DHRD, FBLN3, FBNL, MTLV, S1-5","ENSG00000115380","EGF containing fibulin like extracellular matrix protein 1","2","55865967-55924139","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB016368, HPA049806, HPA070841, HPA071588","Supported",NA,"Uncertain","Mitochondria","Renal cancer:3.89e-8 (unfavourable), Urothelial cancer:6.68e-5 (unfavourable), Endometrial cancer:4.72e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"placenta: 488.7","Group enriched",5,"HHSteC: 719.8;HSkMC: 733.9;HUVEC TERT2: 3552.1;TIME: 3104.2"
"EFEMP2",51,"F9","IOH9643",1332,"0",NA,"EGF-containing fibulin-like extracellular matrix protein 2 (EFEMP2), mRNA.","NM_016938.3","NP_058634.3",30008,"Hs.170622","FBLN4, UPH1","ENSG00000172638","EGF containing fibulin like extracellular matrix protein 2","11","65866441-65873592","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA023270","Approved",NA,NA,NA,"Renal cancer:3.94e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cervix, uterine: 50.3","Cell line enhanced",NA,"BJ hTERT+: 106.7;fHDF/TERT166: 149.3;LHCN-M2: 95.3"
"EFNA1",129,"D9","IOH53776",618,"0",NA,"ephrin-A1 (EFNA1), transcript variant 1, mRNA.","NM_004428.2","NP_004419.2",1942,"Hs.516664","ECKLG, EPLG1, LERK1, TNFAIP4","ENSG00000169242","Ephrin A1","1","155127460-155134857","Cancer-related genes, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","CAB032498","Uncertain",NA,NA,NA,NA,"Expressed in all","Mixed",NA,NA,"placenta: 123.9","Cell line enhanced",NA,"BEWO: 211.4;SiHa: 136.8;SK-BR-3: 146.1"
"EFNA1",67,"G7","IOH27591",618,"0",NA,"ephrin-A1, mRNA (cDNA clone MGC:45272 IMAGE:5402648), complete cds","BC032698.1","AAH32698.1",1942,"Hs.516664","ECKLG, EPLG1, LERK1, TNFAIP4","ENSG00000169242","Ephrin A1","1","155127460-155134857","Cancer-related genes, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","CAB032498","Uncertain",NA,NA,NA,NA,"Expressed in all","Mixed",NA,NA,"placenta: 123.9","Cell line enhanced",NA,"BEWO: 211.4;SiHa: 136.8;SK-BR-3: 146.1"
"EGFL7",12,"C4","IOH10489",822,"0",NA,"EGF-like-domain, multiple 7, mRNA (cDNA clone MGC:8726 IMAGE:3860522), complete cds","BC012377.1","AAH12377.1",51162,"Hs.91481","ZNEU1","ENSG00000172889","EGF like domain multiple 7","9","136658856-136672678","Predicted secreted proteins","Evidence at protein level","HPA050716","Approved",NA,NA,NA,"Colorectal cancer:4.22e-6 (unfavourable), Renal cancer:5.28e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 263.7","Cell line enhanced",NA,"EFO-21: 172.9;HUVEC TERT2: 276.0;TIME: 254.4"
"EGFL7",142,"G11","IOH54905",822,"0",NA,"EGF-like-domain, multiple 7 (EGFL7), transcript variant 1, mRNA.","NM_016215.3","NP_057299.1",51162,"Hs.91481","ZNEU1","ENSG00000172889","EGF like domain multiple 7","9","136658856-136672678","Predicted secreted proteins","Evidence at protein level","HPA050716","Approved",NA,NA,NA,"Colorectal cancer:4.22e-6 (unfavourable), Renal cancer:5.28e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 263.7","Cell line enhanced",NA,"EFO-21: 172.9;HUVEC TERT2: 276.0;TIME: 254.4"
"EGFL8",67,"E8","IOH27589",882,"0",NA,"EGF-like-domain, multiple 8, mRNA (cDNA clone MGC:44938 IMAGE:5247785), complete cds","BC035574.1","AAH35574.1",80864,"Hs.332138","C6orf8, NG3","ENSG00000241404","EGF like domain multiple 8","6","32164583-32168281","Predicted secreted proteins","Evidence at protein level","HPA061173","Uncertain",NA,"Approved","Nuclear speckles<br>Vesicles",NA,"Mixed","Mixed",NA,NA,"skin: 2.7","Mixed",NA,NA
"EGFL8",67,"C6","IOH29389",882,"0",NA,"EGF-like-domain, multiple 8 (EGFL8), mRNA.","NM_030652.2","NP_085155.1",80864,"Hs.332138","C6orf8, NG3","ENSG00000241404","EGF like domain multiple 8","6","32164583-32168281","Predicted secreted proteins","Evidence at protein level","HPA061173","Uncertain",NA,"Approved","Nuclear speckles<br>Vesicles",NA,"Mixed","Mixed",NA,NA,"skin: 2.7","Mixed",NA,NA
"EGFLAM",85,"B5","IOH23237",459,"0",NA,"EGF-like, fibronectin type III and laminin G domains (EGFLAM), transcript variant 4, mRNA.","NM_182801.1","NP_877953.1",133584,"Hs.20103","AGRINL, AGRNL, FLJ39155, PIKA","ENSG00000164318","EGF like, fibronectin type III and laminin G domains","5","38258409-38465021","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:4.47e-5 (unfavourable)","Expressed in all","Tissue enhanced",NA,"placenta: 73.4","adipose tissue: 43.0","Cell line enhanced",NA,"hTERT-HME1: 12.6;HUVEC TERT2: 13.4;LHCN-M2: 30.8;U-2 OS: 16.5"
"EGFLAM",117,"E6","IOH40505",3030,"0",NA,"EGF-like, fibronectin type III and laminin G domains, mRNA (cDNA clone MGC:74567 IMAGE:6187990), complete cds","BC063822.1","AAH63822.1",133584,"Hs.20103","AGRINL, AGRNL, FLJ39155, PIKA","ENSG00000164318","EGF like, fibronectin type III and laminin G domains","5","38258409-38465021","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:4.47e-5 (unfavourable)","Expressed in all","Tissue enhanced",NA,"placenta: 73.4","adipose tissue: 43.0","Cell line enhanced",NA,"hTERT-HME1: 12.6;HUVEC TERT2: 13.4;LHCN-M2: 30.8;U-2 OS: 16.5"
"EGFR",154,"C5","IOH62670",3276,"0",NA,"epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian), mRNA (cDNA clone MGC:104637 IMAGE:30528231), complete cds","BC094761.1","AAH94761.1",1956,"Hs.488293","ERBB, ERBB1","ENSG00000146648","Epidermal growth factor receptor","7","55019021-55211628","Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","CAB000035, HPA001200, HPA018530, CAB068186, CAB073534","Enhanced",NA,"Enhanced","Plasma membrane","Urothelial cancer:2.04e-5 (unfavourable)","Expressed in all","Tissue enhanced",NA,"placenta: 100.0","skin: 58.7","Cell line enriched",15,"A-431: 4682.9"
"EGFR",133,"G7","IOH46438",1218,"0",NA,"epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian) (EGFR), transcript variant 3, mRNA.","NM_201283.1","NP_958440.1",1956,"Hs.488293","ERBB, ERBB1","ENSG00000146648","Epidermal growth factor receptor","7","55019021-55211628","Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","CAB000035, HPA001200, HPA018530, CAB068186, CAB073534","Enhanced",NA,"Enhanced","Plasma membrane","Urothelial cancer:2.04e-5 (unfavourable)","Expressed in all","Tissue enhanced",NA,"placenta: 100.0","skin: 58.7","Cell line enriched",15,"A-431: 4682.9"
"EHF",58,"A2","IOH26169",903,"0",NA,"ets homologous factor (EHF), mRNA.","NM_012153.3","NP_036285.2",26298,"Hs.653859","ESE3, ESEJ","ENSG00000135373","ETS homologous factor","11","34621093-34661057","Predicted intracellular proteins, Predicted secreted proteins, Transcription factors","Evidence at protein level","HPA050923, HPA060734","Enhanced",NA,"Supported","Nucleoplasm<br>Golgi apparatus","Colorectal cancer:5.81e-4 (favourable), Pancreatic cancer:6.94e-4 (unfavourable)","Mixed","Mixed",NA,NA,"esophagus: 228.3","Cell line enhanced",NA,"CAPAN-2: 122.7;HaCaT: 85.2;HBEC3-KT: 76.2;RT4: 172.3;T-47d: 201.8"
"EIF2AK1",141,"E1","IOH5879",1893,"0",NA,"eukaryotic translation initiation factor 2-alpha kinase 1 (EIF2AK1), transcript variant 1, mRNA.","NM_014413.3","NP_055228.2",27102,"Hs.719136","HRI, KIAA1369","ENSG00000086232","Eukaryotic translation initiation factor 2 alpha kinase 1","7","6022244-6059230","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA016496, CAB022082, HPA061675","Approved",NA,"Supported","Nucleus<br>Cytosol","Liver cancer:6.99e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 129.4","Expressed in all",NA,NA
"ELN",94,"E2","IOH40486",1977,"0",NA,"elastin, mRNA (cDNA clone MGC:70763 IMAGE:6153564), complete cds","BC065566.1","AAH65566.1",2006,"Hs.647061","SVAS, WBS, WS","ENSG00000049540","Elastin","7","74027789-74069907","Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB010750, HPA018111, HPA056941","Supported",NA,"Approved","Plasma membrane","Thyroid cancer:6.29e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"smooth muscle: 125.8","Cell line enhanced",NA,"BJ: 121.3;fHDF/TERT166: 160.9;U-2197: 748.2"
"ELSPBP1",34,"A2","IOH13085",672,"0",NA,"epididymal sperm binding protein 1 (ELSPBP1), mRNA.","NM_022142.3","NP_071425.2",64100,"Hs.104894","E12, EDDM12, HE12","ENSG00000169393","Epididymal sperm binding protein 1","19","47994651-48025153","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA044256, HPA050341","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",2038,"epididymis: 3638.2","testis: 1.7","Cell line enhanced",NA,"BEWO: 1.5;HMC-1: 9.1;NB-4: 3.7"
"EMCN",7,"F5","IOH12143",537,"NP_057326.2","AAH17781.1","endomucin, mRNA (cDNA clone MGC:22268 IMAGE:4689608), complete cds","BC017781.1","AAH17781.1",51705,"Hs.152913","MUC14","ENSG00000164035","Endomucin","4","100395341-100880126","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA005928","Approved",NA,NA,NA,"Liver cancer:1.03e-4 (favourable), Renal cancer:2.25e-4 (favourable)","Expressed in all","Mixed",NA,NA,"kidney: 83.7","Cell line enriched",6,"HUVEC TERT2: 25.7"
"EMILIN1",13,"H2","IOH6875",1044,"0",NA,"elastin microfibril interfacer 1, mRNA (cDNA clone IMAGE:3163767), complete cds.","BC007530.1","AAH07530.1",11117,"Hs.63348","DKFZp586M121, gp115","ENSG00000138080","Elastin microfibril interfacer 1","2","27078567-27086408","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA002822","Supported",NA,NA,NA,"Renal cancer:8.13e-9 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"seminal vesicle: 73.7","Cell line enhanced",NA,"BJ: 81.8;HHSteC: 82.2;HSkMC: 78.7;SH-SY5Y: 135.3"
"ENHO",120,"B6","IOH50130",231,"0",NA,"energy homeostasis associated (ENHO), mRNA.","NM_198573.2","NP_940975.2",375704,"Hs.522085","C9orf165, UNQ470","ENSG00000168913","Energy homeostasis associated","9","34521040-34523041","Predicted secreted proteins","Evidence at transcript level","HPA042575","Approved",NA,NA,NA,"Endometrial cancer:3.71e-4 (unfavourable)","Tissue enhanced","Tissue enriched",12,"cerebral cortex: 140.3","testis: 11.5","Cell line enhanced",NA,"AN3-CA: 14.6;NTERA-2: 21.5;SCLC-21H: 12.8;SH-SY5Y: 10.9"
"ENHO",38,"H11","IOH23120",228,"0",NA,"energy homeostasis associated, mRNA (cDNA clone MGC:32084 IMAGE:4871461), complete cds","BC022101.1","AAH22101.1",375704,"Hs.522085","C9orf165, UNQ470","ENSG00000168913","Energy homeostasis associated","9","34521040-34523041","Predicted secreted proteins","Evidence at transcript level","HPA042575","Approved",NA,NA,NA,"Endometrial cancer:3.71e-4 (unfavourable)","Tissue enhanced","Tissue enriched",12,"cerebral cortex: 140.3","testis: 11.5","Cell line enhanced",NA,"AN3-CA: 14.6;NTERA-2: 21.5;SCLC-21H: 12.8;SH-SY5Y: 10.9"
"ENPP6",54,"E8","IOH27128",1323,"0",NA,"ectonucleotide pyrophosphatase/phosphodiesterase 6 (ENPP6), mRNA.","NM_153343.3","NP_699174.1",133121,"Hs.297814","MGC33971","ENSG00000164303","Ectonucleotide pyrophosphatase/phosphodiesterase 6","4","184088706-184221230","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA042740","Approved",NA,"Approved","Golgi apparatus",NA,"Tissue enriched","Tissue enhanced",NA,"kidney: 30.6;ovary: 15.0","cerebral cortex: 8.6","Cell line enhanced",NA,"Karpas-707: 2.3;SH-SY5Y: 3.8;U-266/70: 2.2;U-266/84: 1.1"
"ENPP7",57,"E2","IOH26296",1377,"0",NA,"ectonucleotide pyrophosphatase/phosphodiesterase 7, mRNA (cDNA clone MGC:50179 IMAGE:5186743), complete cds","BC041453.1","AAH41453.2",339221,"Hs.114084","alk-SMase, NPP7","ENSG00000182156","Ectonucleotide pyrophosphatase/phosphodiesterase 7","17","79730919-79742222","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA024603","Approved",NA,NA,NA,NA,"Tissue enriched","Group enriched",22,"duodenum: 45.7;small intestine: 110.2","kidney: 3.5","Cell line enhanced",NA,"Karpas-707: 1.4;U-266/70: 2.1"
"EPCAM",48,"C7","IOH10499",945,"NP_002345.1","AAH14785.1","epithelial cell adhesion molecule, mRNA (cDNA clone MGC:9040 IMAGE:3861826), complete cds","BC014785.1","AAH14785.1",4072,"Hs.542050","17-1A, 323/A3, CD326, CO-17A, EGP-2, EGP34, EGP40, Ep-CAM, ESA, GA733-2, HEA125, KS1/4, KSA, Ly74, M4S1, MH99, MIC18, MK-1, MOC31, TACST-1, TACSTD1, TROP1","ENSG00000119888","Epithelial cell adhesion molecule","2","47345158-47387601","Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB003809, HPA026761, CAB030012, CAB055098, HPA067463","Enhanced",NA,"Supported","Plasma membrane","Renal cancer:1.04e-6 (favourable), Ovarian cancer:3.30e-4 (favourable)","Mixed","Tissue enhanced",NA,"rectum: 680.5;small intestine: 714.7","colon: 659.9","Cell line enhanced",NA,"A-431: 382.2;CACO-2: 461.4;CAPAN-2: 680.1;SCLC-21H: 345.3"
"EPHA10",128,"D9","IOH40061",888,"0",NA,"EPH receptor A10 (EPHA10), transcript variant 2, mRNA.","NM_173641.2","NP_775912.2",284656,"Hs.129435","FLJ16103, FLJ33655","ENSG00000183317","EPH receptor A10","1","37713880-37765133","Enzymes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA027497","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"testis: 20.4","colon: 7.9","Cell line enhanced",NA,"BEWO: 4.7;HDLM-2: 18.1;SCLC-21H: 10.2"
"EPHA3",97,"G8","IOH45194",2952,"NP_005224.2","NP_005224.2","EPH receptor A3 (EPHA3), transcript variant 1, mRNA.","NM_005233.5","NP_005224.2",2042,"Hs.123642","ETK, ETK1, HEK, HEK4, TYRO4","ENSG00000044524","EPH receptor A3","3","89107524-89482134","Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB010462","Approved",NA,"Uncertain","Nucleoplasm<br>Golgi apparatus<br>Cytosol","Renal cancer:3.28e-7 (unfavourable)","Mixed","Tissue enhanced",NA,"prostate: 51.9","gallbladder: 29.8","Cell line enriched",7,"AF22: 192.5"
"EPHA3",113,"D9","IOH44403",1620,"0",NA,"EPH receptor A3 (EPHA3), transcript variant 2, mRNA.","NM_182644.2","NP_872585.1",2042,"Hs.123642","ETK, ETK1, HEK, HEK4, TYRO4","ENSG00000044524","EPH receptor A3","3","89107524-89482134","Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB010462","Approved",NA,"Uncertain","Nucleoplasm<br>Golgi apparatus<br>Cytosol","Renal cancer:3.28e-7 (unfavourable)","Mixed","Tissue enhanced",NA,"prostate: 51.9","gallbladder: 29.8","Cell line enriched",7,"AF22: 192.5"
"EPHA4",148,"E12","IOH62043",2850,"0",NA,"EPH receptor A4, mRNA (cDNA clone MGC:26318 IMAGE:4814429), complete cds","BC026327.1","AAH26327.1",2043,"Hs.371218","Hek8, TYRO1","ENSG00000116106","EPH receptor A4","2","221418027-221574202","Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB028368","Enhanced",NA,NA,NA,"Renal cancer:5.67e-4 (favourable), Ovarian cancer:9.56e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 41.6","testis: 22.2","Cell line enhanced",NA,"AF22: 77.5;CACO-2: 49.0;U-2197: 35.7"
"EPHA4",158,"H4","IOH29750",2961,"0",NA,"EPH receptor A4 (EPHA4), mRNA.","NM_004438.3","NP_004429.1",2043,"Hs.371218","Hek8, TYRO1","ENSG00000116106","EPH receptor A4","2","221418027-221574202","Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB028368","Enhanced",NA,NA,NA,"Renal cancer:5.67e-4 (favourable), Ovarian cancer:9.56e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 41.6","testis: 22.2","Cell line enhanced",NA,"AF22: 77.5;CACO-2: 49.0;U-2197: 35.7"
"EPHA4",16,"C4","IOH14080",741,"0",NA,"cDNA clone MGC:16614 IMAGE:4111344, complete cds.","BC009313.2","AAH09313.1",2043,"Hs.371218","Hek8, TYRO1","ENSG00000116106","EPH receptor A4","2","221418027-221574202","Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB028368","Enhanced",NA,NA,NA,"Renal cancer:5.67e-4 (favourable), Ovarian cancer:9.56e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 41.6","testis: 22.2","Cell line enhanced",NA,"AF22: 77.5;CACO-2: 49.0;U-2197: 35.7"
"EPHA7",124,"D11","IOH11421",840,"0",NA,"EPH receptor A7, mRNA (cDNA clone IMAGE:5204580), complete cds.","BC027940.1","AAH27940.1",2045,"Hs.73962","Hek11","ENSG00000135333","EPH receptor A7","6","93240020-93419547","Cancer-related genes, Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB010496","Approved",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",13,"parathyroid gland: 253.5","prostate: 20.2","Cell line enhanced",NA,"AF22: 15.6;HEK 293: 41.9;RH-30: 41.8;THP-1: 25.7"
"EPHB4",121,"E11","IOH29406",2964,"NP_004435.2","AAH52804.1","EPH receptor B4, mRNA (cDNA clone MGC:59690 IMAGE:6584384), complete cds","BC052804.1","AAH52804.1",2050,"Hs.437008","HTK, Tyro11","ENSG00000196411","EPH receptor B4","7","100802565-100827521","Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB013537","Uncertain",NA,NA,NA,"Colorectal cancer:4.33e-4 (unfavourable), Breast cancer:8.56e-4 (unfavourable), Urothelial cancer:8.84e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 50.6","Mixed",NA,NA
"EPHX1",22,"B9","IOH4991",1368,"0",NA,"epoxide hydrolase 1, microsomal (xenobiotic) (EPHX1), transcript variant 1, mRNA.","NM_000120.3","NP_000111.1",2052,"Hs.89649","EPHX","ENSG00000143819","Epoxide hydrolase 1","1","225810092-225845563","Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA020593, HPA048847","Enhanced",NA,NA,NA,"Lung cancer:7.02e-5 (favourable), Prostate cancer:1.32e-4 (favourable)","Tissue enriched","Expressed in all",NA,NA,"adrenal gland: 1085.6","Cell line enhanced",NA,"ASC diff: 821.1;SiHa: 629.7"
"EPO",150,"E3","IOH61961",582,"0",NA,"erythropoietin (EPO), mRNA.","NM_000799.2","NP_000790.2",2056,"Hs.2303","EP","ENSG00000130427","Erythropoietin","7","100720800-100723700","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Predicted secreted proteins","Evidence at protein level","CAB010336","Supported",NA,NA,NA,"Renal cancer:2.18e-6 (unfavourable), Liver cancer:5.67e-5 (unfavourable)","Group enriched","Tissue enhanced",NA,"cervix, uterine: 2.0;endometrium: 1.7;liver: 1.7","prostate: 1.1","Group enriched",6,"BEWO: 2.0;Hep G2: 5.5"
"EPS8L1",81,"A4","IOH14328",1791,"0",NA,"EPS8-like 1 (EPS8L1), transcript variant 2, mRNA.","NM_017729.3","NP_060199.3",54869,"Hs.438862","DRC3, FLJ20258, MGC23164, MGC4642","ENSG00000131037","EPS8 like 1","19","55072020-55087923","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA041851, HPA043545","Uncertain",NA,"Supported","Cytosol","Colorectal cancer:4.44e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"skin: 18.4;stomach: 23.5","esophagus: 9.0","Cell line enhanced",NA,"BEWO: 51.9;T-47d: 24.8"
"EPS8L1",113,"D4","IOH45841",1656,"0",NA,"EPS8-like 1, mRNA (cDNA clone MGC:4642 IMAGE:3529476), complete cds","BC004907.2","AAH04907.2",54869,"Hs.438862","DRC3, FLJ20258, MGC23164, MGC4642","ENSG00000131037","EPS8 like 1","19","55072020-55087923","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA041851, HPA043545","Uncertain",NA,"Supported","Cytosol","Colorectal cancer:4.44e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"skin: 18.4;stomach: 23.5","esophagus: 9.0","Cell line enhanced",NA,"BEWO: 51.9;T-47d: 24.8"
"EPYC",55,"F5","IOH23152",969,"0",NA,"epiphycan, mRNA (cDNA clone MGC:32553 IMAGE:4604494), complete cds","BC030958.1","AAH30958.1",1833,"Hs.435680","DSPG3, Pg-Lb, SLRR3B","ENSG00000083782","Epiphycan","12","90963679-91005026","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA038212, HPA045455","Approved",NA,NA,NA,"Pancreatic cancer:1.85e-4 (unfavourable)","Tissue enhanced","Tissue enriched",6,"placenta: 8.9","endometrium: 1.5","Not detected",NA,NA
"ERBB3",1,"H3","IOH5340",996,"0",NA,"v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian), mRNA (cDNA clone IMAGE:3629646), complete cds.","BC002706.2","AAH02706.1",2065,"Hs.118681","HER3, LCCS2","ENSG00000065361","Erb-b2 receptor tyrosine kinase 3","12","56079857-56103505","Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB025331, HPA045396","Uncertain",NA,"Approved","Plasma membrane<br>Actin filaments",NA,"Expressed in all","Mixed",NA,NA,"small intestine: 86.8","Cell line enhanced",NA,"Hep G2: 79.5;SK-BR-3: 77.6;SK-MEL-30: 109.7;T-47d: 108.2;WM-115: 145.7"
"ERLIN2",156,"D12","IOH61706",621,"0",NA,"ER lipid raft associated 2, mRNA (cDNA clone MGC:87072 IMAGE:5296776), complete cds","BC067765.1","AAH67765.1",11160,"Hs.705490","C8orf2, Erlin-2, NET32, SPFH2, SPG18","ENSG00000147475","ER lipid raft associated 2","8","37736599-37759101","Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA002025, CAB014894","Enhanced",NA,"Supported","Endoplasmic reticulum","Renal cancer:6.67e-6 (favourable), Glioma:1.96e-4 (unfavourable), Colorectal cancer:5.16e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 80.9","Expressed in all",NA,NA
"ERLIN2",131,"G7","IOH57525",1020,"0",NA,"ER lipid raft associated 2 (ERLIN2), transcript variant 1, mRNA.","NM_007175.6","NP_009106.1",11160,"Hs.705490","C8orf2, Erlin-2, NET32, SPFH2, SPG18","ENSG00000147475","ER lipid raft associated 2","8","37736599-37759101","Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA002025, CAB014894","Enhanced",NA,"Supported","Endoplasmic reticulum","Renal cancer:6.67e-6 (favourable), Glioma:1.96e-4 (unfavourable), Colorectal cancer:5.16e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 80.9","Expressed in all",NA,NA
"ERP27",30,"F5","IOH22595",822,"0",NA,"endoplasmic reticulum protein 27 (ERP27), mRNA.","NM_152321.2","NP_689534.1",121506,"Hs.162143","C12orf46, ERp27, FLJ32115, PDIA8","ENSG00000139055","Endoplasmic reticulum protein 27","12","14914035-14939082","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA039636, HPA052851","Enhanced",NA,NA,NA,NA,"Expressed in all","Group enriched",10,"fallopian tube: 104.4;pancreas: 282.3","kidney: 20.0","Cell line enhanced",NA,"CAPAN-2: 16.3;RT4: 74.3"
"ERP29",106,"F1","IOH41199",786,"0",NA,"endoplasmic reticulum protein 29 (ERP29), transcript variant 1, mRNA.","NM_006817.3","NP_006808.1",10961,"Hs.75841","C12orf8, ERp28, ERp29, ERp31, PDI-DB, PDIA9","ENSG00000089248","Endoplasmic reticulum protein 29","12","112013316-112023451","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA039363, HPA039456","Enhanced",NA,"Uncertain","Nucleoplasm<br>Microtubules","Endometrial cancer:7.43e-5 (favourable), Liver cancer:2.02e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 150.9","Expressed in all",NA,NA
"ERP44",54,"H1","IOH7179",1221,"0",NA,"endoplasmic reticulum protein 44 (ERP44), mRNA.","NM_015051.1","NP_055866.1",23071,"Hs.154023","KIAA0573, PDIA10, TXNDC4","ENSG00000023318","Endoplasmic reticulum protein 44","9","99979179-100099040","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA001318","Supported",NA,NA,NA,"Head and neck cancer:5.69e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 47.4","Expressed in all",NA,NA
"ESM1",74,"F1","IOH11771",555,"0",NA,"endothelial cell-specific molecule 1, mRNA (cDNA clone MGC:9412 IMAGE:3882426), complete cds","BC011989.1","AAH11989.1",11082,"Hs.129944",NA,"ENSG00000164283","Endothelial cell specific molecule 1","5","54977864-55022671","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Cervical cancer:2.11e-7 (unfavourable), Renal cancer:4.00e-4 (unfavourable)","Tissue enriched","Tissue enhanced",NA,"kidney: 19.2;thyroid gland: 27.2","endometrium: 5.8","Group enriched",5,"HUVEC TERT2: 236.2;TIME: 434.9"
"ESM1",142,"G8","IOH59010",555,"0",NA,"endothelial cell-specific molecule 1 (ESM1), transcript variant 1, mRNA.","NM_007036.4","NP_008967.1",11082,"Hs.129944",NA,"ENSG00000164283","Endothelial cell specific molecule 1","5","54977864-55022671","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Cervical cancer:2.11e-7 (unfavourable), Renal cancer:4.00e-4 (unfavourable)","Tissue enriched","Tissue enhanced",NA,"kidney: 19.2;thyroid gland: 27.2","endometrium: 5.8","Group enriched",5,"HUVEC TERT2: 236.2;TIME: 434.9"
"ETNK2",128,"H11","IOH12251",1161,"0",NA,"ethanolamine kinase 2 (ETNK2), mRNA.","NM_018208.2","NP_060678.2",55224,"Hs.497469","EKI2, FLJ10761","ENSG00000143845","Ethanolamine kinase 2","1","204131062-204152003","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA057167","Enhanced",NA,NA,NA,"Glioma:3.43e-4 (unfavourable), Renal cancer:6.50e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"kidney: 110.6;liver: 120.7;testis: 143.1","ovary: 43.4","Mixed",NA,NA
"EXTL2",131,"D3","IOH55051",993,"0",NA,"exostoses (multiple)-like 2 (EXTL2), transcript variant 2, mRNA.","NM_001033025.1","NP_001028197.1",2135,"Hs.357637",NA,"ENSG00000162694","Exostosin like glycosyltransferase 2","1","100872372-100895998","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB020716, HPA068921","Approved",NA,"Approved","Nucleus<br>Cytosol","Liver cancer:1.64e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 34.1","Expressed in all",NA,NA
"EXTL2",147,"C6","IOH62334",993,"0",NA,"exostoses (multiple)-like 2, mRNA (cDNA clone MGC:44576 IMAGE:5300220), complete cds","BC045681.1","AAH45681.1",2135,"Hs.357637",NA,"ENSG00000162694","Exostosin like glycosyltransferase 2","1","100872372-100895998","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB020716, HPA068921","Approved",NA,"Approved","Nucleus<br>Cytosol","Liver cancer:1.64e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 34.1","Expressed in all",NA,NA
"EXTL2",55,"B6","IOH27212",993,"0",NA,"exostoses (multiple)-like 2, mRNA (cDNA clone MGC:32939 IMAGE:5273246), complete cds","BC036015.1","AAH36015.1",2135,"Hs.357637",NA,"ENSG00000162694","Exostosin like glycosyltransferase 2","1","100872372-100895998","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB020716, HPA068921","Approved",NA,"Approved","Nucleus<br>Cytosol","Liver cancer:1.64e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 34.1","Expressed in all",NA,NA
"F11",132,"A5","IOH39389",1878,"0",NA,"coagulation factor XI (F11), mRNA.","NM_000128.3","NP_000119.1",2160,"Hs.1430","FXI","ENSG00000088926","Coagulation factor XI","4","186265945-186288806","Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA039808",NA,NA,"Approved","Vesicles","Liver cancer:3.29e-5 (favourable)","Tissue enriched","Tissue enhanced",NA,"liver: 180.1","kidney: 44.7","Cell line enriched",8,"Hep G2: 6.0"
"F12",29,"B10","IOH11582",903,"0",NA,"coagulation factor XII (Hageman factor), mRNA (cDNA clone IMAGE:3881207), complete cds.","BC012390.1","AAH12390.1",2161,"Hs.1321",NA,"ENSG00000131187","Coagulation factor XII","5","177402140-177409576","Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA003825","Approved",NA,NA,NA,"Liver cancer:4.63e-5 (favourable), Renal cancer:7.09e-4 (unfavourable)","Tissue enriched","Tissue enriched",78,"liver: 141.6","bone marrow: 1.8","Cell line enhanced",NA,"HDLM-2: 6.4;MCF7: 6.7;PC-3: 5.8;SH-SY5Y: 4.5"
"F2",66,"E8","IOH29386",1869,"0",NA,"coagulation factor II (thrombin), mRNA (cDNA clone MGC:59803 IMAGE:6283420), complete cds","BC051332.1","AAH51332.1",2147,"Hs.655207",NA,"ENSG00000180210","Coagulation factor II, thrombin","11","46719180-46739506","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB016780, CAB018650, HPA051476, HPA054698","Enhanced",NA,NA,NA,"Renal cancer:6.75e-12 (unfavourable)","Tissue enriched","Tissue enriched",1472,"liver: 627.3","testis: 0.4","Cell line enriched",18,"Hep G2: 186.7"
"F2",132,"H3","IOH29572",1869,"0",NA,"coagulation factor II (thrombin) (F2), mRNA.","NM_000506.3","NP_000497.1",2147,"Hs.655207",NA,"ENSG00000180210","Coagulation factor II, thrombin","11","46719180-46739506","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB016780, CAB018650, HPA051476, HPA054698","Enhanced",NA,NA,NA,"Renal cancer:6.75e-12 (unfavourable)","Tissue enriched","Tissue enriched",1472,"liver: 627.3","testis: 0.4","Cell line enriched",18,"Hep G2: 186.7"
"F2R",127,"F1","IOH4193",1278,"0",NA,"coagulation factor II (thrombin) receptor, mRNA (cDNA clone MGC:1197 IMAGE:3343051), complete cds","BC002464.2","AAH02464.1",2149,"Hs.482562","CF2R, PAR-1, PAR1, TR","ENSG00000181104","Coagulation factor II thrombin receptor","5","76716043-76735781","FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB008973, CAB012962","Approved",NA,NA,NA,"Renal cancer:2.21e-7 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 94.1","Cell line enhanced",NA,"HUVEC TERT2: 297.4;WM-115: 331.7"
"F2R",75,"A6","IOH27067",1278,"NP_001983.1","NP_001983.2","coagulation factor II (thrombin) receptor (F2R), mRNA.","NM_001992.3","NP_001983.2",2149,"Hs.482562","CF2R, PAR-1, PAR1, TR","ENSG00000181104","Coagulation factor II thrombin receptor","5","76716043-76735781","FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB008973, CAB012962","Approved",NA,NA,NA,"Renal cancer:2.21e-7 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 94.1","Cell line enhanced",NA,"HUVEC TERT2: 297.4;WM-115: 331.7"
"F7",72,"G6","IOH29718",1335,"0",NA,"coagulation factor VII (serum prothrombin conversion accelerator) (F7), transcript variant 2, mRNA.","NM_019616.2","NP_062562.1",2155,"Hs.36989",NA,"ENSG00000057593","Coagulation factor VII","13","113105788-113120681","Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA004826",NA,NA,"Approved","Mitochondria",NA,"Tissue enriched","Tissue enriched",44,"liver: 65.0","testis: 1.4","Group enriched",7,"CACO-2: 11.8;Hep G2: 6.1"
"F8",9,"G1","IOH10704",651,"0",NA,"coagulation factor VIII, procoagulant component (F8), transcript variant 2, mRNA.","NM_019863.2","NP_063916.1",2157,"Hs.654450","DXS1253E, F8C, FVIII, HEMA","ENSG00000185010","Coagulation factor VIII","X","154835788-155026940","Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB018777","Enhanced",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"lung: 23.4","Mixed",NA,NA
"F9",103,"D12","IOH41673",1386,"0",NA,"coagulation factor IX (F9), mRNA.","NM_000133.3","NP_000124.1",2158,"Hs.522798","FIX","ENSG00000101981","Coagulation factor IX","X","139530758-139563458","Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Liver cancer:6.69e-4 (favourable)","Tissue enriched","Tissue enriched",2258,"liver: 365.0","kidney: 0.1","Not detected",NA,NA
"FAM131A",36,"E5","IOH10864",846,"0",NA,"family with sequence similarity 131, member A, mRNA (cDNA clone MGC:21688 IMAGE:4399325), complete cds","BC026221.1","AAH26221.1",131408,"Hs.591307","C3orf40, MGC21688","ENSG00000175182","Family with sequence similarity 131 member A","3","184335926-184348421","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA042800","Uncertain",NA,"Approved","Nucleus<br>Nucleoli","Endometrial cancer:2.22e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 100.5","Mixed",NA,NA
"FAM131A",131,"E7","IOH57510",1008,"0",NA,"family with sequence similarity 131, member A (FAM131A), mRNA.","NM_144635.3","NP_653236.2",131408,"Hs.591307","C3orf40, MGC21688","ENSG00000175182","Family with sequence similarity 131 member A","3","184335926-184348421","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA042800","Uncertain",NA,"Approved","Nucleus<br>Nucleoli","Endometrial cancer:2.22e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 100.5","Mixed",NA,NA
"FAM171B",103,"E11","IOH29236",2487,"0",NA,"family with sequence similarity 171, member B, mRNA (cDNA clone MGC:71825 IMAGE:30347998), complete cds","BC060872.1","AAH60872.1",165215,"Hs.28872","FLJ34104, KIAA1946","ENSG00000144369","Family with sequence similarity 171 member B","2","186693971-186765965","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA010639, HPA013434","Approved",NA,"Approved","Nucleus<br>Mitochondria","Renal cancer:9.51e-7 (unfavourable), Urothelial cancer:5.03e-4 (unfavourable)","Tissue enriched","Tissue enriched",6,"cerebral cortex: 114.5","parathyroid gland: 19.3","Mixed",NA,NA
"FAM172A",9,"A10","IOH11050",1251,"0",NA,"family with sequence similarity 172, member A (FAM172A), transcript variant 1, mRNA.","NM_032042.5","NP_114431.2",83989,"Hs.600086","C5orf21, DKFZP564D172","ENSG00000113391","Family with sequence similarity 172 member A","5","93618069-94111699","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA012299, HPA045505","Approved",NA,"Supported","Nucleoplasm<br>Cytosol","Renal cancer:4.43e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 27.0","Expressed in all",NA,NA
"FAM177A1",52,"G8","IOH21621",642,"0",NA,"family with sequence similarity 177, member A1 (FAM177A1), transcript variant 2, mRNA.","NM_001079519.1","NP_001072987.1",283635,"Hs.446357","C14orf24","ENSG00000151327","Family with sequence similarity 177 member A1","14","35044907-35113130","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA053222, HPA055440","Uncertain",NA,"Approved","Nucleoplasm<br>Vesicles","Ovarian cancer:8.51e-5 (favourable), Head and neck cancer:9.70e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"prostate: 103.2","Expressed in all",NA,NA
"FAM180A",143,"D10","IOH59482",522,"0",NA,"family with sequence similarity 180, member A (FAM180A), mRNA.","NM_205855.3","NP_995327.1",389558,"Hs.55200","HWKM1940, UNQ1940","ENSG00000189320","Family with sequence similarity 180 member A","7","135728348-135748846","Predicted secreted proteins","Evidence at protein level","HPA021224","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"gallbladder: 25.5","heart muscle: 10.4","Cell line enhanced",NA,"BJ hTERT+: 45.6;fHDF/TERT166: 44.5;U-138 MG: 55.9;U-2197: 239.9"
"FAM19A3",110,"E5","IOH42521",402,"0",NA,"family with sequence similarity 19 (chemokine (C-C motif)-like), member A3 (FAM19A3), transcript variant 1, mRNA.","NM_182759.2","NP_877436.1",284467,"Hs.439116","TAFA-3, TAFA3","ENSG00000184599","Family with sequence similarity 19 member A3, C-C motif chemokine like","1","112720419-112727235","Predicted secreted proteins","Evidence at transcript level","HPA055927","Approved",NA,NA,NA,"Glioma:8.24e-4 (unfavourable)","Mixed","Group enriched",15,"adrenal gland: 19.9;testis: 8.7","epididymis: 0.9","Cell line enhanced",NA,"BJ hTERT+: 3.7;HEL: 1.6;U-87 MG: 1.7"
"FAM19A4",38,"F3","IOH22723",423,"0",NA,"family with sequence similarity 19 (chemokine (C-C motif)-like), member A4 (FAM19A4), transcript variant 2, mRNA.","NM_001005527.1","NP_001005527.1",151647,"Hs.187873","TAFA-4","ENSG00000163377","Family with sequence similarity 19 member A4, C-C motif chemokine like","3","68731766-68953297","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Mixed","Tissue enriched",10,"adrenal gland: 18.5","gallbladder: 1.9","Cell line enhanced",NA,"HAP1: 1.8;NTERA-2: 8.8;SCLC-21H: 1.1"
"FAM19A5",52,"B3","IOH25888",399,"0",NA,"family with sequence similarity 19 (chemokine (C-C motif)-like), member A5 (FAM19A5), transcript variant 1, mRNA.","NM_001082967.1","NP_001076436.1",25817,"Hs.436854","TAFA-5","ENSG00000219438","Family with sequence similarity 19 member A5, C-C motif chemokine like","22","48489460-48850912","Predicted intracellular proteins, Predicted secreted proteins","Evidence at transcript level","CAB025629","Approved",NA,NA,NA,NA,"Expressed in all","Tissue enhanced",NA,"cerebral cortex: 49.9","cervix, uterine: 12.9","Cell line enhanced",NA,"fHDF/TERT166: 15.8;HEK 293: 12.4;Hep G2: 21.7;NTERA-2: 17.3;SCLC-21H: 10.2;U-2 OS: 24.8"
"FAM19A5",151,"G2","IOH58707",378,"0",NA,"family with sequence similarity 19 (chemokine (C-C motif)-like), member A5 (FAM19A5), transcript variant 2, mRNA.","NM_015381.5","NP_056196.2",25817,"Hs.436854","TAFA-5","ENSG00000219438","Family with sequence similarity 19 member A5, C-C motif chemokine like","22","48489460-48850912","Predicted intracellular proteins, Predicted secreted proteins","Evidence at transcript level","CAB025629","Approved",NA,NA,NA,NA,"Expressed in all","Tissue enhanced",NA,"cerebral cortex: 49.9","cervix, uterine: 12.9","Cell line enhanced",NA,"fHDF/TERT166: 15.8;HEK 293: 12.4;Hep G2: 21.7;NTERA-2: 17.3;SCLC-21H: 10.2;U-2 OS: 24.8"
"FAM26D",66,"G12","IOH29133",387,"0",NA,"family with sequence similarity 26, member D (FAM26D), mRNA.","NM_153036.2","NP_694581.1",221301,"Hs.350750","C6orf78, FLJ32239","ENSG00000164451","Family with sequence similarity 26 member D","6","116529013-116558868","Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Not detected","Tissue enriched",46,"placenta: 33.8","testis: 0.7","Not detected",NA,NA
"FAM26D",147,"E12","IOH61448",516,"0",NA,"family with sequence similarity 26, member D, mRNA (cDNA clone MGC:71530 IMAGE:30332648), complete cds","BC057769.1","AAH57769.2",221301,"Hs.350750","C6orf78, FLJ32239","ENSG00000164451","Family with sequence similarity 26 member D","6","116529013-116558868","Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Not detected","Tissue enriched",46,"placenta: 33.8","testis: 0.7","Not detected",NA,NA
"FAM78A",57,"C11","IOH26402",792,"0",NA,"family with sequence similarity 78, member A, mRNA (cDNA clone MGC:50920 IMAGE:6050655), complete cds","BC049388.2","AAH49388.1",286336,"Hs.143878","C9orf59, FLJ00024","ENSG00000126882","Family with sequence similarity 78 member A","9","131258076-131276547","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA021472, HPA023914","Uncertain",NA,"Uncertain","Nucleus<br>Vesicles","Head and neck cancer:2.00e-4 (favourable), Cervical cancer:3.67e-4 (favourable)","Expressed in all","Mixed",NA,NA,"lymph node: 27.4","Cell line enhanced",NA,"BEWO: 37.7;HEL: 34.3;HL-60: 30.4;NB-4: 37.9;THP-1: 35.7;U-937: 27.8"
"FAM96A",136,"A2","IOH57021",483,"0",NA,"family with sequence similarity 96, member A (FAM96A), transcript variant 1, mRNA.","NM_032231.4","NP_115607.1",84191,"Hs.439548","CIA2A, FLJ22875","ENSG00000166797","Family with sequence similarity 96 member A","15","64072559-64094018","Predicted secreted proteins","Evidence at protein level","HPA040459, HPA063729","Approved",NA,"Supported","Nucleoplasm<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"liver: 106.1","Expressed in all",NA,NA
"FAS",133,"B1","IOH46221",663,"0",NA,"Fas (TNF receptor superfamily, member 6) (FAS), transcript variant 3, mRNA.","NM_152872.1","NP_690611.1",355,"Hs.244139","APO-1, APT1, CD95, FAS1, TNFRSF6","ENSG00000026103","Fas cell surface death receptor","10","88990582-89015785","Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA027444","Enhanced",NA,"Approved","Plasma membrane<br>Cytosol",NA,"Expressed in all","Mixed",NA,NA,"rectum: 32.9","Cell line enhanced",NA,"Karpas-707: 104.1"
"FAS",125,"C8","IOH50154",261,"0",NA,"Tumor necrosis factor receptor superfamily member 6 Precursor (FASLG receptor)(Apoptosis-mediating surface antigen FAS)(Apo-1 antigen)(CD95 antigen) [Source:UniProtKB/Swiss-Prot;Acc:P25445]","ENST00000352159","ENSP00000345601",355,"Hs.244139","APO-1, APT1, CD95, FAS1, TNFRSF6","ENSG00000026103","Fas cell surface death receptor","10","88990582-89015785","Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA027444","Enhanced",NA,"Approved","Plasma membrane<br>Cytosol",NA,"Expressed in all","Mixed",NA,NA,"rectum: 32.9","Cell line enhanced",NA,"Karpas-707: 104.1"
"FAS",6,"F2","IOH10615",1008,"0",NA,"Fas (TNF receptor superfamily, member 6) (FAS), transcript variant 1, mRNA.","NM_000043.3","NP_000034.1",355,"Hs.244139","APO-1, APT1, CD95, FAS1, TNFRSF6","ENSG00000026103","Fas cell surface death receptor","10","88990582-89015785","Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA027444","Enhanced",NA,"Approved","Plasma membrane<br>Cytosol",NA,"Expressed in all","Mixed",NA,NA,"rectum: 32.9","Cell line enhanced",NA,"Karpas-707: 104.1"
"FBLN1",82,"H4","IOH10659",2052,"0",NA,"fibulin 1, mRNA (cDNA clone MGC:26399 IMAGE:4819750), complete cds","BC022497.1","AAH22497.1",2192,"Hs.24601","FBLN","ENSG00000077942","Fibulin 1","22","45502238-45601135","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA001612, HPA001613, CAB004393, CAB068187","Enhanced",NA,"Approved","Endoplasmic reticulum","Renal cancer:3.02e-10 (unfavourable), Endometrial cancer:9.28e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cervix, uterine: 1324.4","Cell line enhanced",NA,"ASC diff: 1263.9;BJ: 870.2;BJ hTERT+: 1319.9;HSkMC: 979.4;RT4: 1182.4"
"FBLN5",47,"H5","IOH12151",1347,"0",NA,"fibulin 5 (FBLN5), mRNA.","NM_006329.3","NP_006320.2",10516,"Hs.332708","ARMD3, DANCE, EVEC, UP50","ENSG00000140092","Fibulin 5","14","91869412-91947987","Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA000848, HPA000868, CAB025843","Supported",NA,"Supported","Plasma membrane","Liver cancer:6.75e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"gallbladder: 221.0","Group enriched",6,"ASC diff: 345.3;ASC TERT1: 182.9;BJ: 207.7;BJ hTERT+: 185.8;fHDF/TERT166: 343.2;HHSteC: 70.5;HSkMC: 175.5"
"FBXW7",107,"C6","IOH42376",1884,"0",NA,"F-box and WD repeat domain containing 7 (FBXW7), transcript variant 2, mRNA.","NM_018315.4","NP_060785.2",55294,"Hs.679796","AGO, CDC4, FBW7, FBX30, FBXW6, FLJ11071, SEL-10, SEL10","ENSG00000109670","F-box and WD repeat domain containing 7","4","152321259-152536101","Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB013793, CAB029987","Supported",NA,"Supported","Nucleoplasm<br>Vesicles","Renal cancer:1.52e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"skin: 87.4","Expressed in all",NA,NA
"FCAR",17,"D8","IOH11326",864,"0",NA,"Fc fragment of IgA, receptor for (FCAR), transcript variant 1, mRNA.","NM_002000.2","NP_001991.1",2204,"Hs.659872","CD89","ENSG00000186431","Fc fragment of IgA receptor","19","54874248-54890472","CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA014050","Approved",NA,"Supported","Plasma membrane",NA,"Not detected","Tissue enriched",15,"bone marrow: 12.3","appendix: 0.8","Not detected",NA,NA
"FCGR3A",65,"A11","IOH22599",873,"0",NA,"Fc fragment of IgG, low affinity IIIa, receptor (CD16a), mRNA (cDNA clone MGC:34195 IMAGE:5206097), complete cds","BC036723.1","AAH36723.1",2214,"Hs.372679","CD16, CD16a, FCG3, FCGR3","ENSG00000203747","Fc fragment of IgG receptor IIIa","1","161541759-161550737","CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB032435, HPA055431","Supported",NA,NA,NA,"Renal cancer:3.22e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 419.4","Not detected",NA,NA
"FCGR3A",48,"H5","IOH13793",765,"NP_000560.4","AAH17865.1","Fc fragment of IgG, low affinity IIIa, receptor (CD16a), mRNA (cDNA clone MGC:22630 IMAGE:4690249), complete cds","BC017865.1","AAH17865.1",2214,"Hs.372679","CD16, CD16a, FCG3, FCGR3","ENSG00000203747","Fc fragment of IgG receptor IIIa","1","161541759-161550737","CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB032435, HPA055431","Supported",NA,NA,NA,"Renal cancer:3.22e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 419.4","Not detected",NA,NA
"FCN1",81,"F4","IOH13613",981,"0",NA,"ficolin (collagen/fibrinogen domain containing) 1 (FCN1), mRNA.","NM_002003.2","NP_001994.2",2219,"Hs.440898","FCNM","ENSG00000085265","Ficolin 1","9","134905890-134917963","Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA000685, HPA001295, CAB016760","Enhanced",NA,NA,NA,"Renal cancer:3.98e-4 (unfavourable)","Mixed","Group enriched",5,"appendix: 323.4;bone marrow: 634.5","spleen: 94.6","Group enriched",7,"NB-4: 12.4;U-937: 22.6"
"FCN2",103,"D9","IOH35403",942,"0",NA,"ficolin (collagen/fibrinogen domain containing lectin) 2 (hucolin) (FCN2), transcript variant SV0, mRNA.","NM_004108.2","NP_004099.2",2220,"Hs.54517","EBP-37, FCNL, ficolin-2, P35","ENSG00000160339","Ficolin 2","9","134880812-134887520","Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Group enriched","Tissue enriched",5,"liver: 55.0","breast: 10.4","Not detected",NA,NA
"FCN3",18,"A2","IOH14410",867,"0",NA,"ficolin (collagen/fibrinogen domain containing) 3 (Hakata antigen) (FCN3), transcript variant 2, mRNA.","NM_173452.1","NP_775628.1",8547,"Hs.333383","FCNH, HAKA1","ENSG00000142748","Ficolin 3","1","27369112-27374824","Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB025945","Approved",NA,NA,NA,NA,"Mixed","Group enriched",6,"liver: 144.1;lung: 266.5","placenta: 33.0","Not detected",NA,NA
"FCRL1",51,"E1","IOH21872",1290,"0",NA,"Fc receptor-like 1 (FCRL1), transcript variant 1, mRNA.","NM_052938.4","NP_443170.1",115350,"Hs.656112","CD307a, FCRH1, IFGP1, IRTA5","ENSG00000163534","Fc receptor like 1","1","157794403-157820105","CD markers, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA013323","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"lymph node: 30.3;spleen: 23.5;tonsil: 20.0","appendix: 12.5","Group enriched",31,"Daudi: 3.7;U-698: 11.9"
"FCRL5",153,"B3","IOH63395",2934,"NP_112571.1","AAI01068.1","Fc receptor-like 5, mRNA (cDNA clone MGC:119591 IMAGE:40008653), complete cds","BC101067.1","AAI01068.1",83416,"Hs.415950","BXMAS1, CD307e, FCRH5, IRTA2","ENSG00000143297","Fc receptor like 5","1","157513377-157552520","CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"lymph node: 28.7;spleen: 20.5;tonsil: 32.8","appendix: 17.9","Cell line enhanced",NA,"U-266/70: 2.5;U-698: 5.1"
"FCRLA",134,"B4","IOH53952",1131,"0",NA,"Fc receptor-like A (FCRLA), mRNA.","NM_032738.3","NP_116127.3",84824,"Hs.266331","FCRL, FCRLa, FCRLb, FCRLc1, FCRLc2, FCRLd, FCRLe, FCRLM1, FCRLX, FREB, MGC4595","ENSG00000132185","Fc receptor like A","1","161706972-161714352","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB016545","Enhanced",NA,NA,NA,NA,"Tissue enriched","Group enriched",10,"appendix: 31.2;lymph node: 80.5;spleen: 56.4;tonsil: 86.7","urinary bladder: 6.2","Cell line enhanced",NA,"Daudi: 338.0;SK-MEL-30: 150.5;U-698: 179.6"
"FETUB",150,"F1","IOH61923",1149,"0",NA,"fetuin B, mRNA (cDNA clone MGC:103807 IMAGE:30915188), complete cds","BC074734.2","AAH74734.1",26998,"Hs.81073",NA,"ENSG00000090512","Fetuin B","3","186635969-186653141","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA035132","Supported",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",16,"liver: 123.3","esophagus: 7.6","Not detected",NA,NA
"FGA",7,"C10","IOH12307",657,"0",NA,"fibrinogen alpha chain, mRNA (cDNA clone IMAGE:4767540), complete cds.","BC020764.1","AAH20764.1",2243,"Hs.351593",NA,"ENSG00000171560","Fibrinogen alpha chain","4","154583126-154590766","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB016776, HPA051370, HPA064755","Supported",NA,NA,NA,"Renal cancer:4.23e-6 (unfavourable), Liver cancer:7.33e-4 (favourable)","Tissue enriched","Tissue enriched",237,"liver: 9265.4","stomach: 39.0","Cell line enriched",11,"Hep G2: 285.6"
"FGF10",99,"A6","IOH40262",627,"0",NA,"fibroblast growth factor 10 (FGF10), mRNA.","NM_004465.1","NP_004456.1",2255,"Hs.664499",NA,"ENSG00000070193","Fibroblast growth factor 10","5","44303544-44389706","Disease related genes, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","CAB010315","Uncertain",NA,NA,NA,NA,"Tissue enriched","Tissue enhanced",NA,"ovary: 41.4","adipose tissue: 16.9","Cell line enriched",9,"AF22: 51.3"
"FGF18",89,"F9","IOH6319",624,"0",NA,"fibroblast growth factor 18 (FGF18), mRNA.","NM_003862.1","NP_003853.1",8817,"Hs.87191","FGF-18, ZFGF5","ENSG00000156427","Fibroblast growth factor 18","5","171419656-171457623","Cancer-related genes, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","HPA018795","Uncertain",NA,NA,NA,NA,"Group enriched","Tissue enhanced",NA,"heart muscle: 6.6","adipose tissue: 1.9","Cell line enriched",61,"EFO-21: 178.4"
"FGF19",73,"B12","IOH1835",651,"0",NA,"fibroblast growth factor 19 (FGF19), mRNA.","NM_005117.2","NP_005108.1",9965,"Hs.249200",NA,"ENSG00000162344","Fibroblast growth factor 19","11","69698232-69704642","Cancer-related genes, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","HPA036082","Approved",NA,NA,NA,NA,"Mixed","Tissue enriched",28,"gallbladder: 262.2","small intestine: 9.4","Cell line enriched",14,"CAPAN-2: 87.6"
"FGF21",32,"E6","IOH21454",630,"0",NA,"fibroblast growth factor 21, mRNA (cDNA clone MGC:21502 IMAGE:3881069), complete cds","BC018404.1","AAH18404.1",26291,"Hs.283015",NA,"ENSG00000105550","Fibroblast growth factor 21","19","48755559-48758330","Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","HPA061286","Supported",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",38,"liver: 6.6","thyroid gland: 0.1","Group enriched",8,"HHSteC: 1.2;U-2 OS: 5.2"
"FGF23",103,"F8","IOH35360",756,"0",NA,"fibroblast growth factor 23 (FGF23), mRNA.","NM_020638.2","NP_065689.1",8074,"Hs.287370",NA,"ENSG00000118972","Fibroblast growth factor 23","12","4368227-4379728","Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Not detected","Mixed",NA,NA,"epididymis: 1.5","Cell line enhanced",NA,"AF22: 1.9"
"FGF5",111,"D11","IOH42420",372,"0",NA,"fibroblast growth factor 5 (FGF5), transcript variant 2, mRNA.","NM_033143.2","NP_149134.1",2250,"Hs.37055",NA,"ENSG00000138675","Fibroblast growth factor 5","4","80266599-80336680","Disease related genes, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","CAB010313, HPA042442",NA,NA,"Supported","Nucleus<br>Nucleoli fibrillar center<br>Cytosol",NA,"Not detected","Tissue enhanced",NA,"gallbladder: 5.6","smooth muscle: 1.4","Cell line enhanced",NA,"BJ hTERT+: 97.8;fHDF/TERT166: 68.3;HBF TERT88: 85.6;LHCN-M2: 67.6;U-138 MG: 108.3"
"FGF7",17,"A3","IOH13684",294,"0",NA,"fibroblast growth factor 7 (keratinocyte growth factor), mRNA (cDNA clone MGC:13629 IMAGE:4282925), complete cds","BC010956.1","AAH10956.1",2252,"Hs.567268","KGF","ENSG00000140285","Fibroblast growth factor 7","15","49423096-49488775","Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","HPA043605","Uncertain",NA,"Approved","Nucleus<br>Nucleoli",NA,"Mixed","Tissue enhanced",NA,"gallbladder: 55.0","endometrium: 31.1","Cell line enhanced",NA,"ASC diff: 31.5;ASC TERT1: 29.3;HSkMC: 31.1;RH-30: 33.7;U-138 MG: 23.1"
"FGF7",6,"B10","IOH1782",585,"0",NA,"fibroblast growth factor 7 (keratinocyte growth factor) (FGF7), mRNA.","NM_002009.3","NP_002000.1",2252,"Hs.567268","KGF","ENSG00000140285","Fibroblast growth factor 7","15","49423096-49488775","Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","HPA043605","Uncertain",NA,"Approved","Nucleus<br>Nucleoli",NA,"Mixed","Tissue enhanced",NA,"gallbladder: 55.0","endometrium: 31.1","Cell line enhanced",NA,"ASC diff: 31.5;ASC TERT1: 29.3;HSkMC: 31.1;RH-30: 33.7;U-138 MG: 23.1"
"FGFBP1",4,"A4","IOH3926",705,"0",NA,"fibroblast growth factor binding protein 1 (FGFBP1), mRNA.","NM_005130.3","NP_005121.1",9982,"Hs.1690","FGFBP, HBP17","ENSG00000137440","Fibroblast growth factor binding protein 1","4","15935569-15938740","Cancer-related genes, Predicted secreted proteins","Evidence at protein level","HPA004332","Enhanced",NA,NA,NA,"Pancreatic cancer:5.03e-4 (unfavourable)","Tissue enhanced","Tissue enriched",7,"esophagus: 297.8","skin: 40.2","Cell line enhanced",NA,"CAPAN-2: 164.8;HaCaT: 489.2;HBEC3-KT: 688.5"
"FGFBP2",34,"C7","IOH10917",672,"0",NA,"fibroblast growth factor binding protein 2 (FGFBP2), mRNA.","NM_031950.3","NP_114156.1",83888,"Hs.98785","KSP37","ENSG00000137441","Fibroblast growth factor binding protein 2","4","15960243-15969309","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA039180","Uncertain",NA,NA,NA,NA,"Group enriched","Tissue enhanced",NA,"bone marrow: 29.0","spleen: 18.0","Cell line enhanced",NA,"SK-MEL-30: 4.8;T-47d: 2.8;WM-115: 1.2"
"FGFR1",67,"F11","IOH25748",2463,"0",NA,"fibroblast growth factor receptor 1, mRNA (cDNA clone MGC:9228 IMAGE:3911101), complete cds","BC015035.1","AAH15035.1",2260,"Hs.264887","BFGFR, CD331, CEK, FLG, FLT2, H2, H3, H4, H5, KAL2, N-SAM","ENSG00000077782","Fibroblast growth factor receptor 1","8","38411138-38468834","Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","CAB033614, HPA056402, HPA076274","Approved",NA,"Supported","Nucleoli",NA,"Expressed in all","Expressed in all",NA,NA,"cervix, uterine: 109.5","Cell line enhanced",NA,"AN3-CA: 602.2"
"FGFR1",41,"H5","IOH21425",2463,"NP_000595.1","AAH18128.1","fibroblast growth factor receptor 1, mRNA (cDNA clone MGC:9218 IMAGE:3896359), complete cds","BC018128.1","AAH18128.1",2260,"Hs.264887","BFGFR, CD331, CEK, FLG, FLT2, H2, H3, H4, H5, KAL2, N-SAM","ENSG00000077782","Fibroblast growth factor receptor 1","8","38411138-38468834","Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","CAB033614, HPA056402, HPA076274","Approved",NA,"Supported","Nucleoli",NA,"Expressed in all","Expressed in all",NA,NA,"cervix, uterine: 109.5","Cell line enhanced",NA,"AN3-CA: 602.2"
"FGFR1",142,"F7","IOH53548",2196,"0",NA,"fibroblast growth factor receptor 1 (FGFR1), transcript variant 4, mRNA.","NM_023106.2","NP_075594.1",2260,"Hs.264887","BFGFR, CD331, CEK, FLG, FLT2, H2, H3, H4, H5, KAL2, N-SAM","ENSG00000077782","Fibroblast growth factor receptor 1","8","38411138-38468834","Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","CAB033614, HPA056402, HPA076274","Approved",NA,"Supported","Nucleoli",NA,"Expressed in all","Expressed in all",NA,NA,"cervix, uterine: 109.5","Cell line enhanced",NA,"AN3-CA: 602.2"
"FGFR2",116,"D5","IOH36731",2466,"NP_000132.1","NP_000132.3","fibroblast growth factor receptor 2 (FGFR2), transcript variant 1, mRNA.","NM_000141.4","NP_000132.3",2263,"Hs.533683","BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25","ENSG00000066468","Fibroblast growth factor receptor 2","10","121478334-121598458","Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","CAB010886, HPA035305, HPA056562","Uncertain",NA,"Approved","Vesicles","Cervical cancer:8.79e-4 (favourable), Head and neck cancer:9.32e-4 (favourable)","Expressed in all","Mixed",NA,NA,"skin: 129.4","Cell line enhanced",NA,"AN3-CA: 169.6;BEWO: 58.8;HAP1: 61.4;NTERA-2: 58.4"
"FGFR2",116,"B5","IOH36732",2469,"0",NA,"fibroblast growth factor receptor 2 (FGFR2), transcript variant 2, mRNA.","NM_022970.3","NP_075259.4",2263,"Hs.533683","BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25","ENSG00000066468","Fibroblast growth factor receptor 2","10","121478334-121598458","Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","CAB010886, HPA035305, HPA056562","Uncertain",NA,"Approved","Vesicles","Cervical cancer:8.79e-4 (favourable), Head and neck cancer:9.32e-4 (favourable)","Expressed in all","Mixed",NA,NA,"skin: 129.4","Cell line enhanced",NA,"AN3-CA: 169.6;BEWO: 58.8;HAP1: 61.4;NTERA-2: 58.4"
"FGFR2",147,"G8","IOH61419",2115,"0",NA,"fibroblast growth factor receptor 2 (FGFR2), transcript variant 8, mRNA.","NM_001144918.1","NP_001138390.1",2263,"Hs.533683","BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25","ENSG00000066468","Fibroblast growth factor receptor 2","10","121478334-121598458","Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","CAB010886, HPA035305, HPA056562","Uncertain",NA,"Approved","Vesicles","Cervical cancer:8.79e-4 (favourable), Head and neck cancer:9.32e-4 (favourable)","Expressed in all","Mixed",NA,NA,"skin: 129.4","Cell line enhanced",NA,"AN3-CA: 169.6;BEWO: 58.8;HAP1: 61.4;NTERA-2: 58.4"
"FGFR4",85,"C1","IOH13371",2409,"0",NA,"fibroblast growth factor receptor 4 (FGFR4), transcript variant 1, mRNA.","NM_002011.3","NP_002002.3",2264,"Hs.165950","CD334, JTK2","ENSG00000160867","Fibroblast growth factor receptor 4","5","177086886-177098144","Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","CAB005196, HPA027273, HPA027369, HPA028251","Approved",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"lung: 38.9","duodenum: 21.4","Cell line enhanced",NA,"CACO-2: 142.3;Hep G2: 118.3;RH-30: 260.0"
"FGL1",44,"A2","IOH7319",939,"0",NA,"fibrinogen-like 1 (FGL1), transcript variant 1, mRNA.","NM_004467.3","NP_004458.3",2267,"Hs.491143","HFREP-1","ENSG00000104760","Fibrinogen like 1","8","17864380-17910365","Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Stomach cancer:5.38e-4 (unfavourable)","Tissue enriched","Tissue enriched",7,"liver: 1005.3","pancreas: 137.8","Group enriched",12,"A549: 49.7;Hep G2: 89.4"
"FGL2",19,"G6","IOH14391",447,"0",NA,"fibrinogen-like 2, mRNA (cDNA clone IMAGE:4616866), complete cds.","BC017813.1","AAH17813.1",10875,"Hs.520989","pT49, T49","ENSG00000127951","Fibrinogen like 2","7","77193371-77199848","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA021011, HPA026682","Enhanced",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"spleen: 232.5","Cell line enhanced",NA,"RPTEC TERT1: 4.2;U-937: 4.7;WM-115: 6.3"
"FGL2",51,"A3","IOH21881",1320,"0",NA,"fibrinogen-like 2 (FGL2), mRNA.","NM_006682.2","NP_006673.1",10875,"Hs.520989","pT49, T49","ENSG00000127951","Fibrinogen like 2","7","77193371-77199848","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA021011, HPA026682","Enhanced",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"spleen: 232.5","Cell line enhanced",NA,"RPTEC TERT1: 4.2;U-937: 4.7;WM-115: 6.3"
"FHL1",43,"E9","IOH13860",843,"0",NA,"four and a half LIM domains 1 (FHL1), transcript variant 2, mRNA.","NM_001449.4","NP_001440.2",2273,"Hs.435369","bA535K18.1, FHL1B, FLH1A, KYO-T, MGC111107, SLIM1, XMPMA","ENSG00000022267","Four and a half LIM domains 1","X","136146702-136211359","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA001040, HPA001391, CAB020817","Enhanced",NA,"Supported","Plasma membrane<br>Cytosol","Urothelial cancer:2.11e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"skeletal muscle: 3804.7","Cell line enhanced",NA,"BJ hTERT+: 219.3"
"FIBIN",6,"H3","IOH10651",636,"0",NA,"fin bud initiation factor homolog (zebrafish) (FIBIN), mRNA.","NM_203371.1","NP_976249.1",387758,"Hs.712718","MGC24932","ENSG00000176971","Fin bud initiation factor homolog (zebrafish)","11","26994184-26996121","Predicted secreted proteins","Evidence at protein level","HPA040120","Uncertain",NA,NA,NA,"Thyroid cancer:1.85e-6 (unfavourable), Renal cancer:1.93e-5 (favourable), Stomach cancer:6.72e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"seminal vesicle: 124.4","lung: 37.5","Group enriched",9,"ASC diff: 67.5;ASC TERT1: 43.5;fHDF/TERT166: 24.9;HHSteC: 106.9;HSkMC: 96.0;hTCEpi: 25.5"
"FJX1",89,"F5","IOH28033",1314,"0",NA,"four jointed box 1 (Drosophila) (FJX1), mRNA.","NM_014344.3","NP_055159.2",24147,"Hs.39384","FLJ22416, FLJ25593","ENSG00000179431","Four jointed box 1","11","35618419-35620868","Predicted secreted proteins","Evidence at protein level","HPA059220","Uncertain",NA,"Approved","Vesicles","Renal cancer:9.24e-9 (unfavourable), Urothelial cancer:6.56e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 22.4","endometrium: 8.8","Mixed",NA,NA
"FKBP10",50,"B5","IOH10209",1749,"0",NA,"FK506 binding protein 10, 65 kDa (FKBP10), mRNA.","NM_021939.3","NP_068758.3",60681,"Hs.463035","FKBP6, FLJ20683, FLJ22041, FLJ23833, hFKBP65","ENSG00000141756","FK506 binding protein 10","17","41812680-41823217","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA051171, HPA057021","Enhanced",NA,"Approved","Vesicles","Renal cancer:0.00e+0 (unfavourable), Thyroid cancer:3.43e-5 (unfavourable), Cervical cancer:4.16e-4 (unfavourable), Urothelial cancer:4.99e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"placenta: 84.7","Mixed",NA,NA
"FKBP11",17,"C11","IOH11881",606,"NP_057678.1","NP_057678.1","FK506 binding protein 11, 19 kDa (FKBP11), transcript variant 1, mRNA.","NM_016594.2","NP_057678.1",51303,"Hs.655103","FKBP19","ENSG00000134285","FK506 binding protein 11","12","48921518-48926474","Enzymes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA041709","Enhanced",NA,"Approved","Centrosome","Renal cancer:0.00e+0 (unfavourable), Endometrial cancer:7.09e-4 (favourable)","Expressed in all","Mixed",NA,NA,"pancreas: 60.7","Mixed",NA,NA
"FKBP11",58,"F9","IOH26585",321,"0",NA,"FK506 binding protein 11, 19 kDa, mRNA (cDNA clone MGC:54182 IMAGE:5207367), complete cds","BC048292.1","AAH48292.1",51303,"Hs.655103","FKBP19","ENSG00000134285","FK506 binding protein 11","12","48921518-48926474","Enzymes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA041709","Enhanced",NA,"Approved","Centrosome","Renal cancer:0.00e+0 (unfavourable), Endometrial cancer:7.09e-4 (favourable)","Expressed in all","Mixed",NA,NA,"pancreas: 60.7","Mixed",NA,NA
"FKBP14",20,"C6","IOH7284",636,"0",NA,"FK506 binding protein 14, 22 kDa (FKBP14), mRNA.","NM_017946.2","NP_060416.1",55033,"Hs.571333","FKBP22, FLJ20731","ENSG00000106080","FK506 binding protein 14","7","30010587-30026684","Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins","Evidence at protein level","HPA013329, HPA026829","Uncertain",NA,"Approved","Nucleus<br>Golgi apparatus<br>Cytosol","Breast cancer:1.60e-4 (unfavourable), Urothelial cancer:4.25e-4 (unfavourable), Stomach cancer:4.57e-4 (unfavourable), Liver cancer:6.87e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"smooth muscle: 20.3","Mixed",NA,NA
"FKBP2",154,"H4","IOH62665",429,"0",NA,"FK506 binding protein 2, 13kDa, mRNA (cDNA clone MGC:110888 IMAGE:30349098), complete cds","BC091475.1","AAH91475.1",2286,"Hs.227729","FKBP-13, PPIase","ENSG00000173486","FK506 binding protein 2","11","64241003-64244132","Enzymes, Predicted secreted proteins","Evidence at protein level","CAB025561, HPA049405","Enhanced",NA,"Approved","Plasma membrane",NA,"Expressed in all","Expressed in all",NA,NA,"epididymis: 399.2","Expressed in all",NA,NA
"FKBP2",29,"C8","IOH2972",429,"0",NA,"FK506 binding protein 2, 13kDa (FKBP2), transcript variant 1, mRNA.","NM_004470.3","NP_004461.2",2286,"Hs.227729","FKBP-13, PPIase","ENSG00000173486","FK506 binding protein 2","11","64241003-64244132","Enzymes, Predicted secreted proteins","Evidence at protein level","CAB025561, HPA049405","Enhanced",NA,"Approved","Plasma membrane",NA,"Expressed in all","Expressed in all",NA,NA,"epididymis: 399.2","Expressed in all",NA,NA
"FKBP7",49,"D8","IOH9873",669,"0",NA,"FK506 binding protein 7 (FKBP7), transcript variant 1, mRNA.","NM_181342.2","NP_851939.1",51661,"Hs.410378","FKBP23","ENSG00000079150","FK506 binding protein 7","2","178463664-178478600","Enzymes, Predicted secreted proteins","Evidence at protein level","HPA008707","Approved","Supported","Supported","Endoplasmic reticulum","Renal cancer:4.61e-6 (unfavourable)","Expressed in all","Tissue enhanced",NA,"ovary: 60.2","endometrium: 44.1","Cell line enhanced",NA,"ASC diff: 104.3;ASC TERT1: 65.6"
"FLT1",140,"H12","IOH56333",2064,"0",NA,"fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor) (FLT1), transcript variant 2, mRNA.","NM_001159920.1","NP_001153392.1",2321,"Hs.654360","FLT, VEGFR1","ENSG00000102755","Fms related tyrosine kinase 1","13","28300344-28495145","Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","HPA011740, HPA014290, CAB068189, CAB068190","Enhanced",NA,"Supported","Plasma membrane<br>Actin filaments","Renal cancer:2.19e-4 (unfavourable)","Expressed in all","Tissue enriched",8,"placenta: 622.5","thyroid gland: 81.9","Cell line enhanced",NA,"BJ: 61.1;HMC-1: 308.1;WM-115: 126.2"
"FMOD",77,"E11","IOH27313",1131,"0",NA,"fibromodulin (FMOD), mRNA.","NM_002023.3","NP_002014.2",2331,"Hs.519168","SLRR2E","ENSG00000122176","Fibromodulin","1","203340628-203351489","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:1.40e-5 (unfavourable), Urothelial cancer:2.67e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"gallbladder: 171.7","Cell line enhanced",NA,"CACO-2: 28.0;HHSteC: 8.7;HSkMC: 14.1"
"FOLR2",64,"G3","IOH29481",768,"0",NA,"folate receptor 2 (fetal) (FOLR2), transcript variant 4, mRNA.","NM_001113536.1","NP_001107008.1",2350,"Hs.433159",NA,"ENSG00000165457","Folate receptor beta","11","72216601-72221950","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Thyroid cancer:8.41e-4 (favourable), Colorectal cancer:8.42e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 235.4","Group enriched",6,"Daudi: 2.6;U-698: 12.5"
"FOXRED2",122,"G1","IOH14781",2055,"0",NA,"FAD-dependent oxidoreductase domain containing 2, mRNA (cDNA clone MGC:16700 IMAGE:4127473), complete cds","BC027716.2","AAH27716.1",80020,"Hs.387601","ERFAD, FLJ23322","ENSG00000100350","FAD dependent oxidoreductase domain containing 2","22","36487190-36507101","Predicted secreted proteins","Evidence at protein level","HPA031611, HPA031612","Approved",NA,NA,NA,"Cervical cancer:4.86e-5 (favourable), Thyroid cancer:9.32e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 30.8","Cell line enhanced",NA,"SiHa: 155.2"
"FOXRED2",84,"B10","IOH13219",2055,"0",NA,"FAD-dependent oxidoreductase domain containing 2, mRNA (cDNA clone MGC:22928 IMAGE:4866761), complete cds","BC015726.1","AAH15726.1",80020,"Hs.387601","ERFAD, FLJ23322","ENSG00000100350","FAD dependent oxidoreductase domain containing 2","22","36487190-36507101","Predicted secreted proteins","Evidence at protein level","HPA031611, HPA031612","Approved",NA,NA,NA,"Cervical cancer:4.86e-5 (favourable), Thyroid cancer:9.32e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 30.8","Cell line enhanced",NA,"SiHa: 155.2"
"FOXRED2",78,"G2","IOH25766",2055,"0",NA,"FAD-dependent oxidoreductase domain containing 2 (FOXRED2), transcript variant 2, mRNA.","NM_001102371.1","NP_001095841.1",80020,"Hs.387601","ERFAD, FLJ23322","ENSG00000100350","FAD dependent oxidoreductase domain containing 2","22","36487190-36507101","Predicted secreted proteins","Evidence at protein level","HPA031611, HPA031612","Approved",NA,NA,NA,"Cervical cancer:4.86e-5 (favourable), Thyroid cancer:9.32e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 30.8","Cell line enhanced",NA,"SiHa: 155.2"
"FREM1",147,"E8","IOH61417",2130,"0",NA,"FRAS1 related extracellular matrix 1, mRNA (cDNA clone IMAGE:5272747), complete cds.","BC031064.1","AAH31064.2",158326,"Hs.709555","C9orf143, C9orf145, C9orf154, DKFZp686M16108, FLJ25461, TILRR","ENSG00000164946","FRAS1 related extracellular matrix 1","9","14734666-14910995","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"endometrium: 34.0;epididymis: 44.5","smooth muscle: 23.2","Cell line enriched",8,"HEL: 162.3"
"FRMPD2",36,"D12","IOH22805",786,"0",NA,"FERM and PDZ domain containing 2 (FRMPD2), transcript variant 2, mRNA.","NM_001017929.2","NP_001017929.1",143162,"Hs.664786","MGC35285, PDZD5C, PDZK5C","ENSG00000170324","FERM and PDZ domain containing 2","10","48153088-48274870","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"cerebral cortex: 1.6;fallopian tube: 4.6","thyroid gland: 0.8","Cell line enhanced",NA,"BEWO: 2.3;SCLC-21H: 1.2"
"FRZB",33,"D5","IOH11489",978,"0",NA,"frizzled-related protein (FRZB), mRNA.","NM_001463.2","NP_001454.2",2487,"Hs.128453","FRE, FRITZ, FRP-3, FRZB-1, FRZB-PEN, FRZB1, FZRB, hFIZ, SFRP3, SRFP3","ENSG00000162998","Frizzled-related protein","2","182833275-182867162","Disease related genes, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:8.97e-6 (unfavourable)","Expressed in all","Tissue enhanced",NA,"spleen: 101.2","gallbladder: 50.3","Cell line enhanced",NA,"AF22: 16.2;ASC diff: 5.3;NTERA-2: 6.7;SH-SY5Y: 6.0"
"FST",92,"D6","IOH5621",1035,"0",NA,"follistatin (FST), transcript variant FST344, mRNA.","NM_013409.1","NP_037541.1",10468,"Hs.9914","FS","ENSG00000134363","Follistatin","5","53480409-53487134","Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB026025","Approved",NA,NA,NA,"Renal cancer:4.44e-5 (unfavourable)","Expressed in all","Mixed",NA,NA,"liver: 33.0","Cell line enhanced",NA,"BJ hTERT+: 272.8;HaCaT: 253.0;PC-3: 509.0"
"FST",141,"B5","IOH59070",954,"0",NA,"follistatin (FST), transcript variant FST317, mRNA.","NM_006350.2","NP_006341.1",10468,"Hs.9914","FS","ENSG00000134363","Follistatin","5","53480409-53487134","Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB026025","Approved",NA,NA,NA,"Renal cancer:4.44e-5 (unfavourable)","Expressed in all","Mixed",NA,NA,"liver: 33.0","Cell line enhanced",NA,"BJ hTERT+: 272.8;HaCaT: 253.0;PC-3: 509.0"
"FSTL4",19,"D12","IOH12700",1818,"0",NA,"follistatin-like 4, mRNA (cDNA clone MGC:39367 IMAGE:4662520), complete cds","BC024300.1","AAH24300.1",23105,"Hs.483390","KIAA1061","ENSG00000053108","Follistatin like 4","5","133196455-133612564","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA045920","Uncertain",NA,"Approved","Mitochondria",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 9.5","urinary bladder: 7.3","Cell line enhanced",NA,"SCLC-21H: 66.8"
"FSTL5",82,"B9","IOH22074",2544,"0",NA,"follistatin-like 5, mRNA (cDNA clone MGC:43288 IMAGE:5265170), complete cds","BC036502.2","AAH36502.1",56884,"Hs.591707","DKFZp566D234, KIAA1263","ENSG00000168843","Follistatin like 5","4","161383897-162164035","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enriched","Group enriched",11,"adrenal gland: 7.8;cerebral cortex: 16.2","testis: 1.1","Cell line enhanced",NA,"HL-60: 9.8;HUVEC TERT2: 9.0;Karpas-707: 53.8;SH-SY5Y: 11.3;U-2197: 15.1"
"FUCA1",45,"D12","IOH12623",1386,"0",NA,"fucosidase, alpha-L- 1, tissue, mRNA (cDNA clone MGC:29579 IMAGE:4871788), complete cds","BC017338.2","AAH17338.1",2517,"Hs.370858",NA,"ENSG00000179163","Fucosidase, alpha-L- 1, tissue","1","23845077-23868294","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins","Evidence at protein level","HPA046542, HPA056371","Enhanced",NA,NA,NA,"Renal cancer:5.70e-13 (favourable), Endometrial cancer:2.45e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 185.6","Cell line enhanced",NA,"CAPAN-2: 144.5"
"FUCA2",45,"F12","IOH4664",1404,"0",NA,"fucosidase, alpha-L- 2, plasma, mRNA (cDNA clone MGC:1314 IMAGE:3505533), complete cds","BC003060.2","AAH03060.1",2519,"Hs.591332","dJ20N2.5, MGC1314","ENSG00000001036","Fucosidase, alpha-L- 2, plasma","6","143494811-143511690","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA031659, HPA031660, HPA031661","Uncertain",NA,NA,NA,"Liver cancer:2.70e-9 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 154.2","Mixed",NA,NA
"FURIN",63,"A4","IOH13457",2385,"NP_002560.1","NP_002560.1","furin (paired basic amino acid cleaving enzyme) (FURIN), mRNA.","NM_002569.2","NP_002560.1",5045,"Hs.513153","FUR, PACE, PCSK3, SPC1","ENSG00000140564","Furin, paired basic amino acid cleaving enzyme","15","90868592-90883458","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB009499","Approved",NA,"Supported","Nucleoplasm<br>Golgi apparatus","Lung cancer:1.58e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"salivary gland: 92.8","Expressed in all",NA,NA
"FXR1",31,"B9","IOH22379",1620,"0",NA,"fragile X mental retardation, autosomal homolog 1 (FXR1), transcript variant 2, mRNA.","NM_001013438.1","NP_001013456.1",8087,"Hs.478407",NA,"ENSG00000114416","FMR1 autosomal homolog 1","3","180868141-180982753","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA018246, HPA055475","Approved",NA,"Enhanced","Cytosol","Renal cancer:2.19e-5 (unfavourable), Liver cancer:2.70e-4 (unfavourable), Endometrial cancer:5.96e-4 (unfavourable), Pancreatic cancer:7.30e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"skeletal muscle: 276.6","Expressed in all",NA,NA
"FXYD3",89,"F10","IOH7212",264,"0",NA,"FXYD domain containing ion transport regulator 3 (FXYD3), transcript variant 1, mRNA.","NM_005971.3","NP_005962.1",5349,"Hs.301350","MAT-8, PLML","ENSG00000089356","FXYD domain containing ion transport regulator 3","19","35115879-35124324","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA010856","Enhanced",NA,NA,NA,"Renal cancer:1.15e-6 (unfavourable)","Expressed in all","Tissue enhanced",NA,"colon: 1455.6;rectum: 1952.1","stomach: 557.3","Cell line enhanced",NA,"HaCaT: 792.6;hTCEpi: 1156.1;RT4: 686.4;SK-BR-3: 621.3;WM-115: 590.3"
"GABBR1",119,"B2","IOH27756",2535,"NP_001461.1","AAH41332.1","gamma-aminobutyric acid (GABA) B receptor, 1, mRNA (cDNA clone MGC:41792 IMAGE:5275467), complete cds","BC041332.2","AAH41332.1",2550,"Hs.167017","GPRC3A, hGB1a","ENSG00000204681","Gamma-aminobutyric acid type B receptor subunit 1","6","29555629-29633976","FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA050483, HPA058459","Uncertain",NA,"Approved","Centrosome","Renal cancer:3.77e-10 (unfavourable), Pancreatic cancer:2.54e-5 (favourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 20.8","spleen: 13.1","Cell line enhanced",NA,"U-2 OS: 6.7"
"GABBR1",121,"D5","IOH39488",2535,"0",NA,"gamma-aminobutyric acid (GABA) B receptor, 1 (GABBR1), transcript variant 2, mRNA.","NM_021903.2","NP_068703.1",2550,"Hs.167017","GPRC3A, hGB1a","ENSG00000204681","Gamma-aminobutyric acid type B receptor subunit 1","6","29555629-29633976","FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA050483, HPA058459","Uncertain",NA,"Approved","Centrosome","Renal cancer:3.77e-10 (unfavourable), Pancreatic cancer:2.54e-5 (favourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 20.8","spleen: 13.1","Cell line enhanced",NA,"U-2 OS: 6.7"
"GABRA1",31,"E4","IOH22243",1371,"0",NA,"gamma-aminobutyric acid (GABA) A receptor, alpha 1 (GABRA1), transcript variant 1, mRNA.","NM_000806.5","NP_000797.2",2554,"Hs.175934","EJM5","ENSG00000022355","Gamma-aminobutyric acid type A receptor alpha1 subunit","5","161847063-161899981","Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","CAB022502, HPA055746","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",46,"cerebral cortex: 85.0","adrenal gland: 1.8","Not detected",NA,NA
"GABRA2",3,"E8","IOH11238",1104,"NP_000797.1","AAH22488.1","gamma-aminobutyric acid (GABA) A receptor, alpha 2, mRNA (cDNA clone MGC:26342 IMAGE:4812001), complete cds","BC022488.1","AAH22488.1",2555,"Hs.116250",NA,"ENSG00000151834","Gamma-aminobutyric acid type A receptor alpha2 subunit","4","46248427-46475230","FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","CAB079061",NA,"Supported",NA,NA,NA,"Tissue enhanced","Tissue enriched",7,"cerebral cortex: 74.3","epididymis: 11.3","Cell line enhanced",NA,"U-2 OS: 4.9;U-87 MG: 2.2;WM-115: 2.5"
"GABRA5",3,"A8","IOH9744",1389,"0",NA,"gamma-aminobutyric acid (GABA) A receptor, alpha 5 (GABRA5), mRNA.","NM_000810.2","NP_000801.1",2558,"Hs.612087",NA,"ENSG00000186297","Gamma-aminobutyric acid type A receptor alpha5 subunit","15","26866363-26949207","FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA077031, CAB079022",NA,"Supported","Supported","Plasma membrane",NA,"Mixed","Tissue enriched",43,"cerebral cortex: 81.6","esophagus: 1.8","Group enriched",10,"A549: 32.7;HAP1: 12.7;NTERA-2: 14.6;U-2 OS: 13.1"
"GABRD",92,"B4","IOH21818",1359,"NP_000806.1","NP_000806.2","gamma-aminobutyric acid (GABA) A receptor, delta (GABRD), mRNA.","NM_000815.4","NP_000806.2",2563,"Hs.113882",NA,"ENSG00000187730","Gamma-aminobutyric acid type A receptor delta subunit","1","2019298-2030758","Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA044371","Enhanced",NA,"Uncertain","Golgi apparatus<br>Vesicles","Renal cancer:4.12e-8 (unfavourable)","Expressed in all","Tissue enriched",12,"cerebral cortex: 34.0","testis: 2.7","Cell line enhanced",NA,"EFO-21: 1.3;MCF7: 3.1;NB-4: 1.6;SH-SY5Y: 1.6"
"GAL",39,"C5","IOH21513",372,"0",NA,"galanin prepropeptide (GAL), mRNA.","NM_015973.3","NP_057057.2",51083,"Hs.278959","GAL-GMAP, GALN, GLNN, GMAP","ENSG00000069482","Galanin and GMAP prepropeptide","11","68683779-68691175","Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA049864","Enhanced","Supported","Approved","Golgi apparatus<br>Vesicles","Endometrial cancer:1.22e-4 (unfavourable), Lung cancer:8.17e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"appendix: 18.1;smooth muscle: 12.1","colon: 5.2","Cell line enhanced",NA,"CACO-2: 193.9;K-562: 111.4;NB-4: 277.5;SH-SY5Y: 179.1"
"GALC",124,"C2","IOH22482",2010,"0",NA,"galactosylceramidase, mRNA (cDNA clone MGC:33117 IMAGE:5267705), complete cds","BC036518.2","AAH36518.1",2581,"Hs.513439",NA,"ENSG00000054983","Galactosylceramidase","14","87837820-87993665","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB022196","Approved",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"testis: 44.0","Cell line enhanced",NA,"CAPAN-2: 72.3;HMC-1: 67.2"
"GALNS",120,"E1","IOH28897",1569,"0",NA,"galactosamine (N-acetyl)-6-sulfate sulfatase (GALNS), mRNA.","NM_000512.4","NP_000503.1",2588,"Hs.271383","GALNAC6S, GAS","ENSG00000141012","Galactosamine (N-acetyl)-6-sulfatase","16","88813734-88856970","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB026404, HPA042433","Enhanced",NA,"Approved","Cytosol","Liver cancer:3.66e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 29.7","Expressed in all",NA,NA
"GANAB",105,"G3","IOH43836",2835,"0",NA,"glucosidase, alpha; neutral AB (GANAB), transcript variant 2, mRNA.","NM_198334.1","NP_938148.1",23193,"Hs.595071","G2AN, GIIA, GluII, KIAA0088","ENSG00000089597","Glucosidase II alpha subunit","11","62624826-62646726","Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA026874, HPA061426","Enhanced",NA,"Approved","Nuclear membrane<br>Endoplasmic reticulum<br>Cytosol","Liver cancer:1.27e-5 (unfavourable), Urothelial cancer:9.54e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 295.2","Expressed in all",NA,NA
"GANAB",117,"C6","IOH40484",2544,"0",NA,"glucosidase, alpha; neutral AB, mRNA (cDNA clone MGC:70558 IMAGE:6155944), complete cds","BC065266.1","AAH65266.1",23193,"Hs.595071","G2AN, GIIA, GluII, KIAA0088","ENSG00000089597","Glucosidase II alpha subunit","11","62624826-62646726","Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA026874, HPA061426","Enhanced",NA,"Approved","Nuclear membrane<br>Endoplasmic reticulum<br>Cytosol","Liver cancer:1.27e-5 (unfavourable), Urothelial cancer:9.54e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 295.2","Expressed in all",NA,NA
"GAPVD1",14,"A10","IOH14831",1890,"0",NA,"GTPase activating protein and VPS9 domains 1, mRNA (cDNA clone IMAGE:4866709), complete cds.","BC021119.1","AAH21119.1",26130,"Hs.495134","DKFZP434C212, KIAA1521","ENSG00000165219","GTPase activating protein and VPS9 domains 1","9","125261794-125367207","Predicted intracellular proteins","Evidence at protein level","HPA029386, HPA029387","Uncertain",NA,"Supported","Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 49.2","Expressed in all",NA,NA
"GARS",83,"H6","IOH6489",2220,"0",NA,"glycyl-tRNA synthetase, mRNA (cDNA clone MGC:12625 IMAGE:4299853), complete cds","BC007722.2","AAH07722.1",2617,"Hs.404321","CMT2D, DSMAV, GlyRS, SMAD1","ENSG00000106105","Glycyl-tRNA synthetase","7","30594681-30634033","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins","Evidence at protein level","HPA017896, HPA019097","Enhanced",NA,"Supported","Cytosol","Renal cancer:1.70e-5 (unfavourable), Urothelial cancer:3.04e-5 (unfavourable), Liver cancer:8.95e-5 (unfavourable), Breast cancer:1.02e-4 (unfavourable), Endometrial cancer:8.48e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 96.0","Expressed in all",NA,NA
"GAS6",118,"B10","IOH26141",2037,"0",NA,"growth arrest-specific 6 (GAS6), transcript variant 1, mRNA.","NM_000820.2","NP_000811.1",2621,"Hs.646346","AXLLG, AXSF, DKFZp666G247, FLJ34709","ENSG00000183087","Growth arrest specific 6","13","113820549-113864067","Predicted secreted proteins","Evidence at protein level","HPA008275, HPA056080","Approved",NA,"Approved","Microtubule organizing center<br>Cytosol","Urothelial cancer:8.93e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"fallopian tube: 193.7","Cell line enhanced",NA,"BJ: 295.0;BJ hTERT+: 407.1;RPMI-8226: 339.8"
"GAST",99,"E6","IOH40360",306,"0",NA,"gastrin (GAST), mRNA.","NM_000805.3","NP_000796.1",2520,"Hs.2681","GAS","ENSG00000184502","Gastrin","17","41712326-41715969","Cancer-related genes, Predicted secreted proteins","Evidence at protein level","CAB000038","Supported",NA,NA,NA,NA,"Group enriched","Tissue enriched",200,"stomach: 11203.5","duodenum: 55.9","Group enriched",6,"BEWO: 2.6;HaCaT: 4.7;hTCEpi: 2.3"
"GC",70,"A5","IOH29449",1425,"0",NA,"group-specific component (vitamin D binding protein), mRNA (cDNA clone MGC:61910 IMAGE:4767205), complete cds","BC057228.1","AAH57228.1",2638,"Hs.418497","DBP, hDBP, VDBP","ENSG00000145321","GC, vitamin D binding protein","4","71741693-71804041","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA001526, CAB008596, HPA019855","Supported",NA,NA,NA,"Renal cancer:5.81e-5 (unfavourable), Liver cancer:8.08e-4 (favourable)","Tissue enriched","Tissue enriched",5,"liver: 3875.6","gallbladder: 712.5","Cell line enhanced",NA,"HL-60: 1.4;RH-30: 2.5;SiHa: 1.3"
"GCG",37,"C8","IOH7301",543,"0",NA,"glucagon (GCG), mRNA.","NM_002054.2","NP_002045.1",2641,"Hs.516494","GLP1, GLP2, GRPP","ENSG00000115263","Glucagon","2","162142873-162152404","Predicted secreted proteins","Evidence at protein level","CAB000040, HPA036760, HPA036761","Enhanced",NA,"Supported","Endoplasmic reticulum<br>Vesicles",NA,"Tissue enriched","Tissue enhanced",NA,"pancreas: 346.3;rectum: 137.2;small intestine: 123.9","colon: 69.4","Group enriched",7,"EFO-21: 100.6;U-2 OS: 158.1"
"GCGR",77,"G7","IOH39475",1434,"NP_000151.1","NP_000151.1","glucagon receptor (GCGR), mRNA.","NM_000160.2","NP_000151.1",2642,"Hs.208","GGR","ENSG00000215644","Glucagon receptor","17","81804132-81814013","FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA071228",NA,NA,"Approved","Golgi apparatus",NA,"Tissue enhanced","Group enriched",7,"adrenal gland: 6.6;kidney: 8.4;liver: 20.8;parathyroid gland: 8.0","skin: 1.6","Cell line enhanced",NA,"HeLa: 1.2;MCF7: 2.2;SK-BR-3: 1.8;U-87 MG: 2.7"
"GDF10",131,"E11","IOH46511",1437,"0",NA,"growth differentiation factor 10 (GDF10), mRNA.","NM_004962.2","NP_004953.1",2662,"Hs.2171","BMP-3b","ENSG00000266524","Growth differentiation factor 10","10","47300386-47313547","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA015498","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"lung: 19.6","testis: 9.0","Cell line enhanced",NA,"AF22: 14.6;MOLT-4: 2.6;SH-SY5Y: 6.4"
"GDF10",42,"A2","IOH11668",867,"0",NA,"growth differentiation factor 10, mRNA (cDNA clone MGC:39897 IMAGE:5245100), complete cds","BC028237.1","AAH28237.1",2662,"Hs.2171","BMP-3b","ENSG00000266524","Growth differentiation factor 10","10","47300386-47313547","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA015498","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"lung: 19.6","testis: 9.0","Cell line enhanced",NA,"AF22: 14.6;MOLT-4: 2.6;SH-SY5Y: 6.4"
"GDF15",135,"E7","IOH56873",927,"0",NA,"growth differentiation factor 15 (GDF15), mRNA.","NM_004864.2","NP_004855.2",9518,"Hs.616962","MIC-1, MIC1, NAG-1, PDF, PLAB, PTGFB","ENSG00000130513","Growth differentiation factor 15","19","18374731-18389176","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA011191, CAB062554, HPA070957","Enhanced",NA,"Enhanced","Golgi apparatus",NA,"Expressed in all","Tissue enhanced",NA,"placenta: 122.1;prostate: 74.5","kidney: 41.6","Cell line enhanced",NA,"BEWO: 401.5;HHSteC: 474.6"
"GDF2",93,"E10","IOH40347",1290,"0",NA,"growth differentiation factor 2 (GDF2), mRNA.","NM_016204.1","NP_057288.1",2658,"Hs.279463","BMP-9, BMP9","ENSG00000263761","Growth differentiation factor 2","10","47322490-47326270","Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB023357","Uncertain",NA,NA,NA,NA,"Not detected","Tissue enriched",61,"liver: 11.3","placenta,testis: 0.1","Not detected",NA,NA
"GDF3",134,"A4","IOH53947",1095,"0",NA,"growth differentiation factor 3 (GDF3), mRNA.","NM_020634.1","NP_065685.1",9573,"Hs.86232",NA,"ENSG00000184344","Growth differentiation factor 3","12","7689782-7695776","Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA018468","Uncertain",NA,NA,NA,NA,"Tissue enriched","Tissue enhanced",NA,"kidney: 1.1;spleen: 1.1","testis: 0.8","Cell line enriched",14,"NTERA-2: 450.4"
"GDF3",50,"H10","IOH23156",1095,"0",NA,"growth differentiation factor 3, mRNA (cDNA clone MGC:32558 IMAGE:4610141), complete cds","BC030959.1","AAH30959.1",9573,"Hs.86232",NA,"ENSG00000184344","Growth differentiation factor 3","12","7689782-7695776","Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA018468","Uncertain",NA,NA,NA,NA,"Tissue enriched","Tissue enhanced",NA,"kidney: 1.1;spleen: 1.1","testis: 0.8","Cell line enriched",14,"NTERA-2: 450.4"
"GDF5",54,"C12","IOH27548",1506,"0",NA,"growth differentiation factor 5 (GDF5), mRNA.","NM_000557.2","NP_000548.1",8200,"Hs.1573","BMP14, CDMP1","ENSG00000125965","Growth differentiation factor 5","20","35433347-35454746","Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA015648","Uncertain",NA,NA,NA,NA,"Tissue enriched","Tissue enhanced",NA,"salivary gland: 4.1","seminal vesicle: 1.7","Cell line enhanced",NA,"ASC TERT1: 12.2;BJ hTERT+: 4.4;HHSteC: 4.8;HSkMC: 10.3;U-87 MG: 6.5"
"GDF9",110,"D2","IOH43735",1365,"0",NA,"growth differentiation factor 9 (GDF9), mRNA.","NM_005260.3","NP_005251.1",2661,"Hs.25022",NA,"ENSG00000164404","Growth differentiation factor 9","5","132861181-132866884","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA069146","Supported",NA,NA,NA,NA,"Tissue enriched","Group enriched",5,"epididymis: 5.0;testis: 14.1","thyroid gland: 1.8","Mixed",NA,NA
"GDNF",87,"B10","IOH34675",558,"0",NA,"glial cell derived neurotrophic factor (GDNF), transcript variant 2, mRNA.","NM_199231.1","NP_954701.1",2668,"Hs.248114","ATF1, ATF2, HFB1-GDNF","ENSG00000168621","Glial cell derived neurotrophic factor","5","37812677-37839686","Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB005210, HPA070283","Supported",NA,"Approved","Nucleoplasm<br>Vesicles",NA,"Mixed","Mixed",NA,NA,"placenta: 7.0","Cell line enhanced",NA,"hTEC/SVTERT24-B: 41.1;U-87 MG: 12.1;WM-115: 45.1"
"GDNF",108,"B10","IOH35215",636,"0",NA,"glial cell derived neurotrophic factor (GDNF), transcript variant 1, mRNA.","NM_000514.2","NP_000505.1",2668,"Hs.248114","ATF1, ATF2, HFB1-GDNF","ENSG00000168621","Glial cell derived neurotrophic factor","5","37812677-37839686","Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB005210, HPA070283","Supported",NA,"Approved","Nucleoplasm<br>Vesicles",NA,"Mixed","Mixed",NA,NA,"placenta: 7.0","Cell line enhanced",NA,"hTEC/SVTERT24-B: 41.1;U-87 MG: 12.1;WM-115: 45.1"
"GFPT2",73,"C1","IOH4705",2049,"0",NA,"glutamine-fructose-6-phosphate transaminase 2, mRNA (cDNA clone MGC:1837 IMAGE:3506723), complete cds","BC000012.2","AAH00012.1",9945,"Hs.696497","GFAT2","ENSG00000131459","Glutamine-fructose-6-phosphate transaminase 2","5","180300690-180353387","Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA056892, HPA059910","Uncertain",NA,"Supported","Vesicles","Renal cancer:2.58e-14 (unfavourable), Lung cancer:2.95e-4 (unfavourable), Thyroid cancer:3.47e-4 (unfavourable), Cervical cancer:9.09e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"adipose tissue: 90.9","appendix: 25.7","Cell line enhanced",NA,"ASC TERT1: 138.7;hTEC/SVTERT24-B: 242.9;U-87 MG: 409.1"
"GGH",55,"C5","IOH25778",957,"0",NA,"gamma-glutamyl hydrolase (conjugase, folylpolygammaglutamyl hydrolase) (GGH), mRNA.","NM_003878.2","NP_003869.1",8836,"Hs.78619",NA,"ENSG00000137563","Gamma-glutamyl hydrolase","8","63015079-63039171","Enzymes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB019296, HPA025226","Approved",NA,NA,NA,"Endometrial cancer:3.99e-7 (unfavourable), Lung cancer:1.65e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"kidney: 90.0","liver: 63.2","Mixed",NA,NA
"GH1",120,"E6","IOH50057",93,"0",NA,"growth hormone 1 (GH1), transcript variant 5, mRNA.","NM_022562.2","NP_072056.1",2688,"Hs.655229","GH, GH-N, GHN, hGH-N","ENSG00000259384","Growth hormone 1","17","63917200-63918838","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA043715","Supported",NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"placenta: 1.2","duodenum: 0.6","Cell line enhanced",NA,"U-698: 1.8"
"GH1",96,"D6","IOH40047",609,"0",NA,"growth hormone 1 (GH1), transcript variant 2, mRNA.","NM_022559.2","NP_072053.1",2688,"Hs.655229","GH, GH-N, GHN, hGH-N","ENSG00000259384","Growth hormone 1","17","63917200-63918838","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA043715","Supported",NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"placenta: 1.2","duodenum: 0.6","Cell line enhanced",NA,"U-698: 1.8"
"GH1",111,"D7","IOH45734",654,"0",NA,"growth hormone 1 (GH1), transcript variant 1, mRNA.","NM_000515.3","NP_000506.2",2688,"Hs.655229","GH, GH-N, GHN, hGH-N","ENSG00000259384","Growth hormone 1","17","63917200-63918838","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA043715","Supported",NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"placenta: 1.2","duodenum: 0.6","Cell line enhanced",NA,"U-698: 1.8"
"GH2",7,"G8","IOH12292",654,"0",NA,"growth hormone 2 (GH2), transcript variant 1, mRNA.","NM_002059.3","NP_002050.1",2689,"Hs.406754","GH-V, GHL, GHV, hGH-V","ENSG00000136487","Growth hormone 2","17","63880215-63881935","Cancer-related genes, Predicted secreted proteins","Evidence at protein level","HPA043715","Supported",NA,NA,NA,NA,"Not detected","Tissue enriched",199,"placenta: 189.1","smooth muscle: 0.9","Cell line enriched",21,"BEWO: 7.8"
"GHDC",128,"G4","IOH21443",1593,"0",NA,"GH3 domain containing (GHDC), transcript variant 1, mRNA.","NM_032484.4","NP_115873.1",84514,"Hs.38039","LGP1","ENSG00000167925","GH3 domain containing","17","42188799-42194532","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA031650","Uncertain",NA,NA,NA,"Renal cancer:2.00e-6 (favourable), Glioma:5.91e-5 (unfavourable), Endometrial cancer:3.21e-4 (favourable), Ovarian cancer:5.20e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 29.2","Mixed",NA,NA
"GHRH",99,"D8","IOH34992",327,"0",NA,"growth hormone releasing hormone (GHRH), mRNA.","NM_021081.3","NP_066567.1",2691,"Hs.37023","GHRF","ENSG00000118702","Growth hormone releasing hormone","20","37251082-37261835","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enriched","Tissue enhanced",NA,"adrenal gland: 1.4;duodenum: 3.4","small intestine: 1.2","Cell line enhanced",NA,"NTERA-2: 2.0;U-266/84: 5.4"
"GHRH",153,"G1","IOH63328",324,"0",NA,"growth hormone releasing hormone, mRNA (cDNA clone MGC:119780 IMAGE:40014060), complete cds","BC098161.1","AAH98161.1",2691,"Hs.37023","GHRF","ENSG00000118702","Growth hormone releasing hormone","20","37251082-37261835","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enriched","Tissue enhanced",NA,"adrenal gland: 1.4;duodenum: 3.4","small intestine: 1.2","Cell line enhanced",NA,"NTERA-2: 2.0;U-266/84: 5.4"
"GHRL",34,"E7","IOH10822",354,"0",NA,"ghrelin/obestatin prepropeptide, mRNA (cDNA clone MGC:39929 IMAGE:5212768), complete cds","BC025791.1","AAH25791.1",51738,"Hs.590080","ghrelin, MTLRP, obestatin","ENSG00000157017","Ghrelin and obestatin prepropeptide","3","10285675-10292947","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA014246, CAB022731","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enriched",8,"stomach: 156.2","duodenum: 19.0","Cell line enhanced",NA,"Karpas-707: 10.4"
"GIF",82,"A7","IOH26056",1254,"0",NA,"gastric intrinsic factor (vitamin B synthesis) (GIF), mRNA.","NM_005142.2","NP_005133.2",2694,"Hs.110014","IF, IFMH, INF, TCN3","ENSG00000134812","Gastric intrinsic factor","11","59829268-59845501","Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA039908, HPA040774","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",1701,"stomach: 1311.7","cerebral cortex: 0.7","Not detected",NA,NA
"GIP",93,"A11","IOH40365",462,"0",NA,"gastric inhibitory polypeptide (GIP), mRNA.","NM_004123.2","NP_004114.1",2695,"Hs.1454",NA,"ENSG00000159224","Gastric inhibitory polypeptide","17","48958554-48968596","Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB016729, HPA021612","Enhanced",NA,NA,NA,NA,"Tissue enriched","Group enriched",156,"duodenum: 261.3;small intestine: 93.9","stomach: 1.1","Cell line enhanced",NA,"A549: 6.0;BEWO: 5.7;Hep G2: 6.5"
"GKN2",105,"H8","IOH43315",555,"0",NA,"gastrokine 2 (GKN2), mRNA.","NM_182536.2","NP_872342.2",200504,"Hs.16757","blottin, BRICD1B, GDDR, PRO813, TFIZ1, VLTI465","ENSG00000183607","Gastrokine 2","2","68945232-68952970","Predicted secreted proteins","Evidence at protein level","HPA057765","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",37,"stomach: 3843.6","lung: 103.7","Cell line enhanced",NA,"A549: 1.6;HMC-1: 1.5;NTERA-2: 2.1;PC-3: 3.6;U-2 OS: 1.5;U-266/70: 1.3"
"GLA",24,"F10","IOH5271",1290,"0",NA,"galactosidase, alpha (GLA), mRNA.","NM_000169.2","NP_000160.1",2717,"Hs.69089","GALA","ENSG00000102393","Galactosidase alpha","X","101397803-101407925","Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins","Evidence at protein level","HPA000237, HPA000966","Enhanced",NA,NA,NA,"Liver cancer:5.62e-5 (unfavourable), Stomach cancer:6.16e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"seminal vesicle: 59.2","Expressed in all",NA,NA
"GLB1",40,"H1","IOH5894",2034,"0",NA,"galactosidase, beta 1, mRNA (cDNA clone MGC:2315 IMAGE:2988086), complete cds","BC007493.2","AAH07493.1",2720,"Hs.443031","EBP, ELNR1","ENSG00000170266","Galactosidase beta 1","3","32996608-33097230","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB008382, HPA040610, HPA069503","Enhanced",NA,"Supported","Golgi apparatus<br>Vesicles","Renal cancer:1.14e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 122.5","Cell line enriched",5,"BEWO: 804.9"
"GLB1L",113,"F12","IOH41839",1965,"0",NA,"galactosidase, beta 1-like (GLB1L), mRNA.","NM_024506.3","NP_078782.3",79411,"Hs.181173","MGC10771","ENSG00000163521","Galactosidase beta 1 like","2","219236606-219245478","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA043058","Enhanced",NA,NA,NA,NA,"Expressed in all","Tissue enhanced",NA,"testis: 95.4","fallopian tube: 37.3","Mixed",NA,NA
"GLIPR1L1",136,"F6","IOH56020",702,"0",NA,"GLI pathogenesis-related 1 like 1 (GLIPR1L1), mRNA.","NM_152779.2","NP_689992.1",256710,"Hs.567788","MGC26856","ENSG00000173401","GLI pathogenesis related 1 like 1","12","75334639-75370560","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA042095","Enhanced",NA,NA,NA,NA,"Not detected","Tissue enriched",45,"testis: 78.3","skin: 1.7","Cell line enriched",100,"NTERA-2: 109.3"
"GLRB",54,"F11","IOH21923",1494,"NP_000815.1","NP_000815.1","glycine receptor, beta (GLRB), mRNA.","NM_000824.3","NP_000815.1",2743,"Hs.32973",NA,"ENSG00000109738","Glycine receptor beta","4","157076057-157172090","Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA052363","Approved",NA,NA,NA,"Renal cancer:4.89e-4 (favourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 62.0;parathyroid gland: 63.1","cervix, uterine: 14.1","Mixed",NA,NA
"GLT8D2",50,"B12","IOH13397",1050,"0",NA,"glycosyltransferase 8 domain containing 2 (GLT8D2), mRNA.","NM_031302.3","NP_112592.1",83468,"Hs.631650","FLJ31494","ENSG00000120820","Glycosyltransferase 8 domain containing 2","12","103988984-104064183","Predicted intracellular proteins","Evidence at protein level","HPA026904","Approved",NA,"Approved","Cytosol","Renal cancer:1.58e-6 (unfavourable), Cervical cancer:7.37e-4 (unfavourable), Stomach cancer:7.92e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"gallbladder: 57.1","Cell line enhanced",NA,"ASC TERT1: 48.9;BJ hTERT+: 73.1;HSkMC: 47.3"
"GM2A",141,"F2","IOH59020",582,"0",NA,"GM2 ganglioside activator (GM2A), mRNA.","NM_000405.4","NP_000396.2",2760,"Hs.483873","SAP-3","ENSG00000196743","GM2 ganglioside activator","5","151212150-151270440","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA008063","Enhanced",NA,NA,NA,"Liver cancer:1.77e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"skin: 89.5","Expressed in all",NA,NA
"GNLY",96,"H11","IOH27865",438,"0",NA,"granulysin (GNLY), transcript variant NKG5, mRNA.","NM_006433.3","NP_006424.2",10578,"Hs.105806","D2S69E, LAG-2, LAG2, NKG5, TLA519","ENSG00000115523","Granulysin","2","85685175-85698854","Predicted intracellular proteins, Predicted secreted proteins, Transporters","Evidence at protein level","CAB025186, HPA058021","Enhanced",NA,NA,NA,"Endometrial cancer:3.48e-5 (favourable), Melanoma:6.60e-5 (favourable), Renal cancer:1.50e-4 (unfavourable), Urothelial cancer:8.07e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"bone marrow: 152.4;endometrium: 113.5;spleen: 112.9","lung: 51.0","Not detected",NA,NA
"GNPTG",144,"F12","IOH59295",918,"0",NA,"N-acetylglucosamine-1-phosphate transferase, gamma subunit (GNPTG), mRNA.","NM_032520.3","NP_115909.1",84572,"Hs.241575","C16orf27, c316G12.3, CAB56184, GNPTAG","ENSG00000090581","N-acetylglucosamine-1-phosphate transferase gamma subunit","16","1351923-1364113","Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA004055","Approved",NA,"Approved","Endoplasmic reticulum<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"adrenal gland: 66.2","Expressed in all",NA,NA
"GNPTG",18,"A5","IOH11286",915,"0",NA,"N-acetylglucosamine-1-phosphate transferase, gamma subunit, mRNA (cDNA clone MGC:26282 IMAGE:4824054), complete cds","BC014592.1","AAH14592.1",84572,"Hs.241575","C16orf27, c316G12.3, CAB56184, GNPTAG","ENSG00000090581","N-acetylglucosamine-1-phosphate transferase gamma subunit","16","1351923-1364113","Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA004055","Approved",NA,"Approved","Endoplasmic reticulum<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"adrenal gland: 66.2","Expressed in all",NA,NA
"GNRH2",93,"B12","IOH40386",363,"0",NA,"gonadotropin-releasing hormone 2 (GNRH2), transcript variant 1, mRNA.","NM_001501.1","NP_001492.1",2797,"Hs.129715",NA,"ENSG00000125787","Gonadotropin releasing hormone 2","20","3043622-3045747","Predicted secreted proteins","Evidence at transcript level","HPA004338","Uncertain",NA,NA,NA,NA,"Tissue enhanced","Mixed",NA,NA,"ovary: 2.7","Mixed",NA,NA
"GORAB",156,"B3","IOH62399",645,"0",NA,"golgin, RAB6-interacting, mRNA (cDNA clone MGC:51263 IMAGE:5296051), complete cds","BC047476.1","AAH47476.1",92344,"Hs.183702","FLJ11752, GO, NTKL-BP1, SCYL1BP1","ENSG00000120370","Golgin, RAB6 interacting","1","170532129-170553446","Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA027208, HPA027250","Approved",NA,"Enhanced","Nucleus<br>Golgi apparatus<br>Cytosol","Renal cancer:7.83e-12 (unfavourable), Head and neck cancer:1.39e-4 (favourable), Liver cancer:5.26e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"thyroid gland: 7.9","Mixed",NA,NA
"GORAB",96,"A1","IOH39953",741,"0",NA,"golgin, RAB6-interacting (GORAB), transcript variant 3, mRNA.","NM_001146039.1","NP_001139511.1",92344,"Hs.183702","FLJ11752, GO, NTKL-BP1, SCYL1BP1","ENSG00000120370","Golgin, RAB6 interacting","1","170532129-170553446","Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA027208, HPA027250","Approved",NA,"Enhanced","Nucleus<br>Golgi apparatus<br>Cytosol","Renal cancer:7.83e-12 (unfavourable), Head and neck cancer:1.39e-4 (favourable), Liver cancer:5.26e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"thyroid gland: 7.9","Mixed",NA,NA
"GPC5",74,"G2","IOH26127",1719,"0",NA,"glypican 5 (GPC5), mRNA.","NM_004466.4","NP_004457.1",2262,"Hs.655675",NA,"ENSG00000179399","Glypican 5","13","91398607-92873682","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA040152, HPA044081","Enhanced",NA,"Approved","Nucleus<br>Cytosol","Glioma:5.67e-4 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 15.8;kidney: 8.1;testis: 11.5","lung: 4.9","Group enriched",9,"CACO-2: 41.2;HeLa: 18.9"
"GPIHBP1",129,"D4","IOH53742",555,"0",NA,"glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1 (GPIHBP1), mRNA.","NM_178172.3","NP_835466.1",338328,"Hs.426410","GPI-HBP1, LOC338328","ENSG00000277494","Glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1","8","143213193-143217170","Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA066302","Enhanced",NA,NA,NA,NA,"Mixed","Group enriched",6,"adipose tissue: 94.2;lung: 33.0","skeletal muscle: 10.5","Cell line enhanced",NA,"Karpas-707: 2.3"
"GPLD1",73,"F11","IOH13116",531,"0",NA,"glycosylphosphatidylinositol specific phospholipase D1, mRNA (cDNA clone IMAGE:4711131), complete cds.","BC020748.1","AAH20748.1",2822,"Hs.533291",NA,"ENSG00000112293","Glycosylphosphatidylinositol specific phospholipase D1","6","24424565-24495205","Enzymes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB008625, HPA012500","Uncertain",NA,NA,NA,"Liver cancer:1.12e-4 (favourable)","Tissue enriched","Tissue enhanced",NA,"liver: 23.6","skin: 9.0","Cell line enhanced",NA,"Daudi: 5.7;U-698: 5.6"
"GPNMB",18,"F1","IOH13909",621,"NP_002501.1","AAH11595.1","glycoprotein (transmembrane) nmb, mRNA (cDNA clone IMAGE:3345861), complete cds.","BC011595.1","AAH11595.1",10457,"Hs.190495","HGFIN, NMB","ENSG00000136235","Glycoprotein nmb","7","23235967-23275108","Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"skin: 654.6","Cell line enriched",5,"ASC diff: 3230.9"
"GPNMB",59,"A9","IOH21825",1719,"0","NP_001005340.1","glycoprotein (transmembrane) nmb (GPNMB), transcript variant 1, mRNA.","NM_001005340.1","NP_001005340.1",10457,"Hs.190495","HGFIN, NMB","ENSG00000136235","Glycoprotein nmb","7","23235967-23275108","Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"skin: 654.6","Cell line enriched",5,"ASC diff: 3230.9"
"GPR162",145,"H4","IOH63095",915,"0",NA,"G protein-coupled receptor 162, mRNA (cDNA clone MGC:99617 IMAGE:3510624), complete cds","BC080585.1","AAH80585.1",27239,"Hs.631654","A-2, GRCA","ENSG00000250510","G protein-coupled receptor 162","12","6821545-6829972","G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA055135","Enhanced",NA,"Approved","Microtubule organizing center","Renal cancer:1.37e-6 (unfavourable), Pancreatic cancer:4.29e-5 (favourable)","Tissue enriched","Group enriched",6,"cerebral cortex: 84.3;fallopian tube: 29.4","lung: 9.5","Cell line enhanced",NA,"AF22: 17.4;AN3-CA: 19.5;NTERA-2: 19.7;SH-SY5Y: 14.2;U-2 OS: 17.2"
"GPR162",28,"H12","IOH3494",915,"NP_062832.1","NP_055264.1","G protein-coupled receptor 162 (GPR162), transcript variant A-1, mRNA.","NM_014449.1","NP_055264.1",27239,"Hs.631654","A-2, GRCA","ENSG00000250510","G protein-coupled receptor 162","12","6821545-6829972","G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA055135","Enhanced",NA,"Approved","Microtubule organizing center","Renal cancer:1.37e-6 (unfavourable), Pancreatic cancer:4.29e-5 (favourable)","Tissue enriched","Group enriched",6,"cerebral cortex: 84.3;fallopian tube: 29.4","lung: 9.5","Cell line enhanced",NA,"AF22: 17.4;AN3-CA: 19.5;NTERA-2: 19.7;SH-SY5Y: 14.2;U-2 OS: 17.2"
"GPX3",153,"H8","IOH60476",681,"0",NA,"glutathione peroxidase 3 (plasma) (GPX3), mRNA.","NM_002084.3","NP_002075.2",2878,"Hs.386793",NA,"ENSG00000211445","Glutathione peroxidase 3","5","151020438-151028993","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB069456","Uncertain",NA,NA,NA,"Stomach cancer:1.65e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"kidney: 11674.4","Cell line enriched",11,"ASC diff: 5265.2"
"GPX4",120,"B1","IOH28869",594,"0",NA,"glutathione peroxidase 4 (phospholipid hydroperoxidase), mRNA (cDNA clone MGC:57716 IMAGE:5742889), complete cds","BC046163.1","AAH46163.1",2879,"Hs.433951","MCSP, PHGPx","ENSG00000167468","Glutathione peroxidase 4","19","1103926-1106791","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB008630, HPA047224, HPA058546","Enhanced",NA,"Supported","Nucleoplasm<br>Mitochondria","Endometrial cancer:1.84e-5 (favourable), Cervical cancer:7.18e-4 (favourable), Pancreatic cancer:7.72e-4 (favourable), Renal cancer:8.61e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 1140.7","Expressed in all",NA,NA
"GPX5",153,"B8","IOH60395",303,"0",NA,"glutathione peroxidase 5 (epididymal androgen-related protein) (GPX5), transcript variant 2, mRNA.","NM_003996.3","NP_003987.2",2880,"Hs.248129",NA,"ENSG00000224586","Glutathione peroxidase 5","6","28525925-28534952","Enzymes, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Not detected","Tissue enriched",30,"epididymis: 12.2","seminal vesicle: 0.4","Not detected",NA,NA
"GPX7",37,"A5","IOH21874",564,"0",NA,"glutathione peroxidase 7 (GPX7), mRNA.","NM_015696.4","NP_056511.2",2882,"Hs.43728","FLJ14777, GPX6, NPGPx","ENSG00000116157","Glutathione peroxidase 7","1","52602372-52609051","Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins","Evidence at protein level","HPA025829",NA,NA,"Approved","Nucleoli","Renal cancer:2.26e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 42.1","Cell line enhanced",NA,"REH: 69.6;RPMI-8226: 89.3;THP-1: 68.1"
"GREM1",142,"F8","IOH59009",555,"0",NA,"gremlin 1, cysteine knot superfamily, homolog (Xenopus laevis) (GREM1), mRNA.","NM_013372.5","NP_037504.1",26585,"Hs.40098","CKTSF1B1, CRAC1, DAND2, DRM, gremlin, HMPS","ENSG00000166923","Gremlin 1, DAN family BMP antagonist","15","32717974-32745107","Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA007526","Uncertain",NA,NA,NA,"Lung cancer:4.46e-4 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"gallbladder: 92.4;smooth muscle: 67.3","urinary bladder: 22.4","Cell line enhanced",NA,"BJ: 150.1;BJ hTERT+: 219.5;BJ hTERT+ SV40 Large T+ RasG12V: 161.4;fHDF/TERT166: 426.8;hTEC/SVTERT24-B: 168.1"
"GREM2",52,"F5","IOH25848",507,"0",NA,"gremlin 2, cysteine knot superfamily, homolog (Xenopus laevis), mRNA (cDNA clone MGC:44218 IMAGE:5288555), complete cds","BC046632.1","AAH46632.1",64388,"Hs.98206","CKTSF1B2, DAND3, FLJ21195, Prdc","ENSG00000180875","Gremlin 2, DAN family BMP antagonist","1","240489573-240612149","Disease related genes, Predicted secreted proteins","Evidence at protein level","CAB009920","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"gallbladder: 48.8;parathyroid gland: 78.3","rectum: 22.6","Cell line enhanced",NA,"BJ: 5.1;BJ hTERT+: 5.2;fHDF/TERT166: 25.0"
"GRHL3",75,"D11","IOH25955",1668,"0",NA,"grainyhead-like 3 (Drosophila), mRNA (cDNA clone MGC:46624 IMAGE:5502632), complete cds","BC036890.2","AAH36890.1",57822,"Hs.657920","SOM, TFCP2L4","ENSG00000158055","Grainyhead like transcription factor 3","1","24319322-24364482","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors","Evidence at protein level","HPA059960","Enhanced",NA,"Approved","Nucleoplasm",NA,"Tissue enhanced","Group enriched",11,"esophagus: 85.1;skin: 50.1;tonsil: 22.6;urinary bladder: 28.1","testis: 4.3","Cell line enhanced",NA,"BEWO: 43.8;HaCaT: 32.1;MCF7: 43.8;RT4: 51.5"
"GRHL3",144,"C6","IOH52439",1824,"0",NA,"grainyhead-like 3 (Drosophila) (GRHL3), transcript variant 1, mRNA.","NM_021180.2","NP_067003.2",57822,"Hs.657920","SOM, TFCP2L4","ENSG00000158055","Grainyhead like transcription factor 3","1","24319322-24364482","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors","Evidence at protein level","HPA059960","Enhanced",NA,"Approved","Nucleoplasm",NA,"Tissue enhanced","Group enriched",11,"esophagus: 85.1;skin: 50.1;tonsil: 22.6;urinary bladder: 28.1","testis: 4.3","Cell line enhanced",NA,"BEWO: 43.8;HaCaT: 32.1;MCF7: 43.8;RT4: 51.5"
"GRHL3",106,"C5","IOH44757",1809,"0",NA,"grainyhead-like 3 (Drosophila) (GRHL3), transcript variant 2, mRNA.","NM_198173.1","NP_937816.1",57822,"Hs.657920","SOM, TFCP2L4","ENSG00000158055","Grainyhead like transcription factor 3","1","24319322-24364482","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors","Evidence at protein level","HPA059960","Enhanced",NA,"Approved","Nucleoplasm",NA,"Tissue enhanced","Group enriched",11,"esophagus: 85.1;skin: 50.1;tonsil: 22.6;urinary bladder: 28.1","testis: 4.3","Cell line enhanced",NA,"BEWO: 43.8;HaCaT: 32.1;MCF7: 43.8;RT4: 51.5"
"GRIA4",75,"D6","IOH26768",1302,"NP_000820.1","NP_001070712.1","glutamate receptor, ionotrophic, AMPA 4 (GRIA4), transcript variant 3, mRNA.","NM_001077244.1","NP_001070712.1",2893,"Hs.503743","GluA4, GLUR4, GLURD","ENSG00000152578","Glutamate ionotropic receptor AMPA type subunit 4","11","105609994-105982092","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Group enriched","Tissue enriched",10,"cerebral cortex: 73.2","adrenal gland: 7.3","Cell line enhanced",NA,"AF22: 11.9;NTERA-2: 4.0;SCLC-21H: 5.1"
"GRM2",121,"C5","IOH39566",2619,"NP_000830.1","NP_000830.2","glutamate receptor, metabotropic 2 (GRM2), transcript variant 1, mRNA.","NM_000839.3","NP_000830.2",2912,"Hs.121510","GPRC1B, mGlu2, MGLUR2","ENSG00000164082","Glutamate metabotropic receptor 2","3","51707070-51718613","G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA027868, HPA065166","Approved","Supported",NA,NA,NA,"Tissue enhanced","Tissue enriched",10,"cerebral cortex: 4.4","testis: 0.4","Cell line enriched",7,"SCLC-21H: 7.3"
"GRM3",72,"D8","IOH25833",2640,"NP_000831.1","AAH41407.1","glutamate receptor, metabotropic 3, mRNA (cDNA clone MGC:44041 IMAGE:5284378), complete cds","BC041407.1","AAH41407.1",2913,"Hs.590575","GPRC1C, mGlu3, MGLUR3","ENSG00000198822","Glutamate metabotropic receptor 3","7","86643914-86864884","G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enriched","Tissue enriched",43,"cerebral cortex: 62.3","testis: 1.4","Cell line enriched",8,"AF22: 35.5"
"GRM3",134,"A5","IOH54171",2640,"0",NA,"glutamate receptor, metabotropic 3 (GRM3), mRNA.","NM_000840.2","NP_000831.2",2913,"Hs.590575","GPRC1C, mGlu3, MGLUR3","ENSG00000198822","Glutamate metabotropic receptor 3","7","86643914-86864884","G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enriched","Tissue enriched",43,"cerebral cortex: 62.3","testis: 1.4","Cell line enriched",8,"AF22: 35.5"
"GRN",47,"C5","IOH3532",1317,"0",NA,"granulin, mRNA (cDNA clone MGC:8480 IMAGE:2821810), complete cds","BC000324.2","AAH00324.1",2896,"Hs.514220","CLN11, PCDGF, PGRN","ENSG00000030582","Granulin precursor","17","44345086-44353102","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA008763, CAB019394, HPA028747","Approved",NA,"Enhanced","Endoplasmic reticulum<br>Endosomes<br>Lysosomes","Glioma:6.36e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"lung: 439.4","Expressed in all",NA,NA
"GRN",124,"G8","IOH11772",1782,"0",NA,"granulin (GRN), mRNA.","NM_002087.2","NP_002078.1",2896,"Hs.514220","CLN11, PCDGF, PGRN","ENSG00000030582","Granulin precursor","17","44345086-44353102","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA008763, CAB019394, HPA028747","Approved",NA,"Enhanced","Endoplasmic reticulum<br>Endosomes<br>Lysosomes","Glioma:6.36e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"lung: 439.4","Expressed in all",NA,NA
"GSN",122,"E4","IOH13319",2349,"0",NA,"gelsolin (amyloidosis, Finnish type) (GSN), transcript variant 1, mRNA.","NM_000177.4","NP_000168.1",2934,"Hs.522373","DKFZp313L0718","ENSG00000148180","Gelsolin","9","121207794-121332843","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB010823, CAB016728, CAB036009, HPA054026","Supported",NA,"Supported","Actin filaments","Urothelial cancer:1.79e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"adipose tissue: 1354.2","Cell line enhanced",NA,"ASC diff: 964.0;HaCaT: 513.8"
"GSN",112,"C12","IOH45790",2196,"0",NA,"gelsolin (amyloidosis, Finnish type) (GSN), transcript variant 2, mRNA.","NM_198252.2","NP_937895.1",2934,"Hs.522373","DKFZp313L0718","ENSG00000148180","Gelsolin","9","121207794-121332843","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB010823, CAB016728, CAB036009, HPA054026","Supported",NA,"Supported","Actin filaments","Urothelial cancer:1.79e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"adipose tissue: 1354.2","Cell line enhanced",NA,"ASC diff: 964.0;HaCaT: 513.8"
"GTDC1",70,"H1","IOH28620",1122,"0",NA,"glycosyltransferase-like domain containing 1 (GTDC1), transcript variant 2, mRNA.","NM_024659.2","NP_078935.2",79712,"Hs.44780","FLJ11753, Hmat-Xa","ENSG00000121964","Glycosyltransferase like domain containing 1","2","143938068-144332568","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA036694","Uncertain",NA,"Approved","Cytosol","Renal cancer:6.60e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 29.4","Mixed",NA,NA
"GTDC1",64,"E5","IOH29429",879,"0",NA,"glycosyltransferase-like domain containing 1, mRNA (cDNA clone MGC:62086 IMAGE:4608518), complete cds","BC061699.1","AAH61699.1",79712,"Hs.44780","FLJ11753, Hmat-Xa","ENSG00000121964","Glycosyltransferase like domain containing 1","2","143938068-144332568","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA036694","Uncertain",NA,"Approved","Cytosol","Renal cancer:6.60e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 29.4","Mixed",NA,NA
"GUCA2A",108,"G8","IOH35011",348,"0",NA,"guanylate cyclase activator 2A (guanylin) (GUCA2A), mRNA.","NM_033553.2","NP_291031.2",2980,"Hs.778","GUCA2, STARA","ENSG00000197273","Guanylate cyclase activator 2A","1","42162691-42164718","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA018215","Enhanced",NA,NA,NA,NA,"Group enriched","Group enriched",15,"colon: 768.8;rectum: 859.2;small intestine: 1127.0","duodenum: 61.5","Cell line enhanced",NA,"BEWO: 11.8;CACO-2: 8.2;NB-4: 2.0;U-2197: 2.5"
"GUCA2B",99,"D7","IOH40405",339,"0",NA,"guanylate cyclase activator 2B (uroguanylin) (GUCA2B), mRNA.","NM_007102.2","NP_009033.1",2981,"Hs.32966",NA,"ENSG00000044012","Guanylate cyclase activator 2B","1","42153421-42155824","Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"colon: 87.6;small intestine: 148.3","duodenum: 37.5","Group enriched",6,"A549: 1.3;CACO-2: 3.2"
"GUSB",62,"G2","IOH29680",1956,"0",NA,"glucuronidase, beta (GUSB), mRNA.","NM_000181.2","NP_000172.1",2990,"Hs.255230",NA,"ENSG00000169919","Glucuronidase beta","7","65960684-65982314","Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins","Evidence at protein level","HPA036322, HPA036323","Approved",NA,"Supported","Vesicles",NA,"Expressed in all","Expressed in all",NA,NA,"breast: 95.9","Expressed in all",NA,NA
"GUSB",63,"E10","IOH13578",1956,"0",NA,"glucuronidase, beta, mRNA (cDNA clone MGC:20659 IMAGE:4662011), complete cds","BC014142.2","AAH14142.1",2990,"Hs.255230",NA,"ENSG00000169919","Glucuronidase beta","7","65960684-65982314","Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins","Evidence at protein level","HPA036322, HPA036323","Approved",NA,"Supported","Vesicles",NA,"Expressed in all","Expressed in all",NA,NA,"breast: 95.9","Expressed in all",NA,NA
"GYPB",139,"G8","IOH58935",276,"NP_002091.1","NP_002091.2","glycophorin B (MNS blood group) (GYPB), mRNA.","NM_002100.3","NP_002091.2",2994,"Hs.654368","CD235b, GPB, MNS, SS","ENSG00000250361","Glycophorin B (MNS blood group)","4","143996104-144019345","Blood group antigen proteins, CD markers, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Not detected","Tissue enriched",5,"bone marrow: 37.2","placenta: 7.3","Cell line enriched",5,"HEL: 225.3"
"GZMA",19,"B1","IOH14828",789,"0",NA,"granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3) (GZMA), mRNA.","NM_006144.3","NP_006135.1",3001,"Hs.90708","CTLA3, HFSP","ENSG00000145649","Granzyme A","5","55102648-55110252","Enzymes, Predicted secreted proteins","Evidence at protein level","HPA054134","Uncertain",NA,NA,NA,"Renal cancer:1.26e-6 (unfavourable), Endometrial cancer:6.44e-6 (favourable), Breast cancer:7.27e-4 (favourable)","Expressed in all","Mixed",NA,NA,"spleen: 70.9","Cell line enhanced",NA,"HL-60: 3.2"
"GZMB",125,"C4","IOH22608",744,"0",NA,"granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1), mRNA (cDNA clone MGC:34374 IMAGE:5223876), complete cds","BC030195.1","AAH30195.1",3002,"Hs.1051","CCPI, CGL-1, CGL1, CSP-B, CSPB, CTLA1, CTSGL1, HLP, SECT","ENSG00000100453","Granzyme B","14","24630954-24634267","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB000376, HPA003418","Enhanced",NA,NA,NA,"Renal cancer:1.10e-7 (unfavourable), Endometrial cancer:1.58e-5 (favourable), Breast cancer:7.27e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"lymph node: 40.1","bone marrow,spleen: 36.2","Cell line enriched",6,"HMC-1: 17.4"
"GZMH",30,"G6","IOH22624",741,"0",NA,"granzyme H (cathepsin G-like 2, protein h-CCPX) (GZMH), mRNA.","NM_033423.3","NP_219491.1",2999,"Hs.348264","CCP-X, CGL-2, CSP-C, CTLA1, CTSGL2","ENSG00000100450","Granzyme H","14","24606480-24609699","Enzymes, Predicted secreted proteins","Evidence at protein level","HPA029200","Enhanced",NA,NA,NA,"Renal cancer:1.74e-6 (unfavourable), Endometrial cancer:2.00e-6 (favourable)","Expressed in all","Tissue enhanced",NA,"spleen: 35.3","lymph node: 25.3","Not detected",NA,NA
"GZMK",57,"D11","IOH26030",795,"0",NA,"granzyme K (granzyme 3; tryptase II) (GZMK), mRNA.","NM_002104.2","NP_002095.1",3003,"Hs.277937","PRSS, TRYP2","ENSG00000113088","Granzyme K","5","55024253-55034570","Enzymes, Predicted secreted proteins","Evidence at protein level","HPA063181","Enhanced",NA,NA,NA,"Renal cancer:1.06e-4 (unfavourable), Breast cancer:8.68e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"lymph node: 103.9","spleen: 41.9","Not detected",NA,NA
"GZMM",17,"D10","IOH12008",774,"0",NA,"granzyme M (lymphocyte met-ase 1) (GZMM), mRNA.","NM_005317.2","NP_005308.1",3004,"Hs.465511","LMET1, MET1","ENSG00000197540","Granzyme M","19","544034-549924","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA015624","Enhanced",NA,NA,NA,"Head and neck cancer:1.87e-7 (favourable), Renal cancer:1.21e-4 (unfavourable), Endometrial cancer:1.89e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"lymph node: 20.9;spleen: 19.7","appendix: 13.0","Cell line enhanced",NA,"EFO-21: 1.9;HDLM-2: 1.6;HMC-1: 1.8;MOLT-4: 1.1"
"H6PD",158,"H3","IOH61644",2376,"0",NA,"hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase), mRNA (cDNA clone MGC:87643 IMAGE:5266232), complete cds","BC081559.1","AAH81559.1",9563,"Hs.463511","GDH","ENSG00000049239","Hexose-6-phosphate dehydrogenase/glucose 1-dehydrogenase","1","9234775-9271337","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins","Evidence at protein level","HPA004824, HPA005440","Approved",NA,"Uncertain","Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"ovary: 42.8","Mixed",NA,NA
"HABP2",69,"D10","IOH22687",1683,"0",NA,"hyaluronan binding protein 2 (HABP2), mRNA.","NM_004132.3","NP_004123.1",3026,"Hs.422542","FSAP, HABP, HGFAL, PHBP","ENSG00000148702","Hyaluronan binding protein 2","10","113550837-113589602","Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA019518","Approved",NA,NA,NA,NA,"Tissue enriched","Group enriched",12,"gallbladder: 55.8;liver: 225.6","stomach: 11.3","Cell line enriched",5,"RPTEC TERT1: 38.3"
"HADHB",130,"D9","IOH52008",1425,"0",NA,"hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme A hydratase (trifunctional protein), beta subunit (HADHB), nuclear gene encoding mitochondrial protein, mRNA.","NM_000183.2","NP_000174.1",3032,"Hs.515848","MTPB","ENSG00000138029","Hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), beta subunit","2","26243170-26290468","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA037539, HPA037540, HPA066099","Enhanced",NA,"Supported","Mitochondria","Renal cancer:1.37e-9 (favourable)","Expressed in all","Expressed in all",NA,NA,"heart muscle: 300.8","Expressed in all",NA,NA
"HADHB",18,"B1","IOH14468",1428,"0",NA,"hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme A hydratase (trifunctional protein), beta subunit, mRNA (cDNA clone MGC:1727 IMAGE:2988132), complete cds","BC017564.2","AAH17564.1",3032,"Hs.515848","MTPB","ENSG00000138029","Hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), beta subunit","2","26243170-26290468","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA037539, HPA037540, HPA066099","Enhanced",NA,"Supported","Mitochondria","Renal cancer:1.37e-9 (favourable)","Expressed in all","Expressed in all",NA,NA,"heart muscle: 300.8","Expressed in all",NA,NA
"HADHB",20,"A4","IOH13946",1428,"0",NA,"hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme A hydratase (trifunctional protein), beta subunit, mRNA (cDNA clone MGC:22699 IMAGE:3960772), complete cds","BC014572.1","AAH14572.1",3032,"Hs.515848","MTPB","ENSG00000138029","Hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), beta subunit","2","26243170-26290468","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA037539, HPA037540, HPA066099","Enhanced",NA,"Supported","Mitochondria","Renal cancer:1.37e-9 (favourable)","Expressed in all","Expressed in all",NA,NA,"heart muscle: 300.8","Expressed in all",NA,NA
"HAMP",33,"F7","IOH13487",255,"0",NA,"hepcidin antimicrobial peptide (HAMP), mRNA.","NM_021175.2","NP_066998.1",57817,"Hs.8821","HEPC, HFE2B, LEAP-1, LEAP1","ENSG00000105697","Hepcidin antimicrobial peptide","19","35280716-35285143","Disease related genes, Potential drug targets, Predicted secreted proteins, Transporters","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Group enriched","Tissue enriched",12,"liver: 259.1","heart muscle: 21.9","Cell line enriched",127,"Hep G2: 135.7"
"HAPLN1",69,"D12","IOH29176",1065,"0",NA,"hyaluronan and proteoglycan link protein 1, mRNA (cDNA clone MGC:71729 IMAGE:30341037), complete cds","BC057808.1","AAH57808.1",1404,"Hs.2799","CRTL1","ENSG00000145681","Hyaluronan and proteoglycan link protein 1","5","83637805-83721613","Predicted secreted proteins","Evidence at protein level","HPA019105, HPA019482, HPA025238","Enhanced","Approved","Supported","Vesicles","Renal cancer:4.81e-9 (unfavourable)","Mixed","Tissue enriched",8,"placenta: 103.4","cerebral cortex: 12.8","Group enriched",35,"PC-3: 130.7;TIME: 73.5;U-2 OS: 149.3"
"HAPLN1",134,"E3","IOH53939",1065,"0",NA,"hyaluronan and proteoglycan link protein 1 (HAPLN1), mRNA.","NM_001884.3","NP_001875.1",1404,"Hs.2799","CRTL1","ENSG00000145681","Hyaluronan and proteoglycan link protein 1","5","83637805-83721613","Predicted secreted proteins","Evidence at protein level","HPA019105, HPA019482, HPA025238","Enhanced","Approved","Supported","Vesicles","Renal cancer:4.81e-9 (unfavourable)","Mixed","Tissue enriched",8,"placenta: 103.4","cerebral cortex: 12.8","Group enriched",35,"PC-3: 130.7;TIME: 73.5;U-2 OS: 149.3"
"HAPLN3",93,"B2","IOH40677",1083,"0",NA,"hyaluronan and proteoglycan link protein 3 (HAPLN3), mRNA.","NM_178232.2","NP_839946.1",145864,"Hs.447530","EXLD1, HsT19883","ENSG00000140511","Hyaluronan and proteoglycan link protein 3","15","88877288-88895626","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA039237","Uncertain",NA,"Approved","Plasma membrane<br>Cytosol","Renal cancer:4.18e-13 (unfavourable)","Expressed in all","Tissue enhanced",NA,"appendix: 13.8;lymph node: 10.8","spleen: 4.0","Cell line enhanced",NA,"HDLM-2: 29.8;U-2 OS: 31.7"
"HARS2",22,"F12","IOH6231",1521,"0",NA,"histidyl-tRNA synthetase 2, mitochondrial (putative) (HARS2), nuclear gene encoding mitochondrial protein, mRNA.","NM_012208.2","NP_036340.1",23438,"Hs.432560","HARSL, HARSR, HO3","ENSG00000112855","Histidyl-tRNA synthetase 2, mitochondrial","5","140691426-140699291","Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins","Evidence at protein level","HPA035941","Approved",NA,"Approved","Cytosol","Liver cancer:2.92e-4 (unfavourable), Colorectal cancer:6.19e-4 (favourable), Breast cancer:6.49e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 36.5","Expressed in all",NA,NA
"HAVCR1",10,"F1","IOH12162",1095,"NP_036338.1","NP_001092884.1","hepatitis A virus cellular receptor 1 (HAVCR1), transcript variant 2, mRNA.","NM_001099414.1","NP_001092884.1",26762,"Hs.129711","CD365, HAVCR, HAVCR-1, KIM1, TIM-1, TIM1, TIMD1","ENSG00000113249","Hepatitis A virus cellular receptor 1","5","157029413-157059119","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA007173, CAB075697","Approved",NA,"Approved","Vesicles","Urothelial cancer:1.32e-4 (favourable), Stomach cancer:7.81e-4 (unfavourable)","Tissue enriched","Group enriched",6,"colon: 4.8;kidney: 8.3;rectum: 4.1;testis: 1.7","gallbladder: 0.8","Group enriched",5,"A549: 86.4;CACO-2: 95.7;RPTEC TERT1: 33.8"
"HBS1L",122,"H5","IOH4029",2055,"0",NA,"HBS1-like (S. cerevisiae) (HBS1L), transcript variant 1, mRNA.","NM_006620.3","NP_006611.1",10767,"Hs.378532","DKFZp434g247, EF-1a, eRF3c, ERFS, HBS1, HSPC276, KIAA1038","ENSG00000112339","HBS1 like translational GTPase","6","134960378-135103056","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA029728, HPA029729","Approved",NA,"Approved","Nuclear bodies<br>Cytosol","Colorectal cancer:6.77e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 73.2","Expressed in all",NA,NA
"HEATR5A",147,"E7","IOH60369",342,"0",NA,"HEAT repeat containing 5A, mRNA (cDNA clone IMAGE:6733067), complete cds.","BC062720.1","AAH62720.1",25938,"Hs.370299","C14orf125, DKFZP434I1735","ENSG00000129493","HEAT repeat containing 5A","14","31291791-31420582","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA049539","Uncertain",NA,NA,NA,"Renal cancer:1.11e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 18.2","Expressed in all",NA,NA
"HEPH",85,"A2","IOH12438",3477,"NP_620074.1","AAH11561.1","hephaestin, mRNA (cDNA clone MGC:20135 IMAGE:4644318), complete cds","BC011561.1","AAH11561.1",9843,"Hs.31720","CPL, KIAA0698","ENSG00000089472","Hephaestin","X","66162549-66268867","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA005824","Approved",NA,NA,NA,"Renal cancer:7.00e-6 (unfavourable), Glioma:6.23e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"smooth muscle: 119.0","Cell line enhanced",NA,"AF22: 28.1;HEL: 22.8;HSkMC: 26.1;K-562: 64.5;LHCN-M2: 23.8"
"HEXA",116,"E12","IOH12738",1590,"0",NA,"hexosaminidase A (alpha polypeptide), mRNA (cDNA clone MGC:99608 IMAGE:5459166), complete cds","BC084537.1","AAH84537.1",3073,"Hs.604479",NA,"ENSG00000213614","Hexosaminidase subunit alpha","15","72340919-72376476","Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins","Evidence at protein level","HPA054583","Supported",NA,NA,NA,"Endometrial cancer:5.63e-8 (favourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 200.6","Mixed",NA,NA
"HFE2",49,"F11","IOH13470",603,"0",NA,"hemochromatosis type 2 (juvenile) (HFE2), transcript variant c, mRNA.","NM_202004.3","NP_973733.1",148738,"Hs.632436","haemojuvelin, hemojuvelin, HFE2A, HJV, JH, RGMC","ENSG00000168509","Hemochromatosis type 2 (juvenile)","1","146017468-146036746","Disease related genes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enriched","Group enriched",15,"heart muscle: 45.4;liver: 123.4;skeletal muscle: 212.6","esophagus: 8.6","Cell line enhanced",NA,"HSkMC: 1.1;K-562: 1.4"
"HFE2",129,"E9","IOH53795",942,"0",NA,"hemochromatosis type 2 (juvenile) (HFE2), transcript variant b, mRNA.","NM_145277.4","NP_660320.3",148738,"Hs.632436","haemojuvelin, hemojuvelin, HFE2A, HJV, JH, RGMC","ENSG00000168509","Hemochromatosis type 2 (juvenile)","1","146017468-146036746","Disease related genes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enriched","Group enriched",15,"heart muscle: 45.4;liver: 123.4;skeletal muscle: 212.6","esophagus: 8.6","Cell line enhanced",NA,"HSkMC: 1.1;K-562: 1.4"
"HGF",43,"A10","IOH14494",858,"0",NA,"hepatocyte growth factor (hepapoietin A; scatter factor) (HGF), transcript variant 4, mRNA.","NM_001010933.1","NP_001010933.1",3082,"Hs.396530","DFNB39, F-TCF, HGFB, HPTA, SF","ENSG00000019991","Hepatocyte growth factor","7","81699006-81770438","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","CAB010333, HPA040360, HPA044088","Approved",NA,"Approved","Centrosome<br>Cytosol","Renal cancer:5.59e-4 (unfavourable)","Mixed","Tissue enriched",16,"placenta: 438.8","gallbladder: 27.5","Cell line enhanced",NA,"ASC TERT1: 118.1;HHSteC: 111.7;HL-60: 63.0;hTEC/SVTERT24-B: 86.9;Karpas-707: 174.5;U-87 MG: 60.7"
"HGF",142,"E9","IOH54778",633,"0",NA,"hepatocyte growth factor (hepapoietin A; scatter factor) (HGF), transcript variant 5, mRNA.","NM_001010934.1","NP_001010934.1",3082,"Hs.396530","DFNB39, F-TCF, HGFB, HPTA, SF","ENSG00000019991","Hepatocyte growth factor","7","81699006-81770438","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","CAB010333, HPA040360, HPA044088","Approved",NA,"Approved","Centrosome<br>Cytosol","Renal cancer:5.59e-4 (unfavourable)","Mixed","Tissue enriched",16,"placenta: 438.8","gallbladder: 27.5","Cell line enhanced",NA,"ASC TERT1: 118.1;HHSteC: 111.7;HL-60: 63.0;hTEC/SVTERT24-B: 86.9;Karpas-707: 174.5;U-87 MG: 60.7"
"HGF",100,"G10","IOH29794",2187,"0",NA,"hepatocyte growth factor (hepapoietin A; scatter factor) (HGF), transcript variant 1, mRNA.","NM_000601.4","NP_000592.3",3082,"Hs.396530","DFNB39, F-TCF, HGFB, HPTA, SF","ENSG00000019991","Hepatocyte growth factor","7","81699006-81770438","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","CAB010333, HPA040360, HPA044088","Approved",NA,"Approved","Centrosome<br>Cytosol","Renal cancer:5.59e-4 (unfavourable)","Mixed","Tissue enriched",16,"placenta: 438.8","gallbladder: 27.5","Cell line enhanced",NA,"ASC TERT1: 118.1;HHSteC: 111.7;HL-60: 63.0;hTEC/SVTERT24-B: 86.9;Karpas-707: 174.5;U-87 MG: 60.7"
"HGF",142,"E12","IOH54942",873,"0",NA,"hepatocyte growth factor (hepapoietin A; scatter factor) (HGF), transcript variant 2, mRNA.","NM_001010931.1","NP_001010931.1",3082,"Hs.396530","DFNB39, F-TCF, HGFB, HPTA, SF","ENSG00000019991","Hepatocyte growth factor","7","81699006-81770438","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","CAB010333, HPA040360, HPA044088","Approved",NA,"Approved","Centrosome<br>Cytosol","Renal cancer:5.59e-4 (unfavourable)","Mixed","Tissue enriched",16,"placenta: 438.8","gallbladder: 27.5","Cell line enhanced",NA,"ASC TERT1: 118.1;HHSteC: 111.7;HL-60: 63.0;hTEC/SVTERT24-B: 86.9;Karpas-707: 174.5;U-87 MG: 60.7"
"HHIP",84,"A12","IOH23201",2103,"0",NA,"hedgehog interacting protein (HHIP), mRNA.","NM_022475.1","NP_071920.1",64399,"Hs.507991","FLJ20992, HIP","ENSG00000164161","Hedgehog interacting protein","4","144646021-144745271","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA012616","Uncertain",NA,"Approved","Nucleoplasm",NA,"Mixed","Tissue enhanced",NA,"lung: 24.2","cerebral cortex: 10.8","Group enriched",6,"HUVEC TERT2: 269.0;RH-30: 62.9;TIME: 306.5"
"HHIPL2",48,"A6","IOH11396",771,"0",NA,"HHIP-like 2, mRNA (cDNA clone IMAGE:3889322), complete cds.","BC015201.1","AAH15201.1",79802,"Hs.665660","FLJ13840, KIAA1822L","ENSG00000143512","HHIP like 2","1","222522258-222548103","Predicted secreted proteins","Evidence at protein level","HPA059673","Enhanced",NA,"Uncertain","Mitochondria<br>Cytosol","Lung cancer:4.64e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"testis: 9.0;thyroid gland: 3.4","prostate: 1.4","Cell line enhanced",NA,"A549: 3.8;Hep G2: 4.0;RH-30: 20.6;U-87 MG: 10.5"
"HHIPL2",78,"G10","IOH22139",1590,"0",NA,"HHIP-like 2, mRNA (cDNA clone MGC:22143 IMAGE:4452939), complete cds","BC016552.1","AAH16552.1",79802,"Hs.665660","FLJ13840, KIAA1822L","ENSG00000143512","HHIP like 2","1","222522258-222548103","Predicted secreted proteins","Evidence at protein level","HPA059673","Enhanced",NA,"Uncertain","Mitochondria<br>Cytosol","Lung cancer:4.64e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"testis: 9.0;thyroid gland: 3.4","prostate: 1.4","Cell line enhanced",NA,"A549: 3.8;Hep G2: 4.0;RH-30: 20.6;U-87 MG: 10.5"
"HHIPL2",146,"H1","IOH62956",2175,"0",NA,"HHIP-like 2, mRNA (cDNA clone MGC:15905 IMAGE:3533045), complete cds","BC007638.1","AAH07638.1",79802,"Hs.665660","FLJ13840, KIAA1822L","ENSG00000143512","HHIP like 2","1","222522258-222548103","Predicted secreted proteins","Evidence at protein level","HPA059673","Enhanced",NA,"Uncertain","Mitochondria<br>Cytosol","Lung cancer:4.64e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"testis: 9.0;thyroid gland: 3.4","prostate: 1.4","Cell line enhanced",NA,"A549: 3.8;Hep G2: 4.0;RH-30: 20.6;U-87 MG: 10.5"
"HHLA2",117,"C9","IOH27965",1245,"0",NA,"HERV-H LTR-associating 2 (HHLA2), mRNA.","NM_007072.2","NP_009003.1",11148,"Hs.252351","B7-H5, B7H7, B7y","ENSG00000114455","HERV-H LTR-associating 2","3","108296490-108378285","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA055478","Enhanced",NA,NA,NA,NA,"Group enriched","Group enriched",10,"colon: 87.7;duodenum: 87.1;gallbladder: 46.0;rectum: 90.5;small intestine: 143.9","stomach: 9.2","Cell line enhanced",NA,"HDLM-2: 3.7;Karpas-707: 2.0"
"HIBADH",55,"F6","IOH21624",1011,"0",NA,"3-hydroxyisobutyrate dehydrogenase (HIBADH), mRNA.","NM_152740.2","NP_689953.1",11112,"Hs.406758","NS5ATP1","ENSG00000106049","3-hydroxyisobutyrate dehydrogenase","7","27525442-27662995","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA019522, HPA021002","Enhanced",NA,NA,NA,"Renal cancer:5.56e-11 (favourable)","Expressed in all","Expressed in all",NA,NA,"kidney: 113.0","Expressed in all",NA,NA
"HIPK1",124,"D4","IOH22334",3228,"0",NA,"homeodomain interacting protein kinase 1, mRNA (cDNA clone MGC:26642 IMAGE:4830408), complete cds","BC033012.2","AAH33012.1",204851,"Hs.532363","KIAA0630, MGC26642, MGC33446, MGC33548, Myak, Nbak2","ENSG00000163349","Homeodomain interacting protein kinase 1","1","113929192-113977869","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA016664","Approved",NA,"Approved","Nucleoplasm<br>Centrosome<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"bone marrow: 89.7","Expressed in all",NA,NA
"HIPK1",72,"A7","IOH27205",2451,"0",NA,"homeodomain interacting protein kinase 1, mRNA (cDNA clone MGC:33446 IMAGE:5272816), complete cds","BC036057.1","AAH36057.1",204851,"Hs.532363","KIAA0630, MGC26642, MGC33446, MGC33548, Myak, Nbak2","ENSG00000163349","Homeodomain interacting protein kinase 1","1","113929192-113977869","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA016664","Approved",NA,"Approved","Nucleoplasm<br>Centrosome<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"bone marrow: 89.7","Expressed in all",NA,NA
"HLA-A",126,"B7","IOH3290",1098,"NP_002107.3","AAH08611.1","major histocompatibility complex, class I, A, mRNA (cDNA clone MGC:17191 IMAGE:4157200), complete cds","BC008611.1","AAH08611.1",3105,"Hs.181244",NA,"ENSG00000206503","Major histocompatibility complex, class I, A","6","29941260-29945884","Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB078470",NA,NA,"Supported","Golgi apparatus<br>Plasma membrane","Ovarian cancer:6.47e-4 (favourable), Endometrial cancer:9.59e-4 (favourable)","Expressed in all","Mixed",NA,NA,"gallbladder: 340.9","Cell line enhanced",NA,"A-431: 1127.9"
"HLA-A",131,"G3","IOH55132",1098,"0",NA,"major histocompatibility complex, class I, A (HLA-A), mRNA.","NM_002116.5","NP_002107.3",3105,"Hs.181244",NA,"ENSG00000206503","Major histocompatibility complex, class I, A","6","29941260-29945884","Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB078470",NA,NA,"Supported","Golgi apparatus<br>Plasma membrane","Ovarian cancer:6.47e-4 (favourable), Endometrial cancer:9.59e-4 (favourable)","Expressed in all","Mixed",NA,NA,"gallbladder: 340.9","Cell line enhanced",NA,"A-431: 1127.9"
"HLA-A",126,"E10","IOH4770",1098,"0",NA,"major histocompatibility complex, class I, A, mRNA (cDNA clone MGC:2166 IMAGE:3510139), complete cds","BC003069.2","AAH03069.1",3105,"Hs.181244",NA,"ENSG00000206503","Major histocompatibility complex, class I, A","6","29941260-29945884","Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB078470",NA,NA,"Supported","Golgi apparatus<br>Plasma membrane","Ovarian cancer:6.47e-4 (favourable), Endometrial cancer:9.59e-4 (favourable)","Expressed in all","Mixed",NA,NA,"gallbladder: 340.9","Cell line enhanced",NA,"A-431: 1127.9"
"HLA-C",77,"B10","IOH7433",1119,"0",NA,"major histocompatibility complex, class I, C, mRNA (cDNA clone MGC:14707 IMAGE:4249847), complete cds","BC008457.1","AAH08457.1",3107,"Hs.77961","D6S204, HLA-JY3, PSORS1","ENSG00000204525","Major histocompatibility complex, class I, C","6","31268749-31272130","Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Expressed in all","Tissue enhanced",NA,"lung: 744.7","small intestine: 396.9","Cell line enhanced",NA,"A-431: 660.6;EFO-21: 748.1;RPTEC TERT1: 346.0;U-266/70: 367.3;U-266/84: 281.2"
"HLA-C",127,"H2","IOH4228",1101,"NP_002118.1","AAH02463.1","major histocompatibility complex, class I, C, mRNA (cDNA clone MGC:2285 IMAGE:3345005), complete cds","BC002463.1","AAH02463.1",3107,"Hs.77961","D6S204, HLA-JY3, PSORS1","ENSG00000204525","Major histocompatibility complex, class I, C","6","31268749-31272130","Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Expressed in all","Tissue enhanced",NA,"lung: 744.7","small intestine: 396.9","Cell line enhanced",NA,"A-431: 660.6;EFO-21: 748.1;RPTEC TERT1: 346.0;U-266/70: 367.3;U-266/84: 281.2"
"HLA-DOA",11,"A5","IOH10959",753,"NP_002110.1","NP_002110.1","major histocompatibility complex, class II, DO alpha (HLA-DOA), mRNA.","NM_002119.3","NP_002110.1",3111,"Hs.631991","HLA-D0-alpha, HLA-DNA, HLA-DZA","ENSG00000204252","Major histocompatibility complex, class II, DO alpha","6","33004178-33009612","Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA045038","Enhanced",NA,NA,NA,NA,"Expressed in all","Tissue enhanced",NA,"spleen: 14.4","tonsil: 8.9","Cell line enhanced",NA,"Daudi: 4.6;HDLM-2: 4.3;REH: 19.0;U-698: 3.4"
"HLA-DPA1",48,"E6","IOH12720",783,"NP_291032.2","AAH09956.1","major histocompatibility complex, class II, DP alpha 1, mRNA (cDNA clone MGC:14114 IMAGE:4309471), complete cds","BC009956.2","AAH09956.1",3113,"Hs.347270","HLA-DP1A","ENSG00000231389","Major histocompatibility complex, class II, DP alpha 1","6","33064569-33080775","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA017967","Enhanced",NA,"Supported","Vesicles",NA,"Expressed in all","Expressed in all",NA,NA,"lung: 120.6","Cell line enhanced",NA,"Daudi: 26.7;HDLM-2: 107.3;REH: 26.8"
"HLA-DQA1",110,"E3","IOH41004",768,"0",NA,"major histocompatibility complex, class II, DQ alpha 1 (HLA-DQA1), mRNA.","NM_002122.3","NP_002113.2",3117,"Hs.387679","CELIAC1, HLA-DQA","ENSG00000196735","Major histocompatibility complex, class II, DQ alpha 1","6","32628179-32647062","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA012315","Enhanced",NA,NA,NA,NA,"Expressed in all","Tissue enhanced",NA,"lung: 504.8","lymph node: 338.6","Cell line enriched",9,"HDLM-2: 1315.9"
"HLA-DQA1",156,"C1","IOH61809",765,"0",NA,"major histocompatibility complex, class II, DQ alpha 1, mRNA (cDNA clone MGC:87852 IMAGE:6014803), complete cds","BC073977.1","AAH73977.1",3117,"Hs.387679","CELIAC1, HLA-DQA","ENSG00000196735","Major histocompatibility complex, class II, DQ alpha 1","6","32628179-32647062","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA012315","Enhanced",NA,NA,NA,NA,"Expressed in all","Tissue enhanced",NA,"lung: 504.8","lymph node: 338.6","Cell line enriched",9,"HDLM-2: 1315.9"
"HLA-DQB1",8,"E8","IOH13202",786,"XP_167095.3","AAH12106.1","major histocompatibility complex, class II, DQ beta 1, mRNA (cDNA clone MGC:20093 IMAGE:4574913), complete cds","BC012106.1","AAH12106.1",3119,"Hs.409934","CELIAC1, HLA-DQB, IDDM1","ENSG00000179344","Major histocompatibility complex, class II, DQ beta 1","6","32659467-32668383","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA013667","Uncertain",NA,"Supported","Golgi apparatus<br>Rods & Rings",NA,"Expressed in all","Tissue enhanced",NA,"lymph node: 287.3","lung: 268.5","Cell line enriched",8,"HDLM-2: 555.8"
"HLA-DQB2",36,"G6","IOH22158",696,"0",NA,"HLA class II histocompatibility antigen, DX beta chain Precursor  [Source:UniProtKB/Swiss-Prot;Acc:P05538]","ENST00000399658","ENSP00000382566",3120,"Hs.409934","HLA-DXB","ENSG00000232629","Major histocompatibility complex, class II, DQ beta 2","6","32756098-32763534","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Breast cancer:5.55e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"lung: 8.1;skin: 13.3","tonsil: 5.9","Not detected",NA,NA
"HP",145,"H11","IOH62888",846,"0",NA,"haptoglobin, mRNA (cDNA clone MGC:88296 IMAGE:4716454), complete cds","BC070299.1","AAH70299.1",3240,"Hs.513711",NA,"ENSG00000257017","Haptoglobin","16","72054592-72061055","Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB003787, HPA047750","Enhanced",NA,"Approved","Vesicles","Renal cancer:6.94e-13 (unfavourable)","Tissue enriched","Tissue enriched",182,"liver: 28407.0","bone marrow: 155.8","Cell line enhanced",NA,"Hep G2: 153.5;HSkMC: 88.2"
"HP",71,"F3","IOH29444",687,"0",NA,"haptoglobin, mRNA (cDNA clone MGC:61957 IMAGE:4723094), complete cds","BC058031.1","AAH58031.1",3240,"Hs.513711",NA,"ENSG00000257017","Haptoglobin","16","72054592-72061055","Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB003787, HPA047750","Enhanced",NA,"Approved","Vesicles","Renal cancer:6.94e-13 (unfavourable)","Tissue enriched","Tissue enriched",182,"liver: 28407.0","bone marrow: 155.8","Cell line enhanced",NA,"Hep G2: 153.5;HSkMC: 88.2"
"HPX",20,"F5","IOH7260",765,"0",NA,"hemopexin, mRNA (cDNA clone MGC:12533 IMAGE:4071616), complete cds","BC005395.1","AAH05395.1",3263,"Hs.426485",NA,"ENSG00000110169","Hemopexin","11","6431049-6442617","Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB016725","Supported",NA,NA,NA,"Liver cancer:2.26e-4 (favourable)","Tissue enriched","Tissue enriched",506,"liver: 2617.9","breast: 5.1","Cell line enriched",6,"Hep G2: 13.9"
"HRG",101,"C10","IOH40314",1578,"0",NA,"histidine-rich glycoprotein (HRG), mRNA.","NM_000412.2","NP_000403.1",3273,"Hs.1498","HPRG, HRGP","ENSG00000113905","Histidine rich glycoprotein","3","186660216-186678240","Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA050269, HPA054598","Supported",NA,"Uncertain","Nucleoli fibrillar center","Liver cancer:9.64e-5 (favourable)","Tissue enriched","Tissue enriched",83,"liver: 2689.0","kidney: 32.2","Cell line enhanced",NA,"HL-60: 2.0;RH-30: 2.8;SiHa: 1.1"
"HS3ST1",71,"A6","IOH29561",924,"0",NA,"heparan sulfate (glucosamine) 3-O-sulfotransferase 1 (HS3ST1), mRNA.","NM_005114.2","NP_005105.1",9957,"Hs.507348","3OST1","ENSG00000002587","Heparan sulfate-glucosamine 3-sulfotransferase 1","4","11393150-11429765","Enzymes, Predicted secreted proteins","Evidence at protein level","HPA002237","Approved",NA,"Approved","Vesicles","Renal cancer:5.99e-8 (favourable), Endometrial cancer:7.73e-4 (favourable), Urothelial cancer:8.67e-4 (favourable)","Mixed","Tissue enhanced",NA,"gallbladder: 13.9;ovary: 23.2","urinary bladder: 5.6","Cell line enhanced",NA,"CAPAN-2: 12.2;RPTEC TERT1: 9.1;RT4: 8.0;SCLC-21H: 4.3"
"HS3ST1",102,"G3","IOH29253",924,"0",NA,"heparan sulfate (glucosamine) 3-O-sulfotransferase 1, mRNA (cDNA clone MGC:71699 IMAGE:5261530), complete cds","BC057803.1","AAH57803.1",9957,"Hs.507348","3OST1","ENSG00000002587","Heparan sulfate-glucosamine 3-sulfotransferase 1","4","11393150-11429765","Enzymes, Predicted secreted proteins","Evidence at protein level","HPA002237","Approved",NA,"Approved","Vesicles","Renal cancer:5.99e-8 (favourable), Endometrial cancer:7.73e-4 (favourable), Urothelial cancer:8.67e-4 (favourable)","Mixed","Tissue enhanced",NA,"gallbladder: 13.9;ovary: 23.2","urinary bladder: 5.6","Cell line enhanced",NA,"CAPAN-2: 12.2;RPTEC TERT1: 9.1;RT4: 8.0;SCLC-21H: 4.3"
"HSD11B1L",139,"D12","IOH59687",600,"0",NA,"hydroxysteroid (11-beta) dehydrogenase 1-like (HSD11B1L), transcript variant c, mRNA.","NM_198707.1","NP_941996.1",374875,"Hs.631840","SCDR10, SDR26C2","ENSG00000167733","Hydroxysteroid 11-beta dehydrogenase 1 like","19","5680604-5688523","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at transcript level","HPA049078",NA,NA,"Approved","Vesicles","Head and neck cancer:4.38e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 25.6","fallopian tube: 7.9","Cell line enhanced",NA,"SH-SY5Y: 20.1"
"HSD11B1L",105,"C9","IOH43331",459,"0",NA,"hydroxysteroid (11-beta) dehydrogenase 1-like (HSD11B1L), transcript variant d, mRNA.","NM_198708.1","NP_941997.1",374875,"Hs.631840","SCDR10, SDR26C2","ENSG00000167733","Hydroxysteroid 11-beta dehydrogenase 1 like","19","5680604-5688523","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at transcript level","HPA049078",NA,NA,"Approved","Vesicles","Head and neck cancer:4.38e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 25.6","fallopian tube: 7.9","Cell line enhanced",NA,"SH-SY5Y: 20.1"
"HSD17B11",60,"H9","IOH27875",903,"0",NA,"hydroxysteroid (17-beta) dehydrogenase 11, mRNA (cDNA clone MGC:32825 IMAGE:4715042), complete cds","BC036001.1","AAH36001.1",51170,"Hs.594923","17-BETA-HSD11, 17-BETA-HSDXI, DHRS8, PAN1B, RetSDR2, SDR16C2","ENSG00000198189","Hydroxysteroid 17-beta dehydrogenase 11","4","87336610-87391386","Enzymes, Predicted secreted proteins","Evidence at protein level","HPA021608","Approved",NA,"Supported","Lipid droplets",NA,"Expressed in all","Expressed in all",NA,NA,"small intestine: 295.2","Cell line enhanced",NA,"CAPAN-2: 236.8"
"HSP90B1",1,"G11","IOH12344",948,"0",NA,"heat shock protein 90kDa beta (Grp94), member 1, mRNA (cDNA clone IMAGE:3938823), complete cds.","BC009195.2","AAH09195.1",7184,"Hs.192374","GP96, GRP94, TRA1","ENSG00000166598","Heat shock protein 90 beta family member 1","12","103930107-103953645","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA003901, CAB005224, HPA008424","Enhanced",NA,"Enhanced","Endoplasmic reticulum","Renal cancer:1.03e-10 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 2386.1","Expressed in all",NA,NA
"HSPA13",31,"H7","IOH22345",1416,"0",NA,"heat shock protein 70kDa family, member 13, mRNA (cDNA clone MGC:26248 IMAGE:4837136), complete cds","BC036370.2","AAH36370.1",6782,"Hs.352341","STCH","ENSG00000155304","Heat shock protein family A (Hsp70) member 13","21","14371115-14383484","Predicted secreted proteins","Evidence at protein level","HPA014797","Approved",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 55.7","Expressed in all",NA,NA
"HSPA13",131,"B1","IOH55324",1416,"0",NA,"heat shock protein 70kDa family, member 13 (HSPA13), mRNA.","NM_006948.4","NP_008879.3",6782,"Hs.352341","STCH","ENSG00000155304","Heat shock protein family A (Hsp70) member 13","21","14371115-14383484","Predicted secreted proteins","Evidence at protein level","HPA014797","Approved",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 55.7","Expressed in all",NA,NA
"HSPA5",14,"D11","IOH14762",1965,"0",NA,"heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) (HSPA5), mRNA.","NM_005347.3","NP_005338.1",3309,"Hs.716396","BiP, GRP78","ENSG00000044574","Heat shock protein family A (Hsp70) member 5","9","125234853-125241330","Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB005221, HPA038845, HPA038846","Enhanced",NA,"Approved","Cytosol","Renal cancer:3.05e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 968.4","Expressed in all",NA,NA
"HTATIP2",69,"G10","IOH10311",729,"0",NA,"HIV-1 Tat interactive protein 2, 30kDa, mRNA (cDNA clone MGC:21465 IMAGE:3455757), complete cds","BC015358.2","AAH15358.1",10553,"Hs.90753","CC3, FLJ26963, SDR44U1, TIP30","ENSG00000109854","HIV-1 Tat interactive protein 2","11","20363685-20383783","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA006417, HPA024321","Approved",NA,"Supported","Cytosol","Liver cancer:2.86e-4 (unfavourable), Pancreatic cancer:6.18e-4 (unfavourable), Renal cancer:8.01e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"duodenum: 135.2","Mixed",NA,NA
"HTN1",38,"B12","IOH12902",174,"0",NA,"histatin 1 (HTN1), mRNA.","NM_002159.2","NP_002150.1",3346,"Hs.250959","HIS1","ENSG00000126550","Histatin 1","4","70050402-70058845","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Not detected","Tissue enriched",1777,"salivary gland: 24297.5","ovary: 13.6","Not detected",NA,NA
"HTN3",34,"A5","IOH12986",156,"0",NA,"histatin 3 (HTN3), mRNA.","NM_000200.2","NP_000191.1",3347,"Hs.654442","HIS2","ENSG00000205649","Histatin 3","4","70028413-70036538","Predicted secreted proteins, Transporters","Evidence at protein level","CAB073541","Enhanced",NA,"Uncertain","Vesicles",NA,"Tissue enhanced","Tissue enriched",1666,"salivary gland: 47614.6","ovary: 28.5","Mixed",NA,NA
"HTRA4",118,"B7","IOH29239",1431,"0",NA,"HtrA serine peptidase 4, mRNA (cDNA clone MGC:71517 IMAGE:30348811), complete cds","BC057765.1","AAH57765.1",203100,"Hs.661014","FLJ90724","ENSG00000169495","HtrA serine peptidase 4","8","38974164-38988662","Enzymes, Predicted secreted proteins","Evidence at protein level","HPA045402","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",20,"placenta: 94.9","bone marrow: 4.7","Cell line enriched",160,"BEWO: 219.1"
"HYAL1",112,"C5","IOH45449",762,"0",NA,"hyaluronoglucosaminidase 1 (HYAL1), transcript variant 3, mRNA.","NM_153283.1","NP_695015.1",3373,"Hs.75619","FUS2, HYAL-1, LUCA1, NAT6","ENSG00000114378","Hyaluronoglucosaminidase 1","3","50299889-50312381","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA002112","Uncertain",NA,NA,NA,"Renal cancer:1.56e-11 (favourable), Colorectal cancer:2.07e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"liver: 71.1;spleen: 69.3","kidney: 43.5","Cell line enhanced",NA,"Hep G2: 66.6;SK-BR-3: 20.5"
"HYAL1",112,"B5","IOH45448",531,"0",NA,"hyaluronoglucosaminidase 1 (HYAL1), transcript variant 5, mRNA.","NM_153285.1","NP_695017.1",3373,"Hs.75619","FUS2, HYAL-1, LUCA1, NAT6","ENSG00000114378","Hyaluronoglucosaminidase 1","3","50299889-50312381","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA002112","Uncertain",NA,NA,NA,"Renal cancer:1.56e-11 (favourable), Colorectal cancer:2.07e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"liver: 71.1;spleen: 69.3","kidney: 43.5","Cell line enhanced",NA,"Hep G2: 66.6;SK-BR-3: 20.5"
"HYAL3",54,"F2","IOH7527",1254,"0",NA,"hyaluronoglucosaminidase 3, mRNA (cDNA clone MGC:14472 IMAGE:4104459), complete cds","BC005896.1","AAH05896.1",8372,"Hs.129910","LUCA-3, LUCA14, Minna14","ENSG00000186792","Hyaluronoglucosaminidase 3","3","50292831-50299468","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA049402","Uncertain",NA,NA,NA,"Urothelial cancer:2.12e-5 (unfavourable)","Expressed in all","Tissue enhanced",NA,"bone marrow: 22.7","testis: 14.0","Expressed in all",NA,NA
"HYOU1",155,"A12","IOH61814",2037,"0",NA,"hypoxia up-regulated 1, mRNA (cDNA clone MGC:90262 IMAGE:5756154), complete cds","BC072436.1","AAH72436.1",10525,"Hs.277704","Grp170, HSP12A, ORP150","ENSG00000149428","Hypoxia up-regulated 1","11","119044189-119057202","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA049296","Approved",NA,NA,NA,"Renal cancer:5.10e-5 (unfavourable), Endometrial cancer:2.58e-4 (favourable), Thyroid cancer:5.00e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 111.7","Expressed in all",NA,NA
"HYOU1",28,"E4","IOH6376",444,"0",NA,"hypoxia up-regulated 1, mRNA (cDNA clone IMAGE:3959339), complete cds.","BC004560.2","AAH04560.1",10525,"Hs.277704","Grp170, HSP12A, ORP150","ENSG00000149428","Hypoxia up-regulated 1","11","119044189-119057202","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA049296","Approved",NA,NA,NA,"Renal cancer:5.10e-5 (unfavourable), Endometrial cancer:2.58e-4 (favourable), Thyroid cancer:5.00e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 111.7","Expressed in all",NA,NA
"IAPP",104,"D12","IOH43658",270,"0",NA,"islet amyloid polypeptide (IAPP), mRNA.","NM_000415.2","NP_000406.1",3375,"Hs.46835","AMYLIN, DAP, IAP","ENSG00000121351","Islet amyloid polypeptide","12","21354959-21379978","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB000352, HPA053194","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",7,"pancreas: 35.0","testis: 5.3","Cell line enhanced",NA,"U-2 OS: 1.3"
"ICAM1",40,"E2","IOH13766",1599,"NP_000192.1","NP_000192.2","intercellular adhesion molecule 1 (ICAM1), mRNA.","NM_000201.2","NP_000192.2",3383,"Hs.643447","BB2, CD54","ENSG00000090339","Intercellular adhesion molecule 1","19","10270835-10286615","Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA002126, CAB002142, HPA004877","Enhanced",NA,"Uncertain","Plasma membrane<br>Cytosol","Renal cancer:1.32e-6 (unfavourable), Breast cancer:7.09e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"lung: 255.9","Cell line enhanced",NA,"Karpas-707: 302.5"
"ICAM2",88,"F3","IOH4557",828,"NP_000864.1","NP_000864.2","intercellular adhesion molecule 2 (ICAM2), transcript variant 5, mRNA.","NM_000873.3","NP_000864.2",3384,"Hs.431460","CD102","ENSG00000108622","Intercellular adhesion molecule 2","17","64002594-64020634","CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA071155",NA,NA,"Uncertain","Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"spleen: 200.5","Group enriched",7,"HUVEC TERT2: 1043.9;TIME: 259.9"
"ICAM4",73,"E9","IOH4662",819,"0",NA,"intercellular adhesion molecule 4 (Landsteiner-Wiener blood group) (ICAM4), transcript variant 3, mRNA.","NM_001039132.1","NP_001034221.1",3386,"Hs.706750","CD242, LW","ENSG00000105371","Intercellular adhesion molecule 4 (Landsteiner-Wiener blood group)","19","10286967-10288522","Blood group antigen proteins, CD markers, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"bone marrow: 8.7;lung: 14.5","epididymis: 2.9","Cell line enhanced",NA,"HEL: 67.4;K-562: 35.3;NB-4: 20.5"
"ICAM4",86,"G10","IOH23172",816,"NP_001535.1","NP_001535.1","intercellular adhesion molecule 4 (Landsteiner-Wiener blood group) (ICAM4), transcript variant 1, mRNA.","NM_001544.3","NP_001535.1",3386,"Hs.706750","CD242, LW","ENSG00000105371","Intercellular adhesion molecule 4 (Landsteiner-Wiener blood group)","19","10286967-10288522","Blood group antigen proteins, CD markers, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"bone marrow: 8.7;lung: 14.5","epididymis: 2.9","Cell line enhanced",NA,"HEL: 67.4;K-562: 35.3;NB-4: 20.5"
"IDS",137,"C5","IOH52275",1653,"0",NA,"iduronate 2-sulfatase (IDS), transcript variant 1, mRNA.","NM_000202.4","NP_000193.1",3423,"Hs.460960","SIDS","ENSG00000010404","Iduronate 2-sulfatase","X","149476990-149521096","Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Expressed in all","Tissue enriched",5,"cerebral cortex: 435.8","epididymis: 86.8","Expressed in all",NA,NA
"IDS",126,"B5","IOH6639",939,"0",NA,"iduronate 2-sulfatase, mRNA (cDNA clone MGC:13238 IMAGE:4025980), complete cds","BC006170.1","AAH06170.1",3423,"Hs.460960","SIDS","ENSG00000010404","Iduronate 2-sulfatase","X","149476990-149521096","Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Expressed in all","Tissue enriched",5,"cerebral cortex: 435.8","epididymis: 86.8","Expressed in all",NA,NA
"IER3IP1",19,"F7","IOH13339",249,"NP_057181.1","NP_057181.1","immediate early response 3 interacting protein 1 (IER3IP1), mRNA.","NM_016097.3","NP_057181.1",51124,"Hs.653122",NA,"ENSG00000134049","Immediate early response 3 interacting protein 1","18","47152834-47176374","Disease related genes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA010027","Supported",NA,"Supported","Endoplasmic reticulum","Liver cancer:6.47e-6 (unfavourable), Ovarian cancer:8.59e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"kidney: 32.8","Expressed in all",NA,NA
"IFI30",14,"H9","IOH13656",753,"0",NA,"interferon, gamma-inducible protein 30 (IFI30), mRNA.","NM_006332.3","NP_006323.2",10437,"Hs.14623","GILT, IFI-30, IP-30, IP30, MGC32056","ENSG00000216490","IFI30, lysosomal thiol reductase","19","18173162-18178117","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA026650","Approved",NA,"Supported","Vesicles<br>Cytosol",NA,"Mixed","Expressed in all",NA,NA,"appendix: 828.7","Cell line enhanced",NA,"Daudi: 385.9;RPMI-8226: 408.1;U-266/84: 467.0"
"IFI30",60,"G6","IOH27971",753,"0",NA,"interferon, gamma-inducible protein 30, mRNA (cDNA clone MGC:32800 IMAGE:4690088), complete cds","BC031020.1","AAH31020.1",10437,"Hs.14623","GILT, IFI-30, IP-30, IP30, MGC32056","ENSG00000216490","IFI30, lysosomal thiol reductase","19","18173162-18178117","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA026650","Approved",NA,"Supported","Vesicles<br>Cytosol",NA,"Mixed","Expressed in all",NA,NA,"appendix: 828.7","Cell line enhanced",NA,"Daudi: 385.9;RPMI-8226: 408.1;U-266/84: 467.0"
"IFNA1",103,"H4","IOH35235",570,"0",NA,"interferon, alpha 1 (IFNA1), mRNA.","NM_024013.1","NP_076918.1",3439,"Hs.37026","IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA@, IFNA13","ENSG00000197919","Interferon alpha 1","9","21440454-21441316","Cancer-related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA047557","Uncertain",NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"urinary bladder: 0.2","Cell line enhanced",NA,"HeLa: 1.4"
"IFNA10",140,"D1","IOH35229",570,"0",NA,"interferon, alpha 10 (IFNA10), mRNA.","NM_002171.1","NP_002162.1",3446,"Hs.282275","IFN-alphaC","ENSG00000186803","Interferon alpha 10","9","21206181-21207143","Predicted secreted proteins","Evidence at protein level","HPA047557","Uncertain",NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"all non-specific tissues: 0.0","Not detected",NA,NA
"IFNA13",137,"A3","IOH56629",570,"0",NA,"interferon, alpha 13, mRNA (cDNA clone MGC:121023 IMAGE:7939833), complete cds","BC093988.1","AAH93988.1",3447,"Hs.533471",NA,"ENSG00000233816","Interferon alpha 13","9","21367424-21368962","Cancer-related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA047557","Uncertain",NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"epididymis: 0.5","Not detected",NA,NA
"IFNA14",150,"D2","IOH61932",570,"0",NA,"interferon, alpha 14 (IFNA14), mRNA.","NM_002172.2","NP_002163.2",3448,"Hs.93907","IFN-alphaH, LEIF2H","ENSG00000228083","Interferon alpha 14","9","21239002-21239991","Predicted secreted proteins","Evidence at protein level","HPA047557","Uncertain",NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"all non-specific tissues: 0.0","Not detected",NA,NA
"IFNA16",103,"F4","IOH35231",570,"0",NA,"interferon, alpha 16 (IFNA16), mRNA.","NM_002173.2","NP_002164.1",3449,"Hs.56303","IFN-alphaO","ENSG00000147885","Interferon alpha 16","9","21216373-21217311","Predicted secreted proteins","Evidence at transcript level","HPA047557","Uncertain",NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"all non-specific tissues: 0.0","Not detected",NA,NA
"IFNA17",111,"G10","IOH35234",570,"0",NA,"interferon, alpha 17 (IFNA17), mRNA.","NM_021268.1","NP_067091.1",3451,"Hs.282276","IFN-alphaI, LEIF2C1","ENSG00000234829","Interferon alpha 17","9","21227243-21228222","Predicted secreted proteins","Evidence at protein level","HPA047557","Uncertain",NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"all non-specific tissues: 0.0","Not detected",NA,NA
"IFNA2",103,"B4","IOH35221",567,"0",NA,"interferon, alpha 2 (IFNA2), mRNA.","NM_000605.3","NP_000596.2",3440,"Hs.211575","IFN-alphaA, IFNA","ENSG00000188379","Interferon alpha 2","9","21384254-21385388","Predicted secreted proteins","Evidence at protein level","HPA047557","Uncertain",NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"all non-specific tissues: 0.0","Not detected",NA,NA
"IFNA21",95,"G6","IOH40250",570,"0",NA,"interferon, alpha 21 (IFNA21), mRNA.","NM_002175.2","NP_002166.2",3452,"Hs.113211","IFN-alphaI","ENSG00000137080","Interferon alpha 21","9","21165637-21166660","Predicted secreted proteins","Evidence at protein level","HPA047557","Uncertain",NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"lymph node: 0.1","Not detected",NA,NA
"IFNA4",150,"A6","IOH61950",570,"0",NA,"interferon, alpha 4, mRNA (cDNA clone MGC:104059 IMAGE:30915507), complete cds","BC074965.2","AAH74965.1",3441,"Hs.1510","IFN-alpha4a, MGC142200","ENSG00000236637","Interferon alpha 4","9","21186694-21187671","Predicted secreted proteins","Evidence at protein level","HPA047557","Uncertain",NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"all non-specific tissues: 0.0","Not detected",NA,NA
"IFNA4",144,"E3","IOH54736",570,"0",NA,"interferon, alpha 4 (IFNA4), mRNA.","NM_021068.2","NP_066546.1",3441,"Hs.1510","IFN-alpha4a, MGC142200","ENSG00000236637","Interferon alpha 4","9","21186694-21187671","Predicted secreted proteins","Evidence at protein level","HPA047557","Uncertain",NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"all non-specific tissues: 0.0","Not detected",NA,NA
"IFNA5",103,"D4","IOH35227",570,"0",NA,"interferon, alpha 5 (IFNA5), mRNA.","NM_002169.1","NP_002160.1",3442,"Hs.37113","IFN-alphaG","ENSG00000147873","Interferon alpha 5","9","21304326-21305312","Predicted secreted proteins","Evidence at protein level","HPA047557","Uncertain",NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"epididymis: 0.2","Not detected",NA,NA
"IFNA6",103,"G4","IOH35232",570,"0",NA,"interferon, alpha 6 (IFNA6), mRNA.","NM_021002.1","NP_066282.1",3443,"Hs.533470","IFN-alphaK","ENSG00000120235","Interferon alpha 6","9","21349835-21351378","Predicted secreted proteins","Evidence at protein level","HPA047557","Uncertain",NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"all non-specific tissues: 0.0","Not detected",NA,NA
"IFNA8",103,"E4","IOH35228",570,"0",NA,"interferon, alpha 8 (IFNA8), mRNA.","NM_002170.3","NP_002161.2",3445,"Hs.73890","IFN-alphaB","ENSG00000120242","Interferon alpha 8","9","21409147-21410185","Predicted secreted proteins","Evidence at protein level","HPA047557","Uncertain",NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"all non-specific tissues: 0.0","Not detected",NA,NA
"IFNAR1",136,"B9","IOH56150",1674,"NP_000620.1","NP_000620.2","interferon (alpha, beta and omega) receptor 1 (IFNAR1), mRNA.","NM_000629.2","NP_000620.2",3454,"Hs.529400","IFNAR, IFRC","ENSG00000142166","Interferon alpha and beta receptor subunit 1","21","33324477-33359862","Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA018015, HPA029226","Approved",NA,"Approved","Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 61.3","Expressed in all",NA,NA
"IFNB1",103,"A4","IOH35219",564,"0",NA,"interferon, beta 1, fibroblast (IFNB1), mRNA.","NM_002176.2","NP_002167.1",3456,"Hs.93177","IFB, IFF, IFNB","ENSG00000171855","Interferon beta 1","9","21077105-21077963","Cancer-related genes, Predicted secreted proteins","Evidence at protein level","CAB009386","Uncertain",NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"bone marrow: 0.3","Cell line enhanced",NA,"BJ hTERT+ SV40 Large T+ RasG12V: 1.1"
"IFNG",98,"D1","IOH40816",501,"0",NA,"interferon, gamma (IFNG), mRNA.","NM_000619.2","NP_000610.2",3458,"Hs.856",NA,"ENSG00000111537","Interferon gamma","12","68154768-68159747","Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB010344","Approved",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"appendix: 4.7;bone marrow: 7.6;lymph node: 7.9","lung: 2.5","Not detected",NA,NA
"IFNGR1",20,"A7","IOH7300",1470,"NP_000407.1","NP_000407.1","interferon gamma receptor 1 (IFNGR1), mRNA.","NM_000416.2","NP_000407.1",3459,"Hs.520414","CD119, IFNGR","ENSG00000027697","Interferon gamma receptor 1","6","137197484-137219449","CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB025889, HPA063871","Approved",NA,NA,NA,"Renal cancer:5.48e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 221.9","Expressed in all",NA,NA
"IFNW1",103,"C5","IOH35249",588,"0",NA,"interferon, omega 1 (IFNW1), mRNA.","NM_002177.1","NP_002168.1",3467,"Hs.73010",NA,"ENSG00000177047","Interferon omega 1","9","21140214-21142145","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"bone marrow,lymph node,skin,testis,thyroid gland: 0.1","Not detected",NA,NA
"IGF1",141,"G2","IOH58981",462,"0",NA,"insulin-like growth factor 1 (somatomedin C) (IGF1), transcript variant 4, mRNA.","NM_000618.3","NP_000609.1",3479,"Hs.160562","IGF-I, IGF1A, IGFI","ENSG00000017427","Insulin like growth factor 1","12","102395867-102480645","Disease related genes, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","HPA048946","Approved",NA,NA,NA,"Endometrial cancer:1.04e-4 (favourable)","Mixed","Tissue enhanced",NA,"cervix, uterine: 126.8","smooth muscle: 98.2","Cell line enhanced",NA,"ASC diff: 21.1;HDLM-2: 45.4;K-562: 19.8;U-266/70: 10.2"
"IGF2",38,"F2","IOH13185",342,"0",NA,"Putative insulin-like growth factor 2-associated protein.","P09565","P09565",3481,"Hs.272259","C11orf43, FLJ44734, IGF-II","ENSG00000167244","Insulin like growth factor 2","11","2129112-2141238","Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA007556, HPA007993","Enhanced",NA,"Approved","Nucleoplasm<br>Vesicles","Liver cancer:7.12e-4 (favourable)","Group enriched","Tissue enriched",18,"placenta: 3962.9","fallopian tube: 217.6","Cell line enhanced",NA,"CACO-2: 711.5;Hep G2: 406.1;LHCN-M2: 277.7;RH-30: 396.9;SH-SY5Y: 525.9"
"IGF2",26,"F2","IOH3689",543,"0",NA,"insulin-like growth factor 2 (somatomedin A) (IGF2), transcript variant 1, mRNA.","NM_000612.4","NP_000603.1",3481,"Hs.272259","C11orf43, FLJ44734, IGF-II","ENSG00000167244","Insulin like growth factor 2","11","2129112-2141238","Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA007556, HPA007993","Enhanced",NA,"Approved","Nucleoplasm<br>Vesicles","Liver cancer:7.12e-4 (favourable)","Group enriched","Tissue enriched",18,"placenta: 3962.9","fallopian tube: 217.6","Cell line enhanced",NA,"CACO-2: 711.5;Hep G2: 406.1;LHCN-M2: 277.7;RH-30: 396.9;SH-SY5Y: 525.9"
"IGFALS",51,"A4","IOH10631",1818,"0",NA,"insulin-like growth factor binding protein, acid labile subunit, mRNA (cDNA clone MGC:34474 IMAGE:5205012), complete cds","BC025681.1","AAH25681.1",3483,"Hs.839","ALS","ENSG00000099769","Insulin like growth factor binding protein acid labile subunit","16","1790413-1794971","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA040692, HPA040948","Approved",NA,"Supported","Nucleoplasm","Liver cancer:5.97e-4 (favourable), Endometrial cancer:6.06e-4 (unfavourable)","Tissue enhanced","Group enriched",6,"liver: 25.0;stomach: 6.6","gallbladder: 2.5","Cell line enhanced",NA,"Hep G2: 1.2;U-266/70: 1.3"
"IGFBP1",119,"G11","IOH28640",780,"0",NA,"insulin-like growth factor binding protein 1, mRNA (cDNA clone MGC:30041 IMAGE:4800940), complete cds","BC035263.1","AAH35263.2",3484,"Hs.642938","AFBP, hIGFBP-1, IBP1, IGF-BP25, PP12","ENSG00000146678","Insulin like growth factor binding protein 1","7","45888357-45893668","Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB004445, HPA046972, HPA050640","Enhanced",NA,"Approved","Golgi apparatus","Renal cancer:6.90e-11 (unfavourable), Lung cancer:1.03e-4 (unfavourable), Stomach cancer:6.64e-4 (unfavourable)","Tissue enriched","Group enriched",52,"endometrium: 120.4;liver: 563.0;placenta: 265.8","fallopian tube: 6.0","Group enriched",8,"Hep G2: 33.4;U-2197: 71.7;U-87 MG: 128.8"
"IGFBP1",118,"G5","IOH29150",780,"0",NA,"insulin-like growth factor binding protein 1, mRNA (cDNA clone MGC:71720 IMAGE:30337849), complete cds","BC057806.1","AAH57806.1",3484,"Hs.642938","AFBP, hIGFBP-1, IBP1, IGF-BP25, PP12","ENSG00000146678","Insulin like growth factor binding protein 1","7","45888357-45893668","Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB004445, HPA046972, HPA050640","Enhanced",NA,"Approved","Golgi apparatus","Renal cancer:6.90e-11 (unfavourable), Lung cancer:1.03e-4 (unfavourable), Stomach cancer:6.64e-4 (unfavourable)","Tissue enriched","Group enriched",52,"endometrium: 120.4;liver: 563.0;placenta: 265.8","fallopian tube: 6.0","Group enriched",8,"Hep G2: 33.4;U-2197: 71.7;U-87 MG: 128.8"
"IGFBP2",135,"H5","IOH56807",987,"0",NA,"insulin-like growth factor binding protein 2, 36kDa (IGFBP2), mRNA.","NM_000597.2","NP_000588.2",3485,"Hs.438102","IBP2","ENSG00000115457","Insulin like growth factor binding protein 2","2","216632828-216664436","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA077723",NA,NA,"Approved","Endoplasmic reticulum","Renal cancer:2.22e-5 (unfavourable), Melanoma:2.43e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"seminal vesicle: 279.9","Cell line enhanced",NA,"ASC diff: 1479.2;HMC-1: 4500.9"
"IGFBP3",85,"C9","IOH4702",876,"0",NA,"insulin-like growth factor binding protein 3, mRNA (cDNA clone MGC:2305 IMAGE:3506666), complete cds","BC000013.2","AAH00013.1",3486,"Hs.450230","BP-53, IBP3","ENSG00000146674","Insulin like growth factor binding protein 3","7","45912245-45921874","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB010360",NA,NA,"Approved","Nucleoplasm<br>Vesicles<br>Cytosol","Renal cancer:5.07e-7 (unfavourable), Colorectal cancer:1.08e-4 (unfavourable), Liver cancer:1.64e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"placenta: 2671.0","endometrium: 886.0","Cell line enhanced",NA,"fHDF/TERT166: 6647.1;U-2197: 3223.6;U-87 MG: 1735.3"
"IGFBP3",129,"A7","IOH53821",876,"0",NA,"insulin-like growth factor binding protein 3 (IGFBP3), transcript variant 2, mRNA.","NM_000598.4","NP_000589.2",3486,"Hs.450230","BP-53, IBP3","ENSG00000146674","Insulin like growth factor binding protein 3","7","45912245-45921874","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB010360",NA,NA,"Approved","Nucleoplasm<br>Vesicles<br>Cytosol","Renal cancer:5.07e-7 (unfavourable), Colorectal cancer:1.08e-4 (unfavourable), Liver cancer:1.64e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"placenta: 2671.0","endometrium: 886.0","Cell line enhanced",NA,"fHDF/TERT166: 6647.1;U-2197: 3223.6;U-87 MG: 1735.3"
"IGFBP4",34,"B12","IOH12509",777,"0",NA,"insulin-like growth factor binding protein 4 (IGFBP4), mRNA.","NM_001552.2","NP_001543.2",3487,"Hs.462998","BP-4, HT29-IGFBP, IBP4, IGFBP-4","ENSG00000141753","Insulin like growth factor binding protein 4","17","40443461-40457731","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA066240","Supported",NA,NA,NA,"Renal cancer:2.72e-5 (unfavourable), Endometrial cancer:3.54e-4 (favourable), Liver cancer:5.49e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"smooth muscle: 932.6","Cell line enhanced",NA,"A549: 1206.8;HSkMC: 1458.4"
"IGFBP5",41,"H10","IOH9659",819,"0",NA,"insulin-like growth factor binding protein 5 (IGFBP5), mRNA.","NM_000599.3","NP_000590.1",3488,"Hs.607212",NA,"ENSG00000115461","Insulin like growth factor binding protein 5","2","216672105-216695525","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA059827",NA,NA,"Approved","Nuclear bodies<br>Golgi apparatus<br>Vesicles","Endometrial cancer:1.78e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cervix, uterine: 2374.4;ovary: 1646.3","fallopian tube: 949.1","Cell line enhanced",NA,"BJ: 704.3;BJ hTERT+: 1787.5;T-47d: 500.8;U-138 MG: 702.9"
"IGFBP6",85,"H10","IOH5480",723,"0",NA,"insulin-like growth factor binding protein 6 (IGFBP6), mRNA.","NM_002178.2","NP_002169.1",3489,"Hs.274313",NA,"ENSG00000167779","Insulin like growth factor binding protein 6","12","53097436-53102345","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA008005","Uncertain",NA,NA,NA,"Glioma:6.66e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"adipose tissue: 72.2","cervix, uterine: 47.7","Cell line enhanced",NA,"BJ: 290.6;HaCaT: 180.1;U-87 MG: 136.0"
"IGSF1",106,"A2","IOH41224",729,"NP_001546.1","NP_991402.1","immunoglobulin superfamily, member 1 (IGSF1), transcript variant 2, mRNA.","NM_205833.2","NP_991402.1",3547,"Hs.22111","IGCD1, IGDC1, INHBP, KIAA0364, MGC75490, PGSF2","ENSG00000147255","Immunoglobulin superfamily member 1","X","131273506-131578899","Disease related genes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA012732, HPA035582","Enhanced",NA,"Approved","Cytosol","Endometrial cancer:4.25e-8 (unfavourable)","Tissue enriched","Tissue enhanced",NA,"testis: 20.0","adrenal gland: 13.1","Cell line enhanced",NA,"Hep G2: 22.7;SH-SY5Y: 30.6"
"IGSF10",119,"H11","IOH28655",1809,"0",NA,"immunoglobulin superfamily, member 10, mRNA (cDNA clone IMAGE:5271204), complete cds.","BC031063.1","AAH31063.1",285313,"Hs.708245","CMF608, FLJ25972","ENSG00000152580","Immunoglobulin superfamily member 10","3","151425384-151458709","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA012921","Uncertain",NA,"Approved","Nucleoplasm<br>Intermediate filaments",NA,"Mixed","Tissue enhanced",NA,"ovary: 18.1","gallbladder: 14.7","Cell line enhanced",NA,"HeLa: 31.1;HL-60: 18.4;REH: 15.7;RPMI-8226: 38.1"
"IGSF21",91,"G6","IOH6923",1404,"0",NA,"immunoglobin superfamily, member 21, mRNA (cDNA clone MGC:15730 IMAGE:3355289), complete cds","BC007618.1","AAH07618.1",84966,"Hs.212511","MGC15730, RP11-121A23.1","ENSG00000117154","Immunoglobin superfamily member 21","1","18107746-18378483","Predicted secreted proteins","Evidence at protein level","HPA044535","Approved",NA,NA,NA,NA,"Group enriched","Tissue enhanced",NA,"cerebral cortex: 28.9;spleen: 13.2","adrenal gland: 5.9","Cell line enriched",6,"SCLC-21H: 21.2"
"IGSF8",70,"F9","IOH28982",1842,"NP_443100.1","NP_443100.1","immunoglobulin superfamily, member 8 (IGSF8), mRNA.","NM_052868.2","NP_443100.1",93185,"Hs.332012","CD316, CD81P3, EWI2, PGRL","ENSG00000162729","Immunoglobulin superfamily member 8","1","160091340-160098943","CD markers, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA011917","Uncertain",NA,NA,NA,"Cervical cancer:7.32e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 107.8","Expressed in all",NA,NA
"IL10",103,"F10","IOH29878",537,"0",NA,"interleukin 10 (IL10), mRNA.","NM_000572.2","NP_000563.1",3586,"Hs.193717","CSIF, IL-10, IL10A, TGIF","ENSG00000136634","Interleukin 10","1","206767602-206772494","Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB013120","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"appendix: 8.7","adipose tissue: 7.4","Group enriched",7,"HMC-1: 5.2;U-266/70: 6.5"
"IL11",80,"G2","IOH10616",600,"0",NA,"interleukin 11 (IL11), mRNA.","NM_000641.2","NP_000632.1",3589,"Hs.467304","AGIF, IL-11","ENSG00000095752","Interleukin 11","19","55364389-55370463","Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA044955",NA,NA,"Uncertain","Mitochondria","Pancreatic cancer:7.50e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"appendix: 5.7;endometrium: 5.2;gallbladder: 4.9","placenta: 1.7","Cell line enhanced",NA,"BJ: 50.3;BJ hTERT+: 54.5;hTEC/SVTERT24-B: 54.2;U-251 MG: 179.7"
"IL11RA",77,"B7","IOH39599",1269,"NP_004503.1","NP_004503.1","interleukin 11 receptor, alpha (IL11RA), transcript variant 1, mRNA.","NM_004512.3","NP_004503.1",3590,"Hs.591088",NA,"ENSG00000137070","Interleukin 11 receptor subunit alpha","9","34650702-34661892","Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA013162, CAB032830, HPA036652","Supported",NA,NA,NA,"Renal cancer:6.56e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"skin: 72.6","Mixed",NA,NA
"IL11RA",113,"B2","IOH45830",1173,"0",NA,"interleukin 11 receptor, alpha (IL11RA), transcript variant 2, mRNA.","NM_147162.1","NP_671518.1",3590,"Hs.591088",NA,"ENSG00000137070","Interleukin 11 receptor subunit alpha","9","34650702-34661892","Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA013162, CAB032830, HPA036652","Supported",NA,NA,NA,"Renal cancer:6.56e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"skin: 72.6","Mixed",NA,NA
"IL12RB1",42,"E3","IOH22696",1146,"NP_005526.1","AAH29121.1","interleukin 12 receptor, beta 1, mRNA (cDNA clone IMAGE:5189122), complete cds.","BC029121.1","AAH29121.1",3594,"Hs.567294","CD212, IL12RB","ENSG00000096996","Interleukin 12 receptor subunit beta 1","19","18058995-18098944","CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA074414",NA,NA,"Approved","Plasma membrane","Renal cancer:5.90e-5 (unfavourable), Cervical cancer:3.41e-4 (favourable)","Mixed","Tissue enhanced",NA,"lymph node: 25.9","spleen: 20.6","Cell line enhanced",NA,"Daudi: 13.1;HDLM-2: 28.9;Karpas-707: 36.8"
"IL12RB2",110,"D5","IOH44449",2589,"NP_001550.1","NP_001550.1","interleukin 12 receptor, beta 2 (IL12RB2), mRNA.","NM_001559.2","NP_001550.1",3595,"Hs.479347",NA,"ENSG00000081985","Interleukin 12 receptor subunit beta 2","1","67307364-67396900","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA024168","Uncertain",NA,"Uncertain","Plasma membrane<br>Cytosol",NA,"Tissue enhanced","Tissue enhanced",NA,"placenta: 11.8","cerebral cortex: 4.4","Cell line enhanced",NA,"HMC-1: 4.6;SCLC-21H: 12.2;SK-MEL-30: 21.0;THP-1: 10.6"
"IL13",139,"B1","IOH35104",441,"0",NA,"interleukin 13 (IL13), mRNA.","NM_002188.2","NP_002179.2",3596,"Hs.845","ALRH, BHR1, IL-13, MGC116786, MGC116788, MGC116789, P600","ENSG00000169194","Interleukin 13","5","132656263-132661110","Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA042421",NA,NA,"Approved","Plasma membrane<br>Cytosol",NA,"Not detected","Tissue enriched",10,"testis: 19.9","gallbladder: 2.0","Cell line enriched",226,"HDLM-2: 38.1"
"IL13RA1",81,"H3","IOH13584",1284,"0",NA,"interleukin 13 receptor, alpha 1, mRNA (cDNA clone MGC:23204 IMAGE:4868206), complete cds","BC015768.1","AAH15768.1",3597,"Hs.496646","CD213a1, IL-13Ra, NR4","ENSG00000131724","Interleukin 13 receptor subunit alpha 1","X","118727572-118794539","CD markers, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA000293",NA,NA,"Approved","Nucleoplasm<br>Golgi apparatus","Renal cancer:1.19e-8 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"lung: 72.0","Mixed",NA,NA
"IL13RA1",117,"H3","IOH12240",1284,"NP_001551.1","NP_001551.1","interleukin 13 receptor, alpha 1 (IL13RA1), mRNA.","NM_001560.2","NP_001551.1",3597,"Hs.496646","CD213a1, IL-13Ra, NR4","ENSG00000131724","Interleukin 13 receptor subunit alpha 1","X","118727572-118794539","CD markers, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA000293",NA,NA,"Approved","Nucleoplasm<br>Golgi apparatus","Renal cancer:1.19e-8 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"lung: 72.0","Mixed",NA,NA
"IL17A",70,"H12","IOH29641",468,"0",NA,"interleukin 17A (IL17A), mRNA.","NM_002190.2","NP_002181.1",3605,"Hs.41724","CTLA8, IL-17, IL-17A, IL17","ENSG00000112115","Interleukin 17A","6","52186387-52190638","Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA052258","Uncertain",NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"appendix: 1.0;tonsil: 1.3;urinary bladder: 1.5","gallbladder: 0.3","Group enriched",16,"Karpas-707: 1.9;U-266/84: 1.2"
"IL17B",106,"E9","IOH43021",543,"0",NA,"interleukin 17B (IL17B), mRNA.","NM_014443.2","NP_055258.1",27190,"Hs.156979","IL-17B, IL-20, MGC138900, MGC138901, NIRF, ZCYTO7","ENSG00000127743","Interleukin 17B","5","149371324-149404202","Cancer-related genes, Predicted secreted proteins","Evidence at protein level","HPA042441","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"breast: 4.0","smooth muscle: 3.3","Cell line enhanced",NA,"HEL: 1.2"
"IL17C",140,"A2","IOH34775",594,"0",NA,"interleukin 17C (IL17C), mRNA.","NM_013278.3","NP_037410.1",27189,"Hs.278911","CX2, IL-17C, IL-21, MGC126884, MGC138401","ENSG00000124391","Interleukin 17C","16","88638591-88640473","Predicted secreted proteins","Evidence at protein level","HPA065051","Supported",NA,NA,NA,NA,"Mixed","Tissue enriched",6,"endometrium: 3.5","gallbladder: 0.6","Not detected",NA,NA
"IL17D",119,"B10","IOH27522",609,"0",NA,"interleukin 17D (IL17D), mRNA.","NM_138284.1","NP_612141.1",53342,"Hs.655142","FLJ30846, IL-17D, IL-22, IL-27, IL27","ENSG00000172458","Interleukin 17D","13","20702127-20723098","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Group enriched","Group enriched",7,"cerebral cortex: 100.2;skeletal muscle: 45.9","ovary: 10.2","Mixed",NA,NA
"IL17F",146,"D6","IOH63032",492,"0",NA,"interleukin 17F, mRNA (cDNA clone MGC:88102 IMAGE:30417554), complete cds","BC070124.1","AAH70124.1",112744,"Hs.272295","IL-17F, ML-1, ML1","ENSG00000112116","Interleukin 17F","6","52236681-52244537","Disease related genes, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"tonsil: 1.8","urinary bladder: 0.9","Not detected",NA,NA
"IL17F",140,"C2","IOH35145",492,"0",NA,"interleukin 17F (IL17F), mRNA.","NM_052872.3","NP_443104.1",112744,"Hs.272295","IL-17F, ML-1, ML1","ENSG00000112116","Interleukin 17F","6","52236681-52244537","Disease related genes, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"tonsil: 1.8","urinary bladder: 0.9","Not detected",NA,NA
"IL17RA",122,"B1","IOH14478",2601,"NP_055154.3","AAH11624.1","interleukin 17 receptor A, mRNA (cDNA clone MGC:10262 IMAGE:4053746), complete cds","BC011624.2","AAH11624.1",23765,"Hs.129751","CD217, CDw217, hIL-17R, IL-17RA, IL17R","ENSG00000177663","Interleukin 17 receptor A","22","17084954-17115694","CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB024996","Enhanced",NA,"Approved","Nucleoplasm<br>Cytosol","Stomach cancer:8.35e-4 (favourable)","Expressed in all","Mixed",NA,NA,"bone marrow: 20.6","Cell line enhanced",NA,"HL-60: 47.4;THP-1: 50.1"
"IL17RE",97,"H11","IOH40721",816,"NP_705613.1","AAH63110.1","interleukin 17 receptor E, mRNA (cDNA clone IMAGE:30372618), complete cds.","BC063110.1","AAH63110.1",132014,"Hs.390823","FLJ23658","ENSG00000163701","Interleukin 17 receptor E","3","9902612-9916402","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA019011","Uncertain",NA,NA,NA,NA,"Expressed in all","Mixed",NA,NA,"small intestine: 22.6","Cell line enhanced",NA,"ASC TERT1: 27.7;BEWO: 14.7;T-47d: 18.4"
"IL18BP",62,"B10","IOH26376",585,"0",NA,"interleukin 18 binding protein (IL18BP), transcript variant E, mRNA.","NM_001039659.1","NP_001034748.1",10068,"Hs.591967","IL18BPa","ENSG00000137496","Interleukin 18 binding protein","11","71998541-72005715","Predicted secreted proteins","Evidence at protein level","CAB025980, HPA041061","Enhanced",NA,"Approved","Endoplasmic reticulum","Renal cancer:2.93e-6 (unfavourable)","Expressed in all","Tissue enhanced",NA,"spleen: 56.2","appendix: 32.8","Mixed",NA,NA
"IL18R1",132,"B4","IOH39727",1626,"NP_003846.1","NP_003846.1","interleukin 18 receptor 1 (IL18R1), mRNA.","NM_003855.2","NP_003846.1",8809,"Hs.469521","CD218a, IL-1Rrp, IL1RRP","ENSG00000115604","Interleukin 18 receptor 1","2","102311529-102398775","CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA007615","Approved",NA,"Approved","Mitochondria","Renal cancer:4.52e-4 (unfavourable)","Mixed","Mixed",NA,NA,"placenta: 14.4","Cell line enhanced",NA,"HDLM-2: 28.1;HHSteC: 51.3;HMC-1: 36.8;U-937: 54.3"
"IL18RAP",70,"B9","IOH29704",1800,"NP_003844.1","NP_003844.1","interleukin 18 receptor accessory protein (IL18RAP), mRNA.","NM_003853.2","NP_003844.1",8807,"Hs.158315","AcPL, CD218b","ENSG00000115607","Interleukin 18 receptor accessory protein","2","102418689-102452565","CD markers, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB025270","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"bone marrow: 70.9","appendix: 16.9","Cell line enriched",10,"U-937: 42.2"
"IL19",139,"F12","IOH34776",534,"0",NA,"interleukin 19 (IL19), transcript variant 2, mRNA.","NM_013371.2","NP_037503.2",29949,"Hs.661017","IL-10C, IL-19, MDA1, NG.1, ZMDA1","ENSG00000142224","Interleukin 19","1","206798870-206842981","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",9,"cervix, uterine: 21.0","salivary gland: 2.3","Cell line enriched",11,"BJ hTERT+: 4.9"
"IL19",151,"G1","IOH35292",648,"0",NA,"interleukin 19 (IL19), transcript variant 1, mRNA.","NM_153758.1","NP_715639.1",29949,"Hs.661017","IL-10C, IL-19, MDA1, NG.1, ZMDA1","ENSG00000142224","Interleukin 19","1","206798870-206842981","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",9,"cervix, uterine: 21.0","salivary gland: 2.3","Cell line enriched",11,"BJ hTERT+: 4.9"
"IL1R1",95,"H2","IOH40164",1710,"0",NA,"interleukin 1 receptor, type I (IL1R1), mRNA.","NM_000877.2","NP_000868.1",3554,"Hs.701982","CD121A, D2S1473, IL1R, IL1RA","ENSG00000115594","Interleukin 1 receptor type 1","2","102064544-102179874","Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA005823, CAB007779, HPA029560","Approved",NA,NA,NA,"Renal cancer:6.92e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cervix, uterine: 246.0","Cell line enhanced",NA,"ASC diff: 431.3;ASC TERT1: 195.1;HHSteC: 165.4;HSkMC: 562.6"
"IL1R1",155,"H2","IOH62523",1710,"0",NA,"interleukin 1 receptor, type I, mRNA (cDNA clone MGC:79371 IMAGE:7002111), complete cds","BC067508.1","AAH67508.1",3554,"Hs.701982","CD121A, D2S1473, IL1R, IL1RA","ENSG00000115594","Interleukin 1 receptor type 1","2","102064544-102179874","Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA005823, CAB007779, HPA029560","Approved",NA,NA,NA,"Renal cancer:6.92e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cervix, uterine: 246.0","Cell line enhanced",NA,"ASC diff: 431.3;ASC TERT1: 195.1;HHSteC: 165.4;HSkMC: 562.6"
"IL1R2",91,"B1","IOH26113",1197,"NP_004624.1","NP_004624.1","interleukin 1 receptor, type II (IL1R2), transcript variant 1, mRNA.","NM_004633.3","NP_004624.1",7850,"Hs.25333","CD121b, IL1RB","ENSG00000115590","Interleukin 1 receptor type 2","2","101991844-102028544","Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA027597, HPA027598","Uncertain",NA,NA,NA,"Renal cancer:5.58e-12 (unfavourable)","Mixed","Mixed",NA,NA,"appendix: 50.3","Cell line enriched",24,"HDLM-2: 436.8"
"IL1RAP",151,"E6","IOH60824",1071,"NP_002173.1","NP_608273.1","interleukin 1 receptor accessory protein (IL1RAP), transcript variant 2, mRNA.","NM_134470.2","NP_608273.1",3556,"Hs.478673","C3orf13, IL-1RAcP, IL1R3","ENSG00000196083","Interleukin 1 receptor accessory protein","3","190514051-190659750","Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA035293","Uncertain",NA,"Approved","Vesicles<br>Cytosol","Renal cancer:2.16e-7 (unfavourable), Pancreatic cancer:1.31e-4 (unfavourable), Urothelial cancer:6.29e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"liver: 113.0;placenta: 53.7","gallbladder: 19.8","Cell line enhanced",NA,"SK-MEL-30: 193.6"
"IL1RL1",71,"G6","IOH29806",987,"0",NA,"interleukin 1 receptor-like 1 (IL1RL1), transcript variant 2, mRNA.","NM_003856.2","NP_003847.2",9173,"Hs.66","DER4, FIT-1, IL33R, ST2, ST2L, ST2V, T1","ENSG00000115602","Interleukin 1 receptor like 1","2","102311502-102352037","Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA007406, HPA007917","Uncertain",NA,"Approved","Vesicles",NA,"Tissue enhanced","Tissue enriched",12,"placenta: 289.6","gallbladder: 23.7","Group enriched",6,"HHSteC: 206.0;HMC-1: 327.3;HUVEC TERT2: 154.2"
"IL1RL1",110,"E4","IOH41470",780,"0",NA,"Interleukin-1 receptor-like 1 Precursor (Protein ST2) [Source:UniProtKB/Swiss-Prot;Acc:Q01638]","ENST00000393393","ENSP00000377052",9173,"Hs.66","DER4, FIT-1, IL33R, ST2, ST2L, ST2V, T1","ENSG00000115602","Interleukin 1 receptor like 1","2","102311502-102352037","Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA007406, HPA007917","Uncertain",NA,"Approved","Vesicles",NA,"Tissue enhanced","Tissue enriched",12,"placenta: 289.6","gallbladder: 23.7","Group enriched",6,"HHSteC: 206.0;HMC-1: 327.3;HUVEC TERT2: 154.2"
"IL1RN",107,"G2","IOH42169",534,"0",NA,"interleukin 1 receptor antagonist (IL1RN), transcript variant 1, mRNA.","NM_173842.1","NP_776214.1",3557,"Hs.81134","ICIL-1RA, IL-1RN, IL1F3, IL1RA, IRAP, MGC10430","ENSG00000136689","Interleukin 1 receptor antagonist","2","113107214-113134016","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA001482, CAB009633","Enhanced",NA,NA,NA,"Renal cancer:2.66e-6 (unfavourable), Endometrial cancer:3.00e-4 (unfavourable), Pancreatic cancer:6.85e-4 (unfavourable), Testis cancer:8.23e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"esophagus: 1243.9","tonsil: 290.5","Cell line enhanced",NA,"A-431: 51.8;HaCaT: 100.6;RT4: 89.4"
"IL1RN",112,"F12","IOH45793",432,"0",NA,"interleukin 1 receptor antagonist (IL1RN), transcript variant 4, mRNA.","NM_173843.1","NP_776215.1",3557,"Hs.81134","ICIL-1RA, IL-1RN, IL1F3, IL1RA, IRAP, MGC10430","ENSG00000136689","Interleukin 1 receptor antagonist","2","113107214-113134016","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA001482, CAB009633","Enhanced",NA,NA,NA,"Renal cancer:2.66e-6 (unfavourable), Endometrial cancer:3.00e-4 (unfavourable), Pancreatic cancer:6.85e-4 (unfavourable), Testis cancer:8.23e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"esophagus: 1243.9","tonsil: 290.5","Cell line enhanced",NA,"A-431: 51.8;HaCaT: 100.6;RT4: 89.4"
"IL1RN",134,"F9","IOH57147",480,"0",NA,"interleukin 1 receptor antagonist (IL1RN), transcript variant 3, mRNA.","NM_000577.3","NP_000568.1",3557,"Hs.81134","ICIL-1RA, IL-1RN, IL1F3, IL1RA, IRAP, MGC10430","ENSG00000136689","Interleukin 1 receptor antagonist","2","113107214-113134016","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA001482, CAB009633","Enhanced",NA,NA,NA,"Renal cancer:2.66e-6 (unfavourable), Endometrial cancer:3.00e-4 (unfavourable), Pancreatic cancer:6.85e-4 (unfavourable), Testis cancer:8.23e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"esophagus: 1243.9","tonsil: 290.5","Cell line enhanced",NA,"A-431: 51.8;HaCaT: 100.6;RT4: 89.4"
"IL2",99,"A5","IOH40161",462,"0",NA,"interleukin 2 (IL2), mRNA.","NM_000586.3","NP_000577.2",3558,"Hs.89679","IL-2, TCGF","ENSG00000109471","Interleukin 2","4","122451470-122456725","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB010310","Uncertain",NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"rectum,small intestine,tonsil: 0.3","Not detected",NA,NA
"IL2",155,"F10","IOH61852",462,"0",NA,"interleukin 2, mRNA (cDNA clone MGC:79374 IMAGE:6971693), complete cds","BC066256.1","AAH66256.1",3558,"Hs.89679","IL-2, TCGF","ENSG00000109471","Interleukin 2","4","122451470-122456725","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB010310","Uncertain",NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"rectum,small intestine,tonsil: 0.3","Not detected",NA,NA
"IL2",155,"B11","IOH61859",462,"0",NA,"interleukin 2, mRNA (cDNA clone MGC:79372 IMAGE:6971690), complete cds","BC066254.1","AAH66254.1",3558,"Hs.89679","IL-2, TCGF","ENSG00000109471","Interleukin 2","4","122451470-122456725","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB010310","Uncertain",NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"rectum,small intestine,tonsil: 0.3","Not detected",NA,NA
"IL20",95,"A6","IOH40238",531,"0",NA,"interleukin 20 (IL20), mRNA.","NM_018724.3","NP_061194.2",50604,"Hs.272373","IL-20, IL10D, ZCYTO10","ENSG00000162891","Interleukin 20","1","206865354-206869223","Predicted secreted proteins","Evidence at protein level","CAB025802","Uncertain",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"smooth muscle: 1.0","seminal vesicle: 0.8","Cell line enhanced",NA,"SiHa: 1.9"
"IL21",95,"G2","IOH40163",489,"0",NA,"interleukin 21 (IL21), mRNA.","NM_021803.2","NP_068575.1",59067,"Hs.567559","IL-21, Za11","ENSG00000138684","Interleukin 21","4","122612628-122621069","Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"lymph node: 18.1;tonsil: 6.3","testis: 4.1","Not detected",NA,NA
"IL22",155,"B12","IOH61828",540,"0",NA,"interleukin 22, mRNA (cDNA clone MGC:79384 IMAGE:6971857), complete cds","BC066265.1","AAH66265.1",50616,"Hs.287369","IL-21, IL-22, IL-D110, IL-TIF, ILTIF, MGC79382, MGC79384, TIFa, TIFIL-23, zcyto18","ENSG00000127318","Interleukin 22","12","68248242-68253607","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"appendix,urinary bladder: 0.8","Not detected",NA,NA
"IL22",99,"B5","IOH40162",540,"0",NA,"interleukin 22 (IL22), mRNA.","NM_020525.4","NP_065386.1",50616,"Hs.287369","IL-21, IL-22, IL-D110, IL-TIF, ILTIF, MGC79382, MGC79384, TIFa, TIFIL-23, zcyto18","ENSG00000127318","Interleukin 22","12","68248242-68253607","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"appendix,urinary bladder: 0.8","Not detected",NA,NA
"IL22RA2",99,"D9","IOH35056",393,"0",NA,"interleukin 22 receptor, alpha 2 (IL22RA2), transcript variant 3, mRNA.","NM_181310.1","NP_851827.1",116379,"Hs.126891","CRF2-S1, IL-22BP","ENSG00000164485","Interleukin 22 receptor subunit alpha 2","6","137143820-137173648","Predicted secreted proteins","Evidence at protein level","HPA030582, CAB034906","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"breast: 4.1;tonsil: 2.9","appendix: 1.9","Cell line enhanced",NA,"U-937: 1.0"
"IL22RA2",103,"D7","IOH35318",696,"0",NA,"interleukin 22 receptor, alpha 2 (IL22RA2), transcript variant 2, mRNA.","NM_181309.1","NP_851826.1",116379,"Hs.126891","CRF2-S1, IL-22BP","ENSG00000164485","Interleukin 22 receptor subunit alpha 2","6","137143820-137173648","Predicted secreted proteins","Evidence at protein level","HPA030582, CAB034906","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"breast: 4.1;tonsil: 2.9","appendix: 1.9","Cell line enhanced",NA,"U-937: 1.0"
"IL23A",77,"D5","IOH39400",570,"0",NA,"interleukin 23, alpha subunit p19 (IL23A), mRNA.","NM_016584.2","NP_057668.1",51561,"Hs.98309","IL-23, IL-23A, IL23P19, P19, SGRF","ENSG00000110944","Interleukin 23 subunit alpha","12","56334174-56340410","FDA approved drug targets, Predicted secreted proteins","Evidence at protein level","HPA001554","Approved",NA,"Approved","Cytosol",NA,"Expressed in all","Tissue enhanced",NA,"tonsil: 8.0","urinary bladder: 6.5","Cell line enhanced",NA,"A-431: 13.0;CAPAN-2: 22.3;U-266/70: 31.8;U-266/84: 14.0"
"IL23A",155,"E12","IOH61835",570,"0",NA,"interleukin 23, alpha subunit p19, mRNA (cDNA clone MGC:79391 IMAGE:6971851), complete cds","BC066269.1","AAH66269.1",51561,"Hs.98309","IL-23, IL-23A, IL23P19, P19, SGRF","ENSG00000110944","Interleukin 23 subunit alpha","12","56334174-56340410","FDA approved drug targets, Predicted secreted proteins","Evidence at protein level","HPA001554","Approved",NA,"Approved","Cytosol",NA,"Expressed in all","Tissue enhanced",NA,"tonsil: 8.0","urinary bladder: 6.5","Cell line enhanced",NA,"A-431: 13.0;CAPAN-2: 22.3;U-266/70: 31.8;U-266/84: 14.0"
"IL25",98,"E5","IOH40292",534,"0",NA,"interleukin 25 (IL25), transcript variant 1, mRNA.","NM_022789.2","NP_073626.1",64806,"Hs.302036","IL-17E, IL-25, IL17E","ENSG00000166090","Interleukin 25","14","23372809-23376403","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB024864","Approved",NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"testis: 0.3","Not detected",NA,NA
"IL25",108,"F9","IOH35138",486,"0",NA,"interleukin 25 (IL25), transcript variant 2, mRNA.","NM_172314.1","NP_758525.1",64806,"Hs.302036","IL-17E, IL-25, IL17E","ENSG00000166090","Interleukin 25","14","23372809-23376403","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB024864","Approved",NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"testis: 0.3","Not detected",NA,NA
"IL26",95,"A3","IOH40165",516,"0",NA,"interleukin 26 (IL26), mRNA.","NM_018402.1","NP_060872.1",55801,"Hs.272350","AK155, IL-26","ENSG00000111536","Interleukin 26","12","68201351-68225821","Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"appendix: 1.2;urinary bladder: 1.4","tonsil: 0.9","Cell line enriched",19,"HDLM-2: 12.4"
"IL27",93,"H6","IOH40746",732,"0",NA,"interleukin 27, mRNA (cDNA clone MGC:71873 IMAGE:4703457), complete cds","BC062422.1","AAH62422.1",246778,"Hs.528111","IL-27, IL-27A, IL27A, IL27p28, IL30, MGC71873, p28","ENSG00000197272","Interleukin 27","16","28499362-28512051","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB024722","Approved",NA,NA,NA,"Liver cancer:1.30e-4 (favourable)","Tissue enriched","Tissue enhanced",NA,"liver: 8.0","appendix: 1.6","Cell line enriched",15,"BEWO: 17.2"
"IL2RB",33,"B5","IOH11459",1656,"NP_000869.1","NP_000869.1","interleukin 2 receptor, beta (IL2RB), mRNA.","NM_000878.2","NP_000869.1",3560,"Hs.474787","CD122, IL15RB","ENSG00000100385","Interleukin 2 receptor subunit beta","22","37125838-37175054","Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA062657","Enhanced",NA,NA,NA,"Renal cancer:3.50e-7 (unfavourable), Endometrial cancer:3.18e-5 (favourable), Colorectal cancer:6.76e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"placenta: 52.7;spleen: 67.1","lymph node: 39.8","Cell line enriched",10,"HDLM-2: 476.9"
"IL3",95,"C6","IOH40240",459,"0",NA,"interleukin 3 (colony-stimulating factor, multiple) (IL3), mRNA.","NM_000588.3","NP_000579.2",3562,"Hs.694","IL-3, MCGF, MGC79398, MGC79399, MULTI-CSF","ENSG00000164399","Interleukin 3","5","132060529-132063204","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"bone marrow,epididymis,parathyroid gland,testis: 0.1","Cell line enriched",15,"HMC-1: 2.2"
"IL31RA",117,"C2","IOH34840",2199,"NP_620586.2","ENSP00000297015","Interleukin-31 receptor A Precursor (IL-31RA)(Cytokine receptor-like 3)(Gp130-like monocyte receptor)(HGLM-R)(GLM-R)(Gp130-like receptor) [Source:UniProtKB/Swiss-Prot;Acc:Q8NI17]","ENST00000297015","ENSP00000297015",133396,"Hs.55378","CRL, CRL3, GLM-R, Glmr, IL-31RA","ENSG00000164509","Interleukin 31 receptor A","5","55851379-55922853","Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA051532, HPA068114","Approved",NA,"Approved","Nucleoplasm<br>Vesicles",NA,"Mixed","Tissue enhanced",NA,"testis: 3.6","bone marrow: 1.2","Cell line enhanced",NA,"hTERT-HME1: 10.7;U-2 OS: 21.6;U-87 MG: 23.4"
"IL34",36,"G8","IOH22712",729,"0",NA,"interleukin 34 (IL34), mRNA.","NM_152456.1","NP_689669.1",146433,"Hs.461214","C16orf77, IL-34, MGC34647","ENSG00000157368","Interleukin 34","16","70579895-70660682","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:3.52e-8 (unfavourable), Cervical cancer:7.41e-4 (favourable), Head and neck cancer:9.69e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"skin: 58.0;spleen: 145.6","cerebral cortex: 20.8","Cell line enhanced",NA,"NTERA-2: 5.5;U-138 MG: 3.5"
"IL3RA",87,"E6","IOH27463",1137,"NP_002174.1","NP_002174.1","interleukin 3 receptor, alpha (low affinity) (IL3RA), mRNA.","NM_002183.2","NP_002174.1",3563,"Hs.632790","CD123","ENSG00000185291","Interleukin 3 receptor subunit alpha","X","1336616-1382689","CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA003539, CAB018374","Approved",NA,NA,NA,"Cervical cancer:4.27e-4 (favourable), Breast cancer:9.78e-4 (favourable)","Expressed in all","Mixed",NA,NA,"lung: 33.2","Cell line enhanced",NA,"HDLM-2: 109.2;RPMI-8226: 33.2"
"IL4",99,"F4","IOH40149",462,"0",NA,"interleukin 4 (IL4), transcript variant 1, mRNA.","NM_000589.2","NP_000580.1",3565,"Hs.73917","BCGF-1, BCGF1, BSF1, IL-4, MGC79402","ENSG00000113520","Interleukin 4","5","132673986-132682676","Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA072995","Approved",NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"parathyroid gland: 1.6","skin: 0.6","Group enriched",6,"HMC-1: 3.4;MOLT-4: 17.0"
"IL4I1",121,"B6","IOH29725",1704,"0",NA,"interleukin 4 induced 1 (IL4I1), transcript variant 1, mRNA.","NM_152899.1","NP_690863.1",259307,"Hs.574492","FIG1","ENSG00000104951","Interleukin 4 induced 1","19","49889654-49929539","Enzymes, Predicted secreted proteins","Evidence at protein level","HPA045598","Enhanced",NA,NA,NA,"Renal cancer:1.23e-10 (unfavourable), Glioma:1.85e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"appendix: 24.5;testis: 32.0","lymph node: 10.5","Cell line enhanced",NA,"EFO-21: 31.1;HDLM-2: 55.9;Karpas-707: 33.8"
"IL4R",133,"A3","IOH46228",684,"0",NA,"interleukin 4 receptor (IL4R), transcript variant 2, mRNA.","NM_001008699.1","NP_001008699.1",3566,"Hs.513457","CD124","ENSG00000077238","Interleukin 4 receptor","16","27313668-27364778","Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB004451, HPA050124","Enhanced",NA,NA,NA,"Renal cancer:1.23e-5 (unfavourable), Endometrial cancer:6.43e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 137.6","Mixed",NA,NA
"IL5",101,"A10","IOH40150",405,"0",NA,"interleukin 5 (colony-stimulating factor, eosinophil) (IL5), mRNA.","NM_000879.2","NP_000870.1",3567,"Hs.2247","EDF, IL-5, TRF","ENSG00000113525","Interleukin 5","5","132541444-132556838","Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB010304","Approved",NA,NA,NA,NA,"Not detected","Tissue enriched",9,"testis: 9.6","small intestine: 1.0","Cell line enhanced",NA,"Hep G2: 1.9;TIME: 1.0"
"IL5RA",33,"B3","IOH11451",1008,"0",NA,"interleukin 5 receptor, alpha, mRNA (cDNA clone MGC:26560 IMAGE:4829051), complete cds","BC027599.2","AAH27599.1",3568,"Hs.68876","CD125, CDw125, IL5R","ENSG00000091181","Interleukin 5 receptor subunit alpha","3","3066326-3126613","CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"fallopian tube: 22.7","lung: 4.9","Cell line enriched",28,"HMC-1: 66.2"
"IL5RA",133,"H11","IOH53929",1008,"0",NA,"interleukin 5 receptor, alpha (IL5RA), transcript variant 3, mRNA.","NM_175725.2","NP_783852.1",3568,"Hs.68876","CD125, CDw125, IL5R","ENSG00000091181","Interleukin 5 receptor subunit alpha","3","3066326-3126613","CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"fallopian tube: 22.7","lung: 4.9","Cell line enriched",28,"HMC-1: 66.2"
"IL6",49,"H6","IOH11642",639,"0",NA,"interleukin 6 (interferon, beta 2) (IL6), mRNA.","NM_000600.3","NP_000591.1",3569,"Hs.654458","BSF2, HGF, HSF, IFNB2, IL-6","ENSG00000136244","Interleukin 6","7","22725884-22732002","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB023406, CAB072821","Supported",NA,"Approved","Vesicles","Renal cancer:1.10e-11 (unfavourable)","Mixed","Tissue enhanced",NA,"adipose tissue: 136.4","urinary bladder: 73.6","Group enriched",7,"BJ hTERT+: 1844.6;hTEC/SVTERT24-B: 429.5"
"IL6R",131,"D11","IOH46499",1407,"NP_000556.1","NP_000556.1","interleukin 6 receptor (IL6R), transcript variant 1, mRNA.","NM_000565.2","NP_000556.1",3570,"Hs.709210","CD126","ENSG00000160712","Interleukin 6 receptor","1","154405193-154469450","Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Pancreatic cancer:1.65e-4 (favourable)","Expressed in all","Mixed",NA,NA,"appendix: 33.4","Cell line enhanced",NA,"THP-1: 147.4;U-266/84: 186.8"
"IL7",71,"E9","IOH26652",534,"0",NA,"interleukin 7 (IL7), mRNA.","NM_000880.2","NP_000871.1",3574,"Hs.591873","IL-7","ENSG00000104432","Interleukin 7","8","78675743-78805523","Cancer-related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA019590","Approved",NA,NA,NA,"Renal cancer:2.69e-4 (unfavourable)","Mixed","Mixed",NA,NA,"skin: 10.2","Cell line enhanced",NA,"HDLM-2: 15.6;HEL: 15.9;HMC-1: 22.1"
"IL7R",155,"H9","IOH61827",1380,"0",NA,"interleukin 7 receptor, mRNA (cDNA clone MGC:79449 IMAGE:6971844), complete cds","BC067539.1","AAH67539.1",3575,"Hs.591742","CD127","ENSG00000168685","Interleukin 7 receptor","5","35852695-35879603","Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB010215","Approved",NA,"Approved","Plasma membrane<br>Microtubule organizing center",NA,"Expressed in all","Tissue enhanced",NA,"appendix: 182.9;lymph node: 158.5","tonsil: 112.9","Cell line enhanced",NA,"fHDF/TERT166: 149.9;HBF TERT88: 165.6;REH: 372.0"
"IL7R",155,"C12","IOH61829",1380,"0",NA,"interleukin 7 receptor, mRNA (cDNA clone MGC:79448 IMAGE:6971843), complete cds","BC069999.1","AAH69999.1",3575,"Hs.591742","CD127","ENSG00000168685","Interleukin 7 receptor","5","35852695-35879603","Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB010215","Approved",NA,"Approved","Plasma membrane<br>Microtubule organizing center",NA,"Expressed in all","Tissue enhanced",NA,"appendix: 182.9;lymph node: 158.5","tonsil: 112.9","Cell line enhanced",NA,"fHDF/TERT166: 149.9;HBF TERT88: 165.6;REH: 372.0"
"IL7R",155,"A10","IOH61830",1380,"0",NA,"interleukin 7 receptor, mRNA (cDNA clone MGC:79447 IMAGE:6971842), complete cds","BC067538.1","AAH67538.1",3575,"Hs.591742","CD127","ENSG00000168685","Interleukin 7 receptor","5","35852695-35879603","Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB010215","Approved",NA,"Approved","Plasma membrane<br>Microtubule organizing center",NA,"Expressed in all","Tissue enhanced",NA,"appendix: 182.9;lymph node: 158.5","tonsil: 112.9","Cell line enhanced",NA,"fHDF/TERT166: 149.9;HBF TERT88: 165.6;REH: 372.0"
"IL9",155,"B10","IOH61832",435,"0",NA,"interleukin 9, mRNA (cDNA clone MGC:79415 IMAGE:6971721), complete cds","BC066287.1","AAH66287.1",3578,"Hs.960","HP40, IL-9, P40","ENSG00000145839","Interleukin 9","5","135892246-135895827","Cancer-related genes, Predicted secreted proteins","Evidence at transcript level",NA,NA,NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"cerebral cortex: 1.7","skin: 0.5","Cell line enriched",235,"HDLM-2: 41.4"
"IL9",155,"D12","IOH61831",435,"0",NA,"interleukin 9, mRNA (cDNA clone MGC:79412 IMAGE:6971718), complete cds","BC066284.1","AAH66284.1",3578,"Hs.960","HP40, IL-9, P40","ENSG00000145839","Interleukin 9","5","135892246-135895827","Cancer-related genes, Predicted secreted proteins","Evidence at transcript level",NA,NA,NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"cerebral cortex: 1.7","skin: 0.5","Cell line enriched",235,"HDLM-2: 41.4"
"IL9",95,"E2","IOH40159",435,"0",NA,"interleukin 9 (IL9), mRNA.","NM_000590.1","NP_000581.1",3578,"Hs.960","HP40, IL-9, P40","ENSG00000145839","Interleukin 9","5","135892246-135895827","Cancer-related genes, Predicted secreted proteins","Evidence at transcript level",NA,NA,NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"cerebral cortex: 1.7","skin: 0.5","Cell line enriched",235,"HDLM-2: 41.4"
"ILDR1",75,"E9","IOH26372",1509,"NP_787120.1","NP_787120.1","immunoglobulin-like domain containing receptor 1 (ILDR1), mRNA.","NM_175924.2","NP_787120.1",286676,"Hs.98484","DFNB42, MGC50831","ENSG00000145103","Immunoglobulin like domain containing receptor 1","3","121987323-122022204","Disease related genes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA018207","Approved",NA,NA,NA,"Renal cancer:5.79e-9 (favourable)","Mixed","Tissue enhanced",NA,"parathyroid gland: 35.1","cervix, uterine: 20.0","Cell line enhanced",NA,"CAPAN-2: 6.5;HDLM-2: 10.3;MCF7: 5.7;RT4: 7.7;T-47d: 6.4;U-266/70: 5.6"
"IMP4",44,"G3","IOH12991",876,"0",NA,"IMP4, U3 small nucleolar ribonucleoprotein, homolog (yeast) (IMP4), mRNA.","NM_033416.1","NP_219484.1",92856,"Hs.91579","BXDC4, MGC19606","ENSG00000136718","IMP4 homolog, U3 small nucleolar ribonucleoprotein","2","130342225-130347810","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA066222, HPA066673",NA,NA,"Enhanced","Nucleoli","Liver cancer:4.72e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"lymph node: 22.7","Expressed in all",NA,NA
"INHBA",135,"F10","IOH56970",1281,"0",NA,"inhibin, beta A (INHBA), mRNA.","NM_002192.2","NP_002183.1",3624,"Hs.583348",NA,"ENSG00000122641","Inhibin beta A subunit","7","41667168-41705834","Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:7.91e-8 (unfavourable), Cervical cancer:1.46e-5 (unfavourable), Head and neck cancer:4.34e-4 (unfavourable), Lung cancer:7.72e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"endometrium: 28.7;gallbladder: 35.1","lung: 16.4","Group enriched",6,"HBEC3-KT: 54.3;hTEC/SVTERT24-B: 227.2;hTERT-HME1: 71.4;TIME: 97.6;U-138 MG: 172.4;U-2 OS: 52.9"
"INHBB",79,"A9","IOH22450",1224,"0",NA,"inhibin, beta B, mRNA (cDNA clone MGC:33716 IMAGE:5258851), complete cds","BC030029.2","AAH30029.1",3625,"Hs.1735",NA,"ENSG00000163083","Inhibin beta B subunit","2","120346143-120351808","Cancer-related genes, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Thyroid cancer:1.02e-4 (favourable), Colorectal cancer:1.44e-4 (unfavourable), Renal cancer:3.02e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"testis: 27.1","adipose tissue: 24.9","Cell line enhanced",NA,"A549: 42.9;ASC diff: 43.3;MCF7: 44.4;PC-3: 85.1;SK-BR-3: 122.2"
"INHBE",24,"G7","IOH5162",1053,"0",NA,"inhibin, beta E (INHBE), mRNA.","NM_031479.3","NP_113667.1",83729,"Hs.632713","activin, MGC4638","ENSG00000139269","Inhibin beta E subunit","12","57452323-57459280","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA016843, CAB034017","Enhanced",NA,"Approved","Vesicles","Renal cancer:5.66e-8 (unfavourable)","Tissue enriched","Tissue enriched",28,"liver: 68.1","thyroid gland: 2.4","Cell line enhanced",NA,"HHSteC: 43.4;Karpas-707: 57.3;U-266/70: 203.5"
"INS",77,"C4","IOH7334",333,"0",NA,"insulin (INS), mRNA.","NM_000207.2","NP_000198.1",3630,"Hs.272259","IDDM1, IDDM2","ENSG00000254647","Insulin","11","2159779-2161341","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","CAB000048, HPA004932, CAB012098, CAB053843","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",27,"pancreas: 1850.7","skin: 68.2","Group enriched",10,"EFO-21: 194.7;U-2 OS: 281.2;U-698: 61.2"
"INSL4",48,"H1","IOH12347",420,"0",NA,"insulin-like 4 (placenta) (INSL4), mRNA.","NM_002195.1","NP_002186.1",3641,"Hs.418506","EPIL","ENSG00000120211","Insulin like 4","9","5231419-5235304","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",12,"placenta: 22.2","epididymis: 1.8","Cell line enriched",10,"A549: 22.2"
"IPO11",84,"F4","IOH21768",2928,"0",NA,"importin 11 (IPO11), transcript variant 2, mRNA.","NM_016338.4","NP_057422.3",51194,"Hs.482269","RanBP11","ENSG00000086200","Importin 11","5","62403972-62628582","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA067097","Approved",NA,"Enhanced","Nucleus<br>Nucleoli fibrillar center","Liver cancer:4.28e-5 (unfavourable), Colorectal cancer:1.70e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 40.6","Expressed in all",NA,NA
"IRAK3",74,"E3","IOH29139",1791,"0",NA,"interleukin-1 receptor-associated kinase 3, mRNA (cDNA clone MGC:97088 IMAGE:7262303), complete cds","BC069388.1","AAH69388.1",11213,"Hs.369265","IRAK-M","ENSG00000090376","Interleukin 1 receptor associated kinase 3","12","66188879-66254622","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA043097","Approved",NA,"Approved","Vesicles","Renal cancer:6.23e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"bone marrow: 51.0","adipose tissue: 19.3","Cell line enhanced",NA,"HEL: 20.3;HL-60: 24.1;THP-1: 24.3;U-937: 20.5"
"ISM2",130,"F10","IOH52040",1452,"0",NA,"Isthmin-2 Precursor (Thrombospondin and AMOP domain-containing isthmin-like protein 1)(Thrombospondin type-1 domain-containing protein 3) [Source:UniProtKB/Swiss-Prot;Acc:Q6H9L7]","ENST00000393684","ENSP00000377289",145501,"Hs.29742","FLJ32147, TAIL1, THSD3","ENSG00000100593","Isthmin 2","14","77474394-77498850","Predicted secreted proteins","Evidence at protein level","HPA039314, HPA039742","Supported",NA,"Supported","Nucleoplasm",NA,"Mixed","Tissue enriched",112,"placenta: 274.5","epididymis: 2.4","Cell line enriched",21,"BEWO: 345.7"
"ISM2",152,"E1","IOH63518",1716,"0",NA,"isthmin 2 homolog (zebrafish), mRNA (cDNA clone MGC:119414 IMAGE:40007143), complete cds","BC101019.1","AAI01020.1",145501,"Hs.29742","FLJ32147, TAIL1, THSD3","ENSG00000100593","Isthmin 2","14","77474394-77498850","Predicted secreted proteins","Evidence at protein level","HPA039314, HPA039742","Supported",NA,"Supported","Nucleoplasm",NA,"Mixed","Tissue enriched",112,"placenta: 274.5","epididymis: 2.4","Cell line enriched",21,"BEWO: 345.7"
"ITGB1",84,"F3","IOH21479",2397,"NP_002202.2","NP_002202.2","integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) (ITGB1), transcript variant 1A, mRNA.","NM_002211.3","NP_002202.2",3688,"Hs.643813","CD29, FNRB, GPIIA, MDF2, MSK12","ENSG00000150093","Integrin subunit beta 1","10","32900319-33005792","Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","CAB003434, HPA059297, HPA069003","Enhanced",NA,"Supported","Endoplasmic reticulum<br>Plasma membrane<br>Focal adhesion sites","Lung cancer:3.36e-6 (unfavourable), Cervical cancer:5.01e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"smooth muscle: 1069.5","Expressed in all",NA,NA
"ITGB1",131,"H2","IOH46726",2406,"0",NA,"integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) (ITGB1), transcript variant 1D, mRNA.","NM_033668.2","NP_391988.1",3688,"Hs.643813","CD29, FNRB, GPIIA, MDF2, MSK12","ENSG00000150093","Integrin subunit beta 1","10","32900319-33005792","Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","CAB003434, HPA059297, HPA069003","Enhanced",NA,"Supported","Endoplasmic reticulum<br>Plasma membrane<br>Focal adhesion sites","Lung cancer:3.36e-6 (unfavourable), Cervical cancer:5.01e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"smooth muscle: 1069.5","Expressed in all",NA,NA
"ITGB1",83,"H3","IOH36761",2370,"0",NA,"integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) (ITGB1), transcript variant 1B, mRNA.","NM_033666.2","NP_389647.1",3688,"Hs.643813","CD29, FNRB, GPIIA, MDF2, MSK12","ENSG00000150093","Integrin subunit beta 1","10","32900319-33005792","Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","CAB003434, HPA059297, HPA069003","Enhanced",NA,"Supported","Endoplasmic reticulum<br>Plasma membrane<br>Focal adhesion sites","Lung cancer:3.36e-6 (unfavourable), Cervical cancer:5.01e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"smooth muscle: 1069.5","Expressed in all",NA,NA
"ITGB2",83,"E6","IOH6210",2310,"NP_000202.1","AAH05861.1","integrin, beta 2 (complement component 3 receptor 3 and 4 subunit), mRNA (cDNA clone MGC:3628 IMAGE:3532902), complete cds","BC005861.2","AAH05861.1",3689,"Hs.375957","CD18, LFA-1, MAC-1, MFI7","ENSG00000160255","Integrin subunit beta 2","21","44885953-44931989","CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA008877, HPA016894","Enhanced",NA,"Approved","Plasma membrane",NA,"Expressed in all","Expressed in all",NA,NA,"appendix: 239.2","Cell line enhanced",NA,"EFO-21: 120.5;THP-1: 518.6;U-937: 447.2"
"ITGB7",85,"G1","IOH12535",2397,"NP_000880.1","NP_000880.1","integrin, beta 7 (ITGB7), mRNA.","NM_000889.1","NP_000880.1",3695,"Hs.654470",NA,"ENSG00000139626","Integrin subunit beta 7","12","53191318-53207307","Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA042277",NA,NA,"Approved","Plasma membrane<br>Cytosol",NA,"Mixed","Mixed",NA,NA,"spleen: 32.5","Group enriched",97,"Karpas-707: 3399.5;RPMI-8226: 2658.1"
"ITLN1",7,"C6","IOH12875",942,"0",NA,"intelectin 1 (galactofuranose binding) (ITLN1), mRNA.","NM_017625.2","NP_060095.2",55600,"Hs.50813","FLJ20022, hIntL, HL-1, ITLN, LFR","ENSG00000179914","Intelectin 1","1","160876539-160885170","Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB012652, HPA063275, HPA067326","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"colon: 447.7;rectum: 1428.1;small intestine: 468.9","duodenum: 276.3","Cell line enhanced",NA,"HEL: 2.3;HL-60: 1.5;U-937: 5.7"
"JAM3",147,"C5","IOH62958",933,"0",NA,"junctional adhesion molecule 3, mRNA (cDNA clone MGC:20361 IMAGE:4552285), complete cds","BC012147.1","AAH12147.1",83700,"Hs.150718","JAM-C, JAMC","ENSG00000166086","Junctional adhesion molecule 3","11","134068925-134152001","Disease related genes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA003417, HPA050434","Uncertain",NA,"Enhanced","Golgi apparatus","Urothelial cancer:2.68e-4 (unfavourable), Renal cancer:3.73e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 144.4","Cell line enhanced",NA,"RH-30: 119.8"
"KCNIP2",77,"E5","IOH39571",678,"0",NA,"Kv channel interacting protein 2 (KCNIP2), transcript variant 5, mRNA.","NM_173194.2","NP_775286.1",30819,"Hs.97044","KCHIP2","ENSG00000120049","Potassium voltage-gated channel interacting protein 2","10","101825974-101843920","Predicted intracellular proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Mixed","Group enriched",9,"adipose tissue: 238.6;cerebral cortex: 81.4;heart muscle: 108.2","breast: 16.6","Cell line enhanced",NA,"HEL: 13.8;HMC-1: 9.2"
"KCNIP2",32,"D4","IOH21409",759,"0",NA,"Kv channel interacting protein 2 (KCNIP2), transcript variant 3, mRNA.","NM_173192.2","NP_775284.1",30819,"Hs.97044","KCHIP2","ENSG00000120049","Potassium voltage-gated channel interacting protein 2","10","101825974-101843920","Predicted intracellular proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Mixed","Group enriched",9,"adipose tissue: 238.6;cerebral cortex: 81.4;heart muscle: 108.2","breast: 16.6","Cell line enhanced",NA,"HEL: 13.8;HMC-1: 9.2"
"KCNIP2",71,"A3","IOH29635",663,"0",NA,"Kv channel interacting protein 2 (KCNIP2), transcript variant 6, mRNA.","NM_173195.2","NP_775287.1",30819,"Hs.97044","KCHIP2","ENSG00000120049","Potassium voltage-gated channel interacting protein 2","10","101825974-101843920","Predicted intracellular proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Mixed","Group enriched",9,"adipose tissue: 238.6;cerebral cortex: 81.4;heart muscle: 108.2","breast: 16.6","Cell line enhanced",NA,"HEL: 13.8;HMC-1: 9.2"
"KCNIP2",77,"G5","IOH39568",813,"0",NA,"Kv channel interacting protein 2 (KCNIP2), transcript variant 2, mRNA.","NM_173191.2","NP_775283.1",30819,"Hs.97044","KCHIP2","ENSG00000120049","Potassium voltage-gated channel interacting protein 2","10","101825974-101843920","Predicted intracellular proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Mixed","Group enriched",9,"adipose tissue: 238.6;cerebral cortex: 81.4;heart muscle: 108.2","breast: 16.6","Cell line enhanced",NA,"HEL: 13.8;HMC-1: 9.2"
"KCNIP3",3,"F11","IOH9633",771,"0",NA,"Kv channel interacting protein 3, calsenilin (KCNIP3), transcript variant 1, mRNA.","NM_013434.4","NP_038462.1",30818,"Hs.437376","CSEN, DREAM, KCHIP3","ENSG00000115041","Potassium voltage-gated channel interacting protein 3","2","95297304-95386083","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA069797","Approved",NA,NA,NA,"Endometrial cancer:1.58e-5 (unfavourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 40.6;parathyroid gland: 44.0","thyroid gland: 28.0","Cell line enhanced",NA,"BJ hTERT+: 14.6;RPTEC TERT1: 26.5;U-138 MG: 16.1"
"KCNK7",103,"G8","IOH35365",759,"NP_005705.1","NP_203134.1","potassium channel, subfamily K, member 7 (KCNK7), transcript variant B, mRNA.","NM_033348.1","NP_203134.1",10089,"Hs.175218","K2p7.1","ENSG00000173338","Potassium two pore domain channel subfamily K member 7","11","65592855-65595996","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Voltage-gated ion channels","Evidence at transcript level","HPA077577",NA,NA,"Approved","Plasma membrane",NA,"Tissue enhanced","Tissue enriched",7,"skin: 53.2","esophagus: 7.9","Cell line enhanced",NA,"SCLC-21H: 8.4"
"KCNK7",152,"D12","IOH63365",759,"0",NA,"potassium channel, subfamily K, member 7, mRNA (cDNA clone MGC:118784 IMAGE:40000339), complete cds","BC103810.2","AAI03811.1",10089,"Hs.175218","K2p7.1","ENSG00000173338","Potassium two pore domain channel subfamily K member 7","11","65592855-65595996","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Voltage-gated ion channels","Evidence at transcript level","HPA077577",NA,NA,"Approved","Plasma membrane",NA,"Tissue enhanced","Tissue enriched",7,"skin: 53.2","esophagus: 7.9","Cell line enhanced",NA,"SCLC-21H: 8.4"
"KDELC1",35,"G6","IOH3113",1509,"0",NA,"KDEL (Lys-Asp-Glu-Leu) containing 1, mRNA (cDNA clone MGC:5302 IMAGE:3456869), complete cds","BC001297.1","AAH01297.1",79070,"Hs.408629","EP58, MGC5302","ENSG00000134901","KDEL motif containing 1","13","102784281-102799007","Predicted secreted proteins","Evidence at protein level","CAB020780, HPA043946, HPA064398","Approved",NA,"Supported","Nucleus","Head and neck cancer:2.24e-4 (unfavourable), Renal cancer:4.73e-4 (unfavourable), Lung cancer:4.81e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"smooth muscle: 17.7","Mixed",NA,NA
"KDM3B",25,"E6","IOH4491",2280,"0",NA,"jumonji domain containing 1B, mRNA (cDNA clone IMAGE:3356650), complete cds.","BC001202.1","AAH01202.1",51780,"Hs.714832","C5orf7, JMJD1B, KIAA1082, NET22","ENSG00000120733","Lysine demethylase 3B","5","138352596-138437028","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA016610, HPA057202","Supported",NA,"Enhanced","Nucleoplasm","Renal cancer:6.67e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 67.3","Expressed in all",NA,NA
"KDSR",28,"H3","IOH6216",999,"0",NA,"3-ketodihydrosphingosine reductase (KDSR), mRNA.","NM_002035.2","NP_002026.1",2531,"Hs.74050","DHSR, FVT1, SDR35C1","ENSG00000119537","3-ketodihydrosphingosine reductase","18","63327726-63367510","Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB003673, HPA044884","Approved",NA,NA,NA,"Renal cancer:9.53e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 45.5","Expressed in all",NA,NA
"KIFC2",123,"B11","IOH9932",681,"0",NA,"kinesin family member C2, mRNA (cDNA clone IMAGE:3900099), complete cds.","BC015171.2","AAH15171.1",90990,"Hs.528713",NA,"ENSG00000167702","Kinesin family member C2","8","144466043-144474202","Predicted secreted proteins","Evidence at protein level","HPA029264","Approved",NA,"Supported","Nucleoplasm<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"skin: 73.1","Mixed",NA,NA
"KIR2DL4",100,"D6","IOH28039",1134,"NP_002246.2","AAH41611.1","killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4, mRNA (cDNA clone MGC:52132 IMAGE:5485491), complete cds","BC041611.1","AAH41611.1",3805,"Hs.651287","103AS, 15.212, CD158D","ENSG00000189013","Killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 4","19","54803535-54814517","CD markers, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Mixed","Not detected",NA,NA,"all non-specific tissues: 0.0","Not detected",NA,NA
"KIRREL2",44,"H8","IOH6926",660,"0",NA,"kin of IRRE like 2 (Drosophila), mRNA (cDNA clone IMAGE:3353436), complete cds.","BC007312.1","AAH07312.1",84063,"Hs.145729","DKFZp564A1164, FILTRIN, MGC15718, NEPH3, NLG1","ENSG00000126259","Kin of IRRE like 2 (Drosophila)","19","35855861-35867109","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA071587, HPA074326",NA,NA,"Supported","Microtubule organizing center",NA,"Mixed","Tissue enriched",8,"pancreas: 11.6","cerebral cortex: 1.4","Cell line enhanced",NA,"HDLM-2: 20.2;HMC-1: 29.3"
"KISS1",86,"H12","IOH23212",417,"0",NA,"KiSS-1 metastasis-suppressor (KISS1), mRNA.","NM_002256.3","NP_002247.3",3814,"Hs.95008",NA,"ENSG00000170498","KiSS-1 metastasis-suppressor","1","204190341-204196486","Cancer-related genes, Disease related genes, Predicted secreted proteins","Evidence at protein level","CAB017775, HPA035542","Enhanced",NA,"Approved","Vesicles","Urothelial cancer:6.29e-6 (favourable)","Tissue enhanced","Tissue enriched",87,"placenta: 328.1","stomach: 3.7","Group enriched",21,"BJ: 123.9;U-2 OS: 60.5"
"KLHL22",34,"G11","IOH12694",1905,"0",NA,"kelch-like 22 (Drosophila) (KLHL22), mRNA.","NM_032775.2","NP_116164.2",84861,"Hs.517419","FLJ14360, KELCHL","ENSG00000099910","Kelch like family member 22","22","20441519-20495883","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA040766",NA,NA,"Supported","Golgi apparatus<br>Cytokinetic bridge<br>Mitotic spindle","Renal cancer:1.34e-8 (favourable), Pancreatic cancer:3.85e-6 (favourable), Endometrial cancer:4.88e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 35.6","Mixed",NA,NA
"KLK1",20,"A9","IOH7368",789,"0",NA,"kallikrein 1, mRNA (cDNA clone MGC:12389 IMAGE:3949873), complete cds","BC005313.1","AAH05313.1",3816,"Hs.123107","Klk6","ENSG00000167748","Kallikrein 1","19","50819148-50823787","Enzymes, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Group enriched","Group enriched",36,"pancreas: 1994.7;salivary gland: 2549.9","colon: 63.5","Cell line enriched",18,"RPMI-8226: 26.9"
"KLK1",133,"D12","IOH53877",789,"0",NA,"kallikrein 1 (KLK1), mRNA.","NM_002257.2","NP_002248.1",3816,"Hs.123107","Klk6","ENSG00000167748","Kallikrein 1","19","50819148-50823787","Enzymes, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Group enriched","Group enriched",36,"pancreas: 1994.7;salivary gland: 2549.9","colon: 63.5","Cell line enriched",18,"RPMI-8226: 26.9"
"KLK10",88,"B5","IOH5377",831,"0",NA,"kallikrein-related peptidase 10, mRNA (cDNA clone MGC:3667 IMAGE:3632557), complete cds","BC002710.2","AAH02710.1",5655,"Hs.275464","NES1, PRSSL1","ENSG00000129451","Kallikrein related peptidase 10","19","51012739-51020175","Cancer-related genes, Enzymes, Predicted secreted proteins","Evidence at protein level","HPA017195",NA,NA,"Uncertain","Plasma membrane<br>Cytosol","Pancreatic cancer:6.46e-5 (unfavourable), Breast cancer:8.32e-4 (favourable)","Mixed","Tissue enhanced",NA,"esophagus: 138.2;skin: 52.7","tonsil: 45.8","Group enriched",5,"CAPAN-2: 200.9;HaCaT: 307.2"
"KLK11",17,"E4","IOH11649",753,"0",NA,"kallikrein-related peptidase 11 (KLK11), transcript variant 1, mRNA.","NM_006853.2","NP_006844.1",11012,"Hs.57771","PRSS20, TLSP","ENSG00000167757","Kallikrein related peptidase 11","19","51022216-51028039","Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB026340","Approved",NA,NA,NA,"Endometrial cancer:3.78e-4 (favourable), Pancreatic cancer:4.17e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"esophagus: 225.7;skin: 214.5","prostate: 104.9","Cell line enhanced",NA,"CAPAN-2: 5.6;EFO-21: 12.3;HaCaT: 36.6"
"KLK11",104,"D11","IOH43587",849,"0",NA,"kallikrein-related peptidase 11 (KLK11), transcript variant 2, mRNA.","NM_144947.1","NP_659196.1",11012,"Hs.57771","PRSS20, TLSP","ENSG00000167757","Kallikrein related peptidase 11","19","51022216-51028039","Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB026340","Approved",NA,NA,NA,"Endometrial cancer:3.78e-4 (favourable), Pancreatic cancer:4.17e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"esophagus: 225.7;skin: 214.5","prostate: 104.9","Cell line enhanced",NA,"CAPAN-2: 5.6;EFO-21: 12.3;HaCaT: 36.6"
"KLK12",138,"A4","IOH58624",336,"0",NA,"kallikrein-related peptidase 12 (KLK12), transcript variant 3, mRNA.","NM_145895.1","NP_665902.1",43849,"Hs.411572","KLK-L5","ENSG00000186474","Kallikrein related peptidase 12","19","51029092-51035230","Enzymes, Predicted secreted proteins","Evidence at protein level","CAB025473","Uncertain",NA,NA,NA,"Thyroid cancer:8.01e-4 (favourable)","Tissue enhanced","Tissue enhanced",NA,"esophagus: 32.4","tonsil: 8.1","Not detected",NA,NA
"KLK13",95,"E7","IOH40279",834,"0",NA,"kallikrein-related peptidase 13 (KLK13), mRNA.","NM_015596.1","NP_056411.1",26085,"Hs.165296","KLK-L4","ENSG00000167759","Kallikrein related peptidase 13","19","51056206-51065114","Cancer-related genes, Enzymes, Predicted secreted proteins","Evidence at protein level","HPA062136","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",9,"esophagus: 402.2","tonsil: 45.0","Cell line enriched",10,"HaCaT: 16.8"
"KLK15",156,"A1","IOH61867",768,"0",NA,"kallikrein-related peptidase 15, mRNA (cDNA clone MGC:96981 IMAGE:7262190), complete cds","BC069480.1","AAH69480.1",55554,"Hs.567535","ACO, HSRNASPH, prostinogen","ENSG00000174562","Kallikrein related peptidase 15","19","50825289-50837213","Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA019802","Uncertain",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"colon: 3.2;salivary gland: 2.4","adrenal gland: 1.8","Cell line enriched",5,"RPMI-8226: 1.7"
"KLK2",133,"C1","IOH46224",672,"0",NA,"kallikrein-related peptidase 2 (KLK2), transcript variant 2, mRNA.","NM_001002231.1","NP_001002231.1",3817,"Hs.515560",NA,"ENSG00000167751","Kallikrein related peptidase 2","19","50861568-50880567","Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA000764","Supported",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",192,"prostate: 867.2","testis: 4.5","Cell line enhanced",NA,"NB-4: 3.6"
"KLK3",22,"D5","IOH7153",786,"0",NA,"kallikrein-related peptidase 3 (KLK3), transcript variant 1, mRNA.","NM_001648.2","NP_001639.1",354,"Hs.171995","APS, PSA","ENSG00000142515","Kallikrein related peptidase 3","19","50854915-50860764","Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB000070, HPA000764","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",365,"prostate: 12913.0","seminal vesicle: 35.3","Group enriched",165,"BEWO: 30.5;NB-4: 17.7;RPMI-8226: 12.8;SH-SY5Y: 11.1;U-2197: 10.1"
"KLK4",126,"E3","IOH40236",765,"0",NA,"kallikrein-related peptidase 4, mRNA (cDNA clone MGC:96926 IMAGE:7262135), complete cds","BC069429.1","AAH69429.1",9622,"Hs.218366","EMSP, EMSP1, KLK-L1, PRSS17, PSTS","ENSG00000167749","Kallikrein related peptidase 4","19","50906352-50910738","Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA051839","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",37,"prostate: 406.5","skin: 10.8","Cell line enhanced",NA,"CAPAN-2: 5.7;HaCaT: 7.0"
"KLK5",22,"F10","IOH5874",882,"0",NA,"kallikrein-related peptidase 5 (KLK5), transcript variant 1, mRNA.","NM_012427.4","NP_036559.1",25818,"Hs.50915","KLK-L2, SCTE","ENSG00000167754","Kallikrein related peptidase 5","19","50943303-50953093","Cancer-related genes, Enzymes, Predicted secreted proteins","Evidence at protein level","HPA014343, CAB025503, CAB026341","Enhanced",NA,NA,NA,"Urothelial cancer:3.85e-6 (unfavourable), Endometrial cancer:2.33e-4 (unfavourable), Lung cancer:9.79e-4 (unfavourable)","Tissue enhanced","Tissue enriched",6,"skin: 213.5","breast: 37.8","Group enriched",41,"A-431: 414.4;HaCaT: 396.7"
"KLK6",12,"G1","IOH10423",735,"0",NA,"kallikrein-related peptidase 6 (KLK6), transcript variant A, mRNA.","NM_002774.3","NP_002765.1",5653,"Hs.79361","Bssp, Klk7, neurosin, PRSS18, PRSS9","ENSG00000167755","Kallikrein related peptidase 6","19","50958631-50969673","Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA051837",NA,NA,"Supported","Nucleoplasm<br>Nuclear membrane<br>Cytokinetic bridge","Endometrial cancer:1.38e-5 (unfavourable), Urothelial cancer:1.27e-4 (unfavourable), Pancreatic cancer:7.82e-4 (unfavourable), Lung cancer:8.85e-4 (unfavourable)","Tissue enhanced","Group enriched",5,"cerebral cortex: 78.6;esophagus: 63.0;fallopian tube: 44.9;tonsil: 31.3","kidney: 10.2","Group enriched",15,"A-431: 496.5;CAPAN-2: 1158.9"
"KLK6",139,"G9","IOH58966",414,"0",NA,"kallikrein-related peptidase 6 (KLK6), transcript variant C, mRNA.","NM_001012965.1","NP_001012983.1",5653,"Hs.79361","Bssp, Klk7, neurosin, PRSS18, PRSS9","ENSG00000167755","Kallikrein related peptidase 6","19","50958631-50969673","Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA051837",NA,NA,"Supported","Nucleoplasm<br>Nuclear membrane<br>Cytokinetic bridge","Endometrial cancer:1.38e-5 (unfavourable), Urothelial cancer:1.27e-4 (unfavourable), Pancreatic cancer:7.82e-4 (unfavourable), Lung cancer:8.85e-4 (unfavourable)","Tissue enhanced","Group enriched",5,"cerebral cortex: 78.6;esophagus: 63.0;fallopian tube: 44.9;tonsil: 31.3","kidney: 10.2","Group enriched",15,"A-431: 496.5;CAPAN-2: 1158.9"
"KLK7",41,"H9","IOH22164",762,"0",NA,"kallikrein-related peptidase 7 (KLK7), transcript variant 1, mRNA.","NM_005046.2","NP_005037.1",5650,"Hs.151254","PRSS6, SCCE","ENSG00000169035","Kallikrein related peptidase 7","19","50976482-50984099","Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA018994, CAB026342, HPA062126","Enhanced",NA,"Supported","Nuclear membrane<br>Plasma membrane","Endometrial cancer:8.06e-5 (unfavourable), Pancreatic cancer:1.16e-4 (unfavourable)","Tissue enhanced","Group enriched",5,"esophagus: 68.7;skin: 219.6","fallopian tube: 27.9","Group enriched",6,"CAPAN-2: 7.1;HaCaT: 28.1"
"KLK8",141,"B4","IOH59050",783,"0",NA,"kallikrein-related peptidase 8 (KLK8), transcript variant 1, mRNA.","NM_007196.2","NP_009127.1",11202,"Hs.104570","HNP, neuropsin, ovasin, PRSS19, TADG14","ENSG00000129455","Kallikrein related peptidase 8","19","50996007-51002711","Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB019393, HPA035761","Enhanced",NA,"Approved","Vesicles","Pancreatic cancer:1.10e-4 (unfavourable), Endometrial cancer:2.31e-4 (unfavourable), Lung cancer:5.72e-4 (unfavourable), Urothelial cancer:6.17e-4 (unfavourable)","Tissue enhanced","Group enriched",6,"esophagus: 77.9;fallopian tube: 20.9;skin: 96.8","breast: 11.0","Group enriched",7,"A-431: 76.9;CAPAN-2: 98.5;HaCaT: 73.3"
"KLK9",103,"D8","IOH35357",753,"0",NA,"kallikrein-related peptidase 9 (KLK9), mRNA.","NM_012315.1","NP_036447.1",284366,"Hs.104570","KLK-L3","ENSG00000213022","Kallikrein related peptidase 9","19","51003111-51009634","Cancer-related genes, Enzymes, Predicted secreted proteins","Evidence at transcript level","CAB025049","Uncertain",NA,NA,NA,NA,"Tissue enriched","Not detected",NA,NA,"skin,tonsil: 0.8","Not detected",NA,NA
"KNG1",66,"B3","IOH29435",1284,"0",NA,"kininogen 1, mRNA (cDNA clone MGC:61989 IMAGE:4593077), complete cds","BC060039.1","AAH60039.1",3827,"Hs.77741","BDK, BK, KNG","ENSG00000113889","Kininogen 1","3","186717276-186743954","Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA001616, HPA001645, CAB009809","Enhanced",NA,NA,NA,"Liver cancer:1.28e-6 (favourable)","Tissue enriched","Group enriched",994,"kidney: 522.4;liver: 1864.6","rectum: 1.2","Cell line enhanced",NA,"CACO-2: 1.5;Hep G2: 1.2;RH-30: 1.3"
"KNG1",134,"D4","IOH53988",1284,"0",NA,"kininogen 1 (KNG1), transcript variant 2, mRNA.","NM_000893.2","NP_000884.1",3827,"Hs.77741","BDK, BK, KNG","ENSG00000113889","Kininogen 1","3","186717276-186743954","Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA001616, HPA001645, CAB009809","Enhanced",NA,NA,NA,"Liver cancer:1.28e-6 (favourable)","Tissue enriched","Group enriched",994,"kidney: 522.4;liver: 1864.6","rectum: 1.2","Cell line enhanced",NA,"CACO-2: 1.5;Hep G2: 1.2;RH-30: 1.3"
"KREMEN2",86,"B9","IOH22968",1200,"NP_663322.1","AAH09383.1","kringle containing transmembrane protein 2, mRNA (cDNA clone MGC:16709 IMAGE:4127918), complete cds","BC009383.2","AAH09383.1",79412,"Hs.661128","KRM2, MGC10791","ENSG00000131650","Kringle containing transmembrane protein 2","16","2963944-2968383","Predicted membrane proteins, Predicted secreted proteins","Evidence at transcript level","HPA003223","Uncertain",NA,"Approved","Nucleoli","Lung cancer:8.98e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"skin: 6.9","cerebral cortex: 2.1","Cell line enhanced",NA,"HMC-1: 24.6;RPMI-8226: 19.1"
"KREMEN2",127,"B3","IOH5462",1263,"0","NP_078783.1","kringle containing transmembrane protein 2 (KREMEN2), transcript variant 2, mRNA.","NM_024507.2","NP_078783.1",79412,"Hs.661128","KRM2, MGC10791","ENSG00000131650","Kringle containing transmembrane protein 2","16","2963944-2968383","Predicted membrane proteins, Predicted secreted proteins","Evidence at transcript level","HPA003223","Uncertain",NA,"Approved","Nucleoli","Lung cancer:8.98e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"skin: 6.9","cerebral cortex: 2.1","Cell line enhanced",NA,"HMC-1: 24.6;RPMI-8226: 19.1"
"KRTDAP",138,"G7","IOH58581",300,"0",NA,"keratinocyte differentiation-associated protein (KRTDAP), mRNA.","NM_207392.1","NP_997275.1",388533,"Hs.112457","KDAP, UNQ467","ENSG00000188508","Keratinocyte differentiation associated protein","19","35487324-35495558","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA063474","Enhanced",NA,NA,NA,NA,"Group enriched","Tissue enriched",11,"skin: 4647.8","breast: 422.9","Cell line enriched",47,"hTCEpi: 55.8"
"LACRT",97,"G11","IOH40715",417,"0",NA,"lacritin (LACRT), mRNA.","NM_033277.1","NP_150593.1",90070,"Hs.307096","LACRITIN","ENSG00000135413","Lacritin","12","54630811-54634895","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enriched","Tissue enriched",6,"salivary gland: 4.6","breast: 0.7","Not detected",NA,NA
"LAG3",117,"A11","IOH29387",1083,"NP_002277.3","AAH52589.1","lymphocyte-activation gene 3, mRNA (cDNA clone MGC:59698 IMAGE:6301931), complete cds","BC052589.1","AAH52589.1",3902,"Hs.409523","CD223","ENSG00000089692","Lymphocyte activating 3","12","6772512-6778455","CD markers, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB002301, HPA013967","Enhanced",NA,NA,NA,"Renal cancer:4.62e-11 (unfavourable), Cervical cancer:3.89e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"spleen: 32.0","lymph node: 17.6","Cell line enriched",140,"HDLM-2: 136.0"
"LAIR2",95,"B6","IOH40239",459,"0",NA,"leukocyte-associated immunoglobulin-like receptor 2 (LAIR2), transcript variant 1, mRNA.","NM_002288.3","NP_002279.2",3904,"Hs.43803","CD306","ENSG00000167618","Leukocyte associated immunoglobulin like receptor 2","19","54497879-54510687","CD markers, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"lymph node: 1.4","spleen: 0.8","Cell line enhanced",NA,"BEWO: 2.2"
"LAMA4",35,"E3","IOH5530",363,"0",NA,"laminin, alpha 4 (LAMA4), transcript variant 4, mRNA.","NM_001105208.1","NP_001098678.1",3910,"Hs.654572","LAMA3","ENSG00000112769","Laminin subunit alpha 4","6","112108760-112254939","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA015693, CAB078156","Enhanced",NA,"Approved","Plasma membrane<br>Cytosol","Renal cancer:2.00e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"smooth muscle: 146.3","Cell line enhanced",NA,"ASC diff: 216.1;ASC TERT1: 333.0;HSkMC: 271.2;HUVEC TERT2: 340.0;TIME: 306.5"
"LAMB1",101,"H3","IOH39063",5361,"0",NA,"Laminin subunit beta-1.","P07942","P07942",3912,"Hs.650585","CLM","ENSG00000091136","Laminin subunit beta 1","7","107923799-108003255","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA004056, HPA004132, CAB004256","Enhanced",NA,NA,NA,"Liver cancer:2.07e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"placenta: 263.7","adipose tissue: 161.4","Cell line enhanced",NA,"HSkMC: 640.2"
"LAMC1",121,"H1","IOH46065",117,"0",NA,"laminin, gamma 1 (formerly LAMB2), mRNA (cDNA clone IMAGE:4642245), complete cds.","BC015586.2","AAH15586.2",3915,"Hs.609663","LAMB2","ENSG00000135862","Laminin subunit gamma 1","1","183023460-183145592","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA001908, HPA001909, CAB004486, CAB078163","Enhanced",NA,"Approved","Endoplasmic reticulum<br>Plasma membrane","Urothelial cancer:8.85e-5 (unfavourable)","Expressed in all","Tissue enhanced",NA,"placenta: 332.9","smooth muscle: 147.5","Cell line enhanced",NA,"ASC diff: 1091.5;HSkMC: 716.3"
"LAMP3",31,"D7","IOH22328",1251,"NP_055213.1","AAH32940.1","lysosomal-associated membrane protein 3, mRNA (cDNA clone MGC:26448 IMAGE:4829125), complete cds","BC032940.2","AAH32940.1",27074,"Hs.518448","CD208, DC-LAMP, DCLAMP, LAMP, TSC403","ENSG00000078081","Lysosomal associated membrane protein 3","3","183122213-183163839","CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB025133, HPA051467","Enhanced",NA,"Enhanced","Vesicles","Renal cancer:1.89e-7 (unfavourable), Ovarian cancer:9.90e-4 (favourable)","Mixed","Tissue enriched",7,"lung: 319.3","appendix: 44.9","Group enriched",8,"EFO-21: 154.0;HDLM-2: 40.5;HHSteC: 50.0;hTCEpi: 40.3"
"LAT2",21,"F4","IOH6605",732,"0",NA,"linker for activation of T cells family, member 2 (LAT2), transcript variant 3, mRNA.","NM_014146.3","NP_054865.2",7462,"Hs.647049","HSPC046, LAB, NTAL, WBSCR15, WBSCR5, WSCR5","ENSG00000086730","Linker for activation of T-cells family member 2","7","74199652-74229834","Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA003462","Enhanced",NA,NA,NA,"Renal cancer:4.10e-4 (unfavourable), Testis cancer:6.10e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"lymph node: 70.0","tonsil: 58.3","Cell line enhanced",NA,"NB-4: 128.3;REH: 209.9;THP-1: 139.1;U-937: 157.8"
"LBP",118,"D2","IOH13524",1434,"0",NA,"lipopolysaccharide binding protein, mRNA (cDNA clone MGC:22233 IMAGE:4767724), complete cds","BC022256.1","AAH22256.1",3929,"Hs.154078","BPIFD2","ENSG00000129988","Lipopolysaccharide binding protein","20","38346356-38377023","Plasma proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA001508, CAB025905","Approved",NA,NA,NA,"Renal cancer:3.62e-12 (unfavourable), Cervical cancer:5.56e-4 (unfavourable), Stomach cancer:5.76e-4 (unfavourable)","Tissue enriched","Group enriched",5,"adipose tissue: 69.3;liver: 264.7","appendix: 31.3","Group enriched",7,"ASC diff: 6.7;HSkMC: 8.5"
"LCAT",11,"A9","IOH10295",1323,"0",NA,"lecithin-cholesterol acyltransferase (LCAT), mRNA.","NM_000229.1","NP_000220.1",3931,"Hs.387239",NA,"ENSG00000213398","Lecithin-cholesterol acyltransferase","16","67939750-67944131","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA044767",NA,NA,"Approved","Nucleoplasm","Liver cancer:4.21e-8 (favourable), Renal cancer:1.71e-4 (unfavourable), Colorectal cancer:8.50e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"liver: 105.7","Cell line enhanced",NA,"BEWO: 73.6"
"LCN1",93,"F5","IOH40729",531,"0",NA,"lipocalin 1 (tear prealbumin) (LCN1), mRNA.","NM_002297.2","NP_002288.1",3933,"Hs.530311","MGC71975, PMFA, TLC, TP, VEGP","ENSG00000160349","Lipocalin 1","9","135521438-135526532","Cancer-related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enhanced","Group enriched",11,"fallopian tube: 3.1;seminal vesicle: 12.2","testis: 0.6","Not detected",NA,NA
"LCN12",58,"A6","IOH26188",1068,"0",NA,"lipocalin 12, mRNA (cDNA clone MGC:48935 IMAGE:5165480), complete cds","BC041168.1","AAH41168.1",286256,"Hs.440519","MGC48935","ENSG00000184925","Lipocalin 12","9","136949551-136955497","Predicted intracellular proteins, Predicted secreted proteins","Evidence at transcript level",NA,NA,NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",31,"epididymis: 45.4","thyroid gland: 1.4","Not detected",NA,NA
"LCN2",116,"D11","IOH23265",597,"0",NA,"lipocalin 2 (LCN2), mRNA.","NM_005564.3","NP_005555.2",3934,"Hs.204238","24p3, NGAL","ENSG00000148346","Lipocalin 2","9","128149071-128153455","Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA002695, CAB016549, CAB016550","Enhanced",NA,"Supported","Endoplasmic reticulum","Breast cancer:9.61e-4 (favourable)","Mixed","Tissue enhanced",NA,"bone marrow: 1852.1;gallbladder: 3419.4","cervix, uterine: 1163.5","Group enriched",11,"CAPAN-2: 3169.5;EFO-21: 1362.3"
"LEAP2",111,"F11","IOH42463",234,"0",NA,"liver expressed antimicrobial peptide 2 (LEAP2), mRNA.","NM_052971.2","NP_443203.1",116842,"Hs.337588","LEAP-2","ENSG00000164406","Liver enriched antimicrobial peptide 2","5","132872322-132875046","Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Urothelial cancer:2.68e-4 (favourable)","Tissue enriched","Tissue enriched",9,"liver: 66.1","small intestine: 7.7","Mixed",NA,NA
"LEFTY1",124,"F9","IOH11866",1101,"0",NA,"left-right determination factor 1 (LEFTY1), mRNA.","NM_020997.2","NP_066277.1",10637,"Hs.656214","LEFTB, LEFTYB","ENSG00000243709","Left-right determination factor 1","1","225886282-225911382","Predicted intracellular proteins, Predicted secreted proteins","Evidence at transcript level","HPA047883, HPA056210","Approved",NA,NA,NA,"Renal cancer:2.48e-6 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"colon: 58.4;pancreas: 20.4;rectum: 35.2","appendix: 9.6","Cell line enriched",7,"NTERA-2: 50.6"
"LEFTY2",140,"F11","IOH25986",1101,"0",NA,"left-right determination factor 2 (LEFTY2), mRNA.","NM_003240.2","NP_003231.2",7044,"Hs.520187","EBAF, LEFTA, LEFTYA, TGFB4","ENSG00000143768","Left-right determination factor 2","1","225936598-225941489","Disease related genes, Predicted secreted proteins","Evidence at protein level","CAB025801, HPA047883, HPA056210","Approved",NA,NA,NA,NA,"Tissue enriched","Group enriched",6,"endometrium: 264.3;smooth muscle: 57.0","ovary: 26.0","Group enriched",12,"HDLM-2: 8.7;NTERA-2: 40.5;RPMI-8226: 31.4"
"LEP",155,"C11","IOH61861",504,"0",NA,"leptin, mRNA (cDNA clone MGC:96888 IMAGE:7262097), complete cds","BC069323.1","AAH69323.1",3952,"Hs.194236","OB, OBS","ENSG00000174697","Leptin","7","128241284-128257628","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB010490, HPA030721","Approved","Approved",NA,NA,NA,"Tissue enhanced","Tissue enriched",11,"adipose tissue: 322.5","breast: 29.6","Cell line enhanced",NA,"BEWO: 2.1"
"LEP",65,"D7","IOH29146",504,"0",NA,"leptin (LEP), mRNA.","NM_000230.2","NP_000221.1",3952,"Hs.194236","OB, OBS","ENSG00000174697","Leptin","7","128241284-128257628","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB010490, HPA030721","Approved","Approved",NA,NA,NA,"Tissue enhanced","Tissue enriched",11,"adipose tissue: 322.5","breast: 29.6","Cell line enhanced",NA,"BEWO: 2.1"
"LFNG",9,"G12","IOH11293",753,"0",NA,"LFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase, mRNA (cDNA clone MGC:22145 IMAGE:4453156), complete cds","BC014851.1","AAH14851.1",3955,"Hs.159142","SCDO3","ENSG00000106003","LFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase","7","2512529-2529177","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA069130","Approved",NA,NA,NA,"Endometrial cancer:6.36e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"skin: 68.5","Cell line enhanced",NA,"RH-30: 44.5;U-2 OS: 52.5"
"LGALS3BP",85,"C10","IOH3566",1758,"0",NA,"lectin, galactoside-binding, soluble, 3 binding protein (LGALS3BP), mRNA.","NM_005567.3","NP_005558.1",3959,"Hs.514535","90K, BTBD17B, CyCAP, gp90, M2BP, MAC-2-BP, TANGO10B","ENSG00000108679","Galectin 3 binding protein","17","78971238-78980109","Cancer-related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA000554, CAB002158","Supported",NA,NA,NA,"Renal cancer:1.07e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"gallbladder: 323.2","Cell line enhanced",NA,"SK-BR-3: 1216.4"
"LGI1",9,"D1","IOH10604",1674,"0",NA,"leucine-rich, glioma inactivated 1 (LGI1), mRNA.","NM_005097.2","NP_005088.1",9211,"Hs.533670","EPITEMPIN, EPT, ETL1, IB1099","ENSG00000108231","Leucine rich glioma inactivated 1","10","93757809-93806272","Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Group enriched","Tissue enriched",11,"cerebral cortex: 45.4","esophagus: 4.2","Group enriched",5,"AF22: 9.4;NTERA-2: 6.4"
"LGMN",25,"H9","IOH4611",1302,"0",NA,"legumain, mRNA (cDNA clone MGC:1395 IMAGE:3504506), complete cds","BC003061.2","AAH03061.1",5641,"Hs.719135","LGMN1, PRSC1","ENSG00000100600","Legumain","14","92703807-92748702","Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA001426","Enhanced",NA,"Approved","Nucleoplasm<br>Vesicles","Renal cancer:4.70e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 360.0","Cell line enhanced",NA,"RPMI-8226: 587.9;U-266/70: 339.8"
"LGMN",54,"A3","IOH6961",1302,"0",NA,"legumain (LGMN), transcript variant 2, mRNA.","NM_001008530.1","NP_001008530.1",5641,"Hs.719135","LGMN1, PRSC1","ENSG00000100600","Legumain","14","92703807-92748702","Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA001426","Enhanced",NA,"Approved","Nucleoplasm<br>Vesicles","Renal cancer:4.70e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 360.0","Cell line enhanced",NA,"RPMI-8226: 587.9;U-266/70: 339.8"
"LIF",110,"B12","IOH34705",609,"0",NA,"leukemia inhibitory factor (cholinergic differentiation factor) (LIF), mRNA.","NM_002309.3","NP_002300.1",3976,"Hs.2250","CDF, DIA, HILDA","ENSG00000128342","Leukemia inhibitory factor","22","30240447-30246851","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA018844, CAB025985","Approved",NA,"Enhanced","Cytosol","Renal cancer:6.78e-8 (unfavourable), Cervical cancer:9.01e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"gallbladder: 75.6","urinary bladder: 42.0","Cell line enhanced",NA,"hTEC/SVTERT24-B: 111.9;U-138 MG: 121.7;U-251 MG: 77.3;U-87 MG: 95.4"
"LILRA2",52,"B11","IOH11932",1401,"0",NA,"leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 2 (LILRA2), transcript variant 2, mRNA.","NM_006866.2","NP_006857.1",11027,"Hs.655593","CD85h, ILT1, LIR-7, LIR7","ENSG00000239998","Leukocyte immunoglobulin like receptor A2","19","54572920-54590287","CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"bone marrow: 9.9;spleen: 7.0","appendix: 4.0","Cell line enhanced",NA,"REH: 1.8;THP-1: 2.7;U-937: 7.1"
"LIME1",123,"D10","IOH10367",888,"0","NP_060276.2","Lck interacting transmembrane adaptor 1 (LIME1), mRNA.","NM_017806.2","NP_060276.2",54923,"Hs.233220","dJ583P15.4, FLJ20406, LIME","ENSG00000203896","Lck interacting transmembrane adaptor 1","20","63736283-63739103","Predicted secreted proteins","Evidence at protein level","CAB015363","Approved",NA,NA,NA,"Urothelial cancer:6.92e-6 (favourable), Renal cancer:5.04e-5 (unfavourable)","Expressed in all","Tissue enhanced",NA,"liver: 19.6;stomach: 17.6","kidney: 15.2","Cell line enhanced",NA,"MOLT-4: 31.1;RPMI-8226: 97.2;U-266/70: 55.2"
"LINGO1",158,"E3","IOH61633",1845,"0",NA,"leucine rich repeat and Ig domain containing 1, mRNA (cDNA clone MGC:87481 IMAGE:4797856), complete cds","BC068558.1","AAH68558.1",84894,"Hs.656765","FLJ14594, LERN1, LRRN6A","ENSG00000169783","Leucine rich repeat and Ig domain containing 1","15","77613027-77820900","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA074653","Enhanced",NA,"Approved","Plasma membrane","Renal cancer:3.23e-7 (unfavourable)","Expressed in all","Tissue enriched",13,"cerebral cortex: 130.8","placenta: 9.8","Cell line enhanced",NA,"AF22: 23.6;AN3-CA: 18.6;HAP1: 31.4;HEK 293: 19.6;NTERA-2: 56.8"
"LIPA",30,"B12","IOH11829",1200,"0",NA,"lipase A, lysosomal acid, cholesterol esterase, mRNA (cDNA clone MGC:5229 IMAGE:2900168), complete cds","BC012287.1","AAH12287.1",3988,"Hs.643030","CESD, LAL","ENSG00000107798","Lipase A, lysosomal acid type","10","89213569-89414557","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB034892, HPA057052","Enhanced",NA,"Supported","Vesicles",NA,"Expressed in all","Expressed in all",NA,NA,"spleen: 496.6","Mixed",NA,NA
"LIPG",118,"C6","IOH29162",1503,"0",NA,"lipase, endothelial, mRNA (cDNA clone MGC:71687 IMAGE:30338950), complete cds","BC060825.1","AAH60825.1",9388,"Hs.465102","EDL","ENSG00000101670","Lipase G, endothelial type","18","49560699-49599182","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA016966","Uncertain",NA,NA,NA,NA,"Tissue enriched","Group enriched",11,"placenta: 214.4;thyroid gland: 403.2","seminal vesicle: 29.1","Cell line enhanced",NA,"AN3-CA: 113.7;HaCaT: 167.5;RPTEC TERT1: 93.8;TIME: 201.4"
"LIPH",95,"H12","IOH39947",1356,"0",NA,"lipase, member H (LIPH), mRNA.","NM_139248.2","NP_640341.1",200879,"Hs.68864","LPDLR, mPA-PLA1, mPA-PLA1alpha, PLA1B","ENSG00000163898","Lipase H","3","185506262-185552613","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA049079","Approved",NA,NA,NA,"Renal cancer:9.20e-5 (favourable), Thyroid cancer:4.21e-4 (favourable), Pancreatic cancer:4.59e-4 (unfavourable), Endometrial cancer:9.40e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"rectum: 40.8;stomach: 45.0","colon: 35.7","Cell line enhanced",NA,"CAPAN-2: 65.0;RPTEC TERT1: 28.0;T-47d: 16.5"
"LMAN2",15,"F8","IOH14720",1071,"NP_006807.1","NP_006807.1","lectin, mannose-binding 2 (LMAN2), mRNA.","NM_006816.2","NP_006807.1",10960,"Hs.75864","C5orf8, GP36B, VIP36","ENSG00000169223","Lectin, mannose binding 2","5","177331562-177351852","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA003927","Approved",NA,NA,NA,"Renal cancer:8.53e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 164.8","Expressed in all",NA,NA
"LNX1",51,"B4","IOH22717",1899,"0",NA,"ligand of numb-protein X 1 (LNX1), transcript variant 2, mRNA.","NM_032622.2","NP_116011.2",84708,"Hs.518760","LNX, MPDZ, PDZRN2","ENSG00000072201","Ligand of numb-protein X 1","4","53459301-53701405","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA002235, HPA071091","Approved",NA,"Supported","Cell Junctions<br>Cytosol","Renal cancer:3.08e-7 (favourable)","Expressed in all","Mixed",NA,NA,"placenta: 39.4","Mixed",NA,NA
"LNX1",81,"C1","IOH10747",2187,"0",NA,"ligand of numb-protein X 1 (LNX1), transcript variant 1, mRNA.","NM_001126328.1","NP_001119800.1",84708,"Hs.518760","LNX, MPDZ, PDZRN2","ENSG00000072201","Ligand of numb-protein X 1","4","53459301-53701405","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA002235, HPA071091","Approved",NA,"Supported","Cell Junctions<br>Cytosol","Renal cancer:3.08e-7 (favourable)","Expressed in all","Mixed",NA,NA,"placenta: 39.4","Mixed",NA,NA
"LOXL1",122,"D10","IOH13324",1725,"0",NA,"lysyl oxidase-like 1 (LOXL1), mRNA.","NM_005576.2","NP_005567.2",4016,"Hs.65436","LOL, LOXL","ENSG00000129038","Lysyl oxidase like 1","15","73925989-73952137","Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA042111, HPA063583","Approved",NA,"Approved","Endoplasmic reticulum","Glioma:1.33e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"seminal vesicle: 16.8","Cell line enhanced",NA,"BJ hTERT+: 61.2"
"LOXL2",122,"H4","IOH4296",2325,"0",NA,"lysyl oxidase-like 2, mRNA (cDNA clone MGC:1709 IMAGE:3347512), complete cds","BC000594.2","AAH00594.1",4017,"Hs.626637","WS9-14","ENSG00000134013","Lysyl oxidase like 2","8","23297189-23425328","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB025848, HPA036257, HPA056542","Approved",NA,"Approved","Nucleoplasm","Lung cancer:1.46e-7 (unfavourable), Renal cancer:2.91e-7 (unfavourable), Cervical cancer:9.83e-6 (unfavourable), Glioma:1.78e-4 (unfavourable), Pancreatic cancer:9.05e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"smooth muscle: 59.8","placenta: 53.3","Cell line enhanced",NA,"BJ: 809.1;U-87 MG: 911.1"
"LOXL3",145,"A9","IOH63094",1827,"0",NA,"lysyl oxidase-like 3, mRNA (cDNA clone MGC:88537 IMAGE:6650423), complete cds","BC071865.1","AAH71865.1",84695,"Hs.469045",NA,"ENSG00000115318","Lysyl oxidase like 3","2","74532414-74555690","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA035281","Approved",NA,NA,NA,"Renal cancer:7.97e-8 (unfavourable)","Tissue enhanced","Mixed",NA,NA,"placenta: 21.6","Cell line enhanced",NA,"U-138 MG: 238.3;WM-115: 524.2"
"LOXL3",87,"D1","IOH23218",804,"0",NA,"lysyl oxidase-like 3, mRNA (cDNA clone IMAGE:3609203), complete cds.","BC033130.1","AAH33130.1",84695,"Hs.469045",NA,"ENSG00000115318","Lysyl oxidase like 3","2","74532414-74555690","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA035281","Approved",NA,NA,NA,"Renal cancer:7.97e-8 (unfavourable)","Tissue enhanced","Mixed",NA,NA,"placenta: 21.6","Cell line enhanced",NA,"U-138 MG: 238.3;WM-115: 524.2"
"LPL",131,"C1","IOH55334",1428,"0",NA,"lipoprotein lipase (LPL), mRNA.","NM_000237.2","NP_000228.1",4023,"Hs.180878","LIPD","ENSG00000175445","Lipoprotein lipase","8","19901717-19967258","Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA048749",NA,NA,"Supported","Vesicles","Urothelial cancer:6.07e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"adipose tissue: 976.8","heart muscle: 239.2","Cell line enriched",7,"AF22: 363.8"
"LPL",35,"H10","IOH9626",1428,"0",NA,"lipoprotein lipase, mRNA (cDNA clone MGC:17090 IMAGE:4177781), complete cds","BC011353.1","AAH11353.1",4023,"Hs.180878","LIPD","ENSG00000175445","Lipoprotein lipase","8","19901717-19967258","Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA048749",NA,NA,"Supported","Vesicles","Urothelial cancer:6.07e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"adipose tissue: 976.8","heart muscle: 239.2","Cell line enriched",7,"AF22: 363.8"
"LRAT",36,"F6","IOH22523",693,"NP_004735.1","NP_004735.2","lecithin retinol acyltransferase (phosphatidylcholine--retinol O-acyltransferase) (LRAT), mRNA.","NM_004744.3","NP_004735.2",9227,"Hs.658427","LCA14","ENSG00000121207","Lecithin retinol acyltransferase (phosphatidylcholine--retinol O-acyltransferase)","4","154626945-154753118","Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA070726",NA,NA,"Uncertain","Endoplasmic reticulum<br>Golgi apparatus",NA,"Mixed","Tissue enhanced",NA,"thyroid gland: 2.3","testis: 1.6","Cell line enriched",11,"NTERA-2: 11.7"
"LRFN4",86,"E9","IOH23019",1908,"NP_076941.2","NP_076941.2","leucine rich repeat and fibronectin type III domain containing 4 (LRFN4), mRNA.","NM_024036.4","NP_076941.2",78999,"Hs.209979","FIGLER6, MGC3103, SALM3.","ENSG00000173621","Leucine rich repeat and fibronectin type III domain containing 4","11","66856647-66860475","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Expressed in all","Mixed",NA,NA,"cerebral cortex: 13.3","Mixed",NA,NA
"LRFN5",74,"B7","IOH25841",2160,"NP_689660.1","NP_689660.2","leucine rich repeat and fibronectin type III domain containing 5 (LRFN5), mRNA.","NM_152447.3","NP_689660.2",145581,"Hs.136893","C14orf146, FIGLER8, SALM5","ENSG00000165379","Leucine rich repeat and fibronectin type III domain containing 5","14","41607570-41904549","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA001177","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"parathyroid gland: 52.3","cervix, uterine: 16.8","Cell line enhanced",NA,"AN3-CA: 16.8;RPTEC TERT1: 4.6;SCLC-21H: 11.1;U-138 MG: 11.4"
"LRG1",50,"D9","IOH22693",1044,"0",NA,"leucine-rich alpha-2-glycoprotein 1, mRNA (cDNA clone MGC:35405 IMAGE:5187278), complete cds","BC034389.1","AAH34389.1",116844,"Hs.655559","LRG","ENSG00000171236","Leucine rich alpha-2-glycoprotein 1","19","4536409-4540474","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA001888, HPA001889","Enhanced",NA,"Approved","Vesicles","Renal cancer:3.66e-6 (unfavourable), Thyroid cancer:3.49e-4 (favourable)","Tissue enriched","Tissue enriched",8,"liver: 173.8","appendix,esophagus: 21.1","Cell line enhanced",NA,"THP-1: 15.8;U-937: 34.0"
"LRP1",60,"G8","IOH28005",879,"NP_002323.1","AAH45107.1","low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor), mRNA (cDNA clone IMAGE:4859182), complete cds.","BC045107.1","AAH45107.1",4035,"Hs.162757","A2MR, APOER, APR, CD91, LRP, LRP1A","ENSG00000123384","LDL receptor related protein 1","12","57128493-57213351","Candidate cardiovascular disease genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA004182, CAB018621, HPA022903","Supported",NA,"Supported","Nucleoplasm<br>Vesicles","Urothelial cancer:1.29e-5 (unfavourable), Renal cancer:1.52e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"adipose tissue: 123.8","Cell line enhanced",NA,"ASC diff: 333.3;ASC TERT1: 342.9;HSkMC: 232.4"
"LRP11",125,"E10","IOH25840",1503,"NP_116221.1","AAH43141.1","low density lipoprotein receptor-related protein 11, mRNA (cDNA clone MGC:41767 IMAGE:5286304), complete cds","BC043141.2","AAH43141.1",84918,"Hs.408355","bA350J20.3, MANSC3","ENSG00000120256","LDL receptor related protein 11","6","149818798-149864026","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA064002",NA,NA,"Approved","Mitochondria","Breast cancer:2.31e-8 (unfavourable), Liver cancer:2.01e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 89.2","Mixed",NA,NA
"LRRC17",17,"B11","IOH12026",1326,"0",NA,"leucine rich repeat containing 17 (LRRC17), transcript variant 1, mRNA.","NM_001031692.2","NP_001026862.1",10234,"Hs.567412","H_RG318M05.3, P37NB","ENSG00000128606","Leucine rich repeat containing 17","7","102912991-102944949","Predicted secreted proteins","Evidence at protein level","HPA030139",NA,NA,"Approved","Nucleoplasm<br>Nuclear speckles<br>Plasma membrane","Renal cancer:4.12e-6 (unfavourable), Urothelial cancer:6.30e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"ovary: 99.1","gallbladder: 46.8","Group enriched",5,"LHCN-M2: 1100.6;RH-30: 248.7"
"LRRC32",94,"F4","IOH40550",1989,"NP_005503.1","NP_005503.1","leucine rich repeat containing 32 (LRRC32), transcript variant 1, mRNA.","NM_005512.2","NP_005503.1",2615,"Hs.151641","D11S833E, GARP","ENSG00000137507","Leucine rich repeat containing 32","11","76657524-76670747","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA055775, HPA058434",NA,NA,"Supported","Nucleoplasm","Renal cancer:3.93e-5 (unfavourable), Urothelial cancer:2.64e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 76.4","Group enriched",5,"ASC diff: 78.8;ASC TERT1: 49.2;HSkMC: 32.0;HUVEC TERT2: 43.0;U-2197: 100.6"
"LRRC3B",67,"C8","IOH27626",780,"0",NA,"leucine rich repeat containing 3B (LRRC3B), mRNA.","NM_052953.2","NP_443185.1",116135,"Hs.517868","LRP15","ENSG00000179796","Leucine rich repeat containing 3B","3","26622806-26710776","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA015568","Approved",NA,NA,NA,NA,"Group enriched","Group enriched",7,"cerebral cortex: 19.2;skeletal muscle: 3.9;testis: 13.0","endometrium,ovary: 1.6","Cell line enhanced",NA,"NTERA-2: 1.6"
"LRRN3",60,"H2","IOH27696",2127,"0",NA,"leucine rich repeat neuronal 3, mRNA (cDNA clone MGC:43233 IMAGE:5263900), complete cds","BC035133.2","AAH35133.1",54674,"Hs.3781","FIGLER5, FLJ11129, NLRR3","ENSG00000173114","Leucine rich repeat neuronal 3","7","111091006-111125454","Predicted membrane proteins, Predicted secreted proteins","Evidence at transcript level","HPA043820, HPA046792","Uncertain",NA,"Approved","Nucleus<br>Cytosol",NA,"Group enriched","Tissue enhanced",NA,"adrenal gland: 30.8;cerebral cortex: 31.2;testis: 29.1;thyroid gland: 33.6","lung: 11.6","Cell line enhanced",NA,"AF22: 24.9;BJ hTERT+: 25.6;SH-SY5Y: 47.7;T-47d: 23.4"
"LRRTM4",36,"C6","IOH13448",624,"0","AAH17769.1","leucine rich repeat transmembrane neuronal 4, mRNA (cDNA clone IMAGE:4283863), complete cds.","BC017769.1","AAH17769.1",80059,"Hs.285782","FLJ12568","ENSG00000176204","Leucine rich repeat transmembrane neuronal 4","2","76747719-77593319","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",9,"cerebral cortex: 21.3","epididymis: 2.4","Cell line enriched",7,"Karpas-707: 91.1"
"LRRTM4",152,"A12","IOH63361",1557,"0","NP_079269.4","leucine rich repeat transmembrane neuronal 4 (LRRTM4), transcript variant 2, mRNA.","NM_024993.4","NP_079269.4",80059,"Hs.285782","FLJ12568","ENSG00000176204","Leucine rich repeat transmembrane neuronal 4","2","76747719-77593319","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",9,"cerebral cortex: 21.3","epididymis: 2.4","Cell line enriched",7,"Karpas-707: 91.1"
"LSR",98,"G12","IOH40886",1950,"0",NA,"lipolysis stimulated lipoprotein receptor (LSR), transcript variant 2, mRNA.","NM_205834.2","NP_991403.1",51599,"Hs.466507","ILDR3, LISCH7","ENSG00000105699","Lipolysis stimulated lipoprotein receptor","19","35248330-35267964","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA007270","Approved",NA,"Approved","Nucleoplasm<br>Plasma membrane<br>Cytosol","Renal cancer:8.09e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"stomach: 128.7","Cell line enhanced",NA,"A-431: 435.7"
"LST1",120,"A6","IOH50125",228,"0",NA,"leukocyte specific transcript 1 (LST1), transcript variant 2, mRNA.","NM_205837.1","NP_995309.1",7940,"Hs.436066","B144, D6S49E, LST-1","ENSG00000204482","Leukocyte specific transcript 1","6","31586124-31588909","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:5.97e-5 (unfavourable), Testis cancer:7.62e-4 (unfavourable), Cervical cancer:7.89e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"bone marrow: 68.7;spleen: 48.9","appendix: 32.1","Cell line enhanced",NA,"HMC-1: 64.7;NB-4: 50.8;THP-1: 128.8;U-937: 79.6"
"LST1",138,"E5","IOH58659",357,"0",NA,"leukocyte specific transcript 1 (LST1), transcript variant 1, mRNA.","NM_007161.2","NP_009092.2",7940,"Hs.436066","B144, D6S49E, LST-1","ENSG00000204482","Leukocyte specific transcript 1","6","31586124-31588909","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:5.97e-5 (unfavourable), Testis cancer:7.62e-4 (unfavourable), Cervical cancer:7.89e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"bone marrow: 68.7;spleen: 48.9","appendix: 32.1","Cell line enhanced",NA,"HMC-1: 64.7;NB-4: 50.8;THP-1: 128.8;U-937: 79.6"
"LST1",114,"A11","IOH41387",120,"0",NA,"leukocyte specific transcript 1 (LST1), transcript variant 5, mRNA.","NM_205840.1","NP_995312.1",7940,"Hs.436066","B144, D6S49E, LST-1","ENSG00000204482","Leukocyte specific transcript 1","6","31586124-31588909","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:5.97e-5 (unfavourable), Testis cancer:7.62e-4 (unfavourable), Cervical cancer:7.89e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"bone marrow: 68.7;spleen: 48.9","appendix: 32.1","Cell line enhanced",NA,"HMC-1: 64.7;NB-4: 50.8;THP-1: 128.8;U-937: 79.6"
"LST1",120,"E5","IOH50083",156,"0",NA,"leukocyte specific transcript 1 (LST1), transcript variant 3, mRNA.","NM_205838.1","NP_995310.1",7940,"Hs.436066","B144, D6S49E, LST-1","ENSG00000204482","Leukocyte specific transcript 1","6","31586124-31588909","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:5.97e-5 (unfavourable), Testis cancer:7.62e-4 (unfavourable), Cervical cancer:7.89e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"bone marrow: 68.7;spleen: 48.9","appendix: 32.1","Cell line enhanced",NA,"HMC-1: 64.7;NB-4: 50.8;THP-1: 128.8;U-937: 79.6"
"LST1",120,"E3","IOH50101",192,"0",NA,"leukocyte specific transcript 1 (LST1), transcript variant 4, mRNA.","NM_205839.1","NP_995311.1",7940,"Hs.436066","B144, D6S49E, LST-1","ENSG00000204482","Leukocyte specific transcript 1","6","31586124-31588909","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:5.97e-5 (unfavourable), Testis cancer:7.62e-4 (unfavourable), Cervical cancer:7.89e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"bone marrow: 68.7;spleen: 48.9","appendix: 32.1","Cell line enhanced",NA,"HMC-1: 64.7;NB-4: 50.8;THP-1: 128.8;U-937: 79.6"
"LTA",32,"A9","IOH21497",618,"0",NA,"lymphotoxin alpha (TNF superfamily, member 1), mRNA (cDNA clone MGC:17018 IMAGE:4341621), complete cds","BC034729.1","AAH34729.1",4049,"Hs.36","LT, TNFB, TNFSF1","ENSG00000226979","Lymphotoxin alpha","6","31572054-31574324","Cancer-related genes, Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA007729","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"lymph node: 1.5","spleen: 0.9","Not detected",NA,NA
"LTBR",7,"D7","IOH13118",1308,"NP_002333.1","NP_002333.1","lymphotoxin beta receptor (TNFR superfamily, member 3) (LTBR), mRNA.","NM_002342.1","NP_002333.1",4055,"Hs.1116","D12S370, TNF-R-III, TNFCR, TNFR-RP, TNFR2-RP, TNFRSF3","ENSG00000111321","Lymphotoxin beta receptor","12","6375045-6391571","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB026202, HPA061617","Uncertain",NA,"Supported","Golgi apparatus","Liver cancer:5.13e-4 (unfavourable), Renal cancer:5.92e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"smooth muscle: 89.5","Cell line enhanced",NA,"HHSteC: 330.0"
"LTF",84,"H7","IOH13990",2136,"0",NA,"lactotransferrin, mRNA (cDNA clone MGC:23800 IMAGE:4251058), complete cds","BC022347.1","AAH22347.1",4057,"Hs.529517","HLF2","ENSG00000012223","Lactotransferrin","3","46435645-46485234","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB008646, CAB016201, HPA057177, HPA059976","Enhanced",NA,NA,NA,"Renal cancer:6.30e-5 (favourable)","Expressed in all","Tissue enhanced",NA,"bone marrow: 2804.3;cervix, uterine: 1030.7","seminal vesicle: 532.6","Group enriched",10,"RPMI-8226: 28.9;TIME: 11.6"
"LTF",87,"E2","IOH13664",2136,"0",NA,"lactotransferrin, mRNA (cDNA clone MGC:13619 IMAGE:4294752), complete cds","BC015823.1","AAH15823.1",4057,"Hs.529517","HLF2","ENSG00000012223","Lactotransferrin","3","46435645-46485234","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB008646, CAB016201, HPA057177, HPA059976","Enhanced",NA,NA,NA,"Renal cancer:6.30e-5 (favourable)","Expressed in all","Tissue enhanced",NA,"bone marrow: 2804.3;cervix, uterine: 1030.7","seminal vesicle: 532.6","Group enriched",10,"RPMI-8226: 28.9;TIME: 11.6"
"LUM",21,"A10","IOH7237",1017,"0",NA,"lumican (LUM), mRNA.","NM_002345.3","NP_002336.1",4060,"Hs.406475","LDC, SLRR2D","ENSG00000139329","Lumican","12","91102629-91111831","Cancer-related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA001522, CAB025783","Supported",NA,NA,NA,"Renal cancer:1.75e-6 (unfavourable)","Expressed in all","Tissue enhanced",NA,"gallbladder: 929.5","placenta: 602.2","Cell line enhanced",NA,"BJ: 269.9;BJ hTERT+: 1272.0;fHDF/TERT166: 208.2"
"LUZP2",131,"C8","IOH57545",1041,"0",NA,"leucine zipper protein 2 (LUZP2), mRNA.","NM_001009909.2","NP_001009909.2",338645,"Hs.144138",NA,"ENSG00000187398","Leucine zipper protein 2","11","24496970-25082631","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA039007, HPA046161","Enhanced",NA,"Approved","Nucleoplasm<br>Plasma membrane<br>Cytosol",NA,"Group enriched","Group enriched",5,"adrenal gland: 8.6;cerebral cortex: 33.0","prostate: 3.8","Group enriched",6,"HaCaT: 9.2;HAP1: 5.4"
"LY6E",104,"C4","IOH42082",396,"0",NA,"lymphocyte antigen 6 complex, locus E (LY6E), transcript variant 1, mRNA.","NM_002346.2","NP_002337.1",4061,"Hs.521903","RIG-E, SCA-2, TSA-1","ENSG00000160932","Lymphocyte antigen 6 family member E","8","143017982-143023832","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at transcript level",NA,NA,NA,NA,NA,"Renal cancer:6.74e-8 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"lung: 109.0","Cell line enhanced",NA,"BJ hTERT+ SV40 Large T+ RasG12V: 564.1;MCF7: 492.5"
"LY6G5B",141,"D8","IOH59693",606,"0",NA,"lymphocyte antigen 6 complex, locus G5B (LY6G5B), mRNA.","NM_021221.2","NP_067044.2",58496,"Hs.708719","C6orf19, G5b","ENSG00000240053","Lymphocyte antigen 6 family member G5B","6","31670167-31673776","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA048307","Approved",NA,NA,NA,NA,"Mixed","Expressed in all",NA,NA,"skin: 27.1","Expressed in all",NA,NA
"LY6K",107,"H11","IOH44586",672,"0",NA,"lymphocyte antigen 6 complex, locus K, mRNA (cDNA clone MGC:150753 IMAGE:40125695), complete cds","BC117144.1","AAI17145.1",54742,"Hs.69517","CT97, FLJ35226, HSJ001348","ENSG00000160886","Lymphocyte antigen 6 family member K","8","142700111-142705127","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA017770, CAB075742, CAB075743","Enhanced",NA,"Supported","Nucleoplasm<br>Plasma membrane","Lung cancer:9.17e-5 (unfavourable)","Mixed","Tissue enhanced",NA,"testis: 29.0","adipose tissue: 5.9","Cell line enhanced",NA,"A-431: 108.7;BJ: 111.4;HeLa: 95.9;SiHa: 218.6;U-2197: 254.2"
"LY6K",62,"D6","IOH3132",498,"NP_059997.1","NP_059997.3","lymphocyte antigen 6 complex, locus K (LY6K), transcript variant 1, mRNA.","NM_017527.3","NP_059997.3",54742,"Hs.69517","CT97, FLJ35226, HSJ001348","ENSG00000160886","Lymphocyte antigen 6 family member K","8","142700111-142705127","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA017770, CAB075742, CAB075743","Enhanced",NA,"Supported","Nucleoplasm<br>Plasma membrane","Lung cancer:9.17e-5 (unfavourable)","Mixed","Tissue enhanced",NA,"testis: 29.0","adipose tissue: 5.9","Cell line enhanced",NA,"A-431: 108.7;BJ: 111.4;HeLa: 95.9;SiHa: 218.6;U-2197: 254.2"
"LY86",58,"F12","IOH26154",489,"0",NA,"lymphocyte antigen 86 (LY86), mRNA.","NM_004271.3","NP_004262.1",9450,"Hs.653138","dJ80N2.1, MD-1","ENSG00000112799","Lymphocyte antigen 86","6","6588108-6654983","Predicted secreted proteins","Evidence at protein level","CAB025000, HPA044895","Approved",NA,NA,NA,"Testis cancer:5.61e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"lymph node: 82.3","spleen: 66.3","Cell line enhanced",NA,"Daudi: 51.2;RPMI-8226: 162.0;THP-1: 62.7;U-937: 34.1"
"LY96",82,"C5","IOH12176",483,"0",NA,"lymphocyte antigen 96, mRNA (cDNA clone MGC:22424 IMAGE:4767246), complete cds","BC020690.1","AAH20690.1",23643,"Hs.660766","MD-2","ENSG00000154589","Lymphocyte antigen 96","8","73991352-74029087","Predicted secreted proteins","Evidence at protein level","HPA053060",NA,NA,"Approved","Vesicles","Renal cancer:6.38e-11 (unfavourable)","Expressed in all","Mixed",NA,NA,"spleen: 61.2","Cell line enhanced",NA,"Karpas-707: 119.4;U-87 MG: 82.4"
"LYG1",30,"F9","IOH22661",585,"0",NA,"lysozyme G-like 1 (LYG1), mRNA.","NM_174898.2","NP_777558.1",129530,"Hs.164589","SALW1939","ENSG00000144214","Lysozyme g1","2","99284238-99304742","Predicted secreted proteins","Evidence at transcript level",NA,NA,NA,NA,NA,"Renal cancer:8.44e-4 (favourable)","Tissue enriched","Group enriched",5,"kidney: 22.0;testis: 4.8","breast: 2.5","Mixed",NA,NA
"LYG2",103,"D6","IOH35282",639,"0",NA,"lysozyme G-like 2 (LYG2), mRNA.","NM_175735.3","NP_783862.2",254773,"Hs.436468","LYGH","ENSG00000185674","Lysozyme g2","2","99242246-99255282","Predicted secreted proteins","Evidence at protein level","HPA039179","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enriched",6,"testis: 2.5","skin: 0.4","Cell line enhanced",NA,"U-937: 1.9"
"LYG2",151,"E10","IOH63429",537,"0",NA,"lysozyme G-like 2, mRNA (cDNA clone MGC:119047 IMAGE:40003266), complete cds","BC100883.2","AAI00884.1",254773,"Hs.436468","LYGH","ENSG00000185674","Lysozyme g2","2","99242246-99255282","Predicted secreted proteins","Evidence at protein level","HPA039179","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enriched",6,"testis: 2.5","skin: 0.4","Cell line enhanced",NA,"U-937: 1.9"
"LYNX1",105,"G12","IOH43474",351,"0",NA,"Ly6/neurotoxin 1 (LYNX1), transcript variant 3, mRNA.","NM_177457.3","NP_803252.1",66004,"Hs.158665",NA,"ENSG00000283992","Ly6/neurotoxin 1","8","142764338-142769844","Predicted secreted proteins, Transporters","Evidence at protein level",NA,NA,NA,NA,NA,NA,NA,"Group enriched",11,"esophagus: 315.6;skin: 108.1","tonsil: 19.9","Group enriched",16,"EFO-21: 5.6;HaCaT: 24.1"
"LYNX1",105,"G12","IOH43474",351,"0",NA,"Ly6/neurotoxin 1 (LYNX1), transcript variant 3, mRNA.","NM_177457.3","NP_803252.1",66004,"Hs.158665",NA,"ENSG00000284505","Ly6/neurotoxin 1","8","142764334-142778224","Predicted secreted proteins, Transporters","Evidence at protein level",NA,NA,NA,NA,NA,NA,NA,"Tissue enhanced",NA,"esophagus: 5.8","skin: 4.0","Not detected",NA,NA
"LYNX1",105,"G12","IOH43474",351,"0",NA,"Ly6/neurotoxin 1 (LYNX1), transcript variant 3, mRNA.","NM_177457.3","NP_803252.1",66004,"Hs.158665","SLURP2","ENSG00000180155","Ly6/neurotoxin 1","8","142771197-142777810","Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:2.82e-4 (favourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 94.6","parathyroid gland: 58.6","Cell line enhanced",NA,"BJ: 6.9;fHDF/TERT166: 7.9;HHSteC: 6.9;T-47d: 6.7"
"LYNX1",112,"C9","IOH45530",396,"0",NA,"Ly6/neurotoxin 1 (LYNX1), transcript variant 1, mRNA.","NM_023946.2","NP_076435.1",66004,"Hs.158665",NA,"ENSG00000283992","Ly6/neurotoxin 1","8","142764338-142769844","Predicted secreted proteins, Transporters","Evidence at protein level",NA,NA,NA,NA,NA,NA,NA,"Group enriched",11,"esophagus: 315.6;skin: 108.1","tonsil: 19.9","Group enriched",16,"EFO-21: 5.6;HaCaT: 24.1"
"LYNX1",112,"C9","IOH45530",396,"0",NA,"Ly6/neurotoxin 1 (LYNX1), transcript variant 1, mRNA.","NM_023946.2","NP_076435.1",66004,"Hs.158665",NA,"ENSG00000284505","Ly6/neurotoxin 1","8","142764334-142778224","Predicted secreted proteins, Transporters","Evidence at protein level",NA,NA,NA,NA,NA,NA,NA,"Tissue enhanced",NA,"esophagus: 5.8","skin: 4.0","Not detected",NA,NA
"LYNX1",112,"C9","IOH45530",396,"0",NA,"Ly6/neurotoxin 1 (LYNX1), transcript variant 1, mRNA.","NM_023946.2","NP_076435.1",66004,"Hs.158665","SLURP2","ENSG00000180155","Ly6/neurotoxin 1","8","142771197-142777810","Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:2.82e-4 (favourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 94.6","parathyroid gland: 58.6","Cell line enhanced",NA,"BJ: 6.9;fHDF/TERT166: 7.9;HHSteC: 6.9;T-47d: 6.7"
"LYPD1",8,"C1","IOH13321",426,"0",NA,"LY6/PLAUR domain containing 1 (LYPD1), transcript variant 1, mRNA.","NM_144586.5","NP_653187.3",116372,"Hs.719231","LYPDC1, MGC29643","ENSG00000150551","LY6/PLAUR domain containing 1","2","132644853-132671579","Predicted secreted proteins","Evidence at transcript level",NA,NA,NA,NA,NA,NA,"Tissue enhanced","Group enriched",17,"cerebral cortex: 27.2;fallopian tube: 127.3","salivary gland: 4.5","Cell line enhanced",NA,"hTEC/SVTERT24-B: 56.7;U-251 MG: 88.0;WM-115: 207.2"
"LYPD2",151,"H2","IOH58702",378,"0",NA,"LY6/PLAUR domain containing 2 (LYPD2), mRNA.","NM_205545.1","NP_991108.1",137797,"Hs.441280","LYPDC2, RGTR430, UNQ430","ENSG00000197353","LY6/PLAUR domain containing 2","8","142750150-142752534","Predicted secreted proteins","Evidence at protein level","HPA028599","Uncertain",NA,NA,NA,"Cervical cancer:2.00e-4 (favourable), Head and neck cancer:2.63e-4 (favourable)","Group enriched","Tissue enhanced",NA,"esophagus: 99.1;tonsil: 24.0","stomach: 20.9","Group enriched",20,"EFO-21: 9.5;HaCaT: 2.5"
"LYPD4",101,"B1","IOH27656",636,"0",NA,"LY6/PLAUR domain containing 4, mRNA (cDNA clone MGC:42718 IMAGE:4827584), complete cds","BC034629.2","AAH34629.1",147719,"Hs.98660","MGC42718","ENSG00000273111","LY6/PLAUR domain containing 4","19","41837074-41844697","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Not detected","Tissue enriched",749,"testis: 165.3","bone marrow: 0.2","Not detected",NA,NA
"LYPD6",82,"F7","IOH26572",516,"0",NA,"LY6/PLAUR domain containing 6 (LYPD6), mRNA.","NM_194317.2","NP_919298.1",130574,"Hs.21929","MGC52057","ENSG00000187123","LY6/PLAUR domain containing 6","2","149329985-149474148","Predicted secreted proteins","Evidence at protein level","HPA042805","Uncertain",NA,"Approved","Cytosol","Urothelial cancer:2.72e-4 (favourable), Ovarian cancer:3.59e-4 (favourable)","Mixed","Tissue enhanced",NA,"gallbladder: 17.3;placenta: 22.5","breast: 12.0","Cell line enhanced",NA,"AN3-CA: 33.5;fHDF/TERT166: 36.6;LHCN-M2: 38.4;RT4: 30.7"
"LYZ",29,"F3","IOH3791",447,"0",NA,"lysozyme (renal amyloidosis) (LYZ), mRNA.","NM_000239.2","NP_000230.1",4069,"Hs.524579",NA,"ENSG00000090382","Lysozyme","12","69348341-69354234","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins","Evidence at protein level","CAB000055, HPA048284, HPA066182","Enhanced",NA,"Approved","Nucleoplasm<br>Golgi apparatus<br>Actin filaments","Head and neck cancer:7.45e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"stomach: 9651.4","Group enriched",5,"Hep G2: 633.5;THP-1: 321.5;U-937: 404.3"
"LYZL4",18,"C8","IOH10858",441,"0",NA,"lysozyme-like 4 (LYZL4), mRNA.","NM_144634.2","NP_653235.1",131375,"Hs.234895","LYC4, MGC26768","ENSG00000157093","Lysozyme like 4","3","42397078-42410600","Predicted secreted proteins","Evidence at protein level","HPA038806","Approved",NA,NA,NA,NA,"Not detected","Tissue enriched",58,"testis: 43.8","cerebral cortex: 0.7","Not detected",NA,NA
"LYZL6",102,"H3","IOH29483",447,"0",NA,"lysozyme-like 6 (LYZL6), mRNA.","NM_020426.1","NP_065159.1",57151,"Hs.97477","LYC1, PRO1485, TKAL754","ENSG00000275722","Lysozyme like 6","17","35934518-35943699","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA025734, HPA053073","Supported",NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"testis: 0.1","Not detected",NA,NA
"M6PR",94,"G5","IOH40579",834,"NP_002346.1","NP_002346.1","mannose-6-phosphate receptor (cation dependent) (M6PR), mRNA.","NM_002355.2","NP_002346.1",4074,"Hs.134084","CD-M6PR, CD-MPR","ENSG00000003056","Mannose-6-phosphate receptor, cation dependent","12","8940363-8949955","FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB034464, HPA040445","Approved",NA,NA,NA,"Liver cancer:3.89e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 175.3","Expressed in all",NA,NA
"MAD1L1",34,"H10","IOH12340",2157,"0",NA,"MAD1 mitotic arrest deficient-like 1 (yeast) (MAD1L1), transcript variant 1, mRNA.","NM_003550.2","NP_003541.2",8379,"Hs.654838","HsMAD1, MAD1, PIG9, TP53I9, TXBP181","ENSG00000002822","MAD1 mitotic arrest deficient like 1","7","1815793-2233243","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA003635, CAB015338","Supported",NA,"Supported","Nucleoplasm<br>Nuclear membrane",NA,"Expressed in all","Expressed in all",NA,NA,"lymph node: 23.3","Expressed in all",NA,NA
"MAG",69,"A2","IOH28937",1881,"NP_002352.1","NP_002352.1","myelin associated glycoprotein (MAG), transcript variant 1, mRNA.","NM_002361.2","NP_002352.1",4099,"Hs.643440","GMA, S-MAG, SIGLEC-4A, SIGLEC4A","ENSG00000105695","Myelin associated glycoprotein","19","35292125-35313804","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB009345, HPA012499","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",6,"cerebral cortex: 163.6","ovary: 27.5","Cell line enriched",31,"WM-115: 35.4"
"MAG",102,"G6","IOH38014",1749,"0",NA,"myelin associated glycoprotein (MAG), transcript variant 2, mRNA.","NM_080600.1","NP_542167.1",4099,"Hs.643440","GMA, S-MAG, SIGLEC-4A, SIGLEC4A","ENSG00000105695","Myelin associated glycoprotein","19","35292125-35313804","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB009345, HPA012499","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",6,"cerebral cortex: 163.6","ovary: 27.5","Cell line enriched",31,"WM-115: 35.4"
"MAGT1",97,"A1","IOH39803",1008,"NP_115497.1","AAH60842.1","magnesium transporter 1, mRNA (cDNA clone MGC:71748 IMAGE:30338916), complete cds","BC060842.1","AAH60842.1",84061,"Hs.323562","DKFZp564K142, IAP, MRX95, OST3B","ENSG00000102158","Magnesium transporter 1","X","77826364-77895593","Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA049851","Approved",NA,NA,NA,"Breast cancer:1.30e-4 (unfavourable), Pancreatic cancer:3.55e-4 (unfavourable), Melanoma:8.98e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 137.3","Expressed in all",NA,NA
"MAMDC2",82,"G4","IOH11018",699,"0",NA,"MAM domain containing 2, mRNA (cDNA clone IMAGE:4396073), complete cds.","BC015417.2","AAH15417.1",256691,"Hs.547172","MGC21981","ENSG00000165072","MAM domain containing 2","9","70043581-70226970","Predicted secreted proteins","Evidence at protein level","HPA021814, HPA022249","Uncertain",NA,"Approved","Nuclear speckles<br>Plasma membrane","Thyroid cancer:7.78e-4 (unfavourable)","Mixed","Mixed",NA,NA,"endometrium: 60.6","Cell line enhanced",NA,"ASC diff: 35.3;HHSteC: 44.9;LHCN-M2: 57.7;TIME: 54.7"
"MAN2B1",85,"B3","IOH4607",3036,"0",NA,"mannosidase, alpha, class 2B, member 1 (MAN2B1), mRNA.","NM_000528.3","NP_000519.2",4125,"Hs.356769","LAMAN, MANB","ENSG00000104774","Mannosidase alpha class 2B member 1","19","12646511-12666742","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins","Evidence at protein level","HPA041530, HPA053404","Supported",NA,"Approved","Nucleoplasm<br>Vesicles","Renal cancer:1.94e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 95.1","Expressed in all",NA,NA
"MAN2B2",154,"A10","IOH62690",3030,"0",NA,"mannosidase, alpha, class 2B, member 2, mRNA (cDNA clone MGC:104672 IMAGE:30531368), complete cds","BC094773.1","AAH94773.1",23324,"Hs.188464","KIAA0935","ENSG00000013288","Mannosidase alpha class 2B member 2","4","6575175-6623362","Enzymes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA037005","Uncertain",NA,NA,NA,"Endometrial cancer:7.59e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 37.7","Expressed in all",NA,NA
"MANBA",84,"D10","IOH12062",2640,"0",NA,"mannosidase, beta A, lysosomal, mRNA (cDNA clone MGC:23037 IMAGE:4905535), complete cds","BC015743.1","AAH15743.1",4126,"Hs.480415",NA,"ENSG00000109323","Mannosidase beta","4","102631488-102760994","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins","Evidence at protein level","HPA053478","Approved",NA,"Supported","Vesicles","Liver cancer:3.74e-6 (unfavourable), Glioma:1.06e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 37.4","Expressed in all",NA,NA
"MANEAL",115,"C7","IOH44740",708,"0",NA,"mannosidase, endo-alpha-like (MANEAL), transcript variant 2, mRNA.","NM_152496.2","NP_689709.1",149175,"Hs.534562","FLJ31434","ENSG00000185090","Mannosidase endo-alpha like","1","37793802-37801137","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA063423",NA,NA,"Approved","Golgi apparatus","Liver cancer:3.32e-4 (unfavourable), Head and neck cancer:5.28e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 27.2","adrenal gland: 9.5","Cell line enhanced",NA,"SCLC-21H: 167.3"
"MANF",143,"E11","IOH59542",558,"0",NA,"mesencephalic astrocyte-derived neurotrophic factor (MANF), mRNA.","NM_006010.3","NP_006001.2",7873,"Hs.436446","ARMET, ARP","ENSG00000145050","Mesencephalic astrocyte derived neurotrophic factor","3","51385047-51389397","Predicted secreted proteins","Evidence at protein level","HPA011175","Approved",NA,"Supported","Endoplasmic reticulum","Head and neck cancer:9.58e-6 (unfavourable), Liver cancer:7.48e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 125.4","Expressed in all",NA,NA
"MANSC1",31,"E5","IOH22277",1296,"0",NA,"MANSC domain containing 1, mRNA (cDNA clone MGC:26021 IMAGE:4824116), complete cds","BC032998.2","AAH32998.1",54682,"Hs.591145","FLJ10298, LOH12CR3","ENSG00000111261","MANSC domain containing 1","12","12326056-12350541","Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA007955, HPA007956","Approved",NA,"Approved","Golgi apparatus<br>Vesicles","Renal cancer:3.30e-5 (favourable)","Expressed in all","Mixed",NA,NA,"parathyroid gland: 24.7","Cell line enhanced",NA,"HUVEC TERT2: 42.6"
"MARK3",47,"F8","IOH10665",2190,"0",NA,"MAP/microtubule affinity-regulating kinase 3, mRNA (cDNA clone MGC:29880 IMAGE:5138958), complete cds","BC024773.1","AAH24773.1",4140,"Hs.35828","CTAK1, KP78, PAR-1A","ENSG00000075413","Microtubule affinity regulating kinase 3","14","103385392-103503831","Enzymes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA024652","Approved",NA,"Approved","Nuclear membrane","Melanoma:1.14e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"bone marrow: 64.0","Expressed in all",NA,NA
"MASP1",151,"A6","IOH60848",1143,"0",NA,"mannan-binding lectin serine peptidase 1 (C4/C2 activating component of Ra-reactive factor) (MASP1), transcript variant 3, mRNA.","NM_001031849.1","NP_001027019.1",5648,"Hs.89983","CRARF, MASP, PRSS5","ENSG00000127241","Mannan binding lectin serine peptidase 1","3","187217285-187292022","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA001617, HPA009641","Supported",NA,"Supported","Nucleoplasm<br>Cytosol","Liver cancer:2.20e-4 (favourable)","Group enriched","Tissue enhanced",NA,"cervix, uterine: 135.4","endometrium: 94.8","Group enriched",8,"BJ: 107.2;BJ hTERT+: 389.0"
"MASP2",71,"H1","IOH29573",558,"0",NA,"mannan-binding lectin serine peptidase 2 (MASP2), transcript variant 2, mRNA.","NM_139208.1","NP_631947.1",10747,"Hs.655645","MASP1P1","ENSG00000009724","Mannan binding lectin serine peptidase 2","1","11026523-11047233","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins","Evidence at protein level","HPA029313, HPA029314","Approved",NA,"Supported","Golgi apparatus","Liver cancer:1.60e-4 (favourable)","Tissue enriched","Tissue enriched",18,"liver: 105.5","skin: 5.7","Cell line enhanced",NA,"Hep G2: 12.9"
"MASP2",102,"E8","IOH38164",2061,"0",NA,"mannan-binding lectin serine peptidase 2 (MASP2), transcript variant 1, mRNA.","NM_006610.2","NP_006601.2",10747,"Hs.655645","MASP1P1","ENSG00000009724","Mannan binding lectin serine peptidase 2","1","11026523-11047233","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins","Evidence at protein level","HPA029313, HPA029314","Approved",NA,"Supported","Golgi apparatus","Liver cancer:1.60e-4 (favourable)","Tissue enriched","Tissue enriched",18,"liver: 105.5","skin: 5.7","Cell line enhanced",NA,"Hep G2: 12.9"
"MATN2",14,"B9","IOH14752",714,"0",NA,"cDNA clone MGC:31936 IMAGE:4765518, complete cds.","BC020233.1","AAH20233.1",4147,"Hs.189445",NA,"ENSG00000132561","Matrilin 2","8","97868840-98036716","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB033879","Approved",NA,NA,NA,"Thyroid cancer:9.65e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 456.8","Cell line enhanced",NA,"BJ hTERT+ SV40 Large T+: 73.2;BJ hTERT+ SV40 Large T+ RasG12V: 104.0;HaCaT: 101.1;HBF TERT88: 97.3"
"MATN2",116,"G4","IOH41911",2814,"0",NA,"matrilin 2 (MATN2), transcript variant 2, mRNA.","NM_030583.2","NP_085072.2",4147,"Hs.189445",NA,"ENSG00000132561","Matrilin 2","8","97868840-98036716","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB033879","Approved",NA,NA,NA,"Thyroid cancer:9.65e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 456.8","Cell line enhanced",NA,"BJ hTERT+ SV40 Large T+: 73.2;BJ hTERT+ SV40 Large T+ RasG12V: 104.0;HaCaT: 101.1;HBF TERT88: 97.3"
"MATN2",124,"G2","IOH9666",2814,"0",NA,"matrilin 2, mRNA (cDNA clone MGC:17281 IMAGE:4215380), complete cds","BC010444.1","AAH10444.1",4147,"Hs.189445",NA,"ENSG00000132561","Matrilin 2","8","97868840-98036716","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB033879","Approved",NA,NA,NA,"Thyroid cancer:9.65e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 456.8","Cell line enhanced",NA,"BJ hTERT+ SV40 Large T+: 73.2;BJ hTERT+ SV40 Large T+ RasG12V: 104.0;HaCaT: 101.1;HBF TERT88: 97.3"
"MAZ",60,"B7","IOH27995",795,"0",NA,"MYC-associated zinc finger protein (purine-binding transcription factor), mRNA (cDNA clone MGC:52386 IMAGE:4309842), complete cds","BC041629.1","AAH41629.1",4150,"Hs.23650","Pur-1, ZF87, Zif87, ZNF801","ENSG00000103495","MYC associated zinc finger protein","16","29806106-29811164","Predicted intracellular proteins, Predicted secreted proteins, Transcription factors","Evidence at protein level","HPA048315, HPA059495, HPA065930","Approved",NA,"Enhanced","Nucleus","Thyroid cancer:2.22e-4 (unfavourable), Renal cancer:5.15e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"prostate: 197.0","Expressed in all",NA,NA
"MCCD1",139,"H1","IOH54583",360,"0",NA,"mitochondrial coiled-coil domain 1, mRNA (cDNA clone MGC:164625 IMAGE:40147016), complete cds","BC132994.1","AAI32995.1",401250,"Hs.558922",NA,"ENSG00000204511","Mitochondrial coiled-coil domain 1","6","31528717-31530232","Predicted secreted proteins","Evidence at transcript level","HPA046948","Uncertain",NA,NA,NA,"Renal cancer:1.73e-4 (favourable)","Tissue enhanced","Tissue enriched",36,"kidney: 3.5","all non-specific tissues: 0.0","Not detected",NA,NA
"MCF2L",84,"H11","IOH23111",2955,"0",NA,"MCF.2 cell line derived transforming sequence-like, mRNA (cDNA clone MGC:19890 IMAGE:4138009), complete cds","BC011853.2","AAH11853.1",23263,"Hs.170422","ARHGEF14, DBS, KIAA0362, OST","ENSG00000126217","MCF.2 cell line derived transforming sequence like","13","112894378-113099739","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:9.14e-6 (favourable), Urothelial cancer:2.63e-5 (favourable), Pancreatic cancer:4.36e-5 (favourable), Endometrial cancer:6.01e-4 (favourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 62.4","Cell line enhanced",NA,"SCLC-21H: 77.5;SK-BR-3: 33.1;WM-115: 59.3"
"MCFD2",148,"F5","IOH62213",285,"0",NA,"multiple coagulation factor deficiency 2, mRNA (cDNA clone MGC:42267 IMAGE:4815069), complete cds","BC037845.1","AAH37845.1",90411,"Hs.293689","F5F8D, LMAN1IP, SDNSF","ENSG00000180398","Multiple coagulation factor deficiency 2","2","46901870-46941855","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB022410, HPA034593","Supported",NA,NA,NA,"Urothelial cancer:4.64e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"adrenal gland: 206.7","Expressed in all",NA,NA
"MCFD2",83,"A6","IOH25779",441,"0",NA,"multiple coagulation factor deficiency 2 (MCFD2), mRNA.","NM_139279.3","NP_644808.1",90411,"Hs.293689","F5F8D, LMAN1IP, SDNSF","ENSG00000180398","Multiple coagulation factor deficiency 2","2","46901870-46941855","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB022410, HPA034593","Supported",NA,NA,NA,"Urothelial cancer:4.64e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"adrenal gland: 206.7","Expressed in all",NA,NA
"MDK",16,"D6","IOH13794",432,"0",NA,"midkine (neurite growth-promoting factor 2) (MDK), transcript variant 2, mRNA.","NM_001012333.1","NP_001012333.1",4192,"Hs.82045","FLJ27379, MK, NEGF2","ENSG00000110492","Midkine (neurite growth-promoting factor 2)","11","46380756-46383837","Cancer-related genes, Predicted secreted proteins","Evidence at protein level","CAB010055, HPA057126","Uncertain",NA,"Approved","Vesicles","Renal cancer:3.06e-6 (unfavourable), Glioma:9.54e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"ovary: 524.3","Cell line enhanced",NA,"NTERA-2: 890.9;REH: 1226.8;SH-SY5Y: 1163.1"
"MEGF10",103,"A1","IOH38706",3423,"0",NA,"multiple EGF-like-domains 10 (MEGF10), mRNA.","NM_032446.2","NP_115822.1",84466,"Hs.438709","KIAA1780","ENSG00000145794","Multiple EGF like domains 10","5","127290831-127465737","Disease related genes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",7,"cerebral cortex: 15.8","adrenal gland: 2.2","Cell line enhanced",NA,"AF22: 31.3;RH-30: 37.5"
"MEGF10",53,"F1","IOH13308",1704,"NP_115822.1","AAH20198.1","multiple EGF-like-domains 10, mRNA (cDNA clone IMAGE:4904255), complete cds.","BC020198.1","AAH20198.1",84466,"Hs.438709","KIAA1780","ENSG00000145794","Multiple EGF like domains 10","5","127290831-127465737","Disease related genes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",7,"cerebral cortex: 15.8","adrenal gland: 2.2","Cell line enhanced",NA,"AF22: 31.3;RH-30: 37.5"
"MEIS3",129,"D7","IOH53832",1077,"0",NA,"Meis homeobox 3 (MEIS3), transcript variant 2, mRNA.","NM_001009813.1","NP_001009813.1",56917,"Hs.380923","DKFZp547H236, MRG2","ENSG00000105419","Meis homeobox 3","19","47403124-47419523","Predicted intracellular proteins, Predicted secreted proteins, Transcription factors","Evidence at protein level","HPA046699","Uncertain",NA,"Approved","Nucleoplasm","Renal cancer:1.78e-6 (unfavourable)","Mixed","Tissue enhanced",NA,"endometrium: 82.4","cerebral cortex: 64.8","Cell line enhanced",NA,"AF22: 74.7"
"MEIS3",17,"B6","IOH11756",1266,"0",NA,"Meis homeobox 3 (MEIS3), transcript variant 1, mRNA.","NM_020160.1","NP_064545.1",56917,"Hs.380923","DKFZp547H236, MRG2","ENSG00000105419","Meis homeobox 3","19","47403124-47419523","Predicted intracellular proteins, Predicted secreted proteins, Transcription factors","Evidence at protein level","HPA046699","Uncertain",NA,"Approved","Nucleoplasm","Renal cancer:1.78e-6 (unfavourable)","Mixed","Tissue enhanced",NA,"endometrium: 82.4","cerebral cortex: 64.8","Cell line enhanced",NA,"AF22: 74.7"
"MESDC2",51,"C11","IOH14565",705,"0",NA,"mesoderm development candidate 2 (MESDC2), mRNA.","NM_015154.1","NP_055969.1",23184,"Hs.578450","BOCA, KIAA0081, MESD","ENSG00000117899","Mesoderm development candidate 2","15","80946289-80989878","Predicted secreted proteins","Evidence at protein level","HPA039414, HPA041721","Approved",NA,"Supported","Nuclear bodies<br>Endoplasmic reticulum<br>Cytosol","Ovarian cancer:1.12e-4 (favourable), Endometrial cancer:2.31e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 55.7","Expressed in all",NA,NA
"MEST",155,"H6","IOH62587",879,"0",NA,"mesoderm specific transcript homolog (mouse), mRNA (cDNA clone MGC:111102 IMAGE:30379091), complete cds","BC090049.1","AAH90049.1",4232,"Hs.270978","PEG1","ENSG00000106484","Mesoderm specific transcript","7","130486171-130506296","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA005623",NA,NA,"Approved","Golgi apparatus<br>Cytosol","Renal cancer:6.20e-5 (unfavourable)","Expressed in all","Tissue enriched",8,"placenta: 1087.6","adipose tissue: 131.8","Cell line enriched",5,"AN3-CA: 10976.9"
"MEST",111,"D12","IOH45900",981,"0",NA,"mesoderm specific transcript homolog (mouse) (MEST), transcript variant 2, mRNA.","NM_177524.1","NP_803490.1",4232,"Hs.270978","PEG1","ENSG00000106484","Mesoderm specific transcript","7","130486171-130506296","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA005623",NA,NA,"Approved","Golgi apparatus<br>Cytosol","Renal cancer:6.20e-5 (unfavourable)","Expressed in all","Tissue enriched",8,"placenta: 1087.6","adipose tissue: 131.8","Cell line enriched",5,"AN3-CA: 10976.9"
"MEST",26,"A3","IOH3706",1008,"0",NA,"mesoderm specific transcript homolog (mouse) (MEST), transcript variant 1, mRNA.","NM_002402.2","NP_002393.2",4232,"Hs.270978","PEG1","ENSG00000106484","Mesoderm specific transcript","7","130486171-130506296","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA005623",NA,NA,"Approved","Golgi apparatus<br>Cytosol","Renal cancer:6.20e-5 (unfavourable)","Expressed in all","Tissue enriched",8,"placenta: 1087.6","adipose tissue: 131.8","Cell line enriched",5,"AN3-CA: 10976.9"
"MET",101,"E4","IOH36570",4173,"0",NA,"met proto-oncogene (hepatocyte growth factor receptor) (MET), transcript variant 2, mRNA.","NM_000245.2","NP_000236.2",4233,"Hs.132966","DFNB97, HGFR, RCCP2","ENSG00000105976","MET proto-oncogene, receptor tyrosine kinase","7","116672390-116798386","Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","CAB005282, CAB018577, HPA055607","Uncertain",NA,"Supported","Plasma membrane<br>Cytosol","Pancreatic cancer:1.21e-7 (unfavourable), Head and neck cancer:6.75e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 39.0","Mixed",NA,NA
"METTL7B",11,"H12","IOH10392",585,"0",NA,"Methyltransferase-like protein 7B Precursor (EC 2.1.1.-) [Source:UniProtKB/Swiss-Prot;Acc:Q6UX53]","ENST00000307755","ENSP00000304855",196410,"Hs.51483","ALDI, MGC17301","ENSG00000170439","Methyltransferase like 7B","12","55681546-55684611","Predicted secreted proteins","Evidence at protein level","HPA038644","Enhanced",NA,"Supported","Vesicles<br>Microtubules","Thyroid cancer:2.37e-4 (favourable), Head and neck cancer:2.85e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"epididymis: 137.1;liver: 122.2","small intestine: 52.1","Cell line enhanced",NA,"CAPAN-2: 42.8;EFO-21: 33.6;LHCN-M2: 33.5;U-87 MG: 35.3"
"MFAP2",12,"A7","IOH10065",552,"0",NA,"microfibrillar-associated protein 2 (MFAP2), transcript variant 2, mRNA.","NM_002403.3","NP_002394.1",4237,"Hs.389137","MAGP, MAGP-1","ENSG00000117122","Microfibrillar associated protein 2","1","16974502-16980835","Predicted secreted proteins","Evidence at protein level","HPA007354","Enhanced",NA,NA,NA,"Renal cancer:2.52e-8 (unfavourable)","Expressed in all","Tissue enhanced",NA,"gallbladder: 100.7","endometrium: 82.4","Cell line enhanced",NA,"HUVEC TERT2: 193.6;SH-SY5Y: 203.2"
"MFAP3",46,"F9","IOH14281",1089,"NP_005918.1","NP_005918.1","microfibrillar-associated protein 3 (MFAP3), transcript variant 1, mRNA.","NM_005927.4","NP_005918.1",4238,"Hs.432818",NA,"ENSG00000037749","Microfibrillar associated protein 3","5","154038906-154220478","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA015883, HPA049198","Approved",NA,"Approved","Nucleoplasm<br>Golgi apparatus","Cervical cancer:4.28e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 74.8","Expressed in all",NA,NA
"MFAP3L",68,"G8","IOH3213",309,"0",NA,"microfibrillar-associated protein 3-like, mRNA (cDNA clone IMAGE:3458716), complete cds.","BC001279.1","AAH01279.1",9848,"Hs.593942","KIAA0626, NYD-sp9","ENSG00000198948","Microfibrillar associated protein 3 like","4","169986597-170033031","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA017986","Approved",NA,NA,NA,"Renal cancer:1.42e-8 (favourable)","Expressed in all","Tissue enhanced",NA,"testis: 74.1","epididymis: 47.4","Cell line enhanced",NA,"HMC-1: 19.9;RT4: 30.4;SK-BR-3: 25.8"
"MFAP3L",111,"E5","IOH45685",921,"0",NA,"microfibrillar-associated protein 3-like (MFAP3L), transcript variant 2, mRNA.","NM_001009554.2","NP_001009554.1",9848,"Hs.593942","KIAA0626, NYD-sp9","ENSG00000198948","Microfibrillar associated protein 3 like","4","169986597-170033031","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA017986","Approved",NA,NA,NA,"Renal cancer:1.42e-8 (favourable)","Expressed in all","Tissue enhanced",NA,"testis: 74.1","epididymis: 47.4","Cell line enhanced",NA,"HMC-1: 19.9;RT4: 30.4;SK-BR-3: 25.8"
"MFAP4",96,"D4","IOH40006",768,"0",NA,"microfibrillar-associated protein 4, mRNA (cDNA clone MGC:70468 IMAGE:6187998), complete cds","BC062415.1","AAH62415.1",4239,"Hs.296049",NA,"ENSG00000166482","Microfibrillar associated protein 4","17","19383442-19387240","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA054097","Supported",NA,"Approved","Endoplasmic reticulum","Renal cancer:6.83e-7 (unfavourable), Head and neck cancer:3.51e-4 (favourable), Ovarian cancer:4.64e-4 (unfavourable), Urothelial cancer:7.12e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"gallbladder: 972.0","Cell line enhanced",NA,"ASC diff: 262.3;ASC TERT1: 405.8;fHDF/TERT166: 213.0;HHSteC: 224.2;HSkMC: 294.1;MOLT-4: 290.1;SH-SY5Y: 360.1"
"MFAP4",133,"G9","IOH53871",768,"0",NA,"microfibrillar-associated protein 4 (MFAP4), mRNA.","NM_002404.1","NP_002395.1",4239,"Hs.296049",NA,"ENSG00000166482","Microfibrillar associated protein 4","17","19383442-19387240","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA054097","Supported",NA,"Approved","Endoplasmic reticulum","Renal cancer:6.83e-7 (unfavourable), Head and neck cancer:3.51e-4 (favourable), Ovarian cancer:4.64e-4 (unfavourable), Urothelial cancer:7.12e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"gallbladder: 972.0","Cell line enhanced",NA,"ASC diff: 262.3;ASC TERT1: 405.8;fHDF/TERT166: 213.0;HHSteC: 224.2;HSkMC: 294.1;MOLT-4: 290.1;SH-SY5Y: 360.1"
"MFAP5",141,"B3","IOH58997",522,"0",NA,"microfibrillar associated protein 5 (MFAP5), mRNA.","NM_003480.2","NP_003471.1",8076,"Hs.512842","MAGP2, MP25","ENSG00000197614","Microfibrillar associated protein 5","12","8637346-8662888","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA010553","Enhanced",NA,NA,NA,"Urothelial cancer:5.81e-4 (unfavourable), Stomach cancer:6.87e-4 (unfavourable)","Mixed","Expressed in all",NA,NA,"smooth muscle: 207.1","Cell line enhanced",NA,"BEWO: 166.7;EFO-21: 142.4"
"MFGE8",84,"G5","IOH3899",1008,"0",NA,"milk fat globule-EGF factor 8 protein, mRNA (cDNA clone MGC:1373 IMAGE:2988915), complete cds","BC003610.2","AAH03610.1",4240,"Hs.3745","BA46, EDIL1, hP47, HsT19888, MFG-E8, OAcGD3S, SED1, SPAG10","ENSG00000140545","Milk fat globule-EGF factor 8 protein","15","88898683-88913411","Cancer-related genes, Predicted secreted proteins","Evidence at protein level","CAB002753, HPA002807","Uncertain",NA,"Approved","Cytosol","Renal cancer:6.06e-9 (unfavourable), Stomach cancer:3.08e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"heart muscle: 319.8","Cell line enhanced",NA,"ASC diff: 1212.9;ASC TERT1: 638.2;HSkMC: 676.6"
"MFGE8",133,"F7","IOH46424",1164,"0",NA,"Medin.","Q08431","Q08431",4240,"Hs.3745","BA46, EDIL1, hP47, HsT19888, MFG-E8, OAcGD3S, SED1, SPAG10","ENSG00000140545","Milk fat globule-EGF factor 8 protein","15","88898683-88913411","Cancer-related genes, Predicted secreted proteins","Evidence at protein level","CAB002753, HPA002807","Uncertain",NA,"Approved","Cytosol","Renal cancer:6.06e-9 (unfavourable), Stomach cancer:3.08e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"heart muscle: 319.8","Cell line enhanced",NA,"ASC diff: 1212.9;ASC TERT1: 638.2;HSkMC: 676.6"
"MGAT4B",75,"B11","IOH27073",1647,"0",NA,"mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isozyme B, mRNA (cDNA clone MGC:60130 IMAGE:6196058), complete cds","BC051835.1","AAH51835.1",11282,"Hs.567419","GnT-Ivb","ENSG00000161013","Mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isozyme B","5","179797597-179806952","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA052134","Uncertain",NA,NA,NA,"Glioma:8.53e-5 (unfavourable), Renal cancer:5.78e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"small intestine: 153.7","Expressed in all",NA,NA
"MGAT4B",103,"E12","IOH44235",1692,"0",NA,"mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isozyme B (MGAT4B), transcript variant 2, mRNA.","NM_054013.3","NP_463459.1",11282,"Hs.567419","GnT-Ivb","ENSG00000161013","Mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isozyme B","5","179797597-179806952","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA052134","Uncertain",NA,NA,NA,"Glioma:8.53e-5 (unfavourable), Renal cancer:5.78e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"small intestine: 153.7","Expressed in all",NA,NA
"MGP",136,"D3","IOH57048",312,"0",NA,"matrix Gla protein, mRNA (cDNA clone MGC:12316 IMAGE:3930143), complete cds","BC005272.1","AAH05272.1",4256,"Hs.365706",NA,"ENSG00000111341","Matrix Gla protein","12","14881181-14885926","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA013949","Approved",NA,NA,NA,"Renal cancer:4.15e-6 (unfavourable)","Expressed in all","Tissue enhanced",NA,"breast: 4883.1","smooth muscle: 1900.4","Cell line enriched",5,"AN3-CA: 9115.9"
"MGP",145,"C11","IOH63180",312,"0",NA,"matrix Gla protein, mRNA (cDNA clone MGC:111227 IMAGE:30405585), complete cds","BC093078.1","AAH93078.1",4256,"Hs.365706",NA,"ENSG00000111341","Matrix Gla protein","12","14881181-14885926","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA013949","Approved",NA,NA,NA,"Renal cancer:4.15e-6 (unfavourable)","Expressed in all","Tissue enhanced",NA,"breast: 4883.1","smooth muscle: 1900.4","Cell line enriched",5,"AN3-CA: 9115.9"
"MGST2",15,"G12","IOH13576",444,"NP_002404.1","NP_002404.1","microsomal glutathione S-transferase 2 (MGST2), mRNA.","NM_002413.3","NP_002404.1",4258,"Hs.81874","MGST-II","ENSG00000085871","Microsomal glutathione S-transferase 2","4","139665768-139740745","Enzymes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA010707","Approved",NA,"Approved","Nucleoplasm","Renal cancer:3.22e-9 (favourable), Endometrial cancer:5.26e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"liver: 178.3","Mixed",NA,NA
"MIA",38,"B6","IOH7479",396,"0",NA,"melanoma inhibitory activity (MIA), mRNA.","NM_006533.2","NP_006524.1",8190,"Hs.646364","CD-RAP","ENSG00000261857","Melanoma inhibitory activity","19","40771648-40777490","Cancer-related genes, Predicted secreted proteins","Evidence at protein level","HPA031950, HPA042369","Supported","Supported",NA,NA,"Breast cancer:2.08e-4 (favourable)","Tissue enriched","Tissue enhanced",NA,"breast: 62.9;stomach: 50.0","salivary gland: 18.4","Group enriched",41,"AN3-CA: 79.3;CAPAN-2: 63.4;SK-MEL-30: 198.0;WM-115: 233.6"
"MIER1",38,"A11","IOH12806",471,"0",NA,"mesoderm induction early response 1 homolog (Xenopus laevis), mRNA (cDNA clone IMAGE:4692746), complete cds.","BC017423.1","AAH17423.1",57708,"Hs.652983","hMI-ER1, KIAA1610, MI-ER1","ENSG00000198160","MIER1 transcriptional regulator","1","66924895-66988619","Predicted intracellular proteins, Predicted secreted proteins, Transcription factors","Evidence at protein level","HPA019589, HPA050306","Enhanced",NA,"Enhanced","Nucleoplasm","Glioma:6.18e-8 (favourable), Colorectal cancer:4.96e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"bone marrow: 63.1","Expressed in all",NA,NA
"MLN",150,"G5","IOH61914",348,"0",NA,"motilin, mRNA (cDNA clone MGC:97389 IMAGE:7262661), complete cds","BC069675.1","AAH69675.1",4295,"Hs.2813",NA,"ENSG00000096395","Motilin","6","33794673-33804011","Predicted secreted proteins","Evidence at protein level","HPA069392","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",6,"duodenum: 253.3","small intestine: 42.3","Cell line enhanced",NA,"CACO-2: 2.4;TIME: 1.1"
"MMP1",141,"B6","IOH59103",1410,"0",NA,"matrix metallopeptidase 1 (interstitial collagenase) (MMP1), transcript variant 1, mRNA.","NM_002421.3","NP_002412.1",4312,"Hs.83169","CLG","ENSG00000196611","Matrix metallopeptidase 1","11","102789920-102798160","Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA004920",NA,NA,"Approved","Vesicles","Renal cancer:9.86e-10 (unfavourable), Liver cancer:4.22e-6 (unfavourable), Cervical cancer:4.66e-4 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"appendix: 39.2;gallbladder: 126.4","urinary bladder: 29.1","Cell line enhanced",NA,"BJ hTERT+: 921.1;HBF TERT88: 1061.5;HUVEC TERT2: 2464.5;WM-115: 1436.5"
"MMP10",3,"E9","IOH4106",1431,"0",NA,"matrix metallopeptidase 10 (stromelysin 2) (MMP10), mRNA.","NM_002425.1","NP_002416.1",4319,"Hs.2258","STMY2","ENSG00000166670","Matrix metallopeptidase 10","11","102770503-102780628","Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins","Evidence at protein level","CAB002159","Uncertain",NA,"Approved","Plasma membrane<br>Cytosol","Urothelial cancer:7.12e-4 (favourable)","Tissue enhanced","Tissue enriched",40,"endometrium: 443.1","appendix: 11.1","Cell line enhanced",NA,"BJ: 10.0;HUVEC TERT2: 12.6;SCLC-21H: 5.6"
"MMP12",70,"H4","IOH29597",1413,"0",NA,"matrix metallopeptidase 12 (macrophage elastase) (MMP12), mRNA.","NM_002426.3","NP_002417.2",4321,"Hs.1695","HME","ENSG00000262406","Matrix metallopeptidase 12","11","102862736-102875034","Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Liver cancer:1.42e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"appendix: 54.6;urinary bladder: 28.7","tonsil: 17.3","Group enriched",11,"BJ: 2.7;fHDF/TERT166: 8.5;hTEC/SVTERT24-B: 6.1"
"MMP13",155,"E1","IOH62530",1416,"0",NA,"matrix metallopeptidase 13 (collagenase 3), mRNA (cDNA clone MGC:79423 IMAGE:7002185), complete cds","BC067523.1","AAH67523.1",4322,"Hs.2936","CLG3","ENSG00000137745","Matrix metallopeptidase 13","11","102942995-102955734","Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"lung: 1.5;urinary bladder: 1.3","appendix: 0.3","Cell line enhanced",NA,"HaCaT: 15.8;PC-3: 6.2"
"MMP13",99,"C5","IOH40173",1416,"0",NA,"matrix metallopeptidase 13 (collagenase 3) (MMP13), mRNA.","NM_002427.2","NP_002418.1",4322,"Hs.2936","CLG3","ENSG00000137745","Matrix metallopeptidase 13","11","102942995-102955734","Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"lung: 1.5;urinary bladder: 1.3","appendix: 0.3","Cell line enhanced",NA,"HaCaT: 15.8;PC-3: 6.2"
"MMP19",75,"B10","IOH26664",1527,"0",NA,"matrix metallopeptidase 19 (MMP19), transcript variant 1, mRNA.","NM_002429.4","NP_002420.1",4327,"Hs.591033","MMP18, RASI-1","ENSG00000123342","Matrix metallopeptidase 19","12","55835433-55842966","Disease related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins","Evidence at protein level","HPA070804",NA,NA,"Approved","Endoplasmic reticulum<br>Vesicles","Renal cancer:8.56e-9 (unfavourable)","Expressed in all","Tissue enhanced",NA,"adipose tissue: 64.2;gallbladder: 97.3","placenta: 28.2","Cell line enriched",7,"BEWO: 141.1"
"MMP2",3,"F9","IOH4128",1983,"0",NA,"matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) (MMP2), transcript variant 1, mRNA.","NM_004530.4","NP_004521.1",4313,"Hs.513617","CLG4, CLG4A, TBE-1","ENSG00000087245","Matrix metallopeptidase 2","16","55389700-55506691","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA001939, CAB002788","Approved",NA,"Uncertain","Vesicles<br>Cytosol",NA,"Expressed in all","Tissue enhanced",NA,"gallbladder: 1682.1","urinary bladder: 910.7","Cell line enhanced",NA,"ASC diff: 3859.6;U-138 MG: 1525.4;U-87 MG: 1772.5"
"MMP28",38,"A6","IOH12522",393,"0",NA,"matrix metallopeptidase 28 (MMP28), transcript variant 3, mRNA.","NM_001032278.1","NP_001027449.1",79148,"Hs.380710","EPILYSIN, MM28, MMP-25, MMP-28","ENSG00000271447","Matrix metallopeptidase 28","17","35756249-35795707","Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Pancreatic cancer:6.28e-6 (unfavourable)","Mixed","Tissue enhanced",NA,"testis: 6.5","adipose tissue: 4.2","Cell line enriched",9,"HaCaT: 32.1"
"MMP28",126,"H7","IOH5289",1182,"0",NA,"matrix metallopeptidase 28, mRNA (cDNA clone MGC:4164 IMAGE:3610296), complete cds","BC002631.2","AAH02631.1",79148,"Hs.380710","EPILYSIN, MM28, MMP-25, MMP-28","ENSG00000271447","Matrix metallopeptidase 28","17","35756249-35795707","Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Pancreatic cancer:6.28e-6 (unfavourable)","Mixed","Tissue enhanced",NA,"testis: 6.5","adipose tissue: 4.2","Cell line enriched",9,"HaCaT: 32.1"
"MMP3",100,"C8","IOH29837",1434,"0",NA,"matrix metallopeptidase 3 (stromelysin 1, progelatinase) (MMP3), mRNA.","NM_002422.3","NP_002413.1",4314,"Hs.375129","STMY, STMY1","ENSG00000149968","Matrix metallopeptidase 3","11","102835801-102843803","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA007875","Uncertain",NA,"Supported","Vesicles","Pancreatic cancer:4.09e-4 (unfavourable), Cervical cancer:9.73e-4 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"appendix: 26.5;endometrium: 58.6","urinary bladder: 9.0","Group enriched",15,"BJ: 1172.2;BJ hTERT+: 3041.4;fHDF/TERT166: 1276.8"
"MMP3",150,"E5","IOH61906",1434,"0",NA,"matrix metallopeptidase 3 (stromelysin 1, progelatinase), mRNA (cDNA clone MGC:97329 IMAGE:7262578), complete cds","BC069676.1","AAH69676.1",4314,"Hs.375129","STMY, STMY1","ENSG00000149968","Matrix metallopeptidase 3","11","102835801-102843803","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA007875","Uncertain",NA,"Supported","Vesicles","Pancreatic cancer:4.09e-4 (unfavourable), Cervical cancer:9.73e-4 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"appendix: 26.5;endometrium: 58.6","urinary bladder: 9.0","Group enriched",15,"BJ: 1172.2;BJ hTERT+: 3041.4;fHDF/TERT166: 1276.8"
"MMP7",2,"B8","IOH5216",804,"0",NA,"matrix metallopeptidase 7 (matrilysin, uterine), mRNA (cDNA clone MGC:3913 IMAGE:3545760), complete cds","BC003635.2","AAH03635.1",4316,"Hs.2256","MPSL1, PUMP-1","ENSG00000137673","Matrix metallopeptidase 7","11","102520508-102530753","Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB025869, HPA051358","Supported",NA,"Approved","Nucleoplasm<br>Vesicles","Liver cancer:2.53e-4 (unfavourable), Lung cancer:3.38e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"gallbladder: 820.8","breast: 201.7","Cell line enhanced",NA,"A549: 133.0;CAPAN-2: 715.3;EFO-21: 178.3;RPTEC TERT1: 262.4"
"MMP7",133,"E12","IOH53878",804,"0",NA,"matrix metallopeptidase 7 (matrilysin, uterine) (MMP7), mRNA.","NM_002423.3","NP_002414.1",4316,"Hs.2256","MPSL1, PUMP-1","ENSG00000137673","Matrix metallopeptidase 7","11","102520508-102530753","Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB025869, HPA051358","Supported",NA,"Approved","Nucleoplasm<br>Vesicles","Liver cancer:2.53e-4 (unfavourable), Lung cancer:3.38e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"gallbladder: 820.8","breast: 201.7","Cell line enhanced",NA,"A549: 133.0;CAPAN-2: 715.3;EFO-21: 178.3;RPTEC TERT1: 262.4"
"MMP8",111,"B7","IOH45732",1404,"0",NA,"matrix metallopeptidase 8 (neutrophil collagenase) (MMP8), mRNA.","NM_002424.2","NP_002415.1",4317,"Hs.161839","CLG1","ENSG00000118113","Matrix metallopeptidase 8","11","102711795-102727050","Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA021221, HPA022935","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",103,"bone marrow: 335.8","endometrium: 3.2","Cell line enriched",10,"WM-115: 69.6"
"MMP9",83,"D7","IOH6670",2124,"0",NA,"matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase), mRNA (cDNA clone MGC:12688 IMAGE:4054882), complete cds","BC006093.1","AAH06093.1",4318,"Hs.297413","CLG4B","ENSG00000100985","Matrix metallopeptidase 9","20","46008908-46016561","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB000348, HPA001238, HPA063909, CAB068199, CAB068200, CAB068201","Enhanced",NA,"Approved","Cytosol","Renal cancer:4.05e-5 (unfavourable), Endometrial cancer:2.55e-4 (favourable), Liver cancer:7.19e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"bone marrow: 252.6;lymph node: 117.7","appendix: 82.8","Cell line enriched",8,"NB-4: 227.3"
"MMRN2",154,"B9","IOH62659",2850,"0",NA,"multimerin 2, mRNA (cDNA clone MGC:104596 IMAGE:30343159), complete cds","BC094744.1","AAH94744.1",79812,"Hs.524479","EMILIN3, EndoGlyx-1, FLJ13465","ENSG00000173269","Multimerin 2","10","86935540-86969481","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA020741","Approved",NA,"Approved","Vesicles",NA,"Expressed in all","Expressed in all",NA,NA,"placenta: 101.6","Cell line enhanced",NA,"CAPAN-2: 78.1;HUVEC TERT2: 155.0;TIME: 182.9"
"MOXD1",5,"H11","IOH13443",1842,"0",NA,"monooxygenase, DBH-like 1, mRNA (cDNA clone MGC:31962 IMAGE:4841330), complete cds","BC018756.1","AAH18756.1",26002,"Hs.6909","dJ248E1.1, DKFZP564G202, MOX","ENSG00000079931","Monooxygenase DBH like 1","6","132296055-132401545","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA035740","Approved",NA,"Approved","Nucleoplasm<br>Cytosol","Head and neck cancer:7.09e-5 (favourable), Stomach cancer:3.72e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"endometrium: 106.1;smooth muscle: 114.5","seminal vesicle: 53.7","Cell line enhanced",NA,"ASC diff: 111.5;fHDF/TERT166: 149.9;HBF TERT88: 116.1;U-2197: 280.6"
"MPZL1",105,"G10","IOH43374",630,"NP_003944.1","NP_078845.3","myelin protein zero-like 1 (MPZL1), transcript variant 2, mRNA.","NM_024569.4","NP_078845.3",9019,"Hs.493919","FLJ21047, PZR","ENSG00000197965","Myelin protein zero like 1","1","167721192-167791919","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA026966, HPA063538","Approved",NA,"Supported","Vesicles<br>Plasma membrane","Renal cancer:3.99e-7 (unfavourable), Liver cancer:4.27e-6 (unfavourable), Lung cancer:3.98e-4 (unfavourable), Thyroid cancer:8.08e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"breast: 111.6","Expressed in all",NA,NA
"MPZL1",92,"H7","IOH6689",810,"0",NA,"myelin protein zero-like 1 (MPZL1), transcript variant 1, mRNA.","NM_003953.5","NP_003944.1",9019,"Hs.493919","FLJ21047, PZR","ENSG00000197965","Myelin protein zero like 1","1","167721192-167791919","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA026966, HPA063538","Approved",NA,"Supported","Vesicles<br>Plasma membrane","Renal cancer:3.99e-7 (unfavourable), Liver cancer:4.27e-6 (unfavourable), Lung cancer:3.98e-4 (unfavourable), Thyroid cancer:8.08e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"breast: 111.6","Expressed in all",NA,NA
"MPZL1",125,"B6","IOH11267",444,"0",NA,"myelin protein zero-like 1, mRNA (cDNA clone IMAGE:5103084), complete cds.","BC019890.1","AAH19890.1",9019,"Hs.493919","FLJ21047, PZR","ENSG00000197965","Myelin protein zero like 1","1","167721192-167791919","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA026966, HPA063538","Approved",NA,"Supported","Vesicles<br>Plasma membrane","Renal cancer:3.99e-7 (unfavourable), Liver cancer:4.27e-6 (unfavourable), Lung cancer:3.98e-4 (unfavourable), Thyroid cancer:8.08e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"breast: 111.6","Expressed in all",NA,NA
"MR1",73,"A12","IOH10861",891,"NP_001522.1","AAH12485.1","major histocompatibility complex, class I-related, mRNA (cDNA clone MGC:21757 IMAGE:4540305), complete cds","BC012485.1","AAH12485.1",3140,"Hs.101840","HLALS","ENSG00000153029","Major histocompatibility complex, class I-related","1","181033425-181061938","FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA048304",NA,NA,"Supported","Plasma membrane",NA,"Expressed in all","Mixed",NA,NA,"thyroid gland: 28.2","Mixed",NA,NA
"MR1",133,"C6","IOH46372",1026,"0",NA,"major histocompatibility complex, class I-related (MR1), mRNA.","NM_001531.1","NP_001522.1",3140,"Hs.101840","HLALS","ENSG00000153029","Major histocompatibility complex, class I-related","1","181033425-181061938","FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA048304",NA,NA,"Supported","Plasma membrane",NA,"Expressed in all","Mixed",NA,NA,"thyroid gland: 28.2","Mixed",NA,NA
"MRPL32",11,"F4","IOH10716",567,"0",NA,"mitochondrial ribosomal protein L32 (MRPL32), nuclear gene encoding mitochondrial protein, mRNA.","NM_031903.2","NP_114109.1",64983,"Hs.50252","bMRP-59b, HSPC283, L32mt, MRP-L32","ENSG00000106591","Mitochondrial ribosomal protein L32","7","42932200-42948958","Predicted secreted proteins, Ribosomal proteins","Evidence at protein level","HPA048965","Uncertain",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"adrenal gland: 72.1","Expressed in all",NA,NA
"MRPL52",139,"G5","IOH58678",369,"0",NA,"mitochondrial ribosomal protein L52 (MRPL52), nuclear gene encoding mitochondrial protein, transcript variant 3, mRNA.","NM_180982.2","NP_851313.1",122704,"Hs.355935",NA,"ENSG00000172590","Mitochondrial ribosomal protein L52","14","22829879-22835037","Predicted intracellular proteins, Predicted secreted proteins, Ribosomal proteins","Evidence at protein level","HPA012319","Approved",NA,"Approved","Mitochondria",NA,"Expressed in all","Expressed in all",NA,NA,"appendix: 72.1","Expressed in all",NA,NA
"MRPL52",93,"C8","IOH40777",372,"0",NA,"mitochondrial ribosomal protein L52, mRNA (cDNA clone MGC:78604 IMAGE:5458482), complete cds","BC068070.1","AAH68070.1",122704,"Hs.355935",NA,"ENSG00000172590","Mitochondrial ribosomal protein L52","14","22829879-22835037","Predicted intracellular proteins, Predicted secreted proteins, Ribosomal proteins","Evidence at protein level","HPA012319","Approved",NA,"Approved","Mitochondria",NA,"Expressed in all","Expressed in all",NA,NA,"appendix: 72.1","Expressed in all",NA,NA
"MRPL52",113,"G2","IOH45755",195,"0",NA,"mitochondrial ribosomal protein L52 (MRPL52), nuclear gene encoding mitochondrial protein, transcript variant 4, mRNA.","NM_181304.2","NP_851821.1",122704,"Hs.355935",NA,"ENSG00000172590","Mitochondrial ribosomal protein L52","14","22829879-22835037","Predicted intracellular proteins, Predicted secreted proteins, Ribosomal proteins","Evidence at protein level","HPA012319","Approved",NA,"Approved","Mitochondria",NA,"Expressed in all","Expressed in all",NA,NA,"appendix: 72.1","Expressed in all",NA,NA
"MRPS22",8,"C3","IOH12268",1083,"0",NA,"mitochondrial ribosomal protein S22 (MRPS22), nuclear gene encoding mitochondrial protein, mRNA.","NM_020191.2","NP_064576.1",56945,"Hs.75724","C3orf5, GIBT, GK002, MRP-S22","ENSG00000175110","Mitochondrial ribosomal protein S22","3","139005806-139357223","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins, Ribosomal proteins","Evidence at protein level","HPA006083, HPA007830","Enhanced",NA,"Supported","Mitochondria","Endometrial cancer:1.35e-5 (unfavourable), Pancreatic cancer:1.55e-5 (unfavourable), Prostate cancer:1.85e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"adrenal gland: 69.5","Expressed in all",NA,NA
"MRPS28",122,"A11","IOH12228",564,"0",NA,"mitochondrial ribosomal protein S28 (MRPS28), nuclear gene encoding mitochondrial protein, mRNA.","NM_014018.2","NP_054737.1",28957,"Hs.521124","HSPC007, MRP-S28, MRPS35","ENSG00000147586","Mitochondrial ribosomal protein S28","8","79918717-80030289","Predicted intracellular proteins, Predicted secreted proteins, Ribosomal proteins","Evidence at protein level","HPA027202","Approved",NA,"Enhanced","Mitochondria","Renal cancer:1.20e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"adrenal gland: 114.1","Expressed in all",NA,NA
"MSH5",74,"B10","IOH28000",2469,"0",NA,"mutS homolog 5 (E. coli), mRNA (cDNA clone MGC:52249 IMAGE:4591368), complete cds","BC041031.1","AAH41031.1",4439,"Hs.647011","G7","ENSG00000204410","MutS homolog 5","6","31739948-31762834","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA062688",NA,NA,"Approved","Endoplasmic reticulum<br>Vesicles",NA,"Mixed","Mixed",NA,NA,"skin: 1.7","Mixed",NA,NA
"MSH5",64,"B1","IOH3942",2508,"0",NA,"mutS homolog 5 (E. coli) (MSH5), transcript variant 2, mRNA.","NM_172165.2","NP_751897.1",4439,"Hs.647011","G7","ENSG00000204410","MutS homolog 5","6","31739948-31762834","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA062688",NA,NA,"Approved","Endoplasmic reticulum<br>Vesicles",NA,"Mixed","Mixed",NA,NA,"skin: 1.7","Mixed",NA,NA
"MSLN",51,"C4","IOH14502",1869,"0",NA,"mesothelin, mRNA (cDNA clone MGC:10273 IMAGE:3957372), complete cds","BC009272.2","AAH09272.1",10232,"Hs.408488","CAK1, MPF","ENSG00000102854","Mesothelin","16","760762-768865","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB002216, HPA017172","Enhanced",NA,"Approved","Nucleoplasm<br>Vesicles","Renal cancer:5.91e-4 (favourable), Pancreatic cancer:6.66e-4 (unfavourable)","Tissue enhanced","Group enriched",9,"fallopian tube: 445.8;lung: 105.4","epididymis: 29.1","Cell line enhanced",NA,"CAPAN-2: 448.3;EFO-21: 72.6;HeLa: 104.4;hTCEpi: 80.2"
"MSLN",47,"H6","IOH5479",1866,"0",NA,"mesothelin, mRNA (cDNA clone MGC:10686 IMAGE:3611296), complete cds","BC003512.1","AAH03512.1",10232,"Hs.408488","CAK1, MPF","ENSG00000102854","Mesothelin","16","760762-768865","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB002216, HPA017172","Enhanced",NA,"Approved","Nucleoplasm<br>Vesicles","Renal cancer:5.91e-4 (favourable), Pancreatic cancer:6.66e-4 (unfavourable)","Tissue enhanced","Group enriched",9,"fallopian tube: 445.8;lung: 105.4","epididymis: 29.1","Cell line enhanced",NA,"CAPAN-2: 448.3;EFO-21: 72.6;HeLa: 104.4;hTCEpi: 80.2"
"MSMB",106,"A6","IOH44784",234,"0",NA,"microseminoprotein, beta- (MSMB), transcript variant PSP57, mRNA.","NM_138634.1","NP_619540.1",4477,"Hs.255462","IGBF, MSP, MSPB, PN44, PRPS, PSP, PSP-94, PSP57, PSP94","ENSG00000263639","Microseminoprotein beta","10","46033307-46046269","Cancer-related genes, Disease related genes, Predicted secreted proteins","Evidence at protein level","CAB026357, HPA051257","Enhanced",NA,NA,NA,"Urothelial cancer:7.19e-4 (favourable)","Tissue enriched","Tissue enriched",26,"prostate: 15294.0","stomach: 588.5","Cell line enhanced",NA,"BEWO: 24.7;NB-4: 13.6;RPMI-8226: 7.7;SH-SY5Y: 6.3;U-2197: 11.3"
"MSMB",38,"H2","IOH7298",345,"0",NA,"microseminoprotein, beta- (MSMB), transcript variant PSP94, mRNA.","NM_002443.2","NP_002434.1",4477,"Hs.255462","IGBF, MSP, MSPB, PN44, PRPS, PSP, PSP-94, PSP57, PSP94","ENSG00000263639","Microseminoprotein beta","10","46033307-46046269","Cancer-related genes, Disease related genes, Predicted secreted proteins","Evidence at protein level","CAB026357, HPA051257","Enhanced",NA,NA,NA,"Urothelial cancer:7.19e-4 (favourable)","Tissue enriched","Tissue enriched",26,"prostate: 15294.0","stomach: 588.5","Cell line enhanced",NA,"BEWO: 24.7;NB-4: 13.6;RPMI-8226: 7.7;SH-SY5Y: 6.3;U-2197: 11.3"
"MSRA",64,"G2","IOH29124",708,"0",NA,"methionine sulfoxide reductase A (MSRA), transcript variant 1, mRNA.","NM_012331.3","NP_036463.1",4482,"Hs.490981",NA,"ENSG00000175806","Methionine sulfoxide reductase A","8","10054268-10428891","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA023804, HPA053069","Approved",NA,"Enhanced","Nucleoplasm<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"kidney: 113.1","Mixed",NA,NA
"MSRB3",82,"C2","IOH26397",558,"0",NA,"methionine sulfoxide reductase B3 (MSRB3), transcript variant 2, mRNA.","NM_001031679.1","NP_001026849.1",253827,"Hs.339024","DFNB74, DKFZp686C1178, FLJ36866","ENSG00000174099","Methionine sulfoxide reductase B3","12","65278643-65488244","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA014432","Uncertain",NA,NA,NA,"Renal cancer:8.85e-8 (unfavourable), Urothelial cancer:2.17e-4 (unfavourable), Cervical cancer:3.84e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"smooth muscle: 181.5","Mixed",NA,NA
"MST1",118,"C11","IOH26579",2136,"0",NA,"macrophage stimulating 1 (hepatocyte growth factor-like), mRNA (cDNA clone MGC:51837 IMAGE:5190966), complete cds","BC048330.1","AAH48330.1",4485,"Hs.349110","D3F15S2, DNF15S2, HGFL, MSP, NF15S2","ENSG00000173531","Macrophage stimulating 1","3","49683947-49689501","Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA024036","Uncertain",NA,NA,NA,"Pancreatic cancer:7.14e-4 (favourable)","Tissue enriched","Tissue enhanced",NA,"liver: 144.2","duodenum: 51.1","Cell line enhanced",NA,"Hep G2: 57.1;U-266/70: 16.6"
"MSTN",113,"G8","IOH44374",1128,"0",NA,"myostatin (MSTN), mRNA.","NM_005259.2","NP_005250.1",2660,"Hs.41565","GDF8","ENSG00000138379","Myostatin","2","190055697-190062729","Disease related genes, Predicted secreted proteins","Evidence at protein level","CAB009963","Approved",NA,NA,NA,"Glioma:3.98e-4 (favourable)","Tissue enriched","Tissue enhanced",NA,"skeletal muscle: 3.4","cerebral cortex,endometrium: 1.3","Group enriched",13,"LHCN-M2: 21.5;RH-30: 50.3"
"MTMR14",61,"G5","IOH26051",1953,"0",NA,"myotubularin related protein 14 (MTMR14), transcript variant 2, mRNA.","NM_001077525.1","NP_001070993.1",64419,"Hs.475382","C3orf29, FLJ22405, FLJ90311, hEDTP, hJumpy","ENSG00000163719","Myotubularin related protein 14","3","9649433-9702393","Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA054063","Approved",NA,NA,NA,"Renal cancer:2.74e-4 (favourable), Liver cancer:3.95e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 41.8","Expressed in all",NA,NA
"MTMR14",61,"D4","IOH27000",1797,"0",NA,"myotubularin related protein 14 (MTMR14), transcript variant 1, mRNA.","NM_001077526.1","NP_001070994.1",64419,"Hs.475382","C3orf29, FLJ22405, FLJ90311, hEDTP, hJumpy","ENSG00000163719","Myotubularin related protein 14","3","9649433-9702393","Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA054063","Approved",NA,NA,NA,"Renal cancer:2.74e-4 (favourable), Liver cancer:3.95e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 41.8","Expressed in all",NA,NA
"MTTP",93,"B5","IOH40720",456,"0",NA,"microsomal triglyceride transfer protein, mRNA (cDNA clone IMAGE:30382125), complete cds.","BC062696.1","AAH62696.1",4547,"Hs.195799","ABL, MTP","ENSG00000138823","Microsomal triglyceride transfer protein","4","99563761-99623999","Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA051170, HPA054862","Uncertain",NA,"Approved","Cytosol",NA,"Tissue enriched","Group enriched",16,"duodenum: 236.3;liver: 133.9;small intestine: 292.6","testis: 13.5","Cell line enhanced",NA,"AF22: 10.2;Hep G2: 8.0"
"MUC20",127,"E10","IOH26374",1617,"0",NA,"mucin 20, cell surface associated, mRNA (cDNA clone MGC:50835 IMAGE:5754328), complete cds","BC044243.1","AAH44243.1",200958,"Hs.308992","FLJ14408, KIAA1359","ENSG00000176945","Mucin 20, cell surface associated","3","195720882-195741123","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA042249",NA,NA,"Approved","Nucleoplasm<br>Plasma membrane<br>Cytosol","Renal cancer:1.57e-4 (favourable)","Mixed","Mixed",NA,NA,"colon: 10.4","Cell line enriched",7,"SK-BR-3: 20.9"
"MUC20",78,"B11","IOH22830",1668,"0",NA,"mucin 20, cell surface associated, mRNA (cDNA clone MGC:34717 IMAGE:3851952), complete cds","BC029267.1","AAH29267.1",200958,"Hs.308992","FLJ14408, KIAA1359","ENSG00000176945","Mucin 20, cell surface associated","3","195720882-195741123","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA042249",NA,NA,"Approved","Nucleoplasm<br>Plasma membrane<br>Cytosol","Renal cancer:1.57e-4 (favourable)","Mixed","Mixed",NA,NA,"colon: 10.4","Cell line enriched",7,"SK-BR-3: 20.9"
"MUC7",83,"B11","IOH10828",1134,"0",NA,"mucin 7, secreted, mRNA (cDNA clone MGC:34772 IMAGE:5205526), complete cds","BC025688.1","AAH25688.1",4589,"Hs.631946","FLJ27047, MG2","ENSG00000171195","Mucin 7, secreted","4","70430492-70482997","Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA006411","Enhanced",NA,NA,NA,NA,"Group enriched","Tissue enriched",1464,"salivary gland: 11361.9","ovary: 7.7","Not detected",NA,NA
"MUCL1",106,"H7","IOH42944",273,"0",NA,"mucin-like 1 (MUCL1), mRNA.","NM_058173.2","NP_477521.1",118430,"Hs.348419","SBEM","ENSG00000172551","Mucin like 1","12","54830519-54858393","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA039093","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",43,"breast: 3798.1","salivary gland: 89.1","Cell line enhanced",NA,"MCF7: 1.5;SK-BR-3: 3.5"
"MYBBP1A",118,"G11","IOH26928",3987,"0",NA,"MYB binding protein (P160) 1a, mRNA (cDNA clone MGC:57635 IMAGE:5495483), complete cds","BC050546.1","AAH50546.1",10514,"Hs.22824","FLJ37886, P160, PAP2","ENSG00000132382","MYB binding protein 1a","17","4538897-4555631","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA005466","Supported",NA,"Supported","Nucleoli<br>Vesicles","Pancreatic cancer:1.61e-4 (favourable), Renal cancer:5.95e-4 (unfavourable), Thyroid cancer:8.12e-4 (unfavourable), Melanoma:8.47e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"skin: 21.6","Expressed in all",NA,NA
"MYOC",41,"D2","IOH22825",1515,"0",NA,"myocilin, trabecular meshwork inducible glucocorticoid response (MYOC), mRNA.","NM_000261.1","NP_000252.1",4653,"Hs.436037","GLC1A, JOAG1, TIGR","ENSG00000034971","Myocilin","1","171635417-171652683","Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA027364","Approved",NA,NA,NA,NA,"Tissue enriched","Tissue enhanced",NA,"adipose tissue: 45.4","esophagus: 21.4","Not detected",NA,NA
"N4BP2L2",12,"G9","IOH9700",1752,"0",NA,"NEDD4 binding protein 2-like 2 (N4BP2L2), transcript variant 2, mRNA.","NM_014887.2","NP_055702.1",10443,"Hs.507680","CG005, PFAAP5","ENSG00000244754","NEDD4 binding protein 2 like 2","13","32432417-32538885","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA039338, HPA039434, HPA059327","Approved",NA,"Approved","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"endometrium: 57.6","Expressed in all",NA,NA
"NAAA",94,"E7","IOH40605",600,"0",NA,"N-acylethanolamine acid amidase, mRNA (cDNA clone MGC:12829 IMAGE:4122755), complete cds","BC006388.2","AAH06388.2",27163,"Hs.437365","ASAHL","ENSG00000138744","N-acylethanolamine acid amidase","4","75913657-75941051","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB026135","Approved",NA,NA,NA,"Endometrial cancer:1.93e-4 (favourable), Pancreatic cancer:4.90e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"prostate: 114.9","Mixed",NA,NA
"NAGA",34,"G12","IOH4589",1236,"0",NA,"N-acetylgalactosaminidase, alpha- (NAGA), mRNA.","NM_000262.2","NP_000253.1",4668,"Hs.75372","D22S674","ENSG00000198951","Alpha-N-acetylgalactosaminidase","22","42058354-42070842","Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins","Evidence at protein level","HPA000649","Enhanced",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 63.7","Expressed in all",NA,NA
"NAGLU",122,"E1","IOH29377",2232,"0",NA,"N-acetylglucosaminidase, alpha-, mRNA (cDNA clone MGC:59849 IMAGE:6213852), complete cds","BC053991.1","AAH53991.1",4669,"Hs.50727","NAG","ENSG00000108784","N-acetyl-alpha-glucosaminidase","17","42536172-42544449","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA038815","Supported","Approved",NA,NA,"Renal cancer:2.58e-6 (favourable), Glioma:3.43e-4 (unfavourable), Endometrial cancer:4.17e-4 (favourable), Pancreatic cancer:6.90e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 47.5","Expressed in all",NA,NA
"NAPSA",132,"B7","IOH29832",1263,"0",NA,"napsin A aspartic peptidase (NAPSA), mRNA.","NM_004851.1","NP_004842.1",9476,"Hs.714418","KAP, Kdap, NAP1, NAPA","ENSG00000131400","Napsin A aspartic peptidase","19","50358477-50365830","Enzymes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB009591, HPA045280, HPA047236, HPA047744","Enhanced",NA,NA,NA,"Renal cancer:1.21e-4 (favourable)","Tissue enriched","Tissue enriched",14,"lung: 1412.2","kidney: 101.4","Cell line enriched",23,"U-698: 27.1"
"NAPSA",7,"F6","IOH12945",1263,"0",NA,"napsin A aspartic peptidase, mRNA (cDNA clone MGC:22526 IMAGE:4693995), complete cds","BC017842.1","AAH17842.1",9476,"Hs.714418","KAP, Kdap, NAP1, NAPA","ENSG00000131400","Napsin A aspartic peptidase","19","50358477-50365830","Enzymes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB009591, HPA045280, HPA047236, HPA047744","Enhanced",NA,NA,NA,"Renal cancer:1.21e-4 (favourable)","Tissue enriched","Tissue enriched",14,"lung: 1412.2","kidney: 101.4","Cell line enriched",23,"U-698: 27.1"
"NBL1",49,"G2","IOH9786",543,"0",NA,"neuroblastoma, suppression of tumorigenicity 1 (NBL1), transcript variant 2, mRNA.","NM_005380.4","NP_005371.1",4681,"Hs.654502","D1S1733E, DAN, DAND1, NB, NO3","ENSG00000158747","Neuroblastoma 1, DAN family BMP antagonist","1","19640554-19658456","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA007394, CAB026132","Uncertain",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"ovary: 552.0","Cell line enhanced",NA,"SK-MEL-30: 357.2"
"NCAM1",149,"D12","IOH61149",2577,"NP_000606.1","AAH47244.1","neural cell adhesion molecule 1, mRNA (cDNA clone MGC:47611 IMAGE:5590188), complete cds","BC047244.1","AAH47244.1",4684,"Hs.503878","CD56, NCAM","ENSG00000149294","Neural cell adhesion molecule 1","11","112961247-113278436","Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB000142, CAB018071, HPA039835","Enhanced",NA,"Enhanced","Plasma membrane<br>Cytosol","Pancreatic cancer:9.11e-6 (favourable), Renal cancer:8.20e-4 (unfavourable)","Tissue enriched","Tissue enhanced",NA,"cerebral cortex: 334.9","heart muscle: 87.5","Cell line enhanced",NA,"RH-30: 128.0;SCLC-21H: 126.2;U-138 MG: 71.8;WM-115: 77.9"
"NCSTN",69,"G3","IOH28808",2070,"0",NA,"nicastrin, mRNA (cDNA clone MGC:51016 IMAGE:4827966), complete cds","BC047621.1","AAH47621.1",23385,"Hs.517249","APH2, KIAA0253","ENSG00000162736","Nicastrin","1","160343272-160358952","Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB021982, HPA054846, HPA070642","Approved",NA,"Approved","Cytosol","Renal cancer:7.75e-9 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 143.2","Expressed in all",NA,NA
"NDP",38,"D2","IOH22822",402,"0",NA,"Norrie disease (pseudoglioma) (NDP), mRNA.","NM_000266.3","NP_000257.1",4693,"Hs.522615","EVR2, norrin","ENSG00000124479","NDP, norrin cystine knot growth factor","X","43948776-43973504","Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA003095","Uncertain",NA,"Supported","Nucleus<br>Nucleoli<br>Vesicles",NA,"Tissue enhanced","Tissue enhanced",NA,"ovary: 53.3","fallopian tube: 31.3","Cell line enriched",16,"U-87 MG: 67.6"
"NDUFA10",116,"G10","IOH23253",606,"0",NA,"NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 10, 42kDa, mRNA (cDNA clone MGC:45660 IMAGE:4872196), complete cds","BC031332.1","AAH31332.1",4705,"Hs.277677","CI-42k","ENSG00000130414","NADH:ubiquinone oxidoreductase subunit A10","2","239892450-240025402","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA059529, HPA067045, CAB070846","Approved",NA,"Supported","Mitochondria","Renal cancer:2.09e-7 (favourable), Melanoma:2.95e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"heart muscle: 63.8","Expressed in all",NA,NA
"NDUFA10",53,"D11","IOH3043",1068,"0",NA,"NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 10, 42kDa (NDUFA10), nuclear gene encoding mitochondrial protein, mRNA.","NM_004544.2","NP_004535.1",4705,"Hs.277677","CI-42k","ENSG00000130414","NADH:ubiquinone oxidoreductase subunit A10","2","239892450-240025402","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA059529, HPA067045, CAB070846","Approved",NA,"Supported","Mitochondria","Renal cancer:2.09e-7 (favourable), Melanoma:2.95e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"heart muscle: 63.8","Expressed in all",NA,NA
"NDUFB5",29,"G12","IOH22925",570,"NP_002483.1","NP_002483.1","NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5, 16kDa (NDUFB5), nuclear gene encoding mitochondrial protein, mRNA.","NM_002492.2","NP_002483.1",4711,"Hs.718447","CI-SGDH, MGC12314, SGDH","ENSG00000136521","NADH:ubiquinone oxidoreductase subunit B5","3","179604690-179627647","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA005640","Enhanced",NA,"Supported","Nucleoplasm<br>Mitochondria","Renal cancer:3.32e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"heart muscle: 136.7","Expressed in all",NA,NA
"NDUFB5",145,"C8","IOH63162",414,"0",NA,"NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5, 16kDa, mRNA (cDNA clone MGC:111204 IMAGE:30325282), complete cds","BC093071.1","AAH93071.1",4711,"Hs.718447","CI-SGDH, MGC12314, SGDH","ENSG00000136521","NADH:ubiquinone oxidoreductase subunit B5","3","179604690-179627647","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA005640","Enhanced",NA,"Supported","Nucleoplasm<br>Mitochondria","Renal cancer:3.32e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"heart muscle: 136.7","Expressed in all",NA,NA
"NDUFS3",127,"H1","IOH4245",795,"0",NA,"NADH dehydrogenase (ubiquinone) Fe-S protein 3, 30kDa (NADH-coenzyme Q reductase) (NDUFS3), nuclear gene encoding mitochondrial protein, mRNA.","NM_004551.2","NP_004542.1",4722,"Hs.502528","CI-30","ENSG00000213619","NADH:ubiquinone oxidoreductase core subunit S3","11","47565336-47584562","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA004484","Approved",NA,"Supported","Nuclear bodies<br>Mitochondria","Renal cancer:2.61e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"skeletal muscle: 127.2","Expressed in all",NA,NA
"NDUFS8",106,"D2","IOH41235",633,"0",NA,"NADH dehydrogenase (ubiquinone) Fe-S protein 8, 23kDa (NADH-coenzyme Q reductase) (NDUFS8), mRNA.","NM_002496.2","NP_002487.1",4728,"Hs.90443","CI-23k, TYKY","ENSG00000110717","NADH:ubiquinone oxidoreductase core subunit S8","11","68030617-68036644","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA018524","Approved",NA,"Supported","Mitochondria","Renal cancer:3.27e-8 (favourable)","Expressed in all","Expressed in all",NA,NA,"adrenal gland: 152.6","Expressed in all",NA,NA
"NELL1",153,"H10","IOH63204",2292,"0",NA,"NEL-like 1 (chicken), mRNA (cDNA clone MGC:116745 IMAGE:40001479), complete cds","BC096103.3","AAH96103.1",4745,"Hs.657172","FLJ45906, IDH3GL","ENSG00000165973","Neural EGFL like 1","11","20669551-21575681","Predicted secreted proteins","Evidence at protein level","HPA051535","Approved",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 22.9;kidney: 18.8","prostate: 8.8","Cell line enhanced",NA,"HAP1: 4.3;SH-SY5Y: 2.0;U-2 OS: 1.1;WM-115: 1.2"
"NELL1",137,"D3","IOH56675",2433,"0",NA,"NEL-like 1 (chicken) (NELL1), transcript variant 1, mRNA.","NM_006157.3","NP_006148.2",4745,"Hs.657172","FLJ45906, IDH3GL","ENSG00000165973","Neural EGFL like 1","11","20669551-21575681","Predicted secreted proteins","Evidence at protein level","HPA051535","Approved",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 22.9;kidney: 18.8","prostate: 8.8","Cell line enhanced",NA,"HAP1: 4.3;SH-SY5Y: 2.0;U-2 OS: 1.1;WM-115: 1.2"
"NELL1",152,"G7","IOH63200",2292,"0",NA,"NEL-like 1 (chicken), mRNA (cDNA clone MGC:116742 IMAGE:40001476), complete cds","BC096100.1","AAH96100.1",4745,"Hs.657172","FLJ45906, IDH3GL","ENSG00000165973","Neural EGFL like 1","11","20669551-21575681","Predicted secreted proteins","Evidence at protein level","HPA051535","Approved",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 22.9;kidney: 18.8","prostate: 8.8","Cell line enhanced",NA,"HAP1: 4.3;SH-SY5Y: 2.0;U-2 OS: 1.1;WM-115: 1.2"
"NELL2",123,"E12","IOH11105",2451,"0",NA,"NEL-like 2 (chicken) (NELL2), transcript variant 2, mRNA.","NM_006159.2","NP_006150.1",4753,"Hs.505326","NRP2","ENSG00000184613","Neural EGFL like 2","12","44508275-44921848","Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA035714, HPA035715","Uncertain",NA,"Approved","Vesicles","Pancreatic cancer:5.56e-4 (favourable)","Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 204.1;fallopian tube: 96.7","prostate: 46.5","Cell line enhanced",NA,"AF22: 102.5;NTERA-2: 41.0;SCLC-21H: 88.2"
"NENF",85,"B12","IOH6506",519,"0",NA,"neuron derived neurotrophic factor (NENF), transcript variant 1, mRNA.","NM_013349.4","NP_037481.1",29937,"Hs.461787","CIR2, SCIRP10, SPUF","ENSG00000117691","Neudesin neurotrophic factor","1","212432887-212446379","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA026763, HPA028488","Uncertain",NA,"Enhanced","Nucleus","Renal cancer:1.54e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cervix, uterine: 82.9","Expressed in all",NA,NA
"NETO1",75,"E10","IOH26431",1602,"NP_620416.1","AAH50329.1","neuropilin (NRP) and tolloid (TLL)-like 1, mRNA (cDNA clone MGC:48642 IMAGE:4821317), complete cds","BC050329.1","AAH50329.1",81832,"Hs.465407","BCTL1, BTCL1","ENSG00000166342","Neuropilin and tolloid like 1","18","72742314-72868146","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA064630",NA,NA,"Approved","Golgi apparatus",NA,"Tissue enhanced","Tissue enriched",16,"cerebral cortex: 64.0","spleen: 4.1","Cell line enhanced",NA,"MOLT-4: 22.4;REH: 24.8;RPMI-8226: 30.0;RT4: 22.5;SCLC-21H: 43.0"
"NID1",72,"F11","IOH27193",3345,"0",NA,"nidogen 1, mRNA (cDNA clone MGC:33141 IMAGE:5271590), complete cds","BC045606.1","AAH45606.1",4811,"Hs.356624","entactin, NID","ENSG00000116962","Nidogen 1","1","235975830-236065162","Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB010044","Approved",NA,NA,NA,"Renal cancer:5.38e-8 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 326.5","Cell line enhanced",NA,"ASC diff: 1062.5;ASC TERT1: 502.4;HSkMC: 444.4"
"NID2",74,"F12","IOH27578",2910,"0",NA,"nidogen 2 (osteonidogen), mRNA (cDNA clone MGC:45169 IMAGE:5205293), complete cds","BC035608.1","AAH35608.1",22795,"Hs.369840",NA,"ENSG00000087303","Nidogen 2","14","52004803-52069228","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA052460, HPA058772","Enhanced",NA,"Supported","Plasma membrane","Urothelial cancer:2.78e-4 (unfavourable), Stomach cancer:7.34e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"placenta: 88.5","thyroid gland: 54.1","Cell line enhanced",NA,"ASC diff: 198.6;BJ: 133.5;HHSteC: 134.5;HSkMC: 435.7"
"NKAIN4",71,"F10","IOH25895",627,"NP_690603.1","AAH41812.1","Na+/K+ transporting ATPase interacting 4, mRNA (cDNA clone MGC:41932 IMAGE:5302801), complete cds","BC041812.1","AAH41812.1",128414,"Hs.46627","bA261N11.2, C20orf58, FAM77A","ENSG00000101198","Sodium/potassium transporting ATPase interacting 4","20","63240784-63272694","Predicted intracellular proteins, Predicted membrane proteins","Evidence at transcript level","HPA029876","Approved",NA,NA,NA,"Endometrial cancer:3.14e-4 (unfavourable)","Tissue enriched","Tissue enriched",13,"cerebral cortex: 71.8","kidney: 5.5","Cell line enhanced",NA,"BEWO: 23.2;MOLT-4: 33.2"
"NLGN3",136,"D12","IOH56381",2487,"NP_061850.1","AAH51715.1","neuroligin 3, mRNA (cDNA clone MGC:48305 IMAGE:5258980), complete cds","BC051715.1","AAH51715.1",54413,"Hs.438877","ASPGX1, AUTSX1, HNL3, KIAA1480","ENSG00000196338","Neuroligin 3","X","71144831-71171201","Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA003183, HPA004066","Enhanced",NA,"Supported","Golgi apparatus<br>Cell Junctions",NA,"Tissue enriched","Tissue enhanced",NA,"cerebral cortex: 62.2","seminal vesicle: 17.3","Cell line enhanced",NA,"AF22: 6.8;NTERA-2: 5.0;SH-SY5Y: 2.9"
"NLGN4Y",80,"F11","IOH21895",405,"0",NA,"Neuroligin-4, Y-linked Precursor (Neuroligin Y) [Source:UniProtKB/Swiss-Prot;Acc:Q8NFZ3]","ENST00000297967","ENSP00000297967",22829,"Hs.439199","KIAA0951","ENSG00000165246","Neuroligin 4, Y-linked","Y","14522638-14845650","Predicted membrane proteins, Predicted secreted proteins","Evidence at transcript level","HPA001651","Approved",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"prostate: 11.4;seminal vesicle: 12.5","cerebral cortex: 7.5","Cell line enhanced",NA,"BJ hTERT+: 28.5;fHDF/TERT166: 21.5;HDLM-2: 30.2;hTCEpi: 16.2;U-138 MG: 23.0"
"NMB",126,"C7","IOH3331",366,"0",NA,"neuromedin B, mRNA (cDNA clone MGC:17211 IMAGE:4185578), complete cds","BC008603.1","AAH08603.1",4828,"Hs.386470","MGC17211, MGC2277, MGC3936","ENSG00000197696","Neuromedin B","15","84655129-84658563","Predicted secreted proteins","Evidence at protein level","CAB019302","Approved",NA,"Approved","Nucleus<br>Vesicles<br>Plasma membrane","Renal cancer:2.25e-4 (unfavourable), Glioma:5.07e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"adipose tissue: 46.2;cerebral cortex: 47.2","thyroid gland: 14.8","Cell line enhanced",NA,"A-431: 46.7"
"NMB",45,"E9","IOH5830",465,"0",NA,"neuromedin B, mRNA (cDNA clone MGC:2277 IMAGE:3030430), complete cds","BC007407.2","AAH07407.1",4828,"Hs.386470","MGC17211, MGC2277, MGC3936","ENSG00000197696","Neuromedin B","15","84655129-84658563","Predicted secreted proteins","Evidence at protein level","CAB019302","Approved",NA,"Approved","Nucleus<br>Vesicles<br>Plasma membrane","Renal cancer:2.25e-4 (unfavourable), Glioma:5.07e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"adipose tissue: 46.2;cerebral cortex: 47.2","thyroid gland: 14.8","Cell line enhanced",NA,"A-431: 46.7"
"NME3",1,"A3","IOH4515",510,"0",NA,"non-metastatic cells 3, protein expressed in (NME3), mRNA.","NM_002513.2","NP_002504.2",4832,"Hs.514065","DR-nm23, NDPKC, NM23-H3","ENSG00000103024","NME/NM23 nucleoside diphosphate kinase 3","16","1770286-1771730","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA041113, HPA052733","Approved",NA,"Approved","Nucleoplasm<br>Cytosol","Breast cancer:6.81e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"adrenal gland: 36.1","Cell line enhanced",NA,"HEK 293: 64.8"
"NMU",36,"C3","IOH10556",525,"0",NA,"neuromedin U (NMU), mRNA.","NM_006681.2","NP_006672.1",10874,"Hs.418367",NA,"ENSG00000109255","Neuromedin U","4","55595229-55636698","Predicted secreted proteins","Evidence at protein level","HPA025926","Uncertain",NA,NA,NA,"Renal cancer:4.07e-10 (unfavourable), Endometrial cancer:2.60e-5 (unfavourable)","Mixed","Group enriched",6,"esophagus: 34.9;skin: 45.4","tonsil: 6.8","Cell line enhanced",NA,"HaCaT: 336.7;K-562: 278.2"
"NOG",86,"A10","IOH23064",699,"0",NA,"noggin (NOG), mRNA.","NM_005450.4","NP_005441.1",9241,"Hs.248201","SYM1, SYNS1","ENSG00000183691","Noggin","17","56593699-56595590","Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA061318","Approved",NA,NA,NA,"Pancreatic cancer:6.86e-5 (unfavourable), Endometrial cancer:6.66e-4 (favourable)","Mixed","Group enriched",5,"cerebral cortex: 7.3;placenta: 15.8","lymph node: 2.2","Cell line enhanced",NA,"EFO-21: 117.5;LHCN-M2: 32.2;PC-3: 35.7;U-2 OS: 40.3"
"NOTUM",148,"C11","IOH62341",1293,"0",NA,"notum pectinacetylesterase homolog (Drosophila), mRNA (cDNA clone MGC:46492 IMAGE:5225889), complete cds","BC036872.1","AAH36872.2",147111,"Hs.106137",NA,"ENSG00000185269","NOTUM, palmitoleoyl-protein carboxylesterase","17","81952507-81961840","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Mixed","Tissue enriched",56,"placenta: 192.5","liver: 3.4","Cell line enriched",16,"Hep G2: 284.8"
"NOTUM",118,"E5","IOH29141",1293,"0",NA,"notum pectinacetylesterase homolog (Drosophila), mRNA (cDNA clone MGC:71851 IMAGE:30336041), complete cds","BC060882.1","AAH60882.1",147111,"Hs.106137",NA,"ENSG00000185269","NOTUM, palmitoleoyl-protein carboxylesterase","17","81952507-81961840","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Mixed","Tissue enriched",56,"placenta: 192.5","liver: 3.4","Cell line enriched",16,"Hep G2: 284.8"
"NOV",42,"C3","IOH10101",1074,"0",NA,"nephroblastoma overexpressed gene, mRNA (cDNA clone MGC:9036 IMAGE:3916150), complete cds","BC015028.1","AAH15028.1",4856,"Hs.235935","CCN3, IGFBP9","ENSG00000136999","Nephroblastoma overexpressed","8","119416306-119424353","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA018449, HPA019684, CAB034423","Enhanced",NA,"Supported","Vesicles",NA,"Expressed in all","Tissue enriched",39,"adrenal gland: 1392.1","prostate: 35.4","Cell line enhanced",NA,"BJ hTERT+: 99.0;U-2197: 116.0"
"NPC2",4,"H7","IOH4108",456,"0",NA,"Niemann-Pick disease, type C2 (NPC2), mRNA.","NM_006432.3","NP_006423.1",10577,"Hs.433222","EDDM1, HE1, NP-C2","ENSG00000119655","NPC intracellular cholesterol transporter 2","14","74476192-74494177","Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA000835","Enhanced",NA,NA,NA,"Colorectal cancer:4.83e-5 (unfavourable), Stomach cancer:2.66e-4 (unfavourable), Liver cancer:3.13e-4 (unfavourable), Thyroid cancer:6.55e-4 (favourable)","Expressed in all","Tissue enriched",19,"epididymis: 16336.0","lung: 849.0","Expressed in all",NA,NA
"NPFF",150,"D12","IOH63632",351,"0",NA,"neuropeptide FF-amide peptide precursor, mRNA (cDNA clone MGC:126084 IMAGE:40033026), complete cds","BC104234.1","AAI04235.1",8620,"Hs.719390","FMRFAL","ENSG00000139574","Neuropeptide FF-amide peptide precursor","12","53506690-53507638","Predicted secreted proteins","Evidence at transcript level",NA,NA,NA,NA,NA,NA,"Not detected","Tissue enriched",1231,"epididymis: 1000.1","duodenum: 0.8","Cell line enriched",6,"HHSteC: 11.2"
"NPPA",113,"C6","IOH45889",456,"0",NA,"natriuretic peptide precursor A (NPPA), mRNA.","NM_006172.3","NP_006163.1",4878,"Hs.75640","ANP, PND","ENSG00000175206","Natriuretic peptide A","1","11845709-11848345","Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA058269","Enhanced","Supported",NA,NA,NA,"Tissue enriched","Tissue enriched",1345,"heart muscle: 24003.4","epididymis: 17.8","Cell line enhanced",NA,"SCLC-21H: 13.6;SH-SY5Y: 11.7"
"NPPA",20,"C11","IOH7444",462,"0",NA,"natriuretic peptide precursor A, mRNA (cDNA clone MGC:14467 IMAGE:4273949), complete cds","BC005893.1","AAH05893.1",4878,"Hs.75640","ANP, PND","ENSG00000175206","Natriuretic peptide A","1","11845709-11848345","Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA058269","Enhanced","Supported",NA,NA,NA,"Tissue enriched","Tissue enriched",1345,"heart muscle: 24003.4","epididymis: 17.8","Cell line enhanced",NA,"SCLC-21H: 13.6;SH-SY5Y: 11.7"
"NPPB",30,"F6","IOH22623",405,"0",NA,"natriuretic peptide precursor B (NPPB), mRNA.","NM_002521.2","NP_002512.1",4879,"Hs.219140",NA,"ENSG00000120937","Natriuretic peptide B","1","11857464-11858931","Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",1857,"heart muscle: 3255.2","testis: 1.7","Group enriched",7,"BEWO: 134.5;CACO-2: 309.8"
"NPTX2",79,"H10","IOH22745",1296,"0",NA,"neuronal pentraxin II (NPTX2), mRNA.","NM_002523.2","NP_002514.1",4885,"Hs.3281",NA,"ENSG00000106236","Neuronal pentraxin 2","7","98617297-98629868","Predicted secreted proteins","Evidence at protein level","CAB020801, HPA049799, HPA058320","Supported",NA,"Approved","Golgi apparatus<br>Actin filaments<br>Centrosome","Renal cancer:5.46e-9 (unfavourable), Endometrial cancer:5.46e-5 (unfavourable)","Expressed in all","Tissue enhanced",NA,"adrenal gland: 33.5;cerebral cortex: 80.3;testis: 44.3","cervix, uterine: 12.1","Cell line enriched",8,"LHCN-M2: 600.5"
"NPY",39,"B2","IOH22539",294,"0",NA,"neuropeptide Y (NPY), mRNA.","NM_000905.2","NP_000896.1",4852,"Hs.1832","PYY4","ENSG00000122585","Neuropeptide Y","7","24284163-24291865","Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB016733, CAB034368, HPA036636, HPA044572, HPA056798","Supported","Supported","Enhanced","Golgi apparatus","Endometrial cancer:5.78e-4 (unfavourable)","Tissue enriched","Group enriched",18,"adrenal gland: 153.2;cerebral cortex: 211.6;prostate: 495.0","appendix: 16.1","Cell line enriched",39,"SH-SY5Y: 696.9"
"NRCAM",154,"C6","IOH62680",2316,"NP_005001.1","AAH98401.1","neuronal cell adhesion molecule, mRNA (cDNA clone MGC:104689 IMAGE:30528526), complete cds","BC098401.1","AAH98401.1",4897,"Hs.21422","Bravo, KIAA0343","ENSG00000091129","Neuronal cell adhesion molecule","7","108147623-108456717","Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA012606","Approved",NA,NA,NA,NA,"Tissue enriched","Tissue enhanced",NA,"cerebral cortex: 180.4","adrenal gland: 49.5","Cell line enhanced",NA,"A549: 90.2;AF22: 93.7;EFO-21: 165.3;HMC-1: 165.2;SH-SY5Y: 122.8"
"NRG1",43,"H11","IOH5912",891,"0",NA,"neuregulin 1, mRNA (cDNA clone IMAGE:3161700), complete cds.","BC007675.2","AAH07675.1",3084,"Hs.453951","GGF, HGL, HRG, NDF, NRG1-IT2","ENSG00000157168","Neuregulin 1","8","31639386-32767959","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA010964","Uncertain",NA,"Approved","Nucleoplasm",NA,"Tissue enhanced","Mixed",NA,NA,"thyroid gland: 20.0","Cell line enhanced",NA,"A549: 130.4;hTEC/SVTERT24-B: 101.2"
"NRN1L",152,"A5","IOH63510",498,"0",NA,"neuritin 1-like, mRNA (cDNA clone MGC:118990 IMAGE:40002773), complete cds","BC100863.2","AAI00864.1",123904,"Hs.435464","MRCC2446, UNQ2446","ENSG00000188038","Neuritin 1 like","16","67884805-67888855","Predicted intracellular proteins, Predicted secreted proteins","Evidence at transcript level","HPA041761","Uncertain",NA,NA,NA,NA,"Not detected","Mixed",NA,NA,"skin: 3.3","Cell line enriched",5,"BEWO: 31.0"
"NRP1",122,"F11","IOH6423",1830,"NP_003864.1","NP_001019800.1","neuropilin 1 (NRP1), transcript variant 3, mRNA.","NM_001024629.2","NP_001019800.1",8829,"Hs.131704","CD304, NRP, VEGF165R","ENSG00000099250","Neuropilin 1","10","33177492-33336262","Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB004511, HPA030278","Approved",NA,"Uncertain","Mitochondria","Stomach cancer:1.22e-5 (unfavourable), Cervical cancer:7.10e-5 (unfavourable), Renal cancer:3.87e-4 (unfavourable), Glioma:7.78e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 194.1","Cell line enhanced",NA,"U-87 MG: 437.4"
"NRP2",140,"B7","IOH53618",2706,"0",NA,"neuropilin 2 (NRP2), transcript variant 5, mRNA.","NM_201267.1","NP_957719.1",8828,"Hs.471200","VEGF165R2","ENSG00000118257","Neuropilin 2","2","205681990-205798133","Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA039980, HPA054974","Enhanced",NA,"Supported","Vesicles<br>Plasma membrane","Renal cancer:7.68e-7 (unfavourable), Urothelial cancer:7.80e-5 (unfavourable)","Expressed in all","Mixed",NA,NA,"smooth muscle: 84.4","Cell line enhanced",NA,"CAPAN-2: 119.6;U-251 MG: 195.9"
"NRP2",30,"G1","IOH22954",300,"0",NA,"Neuropilin-2 Precursor (Vascular endothelial cell growth factor 165 receptor 2) [Source:UniProtKB/Swiss-Prot;Acc:O60462]","ENST00000340626","ENSP00000339233",8828,"Hs.471200","VEGF165R2","ENSG00000118257","Neuropilin 2","2","205681990-205798133","Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA039980, HPA054974","Enhanced",NA,"Supported","Vesicles<br>Plasma membrane","Renal cancer:7.68e-7 (unfavourable), Urothelial cancer:7.80e-5 (unfavourable)","Expressed in all","Mixed",NA,NA,"smooth muscle: 84.4","Cell line enhanced",NA,"CAPAN-2: 119.6;U-251 MG: 195.9"
"NRP2",116,"F4","IOH41908",2781,"0",NA,"neuropilin 2 (NRP2), transcript variant 2, mRNA.","NM_003872.2","NP_003863.2",8828,"Hs.471200","VEGF165R2","ENSG00000118257","Neuropilin 2","2","205681990-205798133","Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA039980, HPA054974","Enhanced",NA,"Supported","Vesicles<br>Plasma membrane","Renal cancer:7.68e-7 (unfavourable), Urothelial cancer:7.80e-5 (unfavourable)","Expressed in all","Mixed",NA,NA,"smooth muscle: 84.4","Cell line enhanced",NA,"CAPAN-2: 119.6;U-251 MG: 195.9"
"NT5E",158,"F1","IOH61587",1725,"0",NA,"5'-nucleotidase, ecto (CD73), mRNA (cDNA clone MGC:75146 IMAGE:6163101), complete cds","BC065937.1","AAH65937.1",4907,"Hs.153952","CALJA, CD73, eN, eNT, NT5","ENSG00000135318","5'-nucleotidase ecto","6","85449584-85495791","CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA017357","Approved",NA,"Supported","Nucleoplasm<br>Plasma membrane<br>Cytosol","Pancreatic cancer:1.32e-5 (unfavourable), Stomach cancer:1.02e-4 (unfavourable), Lung cancer:6.66e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cervix, uterine: 172.7","smooth muscle: 106.3","Cell line enhanced",NA,"LHCN-M2: 772.3;U-87 MG: 800.0"
"NT5E",89,"B3","IOH10119",795,"NP_002517.1","AAH15940.1","5'-nucleotidase, ecto (CD73), mRNA (cDNA clone IMAGE:3920680), complete cds.","BC015940.1","AAH15940.1",4907,"Hs.153952","CALJA, CD73, eN, eNT, NT5","ENSG00000135318","5'-nucleotidase ecto","6","85449584-85495791","CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA017357","Approved",NA,"Supported","Nucleoplasm<br>Plasma membrane<br>Cytosol","Pancreatic cancer:1.32e-5 (unfavourable), Stomach cancer:1.02e-4 (unfavourable), Lung cancer:6.66e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cervix, uterine: 172.7","smooth muscle: 106.3","Cell line enhanced",NA,"LHCN-M2: 772.3;U-87 MG: 800.0"
"NTF3",128,"A10","IOH40370",774,"0",NA,"neurotrophin 3 (NTF3), transcript variant 2, mRNA.","NM_002527.4","NP_002518.1",4908,"Hs.99171","NGF2","ENSG00000185652","Neurotrophin 3","12","5432112-5521536","Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA032001","Approved",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"ovary: 13.5","spleen: 6.2","Cell line enhanced",NA,"BJ hTERT+: 9.1;BJ hTERT+ SV40 Large T+: 13.6;BJ hTERT+ SV40 Large T+ RasG12V: 18.8;HBF TERT88: 17.3"
"NTF4",77,"E9","IOH10552",633,"0",NA,"neurotrophin 4 (NTF4), mRNA.","NM_006179.4","NP_006170.1",4909,"Hs.266902","GLC1O, NT-4/5, NTF5","ENSG00000225950","Neurotrophin 4","19","49061066-49065054","Cancer-related genes, Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA049376",NA,NA,"Approved","Golgi apparatus",NA,"Mixed","Tissue enhanced",NA,"skin: 36.6","prostate: 11.4","Cell line enhanced",NA,"CAPAN-2: 12.1;HaCaT: 27.5;hTCEpi: 36.4"
"NTM",119,"D7","IOH27065",951,"0",NA,"neurotrimin (NTM), transcript variant 4, mRNA.","NM_001144059.1","NP_001137531.1",50863,"Hs.504352","HNT, IGLON2, NTRI","ENSG00000182667","Neurotrimin","11","131370478-132336822","Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB024875","Enhanced",NA,NA,NA,"Renal cancer:1.10e-8 (unfavourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 116.0","lung: 39.1","Cell line enhanced",NA,"LHCN-M2: 102.1;U-2 OS: 86.6;WM-115: 164.5"
"NTN5",116,"H10","IOH23254",1470,"0",NA,"netrin 5 (NTN5), mRNA.","NM_145807.1","NP_665806.1",126147,"Hs.326217",NA,"ENSG00000142233","Netrin 5","19","48661407-48673081","Predicted intracellular proteins, Predicted secreted proteins","Evidence at transcript level",NA,NA,NA,NA,NA,NA,"Mixed","Mixed",NA,NA,"endometrium,fallopian tube,ovary: 1.5","Not detected",NA,NA
"NTNG1",75,"E6","IOH27301",1317,"0",NA,"netrin G1 (NTNG1), transcript variant 3, mRNA.","NM_014917.2","NP_055732.2",22854,"Hs.657434","KIAA0976, Lmnt1","ENSG00000162631","Netrin G1","1","107140007-107483458","Predicted secreted proteins","Evidence at protein level","HPA065954",NA,NA,"Supported","Plasma membrane",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 8.6","seminal vesicle: 6.7","Cell line enhanced",NA,"ASC TERT1: 34.3;fHDF/TERT166: 19.6;RPTEC TERT1: 20.8;U-138 MG: 22.6;U-87 MG: 25.0"
"NTS",17,"E3","IOH13686",513,"0",NA,"neurotensin (NTS), mRNA.","NM_006183.3","NP_006174.1",4922,"Hs.80962",NA,"ENSG00000133636","Neurotensin","12","85874295-85882992","Predicted secreted proteins","Evidence at protein level","HPA026664","Enhanced",NA,NA,NA,"Cervical cancer:9.94e-5 (favourable), Endometrial cancer:5.10e-4 (unfavourable)","Tissue enhanced","Group enriched",9,"small intestine: 189.6;stomach: 43.5","lymph node: 13.4","Cell line enhanced",NA,"HEL: 45.5;NTERA-2: 10.8"
"NUBPL",6,"B1","IOH11019",870,"0",NA,"nucleotide binding protein-like, mRNA (cDNA clone MGC:21046 IMAGE:4475196), complete cds","BC024919.1","AAH24919.1",80224,"Hs.288981","C14orf127, FLJ12660, huInd1, IND1","ENSG00000151413","Nucleotide binding protein like","14","31489956-31861224","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA029203","Approved",NA,"Approved","Mitochondria","Renal cancer:3.64e-8 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 16.0","Expressed in all",NA,NA
"NUCB1",23,"G11","IOH3531",1386,"0",NA,"nucleobindin 1 (NUCB1), mRNA.","NM_006184.3","NP_006175.2",4924,"Hs.631602","Calnuc, NUC","ENSG00000104805","Nucleobindin 1","19","48900050-48923372","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA008176","Enhanced",NA,"Supported","Golgi apparatus<br>Microtubules",NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 227.7","Expressed in all",NA,NA
"NUDT9",4,"G9","IOH4171",1053,"0",NA,"nudix (nucleoside diphosphate linked moiety X)-type motif 9 (NUDT9), transcript variant 1, mRNA.","NM_024047.3","NP_076952.1",53343,"Hs.149500","MGC3037","ENSG00000170502","Nudix hydrolase 9","4","87422582-87459454","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA036917, HPA044866","Approved",NA,NA,NA,"Renal cancer:8.00e-11 (favourable), Endometrial cancer:7.43e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 85.9","Expressed in all",NA,NA
"NUDT9",113,"E6","IOH45894",903,"0",NA,"nudix (nucleoside diphosphate linked moiety X)-type motif 9 (NUDT9), transcript variant 3, mRNA.","NM_198038.1","NP_932155.1",53343,"Hs.149500","MGC3037","ENSG00000170502","Nudix hydrolase 9","4","87422582-87459454","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA036917, HPA044866","Approved",NA,NA,NA,"Renal cancer:8.00e-11 (favourable), Endometrial cancer:7.43e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 85.9","Expressed in all",NA,NA
"NXPH1",57,"G11","IOH26544",816,"0",NA,"neurexophilin 1 (NXPH1), mRNA.","NM_152745.2","NP_689958.1",30010,"Hs.487564",NA,"ENSG00000122584","Neurexophilin 1","7","8433955-8752963","Predicted intracellular proteins, Predicted secreted proteins","Evidence at transcript level","HPA020062","Uncertain",NA,NA,NA,NA,"Group enriched","Group enriched",81,"adrenal gland: 52.1;cerebral cortex: 47.2","breast: 0.6","Cell line enhanced",NA,"Karpas-707: 7.7;SCLC-21H: 1.3;WM-115: 3.3"
"NXPH2",143,"H9","IOH59414",795,"0",NA,"neurexophilin 2 (NXPH2), mRNA.","NM_007226.2","NP_009157.1",11249,"Hs.435019","NPH2","ENSG00000144227","Neurexophilin 2","2","138670772-138780348","Predicted secreted proteins","Evidence at transcript level","HPA034759","Approved",NA,NA,NA,NA,"Mixed","Group enriched",9,"cerebral cortex: 5.7;kidney: 5.0;ovary: 14.0","endometrium: 0.9","Cell line enhanced",NA,"AF22: 3.8;SCLC-21H: 1.7;SiHa: 4.0;U-2 OS: 6.3;U-251 MG: 1.7"
"NXPH2",150,"G9","IOH63596",795,"0",NA,"neurexophilin 2, mRNA (cDNA clone MGC:125477 IMAGE:40022686), complete cds","BC101461.1","AAI01462.1",11249,"Hs.435019","NPH2","ENSG00000144227","Neurexophilin 2","2","138670772-138780348","Predicted secreted proteins","Evidence at transcript level","HPA034759","Approved",NA,NA,NA,NA,"Mixed","Group enriched",9,"cerebral cortex: 5.7;kidney: 5.0;ovary: 14.0","endometrium: 0.9","Cell line enhanced",NA,"AF22: 3.8;SCLC-21H: 1.7;SiHa: 4.0;U-2 OS: 6.3;U-251 MG: 1.7"
"NXPH3",6,"E5","IOH10772",759,"0",NA,"neurexophilin 3, mRNA (cDNA clone MGC:26801 IMAGE:4794968), complete cds","BC022541.1","AAH22541.1",11248,"Hs.55069","NPH3","ENSG00000182575","Neurexophilin 3","17","49575858-49583827","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 15.6","seminal vesicle: 9.6","Cell line enhanced",NA,"BEWO: 14.1;BJ: 4.0"
"NXPH4",79,"B9","IOH22463",927,"0",NA,"neurexophilin 4, mRNA (cDNA clone MGC:33909 IMAGE:5264190), complete cds","BC036679.1","AAH36679.1",11247,"Hs.719394","NPH4","ENSG00000182379","Neurexophilin 4","12","57216795-57226449","Predicted secreted proteins","Evidence at transcript level",NA,NA,NA,NA,NA,"Renal cancer:7.68e-6 (unfavourable), Liver cancer:2.57e-4 (unfavourable), Endometrial cancer:6.21e-4 (unfavourable), Glioma:8.20e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 8.3;prostate: 7.1;skin: 12.2","placenta: 3.8","Cell line enhanced",NA,"AN3-CA: 71.1;RH-30: 60.3"
"NXPH4",72,"E4","IOH28935",927,"0",NA,"neurexophilin 4 (NXPH4), mRNA.","NM_007224.3","NP_009155.1",11247,"Hs.719394","NPH4","ENSG00000182379","Neurexophilin 4","12","57216795-57226449","Predicted secreted proteins","Evidence at transcript level",NA,NA,NA,NA,NA,"Renal cancer:7.68e-6 (unfavourable), Liver cancer:2.57e-4 (unfavourable), Endometrial cancer:6.21e-4 (unfavourable), Glioma:8.20e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 8.3;prostate: 7.1;skin: 12.2","placenta: 3.8","Cell line enhanced",NA,"AN3-CA: 71.1;RH-30: 60.3"
"OBP2A",99,"H5","IOH40248",513,"0",NA,"odorant binding protein 2A (OBP2A), mRNA.","NM_014582.2","NP_055397.1",29991,"Hs.567489","hOBPIIa, LCN13, OBP","ENSG00000122136","Odorant binding protein 2A","9","135546139-135549969","Predicted secreted proteins","Evidence at protein level","HPA055955","Uncertain",NA,NA,NA,NA,"Tissue enriched","Group enriched",19,"fallopian tube: 35.5;testis: 7.6","skin: 1.1","Group enriched",8,"U-266/70: 1.0;U-266/84: 3.7"
"OCLN",141,"E6","IOH59115",1569,"0",NA,"occludin (OCLN), mRNA.","NM_002538.2","NP_002529.1",4950,"Hs.592605","PPP1R115","ENSG00000197822","Occludin","5","69492292-69558104","Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA005933, CAB013075, CAB068212, CAB068213, CAB068214","Enhanced",NA,"Supported","Plasma membrane<br>Cell Junctions","Renal cancer:6.59e-11 (favourable)","Mixed","Tissue enhanced",NA,"thyroid gland: 78.7","lung: 39.8","Cell line enhanced",NA,"CAPAN-2: 60.2;HaCaT: 48.8"
"OCLN",41,"G4","IOH22823",1569,"0",NA,"occludin, mRNA (cDNA clone MGC:34277 IMAGE:5179203), complete cds","BC029886.1","AAH29886.1",4950,"Hs.592605","PPP1R115","ENSG00000197822","Occludin","5","69492292-69558104","Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA005933, CAB013075, CAB068212, CAB068213, CAB068214","Enhanced",NA,"Supported","Plasma membrane<br>Cell Junctions","Renal cancer:6.59e-11 (favourable)","Mixed","Tissue enhanced",NA,"thyroid gland: 78.7","lung: 39.8","Cell line enhanced",NA,"CAPAN-2: 60.2;HaCaT: 48.8"
"ODAM",28,"F10","IOH23051",462,"0",NA,"odontogenic, ameloblast asssociated, mRNA (cDNA clone MGC:22340 IMAGE:4689080), complete cds","BC017796.1","AAH17796.1",54959,"Hs.143811","APin, FLJ20513","ENSG00000109205","Odontogenic, ameloblast asssociated","4","70196496-70204576","Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA036543",NA,NA,"Supported","Nucleoplasm<br>Cytosol",NA,"Mixed","Tissue enriched",13,"salivary gland: 136.2","smooth muscle: 10.1","Cell line enriched",13,"Hep G2: 21.4"
"OGG1",92,"A9","IOH4353",1038,"0",NA,"8-oxoguanine DNA glycosylase, mRNA (cDNA clone MGC:1841 IMAGE:3350168), complete cds","BC000657.2","AAH00657.1",4968,"Hs.380271","HMMH, HOGG1, MUTM, OGH1","ENSG00000114026","8-oxoguanine DNA glycosylase","3","9749944-9788219","Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA027514, CAB047301","Approved",NA,"Enhanced","Nucleoplasm","Liver cancer:5.77e-5 (unfavourable), Renal cancer:2.65e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 30.5","Expressed in all",NA,NA
"OGG1",141,"A10","IOH59670",588,"0",NA,"8-oxoguanine DNA glycosylase (OGG1), nuclear gene encoding mitochondrial protein, transcript variant 2c, mRNA.","NM_016827.2","NP_058436.1",4968,"Hs.380271","HMMH, HOGG1, MUTM, OGH1","ENSG00000114026","8-oxoguanine DNA glycosylase","3","9749944-9788219","Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA027514, CAB047301","Approved",NA,"Enhanced","Nucleoplasm","Liver cancer:5.77e-5 (unfavourable), Renal cancer:2.65e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 30.5","Expressed in all",NA,NA
"OGG1",104,"D6","IOH42070",969,"0",NA,"8-oxoguanine DNA glycosylase (OGG1), nuclear gene encoding mitochondrial protein, transcript variant 2e, mRNA.","NM_016829.2","NP_058438.1",4968,"Hs.380271","HMMH, HOGG1, MUTM, OGH1","ENSG00000114026","8-oxoguanine DNA glycosylase","3","9749944-9788219","Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA027514, CAB047301","Approved",NA,"Enhanced","Nucleoplasm","Liver cancer:5.77e-5 (unfavourable), Renal cancer:2.65e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 30.5","Expressed in all",NA,NA
"OGG1",143,"H7","IOH59379",975,"0",NA,"8-oxoguanine DNA glycosylase (OGG1), nuclear gene encoding mitochondrial protein, transcript variant 1b, mRNA.","NM_016819.3","NP_058212.1",4968,"Hs.380271","HMMH, HOGG1, MUTM, OGH1","ENSG00000114026","8-oxoguanine DNA glycosylase","3","9749944-9788219","Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA027514, CAB047301","Approved",NA,"Enhanced","Nucleoplasm","Liver cancer:5.77e-5 (unfavourable), Renal cancer:2.65e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 30.5","Expressed in all",NA,NA
"OGN",55,"D3","IOH27143",897,"0",NA,"osteoglycin (OGN), transcript variant 3, mRNA.","NM_014057.3","NP_054776.1",4969,"Hs.109439","mimecan, OIF, SLRR3A","ENSG00000106809","Osteoglycin","9","92383967-92404696","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA013132","Approved",NA,"Supported","Endoplasmic reticulum","Renal cancer:1.92e-4 (unfavourable), Urothelial cancer:2.03e-4 (unfavourable), Ovarian cancer:4.04e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"cervix, uterine: 374.3;parathyroid gland: 604.4","gallbladder: 276.4","Cell line enhanced",NA,"ASC TERT1: 17.1;HSkMC: 8.0;MOLT-4: 27.9"
"OLFM1",35,"C7","IOH4375",510,"0",NA,"olfactomedin 1, mRNA (cDNA clone IMAGE:3351052), complete cds.","BC000189.1","AAH00189.1",10439,"Hs.522484","AMY, NOE1, NOELIN, OlfA","ENSG00000130558","Olfactomedin 1","9","135075422-135121179","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA057444",NA,NA,"Approved","Nucleus<br>Nucleoli<br>Cytosol","Cervical cancer:7.14e-4 (favourable), Glioma:9.38e-4 (unfavourable)","Expressed in all","Tissue enriched",8,"cerebral cortex: 729.9","epididymis: 86.4","Cell line enhanced",NA,"NTERA-2: 108.6;SCLC-21H: 182.9;SiHa: 139.8;T-47d: 189.5;U-2197: 81.2"
"OLFM1",120,"H12","IOH46139",1404,"0",NA,"olfactomedin 1 (OLFM1), transcript variant 1, mRNA.","NM_014279.4","NP_055094.1",10439,"Hs.522484","AMY, NOE1, NOELIN, OlfA","ENSG00000130558","Olfactomedin 1","9","135075422-135121179","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA057444",NA,NA,"Approved","Nucleus<br>Nucleoli<br>Cytosol","Cervical cancer:7.14e-4 (favourable), Glioma:9.38e-4 (unfavourable)","Expressed in all","Tissue enriched",8,"cerebral cortex: 729.9","epididymis: 86.4","Cell line enhanced",NA,"NTERA-2: 108.6;SCLC-21H: 182.9;SiHa: 139.8;T-47d: 189.5;U-2197: 81.2"
"OLFM1",139,"F9","IOH58962",408,"0",NA,"olfactomedin 1 (OLFM1), transcript variant 2, mRNA.","NM_006334.3","NP_006325.1",10439,"Hs.522484","AMY, NOE1, NOELIN, OlfA","ENSG00000130558","Olfactomedin 1","9","135075422-135121179","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA057444",NA,NA,"Approved","Nucleus<br>Nucleoli<br>Cytosol","Cervical cancer:7.14e-4 (favourable), Glioma:9.38e-4 (unfavourable)","Expressed in all","Tissue enriched",8,"cerebral cortex: 729.9","epididymis: 86.4","Cell line enhanced",NA,"NTERA-2: 108.6;SCLC-21H: 182.9;SiHa: 139.8;T-47d: 189.5;U-2197: 81.2"
"OLFM2",45,"C12","IOH9662",1365,"0",NA,"olfactomedin 2 (OLFM2), mRNA.","NM_058164.2","NP_477512.1",93145,"Hs.169743","NOE2, OlfC","ENSG00000105088","Olfactomedin 2","19","9853718-9936552","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA049961, HPA057771","Uncertain",NA,"Approved","Nucleoplasm","Renal cancer:2.21e-4 (unfavourable), Colorectal cancer:3.05e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 124.0;skin: 111.2","adipose tissue: 36.8","Cell line enhanced",NA,"AN3-CA: 23.7;SH-SY5Y: 25.7;U-2 OS: 30.2;WM-115: 25.2"
"OLFM3",87,"F5","IOH10815",1377,"0",NA,"olfactomedin 3, mRNA (cDNA clone MGC:26675 IMAGE:4812035), complete cds","BC022531.1","AAH22531.1",118427,"Hs.484475","NOE3","ENSG00000118733","Olfactomedin 3","1","101802574-101997030","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA050297",NA,NA,"Uncertain","Vesicles",NA,"Mixed","Tissue enriched",15,"cerebral cortex: 26.7","adrenal gland: 1.8","Group enriched",11,"AF22: 5.5;HAP1: 4.0;HEL: 3.2;SCLC-21H: 2.6;SH-SY5Y: 2.3"
"OLFM4",109,"C1","IOH35885",1533,"0",NA,"olfactomedin 4 (OLFM4), mRNA.","NM_006418.3","NP_006409.3",10562,"Hs.508113","GC1, GW112, OlfD","ENSG00000102837","Olfactomedin 4","13","53028759-53052057","Predicted secreted proteins","Evidence at protein level","HPA077718","Enhanced",NA,NA,NA,"Breast cancer:8.77e-4 (favourable)","Group enriched","Tissue enhanced",NA,"duodenum: 1193.9;rectum: 611.5;small intestine: 1437.8","colon: 445.0","Cell line enhanced",NA,"BEWO: 5.1;BJ hTERT+: 15.0;HaCaT: 22.9"
"OLFML2A",120,"A2","IOH28960",1317,"0",NA,"olfactomedin-like 2A, mRNA (cDNA clone MGC:61796 IMAGE:5554812), complete cds","BC054001.1","AAH54001.1",169611,"Hs.357004","FLJ00237","ENSG00000185585","Olfactomedin like 2A","9","124777158-124814885","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA021180, HPA022254","Approved",NA,"Approved","Nucleoplasm<br>Cytosol","Renal cancer:3.73e-5 (unfavourable)","Expressed in all","Mixed",NA,NA,"spleen: 47.5","Cell line enhanced",NA,"ASC TERT1: 112.2;WM-115: 64.5"
"OLFML2B",71,"G12","IOH26486",702,"0",NA,"olfactomedin-like 2B, mRNA (cDNA clone IMAGE:5269601), complete cds.","BC047472.1","AAH47472.1",25903,"Hs.507515","DKFZP586L151","ENSG00000162745","Olfactomedin like 2B","1","161983192-162023854","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA054136, HPA062739","Approved",NA,"Approved","Cytosol","Renal cancer:1.01e-12 (unfavourable), Liver cancer:4.67e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"gallbladder: 76.9","placenta: 58.7","Cell line enhanced",NA,"HSkMC: 82.6;RH-30: 85.9"
"OLFML2B",94,"A3","IOH40497",2253,"0",NA,"olfactomedin-like 2B (OLFML2B), mRNA.","NM_015441.1","NP_056256.1",25903,"Hs.507515","DKFZP586L151","ENSG00000162745","Olfactomedin like 2B","1","161983192-162023854","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA054136, HPA062739","Approved",NA,"Approved","Cytosol","Renal cancer:1.01e-12 (unfavourable), Liver cancer:4.67e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"gallbladder: 76.9","placenta: 58.7","Cell line enhanced",NA,"HSkMC: 82.6;RH-30: 85.9"
"OLFML3",134,"A7","IOH57096",1221,"0",NA,"olfactomedin-like 3 (OLFML3), mRNA.","NM_020190.2","NP_064575.1",56944,"Hs.9315","HNOEL-iso, OLF44","ENSG00000116774","Olfactomedin like 3","1","113979391-114035572","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA027991",NA,NA,"Supported","Vesicles","Renal cancer:3.45e-5 (unfavourable)","Expressed in all","Mixed",NA,NA,"cervix, uterine: 266.9","Cell line enhanced",NA,"ASC diff: 395.8;BJ hTERT+: 302.6;HSkMC: 419.4;LHCN-M2: 496.4"
"OMD",75,"E5","IOH26340",1266,"0",NA,"osteomodulin (OMD), mRNA.","NM_005014.2","NP_005005.1",4958,"Hs.94070","osteoadherin, SLRR2C","ENSG00000127083","Osteomodulin","9","92414245-92424461","Cancer-related genes, Predicted secreted proteins","Evidence at protein level","HPA005731, HPA069948",NA,"Approved","Approved","Nucleoli fibrillar center<br>Endoplasmic reticulum",NA,"Mixed","Mixed",NA,NA,"cervix, uterine: 36.4","Group enriched",13,"ASC diff: 6.2;ASC TERT1: 5.9"
"OMG",9,"A1","IOH10628",1323,"0",NA,"oligodendrocyte myelin glycoprotein (OMG), mRNA.","NM_002544.4","NP_002535.3",4974,"Hs.113874","OMGP","ENSG00000126861","Oligodendrocyte myelin glycoprotein","17","31272013-31297539","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA008206, HPA012693","Enhanced",NA,NA,NA,NA,"Group enriched","Tissue enriched",318,"cerebral cortex: 137.4","bone marrow: 0.4","Not detected",NA,NA
"OPCML",150,"G2","IOH61949",1035,"0",NA,"opioid binding protein/cell adhesion molecule-like, mRNA (cDNA clone MGC:104014 IMAGE:30915458), complete cds","BC074742.2","AAH74742.1",4978,"Hs.4817","IGLON1, OBCAM, OPCM","ENSG00000183715","Opioid binding protein/cell adhesion molecule like","11","132414977-133532519","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Group enriched","Tissue enriched",8,"cerebral cortex: 63.0","parathyroid gland: 7.5","Cell line enhanced",NA,"BJ: 7.9;HDLM-2: 1.8"
"ORM1",142,"A10","IOH54759",606,"0",NA,"Alpha-1-acid glycoprotein 1.","P02763","P02763",5004,"Hs.522356",NA,"ENSG00000229314","Orosomucoid 1","9","114323056-114326475","Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB006265, HPA046438, HPA047725, HPA057726","Approved",NA,"Approved","Golgi apparatus<br>Vesicles","Renal cancer:2.35e-4 (unfavourable)","Tissue enriched","Tissue enriched",69,"liver: 10591.2","bone marrow: 152.4","Cell line enriched",11,"Hep G2: 797.0"
"ORM1",37,"H12","IOH13560",606,"0",NA,"orosomucoid 1 (ORM1), mRNA.","NM_000607.2","NP_000598.2",5004,"Hs.522356",NA,"ENSG00000229314","Orosomucoid 1","9","114323056-114326475","Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB006265, HPA046438, HPA047725, HPA057726","Approved",NA,"Approved","Golgi apparatus<br>Vesicles","Renal cancer:2.35e-4 (unfavourable)","Tissue enriched","Tissue enriched",69,"liver: 10591.2","bone marrow: 152.4","Cell line enriched",11,"Hep G2: 797.0"
"ORM2",33,"D11","IOH12382",606,"0",NA,"orosomucoid 2 (ORM2), mRNA.","NM_000608.2","NP_000599.1",5005,"Hs.522356","AGP-B, AGP-B', AGP2","ENSG00000228278","Orosomucoid 2","9","114329869-114333252","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA046438, HPA047725, HPA057726","Approved",NA,"Approved","Golgi apparatus<br>Vesicles","Renal cancer:1.23e-9 (unfavourable)","Tissue enriched","Tissue enriched",96,"liver: 3772.7","prostate: 39.2","Cell line enriched",195,"Hep G2: 567.8"
"OS9",26,"A7","IOH3696",1839,"0",NA,"osteosarcoma amplified 9, endoplasmic reticulum associated protein (OS9), transcript variant 2, mRNA.","NM_001017956.1","NP_001017956.1",10956,"Hs.527861","ERLEC2, OS-9","ENSG00000135506","OS9, endoplasmic reticulum lectin","12","57693955-57721557","Predicted secreted proteins, Transporters","Evidence at protein level","CAB011518, HPA013694","Supported",NA,"Supported","Endoplasmic reticulum",NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 295.8","Cell line enriched",11,"RH-30: 3430.4"
"OSM",9,"E6","IOH13456",759,"0",NA,"oncostatin M (OSM), mRNA.","NM_020530.3","NP_065391.1",5008,"Hs.248156","MGC20461","ENSG00000099985","Oncostatin M","22","30262829-30266840","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:1.03e-5 (unfavourable)","Mixed","Tissue enhanced",NA,"bone marrow: 78.7","appendix: 20.1","Cell line enhanced",NA,"HDLM-2: 14.6;HMC-1: 9.7;NB-4: 4.2"
"OSMR",48,"B11","IOH13005",1029,"0",NA,"oncostatin M receptor, mRNA (cDNA clone IMAGE:4043935), complete cds.","BC010943.1","AAH10943.1",9180,"Hs.120658","OSMRB","ENSG00000145623","Oncostatin M receptor","5","38845858-38945596","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA017278","Approved",NA,"Approved","Nucleoli","Renal cancer:3.96e-6 (unfavourable), Cervical cancer:4.87e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"smooth muscle: 55.1","Mixed",NA,NA
"OSR2",124,"F10","IOH10639",831,"0",NA,"odd-skipped related 2 (Drosophila) (OSR2), transcript variant 2, mRNA.","NM_053001.2","NP_443727.2",116039,"Hs.253247","FLJ90037","ENSG00000164920","Odd-skipped related transciption factor 2","8","98944403-98952104","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA052425, HPA063486","Uncertain",NA,"Approved","Nucleus<br>Plasma membrane","Head and neck cancer:2.44e-5 (favourable)","Mixed","Tissue enhanced",NA,"endometrium: 205.3;fallopian tube: 144.6","ovary: 102.9","Cell line enriched",13,"ASC diff: 372.1"
"OXCT1",125,"B7","IOH10194",1563,"0",NA,"3-oxoacid CoA transferase 1 (OXCT1), nuclear gene encoding mitochondrial protein, mRNA.","NM_000436.3","NP_000427.1",5019,"Hs.278277","OXCT, SCOT","ENSG00000083720","3-oxoacid CoA-transferase 1","5","41730065-41870519","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA012047, HPA061425","Enhanced",NA,"Enhanced","Mitochondria","Renal cancer:1.86e-8 (favourable), Liver cancer:1.03e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"heart muscle: 162.3","cerebral cortex: 98.7","Cell line enhanced",NA,"SiHa: 338.4"
"P4HA1",59,"D6","IOH26865",1605,"0",NA,"prolyl 4-hydroxylase, alpha polypeptide I (P4HA1), transcript variant 2, mRNA.","NM_001017962.2","NP_001017962.1",5033,"Hs.500047","C-P4Halpha(I), P4HA","ENSG00000122884","Prolyl 4-hydroxylase subunit alpha 1","10","73007217-73096974","Enzymes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA007599, HPA026593","Enhanced",NA,"Supported","Endoplasmic reticulum<br>Vesicles<br>Mitochondria","Renal cancer:9.40e-9 (unfavourable), Head and neck cancer:1.19e-5 (unfavourable), Cervical cancer:3.19e-5 (unfavourable), Pancreatic cancer:2.85e-4 (unfavourable), Lung cancer:5.10e-4 (unfavourable), Breast cancer:9.01e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 91.7","Expressed in all",NA,NA
"P4HA2",125,"B12","IOH26049",1602,"0",NA,"prolyl 4-hydroxylase, alpha polypeptide II (P4HA2), transcript variant 2, mRNA.","NM_001017973.1","NP_001017973.1",8974,"Hs.519568","C-P4Halpha(II)","ENSG00000072682","Prolyl 4-hydroxylase subunit alpha 2","5","132191838-132295315","Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins","Evidence at protein level","HPA016997, HPA027824, CAB062557","Enhanced",NA,"Enhanced","Endoplasmic reticulum<br>Vesicles","Renal cancer:2.77e-7 (unfavourable), Cervical cancer:1.24e-5 (unfavourable), Urothelial cancer:3.12e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 95.3","Mixed",NA,NA
"P4HB",89,"E4","IOH9865",1527,"0",NA,"prolyl 4-hydroxylase, beta polypeptide (P4HB), mRNA.","NM_000918.3","NP_000909.2",5034,"Hs.464336","DSI, ERBA2L, GIT, P4Hbeta, PDI, PDIA1, PO4DB, PO4HB, PROHB","ENSG00000185624","Prolyl 4-hydroxylase subunit beta","17","81843159-81860694","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB012463, HPA018884","Enhanced",NA,"Supported","Endoplasmic reticulum","Renal cancer:2.30e-11 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"small intestine: 504.4","Expressed in all",NA,NA
"PAEP",95,"C7","IOH40263",543,"0",NA,"progestagen-associated endometrial protein (PAEP), transcript variant 2, mRNA.","NM_002571.2","NP_002562.2",5047,"Hs.532325","GD, GdA, GdF, GdS, MGC138509, MGC142288, PAEG, PEP, PP14","ENSG00000122133","Progestagen associated endometrial protein","9","135561756-135566955","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB016762, HPA020108, HPA029473","Enhanced",NA,NA,NA,"Renal cancer:0.00e+0 (unfavourable), Liver cancer:6.61e-6 (unfavourable), Stomach cancer:5.46e-4 (unfavourable)","Tissue enriched","Tissue enriched",7,"endometrium: 437.0","seminal vesicle: 61.5","Cell line enriched",6,"SK-MEL-30: 16.7"
"PAM",39,"B10","IOH11633",2601,"NP_000910.2","NP_620176.1","peptidylglycine alpha-amidating monooxygenase (PAM), transcript variant 3, mRNA.","NM_138821.1","NP_620176.1",5066,"Hs.369430","PAL, PHM","ENSG00000145730","Peptidylglycine alpha-amidating monooxygenase","5","102753981-103031105","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB026119, HPA042260","Enhanced",NA,"Approved","Golgi apparatus<br>Cytosol","Endometrial cancer:1.63e-4 (favourable), Liver cancer:6.20e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"heart muscle: 947.8","Cell line enhanced",NA,"fHDF/TERT166: 553.5"
"PAMR1",129,"F9","IOH53797",2214,"0",NA,"peptidase domain containing associated with muscle regeneration 1 (PAMR1), transcript variant 1, mRNA.","NM_015430.2","NP_056245.2",25891,"Hs.55044","DKFZP586H2123, RAMP","ENSG00000149090","Peptidase domain containing associated with muscle regeneration 1","11","35431823-35530300","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:5.08e-5 (unfavourable), Stomach cancer:6.29e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cervix, uterine: 87.0;endometrium: 92.2","placenta: 76.1","Cell line enhanced",NA,"ASC TERT1: 233.7;BJ hTERT+: 274.9;HSkMC: 84.2;U-87 MG: 78.6"
"PAMR1",131,"G5","IOH46684",2163,"0",NA,"peptidase domain containing associated with muscle regeneration 1 (PAMR1), transcript variant 2, mRNA.","NM_001001991.1","NP_001001991.1",25891,"Hs.55044","DKFZP586H2123, RAMP","ENSG00000149090","Peptidase domain containing associated with muscle regeneration 1","11","35431823-35530300","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:5.08e-5 (unfavourable), Stomach cancer:6.29e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cervix, uterine: 87.0;endometrium: 92.2","placenta: 76.1","Cell line enhanced",NA,"ASC TERT1: 233.7;BJ hTERT+: 274.9;HSkMC: 84.2;U-87 MG: 78.6"
"PARP15",100,"B2","IOH35770",1335,"0",NA,"poly (ADP-ribose) polymerase family, member 15 (PARP15), transcript variant 2, mRNA.","NM_152615.1","NP_689828.1",165631,"Hs.120250","FLJ40597, pART7","ENSG00000173200","Poly(ADP-ribose) polymerase family member 15","3","122577602-122639047","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA035757",NA,NA,"Approved","Mitochondria",NA,"Mixed","Tissue enhanced",NA,"lymph node: 55.0;spleen: 60.4;tonsil: 48.1","appendix: 35.3","Cell line enhanced",NA,"HEL: 7.8;TIME: 8.4"
"PATE2",138,"C8","IOH58631",342,"0",NA,"prostate and testis expressed 2 (PATE2), mRNA.","NM_212555.2","NP_997720.1",399967,"Hs.369185","C11orf38, LVLF3112, PATE-M, UNQ3112","ENSG00000196844","Prostate and testis expressed 2","11","125776113-125778819","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Not detected","Tissue enriched",11,"epididymis: 550.7","seminal vesicle: 50.7","Not detected",NA,NA
"PCCB",68,"F9","IOH11543",1620,"0",NA,"propionyl Coenzyme A carboxylase, beta polypeptide (PCCB), nuclear gene encoding mitochondrial protein, mRNA.","NM_000532.3","NP_000523.2",5096,"Hs.63788",NA,"ENSG00000114054","Propionyl-CoA carboxylase beta subunit","3","136250306-136337896","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA036939, HPA036940","Enhanced",NA,NA,NA,"Renal cancer:6.47e-7 (favourable)","Expressed in all","Expressed in all",NA,NA,"liver: 103.1","Expressed in all",NA,NA
"PCDHA6",82,"F10","IOH22467",2853,"NP_061724.1","NP_061732.1","protocadherin alpha 6 (PCDHA6), transcript variant 1, mRNA.","NM_018909.2","NP_061732.1",56142,"Hs.199343","CNR2, CNRS2, CRNR2, PCDH-ALPHA6","ENSG00000081842","Protocadherin alpha 6","5","140827958-141012344","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA059326, HPA078110","Enhanced",NA,"Approved","Vesicles",NA,"Not detected","Tissue enhanced",NA,"cerebral cortex: 4.8","parathyroid gland: 1.9","Cell line enhanced",NA,"AF22: 2.0;EFO-21: 8.1;U-2 OS: 3.7;WM-115: 5.1"
"PCDHB12",80,"C12","IOH25893",2388,"NP_061755.1","NP_061755.1","protocadherin beta 12 (PCDHB12), mRNA.","NM_018932.3","NP_061755.1",56124,"Hs.429820","PCDH-BETA12","ENSG00000120328","Protocadherin beta 12","5","141208697-141212571","Predicted membrane proteins, Predicted secreted proteins","Evidence at transcript level","HPA045042","Uncertain",NA,"Approved","Plasma membrane",NA,"Mixed","Mixed",NA,NA,"endometrium: 3.6","Cell line enhanced",NA,"EFO-21: 2.8;RH-30: 3.1"
"PCDHGA11",98,"C9","IOH36195",2514,"NP_061737.1","NP_114480.1","protocadherin gamma subfamily A, 11 (PCDHGA11), transcript variant 2, mRNA.","NM_032091.1","NP_114480.1",56105,"Hs.368160","PCDH-GAMMA-A11","ENSG00000253873","Protocadherin gamma subfamily A, 11","5","141421047-141512979","Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA008755, HPA010580","Uncertain",NA,"Approved","Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol",NA,"Mixed","Mixed",NA,NA,"cerebral cortex,placenta: 3.2","Cell line enhanced",NA,"ASC diff: 16.8;ASC TERT1: 18.5;SK-MEL-30: 16.7;WM-115: 43.4"
"PCOLCE",29,"F5","IOH4174",1350,"0",NA,"procollagen C-endopeptidase enhancer (PCOLCE), mRNA.","NM_002593.3","NP_002584.2",5118,"Hs.202097","PCPE, PCPE1","ENSG00000106333","Procollagen C-endopeptidase enhancer","7","100602177-100608175","Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB017623, HPA042927","Approved",NA,"Approved","Golgi apparatus<br>Vesicles","Renal cancer:1.68e-5 (unfavourable), Melanoma:9.76e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cervix, uterine: 216.8","gallbladder: 145.9","Cell line enhanced",NA,"ASC TERT1: 496.8;BJ hTERT+: 447.9;HSkMC: 595.6;SH-SY5Y: 617.5;U-2197: 961.3"
"PCOLCE2",130,"H1","IOH57799",1248,"0",NA,"procollagen C-endopeptidase enhancer 2 (PCOLCE2), mRNA.","NM_013363.2","NP_037495.1",26577,"Hs.8944","PCPE2","ENSG00000163710","Procollagen C-endopeptidase enhancer 2","3","142815922-142889203","Predicted secreted proteins","Evidence at protein level","HPA013203","Uncertain",NA,"Approved","Nucleoplasm<br>Cytosol","Renal cancer:1.96e-5 (unfavourable), Urothelial cancer:1.08e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"adipose tissue: 81.7;placenta: 57.9","heart muscle: 42.3","Cell line enhanced",NA,"ASC diff: 37.5;U-2197: 58.5;U-266/70: 47.2"
"PCSK1N",126,"F8","IOH5441",783,"0",NA,"proprotein convertase subtilisin/kexin type 1 inhibitor (PCSK1N), mRNA.","NM_013271.2","NP_037403.1",27344,"Hs.522640","BigLEN, PEN, proSAAS, SAAS, SCG8, SgVIII","ENSG00000102109","Proprotein convertase subtilisin/kexin type 1 inhibitor","X","48831094-48835633","Predicted secreted proteins","Evidence at protein level","HPA003925, HPA064734","Enhanced",NA,"Approved","Vesicles","Endometrial cancer:1.15e-4 (unfavourable), Renal cancer:1.36e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 93.6;kidney: 65.7","adrenal gland: 28.5","Cell line enhanced",NA,"HEK 293: 52.2;PC-3: 133.3;SCLC-21H: 66.4;SH-SY5Y: 55.2;SiHa: 53.6;U-266/84: 49.2"
"PCSK2",70,"G9","IOH28687",1860,"0",NA,"proprotein convertase subtilisin/kexin type 2, mRNA (cDNA clone MGC:39745 IMAGE:5284427), complete cds","BC040546.1","AAH40546.1",5126,"Hs.315186","NEC2, PC2, SPC2","ENSG00000125851","Proprotein convertase subtilisin/kexin type 2","20","17226107-17484578","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA049627","Enhanced",NA,"Approved","Vesicles",NA,"Group enriched","Tissue enhanced",NA,"adrenal gland: 37.5;cerebral cortex: 31.7","skin: 16.5","Group enriched",6,"AF22: 59.2;SCLC-21H: 18.5"
"PCSK2",53,"F3","IOH6275",1917,"0",NA,"proprotein convertase subtilisin/kexin type 2 (PCSK2), mRNA.","NM_002594.2","NP_002585.2",5126,"Hs.315186","NEC2, PC2, SPC2","ENSG00000125851","Proprotein convertase subtilisin/kexin type 2","20","17226107-17484578","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA049627","Enhanced",NA,"Approved","Vesicles",NA,"Group enriched","Tissue enhanced",NA,"adrenal gland: 37.5;cerebral cortex: 31.7","skin: 16.5","Group enriched",6,"AF22: 59.2;SCLC-21H: 18.5"
"PCSK4",72,"D1","IOH27381",729,"0",NA,"proprotein convertase subtilisin/kexin type 4, mRNA (cDNA clone IMAGE:5172367), complete cds.","BC036354.1","AAH36354.1",54760,"Hs.46884","DKFZp434B217, MGC34749, PC4, SPC5","ENSG00000115257","Proprotein convertase subtilisin/kexin type 4","19","1481428-1490752","Enzymes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA005572","Uncertain",NA,NA,NA,"Endometrial cancer:9.45e-5 (favourable)","Expressed in all","Tissue enriched",9,"testis: 41.3","fallopian tube: 4.8","Cell line enhanced",NA,"AN3-CA: 6.5;HMC-1: 3.2;U-266/70: 5.8"
"PCSK5",90,"D9","IOH12516",2742,"0",NA,"proprotein convertase subtilisin/kexin type 5 (PCSK5), mRNA.","NM_006200.3","NP_006191.2",5125,"Hs.368542","PC5, PC6, SPC6","ENSG00000099139","Proprotein convertase subtilisin/kexin type 5","9","75890644-76362339","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA031072","Enhanced",NA,"Supported","Golgi apparatus","Renal cancer:9.61e-5 (unfavourable)","Mixed","Mixed",NA,NA,"small intestine: 28.1","Cell line enhanced",NA,"BEWO: 31.5;HaCaT: 41.2;RPTEC TERT1: 32.1;U-2 OS: 68.5"
"PCYOX1L",51,"G2","IOH4700",1257,"0",NA,"prenylcysteine oxidase 1 like, mRNA (cDNA clone MGC:3265 IMAGE:3506623), complete cds","BC000014.2","AAH00014.1",78991,"Hs.644397","MGC3265","ENSG00000145882","Prenylcysteine oxidase 1 like","5","149358007-149369653","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA037463, HPA038402","Approved",NA,"Approved","Nucleoplasm<br>Mitochondria",NA,"Expressed in all","Tissue enhanced",NA,"parathyroid gland: 21.4","cerebral cortex: 12.5","Mixed",NA,NA
"PDE7A",130,"E8","IOH51934",1371,"0",NA,"phosphodiesterase 7A (PDE7A), transcript variant 1, mRNA.","NM_002603.2","NP_002594.1",5150,"Hs.527119","HCP1","ENSG00000205268","Phosphodiesterase 7A","8","65717510-65842322","Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB018770, HPA027340","Approved",NA,NA,NA,"Renal cancer:1.35e-4 (unfavourable), Liver cancer:5.64e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 68.9","Expressed in all",NA,NA
"PDE7A",108,"C12","IOH35734",1275,"0",NA,"phosphodiesterase 7A (PDE7A), transcript variant 2, mRNA.","NM_002604.2","NP_002595.1",5150,"Hs.527119","HCP1","ENSG00000205268","Phosphodiesterase 7A","8","65717510-65842322","Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB018770, HPA027340","Approved",NA,NA,NA,"Renal cancer:1.35e-4 (unfavourable), Liver cancer:5.64e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 68.9","Expressed in all",NA,NA
"PDF",125,"C5","IOH11145",732,"0",NA,"peptide deformylase (mitochondrial), mRNA (cDNA clone MGC:30048 IMAGE:4994286), complete cds","BC019912.1","AAH19912.1",64146,"Hs.130849",NA,"ENSG00000258429","Peptide deformylase (mitochondrial)","16","69328621-69330595","Enzymes, Predicted secreted proteins","Evidence at protein level","HPA063409","Approved",NA,"Approved","Nucleoplasm<br>Mitochondria","Head and neck cancer:2.73e-4 (unfavourable), Cervical cancer:4.63e-4 (unfavourable), Renal cancer:6.11e-4 (favourable), Lung cancer:7.35e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"kidney: 7.8","Expressed in all",NA,NA
"PDGFA",140,"H1","IOH35279",636,"0",NA,"platelet-derived growth factor alpha polypeptide (PDGFA), transcript variant 1, mRNA.","NM_002607.5","NP_002598.4",5154,"Hs.535898","PDGF-A, PDGF1","ENSG00000197461","Platelet derived growth factor subunit A","7","497258-520296","Cancer-related genes, Candidate cardiovascular disease genes, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","CAB005579","Uncertain",NA,"Approved","Vesicles<br>Microtubule organizing center","Glioma:1.51e-4 (unfavourable), Head and neck cancer:1.78e-4 (unfavourable), Urothelial cancer:8.67e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 38.8","Cell line enhanced",NA,"WM-115: 307.1"
"PDGFB",41,"E7","IOH22794",726,"0",NA,"platelet-derived growth factor beta polypeptide (simian sarcoma viral (v-sis) oncogene homolog) (PDGFB), transcript variant 1, mRNA.","NM_002608.2","NP_002599.1",5155,"Hs.1976","SIS, SSV","ENSG00000100311","Platelet derived growth factor subunit B","22","39223359-39244751","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","CAB011604, HPA011972, CAB018341","Supported",NA,"Approved","Vesicles","Lung cancer:3.67e-5 (unfavourable)","Expressed in all","Tissue enhanced",NA,"placenta: 59.7","lung: 28.6","Cell line enhanced",NA,"EFO-21: 65.2;HUVEC TERT2: 45.3;SK-BR-3: 40.1;TIME: 55.5"
"PDGFC",106,"D12","IOH42087",1038,"0",NA,"platelet derived growth factor C (PDGFC), mRNA.","NM_016205.1","NP_057289.1",56034,"Hs.570855","fallotein, SCDGF","ENSG00000145431","Platelet derived growth factor C","4","156760454-156971394","Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","HPA009134","Approved",NA,"Supported","Plasma membrane<br>Cytosol","Renal cancer:1.35e-5 (favourable), Stomach cancer:3.05e-4 (unfavourable), Urothelial cancer:3.17e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"parathyroid gland: 40.6","endometrium: 16.8","Cell line enhanced",NA,"fHDF/TERT166: 47.4;U-138 MG: 41.4"
"PDGFD",31,"A6","IOH22283",1095,"0",NA,"platelet derived growth factor D (PDGFD), transcript variant 2, mRNA.","NM_033135.3","NP_149126.1",80310,"Hs.352298","IEGF, MSTP036, SCDGF-B","ENSG00000170962","Platelet derived growth factor D","11","103907186-104164379","Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","HPA046183, HPA066271","Approved",NA,"Approved","Golgi apparatus<br>Vesicles","Stomach cancer:9.60e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"adrenal gland: 140.5;ovary: 96.6","gallbladder: 53.7","Group enriched",6,"ASC diff: 96.8;HHSteC: 36.1"
"PDGFRA",134,"C5","IOH54205",3270,"0",NA,"platelet-derived growth factor receptor, alpha polypeptide (PDGFRA), mRNA.","NM_006206.4","NP_006197.1",5156,"Hs.74615","CD140a, GAS9, PDGFR2","ENSG00000134853","Platelet derived growth factor receptor alpha","4","54229097-54298247","Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","HPA004947, CAB018143","Supported",NA,"Supported","Nucleus<br>Plasma membrane<br>Cell Junctions","Renal cancer:9.79e-6 (unfavourable), Head and neck cancer:9.33e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"ovary: 222.6","Cell line enhanced",NA,"ASC diff: 306.3;ASC TERT1: 145.3;BJ hTERT+: 217.9;fHDF/TERT166: 147.1;HHSteC: 126.5;HSkMC: 276.0"
"PDGFRA",1,"A11","IOH12980",657,"NP_006197.1","AAH15186.1","platelet-derived growth factor receptor, alpha polypeptide, mRNA (cDNA clone IMAGE:4043984), complete cds.","BC015186.1","AAH15186.1",5156,"Hs.74615","CD140a, GAS9, PDGFR2","ENSG00000134853","Platelet derived growth factor receptor alpha","4","54229097-54298247","Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","HPA004947, CAB018143","Supported",NA,"Supported","Nucleus<br>Plasma membrane<br>Cell Junctions","Renal cancer:9.79e-6 (unfavourable), Head and neck cancer:9.33e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"ovary: 222.6","Cell line enhanced",NA,"ASC diff: 306.3;ASC TERT1: 145.3;BJ hTERT+: 217.9;fHDF/TERT166: 147.1;HHSteC: 126.5;HSkMC: 276.0"
"PDGFRA",157,"G11","IOH61544",2232,"0",NA,"platelet-derived growth factor receptor, alpha polypeptide, mRNA (cDNA clone MGC:74795 IMAGE:5205969), complete cds","BC063414.1","AAH63414.1",5156,"Hs.74615","CD140a, GAS9, PDGFR2","ENSG00000134853","Platelet derived growth factor receptor alpha","4","54229097-54298247","Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","HPA004947, CAB018143","Supported",NA,"Supported","Nucleus<br>Plasma membrane<br>Cell Junctions","Renal cancer:9.79e-6 (unfavourable), Head and neck cancer:9.33e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"ovary: 222.6","Cell line enhanced",NA,"ASC diff: 306.3;ASC TERT1: 145.3;BJ hTERT+: 217.9;fHDF/TERT166: 147.1;HHSteC: 126.5;HSkMC: 276.0"
"PDGFRB",140,"C10","IOH22618",3321,"NP_002600.1","AAH32224.1","platelet-derived growth factor receptor, beta polypeptide, mRNA (cDNA clone MGC:34052 IMAGE:5309813), complete cds","BC032224.1","AAH32224.1",5159,"Hs.509067","CD140b, JTK12, PDGFR, PDGFR1","ENSG00000113721","Platelet derived growth factor receptor beta","5","150113837-150155872","Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","CAB003842, CAB018144, HPA028499","Enhanced",NA,"Supported","Golgi apparatus<br>Vesicles","Renal cancer:5.87e-8 (unfavourable), Urothelial cancer:8.11e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"gallbladder: 193.8","Cell line enhanced",NA,"ASC diff: 923.6;ASC TERT1: 324.4"
"PDGFRL",65,"A10","IOH14275",1128,"0",NA,"platelet-derived growth factor receptor-like (PDGFRL), mRNA.","NM_006207.1","NP_006198.1",5157,"Hs.458573","PRLTS","ENSG00000104213","Platelet derived growth factor receptor like","8","17576433-17644071","Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA052801",NA,NA,"Approved","Nucleus<br>Nucleoli<br>Golgi apparatus","Renal cancer:0.00e+0 (unfavourable)","Expressed in all","Mixed",NA,NA,"breast: 49.2","Cell line enhanced",NA,"AN3-CA: 131.2;BJ hTERT+: 93.6;HSkMC: 44.1"
"PDIA3",16,"D7","IOH14276",1518,"0",NA,"protein disulfide isomerase family A, member 3 (PDIA3), mRNA.","NM_005313.4","NP_005304.3",2923,"Hs.591095","ERp57, ERp60, ERp61, GRP57, GRP58, HsT17083, P58, PI-PLC","ENSG00000167004","Protein disulfide isomerase family A member 3","15","43746392-43773279","Enzymes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA002645, HPA003230, CAB011199, CAB075744","Enhanced",NA,"Enhanced","Endoplasmic reticulum","Renal cancer:2.11e-8 (unfavourable), Head and neck cancer:8.95e-5 (unfavourable), Endometrial cancer:2.05e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 91.5","Expressed in all",NA,NA
"PDIA4",26,"C1","IOH3420",1938,"0",NA,"protein disulfide isomerase family A, member 4 (PDIA4), mRNA.","NM_004911.4","NP_004902.1",9601,"Hs.93659","ERP70, ERP72","ENSG00000155660","Protein disulfide isomerase family A member 4","7","149003062-149028641","Enzymes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA006139, HPA006140, CAB017368","Supported",NA,"Supported","Endoplasmic reticulum","Renal cancer:5.20e-9 (unfavourable), Glioma:8.61e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 372.1","Expressed in all",NA,NA
"PDIA5",126,"D11","IOH4882",789,"0",NA,"protein disulfide isomerase family A, member 5, mRNA (cDNA clone MGC:1259 IMAGE:3537659), complete cds","BC001625.1","AAH01625.1",10954,"Hs.477352","FLJ30401, PDIR","ENSG00000065485","Protein disulfide isomerase family A member 5","3","123067062-123225227","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA030353, HPA030355","Enhanced",NA,"Supported","Nucleoplasm<br>Nucleoli fibrillar center<br>Golgi apparatus","Renal cancer:8.09e-11 (unfavourable), Endometrial cancer:4.55e-4 (favourable)","Expressed in all","Mixed",NA,NA,"placenta: 70.8","Mixed",NA,NA
"PDIA5",137,"B5","IOH52174",1560,"0",NA,"protein disulfide isomerase family A, member 5 (PDIA5), mRNA.","NM_006810.2","NP_006801.1",10954,"Hs.477352","FLJ30401, PDIR","ENSG00000065485","Protein disulfide isomerase family A member 5","3","123067062-123225227","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA030353, HPA030355","Enhanced",NA,"Supported","Nucleoplasm<br>Nucleoli fibrillar center<br>Golgi apparatus","Renal cancer:8.09e-11 (unfavourable), Endometrial cancer:4.55e-4 (favourable)","Expressed in all","Mixed",NA,NA,"placenta: 70.8","Mixed",NA,NA
"PDIA6",62,"B6","IOH3098",1323,"0",NA,"protein disulfide isomerase family A, member 6 (PDIA6), mRNA.","NM_005742.2","NP_005733.1",10130,"Hs.212102","ERp5, P5, TXNDC7","ENSG00000143870","Protein disulfide isomerase family A member 6","2","10783391-10837977","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB034347, HPA034652, HPA034653","Enhanced",NA,"Supported","Endoplasmic reticulum<br>Cytosol","Renal cancer:2.51e-6 (unfavourable), Liver cancer:3.63e-5 (unfavourable), Head and neck cancer:1.20e-4 (unfavourable), Cervical cancer:1.80e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 591.9","Expressed in all",NA,NA
"PDILT",59,"E9","IOH27367",1755,"0",NA,"protein disulfide isomerase-like, testis expressed (PDILT), mRNA.","NM_174924.1","NP_777584.1",204474,"Hs.376025","PDIA7","ENSG00000169340","Protein disulfide isomerase like, testis expressed","16","20359170-20404737","Predicted secreted proteins","Evidence at protein level","HPA041913","Approved",NA,NA,NA,NA,"Not detected","Tissue enriched",5,"testis: 31.2","stomach: 6.1","Group enriched",6,"HBEC3-KT: 9.1;hTCEpi: 7.4;hTERT-HME1: 2.4"
"PDYN",9,"F2","IOH11247",765,"0",NA,"prodynorphin (PDYN), mRNA.","NM_024411.2","NP_077722.1",5173,"Hs.22584","ADCA, PENKB, SCA23","ENSG00000101327","Prodynorphin","20","1978757-1994285","Disease related genes, Potential drug targets, Predicted secreted proteins, Transporters","Evidence at protein level","HPA049841, HPA053342","Approved","Supported",NA,NA,NA,"Group enriched","Tissue enriched",11,"cerebral cortex: 63.3","testis: 5.5","Not detected",NA,NA
"PDZRN4",107,"E7","IOH42639",2337,"0",NA,"PDZ domain containing ring finger 4 (PDZRN4), mRNA.","NM_013377.3","NP_037509.3",29951,"Hs.380044","DKFZp434B0417, FLJ33777, IMAGE5767589, LNX4","ENSG00000165966","PDZ domain containing ring finger 4","12","41188448-41574590","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA042101","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"seminal vesicle: 19.6","prostate: 9.3","Cell line enriched",6,"U-266/70: 2.7"
"PEBP4",76,"B7","IOH13200",672,"0",NA,"phosphatidylethanolamine-binding protein 4, mRNA (cDNA clone MGC:22776 IMAGE:4700840), complete cds","BC020779.1","AAH20779.1",157310,"Hs.491242","CORK1, hPEBP4, MGC22776","ENSG00000134020","Phosphatidylethanolamine binding protein 4","8","22713251-23000000","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA025064","Uncertain",NA,NA,NA,NA,"Group enriched","Tissue enhanced",NA,"epididymis: 470.5;lung: 173.6;skeletal muscle: 233.0","thyroid gland: 96.3","Cell line enriched",7,"U-266/70: 3.0"
"PECAM1",9,"E2","IOH10695",2217,"NP_000433.2","AAH51822.1","platelet/endothelial cell adhesion molecule, mRNA (cDNA clone MGC:60076 IMAGE:5768579), complete cds","BC051822.1","AAH51822.1",5175,"Hs.514412","CD31","ENSG00000261371","Platelet and endothelial cell adhesion molecule 1","17","64319415-64413776","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA004690","Supported",NA,NA,NA,"Renal cancer:8.98e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 659.7","Cell line enhanced",NA,"HUVEC TERT2: 644.6;TIME: 437.4"
"PF4",70,"F12","IOH29560",306,"0",NA,"platelet factor 4 (PF4), mRNA.","NM_002619.2","NP_002610.1",5196,"Hs.81564","CXCL4, SCYB4","ENSG00000163737","Platelet factor 4","4","73981077-73982124","Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB026008, HPA052485","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Group enriched",5,"bone marrow: 53.7;spleen: 13.4","placenta: 6.5","Cell line enriched",13,"HEL: 37.2"
"PF4V1",110,"E11","IOH34711",315,"0",NA,"platelet factor 4 variant 1 (PF4V1), mRNA.","NM_002620.2","NP_002611.1",5197,"Hs.72933","CXCL4L1, CXCL4V1, SCYB4V1","ENSG00000109272","Platelet factor 4 variant 1","4","73853189-73854155","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA052485","Supported",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"spleen: 3.9","urinary bladder: 2.8","Cell line enhanced",NA,"CAPAN-2: 1.2;EFO-21: 2.0"
"PFKP",64,"C1","IOH4086",2355,"0",NA,"phosphofructokinase, platelet (PFKP), mRNA.","NM_002627.3","NP_002618.1",5214,"Hs.26010","PFK-C, PFKF","ENSG00000067057","Phosphofructokinase, platelet","10","3066333-3137712","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA018257, HPA056484","Uncertain",NA,"Supported","Cytosol","Liver cancer:8.72e-6 (unfavourable), Head and neck cancer:1.55e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 285.1","Mixed",NA,NA
"PGA5",39,"B8","IOH22660",1167,"0",NA,"pepsinogen 5, group I (pepsinogen A) (PGA5), mRNA.","NM_014224.1","NP_055039.1",5222,"Hs.432854",NA,"ENSG00000256713","Pepsinogen 5, group I (pepsinogen A)","11","61241042-61251448","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA046875","Supported",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",684,"stomach: 3513.1","cerebral cortex: 5.1","Cell line enriched",13,"BJ hTERT+: 23.3"
"PGAP3",111,"B2","IOH45578",963,"NP_219487.2","NP_219487.3","post-GPI attachment to proteins 3 (PGAP3), mRNA.","NM_033419.3","NP_219487.3",93210,"Hs.462971","CAB2, MGC9753, PER1, PERLD1, PP1498","ENSG00000161395","Post-GPI attachment to proteins 3","17","39671122-39696797","Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA016591","Approved",NA,"Approved","Plasma membrane<br>Cytosol","Renal cancer:3.89e-4 (favourable), Liver cancer:3.94e-4 (favourable), Ovarian cancer:6.82e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 35.6","Cell line enhanced",NA,"SK-BR-3: 99.2"
"PGC",52,"C2","IOH27311",315,"0",NA,"progastricsin (pepsinogen C), mRNA (cDNA clone IMAGE:5180836), complete cds.","BC042578.1","AAH42578.1",5225,"Hs.1867",NA,"ENSG00000096088","Progastricsin","6","41736711-41754109","Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA031717, HPA031718","Enhanced",NA,"Supported","Nucleus",NA,"Tissue enhanced","Tissue enriched",17,"stomach: 22276.5","duodenum: 1302.2","Cell line enriched",11,"Hep G2: 171.0"
"PGC",112,"E3","IOH45946",1167,"0",NA,"progastricsin (pepsinogen C) (PGC), mRNA.","NM_002630.2","NP_002621.1",5225,"Hs.1867",NA,"ENSG00000096088","Progastricsin","6","41736711-41754109","Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA031717, HPA031718","Enhanced",NA,"Supported","Nucleus",NA,"Tissue enhanced","Tissue enriched",17,"stomach: 22276.5","duodenum: 1302.2","Cell line enriched",11,"Hep G2: 171.0"
"PGF",28,"E1","IOH4048",513,"0",NA,"placental growth factor (PGF), mRNA.","NM_002632.4","NP_002623.2",5228,"Hs.252820","D12S1900, PGFL, PIGF, PLGF, PlGF-2, SHGC-10760","ENSG00000119630","Placental growth factor","14","74941834-74955784","Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","HPA041624",NA,NA,"Approved","Nucleoplasm<br>Mitochondria<br>Cytosol","Renal cancer:1.33e-6 (unfavourable), Liver cancer:1.40e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"placenta: 71.1;thyroid gland: 64.5","cervix, uterine: 30.1","Group enriched",6,"BEWO: 398.0;HUVEC TERT2: 164.7"
"PGLYRP1",108,"G5","IOH44372",591,"0",NA,"peptidoglycan recognition protein 1 (PGLYRP1), mRNA.","NM_005091.1","NP_005082.1",8993,"Hs.137583","PGLYRP, PGRP, PGRP-S, PGRPS, TAG7, TNFSF3L","ENSG00000008438","Peptidoglycan recognition protein 1","19","46019153-46023065","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA045702","Enhanced",NA,NA,NA,NA,"Not detected","Tissue enriched",57,"bone marrow: 421.1","spleen: 7.4","Cell line enhanced",NA,"A549: 2.9"
"PHACTR1",106,"D11","IOH43117",1743,"0",NA,"phosphatase and actin regulator 1 (PHACTR1), mRNA.","NM_030948.1","NP_112210.1",221692,"Hs.436996","dJ257A7.2, KIAA1733, RPEL1","ENSG00000112137","Phosphatase and actin regulator 1","6","12716805-13290484","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA029755, HPA029756, HPA029757","Enhanced",NA,"Uncertain","Plasma membrane","Renal cancer:5.48e-6 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 26.6","bone marrow: 15.6","Cell line enhanced",NA,"HMC-1: 33.9;U-266/70: 72.3;U-266/84: 46.3"
"PHGDH",26,"E1","IOH3438",1602,"0",NA,"phosphoglycerate dehydrogenase (PHGDH), mRNA.","NM_006623.3","NP_006614.2",26227,"Hs.487296","PDG, PGDH, SERA","ENSG00000092621","Phosphoglycerate dehydrogenase","1","119659798-119744215","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","CAB003681, HPA021241, HPA024031, CAB068216","Enhanced",NA,"Enhanced","Nucleoplasm<br>Plasma membrane<br>Cytosol","Endometrial cancer:1.48e-4 (unfavourable), Glioma:2.26e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"parathyroid gland: 216.7","skin: 115.9","Mixed",NA,NA
"PI15",121,"A6","IOH29651",777,"0",NA,"peptidase inhibitor 15 (PI15), mRNA.","NM_015886.3","NP_056970.1",51050,"Hs.98558","P25TI","ENSG00000137558","Peptidase inhibitor 15","8","74824537-74855029","Predicted secreted proteins","Evidence at protein level","HPA006593, HPA030057","Uncertain",NA,"Approved","Vesicles<br>Cytosol",NA,"Group enriched","Tissue enhanced",NA,"appendix: 73.2;prostate: 50.5;smooth muscle: 67.8","endometrium: 33.0","Group enriched",9,"AF22: 21.0;SH-SY5Y: 22.2;SK-MEL-30: 22.4;U-266/70: 5.5"
"PI3",16,"G10","IOH13658",354,"0",NA,"peptidase inhibitor 3, skin-derived (PI3), mRNA.","NM_002638.3","NP_002629.1",5266,"Hs.112341","cementoin, ELAFIN, ESI, SKALP, WAP3, WFDC14","ENSG00000124102","Peptidase inhibitor 3","20","45174876-45176544","Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB009449, HPA017737","Enhanced",NA,"Approved","Plasma membrane","Renal cancer:1.94e-8 (unfavourable), Ovarian cancer:3.84e-6 (unfavourable), Pancreatic cancer:6.89e-4 (unfavourable), Breast cancer:6.94e-4 (favourable)","Tissue enhanced","Group enriched",15,"esophagus: 2285.4;tonsil: 1739.8","appendix: 133.6","Group enriched",7,"EFO-21: 78.9;HaCaT: 92.0;PC-3: 163.0"
"PIGK",68,"C10","IOH14449",1188,"NP_005473.1","NP_005473.1","phosphatidylinositol glycan anchor biosynthesis, class K (PIGK), mRNA.","NM_005482.2","NP_005473.1",10026,"Hs.178305","GPI8, hGPI8","ENSG00000142892","Phosphatidylinositol glycan anchor biosynthesis class K","1","77088990-77219430","Enzymes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA056383, HPA057040","Uncertain",NA,NA,NA,"Liver cancer:4.68e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 28.4","Expressed in all",NA,NA
"PIGL",135,"A5","IOH57310",759,"0",NA,"phosphatidylinositol glycan anchor biosynthesis, class L (PIGL), mRNA.","NM_004278.3","NP_004269.1",9487,"Hs.499793",NA,"ENSG00000108474","Phosphatidylinositol glycan anchor biosynthesis class L","17","16217191-16351797","Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins","Evidence at protein level","HPA012739","Approved",NA,"Approved","Nucleoplasm<br>Cytosol","Renal cancer:1.47e-4 (unfavourable), Prostate cancer:2.57e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"epididymis,thyroid gland: 14.7","Mixed",NA,NA
"PIGT",12,"G11","IOH10124",1737,"0",NA,"phosphatidylinositol glycan anchor biosynthesis, class T (PIGT), mRNA.","NM_015937.3","NP_057021.2",51604,"Hs.437388",NA,"ENSG00000124155","Phosphatidylinositol glycan anchor biosynthesis class T","20","45416067-45456934","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Pancreatic cancer:2.51e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 123.1","Expressed in all",NA,NA
"PIGZ",68,"B3","IOH28008",1740,"NP_079439.1","AAH44640.1","phosphatidylinositol glycan anchor biosynthesis, class Z, mRNA (cDNA clone MGC:52163 IMAGE:4871581), complete cds","BC044640.1","AAH44640.1",80235,"Hs.518403","FLJ12768, MGC52163, SMP3","ENSG00000119227","Phosphatidylinositol glycan anchor biosynthesis class Z","3","196946343-196969060","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at transcript level","HPA058599, HPA059920","Approved",NA,"Uncertain","Vesicles","Renal cancer:5.60e-5 (unfavourable)","Expressed in all","Tissue enhanced",NA,"colon: 18.5;rectum: 18.1","cerebral cortex: 10.9","Mixed",NA,NA
"PILRA",73,"G8","IOH12960",681,"NP_038467.1","AAH17812.1","paired immunoglobin-like type 2 receptor alpha, mRNA (cDNA clone MGC:22388 IMAGE:4690881), complete cds","BC017812.1","AAH17812.1",29992,"Hs.444407","FDF03","ENSG00000085514","Paired immunoglobin like type 2 receptor alpha","7","100367530-100400099","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA056132","Approved",NA,NA,NA,"Renal cancer:1.61e-4 (unfavourable), Cervical cancer:2.99e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"appendix: 52.4","lung: 43.8","Cell line enhanced",NA,"ASC diff: 18.7;HMC-1: 21.9;NB-4: 12.4"
"PILRB",59,"B5","IOH26954",684,"0",NA,"paired immunoglobin-like type 2 receptor beta (PILRB), transcript variant 1, mRNA.","NM_013440.3","NP_038468.3",29990,"Hs.632314","FDFACT1, FDFACT2","ENSG00000121716","Paired immunoglobin-like type 2 receptor beta","7","100352176-100367733","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA026750","Approved",NA,"Approved","Mitochondria","Renal cancer:1.42e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 166.9","Expressed in all",NA,NA
"PIP",45,"C8","IOH12199",441,"0",NA,"prolactin-induced protein (PIP), mRNA.","NM_002652.2","NP_002643.1",5304,"Hs.99949","GCDFP-15, GCDFP15, GPIP4","ENSG00000159763","Prolactin induced protein","7","143132077-143139746","Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB002661, HPA009177","Enhanced",NA,NA,NA,"Renal cancer:5.96e-5 (favourable)","Tissue enriched","Group enriched",618,"breast: 4504.1;salivary gland: 6904.2;seminal vesicle: 4198.4","cervix, uterine: 8.4","Cell line enriched",415,"T-47d: 649.3"
"PLA1A",57,"G1","IOH26704",1323,"0",NA,"phospholipase A1 member A, mRNA (cDNA clone MGC:51964 IMAGE:6061929), complete cds","BC047703.2","AAH47703.1",51365,"Hs.437451","ps-PLA1","ENSG00000144837","Phospholipase A1 member A","3","119597842-119629811","Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","HPA059740",NA,NA,"Approved","Nuclear speckles","Cervical cancer:2.81e-7 (favourable)","Group enriched","Group enriched",5,"epididymis: 164.9;parathyroid gland: 38.9;seminal vesicle: 93.1","liver: 19.6","Cell line enriched",15,"SK-MEL-30: 19.7"
"PLA1A",130,"E7","IOH51937",1371,"0",NA,"phospholipase A1 member A (PLA1A), mRNA.","NM_015900.2","NP_056984.1",51365,"Hs.437451","ps-PLA1","ENSG00000144837","Phospholipase A1 member A","3","119597842-119629811","Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","HPA059740",NA,NA,"Approved","Nuclear speckles","Cervical cancer:2.81e-7 (favourable)","Group enriched","Group enriched",5,"epididymis: 164.9;parathyroid gland: 38.9;seminal vesicle: 93.1","liver: 19.6","Cell line enriched",15,"SK-MEL-30: 19.7"
"PLA2G10",95,"B8","IOH40301",498,"0",NA,"phospholipase A2, group X (PLA2G10), mRNA.","NM_003561.1","NP_003552.1",8399,"Hs.567366","GXPLA2","ENSG00000069764","Phospholipase A2 group X","16","14672545-14694669","Enzymes, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","HPA041893","Uncertain",NA,NA,NA,"Endometrial cancer:5.74e-5 (favourable)","Mixed","Tissue enhanced",NA,"colon: 6.9;rectum: 6.5;stomach: 10.4","duodenum: 2.2","Cell line enhanced",NA,"CAPAN-2: 1.3"
"PLA2G12A",134,"D12","IOH57186",570,"0",NA,"phospholipase A2, group XIIA (PLA2G12A), mRNA.","NM_030821.4","NP_110448.2",81579,"Hs.389452","PLA2G12","ENSG00000123739","Phospholipase A2 group XIIA","4","109709989-109730077","Enzymes, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","HPA035908, HPA035909","Approved",NA,NA,NA,"Renal cancer:2.54e-9 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 34.0","Expressed in all",NA,NA
"PLA2G15",126,"C1","IOH39852",1239,"0",NA,"phospholipase A2, group XV (PLA2G15), mRNA.","NM_012320.3","NP_036452.1",23659,"Hs.632199","GXVPLA2, LLPL, LYPLA3","ENSG00000103066","Phospholipase A2 group XV","16","68245304-68261062","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA041702, HPA041727","Enhanced",NA,"Supported","Nucleoplasm<br>Vesicles",NA,"Expressed in all","Expressed in all",NA,NA,"placenta: 37.5","Expressed in all",NA,NA
"PLA2G1B",88,"G7","IOH7124",213,"0",NA,"phospholipase A2, group IB (pancreas), mRNA (cDNA clone IMAGE:3950450), complete cds.","BC005386.1","AAH05386.1",5319,"Hs.992","PLA2, PLA2A, PPLA2","ENSG00000170890","Phospholipase A2 group IB","12","120322111-120327789","Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","CAB022329, HPA047822, HPA060803","Enhanced",NA,"Enhanced","Cytosol",NA,"Tissue enriched","Tissue enriched",246,"pancreas: 23843.3","ovary: 96.9","Cell line enhanced",NA,"Hep G2: 1.7;U-2 OS: 1.8"
"PLA2G1B",139,"B4","IOH59921",447,"0",NA,"phospholipase A2, group IB (pancreas) (PLA2G1B), mRNA.","NM_000928.2","NP_000919.1",5319,"Hs.992","PLA2, PLA2A, PPLA2","ENSG00000170890","Phospholipase A2 group IB","12","120322111-120327789","Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","CAB022329, HPA047822, HPA060803","Enhanced",NA,"Enhanced","Cytosol",NA,"Tissue enriched","Tissue enriched",246,"pancreas: 23843.3","ovary: 96.9","Cell line enhanced",NA,"Hep G2: 1.7;U-2 OS: 1.8"
"PLA2G2A",38,"D8","IOH7577",435,"0",NA,"phospholipase A2, group IIA (platelets, synovial fluid) (PLA2G2A), transcript variant 1, mRNA.","NM_000300.3","NP_000291.1",5320,"Hs.466804","PLA2B, PLA2L","ENSG00000188257","Phospholipase A2 group IIA","1","19975431-19980416","Enzymes, FDA approved drug targets, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","HPA015236","Enhanced",NA,"Uncertain","Nucleus<br>Nucleoli","Melanoma:1.49e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"colon: 108.4;rectum: 177.5;small intestine: 233.7","duodenum: 85.7","Group enriched",11,"Hep G2: 50.2;RT4: 53.3"
"PLA2G2D",48,"D2","IOH11316",438,"0",NA,"phospholipase A2, group IID (PLA2G2D), mRNA.","NM_012400.2","NP_036532.1",26279,"Hs.189507","sPLA2S","ENSG00000117215","Phospholipase A2 group IID","1","20111939-20119566","Enzymes, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Cervical cancer:8.15e-5 (favourable), Breast cancer:4.35e-4 (favourable), Endometrial cancer:9.74e-4 (favourable)","Tissue enriched","Tissue enhanced",NA,"lymph node: 118.5;tonsil: 54.0","appendix: 20.5","Cell line enriched",6,"RPMI-8226: 5.9"
"PLA2G5",67,"A2","IOH28759",417,"0",NA,"phospholipase A2, group V (PLA2G5), mRNA.","NM_000929.2","NP_000920.1",5322,"Hs.319438",NA,"ENSG00000127472","Phospholipase A2 group V","1","20028179-20091190","Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","HPA053361","Approved",NA,NA,NA,NA,"Group enriched","Tissue enhanced",NA,"heart muscle: 48.6","seminal vesicle: 19.8","Cell line enhanced",NA,"U-138 MG: 1.0;U-2197: 2.1"
"PLA2G7",75,"G6","IOH25919",1326,"0",NA,"phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma), mRNA (cDNA clone MGC:46165 IMAGE:5216829), complete cds","BC038452.1","AAH38452.1",7941,"Hs.584823","LDL-PLA2, PAFAH","ENSG00000146070","Phospholipase A2 group VII","6","46704201-46735693","Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins","Evidence at protein level","HPA035916",NA,NA,"Uncertain","Vesicles",NA,"Expressed in all","Mixed",NA,NA,"spleen: 37.5","Cell line enhanced",NA,"NTERA-2: 1.7;PC-3: 3.2;RT4: 1.3;U-2 OS: 1.7"
"PLA2R1",117,"G2","IOH34764",4392,"NP_031392.2","NP_031392.3","phospholipase A2 receptor 1, 180kDa (PLA2R1), transcript variant 1, mRNA.","NM_007366.3","NP_031392.3",22925,"Hs.410477","CLEC13C, PLA2-R, PLA2G1R, PLA2IR","ENSG00000153246","Phospholipase A2 receptor 1","2","159932006-160062610","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB068217, CAB068218","Approved",NA,"Approved","Cytosol","Stomach cancer:3.08e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"thyroid gland: 70.6","parathyroid gland: 34.5","Cell line enhanced",NA,"ASC TERT1: 13.7;BJ hTERT+: 13.1;SiHa: 12.5;TIME: 38.6"
"PLAC1",88,"B1","IOH13221",639,"0",NA,"placenta-specific 1 (PLAC1), mRNA.","NM_021796.3","NP_068568.1",10761,"Hs.496811","CT92, OOSP2L","ENSG00000170965","Placenta specific 1","X","134565838-134764322","Predicted secreted proteins","Evidence at protein level","HPA063425","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enriched",21,"placenta: 37.7","testis: 1.7","Cell line enhanced",NA,"HEK 293: 18.2;hTCEpi: 11.1"
"PLAC9",129,"D5","IOH53767",294,"0",NA,"placenta-specific 9 (PLAC9), mRNA.","NM_001012973.1","NP_001012991.1",219348,"Hs.204947",NA,"ENSG00000189129","Placenta specific 9","10","80131682-80145359","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA043469","Uncertain",NA,NA,NA,"Ovarian cancer:6.60e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"adipose tissue: 87.5","breast: 68.4","Cell line enhanced",NA,"ASC diff: 67.4;ASC TERT1: 59.6;BEWO: 31.0"
"PLAT",121,"H5","IOH29603",1689,"0",NA,"plasminogen activator, tissue (PLAT), transcript variant 1, mRNA.","NM_000930.3","NP_000921.1",5327,"Hs.491582",NA,"ENSG00000104368","Plasminogen activator, tissue type","8","42175233-42207724","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA003412, CAB009335","Supported",NA,"Approved","Actin filaments","Renal cancer:4.95e-4 (unfavourable), Breast cancer:7.57e-4 (favourable)","Expressed in all","Tissue enriched",5,"parathyroid gland: 709.4","urinary bladder: 135.9","Cell line enhanced",NA,"CAPAN-2: 590.7;HMC-1: 372.4;U-2197: 417.3;WM-115: 889.6"
"PLAT",154,"A6","IOH62678",1689,"0",NA,"plasminogen activator, tissue, mRNA (cDNA clone MGC:110886 IMAGE:30528441), complete cds","BC095403.1","AAH95403.1",5327,"Hs.491582",NA,"ENSG00000104368","Plasminogen activator, tissue type","8","42175233-42207724","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA003412, CAB009335","Supported",NA,"Approved","Actin filaments","Renal cancer:4.95e-4 (unfavourable), Breast cancer:7.57e-4 (favourable)","Expressed in all","Tissue enriched",5,"parathyroid gland: 709.4","urinary bladder: 135.9","Cell line enhanced",NA,"CAPAN-2: 590.7;HMC-1: 372.4;U-2197: 417.3;WM-115: 889.6"
"PLAU",1,"D9","IOH9871",1296,"0",NA,"plasminogen activator, urokinase (PLAU), transcript variant 1, mRNA.","NM_002658.3","NP_002649.1",5328,"Hs.77274","UPA, URK","ENSG00000122861","Plasminogen activator, urokinase","10","73909177-73917497","Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA008719","Approved",NA,NA,NA,"Pancreatic cancer:1.32e-4 (unfavourable), Head and neck cancer:2.70e-4 (unfavourable), Endometrial cancer:3.38e-4 (favourable), Renal cancer:3.51e-4 (unfavourable), Lung cancer:4.04e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"appendix: 60.3","Cell line enhanced",NA,"CAPAN-2: 757.8;LHCN-M2: 690.9;RPTEC TERT1: 2356.8;U-251 MG: 715.9"
"PLAUR",143,"F9","IOH59468",846,"0",NA,"plasminogen activator, urokinase receptor (PLAUR), transcript variant 2, mRNA.","NM_001005376.1","NP_001005376.1",5329,"Hs.466871","CD87, UPAR, URKR","ENSG00000011422","Plasminogen activator, urokinase receptor","19","43646095-43670547","Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA050843, CAB073533","Uncertain",NA,"Supported","Plasma membrane","Renal cancer:7.83e-9 (unfavourable), Lung cancer:2.33e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"bone marrow: 428.5","Cell line enhanced",NA,"U-251 MG: 341.1;U-87 MG: 336.6;WM-115: 338.6"
"PLAUR",53,"C9","IOH5327",1008,"0",NA,"plasminogen activator, urokinase receptor (PLAUR), transcript variant 1, mRNA.","NM_002659.2","NP_002650.1",5329,"Hs.466871","CD87, UPAR, URKR","ENSG00000011422","Plasminogen activator, urokinase receptor","19","43646095-43670547","Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA050843, CAB073533","Uncertain",NA,"Supported","Plasma membrane","Renal cancer:7.83e-9 (unfavourable), Lung cancer:2.33e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"bone marrow: 428.5","Cell line enhanced",NA,"U-251 MG: 341.1;U-87 MG: 336.6;WM-115: 338.6"
"PLBD1",19,"G2","IOH11938",672,"0",NA,"phospholipase B domain containing 1, mRNA (cDNA clone IMAGE:2984747), complete cds.","BC000909.2","AAH00909.2",79887,"Hs.131933","FLJ22662","ENSG00000121316","Phospholipase B domain containing 1","12","14503661-14568349","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA040303","Approved",NA,NA,NA,"Liver cancer:2.81e-5 (unfavourable), Pancreatic cancer:1.66e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"bone marrow: 167.1","Cell line enhanced",NA,"BEWO: 77.7;CAPAN-2: 186.4"
"PLEKHH3",122,"A2","IOH12183",2118,"0",NA,"pleckstrin homology domain containing, family H (with MyTH4 domain) member 3, mRNA (cDNA clone MGC:23227 IMAGE:4909623), complete cds","BC016062.1","AAH16062.1",79990,"Hs.632251","FLJ21019","ENSG00000068137","Pleckstrin homology, MyTH4 and FERM domain containing H3","17","42667914-42676994","Predicted intracellular proteins","Evidence at protein level","HPA046234","Uncertain",NA,"Approved","Golgi apparatus","Renal cancer:9.62e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"skin: 11.6","Cell line enhanced",NA,"T-47d: 46.9"
"PLG",69,"H5","IOH29428",2433,"0",NA,"plasminogen, mRNA (cDNA clone MGC:61954 IMAGE:4609795), complete cds","BC060513.1","AAH60513.1",5340,"Hs.143436",NA,"ENSG00000122194","Plasminogen","6","160702238-160753315","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB000668, CAB016678, HPA021602, HPA048823, HPA053770","Supported",NA,"Uncertain","Vesicles","Renal cancer:4.22e-4 (favourable)","Tissue enriched","Tissue enriched",6,"liver: 1749.3","kidney: 313.4","Cell line enhanced",NA,"RH-30: 1.0"
"PLG",69,"A6","IOH29872",2433,"0",NA,"plasminogen (PLG), mRNA.","NM_000301.2","NP_000292.1",5340,"Hs.143436",NA,"ENSG00000122194","Plasminogen","6","160702238-160753315","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB000668, CAB016678, HPA021602, HPA048823, HPA053770","Supported",NA,"Uncertain","Vesicles","Renal cancer:4.22e-4 (favourable)","Tissue enriched","Tissue enriched",6,"liver: 1749.3","kidney: 313.4","Cell line enhanced",NA,"RH-30: 1.0"
"PLGLB1",127,"F7","IOH7373",291,"0",NA,"plasminogen-like B1 (PLGLB1), mRNA.","NM_001032392.2","NP_001027564.1",5343,"Hs.652169","PLGL, PRP-B","ENSG00000183281","Plasminogen-like B1","2","87002559-87021852","Predicted secreted proteins","Evidence at transcript level","HPA053770",NA,NA,"Approved","Vesicles",NA,"Tissue enriched","Tissue enriched",8,"liver: 120.5","skin: 15.4","Mixed",NA,NA
"PLOD1",137,"D10","IOH55655",2184,"0",NA,"procollagen-lysine 1, 2-oxoglutarate 5-dioxygenase 1 (PLOD1), mRNA.","NM_000302.2","NP_000293.2",5351,"Hs.75093","LH1, LLH, PLOD","ENSG00000083444","Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1","1","11934205-11975538","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins","Evidence at protein level","HPA049137, HPA055799","Uncertain",NA,"Uncertain","Nucleoplasm<br>Vesicles","Renal cancer:1.91e-12 (unfavourable), Urothelial cancer:2.43e-4 (unfavourable), Liver cancer:2.79e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 122.3","Expressed in all",NA,NA
"PLOD2",116,"E4","IOH41898",2277,"0",NA,"procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 (PLOD2), transcript variant 1, mRNA.","NM_182943.2","NP_891988.1",5352,"Hs.477866","LH2","ENSG00000152952","Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2","3","146069440-146163653","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB025898, HPA069126","Approved",NA,"Uncertain","Nucleoli<br>Cytosol","Renal cancer:4.99e-11 (unfavourable), Liver cancer:7.64e-10 (unfavourable), Lung cancer:1.42e-4 (unfavourable), Cervical cancer:1.97e-4 (unfavourable), Stomach cancer:2.83e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"thyroid gland: 150.8","Cell line enhanced",NA,"HBF TERT88: 615.2;U-87 MG: 554.9"
"PLOD3",8,"H3","IOH12981",2217,"0",NA,"procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 (PLOD3), mRNA.","NM_001084.4","NP_001075.1",8985,"Hs.153357","LH3","ENSG00000106397","Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3","7","101205977-101218420","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA001236","Uncertain",NA,NA,NA,"Cervical cancer:1.91e-5 (unfavourable), Colorectal cancer:3.26e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 48.1","Expressed in all",NA,NA
"PLTP",43,"E4","IOH6579",1326,"0",NA,"phospholipid transfer protein (PLTP), transcript variant 2, mRNA.","NM_182676.1","NP_872617.1",5360,"Hs.439312","BPIFE","ENSG00000100979","Phospholipid transfer protein","20","45898621-45912155","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transporters","Evidence at protein level","CAB032873","Approved",NA,NA,NA,"Renal cancer:9.52e-8 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 635.6","Cell line enhanced",NA,"HSkMC: 229.0;U-87 MG: 331.6"
"PLTP",31,"E8","IOH22372",1482,"0",NA,"phospholipid transfer protein, mRNA (cDNA clone MGC:30183 IMAGE:4992839), complete cds","BC019898.1","AAH19898.1",5360,"Hs.439312","BPIFE","ENSG00000100979","Phospholipid transfer protein","20","45898621-45912155","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transporters","Evidence at protein level","CAB032873","Approved",NA,NA,NA,"Renal cancer:9.52e-8 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 635.6","Cell line enhanced",NA,"HSkMC: 229.0;U-87 MG: 331.6"
"PLXNA4",31,"E11","IOH22435",1569,"0",NA,"plexin A4, mRNA (cDNA clone IMAGE:4828816), complete cds.","BC028744.2","AAH28744.1",91584,"Hs.511454","DKFZp434G0625PRO34003, FAYV2820, KIAA1550, PLXNA4A, PLXNA4B","ENSG00000221866","Plexin A4","7","132123332-132648688","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA029919, HPA052141, HPA075592","Approved",NA,"Approved","Plasma membrane","Endometrial cancer:1.61e-6 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"adipose tissue: 15.2;cervix, uterine: 12.5","cerebral cortex: 10.4","Cell line enhanced",NA,"ASC diff: 17.3;HMC-1: 15.0;RH-30: 17.9;TIME: 46.9"
"PM20D1",148,"B12","IOH62026",1509,"0",NA,"peptidase M20 domain containing 1, mRNA (cDNA clone MGC:21660 IMAGE:4746689), complete cds","BC039170.1","AAH39170.1",148811,"Hs.177744","Cps1, FLJ32569","ENSG00000162877","Peptidase M20 domain containing 1","1","205828022-205850132","Enzymes, Predicted secreted proteins","Evidence at transcript level",NA,NA,NA,NA,NA,NA,"Tissue enriched","Tissue enhanced",NA,"kidney: 6.0;pancreas: 16.6","skin: 3.9","Cell line enriched",10,"Karpas-707: 1.3"
"PMCH",73,"C12","IOH10610",498,"0",NA,"pro-melanin-concentrating hormone (PMCH), mRNA.","NM_002674.2","NP_002665.2",5367,"Hs.707990","MCH","ENSG00000183395","Pro-melanin concentrating hormone","12","102196459-102197845","Predicted secreted proteins","Evidence at protein level","HPA046055, HPA061884","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"lymph node: 1.1","appendix: 0.7","Cell line enriched",9,"HDLM-2: 40.8"
"PMEPA1",9,"G7","IOH12695",714,"0","NP_954639.1","prostate transmembrane protein, androgen induced 1 (PMEPA1), transcript variant 3, mRNA.","NM_199170.1","NP_954639.1",56937,"Hs.517155","STAG1, TMEPAI","ENSG00000124225","Prostate transmembrane protein, androgen induced 1","20","57648392-57711536","Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA072291",NA,NA,"Supported","Vesicles","Renal cancer:2.87e-7 (unfavourable), Lung cancer:4.73e-5 (unfavourable), Cervical cancer:2.45e-4 (unfavourable), Urothelial cancer:7.60e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cervix, uterine: 146.1;prostate: 179.6","endometrium: 60.3","Cell line enhanced",NA,"SiHa: 218.5;U-251 MG: 397.1;WM-115: 233.9"
"PMEPA1",143,"E5","IOH59817",759,"0","NP_954638.1","prostate transmembrane protein, androgen induced 1 (PMEPA1), transcript variant 2, mRNA.","NM_199169.1","NP_954638.1",56937,"Hs.517155","STAG1, TMEPAI","ENSG00000124225","Prostate transmembrane protein, androgen induced 1","20","57648392-57711536","Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA072291",NA,NA,"Supported","Vesicles","Renal cancer:2.87e-7 (unfavourable), Lung cancer:4.73e-5 (unfavourable), Cervical cancer:2.45e-4 (unfavourable), Urothelial cancer:7.60e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cervix, uterine: 146.1;prostate: 179.6","endometrium: 60.3","Cell line enhanced",NA,"SiHa: 218.5;U-251 MG: 397.1;WM-115: 233.9"
"PMEPA1",115,"C1","IOH41590",864,"0","NP_064567.2","prostate transmembrane protein, androgen induced 1 (PMEPA1), transcript variant 1, mRNA.","NM_020182.3","NP_064567.2",56937,"Hs.517155","STAG1, TMEPAI","ENSG00000124225","Prostate transmembrane protein, androgen induced 1","20","57648392-57711536","Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA072291",NA,NA,"Supported","Vesicles","Renal cancer:2.87e-7 (unfavourable), Lung cancer:4.73e-5 (unfavourable), Cervical cancer:2.45e-4 (unfavourable), Urothelial cancer:7.60e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cervix, uterine: 146.1;prostate: 179.6","endometrium: 60.3","Cell line enhanced",NA,"SiHa: 218.5;U-251 MG: 397.1;WM-115: 233.9"
"PNLIP",20,"C4","IOH14532",1398,"0",NA,"pancreatic lipase (PNLIP), mRNA.","NM_000936.2","NP_000927.1",5406,"Hs.501135","PL","ENSG00000175535","Pancreatic lipase","10","116545931-116567855","Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA062430, HPA062494","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",325,"pancreas: 93703.0","ovary: 288.0","Cell line enhanced",NA,"U-2 OS: 1.3"
"PNLIPRP1",21,"G9","IOH7235",561,"0",NA,"pancreatic lipase-related protein 1, mRNA (cDNA clone IMAGE:3950129), complete cds.","BC005233.1","AAH05233.1",5407,"Hs.73923","PLRP1","ENSG00000187021","Pancreatic lipase related protein 1","10","116590385-116609175","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enriched","Tissue enriched",373,"pancreas: 2295.1","ovary: 6.1","Not detected",NA,NA
"PNLIPRP1",78,"B2","IOH11964",1404,"0",NA,"pancreatic lipase-related protein 1, mRNA (cDNA clone MGC:34434 IMAGE:5226231), complete cds","BC025784.2","AAH25784.1",5407,"Hs.73923","PLRP1","ENSG00000187021","Pancreatic lipase related protein 1","10","116590385-116609175","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enriched","Tissue enriched",373,"pancreas: 2295.1","ovary: 6.1","Not detected",NA,NA
"PNOC",38,"H10","IOH22728",531,"0",NA,"prepronociceptin (PNOC), mRNA.","NM_006228.3","NP_006219.1",5368,"Hs.88218","N/OFQ, NOP, PPNOC","ENSG00000168081","Prepronociceptin","8","28316986-28343355","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA044507, HPA056724","Enhanced",NA,NA,NA,"Endometrial cancer:2.94e-6 (unfavourable)","Tissue enriched","Tissue enhanced",NA,"cerebral cortex: 44.2;fallopian tube: 26.3;lymph node: 28.9","tonsil: 21.4","Group enriched",6,"Daudi: 27.2;Karpas-707: 20.9;RPMI-8226: 7.7;U-698: 15.7"
"PNPLA4",48,"E5","IOH14515",762,"0",NA,"patatin-like phospholipase domain containing 4, mRNA (cDNA clone MGC:22585 IMAGE:4717901), complete cds","BC020746.1","AAH20746.1",8228,"Hs.264","DXS1283E, GS2, iPLA2eta","ENSG00000006757","Patatin like phospholipase domain containing 4","X","7898247-7927739","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA003656","Approved",NA,NA,NA,"Renal cancer:2.23e-12 (favourable), Glioma:4.67e-4 (unfavourable), Head and neck cancer:5.37e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 50.2","Mixed",NA,NA
"PNPLA4",142,"A11","IOH54866",762,"0",NA,"patatin-like phospholipase domain containing 4 (PNPLA4), transcript variant 1, mRNA.","NM_004650.2","NP_004641.1",8228,"Hs.264","DXS1283E, GS2, iPLA2eta","ENSG00000006757","Patatin like phospholipase domain containing 4","X","7898247-7927739","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA003656","Approved",NA,NA,NA,"Renal cancer:2.23e-12 (favourable), Glioma:4.67e-4 (unfavourable), Head and neck cancer:5.37e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 50.2","Mixed",NA,NA
"PODNL1",118,"A7","IOH29237",1539,"0",NA,"podocan-like 1, mRNA (cDNA clone MGC:71618 IMAGE:30347370), complete cds","BC057786.1","AAH57786.1",79883,"Hs.448497","FLJ23447, SLRR5B","ENSG00000132000","Podocan like 1","19","13931187-13953392","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA042807","Approved",NA,NA,NA,"Glioma:2.06e-8 (unfavourable), Urothelial cancer:4.49e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"placenta: 12.3","skin: 8.5","Cell line enhanced",NA,"HSkMC: 17.5;SiHa: 21.2;U-2 OS: 16.8"
"POFUT1",90,"B6","IOH4155",585,"0",NA,"protein O-fucosyltransferase 1 (POFUT1), transcript variant 2, mRNA.","NM_172236.1","NP_758436.1",23509,"Hs.472409","FUT12, KIAA0180, O-Fuc-T, O-FUT","ENSG00000101346","Protein O-fucosyltransferase 1","20","32207880-32238667","Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins","Evidence at protein level","HPA054519, HPA059935","Approved",NA,"Approved","Centrosome",NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 35.7","Expressed in all",NA,NA
"POFUT2",95,"G10","IOH39914",1290,"0",NA,"protein O-fucosyltransferase 2 (POFUT2), transcript variant 3, mRNA.","NM_133635.4","NP_598368.2",23275,"Hs.592164","C21orf80, FUT13, KIAA0958","ENSG00000186866","Protein O-fucosyltransferase 2","21","45263928-45287898","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA044297","Uncertain",NA,NA,NA,"Renal cancer:8.66e-12 (unfavourable), Colorectal cancer:4.55e-7 (unfavourable), Liver cancer:2.78e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 24.3","Expressed in all",NA,NA
"POLL",128,"F9","IOH40098",1728,"0",NA,"polymerase (DNA directed), lambda, mRNA (cDNA clone MGC:87359 IMAGE:5267859), complete cds","BC068529.1","AAH68529.1",27343,"Hs.523230",NA,"ENSG00000166169","DNA polymerase lambda","10","101578882-101588270","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA066704",NA,NA,"Enhanced","Nucleus<br>Golgi apparatus",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 49.9","Mixed",NA,NA
"POLL",23,"F7","IOH4864",897,"0",NA,"DNA polymerase lambda (Pol Lambda)(EC 2.7.7.7)(EC 4.2.99.-)(DNA polymerase kappa)(DNA polymerase beta-2)(Pol beta2) [Source:UniProtKB/Swiss-Prot;Acc:Q9UGP5]","ENST00000339310","ENSP00000343102",27343,"Hs.523230",NA,"ENSG00000166169","DNA polymerase lambda","10","101578882-101588270","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA066704",NA,NA,"Enhanced","Nucleus<br>Golgi apparatus",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 49.9","Mixed",NA,NA
"POMC",96,"E6","IOH40048",804,"0",NA,"proopiomelanocortin (POMC), transcript variant 2, mRNA.","NM_000939.2","NP_000930.1",5443,"Hs.1897","ACTH, CLIP, LPH, MSH, NPP, POC","ENSG00000115138","Proopiomelanocortin","2","25160853-25168903","Cancer-related genes, Disease related genes, Predicted secreted proteins","Evidence at protein level","CAB002762, HPA046135, HPA063644","Enhanced",NA,NA,NA,"Pancreatic cancer:5.70e-4 (favourable)","Tissue enriched","Tissue enhanced",NA,"testis: 6.8","pancreas: 5.3","Cell line enhanced",NA,"HMC-1: 1.2;THP-1: 1.2"
"PPBP",34,"C3","IOH12030",387,"0",NA,"pro-platelet basic protein (chemokine (C-X-C motif) ligand 7) (PPBP), mRNA.","NM_002704.2","NP_002695.1",5473,"Hs.2164","b-TG1, Beta-TG, CTAP3, CTAPIII, CXCL7, LA-PF4, LDGF, MDGF, NAP-2, NAP-2-L1, PBP, SCYB7, TGB, TGB1, THBGB1","ENSG00000163736","Pro-platelet basic protein","4","73987038-73988197","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA008354, CAB017624","Supported",NA,NA,NA,"Cervical cancer:6.17e-4 (unfavourable)","Tissue enriched","Tissue enhanced",NA,"bone marrow: 110.6","spleen: 24.3","Cell line enhanced",NA,"HBEC3-KT: 1.6;HEL: 6.2;RPTEC TERT1: 1.1"
"PPIC",126,"G7","IOH5288",639,"0",NA,"peptidylprolyl isomerase C (cyclophilin C) (PPIC), mRNA.","NM_000943.4","NP_000934.1",5480,"Hs.110364","CYPC","ENSG00000168938","Peptidylprolyl isomerase C","5","123023250-123036741","Enzymes, Predicted secreted proteins","Evidence at protein level","HPA039163","Approved",NA,NA,NA,"Liver cancer:4.78e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"thyroid gland: 77.6","Mixed",NA,NA
"PPP1CC",2,"H10","IOH14587",972,"0",NA,"protein phosphatase 1, catalytic subunit, gamma isoform (PPP1CC), mRNA.","NM_002710.2","NP_002701.1",5501,"Hs.79081","PP1C, PP1gamma","ENSG00000186298","Protein phosphatase 1 catalytic subunit gamma","12","110719680-110742939","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB022645","Uncertain",NA,NA,NA,"Liver cancer:2.75e-6 (unfavourable), Cervical cancer:7.44e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 257.5","Expressed in all",NA,NA
"PPT1",90,"E1","IOH7465",921,"0",NA,"palmitoyl-protein thioesterase 1 (PPT1), transcript variant 1, mRNA.","NM_000310.3","NP_000301.1",5538,"Hs.3873","CLN1, INCL, PPT","ENSG00000131238","Palmitoyl-protein thioesterase 1","1","40072705-40097703","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA021546","Supported",NA,NA,NA,"Liver cancer:6.98e-8 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 193.0","Expressed in all",NA,NA
"PPT2",114,"G5","IOH42435",927,"0",NA,"palmitoyl-protein thioesterase 2 (PPT2), transcript variant 2, mRNA.","NM_138717.1","NP_619731.1",9374,"Hs.635690",NA,"ENSG00000221988","Palmitoyl-protein thioesterase 2","6","32153441-32163680","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Endometrial cancer:5.03e-5 (unfavourable)","Expressed in all","Mixed",NA,NA,"skin: 8.6","Cell line enhanced",NA,"ASC diff: 16.4;EFO-21: 16.9;HEK 293: 29.1;SK-MEL-30: 16.2"
"PPT2",43,"H12","IOH3929",909,"0",NA,"palmitoyl-protein thioesterase 2 (PPT2), transcript variant 1, mRNA.","NM_005155.5","NP_005146.3",9374,"Hs.635690",NA,"ENSG00000221988","Palmitoyl-protein thioesterase 2","6","32153441-32163680","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Endometrial cancer:5.03e-5 (unfavourable)","Expressed in all","Mixed",NA,NA,"skin: 8.6","Cell line enhanced",NA,"ASC diff: 16.4;EFO-21: 16.9;HEK 293: 29.1;SK-MEL-30: 16.2"
"PRAP1",114,"F6","IOH42472",456,"0",NA,"proline-rich acidic protein 1, mRNA (cDNA clone MGC:74605 IMAGE:5748898), complete cds","BC061643.1","AAH61643.1",118471,"Hs.15951","UPA","ENSG00000165828","Proline rich acidic protein 1","10","133347146-133352683","Predicted secreted proteins","Evidence at protein level","HPA038713, HPA052451","Supported",NA,"Uncertain","Nucleoplasm<br>Vesicles<br>Plasma membrane",NA,"Group enriched","Group enriched",6,"duodenum: 928.6;liver: 297.4;small intestine: 1097.7","kidney: 125.6","Group enriched",5,"CACO-2: 18.2;Hep G2: 64.2"
"PRB3",153,"A12","IOH63220",489,"0",NA,"proline-rich protein BstNI subfamily 3, mRNA (cDNA clone IMAGE:40004745), complete cds.","BC096212.3","AAH96212.1",5544,"Hs.73031","PRG","ENSG00000197870","Proline rich protein BstNI subfamily 3","12","11265924-11269805","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",3949,"salivary gland: 5770.7","skin: 1.4","Cell line enriched",5,"NTERA-2: 2.2"
"PRCP",41,"B9","IOH13548",1491,"0",NA,"prolylcarboxypeptidase (angiotensinase C) (PRCP), transcript variant 1, mRNA.","NM_005040.2","NP_005031.1",5547,"Hs.523936","HUMPCP, PCP","ENSG00000137509","Prolylcarboxypeptidase","11","82823502-82970584","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA017065","Approved",NA,NA,NA,"Renal cancer:2.65e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 222.7","Expressed in all",NA,NA
"PRDX4",90,"A2","IOH7551",816,"0",NA,"peroxiredoxin 4 (PRDX4), mRNA.","NM_006406.1","NP_006397.1",10549,"Hs.83383","AOE37-2","ENSG00000123131","Peroxiredoxin 4","X","23664262-23686399","Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB008659, CAB027389, CAB047362","Enhanced",NA,"Supported","Endoplasmic reticulum<br>Cytosol","Renal cancer:1.33e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"pancreas: 239.5","Expressed in all",NA,NA
"PRELP",55,"A12","IOH21892",1149,"0",NA,"proline/arginine-rich end leucine-rich repeat protein (PRELP), transcript variant 1, mRNA.","NM_002725.3","NP_002716.1",5549,"Hs.632481","prolargin, SLRR2A","ENSG00000188783","Proline and arginine rich end leucine rich repeat protein","1","203475828-203491352","Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:5.62e-6 (unfavourable), Colorectal cancer:9.70e-5 (unfavourable), Urothelial cancer:1.02e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"seminal vesicle: 108.0","Group enriched",7,"ASC diff: 12.4;BJ: 6.5;fHDF/TERT166: 9.1"
"PRF1",96,"D12","IOH39791",1668,"0",NA,"perforin 1 (pore forming protein) (PRF1), transcript variant 1, mRNA.","NM_005041.4","NP_005032.2",5551,"Hs.2200","HPLH2, P1, PFP","ENSG00000180644","Perforin 1","10","70597348-70602775","Cancer-related genes, Disease related genes, Potential drug targets, Predicted secreted proteins, Transporters","Evidence at protein level","CAB002436, HPA037940","Approved",NA,"Approved","Cytosol","Renal cancer:1.08e-5 (unfavourable), Endometrial cancer:2.09e-4 (favourable), Head and neck cancer:3.54e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"spleen: 52.8","lymph node: 20.8","Cell line enriched",16,"HDLM-2: 221.2"
"PRH2",145,"F8","IOH63166",501,"0",NA,"proline-rich protein HaeIII subfamily 2, mRNA (cDNA clone MGC:111566 IMAGE:30327943), complete cds","BC095488.1","AAH95488.1",5555,"Hs.631731","Pr","ENSG00000134551","Proline rich protein HaeIII subfamily 2","12","10929236-10932341","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enriched","Tissue enriched",1858,"salivary gland: 16591.4","ovary: 8.9","Not detected",NA,NA
"PRH2",142,"C6","IOH53437",501,"0",NA,"proline-rich protein HaeIII subfamily 2 (PRH2), transcript variant 1, mRNA.","NM_005042.4","NP_005033.1",5555,"Hs.631731","Pr","ENSG00000134551","Proline rich protein HaeIII subfamily 2","12","10929236-10932341","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enriched","Tissue enriched",1858,"salivary gland: 16591.4","ovary: 8.9","Not detected",NA,NA
"PRL",49,"G9","IOH14283",684,"0",NA,"prolactin (PRL), transcript variant 1, mRNA.","NM_000948.4","NP_000939.1",5617,"Hs.1905",NA,"ENSG00000172179","Prolactin","6","22287244-22297501","Cancer-related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB023353, HPA042416, HPA062017","Enhanced",NA,"Uncertain","Cytosol",NA,"Not detected","Group enriched",9,"endometrium: 10.7;placenta: 27.2","testis: 2.2","Cell line enhanced",NA,"Daudi: 11.1;SCLC-21H: 6.5;U-937: 2.1"
"PRL",155,"A8","IOH62603",687,"0",NA,"prolactin, mRNA (cDNA clone MGC:111116 IMAGE:30393428), complete cds","BC088370.1","AAH88370.1",5617,"Hs.1905",NA,"ENSG00000172179","Prolactin","6","22287244-22297501","Cancer-related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB023353, HPA042416, HPA062017","Enhanced",NA,"Uncertain","Cytosol",NA,"Not detected","Group enriched",9,"endometrium: 10.7;placenta: 27.2","testis: 2.2","Cell line enhanced",NA,"Daudi: 11.1;SCLC-21H: 6.5;U-937: 2.1"
"PRLR",100,"G9","IOH29204",1869,"NP_000940.1","NP_000940.1","prolactin receptor (PRLR), mRNA.","NM_000949.4","NP_000940.1",5618,"Hs.368587",NA,"ENSG00000113494","Prolactin receptor","5","35048756-35230589","Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enriched","Tissue enhanced",NA,"placenta: 70.9","kidney: 33.1","Cell line enriched",22,"T-47d: 356.8"
"PRNP",10,"F8","IOH10523",762,"NP_000302.1","AAH12844.1","prion protein, mRNA (cDNA clone MGC:8899 IMAGE:3863784), complete cds","BC012844.1","AAH12844.1",5621,"Hs.472010","AltPrP, CD230, CJD, GSS, PRIP, PRP","ENSG00000171867","Prion protein","20","4686236-4701590","CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA042754, HPA043398","Enhanced",NA,"Approved","Nuclear membrane<br>Vesicles<br>Cytosol","Liver cancer:7.41e-5 (unfavourable), Glioma:1.99e-4 (unfavourable), Colorectal cancer:2.96e-4 (unfavourable), Endometrial cancer:4.64e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 619.4","Cell line enhanced",NA,"WM-115: 985.1"
"PRNP",142,"H10","IOH54864",762,"0",NA,"prion protein (PRNP), transcript variant 1, mRNA.","NM_000311.3","NP_000302.1",5621,"Hs.472010","AltPrP, CD230, CJD, GSS, PRIP, PRP","ENSG00000171867","Prion protein","20","4686236-4701590","CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA042754, HPA043398","Enhanced",NA,"Approved","Nuclear membrane<br>Vesicles<br>Cytosol","Liver cancer:7.41e-5 (unfavourable), Glioma:1.99e-4 (unfavourable), Colorectal cancer:2.96e-4 (unfavourable), Endometrial cancer:4.64e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 619.4","Cell line enhanced",NA,"WM-115: 985.1"
"PRNP",136,"E5","IOH56003",762,"0",NA,"prion protein, mRNA (cDNA clone MGC:26679 IMAGE:4813982), complete cds","BC022532.1","AAH22532.1",5621,"Hs.472010","AltPrP, CD230, CJD, GSS, PRIP, PRP","ENSG00000171867","Prion protein","20","4686236-4701590","CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA042754, HPA043398","Enhanced",NA,"Approved","Nuclear membrane<br>Vesicles<br>Cytosol","Liver cancer:7.41e-5 (unfavourable), Glioma:1.99e-4 (unfavourable), Colorectal cancer:2.96e-4 (unfavourable), Endometrial cancer:4.64e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 619.4","Cell line enhanced",NA,"WM-115: 985.1"
"PROC",56,"A7","IOH22689",1386,"0",NA,"protein C (inactivator of coagulation factors Va and VIIIa) (PROC), mRNA.","NM_000312.2","NP_000303.1",5624,"Hs.224698",NA,"ENSG00000115718","Protein C, inactivator of coagulation factors Va and VIIIa","2","127418427-127429246","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA005550, CAB016721, CAB016792","Supported",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",12,"liver: 140.4","kidney: 12.0","Cell line enriched",12,"Hep G2: 105.5"
"PROK1",18,"D7","IOH11285",318,"0",NA,"prokineticin 1, mRNA (cDNA clone MGC:27084 IMAGE:4826496), complete cds","BC025399.1","AAH25399.1",84432,"Hs.514793","EGVEGF, PK1, PRK1","ENSG00000143125","Prokineticin 1","1","110451200-110457354","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enhanced","Group enriched",9,"ovary: 239.3;placenta: 75.8;testis: 119.4","seminal vesicle: 15.2","Cell line enriched",9,"ASC diff: 16.3"
"PROM1",8,"H10","IOH13098",2571,"NP_006008.1","NP_001139319.1","prominin 1 (PROM1), transcript variant 2, mRNA.","NM_001145847.1","NP_001139319.1",8842,"Hs.614734","AC133, CD133, CORD12, MCDR2, PROML1, RP41, STGD4","ENSG00000007062","Prominin 1","4","15963076-16084378","CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA004922, CAB011525, HPA031053","Enhanced",NA,NA,NA,"Renal cancer:2.56e-5 (favourable)","Expressed in all","Tissue enhanced",NA,"cervix, uterine: 67.2","gallbladder: 47.5","Cell line enhanced",NA,"AF22: 36.7;CACO-2: 58.5;EFO-21: 62.9;NTERA-2: 99.9;RPTEC TERT1: 69.7"
"PROS1",89,"A7","IOH10038",2031,"0",NA,"protein S (alpha) (PROS1), mRNA.","NM_000313.3","NP_000304.2",5627,"Hs.64016","PROS","ENSG00000184500","Protein S (alpha)","3","93873033-93974066","Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA007724, HPA023974","Enhanced",NA,NA,NA,"Urothelial cancer:4.42e-5 (unfavourable), Stomach cancer:8.35e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"liver: 177.6","heart muscle: 78.3","Cell line enhanced",NA,"ASC diff: 98.8;SK-MEL-30: 127.4"
"PROZ",70,"F2","IOH29585",1203,"0",NA,"protein Z, vitamin K-dependent plasma glycoprotein (PROZ), mRNA.","NM_003891.1","NP_003882.1",8858,"Hs.1011","PZ","ENSG00000126231","Protein Z, vitamin K dependent plasma glycoprotein","13","113158654-113172383","Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA052006","Enhanced",NA,NA,NA,"Liver cancer:3.46e-4 (favourable)","Tissue enriched","Group enriched",14,"kidney: 14.5;liver: 27.4","testis: 1.5","Cell line enhanced",NA,"HaCaT: 1.9;Hep G2: 2.4"
"PRRG2",108,"C5","IOH44359",609,"0",NA,"proline rich Gla (G-carboxyglutamic acid) 2 (PRRG2), mRNA.","NM_000951.2","NP_000942.1",5639,"Hs.35101","PRGP2","ENSG00000126460","Proline rich and Gla domain 2","19","49580646-49591015","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA010702","Approved",NA,"Approved","Nucleus<br>Nucleoli<br>Cytosol","Renal cancer:3.82e-9 (favourable)","Expressed in all","Mixed",NA,NA,"parathyroid gland: 29.5","Cell line enhanced",NA,"CAPAN-2: 13.1;T-47d: 13.6;U-266/84: 12.9"
"PRRG2",14,"E11","IOH14693",540,"NP_000942.1","AAH26032.1","proline rich Gla (G-carboxyglutamic acid) 2, mRNA (cDNA clone MGC:39251 IMAGE:3960215), complete cds","BC026032.1","AAH26032.1",5639,"Hs.35101","PRGP2","ENSG00000126460","Proline rich and Gla domain 2","19","49580646-49591015","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA010702","Approved",NA,"Approved","Nucleus<br>Nucleoli<br>Cytosol","Renal cancer:3.82e-9 (favourable)","Expressed in all","Mixed",NA,NA,"parathyroid gland: 29.5","Cell line enhanced",NA,"CAPAN-2: 13.1;T-47d: 13.6;U-266/84: 12.9"
"PRSS1",104,"E12","IOH43660",744,"0",NA,"protease, serine, 1 (trypsin 1) (PRSS1), mRNA.","NM_002769.3","NP_002760.1",5644,"Hs.622865","TRY1","ENSG00000204983","Protease, serine 1","7","142749468-142753076","Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB025487, CAB025538, HPA062452, HPA063471","Enhanced",NA,NA,NA,"Endometrial cancer:6.41e-6 (unfavourable), Thyroid cancer:4.91e-4 (favourable), Ovarian cancer:7.05e-4 (favourable)","Tissue enriched","Tissue enriched",318,"pancreas: 81683.0","ovary: 257.2","Cell line enhanced",NA,"EFO-21: 1.3;RPMI-8226: 2.0;U-2 OS: 1.7"
"PRSS12",122,"G9","IOH6445",1518,"0",NA,"protease, serine, 12 (neurotrypsin, motopsin), mRNA (cDNA clone MGC:12722 IMAGE:4126901), complete cds","BC007761.2","AAH07761.1",8492,"Hs.654823","BSSP-3, MRT1","ENSG00000164099","Protease, serine 12","4","118280038-118353003","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins","Evidence at protein level","HPA035054, HPA035055","Uncertain",NA,"Approved","Nucleus<br>Actin filaments","Head and neck cancer:1.03e-4 (favourable), Glioma:1.53e-4 (favourable)","Mixed","Mixed",NA,NA,"cervix, uterine: 22.4","Cell line enhanced",NA,"SH-SY5Y: 228.5;THP-1: 67.4"
"PRSS2",143,"F5","IOH59786",744,"0",NA,"protease, serine, 2 (trypsin 2) (PRSS2), transcript variant 1, mRNA.","NM_002770.2","NP_002761.1",5645,"Hs.622865","TRY2","ENSG00000275896","Protease, serine 2","7","142760398-142774564","Enzymes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA062452, HPA063471","Supported",NA,"Approved","Endoplasmic reticulum<br>Vesicles","Breast cancer:2.32e-4 (favourable)","Tissue enriched","Tissue enriched",53,"pancreas: 30215.4","small intestine: 567.7","Group enriched",6,"RPMI-8226: 46.1;U-2 OS: 14.3"
"PRSS21",110,"D11","IOH45736",945,"0",NA,"protease, serine, 21 (testisin) (PRSS21), transcript variant 1, mRNA.","NM_006799.2","NP_006790.1",10942,"Hs.72026","ESP-1, TEST1","ENSG00000007038","Protease, serine 21","16","2817180-2826304","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA008477","Enhanced",NA,"Approved","Cytosol",NA,"Tissue enhanced","Tissue enriched",10,"testis: 49.5","bone marrow: 4.7","Cell line enhanced",NA,"CAPAN-2: 22.0;HEL: 25.5;HeLa: 48.0;K-562: 30.5;U-698: 70.6"
"PRSS23",42,"H5","IOH3271",1152,"0",NA,"protease, serine, 23 (PRSS23), mRNA.","NM_007173.4","NP_009104.1",11098,"Hs.25338","SIG13, SPUVE","ENSG00000150687","Protease, serine 23","11","86791059-86952910","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA030591","Uncertain",NA,NA,NA,"Head and neck cancer:2.12e-4 (unfavourable), Renal cancer:3.06e-4 (unfavourable), Pancreatic cancer:5.56e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cervix, uterine: 397.1","Cell line enhanced",NA,"HUVEC TERT2: 503.9;TIME: 926.9"
"PRSS3",95,"A8","IOH40288",744,"0",NA,"protease, serine, 3 (PRSS3), transcript variant 2, mRNA.","NM_002771.3","NP_002762.2",5646,"Hs.654513","PRSS4, TRY3, TRY4","ENSG00000010438","Protease, serine 3","9","33750466-33799231","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA062452, HPA063471","Supported",NA,"Approved","Endoplasmic reticulum<br>Vesicles","Endometrial cancer:4.30e-4 (unfavourable)","Group enriched","Tissue enriched",64,"pancreas: 6301.2","small intestine: 99.1","Cell line enriched",9,"PC-3: 632.8"
"PRSS33",119,"G12","IOH28739",843,"0",NA,"protease, serine, 33 (PRSS33), mRNA.","NM_152891.2","NP_690851.2",260429,"Hs.280658","EOS","ENSG00000103355","Protease, serine 33","16","2783953-2787948","Enzymes, Predicted secreted proteins","Evidence at protein level","HPA058082","Uncertain",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",7,"fallopian tube: 7.4","small intestine: 1.0","Group enriched",10,"HMC-1: 2.4;SK-MEL-30: 4.5;U-2 OS: 2.1"
"PRSS35",67,"E9","IOH25932",1242,"0",NA,"protease, serine, 35 (PRSS35), mRNA.","NM_153362.1","NP_699193.1",167681,"Hs.98381","C6orf158, dJ223E3.1, MGC46520","ENSG00000146250","Protease, serine 35","6","83512538-83525704","Enzymes, Predicted secreted proteins","Evidence at protein level","HPA038787, HPA038788","Uncertain",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"ovary: 12.9","cerebral cortex: 9.9","Cell line enhanced",NA,"CACO-2: 71.2;HAP1: 13.2;RPTEC TERT1: 18.6"
"PRSS8",50,"F10","IOH4003",1032,"0",NA,"protease, serine, 8 (PRSS8), mRNA.","NM_002773.3","NP_002764.1",5652,"Hs.75799",NA,"ENSG00000052344","Protease, serine 8","16","31131433-31135762","Enzymes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA030436, HPA063533","Uncertain",NA,"Uncertain","Cytosol","Renal cancer:2.05e-10 (favourable)","Mixed","Mixed",NA,NA,"small intestine: 164.8","Cell line enhanced",NA,"BEWO: 230.2;CACO-2: 133.7;CAPAN-2: 96.1;hTCEpi: 111.3;SK-BR-3: 136.6"
"PRTN3",153,"C11","IOH63211",771,"0",NA,"proteinase 3, mRNA (cDNA clone MGC:116835 IMAGE:40003797), complete cds","BC096184.3","AAH96184.1",5657,"Hs.928","ACPA, AGP7, C-ANCA, MBT, P29, PR-3","ENSG00000196415","Proteinase 3","19","840960-848175","Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA005938, CAB017558","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",724,"bone marrow: 616.4","spleen: 0.8","Cell line enriched",6,"THP-1: 696.6"
"PSAP",13,"D3","IOH6900",1575,"0",NA,"prosaposin (PSAP), transcript variant 1, mRNA.","NM_002778.2","NP_002769.1",5660,"Hs.523004","GLBA, SAP1","ENSG00000197746","Prosaposin","10","71816298-71851375","Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA004426, CAB004647","Enhanced",NA,"Supported","Vesicles",NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 1912.4","Expressed in all",NA,NA
"PSG1",63,"F7","IOH29450",1260,"0",NA,"pregnancy specific beta-1-glycoprotein 1, mRNA (cDNA clone MGC:61825 IMAGE:4770394), complete cds","BC058285.1","AAH58285.1",5669,"Hs.709192","CD66f, PBG1, PSBG1, PSGGA","ENSG00000231924","Pregnancy specific beta-1-glycoprotein 1","19","42866464-42879822","CD markers, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA046327","Approved",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",377,"placenta: 362.6","smooth muscle,spleen: 0.9","Cell line enriched",23,"U-2197: 384.6"
"PSG1",7,"F9","IOH12639",1281,"0",NA,"pregnancy specific beta-1-glycoprotein 1 (PSG1), mRNA.","NM_006905.2","NP_008836.2",5669,"Hs.709192","CD66f, PBG1, PSBG1, PSGGA","ENSG00000231924","Pregnancy specific beta-1-glycoprotein 1","19","42866464-42879822","CD markers, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA046327","Approved",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",377,"placenta: 362.6","smooth muscle,spleen: 0.9","Cell line enriched",23,"U-2197: 384.6"
"PSG11",120,"D11","IOH46097",660,"0",NA,"pregnancy specific beta-1-glycoprotein 11, mRNA (cDNA clone MGC:22484 IMAGE:4732286), complete cds","BC020711.1","AAH20711.2",5680,"Hs.646353","MGC22484, PSG13, PSG14","ENSG00000243130","Pregnancy specific beta-1-glycoprotein 11","19","43007656-43026512","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA042240, HPA046327","Enhanced",NA,NA,NA,NA,"Not detected","Tissue enriched",77,"placenta: 74.1","smooth muscle: 0.9","Cell line enriched",29,"U-2197: 15.6"
"PSG2",42,"F12","IOH12290",1008,"0",NA,"pregnancy specific beta-1-glycoprotein 2, mRNA (cDNA clone MGC:22616 IMAGE:4731250), complete cds","BC022316.1","AAH22316.1",5670,"Hs.709200","CEA, PSBG2, PSG1, PSGGB","ENSG00000242221","Pregnancy specific beta-1-glycoprotein 2","19","43064211-43083045","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Not detected","Tissue enriched",222,"placenta: 343.4","smooth muscle: 1.5","Group enriched",6,"BJ: 9.2;fHDF/TERT166: 18.4;HBF TERT88: 34.3;U-2197: 42.9"
"PSG3",120,"E12","IOH46134",1287,"0",NA,"pregnancy specific beta-1-glycoprotein 3, mRNA (cDNA clone MGC:14526 IMAGE:4043628), complete cds","BC005924.1","AAH05924.2",5671,"Hs.654413",NA,"ENSG00000221826","Pregnancy specific beta-1-glycoprotein 3","19","42721638-42740569","Predicted secreted proteins","Evidence at protein level","HPA046327","Approved",NA,NA,NA,NA,"Not detected","Tissue enriched",162,"placenta: 188.8","testis: 1.1","Cell line enriched",6,"U-2197: 1.2"
"PSG4",93,"A7","IOH40747",1260,"0",NA,"pregnancy specific beta-1-glycoprotein 4, mRNA (cDNA clone MGC:72040 IMAGE:4768860), complete cds","BC063127.1","AAH63127.1",5672,"Hs.654415",NA,"ENSG00000243137","Pregnancy specific beta-1-glycoprotein 4","19","43192702-43207299","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA046327","Approved",NA,NA,NA,NA,"Mixed","Group enriched",8,"parathyroid gland: 244.5;placenta: 193.0","colon: 28.0","Group enriched",7,"fHDF/TERT166: 409.2;U-2197: 129.9"
"PSG4",13,"B11","IOH7536",1260,"0",NA,"pregnancy specific beta-1-glycoprotein 4, mRNA (cDNA clone MGC:14528 IMAGE:4043484), complete cds","BC008405.1","AAH08405.1",5672,"Hs.654415",NA,"ENSG00000243137","Pregnancy specific beta-1-glycoprotein 4","19","43192702-43207299","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA046327","Approved",NA,NA,NA,NA,"Mixed","Group enriched",8,"parathyroid gland: 244.5;placenta: 193.0","colon: 28.0","Group enriched",7,"fHDF/TERT166: 409.2;U-2197: 129.9"
"PSG5",116,"B9","IOH12193",1008,"0",NA,"pregnancy specific beta-1-glycoprotein 5, mRNA (cDNA clone MGC:13608 IMAGE:4043912), complete cds","BC012607.1","AAH12607.1",5673,"Hs.654415","FL-NCA-3, PSG","ENSG00000204941","Pregnancy specific beta-1-glycoprotein 5","19","43166256-43186536","Predicted secreted proteins","Evidence at protein level","HPA046327","Approved",NA,NA,NA,NA,"Mixed","Tissue enriched",108,"placenta: 157.6","smooth muscle: 1.4","Group enriched",8,"BJ: 363.6;fHDF/TERT166: 1157.5"
"PSG6",7,"C11","IOH12790",1275,"0",NA,"pregnancy specific beta-1-glycoprotein 6 (PSG6), transcript variant 2, mRNA.","NM_001031850.2","NP_001027020.1",5675,"Hs.654414",NA,"ENSG00000170848","Pregnancy specific beta-1-glycoprotein 6","19","42902079-42919563","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA046327","Approved",NA,NA,NA,NA,"Not detected","Tissue enriched",75,"placenta: 70.2","bone marrow: 0.9","Cell line enriched",18,"U-2197: 134.3"
"PSG9",51,"B9","IOH13758",1281,"0",NA,"pregnancy specific beta-1-glycoprotein 9, mRNA (cDNA clone MGC:22615 IMAGE:4731739), complete cds","BC020759.1","AAH20759.1",5678,"Hs.502092","PSG11, PSGII","ENSG00000183668","Pregnancy specific beta-1-glycoprotein 9","19","43211791-43269530","Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA046327","Approved",NA,NA,NA,NA,"Not detected","Tissue enriched",118,"placenta: 147.0","smooth muscle: 1.2","Cell line enhanced",NA,"BJ: 4.4;BJ hTERT+ SV40 Large T+: 4.2;HBF TERT88: 9.0;T-47d: 4.0;U-2197: 9.0"
"PTGDS",44,"G5","IOH7500",573,"0",NA,"prostaglandin D2 synthase 21kDa (brain) (PTGDS), mRNA.","NM_000954.5","NP_000945.3",5730,"Hs.446429","L-PGDS, PGDS","ENSG00000107317","Prostaglandin D2 synthase","9","136975092-136981742","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA004938, CAB009916","Approved",NA,"Supported","Nucleoplasm","Renal cancer:1.19e-7 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 2581.3","Group enriched",7,"HHSteC: 440.4;HSkMC: 186.3"
"PTGIR",111,"H4","IOH45676",1161,"0",NA,"prostaglandin I2 (prostacyclin) receptor (IP) (PTGIR), mRNA.","NM_000960.3","NP_000951.1",5739,"Hs.458324","IP","ENSG00000160013","Prostaglandin I2 (prostacyclin) receptor (IP)","19","46620468-46625118","FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:2.09e-8 (unfavourable), Testis cancer:1.74e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"lung: 13.9","appendix: 8.2","Cell line enhanced",NA,"BJ: 9.0;BJ hTERT+: 9.8;fHDF/TERT166: 11.8;HEL: 25.3"
"PTGS1",50,"A5","IOH22798",1800,"0",NA,"prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase), mRNA (cDNA clone MGC:34214 IMAGE:5174923), complete cds","BC029840.1","AAH29840.1",5742,"Hs.201978","COX1, PGHS-1, PTGHS","ENSG00000095303","Prostaglandin-endoperoxide synthase 1","9","122370530-122395703","Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA002834, CAB020315","Enhanced",NA,"Supported","Golgi apparatus<br>Vesicles","Renal cancer:8.68e-4 (unfavourable), Urothelial cancer:9.35e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"skin: 161.6","fallopian tube: 86.1","Cell line enhanced",NA,"ASC diff: 104.2;BJ: 149.8;BJ hTERT+: 187.6;HMC-1: 391.6"
"PTGS2",10,"A12","IOH11237",1815,"0",NA,"prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (PTGS2), mRNA.","NM_000963.2","NP_000954.1",5743,"Hs.196384","COX2","ENSG00000073756","Prostaglandin-endoperoxide synthase 2","1","186671791-186680427","Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins","Evidence at protein level","CAB000113, HPA001335","Approved",NA,"Supported","Endoplasmic reticulum","Renal cancer:9.79e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"seminal vesicle: 180.6","cervix, uterine: 99.3","Group enriched",7,"BJ: 78.6;BJ hTERT+: 327.8"
"PTH",108,"E6","IOH44414",348,"0",NA,"parathyroid hormone (PTH), mRNA.","NM_000315.2","NP_000306.1",5741,"Hs.37045","PTH1","ENSG00000152266","Parathyroid hormone","11","13492055-13496181","Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB000072, CAB023409, CAB026363, HPA048540","Enhanced",NA,NA,NA,NA,"Not detected","Tissue enriched",109145,"parathyroid gland: 59340.8","thyroid gland: 0.5","Not detected",NA,NA
"PTHLH",37,"H6","IOH7420",528,"0",NA,"parathyroid hormone-like hormone (PTHLH), transcript variant 2, mRNA.","NM_002820.2","NP_002811.1",5744,"Hs.591159","HHM, PLP, PTHR, PTHRP","ENSG00000087494","Parathyroid hormone like hormone","12","27958084-27972705","Cancer-related genes, Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA035982","Approved","Approved","Supported","Nucleoplasm<br>Golgi apparatus<br>Cytosol","Renal cancer:1.82e-9 (unfavourable), Liver cancer:3.37e-4 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"breast: 23.9","esophagus: 18.0","Group enriched",7,"HaCaT: 256.2;HBEC3-KT: 257.7;U-251 MG: 64.3"
"PTHLH",107,"F10","IOH44500",534,"0",NA,"parathyroid hormone-like hormone (PTHLH), transcript variant 1, mRNA.","NM_198965.1","NP_945316.1",5744,"Hs.591159","HHM, PLP, PTHR, PTHRP","ENSG00000087494","Parathyroid hormone like hormone","12","27958084-27972705","Cancer-related genes, Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA035982","Approved","Approved","Supported","Nucleoplasm<br>Golgi apparatus<br>Cytosol","Renal cancer:1.82e-9 (unfavourable), Liver cancer:3.37e-4 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"breast: 23.9","esophagus: 18.0","Group enriched",7,"HaCaT: 256.2;HBEC3-KT: 257.7;U-251 MG: 64.3"
"PTN",13,"C11","IOH7539",507,"0",NA,"pleiotrophin (PTN), mRNA.","NM_002825.5","NP_002816.1",5764,"Hs.371249","HBGF8, HBNF, NEGF1","ENSG00000105894","Pleiotrophin","7","137227341-137343865","Cancer-related genes, Predicted secreted proteins","Evidence at protein level","CAB017685","Enhanced",NA,NA,NA,"Renal cancer:1.35e-4 (favourable)","Tissue enriched","Tissue enhanced",NA,"parathyroid gland: 725.3","cerebral cortex: 269.6","Cell line enriched",12,"AF22: 1551.5"
"PTPN5",70,"G7","IOH29621",1698,"0",NA,"protein tyrosine phosphatase, non-receptor type 5 (striatum-enriched) (PTPN5), transcript variant 1, mRNA.","NM_006906.1","NP_008837.1",84867,"Hs.79092","PTPSTEP, STEP, STEP61","ENSG00000110786","Protein tyrosine phosphatase, non-receptor type 5","11","18727928-18792721","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA031014, HPA072091","Supported",NA,"Approved","Endoplasmic reticulum",NA,"Group enriched","Tissue enriched",15,"cerebral cortex: 58.8","testis: 3.8","Cell line enhanced",NA,"NTERA-2: 1.7"
"PTPRA",89,"B6","IOH11085",2382,"NP_002827.1","NP_543030.1","protein tyrosine phosphatase, receptor type, A (PTPRA), transcript variant 2, mRNA.","NM_080840.2","NP_543030.1",5786,"Hs.269577","HLPR, HPTPA, LRP, PTPA, PTPRL2, RPTPA","ENSG00000132670","Protein tyrosine phosphatase, receptor type A","20","2864184-3039076","Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA029412, CAB034366, HPA069480","Approved",NA,"Approved","Nucleus<br>Vesicles","Renal cancer:3.29e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 167.4","Expressed in all",NA,NA
"PTPRC",107,"D12","IOH44598",105,"0",NA,"protein tyrosine phosphatase, receptor type, C (PTPRC), transcript variant 4, mRNA.","NM_080923.2","NP_563580.1",5788,"Hs.654514","CD45, GP180, LCA, T200","ENSG00000081237","Protein tyrosine phosphatase, receptor type C","1","198638671-198757283","Cancer-related genes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB000052, HPA000440, CAB002800, CAB056154, CAB068221","Enhanced",NA,NA,NA,"Renal cancer:2.42e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 372.4","Cell line enhanced",NA,"Daudi: 151.8;HEL: 73.7;HL-60: 73.8;MOLT-4: 105.0;U-698: 84.9;U-937: 62.5"
"PTPRCAP",108,"G7","IOH42040",621,"0",NA,"protein tyrosine phosphatase, receptor type, C-associated protein (PTPRCAP), mRNA.","NM_005608.2","NP_005599.1",5790,"Hs.155975","CD45-AP, LPAP","ENSG00000213402","Protein tyrosine phosphatase, receptor type C associated protein","11","67435510-67438067","Predicted secreted proteins","Evidence at protein level","HPA043734","Enhanced",NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"appendix: 64.0;lymph node: 91.4;spleen: 84.9","tonsil: 29.0","Cell line enhanced",NA,"Daudi: 161.8;HDLM-2: 148.3;MOLT-4: 110.0;NB-4: 409.0;U-698: 109.1"
"PTPRO",115,"A3","IOH41736",3651,"0",NA,"protein tyrosine phosphatase, receptor type, O (PTPRO), transcript variant 1, mRNA.","NM_030667.1","NP_109592.1",5800,"Hs.160871","GLEPP1, NPHS6, PTP-oc, PTP-U2, PTPU2","ENSG00000151490","Protein tyrosine phosphatase, receptor type O","12","15322397-15597399","Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA034525","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"rectum: 33.0","cerebral cortex: 21.7","Cell line enhanced",NA,"NTERA-2: 6.6;SCLC-21H: 4.7;SH-SY5Y: 8.4"
"PTPRO",101,"G8","IOH36740",1218,"NP_109594.1","NP_109594.1","protein tyrosine phosphatase, receptor type, O (PTPRO), transcript variant 3, mRNA.","NM_030669.1","NP_109594.1",5800,"Hs.160871","GLEPP1, NPHS6, PTP-oc, PTP-U2, PTPU2","ENSG00000151490","Protein tyrosine phosphatase, receptor type O","12","15322397-15597399","Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA034525","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"rectum: 33.0","cerebral cortex: 21.7","Cell line enhanced",NA,"NTERA-2: 6.6;SCLC-21H: 4.7;SH-SY5Y: 8.4"
"PTPRO",68,"D3","IOH27969",1794,"NP_002839.1","AAH35960.1","protein tyrosine phosphatase, receptor type, O, mRNA (cDNA clone IMAGE:4610767), complete cds.","BC035960.1","AAH35960.1",5800,"Hs.160871","GLEPP1, NPHS6, PTP-oc, PTP-U2, PTPU2","ENSG00000151490","Protein tyrosine phosphatase, receptor type O","12","15322397-15597399","Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA034525","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"rectum: 33.0","cerebral cortex: 21.7","Cell line enhanced",NA,"NTERA-2: 6.6;SCLC-21H: 4.7;SH-SY5Y: 8.4"
"PTPRS",39,"E6","IOH22520",387,"0",NA,"protein tyrosine phosphatase, receptor type, S, mRNA (cDNA clone IMAGE:5272670), complete cds.","BC029496.1","AAH29496.1",5802,"Hs.644384",NA,"ENSG00000105426","Protein tyrosine phosphatase, receptor type S","19","5158495-5340803","Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA054747",NA,NA,"Approved","Plasma membrane<br>Cytosol","Pancreatic cancer:1.07e-4 (favourable), Renal cancer:1.70e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 70.7","Cell line enhanced",NA,"AN3-CA: 112.7;HaCaT: 110.4"
"PTTG1IP",12,"D1","IOH10419",543,"NP_004330.1","NP_004330.1","pituitary tumor-transforming 1 interacting protein (PTTG1IP), mRNA.","NM_004339.2","NP_004330.1",754,"Hs.474010","C21orf1, C21orf3, PBF","ENSG00000183255","Pituitary tumor-transforming 1 interacting protein","21","44849585-44873903","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB034146, HPA061827","Uncertain",NA,"Supported","Nucleoplasm","Pancreatic cancer:2.28e-4 (unfavourable), Stomach cancer:5.40e-4 (unfavourable), Cervical cancer:8.61e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 243.5","Expressed in all",NA,NA
"PVR",89,"H2","IOH9967",1254,"NP_006496.2","AAH15542.1","poliovirus receptor, mRNA (cDNA clone MGC:9603 IMAGE:3902226), complete cds","BC015542.1","AAH15542.1",5817,"Hs.171844","CD155, HVED, Necl-5, NECL5, PVS, Tage4","ENSG00000073008","Poliovirus receptor","19","44643798-44663583","CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA012568","Approved",NA,"Supported","Nucleoplasm<br>Vesicles<br>Plasma membrane","Cervical cancer:1.29e-4 (unfavourable), Urothelial cancer:2.75e-4 (unfavourable), Lung cancer:9.30e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 17.0","Cell line enhanced",NA,"TIME: 147.4"
"PYY",108,"E1","IOH44656",294,"0",NA,"peptide YY, mRNA (cDNA clone MGC:52233 IMAGE:5441270), complete cds","BC041057.1","AAH41057.1",5697,"Hs.169249","PYY1","ENSG00000131096","Peptide YY","17","43952738-44004469","Predicted secreted proteins","Evidence at protein level","HPA010973, CAB016734","Enhanced",NA,NA,NA,NA,"Group enriched","Group enriched",15,"colon: 52.6;rectum: 39.2;small intestine: 27.4","duodenum: 2.5","Cell line enhanced",NA,"HMC-1: 2.6"
"QPCT",58,"A7","IOH26698",1086,"0",NA,"glutaminyl-peptide cyclotransferase (QPCT), mRNA.","NM_012413.3","NP_036545.1",25797,"Hs.79033","GCT, QC","ENSG00000115828","Glutaminyl-peptide cyclotransferase","2","37344574-37373322","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA008406","Enhanced",NA,"Approved","Cytosol",NA,"Expressed in all","Tissue enhanced",NA,"adrenal gland: 158.9;epididymis: 121.6","skin: 41.1","Cell line enhanced",NA,"SCLC-21H: 130.6;SK-MEL-30: 299.7;U-266/84: 218.7"
"QPRT",13,"G4","IOH6537",894,"0",NA,"quinolinate phosphoribosyltransferase, mRNA (cDNA clone MGC:12951 IMAGE:2960170), complete cds","BC005060.1","AAH05060.1",23475,"Hs.513484","QPRTase","ENSG00000103485","Quinolinate phosphoribosyltransferase","16","29679008-29698699","Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA011887","Approved",NA,NA,NA,"Breast cancer:5.10e-5 (unfavourable), Glioma:7.45e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"kidney: 112.3","Cell line enhanced",NA,"EFO-21: 469.3"
"QPRT",60,"D9","IOH27835",894,"0",NA,"quinolinate phosphoribosyltransferase (QPRT), mRNA.","NM_014298.3","NP_055113.2",23475,"Hs.513484","QPRTase","ENSG00000103485","Quinolinate phosphoribosyltransferase","16","29679008-29698699","Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA011887","Approved",NA,NA,NA,"Breast cancer:5.10e-5 (unfavourable), Glioma:7.45e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"kidney: 112.3","Cell line enhanced",NA,"EFO-21: 469.3"
"R3HDML",108,"G10","IOH35368",762,"0",NA,"R3H domain containing-like (R3HDML), mRNA.","NM_178491.2","NP_848586.1",140902,"Hs.580807","dJ881L22.3","ENSG00000101074","R3H domain containing like","20","44336986-44351235","Predicted secreted proteins","Evidence at protein level","HPA070264","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"duodenum: 2.2;small intestine: 2.7","testis: 0.8","Not detected",NA,NA
"RAET1G",152,"E10","IOH63303",642,"0",NA,"retinoic acid early transcript 1G, mRNA (cDNA clone MGC:119072 IMAGE:40003403), complete cds","BC098152.1","AAH98152.1",353091,"Hs.558792","ULBP5","ENSG00000203722","Retinoic acid early transcript 1G","6","149916878-149923121","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA062673",NA,NA,"Approved","Vesicles","Lung cancer:5.35e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"adrenal gland: 8.2;esophagus: 9.5","skin: 3.4","Cell line enhanced",NA,"HeLa: 21.4;hTCEpi: 18.1;SiHa: 13.3;U-87 MG: 9.8"
"RAMP2",45,"C11","IOH12007",528,"NP_005845.1","NP_005845.2","receptor (G protein-coupled) activity modifying protein 2 (RAMP2), mRNA.","NM_005854.2","NP_005845.2",10266,"Hs.514193",NA,"ENSG00000131477","Receptor activity modifying protein 2","17","42758447-42763041","FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA052020",NA,NA,"Approved","Vesicles",NA,"Expressed in all","Mixed",NA,NA,"lung: 178.6","Cell line enhanced",NA,"ASC diff: 78.4;EFO-21: 72.9;HUVEC TERT2: 29.7"
"RARRES1",79,"E7","IOH22199",885,"0",NA,"retinoic acid receptor responder (tazarotene induced) 1 (RARRES1), transcript variant 1, mRNA.","NM_206963.1","NP_996846.1",5918,"Hs.131269","LXNL, TIG1","ENSG00000118849","Retinoic acid receptor responder 1","3","158696892-158732696","Predicted secreted proteins","Evidence at protein level","HPA003892","Uncertain",NA,"Approved","Endoplasmic reticulum<br>Golgi apparatus","Renal cancer:5.88e-6 (unfavourable)","Expressed in all","Mixed",NA,NA,"appendix: 78.0","Cell line enriched",11,"CAPAN-2: 1010.9"
"RARRES2",45,"E10","IOH4685",492,"0",NA,"retinoic acid receptor responder (tazarotene induced) 2 (RARRES2), mRNA.","NM_002889.3","NP_002880.1",5919,"Hs.647064","HP10433, TIG2","ENSG00000106538","Retinoic acid receptor responder 2","7","150338317-150341674","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA049359",NA,NA,"Uncertain","Cytosol","Renal cancer:6.83e-4 (unfavourable), Glioma:6.90e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"adrenal gland: 1522.8","parathyroid gland: 915.7","Group enriched",8,"AF22: 120.4;Hep G2: 124.8;HHSteC: 130.5;NTERA-2: 372.4"
"RBM3",26,"G11","IOH3158",474,"0",NA,"RNA binding motif (RNP1, RRM) protein 3 (RBM3), mRNA.","NM_006743.3","NP_006734.1",5935,"Hs.301404","IS1-RNPL","ENSG00000102317","RNA binding motif (RNP1, RRM) protein 3","X","48574449-48579066","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA003624, CAB062559","Enhanced",NA,"Enhanced","Nucleoplasm","Colorectal cancer:3.07e-7 (favourable)","Expressed in all","Expressed in all",NA,NA,"breast: 237.2","Expressed in all",NA,NA
"RBP4",144,"G3","IOH54761",606,"0",NA,"retinol binding protein 4, plasma (RBP4), mRNA.","NM_006744.3","NP_006735.2",5950,"Hs.50223",NA,"ENSG00000138207","Retinol binding protein 4","10","93591687-93601744","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA001641, CAB004555","Supported",NA,NA,NA,"Liver cancer:1.74e-8 (favourable), Endometrial cancer:1.50e-4 (unfavourable)","Tissue enriched","Tissue enriched",10,"liver: 6109.2","adipose tissue: 630.9","Cell line enhanced",NA,"CACO-2: 219.3;Hep G2: 755.1;PC-3: 113.0"
"RCN1",81,"H8","IOH13769",996,"0",NA,"reticulocalbin 1, EF-hand calcium binding domain (RCN1), mRNA.","NM_002901.2","NP_002892.1",5954,"Hs.97887","FLJ37041, PIG20, Rcal, RCN","ENSG00000049449","Reticulocalbin 1","11","31812391-32105755","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA038474, HPA062104","Approved",NA,"Enhanced","Endoplasmic reticulum","Renal cancer:2.70e-13 (unfavourable), Lung cancer:7.13e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 470.5","Mixed",NA,NA
"RCN2",85,"A9","IOH4646",954,"0",NA,"reticulocalbin 2, EF-hand calcium binding domain (RCN2), mRNA.","NM_002902.2","NP_002893.1",5955,"Hs.79088","E6BP, ERC-55, ERC55, TCBP49","ENSG00000117906","Reticulocalbin 2","15","76931619-76954392","Predicted secreted proteins","Evidence at protein level","HPA030694, HPA030695","Enhanced","Supported","Enhanced","Endoplasmic reticulum","Liver cancer:7.36e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 391.5","Expressed in all",NA,NA
"RDH11",35,"A4","IOH4632",957,"0",NA,"retinol dehydrogenase 11 (all-trans/9-cis/11-cis) (RDH11), mRNA.","NM_016026.3","NP_057110.3",51109,"Hs.226007","ARSDR1, MDT1, SDR7C1","ENSG00000072042","Retinol dehydrogenase 11 (all-trans/9-cis/11-cis)","14","67676801-67695814","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB046011","Enhanced",NA,NA,NA,"Renal cancer:1.30e-7 (favourable), Head and neck cancer:2.89e-5 (unfavourable), Endometrial cancer:2.62e-4 (favourable)","Tissue enriched","Tissue enriched",7,"prostate: 941.3","parathyroid gland: 125.7","Expressed in all",NA,NA
"RDH11",72,"E5","IOH27920",957,"0",NA,"retinol dehydrogenase 11 (all-trans/9-cis/11-cis), mRNA (cDNA clone MGC:23798 IMAGE:4250934), complete cds","BC026274.1","AAH26274.1",51109,"Hs.226007","ARSDR1, MDT1, SDR7C1","ENSG00000072042","Retinol dehydrogenase 11 (all-trans/9-cis/11-cis)","14","67676801-67695814","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB046011","Enhanced",NA,NA,NA,"Renal cancer:1.30e-7 (favourable), Head and neck cancer:2.89e-5 (unfavourable), Endometrial cancer:2.62e-4 (favourable)","Tissue enriched","Tissue enriched",7,"prostate: 941.3","parathyroid gland: 125.7","Expressed in all",NA,NA
"RDH11",64,"D6","IOH29356",918,"0",NA,"retinol dehydrogenase 11 (all-trans/9-cis/11-cis), mRNA (cDNA clone MGC:59671 IMAGE:3533223), complete cds","BC051291.1","AAH51291.1",51109,"Hs.226007","ARSDR1, MDT1, SDR7C1","ENSG00000072042","Retinol dehydrogenase 11 (all-trans/9-cis/11-cis)","14","67676801-67695814","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB046011","Enhanced",NA,NA,NA,"Renal cancer:1.30e-7 (favourable), Head and neck cancer:2.89e-5 (unfavourable), Endometrial cancer:2.62e-4 (favourable)","Tissue enriched","Tissue enriched",7,"prostate: 941.3","parathyroid gland: 125.7","Expressed in all",NA,NA
"RDH12",42,"D10","IOH10746",951,"0",NA,"retinol dehydrogenase 12 (all-trans/9-cis/11-cis), mRNA (cDNA clone MGC:34672 IMAGE:5199154), complete cds","BC025724.1","AAH25724.1",145226,"Hs.415322","FLJ30273, LCA13, RP53, SDR7C2","ENSG00000139988","Retinol dehydrogenase 12 (all-trans/9-cis/11-cis)","14","67701886-67734452","Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"gallbladder: 27.7;skin: 58.2","kidney: 13.6","Not detected",NA,NA
"RDH13",44,"E12","IOH12664",783,"0",NA,"retinol dehydrogenase 13 (all-trans/9-cis) (RDH13), nuclear gene encoding mitochondrial protein, transcript variant 2, mRNA.","NM_138412.3","NP_612421.1",112724,"Hs.327631","SDR7C3","ENSG00000160439","Retinol dehydrogenase 13","19","55039108-55071291","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA042006","Approved",NA,"Supported","Mitochondria<br>Cytosol","Renal cancer:2.09e-4 (favourable)","Expressed in all","Mixed",NA,NA,"placenta: 3.5","Mixed",NA,NA
"REG1A",63,"B2","IOH7365",501,"0",NA,"regenerating islet-derived 1 alpha (REG1A), mRNA.","NM_002909.4","NP_002900.2",5967,"Hs.49407","PSP, PSPS, PSPS1, PTP, REG","ENSG00000115386","Regenerating family member 1 alpha","2","79120362-79123419","Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB025138, HPA045549, HPA045579","Enhanced",NA,NA,NA,NA,"Group enriched","Group enriched",9,"duodenum: 7122.5;pancreas: 10867.0;small intestine: 4615.5","stomach: 847.5","Cell line enhanced",NA,"BEWO: 11.1;EFO-21: 16.2;HDLM-2: 13.2;RPMI-8226: 20.2;SH-SY5Y: 12.6;U-2 OS: 28.7"
"REG3A",82,"B2","IOH26035",528,"0",NA,"regenerating islet-derived 3 alpha (REG3A), transcript variant 1, mRNA.","NM_002580.1","NP_002571.1",5068,"Hs.567312","HIP, PAP, PAP1, PBCGF, REG-III, REG3","ENSG00000172016","Regenerating family member 3 alpha","2","79157003-79159753","Plasma proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA047894, HPA048334, HPA060705","Supported",NA,"Approved","Cytosol",NA,"Tissue enhanced","Group enriched",56,"duodenum: 5635.7;small intestine: 8081.8","stomach: 122.0","Cell line enhanced",NA,"BEWO: 18.5;EFO-21: 17.0;HDLM-2: 16.3;RPMI-8226: 17.5;SH-SY5Y: 16.7;U-2 OS: 30.9"
"REG3G",108,"H5","IOH44386",528,"0",NA,"regenerating islet-derived 3 gamma (REG3G), transcript variant 1, mRNA.","NM_001008387.1","NP_001008388.1",130120,"Hs.447084","LPPM429, PAP1B, UNQ429","ENSG00000143954","Regenerating family member 3 gamma","2","79025686-79028505","Predicted secreted proteins","Evidence at protein level","HPA047894, HPA048334, HPA060705","Uncertain",NA,"Approved","Cytosol",NA,"Tissue enriched","Group enriched",15,"epididymis: 201.5;testis: 107.2","pancreas: 10.0","Not detected",NA,NA
"REG4",11,"E12","IOH10384",477,"0",NA,"regenerating islet-derived family, member 4 (REG4), transcript variant 2, mRNA.","NM_032044.3","NP_114433.1",83998,"Hs.660883","GISP, REG-IV, RELP","ENSG00000134193","Regenerating family member 4","1","119794018-119811660","Predicted secreted proteins","Evidence at protein level","CAB025867, HPA046555","Enhanced",NA,NA,NA,NA,"Group enriched","Group enriched",9,"colon: 215.7;duodenum: 239.5;rectum: 299.4;small intestine: 664.5","appendix: 39.6","Group enriched",24,"PC-3: 85.3;RT4: 20.5"
"RELT",66,"C3","IOH28887",1293,"0",NA,"RELT tumor necrosis factor receptor, mRNA (cDNA clone MGC:60026 IMAGE:5216988), complete cds","BC051810.1","AAH51810.2",84957,"Hs.533720","FLJ14993, TNFRSF19L","ENSG00000054967","RELT tumor necrosis factor receptor","11","73376264-73397474","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA062824, HPA071518",NA,NA,"Supported","Nucleus","Renal cancer:4.07e-11 (unfavourable)","Mixed","Tissue enriched",6,"bone marrow: 95.8","spleen: 17.2","Mixed",NA,NA
"RELT",8,"A2","IOH12786",1293,"NP_116260.2","NP_116260.2","RELT tumor necrosis factor receptor (RELT), transcript variant 1, mRNA.","NM_032871.3","NP_116260.2",84957,"Hs.533720","FLJ14993, TNFRSF19L","ENSG00000054967","RELT tumor necrosis factor receptor","11","73376264-73397474","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA062824, HPA071518",NA,NA,"Supported","Nucleus","Renal cancer:4.07e-11 (unfavourable)","Mixed","Tissue enriched",6,"bone marrow: 95.8","spleen: 17.2","Mixed",NA,NA
"RET",87,"H3","IOH5435",3219,"0",NA,"ret proto-oncogene, mRNA (cDNA clone MGC:10752 IMAGE:3160389), complete cds","BC004257.1","AAH04257.1",5979,"Hs.350321","CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1, PTC, RET51","ENSG00000165731","Ret proto-oncogene","10","43077027-43130351","Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB002581, HPA008356, HPA008495, CAB018342","Approved","Supported","Supported","Vesicles<br>Plasma membrane<br>Cytosol","Endometrial cancer:5.02e-4 (unfavourable)","Tissue enhanced","Tissue enriched",5,"parathyroid gland: 154.5","adrenal gland: 29.8","Cell line enriched",5,"SH-SY5Y: 404.3"
"RET",43,"A6","IOH4731",1377,"0",NA,"ret proto-oncogene, mRNA (cDNA clone IMAGE:3507569), complete cds.","BC003072.2","AAH03072.1",5979,"Hs.350321","CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1, PTC, RET51","ENSG00000165731","Ret proto-oncogene","10","43077027-43130351","Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB002581, HPA008356, HPA008495, CAB018342","Approved","Supported","Supported","Vesicles<br>Plasma membrane<br>Cytosol","Endometrial cancer:5.02e-4 (unfavourable)","Tissue enhanced","Tissue enriched",5,"parathyroid gland: 154.5","adrenal gland: 29.8","Cell line enriched",5,"SH-SY5Y: 404.3"
"RETN",98,"A4","IOH40390",327,"0",NA,"resistin (RETN), mRNA.","NM_020415.2","NP_065148.1",56729,"Hs.283091","ADSF, FIZZ3, RETN1","ENSG00000104918","Resistin","19","7669044-7670454","Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",6,"bone marrow: 159.4","lung: 26.0","Group enriched",8,"NB-4: 327.2;U-937: 187.7"
"RETSAT",63,"D2","IOH9706",618,"0",NA,"retinol saturase (all-trans-retinol 13,14-reductase), mRNA (cDNA clone IMAGE:3853804), complete cds.","BC011418.1","AAH11418.1",54884,"Hs.440401","FLJ20296","ENSG00000042445","Retinol saturase","2","85342088-85354620","Enzymes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA007961, HPA046513","Uncertain",NA,"Approved","Nucleoli","Renal cancer:1.95e-10 (favourable), Liver cancer:4.23e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"adipose tissue: 265.4","Expressed in all",NA,NA
"RGL4",151,"C9","IOH63473",1233,"0",NA,"ral guanine nucleotide dissociation stimulator-like 4, mRNA (cDNA clone MGC:119680 IMAGE:40011564), complete cds","BC101109.2","AAI01110.1",266747,"Hs.658997","Rgr","ENSG00000159496","Ral guanine nucleotide dissociation stimulator like 4","22","23688136-23699176","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA035979","Uncertain",NA,"Approved","Centrosome",NA,"Not detected","Tissue enriched",8,"bone marrow: 107.4","lymph node: 12.9","Cell line enhanced",NA,"MOLT-4: 21.0;U-937: 47.3"
"RGL4",151,"H8","IOH63465",1071,"0",NA,"ral guanine nucleotide dissociation stimulator-like 4, mRNA (cDNA clone MGC:119678 IMAGE:40011557), complete cds","BC101108.3","AAI01109.1",266747,"Hs.658997","Rgr","ENSG00000159496","Ral guanine nucleotide dissociation stimulator like 4","22","23688136-23699176","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA035979","Uncertain",NA,"Approved","Centrosome",NA,"Not detected","Tissue enriched",8,"bone marrow: 107.4","lymph node: 12.9","Cell line enhanced",NA,"MOLT-4: 21.0;U-937: 47.3"
"RGMB",95,"D1","IOH40139",1437,"0",NA,"RGM domain family, member B, mRNA (cDNA clone MGC:86970 IMAGE:30340500), complete cds","BC067736.1","AAH67736.1",285704,"Hs.526902","DRAGON, FLJ90406","ENSG00000174136","Repulsive guidance molecule family member b","5","98768650-98798643","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA016993",NA,NA,"Approved","Nucleoplasm",NA,"Expressed in all","Mixed",NA,NA,"cerebral cortex: 43.6","Cell line enhanced",NA,"BJ: 267.0;HBF TERT88: 210.1"
"RLN1",13,"F12","IOH7561",558,"0",NA,"relaxin 1 (RLN1), mRNA.","NM_006911.2","NP_008842.1",6013,"Hs.368996","H1","ENSG00000107018","Relaxin 1","9","5334969-5339873","Plasma proteins, Predicted secreted proteins","Evidence at transcript level",NA,NA,NA,NA,NA,NA,"Tissue enriched","Tissue enriched",64,"prostate: 40.0","testis: 0.6","Cell line enhanced",NA,"HEL: 1.0"
"RNASE1",21,"B9","IOH7223",471,"0",NA,"ribonuclease, RNase A family, 1 (pancreatic) (RNASE1), transcript variant 4, mRNA.","NM_002933.4","NP_002924.1",6035,"Hs.78224","RAC1, RNS1","ENSG00000129538","Ribonuclease A family member 1, pancreatic","14","20801228-20803278","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA001140","Supported",NA,"Approved","Nucleoplasm<br>Vesicles",NA,"Expressed in all","Expressed in all",NA,NA,"pancreas: 1946.8","Group enriched",6,"HUVEC TERT2: 239.6;RT4: 91.0;TIME: 122.8"
"RNASE10",142,"B10","IOH54788",651,"0",NA,"ribonuclease, RNase A family, 10 (non-active) (RNASE10), mRNA.","NM_001012975.1","NP_001012993.1",338879,"Hs.451057","RAH1, RNASE9","ENSG00000182545","Ribonuclease A family member 10 (inactive)","14","20505537-20511169","Predicted intracellular proteins, Predicted secreted proteins","Evidence at transcript level","HPA052593","Uncertain",NA,NA,NA,NA,"Group enriched","Mixed",NA,NA,"testis: 3.8","Cell line enhanced",NA,"SiHa: 7.3;U-2 OS: 11.5"
"RNASE11",37,"A12","IOH11197",600,"0",NA,"ribonuclease, RNase A family, 11 (non-active) (RNASE11), mRNA.","NM_145250.3","NP_660293.1",122651,"Hs.112761","C14orf6, RAJ1","ENSG00000173464","Ribonuclease A family member 11 (inactive)","14","20583559-20609884","Predicted secreted proteins","Evidence at protein level","HPA003724","Uncertain",NA,NA,NA,NA,"Not detected","Tissue enriched",7,"epididymis: 541.2","testis: 82.0","Not detected",NA,NA
"RNASE2",108,"G4","IOH44348",486,"0",NA,"ribonuclease, RNase A family, 2 (liver, eosinophil-derived neurotoxin) (RNASE2), mRNA.","NM_002934.2","NP_002925.1",6036,"Hs.728","EDN, RAF3, RNS2","ENSG00000169385","Ribonuclease A family member 2","14","20955452-20956436","Enzymes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA044983","Enhanced",NA,NA,NA,"Renal cancer:3.28e-13 (unfavourable)","Tissue enriched","Tissue enriched",73,"bone marrow: 995.8","smooth muscle: 13.6","Group enriched",286,"HL-60: 411.9;NB-4: 325.9;THP-1: 920.7;U-937: 968.9"
"RNASE4",48,"F2","IOH11688",444,"0",NA,"ribonuclease, RNase A family, 4 (RNASE4), transcript variant 2, mRNA.","NM_002937.3","NP_002928.1",6038,"Hs.283749","RAB1","ENSG00000258818","Ribonuclease A family member 4","14","20684100-20701215","Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Liver cancer:9.62e-5 (favourable)","Tissue enhanced","Tissue enhanced",NA,"liver: 232.5","prostate: 117.7","Cell line enhanced",NA,"ASC diff: 59.9;ASC TERT1: 68.7;Hep G2: 89.2;HSkMC: 42.8"
"RNASE6",7,"D9","IOH12065",453,"0",NA,"ribonuclease, RNase A family, k6 (RNASE6), mRNA.","NM_005615.4","NP_005606.1",6039,"Hs.23262","RAD1, RNaseK6, RNS6","ENSG00000169413","Ribonuclease A family member k6","14","20781051-20782467","Predicted secreted proteins","Evidence at protein level","HPA000698","Approved",NA,NA,NA,NA,"Expressed in all","Mixed",NA,NA,"lymph node: 90.2","Cell line enriched",6,"RPMI-8226: 36.0"
"RNASE7",99,"E9","IOH35124",471,"0",NA,"ribonuclease, RNase A family, 7, mRNA (cDNA clone MGC:104056 IMAGE:30915504), complete cds","BC074960.2","AAH74960.1",84659,"Hs.525206","RAE1","ENSG00000165799","Ribonuclease A family member 7","14","21042226-21044234","Predicted secreted proteins","Evidence at protein level","HPA005690, CAB062560, CAB068225","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"esophagus: 72.0;skin: 29.2;tonsil: 19.6","gallbladder: 11.1","Cell line enhanced",NA,"HBEC3-KT: 17.9;hTCEpi: 7.6;hTERT-HME1: 40.4"
"RNASE8",108,"D9","IOH35122",465,"0",NA,"ribonuclease, RNase A family, 8 (RNASE8), mRNA.","NM_138331.1","NP_612204.1",122665,"Hs.553572","RAE2","ENSG00000173431","Ribonuclease A family member 8","14","21057822-21058455","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Not detected","Tissue enriched",105,"salivary gland: 27.2","skin: 0.2","Not detected",NA,NA
"RNASEH1",23,"H7","IOH4870",861,"0",NA,"ribonuclease H1 (RNASEH1), mRNA.","NM_002936.3","NP_002927.2",246243,"Hs.568006",NA,"ENSG00000171865","Ribonuclease H1","2","3544793-3558616","Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins","Evidence at protein level","HPA043037","Uncertain",NA,NA,NA,"Liver cancer:7.83e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"smooth muscle: 10.9","Expressed in all",NA,NA
"RNASET2",132,"B12","IOH3795",771,"0",NA,"ribonuclease T2 (RNASET2), mRNA.","NM_003730.4","NP_003721.2",8635,"Hs.529989","bA514O12.3, FLJ10907, RNASE6PL","ENSG00000026297","Ribonuclease T2","6","166929504-166957191","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA029013, HPA066509","Approved",NA,NA,NA,"Renal cancer:1.70e-14 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 279.9","Cell line enhanced",NA,"EFO-21: 187.2;THP-1: 346.2"
"RNF146",5,"G6","IOH3374",1077,"0",NA,"ring finger protein 146 (RNF146), mRNA.","NM_030963.2","NP_112225.2",81847,"Hs.267120","dactylidin, dJ351K20.1, DKFZp434O1427","ENSG00000118518","Ring finger protein 146","6","127266610-127288567","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA027158, HPA027209","Approved",NA,"Supported","Nucleoplasm<br>Plasma membrane<br>Cytosol","Pancreatic cancer:5.26e-5 (favourable), Renal cancer:7.32e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"endometrium: 94.6","Expressed in all",NA,NA
"RNF148",42,"E1","IOH22786",918,"0",NA,"ring finger protein 148 (RNF148), mRNA.","NM_198085.1","NP_932351.1",378925,"Hs.675191","MGC35222","ENSG00000235631","Ring finger protein 148","7","122701664-122702967","Predicted membrane proteins, Predicted secreted proteins","Evidence at transcript level",NA,NA,NA,NA,NA,NA,"Not detected","Tissue enriched",228,"testis: 73.5","lung: 0.3","Cell line enhanced",NA,"Karpas-707: 1.9"
"RNF150",150,"A11","IOH63603",945,"0",NA,"ring finger protein 150, mRNA (cDNA clone MGC:125502 IMAGE:40023129), complete cds","BC101992.1","AAI01993.1",57484,"Hs.659104","KIAA1214","ENSG00000170153","Ring finger protein 150","4","140859807-141212877","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA037987","Uncertain",NA,NA,NA,"Breast cancer:1.41e-4 (favourable)","Mixed","Mixed",NA,NA,"endometrium,fallopian tube: 21.3","Cell line enhanced",NA,"fHDF/TERT166: 21.9;SH-SY5Y: 42.3"
"RNF167",15,"C4","IOH14407",1053,"NP_056343.1","NP_056343.1","ring finger protein 167 (RNF167), mRNA.","NM_015528.1","NP_056343.1",26001,"Hs.7158","DKFZP566H073","ENSG00000108523","Ring finger protein 167","17","4940008-4945222","Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA049810","Approved",NA,"Approved","Cytosol","Pancreatic cancer:2.03e-6 (favourable), Renal cancer:4.47e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 116.9","Expressed in all",NA,NA
"RNPEP",40,"C1","IOH3753",1953,"0",NA,"arginyl aminopeptidase (aminopeptidase B) (RNPEP), mRNA.","NM_020216.3","NP_064601.3",6051,"Hs.497391",NA,"ENSG00000176393","Arginyl aminopeptidase","1","201982372-202006147","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA036074, HPA036075, HPA061487","Approved",NA,"Supported","Nucleoplasm<br>Golgi apparatus",NA,"Expressed in all","Expressed in all",NA,NA,"duodenum: 66.5","Expressed in all",NA,NA
"RPN2",47,"A7","IOH4972",1896,"NP_002942.1","NP_002942.2","ribophorin II (RPN2), transcript variant 1, mRNA.","NM_002951.3","NP_002942.2",6185,"Hs.370895","RIBIIR, RPN-II, RPNII, SWP1","ENSG00000118705","Ribophorin II","20","37178410-37241623","Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA008297, CAB019277, HPA025922","Enhanced",NA,"Supported","Endoplasmic reticulum","Renal cancer:1.44e-10 (unfavourable), Liver cancer:1.38e-4 (unfavourable), Urothelial cancer:2.44e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 364.2","Expressed in all",NA,NA
"RPS27L",123,"F7","IOH57353",255,"0",NA,"ribosomal protein S27-like (RPS27L), mRNA.","NM_015920.3","NP_057004.1",51065,"Hs.108957",NA,"ENSG00000185088","Ribosomal protein S27 like","15","63125872-63158021","Predicted intracellular proteins, Predicted secreted proteins, Ribosomal proteins","Evidence at protein level","HPA066851",NA,NA,"Supported","Nucleoli<br>Endoplasmic reticulum<br>Cytosol","Endometrial cancer:9.08e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"adrenal gland: 222.3","Expressed in all",NA,NA
"RSPO2",45,"D11","IOH11522",531,"0",NA,"R-spondin 2 homolog (Xenopus laevis), mRNA (cDNA clone MGC:35555 IMAGE:5201681), complete cds","BC027938.1","AAH27938.1",340419,"Hs.444834","MGC35555","ENSG00000147655","R-spondin 2","8","107899316-108083648","Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA024764, CAB025900, HPA053068","Approved",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 20.2;placenta: 25.7","prostate: 15.8","Cell line enhanced",NA,"HEK 293: 1.7;HEL: 1.6;NTERA-2: 1.0;U-138 MG: 1.8;U-266/70: 4.2"
"RSPO3",43,"G7","IOH12753",819,"0",NA,"R-spondin 3 homolog (Xenopus laevis) (RSPO3), mRNA.","NM_032784.3","NP_116173.2",84870,"Hs.135254","FLJ14440, THSD2","ENSG00000146374","R-spondin 3","6","127118604-127197765","Cancer-related genes, Predicted secreted proteins","Evidence at protein level","HPA029957","Approved",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"endometrium: 103.2;smooth muscle: 102.9","placenta: 73.2","Cell line enhanced",NA,"A549: 24.0;U-138 MG: 5.6;U-87 MG: 5.4"
"RSPRY1",53,"D2","IOH11125",1731,"0",NA,"ring finger and SPRY domain containing 1 (RSPRY1), mRNA.","NM_133368.1","NP_588609.1",89970,"Hs.460885","KIAA1972","ENSG00000159579","Ring finger and SPRY domain containing 1","16","57186137-57240475","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA003729","Approved",NA,NA,NA,"Head and neck cancer:8.21e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 39.7","Expressed in all",NA,NA
"RTBDN",92,"A7","IOH6550",786,"0",NA,"retbindin (RTBDN), transcript variant 2, mRNA.","NM_031429.1","NP_113617.1",83546,"Hs.21162","FLJ36353","ENSG00000132026","Retbindin","19","12825478-12835428","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA052511",NA,NA,"Approved","Endoplasmic reticulum",NA,"Mixed","Group enriched",6,"adrenal gland: 4.6;cerebral cortex: 14.6;testis: 3.5","stomach: 1.2","Cell line enhanced",NA,"SCLC-21H: 9.8;SH-SY5Y: 5.8;U-266/84: 16.0"
"SAA1",76,"F5","IOH7234",369,"0",NA,"serum amyloid A1, mRNA (cDNA clone MGC:12369 IMAGE:4071612), complete cds","BC007022.1","AAH07022.1",6288,"Hs.632144","PIG4, SAA, TP53I4","ENSG00000173432","Serum amyloid A1","11","18266174-18269977","Disease related genes, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:4.57e-12 (unfavourable)","Tissue enriched","Tissue enhanced",NA,"adipose tissue: 3976.7;liver: 1183.1","cervix, uterine: 635.0","Group enriched",5,"HBEC3-KT: 868.8;HHSteC: 212.1"
"SAA1",139,"G7","IOH58953",369,"0",NA,"serum amyloid A1 (SAA1), transcript variant 1, mRNA.","NM_000331.3","NP_000322.2",6288,"Hs.632144","PIG4, SAA, TP53I4","ENSG00000173432","Serum amyloid A1","11","18266174-18269977","Disease related genes, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:4.57e-12 (unfavourable)","Tissue enriched","Tissue enhanced",NA,"adipose tissue: 3976.7;liver: 1183.1","cervix, uterine: 635.0","Group enriched",5,"HBEC3-KT: 868.8;HHSteC: 212.1"
"SAA2",33,"G7","IOH12636",369,"0",NA,"serum amyloid A2, mRNA (cDNA clone MGC:23693 IMAGE:4767650), complete cds","BC020795.1","AAH20795.1",6289,"Hs.1955",NA,"ENSG00000134339","Serum amyloid A2","11","18239223-18248643","Disease related genes, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:1.30e-8 (unfavourable)","Tissue enriched","Tissue enhanced",NA,"adipose tissue: 713.3;cervix, uterine: 414.7;liver: 581.2","appendix: 211.6","Cell line enhanced",NA,"A-431: 25.4;EFO-21: 20.0;HaCaT: 23.6;HBEC3-KT: 41.5"
"SAA4",22,"G5","IOH7161",393,"0",NA,"serum amyloid A4, constitutive (SAA4), mRNA.","NM_006512.2","NP_006503.1",6291,"Hs.654493","C-SAA, CSAA","ENSG00000148965","Serum amyloid A4, constitutive","11","18231349-18236893","Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB026061, HPA060139","Supported",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",42,"liver: 776.2","cervix, uterine: 18.6","Cell line enriched",14,"Hep G2: 15.6"
"SAR1A",77,"E1","IOH5222",597,"0",NA,"SAR1 homolog A (S. cerevisiae) (SAR1A), transcript variant 2, mRNA.","NM_020150.4","NP_064535.1",56681,"Hs.499960","SAR1, Sara, SARA1","ENSG00000079332","Secretion associated Ras related GTPase 1A","10","70147289-70170523","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA006923, CAB022545, HPA048368","Supported",NA,"Supported","Endoplasmic reticulum","Head and neck cancer:7.00e-5 (unfavourable), Liver cancer:4.04e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 116.4","Expressed in all",NA,NA
"SBSN",126,"C3","IOH39839",744,"0",NA,"suprabasin (SBSN), mRNA.","NM_198538.1","NP_940940.1",374897,"Hs.433484","HLAR698, UNQ698","ENSG00000189001","Suprabasin","19","35523367-35528351","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA062568, HPA067734","Enhanced",NA,"Approved","Vesicles",NA,"Group enriched","Group enriched",12,"esophagus: 1055.9;skin: 2690.8","tonsil: 151.8","Cell line enhanced",NA,"ASC diff: 42.6;ASC TERT1: 75.3;HSkMC: 106.4;U-2197: 48.0;U-87 MG: 117.4"
"SCG2",63,"F3","IOH10669",1854,"0",NA,"secretogranin II (chromogranin C), mRNA (cDNA clone MGC:26541 IMAGE:4820104), complete cds","BC022509.1","AAH22509.1",7857,"Hs.516726","CHGC, SgII, SN","ENSG00000171951","Secretogranin II","2","223596940-223602503","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA011893, HPA075062","Enhanced","Supported",NA,NA,"Renal cancer:7.01e-10 (unfavourable), Pancreatic cancer:5.58e-4 (favourable)","Group enriched","Group enriched",8,"adrenal gland: 446.7;cerebral cortex: 232.0","duodenum: 45.1","Cell line enhanced",NA,"ASC TERT1: 35.0;HSkMC: 31.4;SCLC-21H: 52.8;SH-SY5Y: 20.7;WM-115: 32.8"
"SCG3",10,"B5","IOH12145",1407,"0",NA,"secretogranin III, mRNA (cDNA clone MGC:13448 IMAGE:4283082), complete cds","BC014539.1","AAH14539.1",29106,"Hs.232618","FLJ90833, SgIII","ENSG00000104112","Secretogranin III","15","51681353-51721031","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA006880, CAB033274, HPA053715","Enhanced","Approved","Enhanced","Vesicles",NA,"Group enriched","Tissue enriched",13,"cerebral cortex: 278.4","adrenal gland: 21.9","Group enriched",8,"NTERA-2: 50.4;SCLC-21H: 140.8;SH-SY5Y: 60.1"
"SCG3",131,"A1","IOH55319",1407,"0",NA,"secretogranin III (SCG3), mRNA.","NM_013243.2","NP_037375.2",29106,"Hs.232618","FLJ90833, SgIII","ENSG00000104112","Secretogranin III","15","51681353-51721031","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA006880, CAB033274, HPA053715","Enhanced","Approved","Enhanced","Vesicles",NA,"Group enriched","Tissue enriched",13,"cerebral cortex: 278.4","adrenal gland: 21.9","Group enriched",8,"NTERA-2: 50.4;SCLC-21H: 140.8;SH-SY5Y: 60.1"
"SCG5",20,"C7","IOH7305",639,"0",NA,"secretogranin V (7B2 protein), mRNA (cDNA clone MGC:12446 IMAGE:3949961), complete cds","BC005349.1","AAH05349.1",6447,"Hs.156540","7B2, SGNE1, SgV","ENSG00000166922","Secretogranin V","15","32641676-32697098","Predicted secreted proteins","Evidence at protein level","HPA013136, HPA074618","Enhanced",NA,NA,NA,"Renal cancer:4.51e-9 (unfavourable), Head and neck cancer:9.64e-4 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 233.7;parathyroid gland: 192.7","adrenal gland: 80.4","Group enriched",6,"HHSteC: 22.6;HSkMC: 24.3;NTERA-2: 15.6;SCLC-21H: 37.1;SH-SY5Y: 38.6;U-87 MG: 46.3"
"SCGB1A1",24,"E5","IOH5625",276,"0",NA,"secretoglobin, family 1A, member 1 (uteroglobin) (SCGB1A1), mRNA.","NM_003357.3","NP_003348.1",7356,"Hs.523732","CC10, CC16, CCSP, UGB","ENSG00000149021","Secretoglobin family 1A member 1","11","62405103-62423195","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB025686, HPA031828","Supported",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",9,"lung: 4742.5","fallopian tube: 521.2","Cell line enriched",70,"HaCaT: 1741.2"
"SCGB1D1",93,"A5","IOH40719",273,"0",NA,"secretoglobin, family 1D, member 1 (SCGB1D1), mRNA.","NM_006552.1","NP_006543.1",10648,"Hs.202686","LIPA, LPHA, MGC71958","ENSG00000168515","Secretoglobin family 1D member 1","11","62190216-62193539","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Group enriched","Tissue enhanced",NA,"cervix, uterine: 2.0;fallopian tube: 1.3","endometrium: 0.5","Cell line enriched",43,"SCLC-21H: 7.1"
"SCGB1D4",120,"D6","IOH50145",252,"0",NA,"secretoglobin, family 1D, member 4 (SCGB1D4), mRNA.","NM_206998.1","NP_996881.1",404552,"Hs.473247","IIS","ENSG00000197745","Secretoglobin family 1D member 4","11","62296277-62299064","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enriched","Group enriched",6,"cervix, uterine: 76.0;epididymis: 55.4;fallopian tube: 74.8","endometrium: 11.8","Not detected",NA,NA
"SCGB2A1",97,"A12","IOH40725",288,"0",NA,"secretoglobin, family 2A, member 1 (SCGB2A1), mRNA.","NM_002407.2","NP_002398.1",4246,"Hs.97644","LPHC, MGB2, MGC71973, UGB3","ENSG00000124939","Secretoglobin family 2A member 1","11","62208668-62213939","Cancer-related genes, Predicted secreted proteins","Evidence at protein level","HPA034584","Enhanced",NA,NA,NA,"Endometrial cancer:1.54e-8 (favourable), Colorectal cancer:1.22e-4 (favourable), Renal cancer:6.36e-4 (favourable)","Group enriched","Group enriched",6,"cervix, uterine: 2863.6;epididymis: 1665.3","fallopian tube: 381.7","Cell line enhanced",NA,"EFO-21: 8.1;NB-4: 1.3;SCLC-21H: 1.9"
"SCGB2A2",125,"A8","IOH50178",282,"0",NA,"secretoglobin, family 2A, member 2 (SCGB2A2), mRNA.","NM_002411.2","NP_002402.1",4250,"Hs.46452","MGB1, MGC71974, UGB2","ENSG00000110484","Secretoglobin family 2A member 2","11","62270155-62273156","Cancer-related genes, Predicted secreted proteins","Evidence at protein level","CAB026270","Supported",NA,NA,NA,"Endometrial cancer:9.57e-8 (favourable)","Tissue enriched","Tissue enriched",7,"breast: 3687.7","cervix, uterine: 507.6","Cell line enriched",95,"SK-BR-3: 13.3"
"SCGB2A2",93,"C4","IOH40709",363,"0",NA,"secretoglobin, family 2A, member 2, mRNA (cDNA clone MGC:71974 IMAGE:30321681), complete cds","BC067220.1","AAH67220.1",4250,"Hs.46452","MGB1, MGC71974, UGB2","ENSG00000110484","Secretoglobin family 2A member 2","11","62270155-62273156","Cancer-related genes, Predicted secreted proteins","Evidence at protein level","CAB026270","Supported",NA,NA,NA,"Endometrial cancer:9.57e-8 (favourable)","Tissue enriched","Tissue enriched",7,"breast: 3687.7","cervix, uterine: 507.6","Cell line enriched",95,"SK-BR-3: 13.3"
"SCGB3A1",30,"B8","IOH22643",315,"0",NA,"secretoglobin, family 3A, member 1 (SCGB3A1), mRNA.","NM_052863.2","NP_443095.2",92304,"Hs.62492","HIN-1, HIN1, LU105, PnSP-2, UGRP2","ENSG00000161055","Secretoglobin family 3A member 1","5","180590103-180591540","Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Group enriched","Group enriched",6,"breast: 125.3;cervix, uterine: 345.8;lung: 301.1;salivary gland: 193.1","stomach: 40.9","Cell line enhanced",NA,"NB-4: 1.3"
"SCGB3A2",33,"B8","IOH12827",282,"0",NA,"secretoglobin, family 3A, member 2 (SCGB3A2), mRNA.","NM_054023.3","NP_473364.1",117156,"Hs.483765","LU103, PNSP1, UGRP1","ENSG00000164265","Secretoglobin family 3A member 2","5","147870682-147882191","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enriched","Tissue enriched",188,"lung: 1867.1","thyroid gland: 9.9","Cell line enhanced",NA,"A-431: 76.2;EFO-21: 49.6;NTERA-2: 60.1;PC-3: 279.6"
"SCN3B",71,"G2","IOH29595",648,"NP_060870.1","NP_060870.1","sodium channel, voltage-gated, type III, beta (SCN3B), transcript variant 1, mRNA.","NM_018400.3","NP_060870.1",55800,"Hs.4865","HSA243396","ENSG00000166257","Sodium voltage-gated channel beta subunit 3","11","123629187-123655244","Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA041707",NA,NA,"Approved","Intermediate filaments<br>Cytosol",NA,"Tissue enhanced","Tissue enriched",11,"cerebral cortex: 132.1","adrenal gland: 11.5","Cell line enhanced",NA,"hTCEpi: 4.6;RH-30: 2.8;SCLC-21H: 7.5;SH-SY5Y: 5.0"
"SCRG1",102,"H1","IOH50201",297,"0",NA,"stimulator of chondrogenesis 1 (SCRG1), mRNA.","NM_007281.2","NP_009212.1",11341,"Hs.7122","SCRG-1","ENSG00000164106","Stimulator of chondrogenesis 1","4","173384701-173406380","Predicted secreted proteins","Evidence at protein level","HPA012882","Approved",NA,NA,NA,NA,"Tissue enriched","Tissue enhanced",NA,"cerebral cortex: 24.4;testis: 15.5","smooth muscle: 11.0","Group enriched",13,"HSkMC: 4.3;WM-115: 17.6"
"SCT",108,"A9","IOH35021",366,"0",NA,"secretin (SCT), mRNA.","NM_021920.2","NP_068739.1",6343,"Hs.632324",NA,"ENSG00000070031","Secretin","11","626431-627143","Predicted secreted proteins","Evidence at protein level","HPA050961","Enhanced",NA,NA,NA,"Colorectal cancer:3.70e-4 (unfavourable)","Mixed","Group enriched",6,"duodenum: 34.9;small intestine: 7.8","spleen: 3.4","Cell line enhanced",NA,"HSkMC: 1.1"
"SDC1",88,"C6","IOH5957",933,"0",NA,"syndecan 1, mRNA (cDNA clone MGC:1622 IMAGE:3347793), complete cds","BC008765.2","AAH08765.1",6382,"Hs.224607","CD138, SDC, SYND1, syndecan","ENSG00000115884","Syndecan 1","2","20200797-20225433","Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","CAB002424, HPA006185","Approved",NA,"Supported","Focal adhesion sites","Breast cancer:2.22e-4 (unfavourable), Glioma:8.05e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"esophagus: 250.7;skin: 287.9","liver: 144.7","Cell line enhanced",NA,"U-266/84: 739.8"
"SDC1",143,"E1","IOH54992",933,"0",NA,"syndecan 1 (SDC1), transcript variant 1, mRNA.","NM_001006946.1","NP_001006947.1",6382,"Hs.224607","CD138, SDC, SYND1, syndecan","ENSG00000115884","Syndecan 1","2","20200797-20225433","Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","CAB002424, HPA006185","Approved",NA,"Supported","Focal adhesion sites","Breast cancer:2.22e-4 (unfavourable), Glioma:8.05e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"esophagus: 250.7;skin: 287.9","liver: 144.7","Cell line enhanced",NA,"U-266/84: 739.8"
"SDF2",22,"A8","IOH4099",636,"0",NA,"stromal cell-derived factor 2 (SDF2), mRNA.","NM_006923.2","NP_008854.2",6388,"Hs.514036",NA,"ENSG00000132581","Stromal cell derived factor 2","17","28648356-28662189","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA042799",NA,NA,"Approved","Vesicles","Liver cancer:1.16e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"adrenal gland: 27.8","Expressed in all",NA,NA
"SDF2L1",89,"G9","IOH6314",666,"0",NA,"stromal cell-derived factor 2-like 1 (SDF2L1), mRNA.","NM_022044.2","NP_071327.2",23753,"Hs.303116","AP000553.C22.4, OTTHUMT00000075032","ENSG00000128228","Stromal cell derived factor 2 like 1","22","21642261-21644298","Predicted secreted proteins","Evidence at protein level","HPA005638","Approved",NA,NA,NA,"Endometrial cancer:4.98e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 45.4","Expressed in all",NA,NA
"SDF4",11,"D7","IOH10229",1089,"0",NA,"stromal cell derived factor 4 (SDF4), transcript variant 2, mRNA.","NM_016176.3","NP_057260.2",51150,"Hs.42806","Cab45","ENSG00000078808","Stromal cell derived factor 4","1","1216908-1232031","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA011249, CAB015227","Enhanced",NA,"Enhanced","Golgi apparatus","Cervical cancer:5.89e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"small intestine: 128.7","Expressed in all",NA,NA
"SDHA",74,"B2","IOH3984",1995,"0",NA,"succinate dehydrogenase complex, subunit A, flavoprotein (Fp) (SDHA), nuclear gene encoding mitochondrial protein, mRNA.","NM_004168.2","NP_004159.2",6389,"Hs.440475","FP, SDH2, SDHF","ENSG00000073578","Succinate dehydrogenase complex flavoprotein subunit A","5","218241-256700","Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","CAB034929, HPA041981, HPA064582","Enhanced",NA,"Enhanced","Mitochondria","Renal cancer:9.53e-8 (favourable), Breast cancer:6.00e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"heart muscle: 248.9","Expressed in all",NA,NA
"SDHA",117,"E9","IOH27990",1560,"0",NA,"succinate dehydrogenase complex, subunit A, flavoprotein (Fp), mRNA (cDNA clone MGC:52232 IMAGE:3138724), complete cds","BC041016.1","AAH41016.1",6389,"Hs.440475","FP, SDH2, SDHF","ENSG00000073578","Succinate dehydrogenase complex flavoprotein subunit A","5","218241-256700","Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","CAB034929, HPA041981, HPA064582","Enhanced",NA,"Enhanced","Mitochondria","Renal cancer:9.53e-8 (favourable), Breast cancer:6.00e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"heart muscle: 248.9","Expressed in all",NA,NA
"SDHD",145,"A12","IOH62889",480,"0",NA,"succinate dehydrogenase complex, subunit D, integral membrane protein, mRNA (cDNA clone MGC:88307 IMAGE:4277540), complete cds","BC070307.1","AAH70307.1",6392,"Hs.356270","cybS, PGL, PGL1","ENSG00000204370","Succinate dehydrogenase complex subunit D","11","112086773-112120013","Cancer-related genes, Citric acid cycle related proteins, Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA045727","Approved",NA,NA,NA,"Renal cancer:1.99e-10 (favourable)","Expressed in all","Expressed in all",NA,NA,"kidney: 305.5","Expressed in all",NA,NA
"SDHD",84,"E5","IOH7395",480,"0",NA,"succinate dehydrogenase complex, subunit D, integral membrane protein (SDHD), nuclear gene encoding mitochondrial protein, mRNA.","NM_003002.2","NP_002993.1",6392,"Hs.356270","cybS, PGL, PGL1","ENSG00000204370","Succinate dehydrogenase complex subunit D","11","112086773-112120013","Cancer-related genes, Citric acid cycle related proteins, Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA045727","Approved",NA,NA,NA,"Renal cancer:1.99e-10 (favourable)","Expressed in all","Expressed in all",NA,NA,"kidney: 305.5","Expressed in all",NA,NA
"SEC16B",77,"D2","IOH10263",1878,"0",NA,"SEC16 homolog B (S. cerevisiae), mRNA (cDNA clone MGC:17455 IMAGE:3448742), complete cds","BC009106.1","AAH09106.1",89866,"Hs.709633","LZTR2, PGPR-p117, RGPR, Sec16S","ENSG00000120341","SEC16 homolog B, endoplasmic reticulum export factor","1","177923956-177984303","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA054292, HPA072913","Enhanced",NA,"Approved","Endoplasmic reticulum<br>Plasma membrane<br>Actin filaments",NA,"Not detected","Tissue enhanced",NA,"duodenum: 28.2;small intestine: 30.9","liver: 18.8","Cell line enhanced",NA,"CAPAN-2: 6.3;EFO-21: 5.1;HDLM-2: 5.3"
"SEC31A",57,"G5","IOH26992",1530,"0",NA,"SEC31 homolog A (S. cerevisiae), mRNA (cDNA clone IMAGE:6203896), complete cds.","BC047883.2","AAH47883.1",22872,"Hs.370024","ABP125, ABP130, KIAA0905, SEC31L1","ENSG00000138674","SEC31 homolog A, COPII coat complex component","4","82818661-82901166","Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA005457","Approved",NA,"Supported","Vesicles<br>Cytosol","Urothelial cancer:2.69e-4 (unfavourable), Liver cancer:3.32e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 281.0","Expressed in all",NA,NA
"SECTM1",78,"A1","IOH11983",747,"NP_002995.1","AAH17716.1","secreted and transmembrane 1, mRNA (cDNA clone MGC:21265 IMAGE:4413387), complete cds","BC017716.1","AAH17716.1",6398,"Hs.558009","K12","ENSG00000141574","Secreted and transmembrane 1","17","82321024-82334074","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA051214","Approved",NA,NA,NA,NA,"Expressed in all","Tissue enhanced",NA,"small intestine: 96.6","duodenum: 64.4","Cell line enhanced",NA,"SiHa: 125.5;U-2197: 82.3"
"SECTM1",83,"F4","IOH1886",747,"0","NP_002995.1","secreted and transmembrane 1 (SECTM1), mRNA.","NM_003004.2","NP_002995.1",6398,"Hs.558009","K12","ENSG00000141574","Secreted and transmembrane 1","17","82321024-82334074","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA051214","Approved",NA,NA,NA,NA,"Expressed in all","Tissue enhanced",NA,"small intestine: 96.6","duodenum: 64.4","Cell line enhanced",NA,"SiHa: 125.5;U-2197: 82.3"
"SEMA3B",80,"E3","IOH21436",1908,"0",NA,"sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3B, mRNA (cDNA clone MGC:18122 IMAGE:4153377), complete cds","BC009113.1","AAH09113.1",7869,"Hs.82222","LUCA-1, SemA, sema5, SEMAA, semaV","ENSG00000012171","Semaphorin 3B","3","50267558-50277546","Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA030651","Approved",NA,NA,NA,"Breast cancer:1.27e-4 (favourable)","Expressed in all","Mixed",NA,NA,"adrenal gland: 75.5","Cell line enhanced",NA,"Hep G2: 74.9;WM-115: 171.7"
"SEMA3C",40,"E9","IOH22289",2256,"0",NA,"sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3C (SEMA3C), mRNA.","NM_006379.2","NP_006370.1",10512,"Hs.269109","SEMAE, SemE","ENSG00000075223","Semaphorin 3C","7","80742538-80922359","Predicted secreted proteins","Evidence at protein level","HPA042418","Uncertain",NA,"Approved","Golgi apparatus<br>Plasma membrane<br>Cytosol","Pancreatic cancer:4.08e-5 (unfavourable), Head and neck cancer:5.72e-5 (unfavourable)","Mixed","Mixed",NA,NA,"prostate: 103.0","Cell line enhanced",NA,"T-47d: 248.8;U-2197: 317.7"
"SEMA3F",127,"A4","IOH28026",2358,"0",NA,"sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3F, mRNA (cDNA clone MGC:52231 IMAGE:5477898), complete cds","BC042914.1","AAH42914.1",6405,"Hs.32981","Sema4, SEMAK","ENSG00000001617","Semaphorin 3F","3","50155045-50189075","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA035008","Approved",NA,NA,NA,"Liver cancer:5.15e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"skin: 89.1","Cell line enhanced",NA,"HUVEC TERT2: 156.4;SK-BR-3: 129.8;TIME: 276.8"
"SEMA3G",107,"C8","IOH42833",2349,"0",NA,"sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3G (SEMA3G), mRNA.","NM_020163.1","NP_064548.1",56920,"Hs.59729","FLJ00014, sem2","ENSG00000010319","Semaphorin 3G","3","52433053-52445085","Predicted secreted proteins","Evidence at protein level","HPA001761","Uncertain",NA,NA,NA,"Renal cancer:8.86e-5 (favourable)","Expressed in all","Tissue enhanced",NA,"adipose tissue: 82.2","placenta: 42.3","Cell line enhanced",NA,"ASC diff: 18.3;HUVEC TERT2: 6.5"
"SEMA4A",51,"G5","IOH10371",2286,"NP_071762.2","NP_071762.2","sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4A (SEMA4A), mRNA.","NM_022367.2","NP_071762.2",64218,"Hs.408846","CORD10, FLJ12287, SEMAB, SemB","ENSG00000196189","Semaphorin 4A","1","156147366-156177752","Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA053726, HPA066006, HPA069136","Supported",NA,"Enhanced","Nucleus","Head and neck cancer:1.09e-4 (favourable), Renal cancer:8.20e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"epididymis: 62.3","Cell line enhanced",NA,"Karpas-707: 108.3;U-698: 46.5"
"SEMA4G",36,"C2","IOH10418",384,"0","AAH20960.1","sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4G, mRNA (cDNA clone IMAGE:3851526), complete cds.","BC020960.1","AAH20960.1",57715,"Hs.591923","FLJ20590, KIAA1619","ENSG00000095539","Semaphorin 4G","10","100969518-100985871","Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA038362, HPA077752","Uncertain",NA,"Uncertain","Vesicles<br>Lipid droplets",NA,"Mixed","Tissue enhanced",NA,"rectum: 92.7","duodenum: 53.8","Cell line enhanced",NA,"A549: 28.9;CACO-2: 25.3;Hep G2: 76.9"
"SEMA4G",156,"D6","IOH62410",2517,"0","AAH51030.1","sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4G, mRNA (cDNA clone MGC:51988 IMAGE:5164957), complete cds","BC051030.1","AAH51030.1",57715,"Hs.591923","FLJ20590, KIAA1619","ENSG00000095539","Semaphorin 4G","10","100969518-100985871","Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA038362, HPA077752","Uncertain",NA,"Uncertain","Vesicles<br>Lipid droplets",NA,"Mixed","Tissue enhanced",NA,"rectum: 92.7","duodenum: 53.8","Cell line enhanced",NA,"A549: 28.9;CACO-2: 25.3;Hep G2: 76.9"
"SEMA6A",104,"C1","IOH44076",3093,"NP_065847.1","NP_065847.1","sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6A (SEMA6A), mRNA.","NM_020796.3","NP_065847.1",57556,"Hs.156967","HT018, KIAA1368, SEMA, SEMA6A1, SEMAQ","ENSG00000092421","Semaphorin 6A","5","116443616-116574934","Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA031265, HPA031267","Approved",NA,"Supported","Nucleus<br>Intermediate filaments","Liver cancer:4.39e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"adrenal gland: 49.1","Cell line enhanced",NA,"AF22: 36.5;AN3-CA: 41.0;BEWO: 36.9;HAP1: 53.6;NTERA-2: 115.0"
"SEMA6C",140,"F5","IOH60026",2793,"0","NP_112175.2","sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6C (SEMA6C), mRNA.","NM_030913.3","NP_112175.2",10500,"Hs.516316","KIAA1869","ENSG00000143434","Semaphorin 6C","1","151131685-151146664","Predicted membrane proteins, Predicted secreted proteins","Evidence at transcript level","HPA076150, HPA077625",NA,NA,"Approved","Nucleoplasm<br>Nucleoli fibrillar center<br>Plasma membrane<br>Cytosol","Pancreatic cancer:3.06e-5 (favourable), Endometrial cancer:3.27e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"skeletal muscle: 111.3","testis: 33.8","Cell line enhanced",NA,"AF22: 13.8;HUVEC TERT2: 20.6"
"SEMA6D",108,"G12","IOH35829",1431,"NP_065909.1","NP_079242.2","sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6D (SEMA6D), transcript variant 6, mRNA.","NM_024966.2","NP_079242.2",80031,"Hs.511265","FLJ11598, KIAA1479","ENSG00000137872","Semaphorin 6D","15","47184101-47774223","Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA043109",NA,NA,"Approved","Golgi apparatus<br>Plasma membrane","Renal cancer:5.96e-5 (favourable)","Tissue enhanced","Tissue enhanced",NA,"placenta: 63.6","small intestine: 44.3","Cell line enhanced",NA,"BJ hTERT+: 12.7;SCLC-21H: 16.1;SH-SY5Y: 13.4"
"SEMG1",20,"E10","IOH7422",1209,"0",NA,"semenogelin I, mRNA (cDNA clone MGC:14719 IMAGE:4251523), complete cds","BC007096.1","AAH07096.1",6406,"Hs.1968","CT103, SEMG","ENSG00000124233","Semenogelin I","20","45206997-45209772","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA042476, HPA064892","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",17692,"seminal vesicle: 41483.3","cervix, uterine: 2.3","Cell line enhanced",NA,"NTERA-2: 1.2;THP-1: 2.0"
"SEMG2",147,"D2","IOH62877",1749,"0",NA,"semenogelin II, mRNA (cDNA clone MGC:88306 IMAGE:4356587), complete cds","BC070306.1","AAH70306.1",6407,"Hs.537218","SGII","ENSG00000124157","Semenogelin II","20","45221300-45224458","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA042767, HPA042835","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",18571,"seminal vesicle: 14103.4","cervix, uterine,kidney: 0.7","Not detected",NA,NA
"SERPINA1",36,"D2","IOH10470",1257,"0",NA,"serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1, mRNA (cDNA clone MGC:9222 IMAGE:3859644), complete cds","BC011991.1","AAH11991.1",5265,"Hs.525557","A1A, A1AT, AAT, alpha-1-antitrypsin, alpha1AT, PI, PI1","ENSG00000197249","Serpin family A member 1","14","94376747-94390693","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA000927, HPA001292, CAB013211, CAB016648, CAB073396","Enhanced",NA,"Enhanced","Vesicles","Breast cancer:1.61e-5 (favourable), Colorectal cancer:5.86e-4 (favourable)","Tissue enriched","Tissue enriched",20,"liver: 17144.0","small intestine: 857.0","Cell line enriched",6,"Hep G2: 3254.2"
"SERPINA1",61,"E3","IOH27904",1257,"0",NA,"serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1, mRNA (cDNA clone MGC:23330 IMAGE:4644658), complete cds","BC015642.2","AAH15642.1",5265,"Hs.525557","A1A, A1AT, AAT, alpha-1-antitrypsin, alpha1AT, PI, PI1","ENSG00000197249","Serpin family A member 1","14","94376747-94390693","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA000927, HPA001292, CAB013211, CAB016648, CAB073396","Enhanced",NA,"Enhanced","Vesicles","Breast cancer:1.61e-5 (favourable), Colorectal cancer:5.86e-4 (favourable)","Tissue enriched","Tissue enriched",20,"liver: 17144.0","small intestine: 857.0","Cell line enriched",6,"Hep G2: 3254.2"
"SERPINA10",7,"F7","IOH12195",1335,"0",NA,"serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 10 (SERPINA10), transcript variant 1, mRNA.","NM_016186.2","NP_057270.1",51156,"Hs.118620","PZI, ZPI","ENSG00000140093","Serpin family A member 10","14","94280455-94293271","Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA048739",NA,NA,"Approved","Nucleoplasm<br>Cytosol","Liver cancer:9.00e-4 (favourable)","Tissue enriched","Tissue enriched",89,"liver: 193.7","bone marrow: 2.1","Cell line enriched",6,"Hep G2: 13.4"
"SERPINA12",56,"B12","IOH26319",1245,"0",NA,"serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 12 (SERPINA12), mRNA.","NM_173850.2","NP_776249.1",145264,"Hs.99476","OL-64, Vaspin","ENSG00000165953","Serpin family A member 12","14","94487274-94517844","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",10,"skin: 349.1","breast: 35.5","Cell line enhanced",NA,"Hep G2: 1.5"
"SERPINA3",54,"E6","IOH25751",1272,"0",NA,"serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3, mRNA (cDNA clone MGC:18107 IMAGE:4152390), complete cds","BC034554.1","AAH34554.1",12,"Hs.534293","AACT, ACT","ENSG00000196136","Serpin family A member 3","14","94612377-94624055","Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA000893, HPA002560, CAB016647","Enhanced",NA,NA,NA,"Breast cancer:8.92e-4 (favourable)","Mixed","Group enriched",6,"cervix, uterine: 515.4;liver: 2304.3","gallbladder: 228.3","Cell line enriched",6,"Hep G2: 302.6"
"SERPINA3",22,"C9","IOH4992",1272,"0",NA,"serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 (SERPINA3), mRNA.","NM_001085.4","NP_001076.2",12,"Hs.534293","AACT, ACT","ENSG00000196136","Serpin family A member 3","14","94612377-94624055","Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA000893, HPA002560, CAB016647","Enhanced",NA,NA,NA,"Breast cancer:8.92e-4 (favourable)","Mixed","Group enriched",6,"cervix, uterine: 515.4;liver: 2304.3","gallbladder: 228.3","Cell line enriched",6,"Hep G2: 302.6"
"SERPINA4",19,"F11","IOH12257",1284,"0",NA,"serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 4 (SERPINA4), mRNA.","NM_006215.2","NP_006206.2",5267,"Hs.159628","KAL, kallistatin, KLST, KST, PI4","ENSG00000100665","Serpin family A member 4","14","94561091-94569913","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA003607","Approved",NA,NA,NA,"Endometrial cancer:2.95e-4 (favourable)","Group enriched","Tissue enhanced",NA,"gallbladder: 72.6;liver: 242.7","epididymis: 42.8","Group enriched",36,"CACO-2: 4.7;Hep G2: 16.4"
"SERPINA5",90,"A3","IOH7053",1221,"0",NA,"serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5, mRNA (cDNA clone MGC:16086 IMAGE:3618167), complete cds","BC008915.2","AAH08915.1",5104,"Hs.159628","PAI3, PCI, PLANH3, PROCI","ENSG00000188488","Serpin family A member 5","14","94561442-94593120","Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA056919",NA,NA,"Approved","Mitochondria","Endometrial cancer:7.72e-4 (favourable)","Tissue enhanced","Tissue enhanced",NA,"adrenal gland: 514.2;liver: 405.3;testis: 818.8","gallbladder: 250.7","Cell line enriched",10,"Hep G2: 176.3"
"SERPINA6",7,"D2","IOH2195",1218,"0",NA,"Corticosteroid-binding globulin Precursor (CBG)(Transcortin)(Serpin A6) [Source:UniProtKB/Swiss-Prot;Acc:P08185]","ENST00000341584","ENSP00000342850",866,"Hs.532635","CBG","ENSG00000170099","Serpin family A member 6","14","94304248-94323394","Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA017864","Approved",NA,NA,NA,"Endometrial cancer:6.96e-5 (favourable)","Tissue enriched","Tissue enriched",6,"liver: 217.2","gallbladder: 33.9","Cell line enriched",15,"T-47d: 583.2"
"SERPINA6",63,"H6","IOH29452",1218,"0",NA,"serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 6 (SERPINA6), mRNA.","NM_001756.3","NP_001747.2",866,"Hs.532635","CBG","ENSG00000170099","Serpin family A member 6","14","94304248-94323394","Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA017864","Approved",NA,NA,NA,"Endometrial cancer:6.96e-5 (favourable)","Tissue enriched","Tissue enriched",6,"liver: 217.2","gallbladder: 33.9","Cell line enriched",15,"T-47d: 583.2"
"SERPINA7",18,"A3","IOH14518",1248,"0",NA,"serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 7 (SERPINA7), mRNA.","NM_000354.4","NP_000345.2",6906,"Hs.76838","TBG","ENSG00000123561","Serpin family A member 7","X","106032442-106038738","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA002803","Approved",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",288,"liver: 216.0","small intestine: 0.7","Cell line enriched",406,"Hep G2: 71.5"
"SERPINC1",48,"D6","IOH14497",780,"0",NA,"serpin peptidase inhibitor, clade C (antithrombin), member 1, mRNA (cDNA clone MGC:22579 IMAGE:4734914), complete cds","BC022309.1","AAH22309.1",462,"Hs.75599","AT3, ATIII, MGC22579","ENSG00000117601","Serpin family C member 1","1","173903804-173917378","Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA001816, CAB016790, HPA024007","Supported",NA,NA,NA,"Liver cancer:3.40e-5 (favourable)","Tissue enriched","Tissue enriched",670,"liver: 2517.8","kidney: 3.7","Cell line enriched",26,"Hep G2: 55.1"
"SERPIND1",54,"H11","IOH27133",1500,"0",NA,"serpin peptidase inhibitor, clade D (heparin cofactor), member 1, mRNA (cDNA clone MGC:33758 IMAGE:5262187), complete cds","BC035028.2","AAH35028.1",3053,"Hs.474270","D22S673, HC-II, HC2, HCF2, HLS2","ENSG00000099937","Serpin family D member 1","22","20773879-20787720","Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB008639, HPA055767","Supported",NA,"Approved","Vesicles","Endometrial cancer:4.09e-4 (favourable)","Tissue enriched","Tissue enriched",16,"liver: 585.3","parathyroid gland: 36.2","Cell line enriched",8,"Hep G2: 126.1"
"SERPINE1",13,"B7","IOH9882",1209,"0",NA,"serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 (SERPINE1), mRNA.","NM_000602.2","NP_000593.1",5054,"Hs.414795","PAI, PAI1, PLANH1","ENSG00000106366","Serpin family E member 1","7","101127089-101139266","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA050039, CAB068501","Uncertain",NA,"Approved","Cytosol","Renal cancer:5.88e-8 (unfavourable), Stomach cancer:3.27e-6 (unfavourable), Lung cancer:4.41e-6 (unfavourable), Head and neck cancer:2.84e-5 (unfavourable), Colorectal cancer:2.82e-4 (unfavourable), Cervical cancer:5.01e-4 (unfavourable), Urothelial cancer:5.51e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"gallbladder: 580.3;placenta: 600.2","adipose tissue: 215.8","Cell line enhanced",NA,"TIME: 8072.1;U-138 MG: 4492.2;U-251 MG: 3465.4"
"SERPINE2",75,"G4","IOH27650",1194,"0",NA,"serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 2 (SERPINE2), transcript variant 2, mRNA.","NM_001136528.1","NP_001130000.1",5270,"Hs.38449","GDN, nexin, PI7, PN1, PNI","ENSG00000135919","Serpin family E member 2","2","223975112-224039319","Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Urothelial cancer:6.48e-5 (unfavourable)","Tissue enriched","Tissue enriched",7,"placenta: 1628.0","cerebral cortex: 235.8","Cell line enhanced",NA,"fHDF/TERT166: 5130.1;SK-MEL-30: 2298.5;WM-115: 2211.8"
"SERPINE2",34,"G1","IOH12816",1197,"0",NA,"serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 2 (SERPINE2), transcript variant 1, mRNA.","NM_006216.3","NP_006207.1",5270,"Hs.38449","GDN, nexin, PI7, PN1, PNI","ENSG00000135919","Serpin family E member 2","2","223975112-224039319","Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Urothelial cancer:6.48e-5 (unfavourable)","Tissue enriched","Tissue enriched",7,"placenta: 1628.0","cerebral cortex: 235.8","Cell line enhanced",NA,"fHDF/TERT166: 5130.1;SK-MEL-30: 2298.5;WM-115: 2211.8"
"SERPINF1",29,"G2","IOH3622",1257,"0",NA,"serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 1 (SERPINF1), mRNA.","NM_002615.4","NP_002606.3",5176,"Hs.532768","EPC-1, PEDF, PIG35","ENSG00000132386","Serpin family F member 1","17","1761959-1777574","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA005825","Approved",NA,NA,NA,"Renal cancer:1.40e-8 (unfavourable), Cervical cancer:5.49e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"gallbladder: 739.1","Cell line enhanced",NA,"ASC diff: 752.1;ASC TERT1: 594.5;Hep G2: 362.7;HHSteC: 306.9;HSkMC: 845.8"
"SERPINF1",61,"D3","IOH27848",1257,"0",NA,"serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 1, mRNA (cDNA clone MGC:20155 IMAGE:3531777), complete cds","BC013984.2","AAH13984.1",5176,"Hs.532768","EPC-1, PEDF, PIG35","ENSG00000132386","Serpin family F member 1","17","1761959-1777574","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA005825","Approved",NA,NA,NA,"Renal cancer:1.40e-8 (unfavourable), Cervical cancer:5.49e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"gallbladder: 739.1","Cell line enhanced",NA,"ASC diff: 752.1;ASC TERT1: 594.5;Hep G2: 362.7;HHSteC: 306.9;HSkMC: 845.8"
"SERPINF2",41,"G8","IOH22703",1476,"0",NA,"serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 2, mRNA (cDNA clone MGC:34213 IMAGE:5190061), complete cds","BC031592.1","AAH31592.1",5345,"Hs.159509","A2AP, AAP, ALPHA-2-PI, API, PLI","ENSG00000167711","Serpin family F member 2","17","1742836-1755268","Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA001885, CAB024863","Approved",NA,"Uncertain","Nucleoplasm<br>Vesicles","Liver cancer:2.26e-5 (favourable)","Tissue enriched","Tissue enhanced",NA,"epididymis: 117.4;liver: 452.5","kidney: 63.3","Cell line enriched",24,"Hep G2: 99.1"
"SERPING1",89,"D3","IOH10224",1503,"0",NA,"serpin peptidase inhibitor, clade G (C1 inhibitor), member 1, mRNA (cDNA clone MGC:17091 IMAGE:4150091), complete cds","BC011171.2","AAH11171.1",710,"Hs.384598","C1-INH, C1IN, C1NH, HAE1, HAE2","ENSG00000149131","Serpin family G member 1","11","57597387-57614853","Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB026161, HPA048738","Supported",NA,NA,NA,"Renal cancer:1.55e-4 (unfavourable), Ovarian cancer:8.03e-4 (favourable), Colorectal cancer:9.96e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"liver: 1365.0","Group enriched",5,"ASC diff: 881.8;ASC TERT1: 462.5;HSkMC: 802.1"
"SERPINH1",8,"H5","IOH12482",1257,"0",NA,"serpin peptidase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1) (SERPINH1), mRNA.","NM_001235.2","NP_001226.2",871,"Hs.596449","CBP1, CBP2, colligen, HSP47, SERPINH2","ENSG00000149257","Serpin family H member 1","11","75562056-75572783","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB004441, HPA029198","Supported",NA,"Enhanced","Endoplasmic reticulum","Renal cancer:3.22e-15 (unfavourable), Head and neck cancer:1.85e-4 (unfavourable), Cervical cancer:2.10e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 329.1","Mixed",NA,NA
"SERPINI2",54,"F1","IOH11838",1218,"0",NA,"serpin peptidase inhibitor, clade I (pancpin), member 2 (SERPINI2), mRNA.","NM_006217.3","NP_006208.1",5276,"Hs.445555","MEPI, PANCPIN, PI14, TSA2004","ENSG00000114204","Serpin family I member 2","3","167441789-167479004","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enriched","Tissue enriched",47,"pancreas: 288.1","fallopian tube: 6.1","Group enriched",10,"THP-1: 6.0;U-937: 1.2"
"SERPINI2",147,"G9","IOH61431",1248,"0",NA,"serpin peptidase inhibitor, clade I (pancpin), member 2, mRNA (cDNA clone MGC:34230 IMAGE:5228038), complete cds","BC027859.2","AAH27859.2",5276,"Hs.445555","MEPI, PANCPIN, PI14, TSA2004","ENSG00000114204","Serpin family I member 2","3","167441789-167479004","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enriched","Tissue enriched",47,"pancreas: 288.1","fallopian tube: 6.1","Group enriched",10,"THP-1: 6.0;U-937: 1.2"
"SEZ6L2",83,"G8","IOH4178",2430,"NP_036542.1","AAH00567.1","seizure related 6 homolog (mouse)-like 2, mRNA (cDNA clone MGC:1200 IMAGE:3163764), complete cds","BC000567.2","AAH00567.1",26470,"Hs.6314","FLJ90517, PSK-1","ENSG00000174938","Seizure related 6 homolog like 2","16","29871159-29899547","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA064471","Enhanced",NA,NA,NA,"Colorectal cancer:1.31e-4 (unfavourable), Glioma:7.27e-4 (unfavourable), Cervical cancer:7.46e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 82.4;parathyroid gland: 58.4","adrenal gland: 30.6","Cell line enhanced",NA,"EFO-21: 72.2"
"SFRP4",100,"C12","IOH29070",1041,"0",NA,"secreted frizzled-related protein 4 (SFRP4), mRNA.","NM_003014.3","NP_003005.2",6424,"Hs.658169","FRP-4, frpHE","ENSG00000106483","Secreted frizzled related protein 4","7","37905932-38025695","Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA009712, HPA050585","Enhanced",NA,NA,NA,"Renal cancer:1.36e-5 (unfavourable)","Expressed in all","Group enriched",5,"cervix, uterine: 935.5;endometrium: 776.1;fallopian tube: 338.6","smooth muscle: 130.5","Cell line enhanced",NA,"ASC diff: 6.5;HSkMC: 2.7;U-937: 2.9"
"SFTA2",105,"G8","IOH43313",237,"0",NA,"surfactant associated 2 (SFTA2), mRNA.","NM_205854.2","NP_995326.1",389376,"Hs.211267","SFTPG","ENSG00000196260","Surfactant associated 2","6","30931353-30955636","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Pancreatic cancer:1.26e-4 (unfavourable)","Tissue enhanced","Tissue enriched",10,"lung: 53.8","esophagus: 5.2","Group enriched",5,"CACO-2: 7.9;CAPAN-2: 4.5"
"SFTPB",41,"A8","IOH21829",1146,"0",NA,"surfactant protein B (SFTPB), transcript variant 1, mRNA.","NM_000542.2","NP_000533.2",6439,"Hs.512690","SFTP3, SP-B","ENSG00000168878","Surfactant protein B","2","85657314-85668741","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB002440, HPA034820, HPA062148","Enhanced",NA,NA,NA,"Endometrial cancer:1.71e-6 (unfavourable), Renal cancer:2.99e-6 (unfavourable)","Group enriched","Tissue enriched",912,"lung: 5318.7","adrenal gland: 5.8","Cell line enhanced",NA,"BEWO: 2.8;U-2197: 6.3"
"SFTPD",51,"E8","IOH13776",1128,"0",NA,"surfactant protein D, mRNA (cDNA clone MGC:22626 IMAGE:4696173), complete cds","BC022318.1","AAH22318.1",6441,"Hs.253495","COLEC7, SFTP4, SP-D","ENSG00000133661","Surfactant protein D","10","79937740-79982614","Predicted secreted proteins","Evidence at protein level","CAB004578, HPA044582, HPA056768","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",56,"lung: 782.5","bone marrow: 13.8","Cell line enhanced",NA,"BEWO: 1.3;hTCEpi: 2.3;MCF7: 1.1"
"SGCA",9,"H4","IOH10645",1164,"NP_000014.1","NP_000014.1","sarcoglycan, alpha (50kDa dystrophin-associated glycoprotein) (SGCA), transcript variant 1, mRNA.","NM_000023.2","NP_000014.1",6442,"Hs.463412","A2, adhalin, ADL, DMDA2, LGMD2D, SCARMD1","ENSG00000108823","Sarcoglycan alpha","17","50164214-50175931","Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA007537","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"heart muscle: 79.5;skeletal muscle: 181.4","seminal vesicle: 38.3","Cell line enriched",13,"LHCN-M2: 65.0"
"SGSH",78,"F5","IOH26596",1509,"0",NA,"N-sulfoglucosamine sulfohydrolase (SGSH), mRNA.","NM_000199.3","NP_000190.1",6448,"Hs.31074","HSS, MPS3A, SFMD","ENSG00000181523","N-sulfoglucosamine sulfohydrolase","17","80206716-80220923","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA023436, HPA023451","Enhanced",NA,NA,NA,"Renal cancer:2.66e-4 (unfavourable), Lung cancer:2.72e-4 (favourable), Pancreatic cancer:3.10e-4 (favourable), Testis cancer:5.37e-4 (unfavourable), Liver cancer:7.71e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"adrenal gland: 36.3","Mixed",NA,NA
"SH2B1",13,"H4","IOH9730",1281,"0",NA,"SH2B adaptor protein 1, mRNA (cDNA clone MGC:16976 IMAGE:3866324), complete cds","BC010704.1","AAH10704.1",25970,"Hs.15744","FLJ30542, SH2B","ENSG00000178188","SH2B adaptor protein 1","16","28846600-28874212","Predicted intracellular proteins","Evidence at protein level","HPA076175",NA,NA,"Approved","Vesicles","Renal cancer:2.81e-6 (favourable), Urothelial cancer:1.60e-4 (favourable), Pancreatic cancer:4.38e-4 (favourable), Lung cancer:9.40e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 105.8","Expressed in all",NA,NA
"SHKBP1",18,"H10","IOH13855",2124,"0",NA,"SH3KBP1 binding protein 1, mRNA (cDNA clone MGC:22658 IMAGE:4102901), complete cds","BC022855.1","AAH22855.1",92799,"Hs.26506","PP203, Sb1","ENSG00000160410","SH3KBP1 binding protein 1","19","40576851-40591399","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA041887","Uncertain",NA,"Approved","Cell Junctions",NA,"Expressed in all","Expressed in all",NA,NA,"spleen: 53.4","Expressed in all",NA,NA
"SIAE",111,"C6","IOH45697",1572,"0",NA,"sialic acid acetylesterase (SIAE), mRNA.","NM_170601.3","NP_733746.1",54414,"Hs.10056","CSE-C, LSE, MGC87009, YSG2","ENSG00000110013","Sialic acid acetylesterase","11","124633113-124695707","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA038052, HPA038053","Approved",NA,NA,NA,"Renal cancer:4.42e-11 (favourable), Endometrial cancer:4.66e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"rectum: 114.5","Mixed",NA,NA
"SIGLEC6",54,"A8","IOH27405",1314,"NP_001236.1","NP_942142.3","sialic acid binding Ig-like lectin 6 (SIGLEC6), transcript variant 2, mRNA.","NM_198845.3","NP_942142.3",946,"Hs.397255","CD327, CD33L, CD33L1, OB-BP1, SIGLEC-6","ENSG00000105492","Sialic acid binding Ig like lectin 6","19","51519525-51531856","CD markers, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA009084, HPA018198","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",25,"placenta: 147.9","lung: 6.0","Cell line enriched",7,"HMC-1: 401.5"
"SIGLEC7",34,"D3","IOH11617",1404,"NP_055200.1","NP_055200.1","sialic acid binding Ig-like lectin 7 (SIGLEC7), transcript variant 1, mRNA.","NM_014385.2","NP_055200.1",27036,"Hs.655393","CD328, p75/AIRM1, QA79, SIGLEC-7, SIGLEC19P, SIGLECP2","ENSG00000168995","Sialic acid binding Ig like lectin 7","19","51142299-51153526","CD markers, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"spleen: 21.0","appendix: 14.4","Group enriched",10,"Karpas-707: 39.7;RPMI-8226: 23.1;U-937: 27.4"
"SIGMAR1",36,"A9","IOH5170",672,"NP_671514.1","NP_005857.1","sigma non-opioid intracellular receptor 1 (SIGMAR1), transcript variant 1, mRNA.","NM_005866.2","NP_005857.1",10280,"Hs.522087","OPRS1, SR-BP1","ENSG00000147955","Sigma non-opioid intracellular receptor 1","9","34634722-34637809","Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","CAB013470, HPA018002, HPA024071","Approved",NA,NA,NA,"Urothelial cancer:3.42e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"liver: 67.8","Expressed in all",NA,NA
"SIL1",8,"B10","IOH13140",1386,"0",NA,"SIL1 homolog, endoplasmic reticulum chaperone (S. cerevisiae) (SIL1), transcript variant 2, mRNA.","NM_022464.4","NP_071909.1",64374,"Hs.483521","BAP, MSS, ULG5","ENSG00000120725","SIL1 nucleotide exchange factor","5","138946720-139293557","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA011949","Enhanced",NA,NA,NA,"Glioma:3.77e-4 (unfavourable), Endometrial cancer:4.34e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 60.1","Expressed in all",NA,NA
"SIRPB1",49,"A3","IOH13178",546,"NP_006056.1","AAH75835.1","signal-regulatory protein beta 1, mRNA (cDNA clone IMAGE:5483064), complete cds.","BC075835.1","AAH75835.1",10326,"Hs.709487","CD172b, SIRP-BETA-1","ENSG00000101307","Signal regulatory protein beta 1","20","1563521-1620061","CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA047463","Uncertain",NA,"Uncertain","Vesicles",NA,"Mixed","Tissue enhanced",NA,"appendix: 38.7;bone marrow: 33.7","lung: 28.0","Cell line enhanced",NA,"HMC-1: 46.6;NB-4: 46.7;THP-1: 38.2"
"SIRPD",52,"H7","IOH27384",594,"0",NA,"signal-regulatory protein delta (SIRPD), mRNA.","NM_178460.1","NP_848555.1",128646,"Hs.664861","dJ576H24.4, PTPNS1L2","ENSG00000125900","Signal regulatory protein delta","20","1534251-1558843","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA042663","Enhanced",NA,NA,NA,NA,"Not detected","Tissue enriched",18,"testis: 72.6","appendix: 3.9","Cell line enhanced",NA,"HL-60: 1.1;HMC-1: 1.5;NB-4: 1.5;THP-1: 3.5"
"SIRT3",65,"H9","IOH3763",1200,"0",NA,"sirtuin (silent mating type information regulation 2 homolog) 3 (S. cerevisiae) (SIRT3), transcript variant 1, mRNA.","NM_012239.5","NP_036371.1",23410,"Hs.716456","SIR2L3","ENSG00000142082","Sirtuin 3","11","215458-236931","Predicted intracellular proteins","Evidence at protein level","HPA026809, CAB037142","Approved",NA,NA,NA,"Renal cancer:4.85e-9 (favourable), Endometrial cancer:8.51e-5 (favourable), Pancreatic cancer:4.45e-4 (favourable), Glioma:9.21e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 50.7","Expressed in all",NA,NA
"SIRT3",129,"E8","IOH53808",774,"0",NA,"sirtuin (silent mating type information regulation 2 homolog) 3 (S. cerevisiae) (SIRT3), transcript variant 2, mRNA.","NM_001017524.2","NP_001017524.1",23410,"Hs.716456","SIR2L3","ENSG00000142082","Sirtuin 3","11","215458-236931","Predicted intracellular proteins","Evidence at protein level","HPA026809, CAB037142","Approved",NA,NA,NA,"Renal cancer:4.85e-9 (favourable), Endometrial cancer:8.51e-5 (favourable), Pancreatic cancer:4.45e-4 (favourable), Glioma:9.21e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 50.7","Expressed in all",NA,NA
"SLAIN1",55,"C4","IOH25832",918,"0",NA,"SLAIN motif family, member 1 (SLAIN1), transcript variant 2, mRNA.","NM_144595.3","NP_653196.1",122060,"Hs.349955","C13orf32, FLJ30046","ENSG00000139737","SLAIN motif family member 1","13","77697854-77764242","Predicted intracellular proteins","Evidence at protein level","HPA040798",NA,NA,"Approved","Nucleoplasm<br>Intermediate filaments<br>Cytosol","Ovarian cancer:9.07e-4 (favourable)","Tissue enhanced","Expressed in all",NA,NA,"cerebral cortex: 217.1","Cell line enhanced",NA,"HL-60: 61.7;MOLT-4: 72.0;SCLC-21H: 69.0"
"SLAMF1",15,"F12","IOH14457",435,"NP_003028.1","AAH12602.1","signaling lymphocytic activation molecule family member 1, mRNA (cDNA clone IMAGE:4296969), complete cds.","BC012602.1","AAH12602.1",6504,"Hs.523660","CD150, SLAM","ENSG00000117090","Signaling lymphocytic activation molecule family member 1","1","160608100-160647295","CD markers, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB002438, HPA069319","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"appendix: 15.4;lymph node: 21.1;tonsil: 14.3","spleen: 7.9","Cell line enriched",134,"HDLM-2: 142.1"
"SLAMF1",133,"E6","IOH46363",1008,"0",NA,"signaling lymphocytic activation molecule family member 1 (SLAMF1), mRNA.","NM_003037.2","NP_003028.1",6504,"Hs.523660","CD150, SLAM","ENSG00000117090","Signaling lymphocytic activation molecule family member 1","1","160608100-160647295","CD markers, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB002438, HPA069319","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"appendix: 15.4;lymph node: 21.1;tonsil: 14.3","spleen: 7.9","Cell line enriched",134,"HDLM-2: 142.1"
"SLAMF7",133,"F6","IOH46364",1008,"0",NA,"SLAM family member 7 (SLAMF7), mRNA.","NM_021181.3","NP_067004.3",57823,"Hs.517265","19A, CD319, CRACC, CS1","ENSG00000026751","SLAM family member 7","1","160739057-160754821","CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB015445, HPA055945, HPA061654","Enhanced",NA,"Approved","Vesicles","Renal cancer:8.57e-5 (unfavourable), Ovarian cancer:3.93e-4 (favourable)","Mixed","Mixed",NA,NA,"spleen: 58.3","Group enriched",7,"SK-MEL-30: 45.6;U-266/70: 216.2"
"SLAMF7",17,"D9","IOH11890",891,"NP_067004.3","AAH27867.1","SLAM family member 7, mRNA (cDNA clone MGC:34188 IMAGE:5203638), complete cds","BC027867.1","AAH27867.1",57823,"Hs.517265","19A, CD319, CRACC, CS1","ENSG00000026751","SLAM family member 7","1","160739057-160754821","CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB015445, HPA055945, HPA061654","Enhanced",NA,"Approved","Vesicles","Renal cancer:8.57e-5 (unfavourable), Ovarian cancer:3.93e-4 (favourable)","Mixed","Mixed",NA,NA,"spleen: 58.3","Group enriched",7,"SK-MEL-30: 45.6;U-266/70: 216.2"
"SLC10A3",25,"G8","IOH4560",1347,"NP_062822.1","NP_001135863.1","solute carrier family 10 (sodium/bile acid cotransporter family), member 3 (SLC10A3), transcript variant 2, mRNA.","NM_001142391.1","NP_001135863.1",8273,"Hs.522826","DXS253E, P3","ENSG00000126903","Solute carrier family 10 member 3","X","154487306-154490690","Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA021656","Approved",NA,"Approved","Intermediate filaments","Colorectal cancer:4.15e-5 (unfavourable), Cervical cancer:4.53e-4 (favourable), Pancreatic cancer:7.22e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"gallbladder: 33.0","Expressed in all",NA,NA
"SLC10A3",130,"D10","IOH52023",1434,"0",NA,"solute carrier family 10 (sodium/bile acid cotransporter family), member 3 (SLC10A3), transcript variant 1, mRNA.","NM_019848.3","NP_062822.1",8273,"Hs.522826","DXS253E, P3","ENSG00000126903","Solute carrier family 10 member 3","X","154487306-154490690","Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA021656","Approved",NA,"Approved","Intermediate filaments","Colorectal cancer:4.15e-5 (unfavourable), Cervical cancer:4.53e-4 (favourable), Pancreatic cancer:7.22e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"gallbladder: 33.0","Expressed in all",NA,NA
"SLC25A14",130,"F3","IOH57470",978,"0",NA,"solute carrier family 25 (mitochondrial carrier, brain), member 14 (SLC25A14), nuclear gene encoding mitochondrial protein, transcript variant long, mRNA.","NM_003951.2","NP_003942.1",9016,"Hs.194686","BMCP1, UCP5","ENSG00000102078","Solute carrier family 25 member 14","X","130339888-130373361","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA060316",NA,NA,"Approved","Mitochondria","Renal cancer:5.52e-6 (unfavourable), Urothelial cancer:1.39e-5 (favourable), Cervical cancer:1.72e-5 (favourable), Pancreatic cancer:1.78e-4 (favourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 20.4","Expressed in all",NA,NA
"SLC25A25",106,"G11","IOH42062",1410,"0",NA,"solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 25 (SLC25A25), nuclear gene encoding mitochondrial protein, transcript variant 1, mRNA.","NM_052901.2","NP_443133.2",114789,"Hs.5476","KIAA1896, MCSC, PCSCL","ENSG00000148339","Solute carrier family 25 member 25","9","128068201-128109245","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA020381","Uncertain",NA,"Supported","Vesicles<br>Mitochondria","Renal cancer:4.65e-6 (favourable), Liver cancer:1.01e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"gallbladder: 62.9","Expressed in all",NA,NA
"SLC25A25",137,"D4","IOH52122",1512,"0",NA,"solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 25 (SLC25A25), nuclear gene encoding mitochondrial protein, transcript variant 2, mRNA.","NM_001006641.1","NP_001006642.1",114789,"Hs.5476","KIAA1896, MCSC, PCSCL","ENSG00000148339","Solute carrier family 25 member 25","9","128068201-128109245","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA020381","Uncertain",NA,"Supported","Vesicles<br>Mitochondria","Renal cancer:4.65e-6 (favourable), Liver cancer:1.01e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"gallbladder: 62.9","Expressed in all",NA,NA
"SLC35E3",94,"H8","IOH40620",942,"0",NA,"solute carrier family 35, member E3 (SLC35E3), mRNA.","NM_018656.2","NP_061126.2",55508,"Hs.506011","BLOV1","ENSG00000175782","Solute carrier family 35 member E3","12","68746106-68793964","Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at transcript level","HPA049403","Uncertain",NA,NA,NA,"Endometrial cancer:1.78e-4 (favourable)","Expressed in all","Mixed",NA,NA,"skin: 6.1","Mixed",NA,NA
"SLC39A10",114,"A5","IOH44839",2496,"XP_047707.1","NP_065075.1","solute carrier family 39 (zinc transporter), member 10 (SLC39A10), transcript variant 2, mRNA.","NM_020342.2","NP_065075.1",57181,"Hs.650158","DKFZp564L2123, FLJ90515, KIAA1265","ENSG00000196950","Solute carrier family 39 member 10","2","195575977-195737702","Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA036512, HPA036513, HPA066087","Approved",NA,"Approved","Nucleoplasm<br>Plasma membrane<br>Cytosol","Glioma:2.05e-5 (favourable), Liver cancer:4.39e-5 (unfavourable), Pancreatic cancer:3.23e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 77.7;thyroid gland: 79.2","prostate: 30.8","Expressed in all",NA,NA
"SLC39A11",67,"G8","IOH27584",1008,"NP_631916.1","AAH35631.1","solute carrier family 39 (metal ion transporter), member 11, mRNA (cDNA clone MGC:45399 IMAGE:5219031), complete cds","BC035631.1","AAH35631.1",201266,"Hs.221127","C17orf26","ENSG00000133195","Solute carrier family 39 member 11","17","72645949-73092712","Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA021455",NA,NA,"Approved","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"thyroid gland: 60.1","Expressed in all",NA,NA
"SLC39A14",52,"G11","IOH12201",1446,"XP_046677.3","AAH15770.1","solute carrier family 39 (zinc transporter), member 14, mRNA (cDNA clone MGC:23235 IMAGE:4865469), complete cds","BC015770.1","AAH15770.1",23516,"Hs.491232","KIAA0062, NET34, ZIP14","ENSG00000104635","Solute carrier family 39 member 14","8","22367249-22434129","Disease related genes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA016508","Approved",NA,"Approved","Endoplasmic reticulum<br>Golgi apparatus<br>Plasma membrane","Renal cancer:3.79e-7 (unfavourable), Colorectal cancer:5.00e-5 (favourable)","Expressed in all","Mixed",NA,NA,"liver: 203.0","Expressed in all",NA,NA
"SLC39A4",98,"F11","IOH39875",1944,"NP_570901.1","AAH62625.1","solute carrier family 39 (zinc transporter), member 4, mRNA (cDNA clone MGC:74741 IMAGE:5203858), complete cds","BC062625.1","AAH62625.1",55630,"Hs.521934","AEZ, AWMS2, ZIP4","ENSG00000147804","Solute carrier family 39 member 4","8","144409742-144416895","Disease related genes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:9.04e-4 (favourable)","Expressed in all","Group enriched",8,"duodenum: 134.2;small intestine: 95.7","kidney: 14.3","Group enriched",9,"CAPAN-2: 50.5;Hep G2: 102.1"
"SLC39A5",124,"B12","IOH11589",1620,"NP_775867.1","AAH27884.1","solute carrier family 39 (metal ion transporter), member 5, mRNA (cDNA clone MGC:34778 IMAGE:5221329), complete cds","BC027884.1","AAH27884.1",283375,"Hs.591018",NA,"ENSG00000139540","Solute carrier family 39 member 5","12","56230049-56237846","Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA018423",NA,NA,"Approved","Nucleoplasm<br>Vesicles<br>Cytosol","Renal cancer:5.05e-4 (favourable)","Tissue enhanced","Group enriched",12,"colon: 73.2;duodenum: 240.2;kidney: 115.0;liver: 86.0;pancreas: 53.1;rectum: 48.9;small intestine: 240.4","gallbladder: 10.0","Group enriched",62,"CACO-2: 33.1;Hep G2: 39.7"
"SLC3A1",84,"E10","IOH12262",2058,"0",NA,"solute carrier family 3 (cystine, dibasic and neutral amino acid transporters, activator of cystine, dibasic and neutral amino acid transport), member 1, mRNA (cDNA clone MGC:24059 IMAGE:4556946), complete cds","BC022386.1","AAH22386.1",6519,"Hs.112916","ATR1, CSNU1, D2H, NBAT, RBAT","ENSG00000138079","Solute carrier family 3 member 1","2","44275458-44321494","Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA038360, HPA071102","Enhanced",NA,"Approved","Nuclear bodies<br>Mitochondria","Renal cancer:3.67e-7 (favourable)","Tissue enriched","Tissue enhanced",NA,"kidney: 688.2","small intestine: 148.9","Cell line enriched",14,"RPTEC TERT1: 80.7"
"SLC3A1",150,"D3","IOH61960",2058,"0",NA,"solute carrier family 3 (cystine, dibasic and neutral amino acid transporters, activator of cystine, dibasic and neutral amino acid transport), member 1 (SLC3A1), mRNA.","NM_000341.3","NP_000332.2",6519,"Hs.112916","ATR1, CSNU1, D2H, NBAT, RBAT","ENSG00000138079","Solute carrier family 3 member 1","2","44275458-44321494","Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA038360, HPA071102","Enhanced",NA,"Approved","Nuclear bodies<br>Mitochondria","Renal cancer:3.67e-7 (favourable)","Tissue enriched","Tissue enhanced",NA,"kidney: 688.2","small intestine: 148.9","Cell line enriched",14,"RPTEC TERT1: 80.7"
"SLC6A16",127,"D9","IOH26822",1980,"0",NA,"solute carrier family 6, member 16, mRNA (cDNA clone MGC:26112 IMAGE:4821848), complete cds","BC034948.1","AAH34948.1",28968,"Hs.130949","NTT5","ENSG00000063127","Solute carrier family 6 member 16","19","49289638-49325225","Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA076812",NA,NA,"Supported","Golgi apparatus",NA,"Mixed","Tissue enriched",18,"testis: 162.8","lymph node: 8.8","Cell line enhanced",NA,"AF22: 18.0"
"SLC6A8",156,"H8","IOH61632",1908,"XP_047748.5","AAH81558.1","solute carrier family 6 (neurotransmitter transporter, creatine), member 8, mRNA (cDNA clone MGC:87396 IMAGE:4823748), complete cds","BC081558.1","AAH81558.1",6535,"Hs.540696","CRTR, CT1","ENSG00000130821","Solute carrier family 6 member 8","X","153688099-153696593","Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:1.53e-4 (unfavourable), Thyroid cancer:7.39e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"small intestine: 89.2","Mixed",NA,NA
"SLITRK3",102,"D12","IOH38551",2934,"NP_055741.1","NP_055741.2","SLIT and NTRK-like family, member 3 (SLITRK3), mRNA.","NM_014926.2","NP_055741.2",22865,"Hs.101745","KIAA0848","ENSG00000121871","SLIT and NTRK like family member 3","3","165186720-165197109","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA017636, HPA048042","Enhanced",NA,"Approved","Mitochondria",NA,"Tissue enriched","Tissue enhanced",NA,"cerebral cortex: 17.3;endometrium: 12.3","fallopian tube: 9.8","Cell line enhanced",NA,"AF22: 2.6;HAP1: 2.3;SCLC-21H: 1.7"
"SLURP1",93,"G12","IOH40403",312,"0",NA,"secreted LY6/PLAUR domain containing 1 (SLURP1), mRNA.","NM_020427.2","NP_065160.1",57152,"Hs.103505","ANUP, ARS, ArsB, LY6LS, MDM","ENSG00000126233","Secreted LY6/PLAUR domain containing 1","8","142740944-142742411","Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA050967","Approved",NA,NA,NA,NA,"Tissue enhanced","Group enriched",33,"esophagus: 740.6;skin: 297.1","tonsil: 15.7","Cell line enhanced",NA,"HaCaT: 1.1;MCF7: 1.1;T-47d: 2.4"
"SMOC1",47,"A5","IOH14749",1308,"0",NA,"SPARC related modular calcium binding 1 (SMOC1), transcript variant 1, mRNA.","NM_001034852.1","NP_001030024.1",64093,"Hs.497349",NA,"ENSG00000198732","SPARC related modular calcium binding 1","14","69854131-70032366","Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA004153, CAB034427","Approved",NA,"Approved","Plasma membrane",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 135.8","prostate: 66.2","Cell line enhanced",NA,"AF22: 61.2;HeLa: 115.9;SiHa: 108.4;U-266/70: 48.2;U-87 MG: 61.4"
"SMOC1",127,"E12","IOH3293",1305,"0",NA,"SPARC related modular calcium binding 1 (SMOC1), transcript variant 2, mRNA.","NM_022137.4","NP_071420.1",64093,"Hs.497349",NA,"ENSG00000198732","SPARC related modular calcium binding 1","14","69854131-70032366","Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA004153, CAB034427","Approved",NA,"Approved","Plasma membrane",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 135.8","prostate: 66.2","Cell line enhanced",NA,"AF22: 61.2;HeLa: 115.9;SiHa: 108.4;U-266/70: 48.2;U-87 MG: 61.4"
"SMOC2",57,"B2","IOH26438",1341,"0",NA,"SPARC related modular calcium binding 2, mRNA (cDNA clone MGC:48409 IMAGE:4826950), complete cds","BC047583.1","AAH47583.1",64094,"Hs.487200","SMAP2","ENSG00000112562","SPARC related modular calcium binding 2","6","168441151-168673445","Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB033979","Uncertain",NA,NA,NA,"Renal cancer:1.16e-6 (unfavourable)","Expressed in all","Mixed",NA,NA,"endometrium: 183.6","Cell line enhanced",NA,"AF22: 8.0;EFO-21: 2.6;RPMI-8226: 7.7;RPTEC TERT1: 2.8"
"SMOC2",149,"F8","IOH62103",1341,"0",NA,"SPARC related modular calcium binding 2, mRNA (cDNA clone MGC:33625 IMAGE:4826774), complete cds","BC028420.1","AAH28420.1",64094,"Hs.487200","SMAP2","ENSG00000112562","SPARC related modular calcium binding 2","6","168441151-168673445","Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB033979","Uncertain",NA,NA,NA,"Renal cancer:1.16e-6 (unfavourable)","Expressed in all","Mixed",NA,NA,"endometrium: 183.6","Cell line enhanced",NA,"AF22: 8.0;EFO-21: 2.6;RPMI-8226: 7.7;RPTEC TERT1: 2.8"
"SMPDL3A",129,"B2","IOH45778",1362,"0",NA,"sphingomyelin phosphodiesterase, acid-like 3A (SMPDL3A), mRNA.","NM_006714.3","NP_006705.1",10924,"Hs.486357","ASM3A, ASML3a, FLJ20177, yR36GH4.1","ENSG00000172594","Sphingomyelin phosphodiesterase acid like 3A","6","122789049-122809720","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA030148","Uncertain",NA,"Approved","Nucleus<br>Nucleoli<br>Mitochondria","Colorectal cancer:6.11e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"small intestine: 81.9","Mixed",NA,NA
"SMPDL3B",51,"D8","IOH13402",1122,"0",NA,"sphingomyelin phosphodiesterase, acid-like 3B (SMPDL3B), transcript variant 2, mRNA.","NM_001009568.1","NP_001009568.1",27293,"Hs.123659","ASML3B","ENSG00000130768","Sphingomyelin phosphodiesterase acid like 3B","1","27934993-27959157","Predicted secreted proteins","Evidence at protein level","HPA030561",NA,NA,"Approved","Golgi apparatus<br>Cytosol",NA,"Mixed","Mixed",NA,NA,"rectum: 25.6","Cell line enhanced",NA,"BEWO: 44.0;CAPAN-2: 31.4;SK-BR-3: 34.4;T-47d: 31.2"
"SMR3A",138,"H10","IOH58764",405,"0",NA,"submaxillary gland androgen regulated protein 3A (SMR3A), mRNA.","NM_012390.3","NP_036522.3",26952,"Hs.701334","PBI, PRL5, PROL5","ENSG00000109208","Submaxillary gland androgen regulated protein 3A","4","70360761-70367158","Predicted secreted proteins","Evidence at protein level","HPA044567","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",24,"salivary gland: 24.1","thyroid gland: 0.9","Not detected",NA,NA
"SMR3B",9,"C10","IOH11229",240,"0",NA,"submaxillary gland androgen regulated protein 3B (SMR3B), mRNA.","NM_006685.3","NP_006676.1",10879,"Hs.650650","P-B, PRL3, PROL3","ENSG00000171201","Submaxillary gland androgen regulated protein 3B","4","70370093-70390244","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enriched","Tissue enriched",1608,"salivary gland: 85397.1","ovary: 53.0","Cell line enriched",34,"EFO-21: 3.9"
"SMR3B",157,"B7","IOH63173",321,"0",NA,"submaxillary gland androgen regulated protein 3B, mRNA (cDNA clone MGC:104379 IMAGE:30350039), complete cds","BC094707.1","AAH94707.1",10879,"Hs.650650","P-B, PRL3, PROL3","ENSG00000171201","Submaxillary gland androgen regulated protein 3B","4","70370093-70390244","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enriched","Tissue enriched",1608,"salivary gland: 85397.1","ovary: 53.0","Cell line enriched",34,"EFO-21: 3.9"
"SNED1",17,"B9","IOH11521",1803,"0",NA,"sushi, nidogen and EGF-like domains 1, mRNA (cDNA clone IMAGE:5201665), complete cds.","BC027939.1","AAH27939.1",25992,"Hs.471834","FLJ00133, Snep, SST3","ENSG00000162804","Sushi, nidogen and EGF like domains 1","2","240998838-241095568","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA036414, HPA036415","Uncertain",NA,NA,NA,NA,"Mixed","Mixed",NA,NA,"endometrium: 29.8","Cell line enhanced",NA,"ASC TERT1: 290.9;HSkMC: 154.1"
"SNX14",113,"H5","IOH45873",2682,"0",NA,"sorting nexin 14 (SNX14), transcript variant 2, mRNA.","NM_020468.3","NP_065201.1",57231,"Hs.485871","RGS-PX2","ENSG00000135317","Sorting nexin 14","6","85505496-85594156","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA017639","Approved",NA,"Supported","Cytosol","Head and neck cancer:2.78e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 156.6","Expressed in all",NA,NA
"SNX14",155,"B9","IOH62627",2841,"0",NA,"sorting nexin 14, mRNA (cDNA clone MGC:110946 IMAGE:5268442), complete cds","BC095419.1","AAH95419.1",57231,"Hs.485871","RGS-PX2","ENSG00000135317","Sorting nexin 14","6","85505496-85594156","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA017639","Approved",NA,"Supported","Cytosol","Head and neck cancer:2.78e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 156.6","Expressed in all",NA,NA
"SOSTDC1",20,"H10","IOH7434",621,"0",NA,"sclerostin domain containing 1 (SOSTDC1), mRNA.","NM_015464.2","NP_056279.1",25928,"Hs.648106","DAND7, DKFZp564D206, USAG1","ENSG00000171243","Sclerostin domain containing 1","7","16461481-16530580","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:3.22e-5 (favourable), Ovarian cancer:8.69e-4 (favourable), Urothelial cancer:8.72e-4 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"lung: 57.1;stomach: 53.4","kidney: 23.0","Cell line enhanced",NA,"AF22: 8.0;EFO-21: 11.2;NTERA-2: 4.7;RPTEC TERT1: 16.9"
"SPACA3",106,"G8","IOH42995",648,"0",NA,"sperm acrosome associated 3 (SPACA3), mRNA.","NM_173847.3","NP_776246.1",124912,"Hs.434112","ALLP17, CT54, LYC3, LYZL3, SLLP1","ENSG00000141316","Sperm acrosome associated 3","17","32970376-32997877","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA023633","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",17,"testis: 77.5","pancreas: 4.5","Cell line enriched",17,"U-266/70: 72.1"
"SPACA4",58,"G10","IOH26564",375,"0",NA,"sperm acrosome associated 4 (SPACA4), mRNA.","NM_133498.2","NP_598005.1",171169,"Hs.122599","SAMP14","ENSG00000177202","Sperm acrosome associated 4","19","48606743-48607714","Predicted secreted proteins","Evidence at protein level","HPA041927, HPA061302","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enriched",18,"testis: 64.9","stomach: 3.5","Not detected",NA,NA
"SPAG11B",138,"H2","IOH58592",312,"0",NA,"sperm associated antigen 11B (SPAG11B), transcript variant A, mRNA.","NM_016512.3","NP_057596.1",10407,"Hs.2717","EDDM2B, EP2, EP2C, EP2D, HE2","ENSG00000164871","Sperm associated antigen 11B","8","7442684-7463674","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA023842","Supported",NA,NA,NA,NA,"Not detected","Tissue enriched",5739,"epididymis: 6744.6","seminal vesicle: 1.1","Group enriched",7,"BEWO: 3.9;NB-4: 5.5;RPMI-8226: 2.2;SH-SY5Y: 3.8"
"SPAG11B",120,"B5","IOH50141",249,"0",NA,"sperm associated antigen 11B (SPAG11B), transcript variant H, mRNA.","NM_058202.2","NP_478109.1",10407,"Hs.2717","EDDM2B, EP2, EP2C, EP2D, HE2","ENSG00000164871","Sperm associated antigen 11B","8","7442684-7463674","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA023842","Supported",NA,NA,NA,NA,"Not detected","Tissue enriched",5739,"epididymis: 6744.6","seminal vesicle: 1.1","Group enriched",7,"BEWO: 3.9;NB-4: 5.5;RPMI-8226: 2.2;SH-SY5Y: 3.8"
"SPARC",21,"G8","IOH5095",912,"0",NA,"secreted protein, acidic, cysteine-rich (osteonectin) (SPARC), mRNA.","NM_003118.2","NP_003109.1",6678,"Hs.111779","ON","ENSG00000113140","Secreted protein acidic and cysteine rich","5","151661096-151687165","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB002306, HPA002989, HPA003020","Supported",NA,NA,NA,"Renal cancer:3.53e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 3240.9","Cell line enhanced",NA,"ASC diff: 3432.3;BJ: 3597.1;fHDF/TERT166: 5254.9;WM-115: 4850.9"
"SPARCL1",47,"C7","IOH21780",1995,"0",NA,"SPARC-like 1 (hevin), mRNA (cDNA clone MGC:45264 IMAGE:4939390), complete cds","BC033721.1","AAH33721.1",8404,"Hs.62886","MAST9","ENSG00000152583","SPARC like 1","4","87473335-87531061","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB026225","Enhanced",NA,NA,NA,"Urothelial cancer:3.33e-4 (unfavourable), Colorectal cancer:4.06e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 2035.8","Cell line enhanced",NA,"AF22: 23.6;U-266/70: 7.1"
"SPATA20",158,"B2","IOH61598",2229,"0",NA,"spermatogenesis associated 20, mRNA (cDNA clone MGC:70686 IMAGE:6149633), complete cds","BC065526.1","AAH65526.1",64847,"Hs.103147","FLJ21347, SSP411, Tisp78","ENSG00000006282","Spermatogenesis associated 20","17","50543058-50555852","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA022023, HPA027144, HPA031442","Enhanced",NA,"Approved","Nucleoplasm","Urothelial cancer:9.69e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 97.7","Mixed",NA,NA
"SPATA20",122,"F4","IOH12469",2409,"0",NA,"spermatogenesis associated 20 (SPATA20), mRNA.","NM_022827.2","NP_073738.2",64847,"Hs.103147","FLJ21347, SSP411, Tisp78","ENSG00000006282","Spermatogenesis associated 20","17","50543058-50555852","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA022023, HPA027144, HPA031442","Enhanced",NA,"Approved","Nucleoplasm","Urothelial cancer:9.69e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 97.7","Mixed",NA,NA
"SPESP1",87,"H12","IOH12705",1053,"0",NA,"sperm equatorial segment protein 1 (SPESP1), mRNA.","NM_145658.2","NP_663633.1",246777,"Hs.657932","SP-ESP","ENSG00000258484","Sperm equatorial segment protein 1","15","68818221-68946811","Predicted secreted proteins","Evidence at protein level","HPA045936, HPA051040","Enhanced",NA,NA,NA,NA,"Expressed in all","Tissue enriched",7,"testis: 128.4","placenta: 18.0","Cell line enhanced",NA,"BJ hTERT+ SV40 Large T+: 16.1;BJ hTERT+ SV40 Large T+ RasG12V: 17.7;HBF TERT88: 20.5;RPTEC TERT1: 19.6;SCLC-21H: 23.0;WM-115: 30.5"
"SPINK1",76,"A1","IOH10627",240,"0",NA,"serine peptidase inhibitor, Kazal type 1 (SPINK1), mRNA.","NM_003122.3","NP_003113.2",6690,"Hs.407856","PCTT, PSTI, Spink3, TATI","ENSG00000164266","Serine peptidase inhibitor, Kazal type 1","5","147824568-147831786","Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB026366, HPA027498","Enhanced",NA,NA,NA,"Renal cancer:5.44e-7 (unfavourable), Urothelial cancer:2.15e-5 (favourable)","Tissue enhanced","Tissue enriched",8,"pancreas: 7127.3","stomach: 927.5","Group enriched",9,"CACO-2: 208.3;RT4: 548.2"
"SPINK2",136,"F5","IOH56004",255,"0",NA,"serine peptidase inhibitor, Kazal type 2 (acrosin-trypsin inhibitor) (SPINK2), mRNA.","NM_021114.2","NP_066937.1",6691,"Hs.98243","HUSI-II","ENSG00000128040","Serine peptidase inhibitor, Kazal type 2","4","56809860-56821742","Predicted secreted proteins","Evidence at protein level","CAB020824, HPA026813","Enhanced",NA,NA,NA,"Lung cancer:2.82e-4 (favourable)","Group enriched","Tissue enriched",15,"epididymis: 6416.1","testis: 428.6","Cell line enhanced",NA,"Daudi: 15.0;NB-4: 11.4;U-266/70: 67.9"
"SPINK6",38,"E12","IOH22182",243,"0",NA,"serine peptidase inhibitor, Kazal type 6, mRNA (cDNA clone MGC:21394 IMAGE:4754193), complete cds","BC032003.1","AAH32003.1",404203,"Hs.334274","BUSI2, MGC21394, UNQ844","ENSG00000178172","Serine peptidase inhibitor, Kazal type 6","5","148202794-148215137","Predicted secreted proteins","Evidence at protein level","HPA011039","Uncertain",NA,NA,NA,"Head and neck cancer:7.16e-4 (favourable)","Group enriched","Not detected",NA,NA,"epididymis: 0.9","Group enriched",73,"HeLa: 1936.6;SiHa: 1473.3"
"SPINK7",106,"F9","IOH43032",258,"0",NA,"serine peptidase inhibitor, Kazal type 7 (putative) (SPINK7), mRNA.","NM_032566.2","NP_115955.1",84651,"Hs.244569","ECG2, ECRG2","ENSG00000145879","Serine peptidase inhibitor, Kazal type 7 (putative)","5","148312419-148315922","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA036294","Enhanced",NA,NA,NA,NA,"Group enriched","Group enriched",25,"esophagus: 416.8;tonsil: 106.3","cervix, uterine: 10.5","Not detected",NA,NA
"SPINT1",121,"D12","IOH3790",1542,"NP_003701.1","NP_001027539.1","serine peptidase inhibitor, Kunitz type 1 (SPINT1), transcript variant 3, mRNA.","NM_001032367.1","NP_001027539.1",6692,"Hs.233950","HAI, MANSC2","ENSG00000166145","Serine peptidase inhibitor, Kunitz type 1","15","40844018-40858207","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA006903, HPA031178","Uncertain",NA,"Supported","Nucleoplasm<br>Plasma membrane<br>Cytosol","Renal cancer:1.37e-7 (favourable), Breast cancer:6.97e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"parathyroid gland: 217.3","Cell line enhanced",NA,"BEWO: 311.8;HaCaT: 333.0;RT4: 245.6;SK-BR-3: 418.2;T-47d: 251.3"
"SPINT2",132,"H9","IOH3792",759,"0",NA,"serine peptidase inhibitor, Kunitz type, 2 (SPINT2), mRNA.","NM_021102.2","NP_066925.1",10653,"Hs.31439","HAI-2, Kop","ENSG00000167642","Serine peptidase inhibitor, Kunitz type 2","19","38244035-38292614","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA011101, CAB018969","Approved",NA,"Uncertain","Plasma membrane<br>Intermediate filaments<br>Cytosol","Renal cancer:3.41e-4 (favourable)","Expressed in all","Mixed",NA,NA,"thyroid gland: 539.2","Cell line enhanced",NA,"A-431: 736.5;CAPAN-2: 1060.7"
"SPINT2",84,"B1","IOH10439",759,"NP_066925.1","AAH11951.1","serine peptidase inhibitor, Kunitz type, 2, mRNA (cDNA clone MGC:17171 IMAGE:3856970), complete cds","BC011951.1","AAH11951.1",10653,"Hs.31439","HAI-2, Kop","ENSG00000167642","Serine peptidase inhibitor, Kunitz type 2","19","38244035-38292614","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA011101, CAB018969","Approved",NA,"Uncertain","Plasma membrane<br>Intermediate filaments<br>Cytosol","Renal cancer:3.41e-4 (favourable)","Expressed in all","Mixed",NA,NA,"thyroid gland: 539.2","Cell line enhanced",NA,"A-431: 736.5;CAPAN-2: 1060.7"
"SPOCK1",54,"C8","IOH22248",1320,"0",NA,"sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 1, mRNA (cDNA clone MGC:26308 IMAGE:4821322), complete cds","BC030691.2","AAH30691.1",6695,"Hs.643338","SPOCK, testican-1, TIC1","ENSG00000152377","SPARC/osteonectin, cwcv and kazal like domains proteoglycan 1","5","136975298-137598379","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA007450, HPA026770","Uncertain",NA,"Approved","Vesicles","Head and neck cancer:1.93e-5 (unfavourable), Renal cancer:3.77e-5 (unfavourable), Colorectal cancer:1.93e-4 (unfavourable), Ovarian cancer:4.72e-4 (unfavourable), Lung cancer:9.08e-4 (unfavourable), Stomach cancer:9.40e-4 (unfavourable)","Tissue enriched","Tissue enhanced",NA,"cerebral cortex: 209.2","prostate: 108.0","Cell line enhanced",NA,"AF22: 299.3;ASC diff: 403.2;HUVEC TERT2: 508.1;U-138 MG: 298.1"
"SPOCK2",64,"H12","IOH27843",1275,"0",NA,"sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 2 (SPOCK2), transcript variant 2, mRNA.","NM_014767.2","NP_055582.1",9806,"Hs.523009","KIAA0275, testican-2","ENSG00000107742","SPARC/osteonectin, cwcv and kazal like domains proteoglycan 2","10","72059035-72089032","Predicted secreted proteins","Evidence at protein level","HPA044605","Supported",NA,"Uncertain","Nuclear speckles","Head and neck cancer:1.95e-5 (favourable), Breast cancer:4.05e-4 (favourable), Melanoma:4.72e-4 (favourable), Ovarian cancer:7.19e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 161.8;lung: 127.8","lymph node: 75.1","Group enriched",8,"Hep G2: 33.9;SCLC-21H: 79.9"
"SPOCK3",97,"B6","IOH3552",1302,"0",NA,"sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 3 (SPOCK3), transcript variant 1, mRNA.","NM_001040159.1","NP_001035249.1",50859,"Hs.481133","testican-3","ENSG00000196104","SPARC/osteonectin, cwcv and kazal like domains proteoglycan 3","4","166733384-167234796","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA075020",NA,NA,"Approved","Nucleus<br>Nucleoli<br>Golgi apparatus",NA,"Tissue enhanced","Tissue enriched",7,"parathyroid gland: 800.5","prostate: 120.0","Cell line enhanced",NA,"PC-3: 2.4;RH-30: 6.7;SCLC-21H: 3.5"
"SPON2",50,"C10","IOH5356",996,"0",NA,"spondin 2, extracellular matrix protein, mRNA (cDNA clone MGC:3472 IMAGE:3630467), complete cds","BC002707.2","AAH02707.1",10417,"Hs.302963","DIL1","ENSG00000159674","Spondin 2","4","1166932-1208962","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA040170, HPA066095","Uncertain",NA,"Approved","Vesicles","Endometrial cancer:2.03e-4 (favourable), Urothelial cancer:9.22e-4 (unfavourable)","Tissue enriched","Tissue enhanced",NA,"endometrium: 105.2;prostate: 113.0","cervix, uterine: 53.6","Group enriched",6,"HHSteC: 216.0;HSkMC: 330.1"
"SPP1",155,"E9","IOH62633",864,"0",NA,"secreted phosphoprotein 1 (SPP1), transcript variant 3, mRNA.","NM_001040060.1","NP_001035149.1",6696,"Hs.313","BNSP, BSPI, ETA-1, OPN","ENSG00000118785","Secreted phosphoprotein 1","4","87975650-87983426","Cancer-related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB002212, HPA027540, HPA027541","Enhanced",NA,"Supported","Golgi apparatus","Liver cancer:2.84e-6 (unfavourable), Pancreatic cancer:5.89e-4 (unfavourable), Cervical cancer:9.52e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"gallbladder: 3987.0;kidney: 2404.4;placenta: 4045.7","cerebral cortex: 795.2","Group enriched",6,"EFO-21: 4669.3;Hep G2: 1742.5;RPTEC TERT1: 8242.5"
"SPP1",43,"F12","IOH7288",903,"0",NA,"secreted phosphoprotein 1 (SPP1), transcript variant 2, mRNA.","NM_000582.2","NP_000573.1",6696,"Hs.313","BNSP, BSPI, ETA-1, OPN","ENSG00000118785","Secreted phosphoprotein 1","4","87975650-87983426","Cancer-related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB002212, HPA027540, HPA027541","Enhanced",NA,"Supported","Golgi apparatus","Liver cancer:2.84e-6 (unfavourable), Pancreatic cancer:5.89e-4 (unfavourable), Cervical cancer:9.52e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"gallbladder: 3987.0;kidney: 2404.4;placenta: 4045.7","cerebral cortex: 795.2","Group enriched",6,"EFO-21: 4669.3;Hep G2: 1742.5;RPTEC TERT1: 8242.5"
"SPP1",48,"D7","IOH13923",945,"0",NA,"secreted phosphoprotein 1 (SPP1), transcript variant 1, mRNA.","NM_001040058.1","NP_001035147.1",6696,"Hs.313","BNSP, BSPI, ETA-1, OPN","ENSG00000118785","Secreted phosphoprotein 1","4","87975650-87983426","Cancer-related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB002212, HPA027540, HPA027541","Enhanced",NA,"Supported","Golgi apparatus","Liver cancer:2.84e-6 (unfavourable), Pancreatic cancer:5.89e-4 (unfavourable), Cervical cancer:9.52e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"gallbladder: 3987.0;kidney: 2404.4;placenta: 4045.7","cerebral cortex: 795.2","Group enriched",6,"EFO-21: 4669.3;Hep G2: 1742.5;RPTEC TERT1: 8242.5"
"SRGN",32,"C11","IOH11800",477,"0",NA,"serglycin, mRNA (cDNA clone MGC:9289 IMAGE:3883161), complete cds","BC015516.1","AAH15516.1",5552,"Hs.1908","PPG, PRG, PRG1","ENSG00000122862","Serglycin","10","69088106-69104811","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA000759","Enhanced",NA,NA,NA,"Renal cancer:3.18e-5 (unfavourable)","Expressed in all","Group enriched",6,"appendix: 1121.8;bone marrow: 5139.0","gallbladder: 509.4","Cell line enhanced",NA,"HL-60: 3514.5;THP-1: 2938.4;TIME: 2120.9;U-937: 2758.4"
"SRGN",144,"B3","IOH54658",477,"0",NA,"serglycin (SRGN), mRNA.","NM_002727.2","NP_002718.2",5552,"Hs.1908","PPG, PRG, PRG1","ENSG00000122862","Serglycin","10","69088106-69104811","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA000759","Enhanced",NA,NA,NA,"Renal cancer:3.18e-5 (unfavourable)","Expressed in all","Group enriched",6,"appendix: 1121.8;bone marrow: 5139.0","gallbladder: 509.4","Cell line enhanced",NA,"HL-60: 3514.5;THP-1: 2938.4;TIME: 2120.9;U-937: 2758.4"
"SRPX",18,"G3","IOH13589",1395,"0",NA,"sushi-repeat-containing protein, X-linked (SRPX), mRNA.","NM_006307.3","NP_006298.1",8406,"Hs.15154","ETX1","ENSG00000101955","Sushi repeat containing protein, X-linked","X","38149336-38220924","Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:7.80e-13 (unfavourable), Endometrial cancer:1.18e-4 (unfavourable), Urothelial cancer:3.36e-4 (unfavourable)","Group enriched","Tissue enhanced",NA,"adipose tissue: 162.7","placenta: 122.1","Cell line enhanced",NA,"ASC diff: 2526.0;ASC TERT1: 571.9;HSkMC: 899.7;HUVEC TERT2: 659.1"
"SRPX2",7,"G10","IOH13021",1398,"0",NA,"sushi-repeat-containing protein, X-linked 2, mRNA (cDNA clone MGC:22551 IMAGE:4769946), complete cds","BC020733.1","AAH20733.1",27286,"Hs.306339","SRPUL","ENSG00000102359","Sushi repeat containing protein, X-linked 2","X","100644166-100675788","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA038786","Uncertain",NA,"Uncertain","Microtubules","Renal cancer:0.00e+0 (unfavourable)","Expressed in all","Mixed",NA,NA,"adipose tissue: 18.8","Cell line enhanced",NA,"ASC diff: 191.6;ASC TERT1: 83.0;HSkMC: 77.9;HUVEC TERT2: 65.3"
"SRPX2",130,"H12","IOH55311",1398,"0",NA,"sushi-repeat-containing protein, X-linked 2 (SRPX2), mRNA.","NM_014467.2","NP_055282.1",27286,"Hs.306339","SRPUL","ENSG00000102359","Sushi repeat containing protein, X-linked 2","X","100644166-100675788","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA038786","Uncertain",NA,"Uncertain","Microtubules","Renal cancer:0.00e+0 (unfavourable)","Expressed in all","Mixed",NA,NA,"adipose tissue: 18.8","Cell line enhanced",NA,"ASC diff: 191.6;ASC TERT1: 83.0;HSkMC: 77.9;HUVEC TERT2: 65.3"
"ST6GALNAC2",75,"D3","IOH27921",1125,"0",NA,"ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1, 3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 2 (ST6GALNAC2), mRNA.","NM_006456.2","NP_006447.2",10610,"Hs.592105","SIAT7, SIAT7B, SIATL1, ST6GalNAII, STHM","ENSG00000070731","ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 2","17","76565379-76586956","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA048849","Uncertain",NA,NA,NA,"Pancreatic cancer:6.48e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"fallopian tube: 68.6;skin: 50.8","testis: 38.9","Cell line enhanced",NA,"BEWO: 20.9;HaCaT: 23.9;hTCEpi: 48.8;MCF7: 20.9;SK-MEL-30: 70.3"
"ST8SIA2",153,"E11","IOH63213",1128,"0",NA,"ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2, mRNA (cDNA clone MGC:116854 IMAGE:40004644), complete cds","BC096202.3","AAH96202.1",8128,"Hs.302341","HsT19690, SIAT8B, ST8SIA-II, STX","ENSG00000140557","ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2","15","92393828-92468728","Predicted secreted proteins","Evidence at protein level","HPA054518","Approved",NA,"Approved","Microtubule organizing center",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 2.1;heart muscle: 2.4","cervix, uterine: 1.2","Cell line enhanced",NA,"AF22: 25.4;LHCN-M2: 6.4;RH-30: 11.3;RPMI-8226: 6.1;WM-115: 7.1"
"ST8SIA2",153,"H11","IOH63218",1065,"0",NA,"ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2, mRNA (cDNA clone MGC:116857 IMAGE:40004648), complete cds","BC096205.3","AAH96205.1",8128,"Hs.302341","HsT19690, SIAT8B, ST8SIA-II, STX","ENSG00000140557","ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2","15","92393828-92468728","Predicted secreted proteins","Evidence at protein level","HPA054518","Approved",NA,"Approved","Microtubule organizing center",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 2.1;heart muscle: 2.4","cervix, uterine: 1.2","Cell line enhanced",NA,"AF22: 25.4;LHCN-M2: 6.4;RH-30: 11.3;RPMI-8226: 6.1;WM-115: 7.1"
"ST8SIA4",112,"E7","IOH45486",507,"0",NA,"ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4 (ST8SIA4), transcript variant 2, mRNA.","NM_175052.1","NP_778222.1",7903,"Hs.308628","PST, PST1, SIAT8D","ENSG00000113532","ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4","5","100806935-100903266","Predicted secreted proteins","Evidence at protein level","HPA051126, HPA053995","Approved",NA,"Approved","Golgi apparatus","Renal cancer:7.80e-7 (unfavourable)","Expressed in all","Mixed",NA,NA,"appendix: 19.3","Cell line enhanced",NA,"AF22: 40.7;HDLM-2: 64.4;Karpas-707: 41.2;RPMI-8226: 30.6"
"ST8SIA4",45,"G10","IOH12025",507,"0",NA,"ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4, mRNA (cDNA clone IMAGE:5203343), complete cds.","BC027866.1","AAH27866.1",7903,"Hs.308628","PST, PST1, SIAT8D","ENSG00000113532","ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4","5","100806935-100903266","Predicted secreted proteins","Evidence at protein level","HPA051126, HPA053995","Approved",NA,"Approved","Golgi apparatus","Renal cancer:7.80e-7 (unfavourable)","Expressed in all","Mixed",NA,NA,"appendix: 19.3","Cell line enhanced",NA,"AF22: 40.7;HDLM-2: 64.4;Karpas-707: 41.2;RPMI-8226: 30.6"
"ST8SIA4",120,"C2","IOH28983",1080,"0",NA,"ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4 (ST8SIA4), transcript variant 1, mRNA.","NM_005668.4","NP_005659.1",7903,"Hs.308628","PST, PST1, SIAT8D","ENSG00000113532","ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4","5","100806935-100903266","Predicted secreted proteins","Evidence at protein level","HPA051126, HPA053995","Approved",NA,"Approved","Golgi apparatus","Renal cancer:7.80e-7 (unfavourable)","Expressed in all","Mixed",NA,NA,"appendix: 19.3","Cell line enhanced",NA,"AF22: 40.7;HDLM-2: 64.4;Karpas-707: 41.2;RPMI-8226: 30.6"
"STATH",120,"A3","IOH50084",159,"0",NA,"statherin (STATH), transcript variant 2, mRNA.","NM_001009181.1","NP_001009181.1",6779,"Hs.654495","STR","ENSG00000126549","Statherin","4","69995930-70002570","Plasma proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA044569","Enhanced",NA,NA,NA,NA,"Group enriched","Tissue enriched",1719,"salivary gland: 44726.6","ovary: 26.0","Not detected",NA,NA
"STATH",93,"G5","IOH40730",189,"0",NA,"statherin (STATH), transcript variant 1, mRNA.","NM_003154.2","NP_003145.1",6779,"Hs.654495","STR","ENSG00000126549","Statherin","4","69995930-70002570","Plasma proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA044569","Enhanced",NA,NA,NA,NA,"Group enriched","Tissue enriched",1719,"salivary gland: 44726.6","ovary: 26.0","Not detected",NA,NA
"STC2",22,"D6","IOH4289",909,"0",NA,"stanniocalcin 2 (STC2), mRNA.","NM_003714.2","NP_003705.1",8614,"Hs.233160","STC-2","ENSG00000113739","Stanniocalcin 2","5","173314713-173329503","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA045372","Uncertain",NA,"Approved","Endoplasmic reticulum","Renal cancer:4.17e-8 (unfavourable), Head and neck cancer:1.76e-6 (unfavourable), Liver cancer:3.07e-5 (unfavourable), Breast cancer:7.40e-5 (favourable), Stomach cancer:7.57e-4 (unfavourable)","Tissue enriched","Tissue enhanced",NA,"breast: 164.6","placenta: 33.2","Cell line enhanced",NA,"LHCN-M2: 707.5;T-47d: 753.9;U-138 MG: 321.3"
"STXBP2",92,"E6","IOH5705",1773,"0",NA,"syntaxin binding protein 2 (STXBP2), transcript variant 2, mRNA.","NM_001127396.1","NP_001120868.1",6813,"Hs.515104","Hunc18b, UNC18B","ENSG00000076944","Syntaxin binding protein 2","19","7636881-7647873","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA015564, HPA063868","Approved",NA,"Enhanced","Cytosol","Urothelial cancer:5.13e-6 (favourable), Endometrial cancer:2.29e-4 (favourable), Liver cancer:4.65e-4 (unfavourable), Thyroid cancer:7.68e-4 (favourable)","Expressed in all","Mixed",NA,NA,"bone marrow: 125.3","Mixed",NA,NA
"STXBP2",144,"E7","IOH52408",1782,"0",NA,"Syntaxin-binding protein 2.","Q15833","Q15833",6813,"Hs.515104","Hunc18b, UNC18B","ENSG00000076944","Syntaxin binding protein 2","19","7636881-7647873","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA015564, HPA063868","Approved",NA,"Enhanced","Cytosol","Urothelial cancer:5.13e-6 (favourable), Endometrial cancer:2.29e-4 (favourable), Liver cancer:4.65e-4 (unfavourable), Thyroid cancer:7.68e-4 (favourable)","Expressed in all","Mixed",NA,NA,"bone marrow: 125.3","Mixed",NA,NA
"SULF1",102,"C11","IOH38422",2616,"0",NA,"sulfatase 1 (SULF1), transcript variant 3, mRNA.","NM_015170.2","NP_055985.2",23213,"Hs.409602","hSulf-1, KIAA1077, SULF-1","ENSG00000137573","Sulfatase 1","8","69466624-69660915","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA054728","Supported",NA,NA,NA,"Renal cancer:1.06e-7 (unfavourable)","Expressed in all","Tissue enhanced",NA,"smooth muscle: 105.4","prostate: 85.8","Cell line enhanced",NA,"BJ: 265.6;BJ hTERT+: 341.5;fHDF/TERT166: 405.6;WM-115: 176.0"
"SULF2",142,"F2","IOH52912",2613,"0",NA,"sulfatase 2 (SULF2), transcript variant 1, mRNA.","NM_018837.3","NP_061325.1",55959,"Hs.162016","HSULF-2, KIAA1247, SULF-2","ENSG00000196562","Sulfatase 2","20","47656348-47786616","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA002325","Approved",NA,NA,NA,"Cervical cancer:6.43e-5 (unfavourable), Renal cancer:4.02e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"endometrium: 166.9","Cell line enhanced",NA,"EFO-21: 318.0;hTCEpi: 589.4;MCF7: 529.8"
"SULF2",11,"B12","IOH10372",450,"0",NA,"sulfatase 2, mRNA (cDNA clone IMAGE:3848759), complete cds.","BC020962.1","AAH20962.1",55959,"Hs.162016","HSULF-2, KIAA1247, SULF-2","ENSG00000196562","Sulfatase 2","20","47656348-47786616","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA002325","Approved",NA,NA,NA,"Cervical cancer:6.43e-5 (unfavourable), Renal cancer:4.02e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"endometrium: 166.9","Cell line enhanced",NA,"EFO-21: 318.0;hTCEpi: 589.4;MCF7: 529.8"
"SYCN",104,"E11","IOH43598",405,"0",NA,"syncollin (SYCN), mRNA.","NM_001080468.2","NP_001073937.1",342898,"Hs.124123","FLJ27441, INSSA1, SYL","ENSG00000179751","Syncollin","19","39202831-39204266","Predicted secreted proteins","Evidence at protein level","HPA047654","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",401,"pancreas: 6057.1","ovary: 15.0","Not detected",NA,NA
"TAC1",108,"H4","IOH44355",390,"0",NA,"tachykinin, precursor 1 (TAC1), transcript variant beta, mRNA.","NM_003182.2","NP_003173.1",6863,"Hs.2563","NKNA, NPK, TAC2","ENSG00000006128","Tachykinin precursor 1","7","97731908-97740472","Predicted secreted proteins","Evidence at protein level","CAB004588, HPA014429","Approved",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 77.7;spleen: 47.0","appendix: 13.2","Cell line enriched",14,"U-266/70: 16.5"
"TAC3",138,"G9","IOH58767",408,"0",NA,"Tachykinin-3 Precursor (ZNEUROK1) [Contains Neurokinin-B(NKB)(Neuromedin-K)] [Source:UniProtKB/Swiss-Prot;Acc:Q9UHF0]","ENST00000357616","ENSP00000350236",6866,"Hs.9730","NKB, NKNB, ZNEUROK1","ENSG00000166863","Tachykinin 3","12","57010000-57028883","Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA045919","Supported","Approved","Approved","Vesicles",NA,"Tissue enriched","Tissue enriched",23,"placenta: 617.0","cerebral cortex: 27.2","Cell line enhanced",NA,"K-562: 13.1;SCLC-21H: 2.7"
"TAC3",39,"A5","IOH23098",366,"0",NA,"tachykinin 3 (TAC3), mRNA.","NM_013251.2","NP_037383.1",6866,"Hs.9730","NKB, NKNB, ZNEUROK1","ENSG00000166863","Tachykinin 3","12","57010000-57028883","Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA045919","Supported","Approved","Approved","Vesicles",NA,"Tissue enriched","Tissue enriched",23,"placenta: 617.0","cerebral cortex: 27.2","Cell line enhanced",NA,"K-562: 13.1;SCLC-21H: 2.7"
"TAPBP",144,"H11","IOH59271",900,"0",NA,"TAP binding protein (tapasin) (TAPBP), transcript variant 2, mRNA.","NM_172208.1","NP_757345.1",6892,"Hs.714746","TAPA","ENSG00000231925","TAP binding protein","6","33299694-33314387","Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA007066","Approved",NA,NA,NA,"Breast cancer:2.76e-4 (favourable), Melanoma:6.29e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 30.7","Cell line enhanced",NA,"CAPAN-2: 67.6"
"TAPBP",145,"D9","IOH63130",1515,"0",NA,"TAP binding protein (tapasin), mRNA (cDNA clone MGC:99465 IMAGE:6572933), complete cds","BC080574.1","AAH80574.1",6892,"Hs.714746","TAPA","ENSG00000231925","TAP binding protein","6","33299694-33314387","Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA007066","Approved",NA,NA,NA,"Breast cancer:2.76e-4 (favourable), Melanoma:6.29e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 30.7","Cell line enhanced",NA,"CAPAN-2: 67.6"
"TAPBP",130,"E3","IOH57913",1347,"0",NA,"TAP binding protein (tapasin) (TAPBP), transcript variant 1, mRNA.","NM_003190.3","NP_003181.3",6892,"Hs.714746","TAPA","ENSG00000231925","TAP binding protein","6","33299694-33314387","Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA007066","Approved",NA,NA,NA,"Breast cancer:2.76e-4 (favourable), Melanoma:6.29e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 30.7","Cell line enhanced",NA,"CAPAN-2: 67.6"
"TAPBPL",12,"G10","IOH10097",1407,"NP_060479.1","AAH15017.1","TAP binding protein-like, mRNA (cDNA clone MGC:8836 IMAGE:3916213), complete cds","BC015017.2","AAH15017.1",55080,"Hs.504597","FLJ10143, TAPBP-R, TAPBPR","ENSG00000139192","TAP binding protein like","12","6451690-6466517","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA039545","Uncertain",NA,NA,NA,"Renal cancer:6.04e-5 (favourable), Breast cancer:1.98e-4 (favourable), Urothelial cancer:7.86e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 39.2","Cell line enhanced",NA,"CAPAN-2: 58.5"
"TBCA",45,"H2","IOH10504",327,"0",NA,"tubulin folding cofactor A (TBCA), mRNA.","NM_004607.2","NP_004598.1",6902,"Hs.291212",NA,"ENSG00000171530","Tubulin folding cofactor A","5","77691166-77868780","Predicted intracellular proteins","Evidence at protein level","HPA036487","Approved",NA,"Supported","Nucleoli<br>Microtubules",NA,"Expressed in all","Expressed in all",NA,NA,"adrenal gland: 305.8","Expressed in all",NA,NA
"TBL2",130,"D3","IOH57912",1344,"0",NA,"transducin (beta)-like 2 (TBL2), mRNA.","NM_012453.2","NP_036585.1",26608,"Hs.647044","DKFZP43N024, WBSCR13, WS-betaTRP","ENSG00000106638","Transducin beta like 2","7","73568932-73578791","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA007477, HPA051533",NA,NA,"Supported","Cytosol","Renal cancer:1.88e-5 (unfavourable), Head and neck cancer:4.93e-4 (unfavourable)","Expressed in all","Tissue enriched",6,"testis: 83.8","parathyroid gland: 13.0","Expressed in all",NA,NA
"TCF12",74,"G6","IOH26962",2121,"0",NA,"transcription factor 12 (TCF12), transcript variant 1, mRNA.","NM_207036.1","NP_996919.1",6938,"Hs.511504","bHLHb20, HEB, HsT17266, HTF4","ENSG00000140262","Transcription factor 12","15","56918623-57299281","Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors","Evidence at protein level","CAB004432, HPA065827","Approved",NA,"Supported","Nucleoplasm<br>Nuclear speckles","Renal cancer:5.24e-5 (unfavourable), Melanoma:8.89e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cervix, uterine: 116.2","Expressed in all",NA,NA
"TCN1",130,"F2","IOH57860",1302,"0",NA,"transcobalamin I (vitamin B12 binding protein, R binder family) (TCN1), mRNA.","NM_001062.3","NP_001053.2",6947,"Hs.2012","TC1, TCI","ENSG00000134827","Transcobalamin 1","11","59852800-59866575","Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:1.56e-8 (unfavourable), Breast cancer:1.90e-4 (favourable)","Tissue enhanced","Tissue enhanced",NA,"bone marrow: 123.8;gallbladder: 254.4;salivary gland: 315.5","stomach: 75.5","Cell line enhanced",NA,"CAPAN-2: 4.7;HaCaT: 4.6;PC-3: 6.4;SiHa: 7.7"
"TCN2",11,"G7","IOH10245",1203,"0",NA,"transcobalamin II; macrocytic anemia, mRNA (cDNA clone MGC:17407 IMAGE:4153362), complete cds","BC011239.1","AAH11239.1",6948,"Hs.417948","D22S676, D22S750, TC2","ENSG00000185339","Transcobalamin 2","22","30606838-30627278","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA000837",NA,NA,"Approved","Cytosol","Liver cancer:2.64e-4 (unfavourable), Cervical cancer:3.47e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"kidney: 122.6","Cell line enhanced",NA,"ASC TERT1: 84.6;HUVEC TERT2: 123.3;Karpas-707: 137.2"
"TCN2",131,"C4","IOH55245",1284,"0",NA,"transcobalamin II; macrocytic anemia (TCN2), mRNA.","NM_000355.2","NP_000346.2",6948,"Hs.417948","D22S676, D22S750, TC2","ENSG00000185339","Transcobalamin 2","22","30606838-30627278","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA000837",NA,NA,"Approved","Cytosol","Liver cancer:2.64e-4 (unfavourable), Cervical cancer:3.47e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"kidney: 122.6","Cell line enhanced",NA,"ASC TERT1: 84.6;HUVEC TERT2: 123.3;Karpas-707: 137.2"
"TCN2",25,"F3","IOH4409",1284,"0",NA,"transcobalamin II; macrocytic anemia, mRNA (cDNA clone MGC:2220 IMAGE:3353271), complete cds","BC001176.1","AAH01176.1",6948,"Hs.417948","D22S676, D22S750, TC2","ENSG00000185339","Transcobalamin 2","22","30606838-30627278","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA000837",NA,NA,"Approved","Cytosol","Liver cancer:2.64e-4 (unfavourable), Cervical cancer:3.47e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"kidney: 122.6","Cell line enhanced",NA,"ASC TERT1: 84.6;HUVEC TERT2: 123.3;Karpas-707: 137.2"
"TCTN1",57,"F8","IOH26277",1722,"0",NA,"tectonic family member 1 (TCTN1), transcript variant 3, mRNA.","NM_024549.4","NP_078825.2",79600,"Hs.211511","FLJ21127, JBTS13, TECT1","ENSG00000204852","Tectonic family member 1","12","110614027-110649430","Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA039687, HPA040036","Approved",NA,"Approved","Nucleoplasm<br>Actin filaments","Endometrial cancer:1.13e-5 (favourable)","Expressed in all","Mixed",NA,NA,"fallopian tube: 42.2","Mixed",NA,NA
"TCTN3",94,"B12","IOH40116",1824,"0",NA,"tectonic family member 3 (TCTN3), transcript variant 1, mRNA.","NM_015631.5","NP_056446.4",26123,"Hs.438991","C10orf61, DKFZP564D116, JBTS18, TECT3","ENSG00000119977","Tectonic family member 3","10","95663396-95694143","Disease related genes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA026987","Approved",NA,"Approved","Microtubules","Endometrial cancer:5.77e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 138.1","Expressed in all",NA,NA
"TEX101",24,"H8","IOH5206",750,"0",NA,"testis expressed 101 (TEX101), transcript variant 2, mRNA.","NM_001130011.1","NP_001123483.1",83639,"Hs.97978","CT131, MGC4766, SGRG, SPATA44","ENSG00000131126","Testis expressed 101","19","43401496-43418597","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA041915, HPA042513","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enriched",108,"testis: 173.9","skin: 1.6","Not detected",NA,NA
"TEX101",97,"B10","IOH40580",804,"0",NA,"testis expressed 101, mRNA (cDNA clone MGC:4766 IMAGE:3538494), complete cds","BC001861.2","AAH01861.2",83639,"Hs.97978","CT131, MGC4766, SGRG, SPATA44","ENSG00000131126","Testis expressed 101","19","43401496-43418597","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA041915, HPA042513","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enriched",108,"testis: 173.9","skin: 1.6","Not detected",NA,NA
"TEX2",72,"A12","IOH27477",3405,"0",NA,"testis expressed 2, mRNA (cDNA clone MGC:39510 IMAGE:4837394), complete cds","BC040521.1","AAH40521.1",55852,"Hs.175414","HT008, KIAA1738, TMEM96","ENSG00000136478","Testis expressed 2","17","64147227-64263301","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA020648, HPA057116","Approved",NA,"Approved","Nucleus","Colorectal cancer:3.90e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 99.6","Expressed in all",NA,NA
"TF",137,"E8","IOH55628",2097,"0",NA,"transferrin (TF), mRNA.","NM_001063.2","NP_001054.1",7018,"Hs.518267","PRO1557, PRO2086","ENSG00000091513","Transferrin","3","133745956-133779006","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA001527, HPA005692, CAB009538","Enhanced",NA,"Uncertain","Mitochondria","Renal cancer:2.35e-13 (unfavourable), Breast cancer:4.05e-4 (favourable)","Tissue enriched","Tissue enriched",14,"liver: 5391.9","cerebral cortex: 385.9","Cell line enriched",50,"Hep G2: 842.8"
"TF",69,"B4","IOH29256",2097,"0",NA,"transferrin, mRNA (cDNA clone MGC:71545 IMAGE:5264299), complete cds","BC059367.1","AAH59367.1",7018,"Hs.518267","PRO1557, PRO2086","ENSG00000091513","Transferrin","3","133745956-133779006","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA001527, HPA005692, CAB009538","Enhanced",NA,"Uncertain","Mitochondria","Renal cancer:2.35e-13 (unfavourable), Breast cancer:4.05e-4 (favourable)","Tissue enriched","Tissue enriched",14,"liver: 5391.9","cerebral cortex: 385.9","Cell line enriched",50,"Hep G2: 842.8"
"TFAM",107,"A2","IOH42148",741,"0",NA,"transcription factor A, mitochondrial (TFAM), nuclear gene encoding mitochondrial protein, mRNA.","NM_003201.1","NP_003192.1",7019,"Hs.642966","TCF6, TCF6L2","ENSG00000108064","Transcription factor A, mitochondrial","10","58385022-58399221","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors","Evidence at protein level","HPA040648, HPA063684","Supported",NA,"Enhanced","Mitochondria","Renal cancer:2.22e-5 (favourable), Ovarian cancer:2.74e-4 (favourable), Endometrial cancer:8.73e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 62.3","Expressed in all",NA,NA
"TFF1",39,"B1","IOH21839",255,"0",NA,"trefoil factor 1 (TFF1), mRNA.","NM_003225.2","NP_003216.1",7031,"Hs.162807","BCEI, D21S21, HP1.A, HPS2, pNR-2, pS2","ENSG00000160182","Trefoil factor 1","21","42362282-42366594","Cancer-related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB002170, HPA003425","Enhanced",NA,NA,NA,"Breast cancer:5.00e-4 (favourable), Endometrial cancer:5.67e-4 (favourable)","Group enriched","Tissue enriched",32,"stomach: 6419.9","gallbladder: 203.1","Cell line enriched",49,"MCF7: 8447.1"
"TFF2",39,"F6","IOH21844",390,"0",NA,"trefoil factor 2 (TFF2), mRNA.","NM_005423.4","NP_005414.1",7032,"Hs.2979","SML1","ENSG00000160181","Trefoil factor 2","21","42346357-42351128","Cancer-related genes, Predicted secreted proteins","Evidence at protein level","CAB025834, HPA036705","Enhanced",NA,NA,NA,"Liver cancer:1.99e-4 (unfavourable)","Group enriched","Group enriched",29,"duodenum: 1027.1;stomach: 5110.7","gallbladder: 107.1","Group enriched",20,"CAPAN-2: 32.8;PC-3: 124.0"
"TFF3",138,"C10","IOH58738",393,"0",NA,"trefoil factor 3 (intestinal) (TFF3), mRNA.","NM_003226.2","NP_003217.2",7033,"Hs.82961","HITF, ITF","ENSG00000160180","Trefoil factor 3","21","42311667-42315651","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB020681, HPA035464","Enhanced",NA,"Approved","Nucleus<br>Nucleoli","Endometrial cancer:5.60e-6 (favourable)","Expressed in all","Tissue enhanced",NA,"cervix, uterine: 470.7;colon: 496.2;rectum: 504.3;thyroid gland: 620.1","small intestine: 457.0","Cell line enhanced",NA,"MCF7: 63.2;SCLC-21H: 28.3;T-47d: 35.0;TIME: 85.5"
"TFF3",7,"H6","IOH13105",222,"0",NA,"trefoil factor 3 (intestinal), mRNA (cDNA clone MGC:22588 IMAGE:4696566), complete cds","BC017859.1","AAH17859.1",7033,"Hs.82961","HITF, ITF","ENSG00000160180","Trefoil factor 3","21","42311667-42315651","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB020681, HPA035464","Enhanced",NA,"Approved","Nucleus<br>Nucleoli","Endometrial cancer:5.60e-6 (favourable)","Expressed in all","Tissue enhanced",NA,"cervix, uterine: 470.7;colon: 496.2;rectum: 504.3;thyroid gland: 620.1","small intestine: 457.0","Cell line enhanced",NA,"MCF7: 63.2;SCLC-21H: 28.3;T-47d: 35.0;TIME: 85.5"
"TFPI",143,"C7","IOH59292",915,"0",NA,"tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) (TFPI), transcript variant 1, mRNA.","NM_006287.4","NP_006278.1",7035,"Hs.516578","EPI, LACI, TFI, TFPI1","ENSG00000003436","Tissue factor pathway inhibitor","2","187464230-187565760","Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA005575, CAB020842","Supported",NA,"Approved","Intermediate filaments<br>Cytosol","Cervical cancer:2.02e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 267.0","Cell line enhanced",NA,"HHSteC: 309.8;HUVEC TERT2: 601.4;LHCN-M2: 367.6;TIME: 354.9"
"TFPI",19,"E3","IOH11731",756,"0",NA,"tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) (TFPI), transcript variant 2, mRNA.","NM_001032281.2","NP_001027452.1",7035,"Hs.516578","EPI, LACI, TFI, TFPI1","ENSG00000003436","Tissue factor pathway inhibitor","2","187464230-187565760","Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA005575, CAB020842","Supported",NA,"Approved","Intermediate filaments<br>Cytosol","Cervical cancer:2.02e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 267.0","Cell line enhanced",NA,"HHSteC: 309.8;HUVEC TERT2: 601.4;LHCN-M2: 367.6;TIME: 354.9"
"TFPI2",89,"A11","IOH7275",708,"0",NA,"tissue factor pathway inhibitor 2 (TFPI2), mRNA.","NM_006528.2","NP_006519.1",7980,"Hs.438231","PP5, REF1, TFPI-2","ENSG00000105825","Tissue factor pathway inhibitor 2","7","93885397-93890991","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB010142, HPA049158","Enhanced",NA,NA,NA,"Breast cancer:8.33e-7 (favourable), Endometrial cancer:5.42e-4 (favourable), Renal cancer:8.53e-4 (unfavourable)","Expressed in all","Tissue enriched",23,"placenta: 1208.2","ovary: 52.0","Cell line enhanced",NA,"EFO-21: 1987.5;hTEC/SVTERT24-B: 1055.6;U-138 MG: 999.0;U-2197: 850.7;U-87 MG: 1680.0"
"TGFB1",92,"D9","IOH4479",1173,"0",NA,"transforming growth factor, beta 1, mRNA (cDNA clone MGC:2323 IMAGE:3356605), complete cds","BC001180.1","AAH01180.1",7040,"Hs.645227","CED, DPD1, TGFB, TGFbeta","ENSG00000105329","Transforming growth factor beta 1","19","41301587-41353911","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB000361, CAB073543","Approved",NA,"Uncertain","Cytosol","Renal cancer:1.19e-8 (unfavourable), Head and neck cancer:3.38e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 83.5","Mixed",NA,NA
"TGFB2",111,"G8","IOH42941",1245,"0",NA,"transforming growth factor, beta 2 (TGFB2), transcript variant 2, mRNA.","NM_003238.2","NP_003229.1",7042,"Hs.133379",NA,"ENSG00000092969","Transforming growth factor beta 2","1","218346235-218444619","Cancer-related genes, Disease related genes, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Expressed in all","Tissue enhanced",NA,"prostate: 30.4","placenta: 20.4","Cell line enhanced",NA,"EFO-21: 58.6;U-2 OS: 64.1"
"TGFBI",25,"B11","IOH5136",2052,"0",NA,"transforming growth factor, beta-induced, 68kDa (TGFBI), mRNA.","NM_000358.2","NP_000349.1",7045,"Hs.369397","BIGH3, CDB1, CDGG1, CSD1, CSD2, CSD3, LCD1","ENSG00000120708","Transforming growth factor beta induced","5","136028895-136063818","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA008612, HPA017019","Enhanced",NA,NA,NA,"Renal cancer:7.82e-10 (unfavourable), Cervical cancer:1.03e-5 (unfavourable), Ovarian cancer:1.14e-5 (unfavourable), Endometrial cancer:1.17e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 607.8","Cell line enhanced",NA,"fHDF/TERT166: 2100.5;HSkMC: 1955.4;U-87 MG: 3543.6"
"THBS1",113,"G10","IOH42568",3513,"0",NA,"thrombospondin 1 (THBS1), mRNA.","NM_003246.2","NP_003237.2",7057,"Hs.164226","THBS, THBS-1, TSP, TSP-1, TSP1","ENSG00000137801","Thrombospondin 1","15","39581079-39599466","Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB033678, HPA059756","Approved",NA,"Approved","Plasma membrane","Renal cancer:8.47e-5 (unfavourable), Stomach cancer:8.50e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"appendix: 573.9","Cell line enhanced",NA,"fHDF/TERT166: 2033.2;HUVEC TERT2: 2095.4;TIME: 3015.4"
"THBS4",68,"E1","IOH26721",2886,"0",NA,"thrombospondin 4 (THBS4), mRNA.","NM_003248.3","NP_003239.2",7060,"Hs.211426",NA,"ENSG00000113296","Thrombospondin 4","5","79991311-80083287","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB004597, HPA042426","Approved",NA,"Approved","Vesicles","Urothelial cancer:3.33e-4 (unfavourable)","Expressed in all","Group enriched",6,"adipose tissue: 234.3;heart muscle: 113.6;smooth muscle: 388.9","thyroid gland: 44.6","Cell line enhanced",NA,"AF22: 3.1;SCLC-21H: 2.9;THP-1: 4.7;U-2 OS: 3.0"
"THOC3",92,"B5","IOH3160",1056,"0",NA,"THO complex 3 (THOC3), mRNA.","NM_032361.2","NP_115737.1",84321,"Hs.484227","MGC5469, TEX1","ENSG00000051596","THO complex 3","5","175917873-176034680","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA042764, HPA044009, HPA045071","Approved",NA,"Enhanced","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"epididymis: 77.2","Expressed in all",NA,NA
"THOC3",156,"E11","IOH61690",984,"0",NA,"THO complex 3, mRNA (cDNA clone MGC:87234 IMAGE:5303134), complete cds","BC066325.1","AAH66325.1",84321,"Hs.484227","MGC5469, TEX1","ENSG00000051596","THO complex 3","5","175917873-176034680","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA042764, HPA044009, HPA045071","Approved",NA,"Enhanced","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"epididymis: 77.2","Expressed in all",NA,NA
"THPO",140,"H6","IOH53592",1050,"0",NA,"thrombopoietin, mRNA (cDNA clone MGC:163194 IMAGE:40146353), complete cds","BC130322.1","AAI30323.1",7066,"Hs.1166","MGDF, MPLLG, TPO","ENSG00000090534","Thrombopoietin","3","184371935-184378144","Cancer-related genes, Disease related genes, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:2.48e-6 (unfavourable)","Tissue enriched","Tissue enhanced",NA,"liver: 8.9","testis: 3.9","Cell line enhanced",NA,"CACO-2: 4.9;Hep G2: 10.6;K-562: 2.5;RPMI-8226: 2.8"
"TIMP1",26,"F12","IOH3196",624,"0",NA,"TIMP metallopeptidase inhibitor 1 (TIMP1), mRNA.","NM_003254.2","NP_003245.1",7076,"Hs.522632","CLGI, EPO, TIMP","ENSG00000102265","TIMP metallopeptidase inhibitor 1","X","47582313-47586789","Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB022360, HPA053417","Approved",NA,"Approved","Golgi apparatus","Renal cancer:2.90e-11 (unfavourable), Colorectal cancer:2.09e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"appendix: 2036.7","Expressed in all",NA,NA
"TIMP2",71,"A12","IOH29379",663,"0",NA,"TIMP metallopeptidase inhibitor 2 (TIMP2), mRNA.","NM_003255.4","NP_003246.1",7077,"Hs.633514","CSC-21K","ENSG00000035862","TIMP metallopeptidase inhibitor 2","17","78852977-78925387","Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB010203","Approved",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"ovary: 1178.9","Cell line enhanced",NA,"ASC TERT1: 1134.2"
"TIMP3",132,"F5","IOH29847",636,"0",NA,"TIMP metallopeptidase inhibitor 3 (TIMP3), mRNA.","NM_000362.4","NP_000353.1",7078,"Hs.644633","SFD","ENSG00000100234","TIMP metallopeptidase inhibitor 3","22","32801701-32863043","Cancer-related genes, Disease related genes, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Ovarian cancer:1.90e-5 (unfavourable), Renal cancer:1.50e-4 (favourable)","Mixed","Tissue enhanced",NA,"placenta: 1439.9","adipose tissue: 729.9","Cell line enhanced",NA,"BJ: 988.6;fHDF/TERT166: 830.6;WM-115: 879.2"
"TIMP4",36,"F9","IOH10243",675,"0",NA,"TIMP metallopeptidase inhibitor 4 (TIMP4), mRNA.","NM_003256.2","NP_003247.1",7079,"Hs.591665",NA,"ENSG00000157150","TIMP metallopeptidase inhibitor 4","3","12153051-12159351","Plasma proteins, Predicted secreted proteins","Evidence at transcript level",NA,NA,NA,NA,NA,NA,"Tissue enriched","Tissue enriched",5,"adipose tissue: 138.8","cerebral cortex: 27.5","Cell line enhanced",NA,"ASC diff: 99.5;HSkMC: 45.7;NTERA-2: 37.0;U-87 MG: 36.7"
"TINAGL1",95,"E11","IOH39923",1404,"0",NA,"tubulointerstitial nephritis antigen-like 1 (TINAGL1), mRNA.","NM_022164.2","NP_071447.1",64129,"Hs.199368","ARG1, LCN7, LIECG3, P3ECSL, TINAGRP","ENSG00000142910","Tubulointerstitial nephritis antigen like 1","1","31576485-31587686","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA048695","Approved",NA,NA,NA,"Renal cancer:3.65e-6 (favourable), Thyroid cancer:9.64e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"placenta: 268.9","adipose tissue: 102.6","Cell line enhanced",NA,"BEWO: 313.9;EFO-21: 383.9;TIME: 309.9"
"TINAGL1",5,"B6","IOH3342",657,"0",NA,"tubulointerstitial nephritis antigen-like 1, mRNA (cDNA clone IMAGE:3852606), complete cds.","BC009048.1","AAH09048.1",64129,"Hs.199368","ARG1, LCN7, LIECG3, P3ECSL, TINAGRP","ENSG00000142910","Tubulointerstitial nephritis antigen like 1","1","31576485-31587686","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA048695","Approved",NA,NA,NA,"Renal cancer:3.65e-6 (favourable), Thyroid cancer:9.64e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"placenta: 268.9","adipose tissue: 102.6","Cell line enhanced",NA,"BEWO: 313.9;EFO-21: 383.9;TIME: 309.9"
"TLR1",114,"H2","IOH42640",2361,"0",NA,"toll-like receptor 1 (TLR1), mRNA.","NM_003263.3","NP_003254.2",7096,"Hs.621817","CD281, KIAA0012, rsc786","ENSG00000174125","Toll like receptor 1","4","38790677-38856817","CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Expressed in all","Mixed",NA,NA,"appendix: 37.2","Cell line enhanced",NA,"Daudi: 8.0;HUVEC TERT2: 10.5;RPMI-8226: 9.8;U-698: 14.4"
"TLR1",154,"B10","IOH62701",2361,"0",NA,"toll-like receptor 1, mRNA (cDNA clone MGC:104956 IMAGE:3063206), complete cds","BC089403.1","AAH89403.1",7096,"Hs.621817","CD281, KIAA0012, rsc786","ENSG00000174125","Toll like receptor 1","4","38790677-38856817","CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Expressed in all","Mixed",NA,NA,"appendix: 37.2","Cell line enhanced",NA,"Daudi: 8.0;HUVEC TERT2: 10.5;RPMI-8226: 9.8;U-698: 14.4"
"TLR3",154,"G6","IOH62689",2715,"NP_003256.1","AAH94737.1","toll-like receptor 3, mRNA (cDNA clone MGC:104573 IMAGE:30531515), complete cds","BC094737.1","AAH94737.1",7098,"Hs.657724","CD283","ENSG00000164342","Toll like receptor 3","4","186069152-186088069","CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB025658","Enhanced",NA,NA,NA,"Pancreatic cancer:3.09e-4 (unfavourable)","Mixed","Mixed",NA,NA,"placenta: 24.5","Cell line enhanced",NA,"BJ hTERT+ SV40 Large T+ RasG12V: 29.4;CAPAN-2: 42.4"
"TM2D3",136,"H2","IOH57035",666,"NP_079417.1","AAH08873.1","TM2 domain containing 3, mRNA (cDNA clone MGC:14889 IMAGE:4137334), complete cds","BC008873.2","AAH08873.1",80213,"Hs.288912","BLP2, FLJ22604","ENSG00000184277","TM2 domain containing 3","15","101621444-101652391","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA054064","Uncertain",NA,"Approved","Nucleoplasm<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 97.2","Expressed in all",NA,NA
"TM9SF1",13,"E8","IOH9944",1821,"NP_006396.2","NP_006396.2","transmembrane 9 superfamily member 1 (TM9SF1), transcript variant 1, mRNA.","NM_006405.5","NP_006396.2",10548,"Hs.91586","HMP70, MP70","ENSG00000100926","Transmembrane 9 superfamily member 1","14","24189143-24195687","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA059249","Supported",NA,"Approved","Golgi apparatus","Lung cancer:2.04e-4 (unfavourable), Cervical cancer:8.94e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 73.0","Expressed in all",NA,NA
"TMED1",92,"B9","IOH4254",684,"NP_006849.1","NP_006849.1","transmembrane emp24 protein transport domain containing 1 (TMED1), mRNA.","NM_006858.2","NP_006849.1",11018,"Hs.515139","Il1rl1l, IL1RL1LG, MGC1270, p24g1, p24gamma1, ST2L","ENSG00000099203","Transmembrane p24 trafficking protein 1","19","10832438-10836318","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA018507","Uncertain",NA,NA,NA,"Renal cancer:8.66e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 47.6","Expressed in all",NA,NA
"TMED2",15,"D2","IOH14559",606,"NP_006806.1","NP_006806.1","transmembrane emp24 domain trafficking protein 2 (TMED2), mRNA.","NM_006815.3","NP_006806.1",10959,"Hs.75914","P24A, p24b1, p24beta1, RNP24","ENSG00000086598","Transmembrane p24 trafficking protein 2","12","123584531-123598577","Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA014060","Approved",NA,"Supported","Vesicles","Renal cancer:2.35e-7 (unfavourable), Head and neck cancer:3.36e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 328.1","Expressed in all",NA,NA
"TMED3",12,"D12","IOH10137",654,"0","NP_031390.1","transmembrane emp24 protein transport domain containing 3 (TMED3), mRNA.","NM_007364.2","NP_031390.1",23423,"Hs.513058","C15orf22, p24B, p24g4, p24gamma4","ENSG00000166557","Transmembrane p24 trafficking protein 3","15","79311062-79427432","Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA049314, HPA076949","Approved",NA,"Supported","Golgi apparatus","Renal cancer:3.73e-4 (unfavourable), Breast cancer:7.71e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"salivary gland: 163.2","Mixed",NA,NA
"TMED4",67,"A3","IOH28950",684,"XP_166556.1","NP_872353.2","transmembrane emp24 protein transport domain containing 4 (TMED4), mRNA.","NM_182547.2","NP_872353.2",222068,"Hs.598832","HNLF, p24a3, p24alpha3","ENSG00000158604","Transmembrane p24 trafficking protein 4","7","44577894-44582287","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA014650","Approved",NA,NA,NA,"Renal cancer:1.37e-4 (favourable), Endometrial cancer:7.37e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 190.7","Expressed in all",NA,NA
"TMED5",64,"B12","IOH27881",690,"0","AAH16365.1","transmembrane emp24 protein transport domain containing 5, mRNA (cDNA clone MGC:24580 IMAGE:4133205), complete cds","BC016365.1","AAH16365.1",50999,"Hs.482873","CGI-100, p24g2, p24gamma2","ENSG00000117500","Transmembrane p24 trafficking protein 5","1","93149742-93180728","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA050289","Approved",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"kidney: 28.2","Expressed in all",NA,NA
"TMED5",148,"D6","IOH62247",519,"0","AAH38511.1","transmembrane emp24 protein transport domain containing 5, mRNA (cDNA clone MGC:43175 IMAGE:5262507), complete cds","BC038511.1","AAH38511.1",50999,"Hs.482873","CGI-100, p24g2, p24gamma2","ENSG00000117500","Transmembrane p24 trafficking protein 5","1","93149742-93180728","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA050289","Approved",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"kidney: 28.2","Expressed in all",NA,NA
"TMED5",30,"H12","IOH11975",690,"NP_057124.2","NP_057124.2","transmembrane emp24 protein transport domain containing 5 (TMED5), mRNA.","NM_016040.3","NP_057124.2",50999,"Hs.482873","CGI-100, p24g2, p24gamma2","ENSG00000117500","Transmembrane p24 trafficking protein 5","1","93149742-93180728","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA050289","Approved",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"kidney: 28.2","Expressed in all",NA,NA
"TMED7",63,"D3","IOH13273",675,"XP_038077.1","NP_861974.1","transmembrane emp24 protein transport domain containing 7 (TMED7), mRNA.","NM_181836.4","NP_861974.1",51014,"Hs.642817","CGI-109, FLJ90481, p24g3, p24gamma3","ENSG00000134970","Transmembrane p24 trafficking protein 7","5","115613508-115632992","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA008960, CAB025883","Supported",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"thyroid gland: 138.8","Expressed in all",NA,NA
"TMEM108",121,"G12","IOH4185",1728,"XP_039805.6","NP_076432.1","transmembrane protein 108 (TMEM108), transcript variant 1, mRNA.","NM_023943.2","NP_076432.1",66000,"Hs.191616","CT124, MGC3040","ENSG00000144868","Transmembrane protein 108","3","133038391-133397792","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA063350","Uncertain",NA,"Approved","Nucleoli<br>Vesicles<br>Plasma membrane<br>Cytosol",NA,"Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 21.9;testis: 25.8","adrenal gland: 15.0","Cell line enhanced",NA,"HMC-1: 21.3;SCLC-21H: 24.8;SH-SY5Y: 98.2"
"TMEM205",44,"F5","IOH5958",570,"0","NP_940938.1","transmembrane protein 205 (TMEM205), transcript variant 1, mRNA.","NM_198536.2","NP_940938.1",374882,"Hs.8036","MBC3205, UNQ501","ENSG00000105518","Transmembrane protein 205","19","11342776-11346518","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA041504","Approved",NA,"Approved","Nucleoplasm<br>Nuclear membrane<br>Endoplasmic reticulum",NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 258.0","Expressed in all",NA,NA
"TMEM25",55,"B10","IOH27361",1101,"NP_116169.1","NP_116169.2","transmembrane protein 25 (TMEM25), transcript variant 1, mRNA.","NM_032780.3","NP_116169.2",84866,"Hs.564188","FLJ14399","ENSG00000149582","Transmembrane protein 25","11","118531041-118547280","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA012163, HPA051562","Approved",NA,"Approved","Golgi apparatus<br>Vesicles","Renal cancer:0.00e+0 (favourable)","Expressed in all","Expressed in all",NA,NA,"duodenum: 47.0","Cell line enhanced",NA,"T-47d: 41.7"
"TMEM25",65,"H12","IOH28892",969,"0","AAH51841.1","transmembrane protein 25, mRNA (cDNA clone MGC:60150 IMAGE:5725777), complete cds","BC051841.1","AAH51841.1",84866,"Hs.564188","FLJ14399","ENSG00000149582","Transmembrane protein 25","11","118531041-118547280","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA012163, HPA051562","Approved",NA,"Approved","Golgi apparatus<br>Vesicles","Renal cancer:0.00e+0 (favourable)","Expressed in all","Expressed in all",NA,NA,"duodenum: 47.0","Cell line enhanced",NA,"T-47d: 41.7"
"TMEM59",25,"A8","IOH4523",903,"0","AAH03106.1","transmembrane protein 59, mRNA (cDNA clone MGC:1961 IMAGE:3501639), complete cds","BC003106.1","AAH03106.1",9528,"Hs.523262","C1orf8, HSPC001","ENSG00000116209","Transmembrane protein 59","1","54026681-54053504","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"fallopian tube: 650.0","Expressed in all",NA,NA
"TMEM59",50,"C6","IOH23073",975,"0","AAH16374.1","transmembrane protein 59, mRNA (cDNA clone MGC:27259 IMAGE:4618034), complete cds","BC016374.1","AAH16374.1",9528,"Hs.523262","C1orf8, HSPC001","ENSG00000116209","Transmembrane protein 59","1","54026681-54053504","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"fallopian tube: 650.0","Expressed in all",NA,NA
"TMEM59",153,"H6","IOH62759",972,"0","AAH95464.1","transmembrane protein 59, mRNA (cDNA clone MGC:111362 IMAGE:30554552), complete cds","BC095464.1","AAH95464.1",9528,"Hs.523262","C1orf8, HSPC001","ENSG00000116209","Transmembrane protein 59","1","54026681-54053504","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"fallopian tube: 650.0","Expressed in all",NA,NA
"TMEM59",16,"E2","IOH14687",972,"NP_004863.2","NP_004863.2","transmembrane protein 59 (TMEM59), mRNA.","NM_004872.3","NP_004863.2",9528,"Hs.523262","C1orf8, HSPC001","ENSG00000116209","Transmembrane protein 59","1","54026681-54053504","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"fallopian tube: 650.0","Expressed in all",NA,NA
"TMEM87A",145,"F1","IOH62988",1485,"NP_056312.1","AAH69240.1","transmembrane protein 87A, mRNA (cDNA clone MGC:78494 IMAGE:4650822), complete cds","BC069240.1","AAH69240.1",25963,"Hs.511138","DKFZP564G2022","ENSG00000103978","Transmembrane protein 87A","15","42210452-42273663","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA018104, HPA018189","Enhanced",NA,"Supported","Golgi apparatus",NA,"Expressed in all","Expressed in all",NA,NA,"prostate: 124.3","Expressed in all",NA,NA
"TMIGD1",143,"C9","IOH59406",789,"0","NP_996663.1","transmembrane and immunoglobulin domain containing 1 (TMIGD1), mRNA.","NM_206832.1","NP_996663.1",388364,"Hs.371005","TMIGD, UNQ9372","ENSG00000182271","Transmembrane and immunoglobulin domain containing 1","17","30316333-30334059","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA021946",NA,NA,"Approved","Mitochondria",NA,"Tissue enhanced","Group enriched",23,"colon: 81.8;rectum: 109.8;small intestine: 162.9","kidney: 5.1","Not detected",NA,NA
"TMPRSS12",58,"A5","IOH26752",1047,"0","NP_872365.1","transmembrane protease, serine 12 (TMPRSS12), mRNA.","NM_182559.2","NP_872365.1",283471,"Hs.125571","CT151, MGC57341","ENSG00000186452","Transmembrane protease, serine 12","12","50842920-50887884","Enzymes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Not detected","Tissue enriched",75,"testis: 39.5","epididymis: 0.5","Not detected",NA,NA
"TMUB1",90,"A12","IOH3021",741,"NP_113622.1","NP_113622.1","transmembrane and ubiquitin-like domain containing 1 (TMUB1), transcript variant 1, mRNA.","NM_031434.3","NP_113622.1",83590,"Hs.647096","C7orf21, SB144","ENSG00000164897","Transmembrane and ubiquitin like domain containing 1","7","151081080-151083546","Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA029429","Approved",NA,"Supported","Nucleoplasm<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"small intestine: 52.2","Expressed in all",NA,NA
"TMX3",130,"D8","IOH51926",1365,"0","NP_061895.3","thioredoxin-related transmembrane protein 3 (TMX3), mRNA.","NM_019022.3","NP_061895.3",54495,"Hs.440534","FLJ20793, KIAA1830, PDIA13, TXNDC10","ENSG00000166479","Thioredoxin related transmembrane protein 3","18","68673688-68715298","Enzymes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA014157","Uncertain",NA,NA,NA,"Renal cancer:2.87e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 31.4","Expressed in all",NA,NA
"TMX3",52,"E7","IOH21628",588,"0","AAH32325.1","thioredoxin-related transmembrane protein 3, mRNA (cDNA clone IMAGE:3920251), complete cds.","BC032325.2","AAH32325.1",54495,"Hs.440534","FLJ20793, KIAA1830, PDIA13, TXNDC10","ENSG00000166479","Thioredoxin related transmembrane protein 3","18","68673688-68715298","Enzymes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA014157","Uncertain",NA,NA,NA,"Renal cancer:2.87e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 31.4","Expressed in all",NA,NA
"TNFAIP6",79,"C10","IOH22602",834,"0",NA,"tumor necrosis factor, alpha-induced protein 6 (TNFAIP6), mRNA.","NM_007115.2","NP_009046.2",7130,"Hs.437322","TSG-6, TSG6","ENSG00000123610","TNF alpha induced protein 6","2","151357592-151380048","Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB032719, HPA050884","Approved",NA,NA,NA,"Cervical cancer:8.18e-5 (unfavourable), Urothelial cancer:9.16e-5 (unfavourable), Renal cancer:5.59e-4 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"appendix: 38.7;gallbladder: 31.8","adipose tissue: 18.7","Cell line enhanced",NA,"BJ hTERT+: 54.6;HHSteC: 33.8;hTEC/SVTERT24-B: 54.8;U-2197: 41.1"
"TNFRSF11B",42,"G5","IOH23095",1206,"0",NA,"tumor necrosis factor receptor superfamily, member 11b (TNFRSF11B), mRNA.","NM_002546.3","NP_002537.3",4982,"Hs.81791","OCIF, OPG, TR1","ENSG00000164761","TNF receptor superfamily member 11b","8","118923557-118952200","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB034939","Approved",NA,NA,NA,"Urothelial cancer:3.88e-4 (unfavourable), Cervical cancer:6.22e-4 (unfavourable), Renal cancer:6.79e-4 (favourable)","Expressed in all","Tissue enriched",5,"thyroid gland: 140.4","kidney: 25.7","Cell line enhanced",NA,"BJ: 369.9;BJ hTERT+: 1312.6;fHDF/TERT166: 188.6"
"TNFRSF14",41,"F12","IOH5309",852,"0",NA,"tumor necrosis factor receptor superfamily, member 14 (herpesvirus entry mediator), mRNA (cDNA clone MGC:3753 IMAGE:3614650), complete cds","BC002794.2","AAH02794.1",8764,"Hs.512898","ATAR, CD270, HVEA, HVEM, LIGHTR, TR2","ENSG00000157873","TNF receptor superfamily member 14","1","2555639-2565382","Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA006404, CAB026150, CAB030007","Approved",NA,"Approved","Cytosol<br>Rods & Rings","Urothelial cancer:7.79e-6 (favourable), Endometrial cancer:8.01e-6 (favourable), Breast cancer:4.39e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"duodenum: 45.5","Cell line enhanced",NA,"CAPAN-2: 23.4;HDLM-2: 25.7;HHSteC: 25.4;SK-MEL-30: 41.0"
"TNFRSF14",37,"E7","IOH22821",600,"NP_003811.2","AAH29848.1","tumor necrosis factor receptor superfamily, member 14 (herpesvirus entry mediator), mRNA (cDNA clone MGC:35320 IMAGE:5178561), complete cds","BC029848.1","AAH29848.1",8764,"Hs.512898","ATAR, CD270, HVEA, HVEM, LIGHTR, TR2","ENSG00000157873","TNF receptor superfamily member 14","1","2555639-2565382","Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA006404, CAB026150, CAB030007","Approved",NA,"Approved","Cytosol<br>Rods & Rings","Urothelial cancer:7.79e-6 (favourable), Endometrial cancer:8.01e-6 (favourable), Breast cancer:4.39e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"duodenum: 45.5","Cell line enhanced",NA,"CAPAN-2: 23.4;HDLM-2: 25.7;HHSteC: 25.4;SK-MEL-30: 41.0"
"TNFRSF14",141,"H6","IOH59060",852,"0",NA,"tumor necrosis factor receptor superfamily, member 14 (herpesvirus entry mediator) (TNFRSF14), mRNA.","NM_003820.2","NP_003811.2",8764,"Hs.512898","ATAR, CD270, HVEA, HVEM, LIGHTR, TR2","ENSG00000157873","TNF receptor superfamily member 14","1","2555639-2565382","Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA006404, CAB026150, CAB030007","Approved",NA,"Approved","Cytosol<br>Rods & Rings","Urothelial cancer:7.79e-6 (favourable), Endometrial cancer:8.01e-6 (favourable), Breast cancer:4.39e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"duodenum: 45.5","Cell line enhanced",NA,"CAPAN-2: 23.4;HDLM-2: 25.7;HHSteC: 25.4;SK-MEL-30: 41.0"
"TNFRSF18",107,"F4","IOH42255",726,"NP_004186.1","NP_004186.1","tumor necrosis factor receptor superfamily, member 18 (TNFRSF18), transcript variant 1, mRNA.","NM_004195.2","NP_004186.1",8784,"Hs.212680","AITR, CD357, GITR","ENSG00000186891","TNF receptor superfamily member 18","1","1203508-1206691","CD markers, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA008025","Approved",NA,NA,NA,"Renal cancer:4.40e-11 (unfavourable), Endometrial cancer:7.72e-6 (favourable), Head and neck cancer:4.12e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"skin: 43.3","parathyroid gland: 18.0","Group enriched",11,"RPMI-8226: 148.8;SCLC-21H: 173.4"
"TNFRSF1B",63,"C9","IOH28913",1386,"NP_001057.1","NP_001057.1","tumor necrosis factor receptor superfamily, member 1B (TNFRSF1B), mRNA.","NM_001066.2","NP_001057.1",7133,"Hs.256278","CD120b, p75, TNF-R-II, TNF-R75, TNFBR, TNFR2, TNFR80","ENSG00000028137","TNF receptor superfamily member 1B","1","12167003-12209228","Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA004796","Approved",NA,NA,NA,"Renal cancer:8.35e-5 (unfavourable), Testis cancer:8.68e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"appendix: 100.4","spleen: 77.8","Cell line enhanced",NA,"CAPAN-2: 31.7;K-562: 41.3;THP-1: 35.7;U-87 MG: 34.0"
"TNFSF15",103,"E8","IOH35359",756,"0",NA,"tumor necrosis factor (ligand) superfamily, member 15 (TNFSF15), mRNA.","NM_005118.2","NP_005109.2",9966,"Hs.241382","MGC129934, MGC129935, TL1, TL1A, VEGI, VEGI192A","ENSG00000181634","Tumor necrosis factor superfamily member 15","9","114784635-114806126","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA012948, HPA046522","Approved",NA,"Approved","Nucleus<br>Nuclear membrane<br>Cytosol",NA,"Mixed","Mixed",NA,NA,"duodenum: 9.5","Cell line enhanced",NA,"HaCaT: 11.6;hTEC/SVTERT24-B: 8.5;HUVEC TERT2: 13.6;RT4: 12.9;TIME: 6.2"
"TNXB",60,"F1","IOH21832",2022,"0",NA,"tenascin XB, mRNA (cDNA clone IMAGE:5179997), complete cds.","BC033740.1","AAH33740.1",7148,"Hs.42853","TNXB1, TNXB2, TNXBS, XB, XBS","ENSG00000168477","Tenascin XB","6","32041154-32115334","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"adrenal gland: 91.6","endometrium: 18.6","Cell line enhanced",NA,"ASC diff: 8.6;ASC TERT1: 14.3;U-2197: 15.6;U-87 MG: 8.2"
"TOMM7",28,"B2","IOH4458",168,"0",NA,"translocase of outer mitochondrial membrane 7 homolog (yeast) (TOMM7), nuclear gene encoding mitochondrial protein, mRNA.","NM_019059.2","NP_061932.1",54543,"Hs.112318","Tom7","ENSG00000196683","Translocase of outer mitochondrial membrane 7","7","22812628-22822852","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Head and neck cancer:6.30e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"ovary: 677.6","Expressed in all",NA,NA
"TOR1A",132,"C5","IOH39449",999,"0",NA,"torsin family 1, member A (torsin A) (TOR1A), mRNA.","NM_000113.2","NP_000104.1",1861,"Hs.534312","DQ2, DYT1","ENSG00000136827","Torsin family 1 member A","9","129812944-129824134","Disease related genes, Predicted secreted proteins","Evidence at protein level","CAB012473, HPA051195","Approved",NA,"Supported","Nuclear membrane<br>Vesicles","Lung cancer:5.45e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 39.9","Expressed in all",NA,NA
"TOR1A",19,"D2","IOH13585",594,"0",NA,"torsin family 1, member A (torsin A), mRNA (cDNA clone MGC:23205 IMAGE:4869856), complete cds","BC014484.1","AAH14484.1",1861,"Hs.534312","DQ2, DYT1","ENSG00000136827","Torsin family 1 member A","9","129812944-129824134","Disease related genes, Predicted secreted proteins","Evidence at protein level","CAB012473, HPA051195","Approved",NA,"Supported","Nuclear membrane<br>Vesicles","Lung cancer:5.45e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 39.9","Expressed in all",NA,NA
"TOR3A",28,"D7","IOH6845",1194,"0",NA,"torsin family 3, member A, mRNA (cDNA clone MGC:19663 IMAGE:3343691), complete cds","BC011746.1","AAH11746.1",64222,"Hs.584957","ADIR, ADIR2, FLJ22345","ENSG00000186283","Torsin family 3 member A","1","179081377-179098023","Predicted secreted proteins","Evidence at protein level","HPA028766","Approved",NA,NA,NA,"Renal cancer:4.78e-8 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 39.6","Expressed in all",NA,NA
"TOR3A",83,"E12","IOH10299",1194,"0",NA,"torsin family 3, member A, mRNA (cDNA clone MGC:17514 IMAGE:3457259), complete cds","BC018292.1","AAH18292.1",64222,"Hs.584957","ADIR, ADIR2, FLJ22345","ENSG00000186283","Torsin family 3 member A","1","179081377-179098023","Predicted secreted proteins","Evidence at protein level","HPA028766","Approved",NA,NA,NA,"Renal cancer:4.78e-8 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 39.6","Expressed in all",NA,NA
"TPO",93,"D4","IOH40711",525,"0",NA,"thyroid peroxidase, mRNA (cDNA clone IMAGE:30325379), complete cds.","BC063107.1","AAH63107.1",7173,"Hs.467554","TPX","ENSG00000115705","Thyroid peroxidase","2","1374223-1543711","Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA007987, CAB009587","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",103,"thyroid gland: 1817.4","spleen: 17.6","Cell line enhanced",NA,"Karpas-707: 6.9;RPMI-8226: 2.9"
"TPO",145,"F10","IOH63169",2802,"0",NA,"thyroid peroxidase, mRNA (cDNA clone MGC:111197 IMAGE:30329791), complete cds","BC095448.1","AAH95448.1",7173,"Hs.467554","TPX","ENSG00000115705","Thyroid peroxidase","2","1374223-1543711","Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA007987, CAB009587","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",103,"thyroid gland: 1817.4","spleen: 17.6","Cell line enhanced",NA,"Karpas-707: 6.9;RPMI-8226: 2.9"
"TPP1",90,"C7","IOH11352",1692,"0",NA,"tripeptidyl peptidase I, mRNA (cDNA clone MGC:21297 IMAGE:4385872), complete cds","BC014863.1","AAH14863.1",1200,"Hs.523454","CLN2, SCAR7","ENSG00000166340","Tripeptidyl peptidase 1","11","6612763-6619461","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA037709, HPA044868","Enhanced",NA,NA,NA,"Liver cancer:1.11e-4 (unfavourable), Head and neck cancer:4.31e-4 (unfavourable), Stomach cancer:4.46e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 206.9","Expressed in all",NA,NA
"TPP1",144,"H10","IOH54067",1692,"0",NA,"tripeptidyl peptidase I (TPP1), mRNA.","NM_000391.3","NP_000382.3",1200,"Hs.523454","CLN2, SCAR7","ENSG00000166340","Tripeptidyl peptidase 1","11","6612763-6619461","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA037709, HPA044868","Enhanced",NA,NA,NA,"Liver cancer:1.11e-4 (unfavourable), Head and neck cancer:4.31e-4 (unfavourable), Stomach cancer:4.46e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 206.9","Expressed in all",NA,NA
"TPSAB1",150,"E2","IOH61933",828,"0",NA,"tryptase alpha/beta 1, mRNA (cDNA clone MGC:103905 IMAGE:30915294), complete cds","BC074975.2","AAH74975.1",7177,"Hs.405479","TPS1, TPS2, TPSB1","ENSG00000172236","Tryptase alpha/beta 1","16","1240696-1242554","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB016369, CAB022175, HPA049153, HPA049554","Supported",NA,NA,NA,"Head and neck cancer:9.62e-6 (favourable)","Mixed","Tissue enhanced",NA,"gallbladder: 211.6","lung: 158.5","Cell line enriched",163,"HMC-1: 3406.5"
"TPSAB1",141,"E4","IOH59056",828,"0",NA,"tryptase alpha/beta 1, mRNA (cDNA clone MGC:39869 IMAGE:5181815), complete cds","BC028059.1","AAH28059.1",7177,"Hs.405479","TPS1, TPS2, TPSB1","ENSG00000172236","Tryptase alpha/beta 1","16","1240696-1242554","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB016369, CAB022175, HPA049153, HPA049554","Supported",NA,NA,NA,"Head and neck cancer:9.62e-6 (favourable)","Mixed","Tissue enhanced",NA,"gallbladder: 211.6","lung: 158.5","Cell line enriched",163,"HMC-1: 3406.5"
"TPSAB1",132,"H6","IOH29733",828,"0",NA,"tryptase alpha/beta 1 (TPSAB1), mRNA.","NM_003294.3","NP_003285.2",7177,"Hs.405479","TPS1, TPS2, TPSB1","ENSG00000172236","Tryptase alpha/beta 1","16","1240696-1242554","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB016369, CAB022175, HPA049153, HPA049554","Supported",NA,NA,NA,"Head and neck cancer:9.62e-6 (favourable)","Mixed","Tissue enhanced",NA,"gallbladder: 211.6","lung: 158.5","Cell line enriched",163,"HMC-1: 3406.5"
"TPSB2",56,"B8","IOH23176",828,"0",NA,"tryptase beta 2, mRNA (cDNA clone MGC:32523 IMAGE:4695458), complete cds","BC029356.1","AAH29356.1",64499,"Hs.405479",NA,"ENSG00000197253","Tryptase beta 2 (gene/pseudogene)","16","1227272-1230184","Enzymes, Predicted secreted proteins","Evidence at protein level","HPA049153, HPA049554","Supported",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"gallbladder: 156.9","lung: 117.5","Cell line enriched",7,"HMC-1: 262.0"
"TPSD1",141,"D9","IOH59766",729,"0",NA,"tryptase delta 1 (TPSD1), mRNA.","NM_012217.2","NP_036349.1",23430,"Hs.677789",NA,"ENSG00000095917","Tryptase delta 1","16","1256059-1258998","Enzymes, Predicted secreted proteins","Evidence at protein level","CAB002215, CAB032871, HPA040182, HPA049554","Supported",NA,"Uncertain","Nuclear speckles",NA,"Mixed","Tissue enhanced",NA,"lung: 26.9","gallbladder: 20.3","Group enriched",46,"HEL: 25.4;HMC-1: 36.4"
"TPST2",126,"C10","IOH4763",1134,"0",NA,"tyrosylprotein sulfotransferase 2 (TPST2), transcript variant 1, mRNA.","NM_001008566.1","NP_001008566.1",8459,"Hs.632768","TANGO13B","ENSG00000128294","Tyrosylprotein sulfotransferase 2","22","26521983-26596717","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA021054","Approved",NA,NA,NA,"Renal cancer:2.34e-6 (unfavourable), Endometrial cancer:8.08e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 135.8","Expressed in all",NA,NA
"TREM1",51,"B11","IOH12076",705,"NP_061113.1","NP_061113.1","triggering receptor expressed on myeloid cells 1 (TREM1), mRNA.","NM_018643.2","NP_061113.1",54210,"Hs.283022","CD354, TREM-1","ENSG00000124731","Triggering receptor expressed on myeloid cells 1","6","41267926-41286719","CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA005563","Uncertain",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"appendix: 67.7;bone marrow: 63.0;lung: 103.1","adipose tissue: 26.9","Cell line enriched",11,"U-87 MG: 24.5"
"TREM2",133,"B3","IOH46230",693,"NP_061838.1","NP_061838.1","triggering receptor expressed on myeloid cells 2 (TREM2), mRNA.","NM_018965.2","NP_061838.1",54209,"Hs.435295","TREM-2, Trem2a, Trem2b, Trem2c","ENSG00000095970","Triggering receptor expressed on myeloid cells 2","6","41158506-41163186","Disease related genes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA010917, HPA012571","Approved",NA,NA,NA,"Liver cancer:4.24e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 37.0;lung: 40.5","adrenal gland: 16.1","Cell line enhanced",NA,"HBEC3-KT: 9.0;hTCEpi: 49.6;THP-1: 26.6"
"TRH",98,"E6","IOH40291",729,"0",NA,"thyrotropin-releasing hormone (TRH), mRNA.","NM_007117.2","NP_009048.1",7200,"Hs.182231",NA,"ENSG00000170893","Thyrotropin releasing hormone","3","129974305-129977938","Predicted secreted proteins","Evidence at protein level","HPA035596","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Group enriched",9,"cervix, uterine: 32.1;endometrium: 27.4","fallopian tube: 3.4","Not detected",NA,NA
"TSKU",69,"E10","IOH10376",1062,"0",NA,"tsukushin (TSKU), mRNA.","NM_015516.3","NP_056331.2",25987,"Hs.8361","E2IG4, LRRC54, TSK","ENSG00000182704","Tsukushi, small leucine rich proteoglycan","11","76782251-76798154","Predicted secreted proteins","Evidence at protein level","HPA008164","Approved",NA,"Approved","Nucleus<br>Nuclear bodies","Renal cancer:2.80e-8 (unfavourable), Prostate cancer:1.66e-4 (favourable), Pancreatic cancer:2.87e-4 (unfavourable), Endometrial cancer:3.66e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"liver: 114.4","Cell line enhanced",NA,"A549: 150.8;ASC diff: 186.5"
"TSPAN31",44,"A8","IOH14295",633,"NP_005972.1","NP_005972.1","tetraspanin 31 (TSPAN31), mRNA.","NM_005981.3","NP_005972.1",6302,"Hs.632708","SAS","ENSG00000135452","Tetraspanin 31","12","57738013-57750211","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA057489","Approved",NA,NA,NA,"Renal cancer:9.91e-5 (favourable), Head and neck cancer:1.09e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 74.5","Expressed in all",NA,NA
"TSPAN6",129,"C12","IOH10449",738,"NP_003261.1","NP_003261.1","tetraspanin 6 (TSPAN6), mRNA.","NM_003270.2","NP_003261.1",7105,"Hs.43233","T245, TM4SF6, TSPAN-6","ENSG00000000003","Tetraspanin 6","X","100627109-100639991","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA004109","Approved",NA,"Approved","Cytosol",NA,"Expressed in all","Mixed",NA,NA,"fallopian tube: 102.1","Cell line enhanced",NA,"NTERA-2: 165.6;RT4: 203.5"
"TTR",33,"G1","IOH14065",444,"0",NA,"transthyretin (TTR), mRNA.","NM_000371.3","NP_000362.1",7276,"Hs.427202","CTS, CTS1, HsT2651, PALB","ENSG00000118271","Transthyretin","18","31591726-31599021","Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB002517, HPA002550, CAB062567, CAB073406","Supported",NA,"Approved","Golgi apparatus",NA,"Group enriched","Tissue enriched",27,"liver: 6343.2","pancreas: 235.0","Group enriched",7,"CACO-2: 68.3;EFO-21: 26.5;Hep G2: 87.1;U-2 OS: 38.2"
"TWSG1",11,"A1","IOH10689",672,"0",NA,"twisted gastrulation homolog 1 (Drosophila) (TWSG1), mRNA.","NM_020648.5","NP_065699.1",57045,"Hs.514685","TSG","ENSG00000128791","Twisted gastrulation BMP signaling modulator 1","18","9334767-9402420","Predicted secreted proteins","Evidence at protein level","HPA014898","Uncertain",NA,"Supported","Centrosome<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"smooth muscle: 116.3","Expressed in all",NA,NA
"TXNDC12",49,"B2","IOH4686",519,"0",NA,"thioredoxin domain containing 12 (endoplasmic reticulum) (TXNDC12), mRNA.","NM_015913.2","NP_056997.1",51060,"Hs.476033","AGR1, ERP18, ERP19, hAG-1, PDIA16, TLP19","ENSG00000117862","Thioredoxin domain containing 12","1","52020131-52056171","Enzymes, Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:1.40e-12 (unfavourable), Liver cancer:1.28e-5 (unfavourable), Head and neck cancer:2.61e-4 (unfavourable), Colorectal cancer:4.44e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"fallopian tube: 49.8","Expressed in all",NA,NA
"TXNDC12",135,"H12","IOH57002",519,"0",NA,"thioredoxin domain containing 12 (endoplasmic reticulum), mRNA (cDNA clone MGC:15395 IMAGE:3659407), complete cds","BC008913.2","AAH08913.1",51060,"Hs.476033","AGR1, ERP18, ERP19, hAG-1, PDIA16, TLP19","ENSG00000117862","Thioredoxin domain containing 12","1","52020131-52056171","Enzymes, Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:1.40e-12 (unfavourable), Liver cancer:1.28e-5 (unfavourable), Head and neck cancer:2.61e-4 (unfavourable), Colorectal cancer:4.44e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"fallopian tube: 49.8","Expressed in all",NA,NA
"TXNDC5",60,"B12","IOH28133",1083,"0",NA,"thioredoxin domain containing 5 (endoplasmic reticulum), mRNA (cDNA clone MGC:59718 IMAGE:6671945), complete cds","BC052310.1","AAH52310.1",81567,"Hs.150837","EndoPDI, ERp46, FLJ21353, FLJ90810, Hcc-2, MGC3178, PDIA15","ENSG00000239264","Thioredoxin domain containing 5","6","7881517-7910814","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA034677, HPA034678","Enhanced",NA,"Approved","Endoplasmic reticulum","Renal cancer:1.16e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"urinary bladder: 312.7","Expressed in all",NA,NA
"TXNDC5",25,"G5","IOH4474",975,"0",NA,"thioredoxin domain containing 5 (endoplasmic reticulum) (TXNDC5), transcript variant 3, mRNA.","NM_001145549.1","NP_001139021.1",81567,"Hs.150837","EndoPDI, ERp46, FLJ21353, FLJ90810, Hcc-2, MGC3178, PDIA15","ENSG00000239264","Thioredoxin domain containing 5","6","7881517-7910814","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA034677, HPA034678","Enhanced",NA,"Approved","Endoplasmic reticulum","Renal cancer:1.16e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"urinary bladder: 312.7","Expressed in all",NA,NA
"TYRP1",100,"A8","IOH29383",1614,"NP_000541.1","NP_000541.1","tyrosinase-related protein 1 (TYRP1), mRNA.","NM_000550.2","NP_000541.1",7306,"Hs.270279","b-PROTEIN, CAS2, CATB, GP75, OCA3, TRP, TYRP","ENSG00000107165","Tyrosinase related protein 1","9","12685439-12710290","Disease related genes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA000937, CAB002520","Enhanced",NA,"Supported","Vesicles",NA,"Tissue enriched","Group enriched",6,"heart muscle: 40.2;skin: 169.1","kidney: 17.0","Cell line enriched",51,"SK-MEL-30: 1084.9"
"UBR3",102,"F9","IOH38243",2226,"0",NA,"E3 ubiquitin-protein ligase UBR3 (EC 6.3.2.-)(N-recognin-3)(Ubiquitin-protein ligase E3-alpha-3)(Ubiquitin-protein ligase E3-alpha-III)(Zinc finger protein 650) [Source:UniProtKB/Swiss-Prot;Acc:Q6ZT12]","ENST00000421104","ENSP00000398293",130507,"Hs.379548","DKFZp434P117, FLJ37422, KIAA2024, ZNF650","ENSG00000144357","Ubiquitin protein ligase E3 component n-recognin 3 (putative)","2","169827458-170084131","Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA035390","Approved",NA,"Approved","Nucleus<br>Nucleoli",NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 39.6","Expressed in all",NA,NA
"UBXN8",88,"C1","IOH12207",813,"0",NA,"UBX domain protein 8 (UBXN8), mRNA.","NM_005671.2","NP_005662.1",7993,"Hs.153678","D8S2298E, REP8, UBXD6","ENSG00000104691","UBX domain protein 8","8","30732247-30767006","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA017725, HPA077538","Approved",NA,"Supported","Nucleoplasm<br>Nucleoli<br>Endoplasmic reticulum","Renal cancer:5.25e-5 (unfavourable), Colorectal cancer:6.13e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"ovary: 109.4","Expressed in all",NA,NA
"UCMA",112,"A10","IOH45549",417,"0",NA,"upper zone of growth plate and cartilage matrix associated (UCMA), mRNA.","NM_145314.1","NP_660357.2",221044,"Hs.112998","C10orf49","ENSG00000165623","Upper zone of growth plate and cartilage matrix associated","10","13221767-13234334","Predicted secreted proteins","Evidence at transcript level","HPA046718","Uncertain",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"ovary: 1.4","heart muscle: 0.4","Not detected",NA,NA
"UCN2",35,"F11","IOH10099",339,"0",NA,"urocortin 2 (UCN2), mRNA.","NM_033199.3","NP_149976.1",90226,"Hs.631914","SRP, UCN-II, UCNI, URP","ENSG00000145040","Urocortin 2","3","48561727-48563773","Predicted secreted proteins","Evidence at protein level","HPA066841","Uncertain",NA,"Approved","Vesicles",NA,"Tissue enhanced","Tissue enriched",8,"skin: 15.5","endometrium: 2.0","Cell line enhanced",NA,"hTCEpi: 19.9;hTEC/SVTERT24-B: 21.7;SiHa: 20.5;WM-115: 55.5"
"UCN3",137,"B3","IOH56631",486,"0",NA,"urocortin 3 (stresscopin), mRNA (cDNA clone MGC:96972 IMAGE:7262181), complete cds","BC069530.1","AAH69530.1",114131,"Hs.511775","SPC, UCNIII","ENSG00000178473","Urocortin 3","10","5365009-5374692","Predicted secreted proteins","Evidence at protein level","HPA038281","Uncertain",NA,NA,NA,NA,"Group enriched","Tissue enhanced",NA,"duodenum: 9.3;small intestine: 7.5","stomach: 3.6","Cell line enriched",10,"SCLC-21H: 1.5"
"UCN3",144,"C2","IOH54667",486,"0",NA,"urocortin 3 (stresscopin) (UCN3), mRNA.","NM_053049.2","NP_444277.2",114131,"Hs.511775","SPC, UCNIII","ENSG00000178473","Urocortin 3","10","5365009-5374692","Predicted secreted proteins","Evidence at protein level","HPA038281","Uncertain",NA,NA,NA,NA,"Group enriched","Tissue enhanced",NA,"duodenum: 9.3;small intestine: 7.5","stomach: 3.6","Cell line enriched",10,"SCLC-21H: 1.5"
"UGGT2",80,"G7","IOH21655",837,"0",NA,"UDP-glucose ceramide glucosyltransferase-like 2, mRNA (cDNA clone IMAGE:5169731), complete cds.","BC032302.1","AAH32302.1",55757,"Hs.193226","FLJ10873, FLJ11485, HUGT2, MGC117360, MGC150689, MGC87276, UGCGL2","ENSG00000102595","UDP-glucose glycoprotein glucosyltransferase 2","13","95801580-96053482","Predicted secreted proteins","Evidence at protein level","HPA047955","Uncertain",NA,NA,NA,"Lung cancer:5.47e-4 (unfavourable), Liver cancer:9.99e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"testis: 22.7","Mixed",NA,NA
"UGT1A10",29,"G8","IOH10400",1593,"NP_061948.1","NP_061948.1","UDP glucuronosyltransferase 1 family, polypeptide A10 (UGT1A10), mRNA.","NM_019075.2","NP_061948.1",54575,"Hs.554822","UGT1J","ENSG00000242515","UDP glucuronosyltransferase family 1 member A10","2","233636454-233773305","Cancer-related genes, Enzymes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Pancreatic cancer:4.55e-4 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"colon: 49.7;duodenum: 80.9;small intestine: 59.1","rectum: 39.6","Cell line enriched",108,"RT4: 416.9"
"UGT1A10",120,"F1","IOH28927",1326,"0",NA,"UDP glucuronosyltransferase 1 family, polypeptide A10, mRNA (cDNA clone MGC:61718 IMAGE:4452440), complete cds","BC053576.1","AAH53576.1",54575,"Hs.554822","UGT1J","ENSG00000242515","UDP glucuronosyltransferase family 1 member A10","2","233636454-233773305","Cancer-related genes, Enzymes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Pancreatic cancer:4.55e-4 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"colon: 49.7;duodenum: 80.9;small intestine: 59.1","rectum: 39.6","Cell line enriched",108,"RT4: 416.9"
"UGT2B4",33,"E7","IOH12309",1587,"NP_001064.1","NP_066962.2","UDP glucuronosyltransferase 2 family, polypeptide B4 (UGT2B4), mRNA.","NM_021139.2","NP_066962.2",7363,"Hs.285887","UGT2B11","ENSG00000156096","UDP glucuronosyltransferase family 2 member B4","4","69480165-69526014","Enzymes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB033260, HPA045108","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",78,"liver: 655.5","heart muscle: 8.3","Cell line enriched",11,"RH-30: 4.5"
"UGT3A1",94,"G11","IOH40110",1572,"NP_689617.2","AAH68446.1","UDP glycosyltransferase 3 family, polypeptide A1, mRNA (cDNA clone MGC:86988 IMAGE:5295502), complete cds","BC068446.1","AAH68446.1",133688,"Hs.254699","FLJ34658","ENSG00000145626","UDP glycosyltransferase family 3 member A1","5","35951010-36001028","Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA047697, HPA056290","Uncertain",NA,"Approved","Vesicles<br>Cytosol",NA,"Group enriched","Tissue enhanced",NA,"kidney: 53.4;liver: 29.2","duodenum: 9.5","Cell line enriched",51,"RH-30: 26.5"
"UGT3A2",151,"D8","IOH63460",1572,"0",NA,"UDP glycosyltransferase 3 family, polypeptide A2, mRNA (cDNA clone MGC:119426 IMAGE:40007344), complete cds","BC103924.1","AAI03925.1",167127,"Hs.348941",NA,"ENSG00000168671","UDP glycosyltransferase family 3 member A2","5","36035017-36071358","Enzymes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA059475","Uncertain",NA,"Approved","Nucleus<br>Cytosol",NA,"Tissue enriched","Tissue enhanced",NA,"skin: 11.9;testis: 4.6","bone marrow: 3.2","Cell line enhanced",NA,"HDLM-2: 6.3;MOLT-4: 9.8;REH: 25.8;T-47d: 6.7;THP-1: 11.2"
"UMOD",117,"B9","IOH27963",1836,"0",NA,"uromodulin, mRNA (cDNA clone MGC:32619 IMAGE:4556427), complete cds","BC035975.1","AAH35975.1",7369,"Hs.654425",NA,"ENSG00000169344","Uromodulin","16","20333052-20356301","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB009446, HPA043420, HPA054721","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",726,"kidney: 2392.4","cerebral cortex: 3.2","Not detected",NA,NA
"UPK3B",92,"H5","IOH5529",963,"0",NA,"uroplakin 3B (UPK3B), transcript variant 1, mRNA.","NM_030570.2","NP_085047.1",80761,"Hs.488861","FLJ32198, MGC10902, p35, UPIIIb","ENSG00000243566","Uroplakin 3B","7","76510428-76516521","Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA010506","Approved",NA,"Approved","Nucleus<br>Vesicles<br>Cytosol",NA,"Group enriched","Group enriched",11,"esophagus: 12.4;lung: 29.8;urinary bladder: 11.0","tonsil: 1.6","Group enriched",8,"A549: 12.0;CAPAN-2: 41.9;HaCaT: 8.6;RT4: 26.3;T-47d: 25.4"
"UPK3B",115,"G5","IOH44464",831,"0",NA,"uroplakin 3B (UPK3B), transcript variant 2, mRNA.","NM_182684.1","NP_872625.1",80761,"Hs.488861","FLJ32198, MGC10902, p35, UPIIIb","ENSG00000243566","Uroplakin 3B","7","76510428-76516521","Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA010506","Approved",NA,"Approved","Nucleus<br>Vesicles<br>Cytosol",NA,"Group enriched","Group enriched",11,"esophagus: 12.4;lung: 29.8;urinary bladder: 11.0","tonsil: 1.6","Group enriched",8,"A549: 12.0;CAPAN-2: 41.9;HaCaT: 8.6;RT4: 26.3;T-47d: 25.4"
"USP3",11,"A4","IOH11302",1563,"0",NA,"ubiquitin specific peptidase 3 (USP3), mRNA.","NM_006537.2","NP_006528.2",9960,"Hs.458499",NA,"ENSG00000140455","Ubiquitin specific peptidase 3","15","63504511-63594640","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA053275, HPA060513, HPA077975",NA,NA,"Supported","Nucleoplasm","Urothelial cancer:1.38e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"bone marrow: 32.1","Expressed in all",NA,NA
"UTS2",139,"D6","IOH58698",375,"0",NA,"urotensin 2 (UTS2), transcript variant 2, mRNA.","NM_006786.3","NP_006777.1",10911,"Hs.715862","PRO1068, U-II, UCN2, UII","ENSG00000049247","Urotensin 2","1","7843083-7853512","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA017000","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"adrenal gland: 3.9","bone marrow,lymph node: 1.9","Group enriched",17,"CACO-2: 17.2;HEL: 6.6;HMC-1: 5.3;THP-1: 17.9"
"UTS2",31,"D12","IOH11913",420,"0",NA,"Urotensin-2 Precursor (Urotensin-II)(U-II)(UII) [Source:UniProtKB/Swiss-Prot;Acc:O95399]","ENST00000377516","ENSP00000366738",10911,"Hs.715862","PRO1068, U-II, UCN2, UII","ENSG00000049247","Urotensin 2","1","7843083-7853512","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA017000","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"adrenal gland: 3.9","bone marrow,lymph node: 1.9","Group enriched",17,"CACO-2: 17.2;HEL: 6.6;HMC-1: 5.3;THP-1: 17.9"
"VASH1",91,"D9","IOH27006",1098,"0",NA,"vasohibin 1 (VASH1), mRNA.","NM_014909.4","NP_055724.1",22846,"Hs.525479","KIAA1036","ENSG00000071246","Vasohibin 1","14","76762189-76783015","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA000653","Uncertain",NA,NA,NA,"Pancreatic cancer:6.56e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 34.4","Cell line enhanced",NA,"AF22: 50.3;HUVEC TERT2: 78.5"
"VASH1",127,"B12","IOH3282",615,"0",NA,"vasohibin 1, mRNA (cDNA clone MGC:17043 IMAGE:4156063), complete cds","BC009031.1","AAH09031.1",22846,"Hs.525479","KIAA1036","ENSG00000071246","Vasohibin 1","14","76762189-76783015","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA000653","Uncertain",NA,NA,NA,"Pancreatic cancer:6.56e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 34.4","Cell line enhanced",NA,"AF22: 50.3;HUVEC TERT2: 78.5"
"VCAN",75,"D1","IOH26923",1065,"0",NA,"versican, mRNA (cDNA clone IMAGE:5218077), complete cds.","BC050524.1","AAH50524.1",1462,"Hs.643801","CSPG2, PG-M","ENSG00000038427","Versican","5","83471465-83582303","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA004726, CAB008979","Enhanced",NA,"Supported","Vesicles","Stomach cancer:1.41e-4 (unfavourable), Renal cancer:5.17e-4 (unfavourable), Melanoma:7.59e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"appendix: 105.5;placenta: 104.6","smooth muscle: 67.1","Cell line enhanced",NA,"AF22: 296.8;RPTEC TERT1: 288.7;U-2197: 156.9"
"VEGFB",141,"F3","IOH59025",624,"0",NA,"vascular endothelial growth factor B (VEGFB), mRNA.","NM_003377.3","NP_003368.1",7423,"Hs.78781","VEGFL, VRF","ENSG00000173511","Vascular endothelial growth factor B","11","64234538-64238793","Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"adipose tissue: 195.0","Expressed in all",NA,NA
"VIP",77,"A1","IOH14426",510,"0",NA,"vasoactive intestinal peptide (VIP), transcript variant 2, mRNA.","NM_194435.1","NP_919416.1",7432,"Hs.53973",NA,"ENSG00000146469","Vasoactive intestinal peptide","6","152750798-152759765","Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA017324, CAB018649, HPA072701","Supported",NA,"Approved","Endoplasmic reticulum",NA,"Group enriched","Group enriched",5,"appendix: 209.4;colon: 71.4;rectum: 68.3;small intestine: 52.7;smooth muscle: 58.1","duodenum: 16.8","Cell line enhanced",NA,"SH-SY5Y: 2.8;TIME: 1.6"
"VIPR2",3,"B5","IOH9624",1317,"NP_003373.2","NP_003373.2","vasoactive intestinal peptide receptor 2 (VIPR2), mRNA.","NM_003382.4","NP_003373.2",7434,"Hs.585052","VPAC2, VPAC2R","ENSG00000106018","Vasoactive intestinal peptide receptor 2","7","159028175-159144957","G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA062707","Approved",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"seminal vesicle: 28.3","epididymis: 14.9","Cell line enhanced",NA,"HMC-1: 7.8;MOLT-4: 10.2;U-266/70: 30.8"
"VIT",65,"H8","IOH29299",612,"0",NA,"vitrin, mRNA (cDNA clone IMAGE:6193636), complete cds.","BC061519.1","AAH61519.1",5212,"Hs.137415",NA,"ENSG00000205221","Vitrin","2","36696690-36814792","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"ovary: 35.7","adipose tissue: 18.5","Cell line enhanced",NA,"ASC diff: 23.1;ASC TERT1: 45.7;BJ: 27.8;fHDF/TERT166: 87.0;THP-1: 23.9"
"VKORC1",104,"B4","IOH42079",279,"NP_076869.1","NP_996560.1","vitamin K epoxide reductase complex, subunit 1 (VKORC1), transcript variant 2, mRNA.","NM_206824.1","NP_996560.1",79001,"Hs.324844","VKCFD2","ENSG00000167397","Vitamin K epoxide reductase complex subunit 1","16","31090842-31095980","Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA042720","Approved",NA,"Supported","Endoplasmic reticulum","Renal cancer:2.09e-10 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"liver: 141.4","Expressed in all",NA,NA
"VKORC1",24,"A3","IOH5719",492,"0",NA,"vitamin K epoxide reductase complex, subunit 1 (VKORC1), transcript variant 1, mRNA.","NM_024006.4","NP_076869.1",79001,"Hs.324844","VKCFD2","ENSG00000167397","Vitamin K epoxide reductase complex subunit 1","16","31090842-31095980","Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA042720","Approved",NA,"Supported","Endoplasmic reticulum","Renal cancer:2.09e-10 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"liver: 141.4","Expressed in all",NA,NA
"VMO1",126,"H2","IOH25921",213,"0",NA,"vitelline membrane outer layer 1 homolog (chicken), mRNA (cDNA clone IMAGE:5223751), complete cds.","BC038467.1","AAH38467.1",284013,"Hs.122561",NA,"ENSG00000182853","Vitelline membrane outer layer 1 homolog","17","4785285-4786433","Predicted secreted proteins","Evidence at protein level","HPA023038","Uncertain",NA,NA,NA,"Renal cancer:1.34e-6 (unfavourable)","Expressed in all","Tissue enhanced",NA,"parathyroid gland: 34.4","spleen: 14.6","Cell line enhanced",NA,"A549: 2.7;MCF7: 3.0"
"VNN1",152,"D8","IOH63225",1542,"0",NA,"vanin 1 (VNN1), mRNA.","NM_004666.2","NP_004657.2",8876,"Hs.12114","Tiff66","ENSG00000112299","Vanin 1","6","132681590-132714049","Enzymes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA064145","Approved",NA,NA,NA,"Renal cancer:2.52e-4 (unfavourable)","Tissue enhanced","Group enriched",5,"duodenum: 171.4;gallbladder: 174.7;liver: 142.4;small intestine: 106.3","kidney: 27.5","Cell line enhanced",NA,"EFO-21: 10.3"
"VNN1",153,"G12","IOH63233",1542,"0",NA,"vanin 1, mRNA (cDNA clone MGC:116932 IMAGE:40006207), complete cds","BC096267.3","AAH96267.1",8876,"Hs.12114","Tiff66","ENSG00000112299","Vanin 1","6","132681590-132714049","Enzymes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA064145","Approved",NA,NA,NA,"Renal cancer:2.52e-4 (unfavourable)","Tissue enhanced","Group enriched",5,"duodenum: 171.4;gallbladder: 174.7;liver: 142.4;small intestine: 106.3","kidney: 27.5","Cell line enhanced",NA,"EFO-21: 10.3"
"VNN2",111,"E11","IOH42450",1404,"NP_004656.2","NP_511043.1","vanin 2 (VNN2), transcript variant 2, mRNA.","NM_078488.1","NP_511043.1",8875,"Hs.293130","FOAP-4, GPI-80","ENSG00000112303","Vanin 2","6","132743870-132763459","Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:2.72e-7 (unfavourable)","Mixed","Tissue enhanced",NA,"spleen: 76.9","lymph node: 45.0","Cell line enriched",6,"Daudi: 40.8"
"VNN3",109,"F9","IOH42141",444,"0",NA,"vanin 3 (VNN3), transcript variant 2, mRNA.","NM_078625.2","NP_523239.1",55350,"Hs.183656","HSA238982","ENSG00000093134","Vanin 3","6","132722787-132734765","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at transcript level",NA,NA,NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"bone marrow: 35.3;liver: 15.2","spleen: 9.5","Not detected",NA,NA
"VPREB3",7,"E11","IOH12884",372,"0",NA,"pre-B lymphocyte 3 (VPREB3), mRNA.","NM_013378.2","NP_037510.1",29802,"Hs.136713","8HS20","ENSG00000128218","Pre-B lymphocyte 3","22","23752743-23754468","Predicted secreted proteins","Evidence at protein level","HPA003041","Supported",NA,NA,NA,NA,"Expressed in all","Tissue enhanced",NA,"lymph node: 117.3;tonsil: 95.8","spleen: 61.1","Cell line enhanced",NA,"Daudi: 168.5;REH: 255.6;U-698: 50.4"
"VPS37B",135,"G8","IOH56912",858,"0",NA,"vacuolar protein sorting 37 homolog B (S. cerevisiae) (VPS37B), mRNA.","NM_024667.2","NP_078943.1",79720,"Hs.507162","FLJ12750","ENSG00000139722","VPS37B, ESCRT-I subunit","12","122865328-122896444","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA038217, HPA038218","Enhanced",NA,NA,NA,"Renal cancer:1.35e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"esophagus: 34.8","Mixed",NA,NA
"VSIG1",55,"D12","IOH25853",1164,"XP_291331.1","NP_872413.1","V-set and immunoglobulin domain containing 1 (VSIG1), mRNA.","NM_182607.3","NP_872413.1",340547,"Hs.177164","MGC44287","ENSG00000101842","V-set and immunoglobulin domain containing 1","X","108044970-108079184","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA001445, HPA036310, HPA036311","Enhanced",NA,"Approved","Vesicles<br>Cytosol",NA,"Group enriched","Group enriched",10,"stomach: 185.7;testis: 91.1","gallbladder: 14.3","Cell line enhanced",NA,"HBEC3-KT: 2.5;HUVEC TERT2: 5.9;PC-3: 2.2"
"VSTM1",152,"F1","IOH63519",525,"0","AAI00943.1","V-set and transmembrane domain containing 1, mRNA (cDNA clone MGC:119160 IMAGE:40004094), complete cds","BC100942.2","AAI00943.1",284415,"Hs.444431","UNQ3033","ENSG00000189068","V-set and transmembrane domain containing 1","19","54040825-54063953","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA059365",NA,NA,"Approved","Vesicles",NA,"Mixed","Tissue enriched",38,"bone marrow: 35.4","urinary bladder: 0.9","Not detected",NA,NA
"VSTM2A",17,"E5","IOH11900",732,"0","AAH28404.1","V-set and transmembrane domain containing 2A, mRNA (cDNA clone MGC:33530 IMAGE:4820705), complete cds","BC028404.1","AAH28404.1",222008,"Hs.335933","MGC33530, VSTM2","ENSG00000170419","V-set and transmembrane domain containing 2A","7","54542325-54571080","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA021404, HPA024134","Uncertain",NA,NA,NA,"Renal cancer:5.34e-4 (favourable)","Tissue enhanced","Tissue enhanced",NA,"adrenal gland: 12.7;cerebral cortex: 40.8;prostate: 15.5","stomach: 4.8","Cell line enhanced",NA,"Karpas-707: 1.3;SCLC-21H: 6.9;SH-SY5Y: 4.3"
"VSTM2L",142,"E10","IOH54767",615,"0","NP_542174.1","V-set and transmembrane domain containing 2 like (VSTM2L), mRNA.","NM_080607.2","NP_542174.1",128434,"Hs.517029","C20orf102, dJ1118M15.2","ENSG00000132821","V-set and transmembrane domain containing 2 like","20","37903104-37945350","Predicted secreted proteins","Evidence at protein level","HPA043832","Uncertain",NA,NA,NA,"Endometrial cancer:1.63e-5 (unfavourable), Urothelial cancer:8.14e-4 (unfavourable)","Group enriched","Tissue enhanced",NA,"cerebral cortex: 55.1","gallbladder: 26.8","Cell line enhanced",NA,"CAPAN-2: 58.1;HDLM-2: 86.5;SK-BR-3: 59.9"
"VSTM2L",37,"D9","IOH21869",615,"0","AAH33818.1","V-set and transmembrane domain containing 2 like, mRNA (cDNA clone MGC:45439 IMAGE:5201150), complete cds","BC033818.1","AAH33818.1",128434,"Hs.517029","C20orf102, dJ1118M15.2","ENSG00000132821","V-set and transmembrane domain containing 2 like","20","37903104-37945350","Predicted secreted proteins","Evidence at protein level","HPA043832","Uncertain",NA,NA,NA,"Endometrial cancer:1.63e-5 (unfavourable), Urothelial cancer:8.14e-4 (unfavourable)","Group enriched","Tissue enhanced",NA,"cerebral cortex: 55.1","gallbladder: 26.8","Cell line enhanced",NA,"CAPAN-2: 58.1;HDLM-2: 86.5;SK-BR-3: 59.9"
"VTN",121,"A11","IOH6660",1437,"0",NA,"vitronectin, mRNA (cDNA clone MGC:12819 IMAGE:4040317), complete cds","BC005046.1","AAH05046.1",7448,"Hs.2257","VN","ENSG00000109072","Vitronectin","17","28367276-28373091","Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB016695, CAB016765, HPA060933","Supported",NA,"Supported","Endoplasmic reticulum<br>Vesicles","Renal cancer:4.10e-11 (unfavourable), Liver cancer:3.74e-4 (favourable)","Tissue enriched","Tissue enriched",28,"liver: 2554.5","gallbladder: 91.2","Cell line enriched",9,"CACO-2: 1044.7"
"VWF",7,"B5","IOH12079",822,"0",NA,"von Willebrand factor Precursor (vWF) [Contains von Willebrand antigen 2(von Willebrand antigen II)] [Source:UniProtKB/Swiss-Prot;Acc:P04275]","ENST00000321023","ENSP00000316900",7450,"Hs.440848","F8VWF","ENSG00000110799","Von Willebrand factor","12","5948874-6124770","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB001694, HPA001815, HPA002082, CAB072874, CAB072875","Supported",NA,NA,NA,"Stomach cancer:2.31e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"adipose tissue: 155.1","lung: 115.9","Cell line enriched",57,"HUVEC TERT2: 468.1"
"WDR25",24,"B8","IOH5172",864,"0",NA,"WD repeat domain 25, mRNA (cDNA clone MGC:4645 IMAGE:3529568), complete cds","BC003641.2","AAH03641.1",79446,"Hs.497600","C14orf67, MGC4645","ENSG00000176473","WD repeat domain 25","14","100376418-100530303","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA003113","Approved",NA,"Supported","Nucleoplasm","Renal cancer:3.89e-5 (favourable), Liver cancer:7.36e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 13.6","Mixed",NA,NA
"WFDC1",79,"E10","IOH22666",663,"0",NA,"WAP four-disulfide core domain 1 (WFDC1), mRNA.","NM_021197.2","NP_067020.2",58189,"Hs.36688","PS20","ENSG00000103175","WAP four-disulfide core domain 1","16","84294646-84329851","Predicted secreted proteins","Evidence at transcript level","HPA031411","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"placenta: 121.8;seminal vesicle: 135.6","prostate: 88.4","Cell line enhanced",NA,"AN3-CA: 24.0;BJ: 15.1;HEL: 13.6;HeLa: 16.0"
"WFDC11",93,"B7","IOH40750",264,"0",NA,"WAP four-disulfide core domain 11 (WFDC11), mRNA.","NM_147197.2","NP_671730.1",259239,"Hs.374924","WAP11","ENSG00000180083","WAP four-disulfide core domain 11","20","45648563-45670270","Predicted secreted proteins","Evidence at transcript level",NA,NA,NA,NA,NA,NA,"Not detected","Tissue enriched",14,"epididymis: 115.8","testis: 8.5","Group enriched",6,"HeLa: 5.5;RPMI-8226: 3.6;U-937: 1.1"
"WFDC2",58,"H10","IOH26919",375,"0",NA,"WAP four-disulfide core domain 2 (WFDC2), mRNA.","NM_006103.3","NP_006094.3",10406,"Hs.2719","dJ461P17.6, EDDM4, HE4, WAP5","ENSG00000101443","WAP four-disulfide core domain 2","20","45469706-45481532","Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA042302","Enhanced",NA,"Approved","Cytosol","Renal cancer:4.44e-5 (favourable), Glioma:5.87e-5 (unfavourable)","Expressed in all","Tissue enriched",6,"cervix, uterine: 6567.2","seminal vesicle: 1051.7","Group enriched",8,"A-431: 90.4;CAPAN-2: 165.0;EFO-21: 144.7;HaCaT: 121.3;RPTEC TERT1: 108.5"
"WFDC2",101,"G2","IOH34925",222,"0",NA,"WAP four-disulfide core domain protein 2 Precursor (Major epididymis-specific protein E4)(Epididymal secretory protein E4)(Putative protease inhibitor WAP5) [Source:UniProtKB/Swiss-Prot;Acc:Q14508]","ENST00000342873","ENSP00000342890",10406,"Hs.2719","dJ461P17.6, EDDM4, HE4, WAP5","ENSG00000101443","WAP four-disulfide core domain 2","20","45469706-45481532","Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA042302","Enhanced",NA,"Approved","Cytosol","Renal cancer:4.44e-5 (favourable), Glioma:5.87e-5 (unfavourable)","Expressed in all","Tissue enriched",6,"cervix, uterine: 6567.2","seminal vesicle: 1051.7","Group enriched",8,"A-431: 90.4;CAPAN-2: 165.0;EFO-21: 144.7;HaCaT: 121.3;RPTEC TERT1: 108.5"
"WFDC3",120,"F6","IOH50079",147,"0",NA,"WAP four-disulfide core domain 3, mRNA (cDNA clone IMAGE:5267892), complete cds.","BC026014.1","AAH26014.2",140686,"Hs.419126","dJ447F3.3, WAP14","ENSG00000124116","WAP four-disulfide core domain 3","20","45747944-45791932","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Mixed","Tissue enriched",19,"testis: 31.9","breast: 1.7","Cell line enhanced",NA,"PC-3: 1.1"
"WFDC5",52,"G2","IOH25810",372,"0",NA,"WAP four-disulfide core domain 5 (WFDC5), mRNA.","NM_145652.2","NP_663627.1",149708,"Hs.375031","dJ211D12.5, WAP1","ENSG00000175121","WAP four-disulfide core domain 5","20","45109452-45115172","Predicted secreted proteins","Evidence at transcript level",NA,NA,NA,NA,NA,"Renal cancer:2.32e-5 (unfavourable)","Tissue enhanced","Tissue enriched",35,"skin: 468.5","breast: 13.2","Not detected",NA,NA
"WFDC6",108,"E8","IOH34944",261,"0",NA,"WAP four-disulfide core domain 6 (WFDC6), mRNA.","NM_080827.1","NP_543017.1",140870,"Hs.673237","C20orf171, dJ461P17.11, WAP6","ENSG00000243543","WAP four-disulfide core domain 6","20","45534196-45539495","Predicted secreted proteins","Evidence at transcript level",NA,NA,NA,NA,NA,NA,"Tissue enhanced","Group enriched",16,"epididymis: 323.7;testis: 83.8","fallopian tube: 12.5","Cell line enriched",7,"U-87 MG: 2.6"
"WFDC9",101,"D3","IOH34948",270,"0",NA,"WAP four-disulfide core domain 9 (WFDC9), mRNA.","NM_147198.2","NP_671731.1",259240,"Hs.249828","dJ688G8.2, WAP9","ENSG00000180205","WAP four-disulfide core domain 9","20","45607939-45631268","Predicted intracellular proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Not detected","Tissue enriched",405,"epididymis: 1257.7","seminal vesicle: 3.1","Not detected",NA,NA
"WFIKKN2",114,"C2","IOH42617",1731,"0",NA,"WAP, follistatin/kazal, immunoglobulin, kunitz and netrin domain containing 2 (WFIKKN2), mRNA.","NM_175575.5","NP_783165.1",124857,"Hs.211475","WFDC20B, WFIKKNRP","ENSG00000173714","WAP, follistatin/kazal, immunoglobulin, kunitz and netrin domain containing 2","17","50834650-50842348","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Group enriched","Tissue enriched",17,"ovary: 76.5","testis: 4.4","Not detected",NA,NA
"WIF1",9,"C1","IOH11153",1140,"0",NA,"WNT inhibitory factor 1, mRNA (cDNA clone MGC:26240 IMAGE:4801033), complete cds","BC018037.1","AAH18037.1",11197,"Hs.284122",NA,"ENSG00000156076","WNT inhibitory factor 1","12","65050626-65121566","Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA039104","Approved",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",6,"lung: 159.4","cerebral cortex: 26.4","Cell line enhanced",NA,"HEK 293: 1.9;NTERA-2: 2.7"
"WISP1",114,"B6","IOH42456",843,"0",NA,"WNT1 inducible signaling pathway protein 1 (WISP1), transcript variant 2, mRNA.","NM_080838.1","NP_543028.1",8840,"Hs.492974","CCN4","ENSG00000104415","WNT1 inducible signaling pathway protein 1","8","133191039-133230344","Cancer-related genes, Predicted secreted proteins","Evidence at protein level","HPA007121, CAB012205","Uncertain",NA,"Approved","Cytosol","Renal cancer:1.91e-5 (unfavourable)","Expressed in all","Mixed",NA,NA,"smooth muscle: 22.1","Cell line enhanced",NA,"HSkMC: 85.7;hTEC/SVTERT24-B: 73.5;U-2197: 64.2"
"WISP2",33,"H6","IOH12154",753,"0",NA,"WNT1 inducible signaling pathway protein 2 (WISP2), mRNA.","NM_003881.2","NP_003872.1",8839,"Hs.592145","CCN5, CT58, CTGF-L","ENSG00000064205","WNT1 inducible signaling pathway protein 2","20","44714844-44728509","Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB019273","Approved",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"cervix, uterine: 459.5;ovary: 167.2","breast: 70.0","Cell line enhanced",NA,"ASC TERT1: 71.5;HeLa: 40.1;U-2197: 313.4"
"WISP2",135,"E5","IOH56524",657,"0",NA,"WNT1 inducible signaling pathway protein 2, mRNA (cDNA clone MGC:64884 IMAGE:5194313), complete cds","BC058074.1","AAH58074.1",8839,"Hs.592145","CCN5, CT58, CTGF-L","ENSG00000064205","WNT1 inducible signaling pathway protein 2","20","44714844-44728509","Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB019273","Approved",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"cervix, uterine: 459.5;ovary: 167.2","breast: 70.0","Cell line enhanced",NA,"ASC TERT1: 71.5;HeLa: 40.1;U-2197: 313.4"
"WISP3",105,"G5","IOH43121",1119,"0",NA,"WNT1 inducible signaling pathway protein 3 (WISP3), transcript variant 3, mRNA.","NM_198239.1","NP_937882.1",8838,"Hs.558428","CCN6","ENSG00000112761","WNT1 inducible signaling pathway protein 3","6","112054072-112070969","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA062438, HPA078340",NA,NA,"Approved","Endoplasmic reticulum",NA,"Mixed","Tissue enhanced",NA,"epididymis: 3.0;skin: 2.0","fallopian tube: 1.8","Cell line enhanced",NA,"RT4: 4.6;THP-1: 1.2;U-2197: 1.2"
"WNT2",43,"G1","IOH22817",1083,"0",NA,"wingless-type MMTV integration site family member 2 (WNT2), transcript variant 1, mRNA.","NM_003391.2","NP_003382.1",7472,"Hs.567356","INT1L1, IRP","ENSG00000105989","Wnt family member 2","7","117276631-117323289","Cancer-related genes, Predicted secreted proteins","Evidence at protein level","HPA020920",NA,NA,"Approved","Vesicles",NA,"Mixed","Group enriched",6,"endometrium: 23.8;placenta: 93.2","lung: 9.2","Cell line enriched",6,"U-2197: 19.1"
"WNT3A",153,"H2","IOH63385",1158,"0",NA,"wingless-type MMTV integration site family, member 3A, mRNA (cDNA clone MGC:119418 IMAGE:40007188), complete cds","BC103921.1","AAI03922.1",89780,"Hs.336930",NA,"ENSG00000154342","Wnt family member 3A","1","228007051-228061260","Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Cervical cancer:6.11e-5 (favourable)","Mixed","Tissue enriched",6,"placenta: 23.2","lung: 3.8","Group enriched",9,"HEK 293: 1.1;U-2 OS: 3.9"
"WNT5A",97,"A2","IOH39817",1143,"0",NA,"wingless-type MMTV integration site family, member 5A (WNT5A), mRNA.","NM_003392.3","NP_003383.2",7474,"Hs.696364","hWNT5A","ENSG00000114251","Wnt family member 5A","3","55465715-55490539","Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Colorectal cancer:2.94e-5 (favourable)","Expressed in all","Tissue enhanced",NA,"endometrium: 45.3","urinary bladder: 35.4","Cell line enhanced",NA,"BJ: 189.9;BJ hTERT+: 249.3;SiHa: 371.6;U-87 MG: 239.2"
"WNT5B",85,"F9","IOH4794",1080,"0",NA,"wingless-type MMTV integration site family, member 5B (WNT5B), transcript variant 2, mRNA.","NM_030775.2","NP_110402.2",81029,"Hs.306051",NA,"ENSG00000111186","Wnt family member 5B","12","1529891-1647243","Predicted secreted proteins","Evidence at protein level","HPA061991",NA,NA,"Approved","Vesicles",NA,"Expressed in all","Tissue enhanced",NA,"prostate: 34.7","seminal vesicle: 27.9","Cell line enhanced",NA,"BJ: 195.3;BJ hTERT+ SV40 Large T+: 154.0;BJ hTERT+ SV40 Large T+ RasG12V: 132.9;HBF TERT88: 139.5;hTEC/SVTERT24-B: 144.8;U-138 MG: 140.4"
"WNT6",123,"G3","IOH5553",1098,"0",NA,"wingless-type MMTV integration site family, member 6 (WNT6), mRNA.","NM_006522.3","NP_006513.1",7475,"Hs.29764",NA,"ENSG00000115596","Wnt family member 6","2","218859821-218874233","Predicted secreted proteins","Evidence at protein level","HPA070759","Approved",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"placenta: 2.9","spleen: 1.5","Cell line enriched",6,"BEWO: 33.5"
"WNT8A",99,"A12","IOH35591",1056,"0",NA,"wingless-type MMTV integration site family, member 8A (WNT8A), mRNA.","NM_058244.2","NP_490645.1",7478,"Hs.591274","WNT8D","ENSG00000061492","Wnt family member 8A","5","138083892-138092365","Predicted secreted proteins","Evidence at transcript level","HPA038539","Uncertain",NA,"Uncertain","Plasma membrane<br>Cytosol",NA,"Tissue enriched","Not detected",NA,NA,"testis: 0.7","Not detected",NA,NA
"WNT9B",95,"F10","IOH39910",990,"0",NA,"wingless-type MMTV integration site family, member 9B, mRNA (cDNA clone MGC:70631 IMAGE:5588904), complete cds","BC064534.1","AAH64534.1",7484,"Hs.326420","WNT14B, WNT15","ENSG00000158955","Wnt family member 9B","17","46833201-46886730","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA058361, HPA059572","Approved",NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"parathyroid gland: 3.1;seminal vesicle: 9.4","skin: 1.4","Not detected",NA,NA
"WSB1",5,"C12","IOH12660",1266,"0",NA,"WD repeat and SOCS box-containing 1 (WSB1), transcript variant 1, mRNA.","NM_015626.8","NP_056441.6",26118,"Hs.446017","DKFZp564A122, DKFZp564B0482, SWIP1","ENSG00000109046","WD repeat and SOCS box containing 1","17","27294076-27315926","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA003293","Approved",NA,"Approved","Mitochondria","Renal cancer:1.02e-7 (unfavourable), Liver cancer:4.07e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 107.4","Expressed in all",NA,NA
"XCL1",82,"H12","IOH34717",345,"0",NA,"chemokine (C motif) ligand 1 (XCL1), mRNA.","NM_002995.1","NP_002986.1",6375,"Hs.546295","ATAC, LPTN, LTN, SCM-1, SCM-1a, SCYC1","ENSG00000143184","X-C motif chemokine ligand 1","1","168576473-168582077","Predicted secreted proteins","Evidence at protein level","HPA057725","Approved",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"spleen: 5.7","endometrium: 3.3","Cell line enhanced",NA,"CACO-2: 2.4;Hep G2: 2.5;SCLC-21H: 4.0;U-266/70: 3.7"
"ZG16",38,"H8","IOH22692",504,"0",NA,"zymogen granule protein 16 homolog (rat) (ZG16), mRNA.","NM_152338.2","NP_689551.1",653808,"Hs.632195","hZG16, JCLN, JCLN1, ZG16A","ENSG00000174992","Zymogen granule protein 16","16","29778240-29782973","Predicted secreted proteins","Evidence at protein level","HPA052066, HPA052512","Enhanced",NA,NA,NA,NA,"Tissue enriched","Group enriched",6,"colon: 363.4;rectum: 502.4;small intestine: 121.4","duodenum: 57.7","Cell line enhanced",NA,"SK-BR-3: 1.7"
"ZIC4",107,"C4","IOH42240",1005,"0",NA,"Zic family member 4 (ZIC4), mRNA.","NM_032153.3","NP_115529.2",84107,"Hs.415766",NA,"ENSG00000174963","Zic family member 4","3","147386046-147406860","Predicted intracellular proteins, Predicted secreted proteins, Transcription factors","Evidence at transcript level","HPA030194","Uncertain",NA,"Approved","Nucleus<br>Cytosol",NA,"Mixed","Group enriched",6,"cerebral cortex: 4.3;skin: 1.4","skeletal muscle: 0.5","Cell line enhanced",NA,"AF22: 17.0;SH-SY5Y: 5.5"
"ZNF207",123,"B5","IOH3584",1392,"0",NA,"zinc finger protein 207 (ZNF207), transcript variant 2, mRNA.","NM_001032293.2","NP_001027464.1",7756,"Hs.500775",NA,"ENSG00000010244","Zinc finger protein 207","17","32350117-32381886","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA017013, HPA063908","Enhanced",NA,"Enhanced","Nucleus","Renal cancer:4.17e-8 (unfavourable), Liver cancer:7.30e-8 (unfavourable), Colorectal cancer:2.81e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"bone marrow: 151.3","Expressed in all",NA,NA
"ZNF207",22,"F3","IOH6997",1188,"0",NA,"zinc finger protein 207, mRNA (cDNA clone MGC:15953 IMAGE:3538197), complete cds","BC008023.1","AAH08023.1",7756,"Hs.500775",NA,"ENSG00000010244","Zinc finger protein 207","17","32350117-32381886","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA017013, HPA063908","Enhanced",NA,"Enhanced","Nucleus","Renal cancer:4.17e-8 (unfavourable), Liver cancer:7.30e-8 (unfavourable), Colorectal cancer:2.81e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"bone marrow: 151.3","Expressed in all",NA,NA
"ZNF26",57,"A7","IOH26974",1602,"0",NA,"zinc finger protein 26 (ZNF26), mRNA.","NM_019591.2","NP_062537.2",7574,"Hs.489608","FLJ20755, KOX20","ENSG00000198393","Zinc finger protein 26","12","132986365-133032952","Predicted intracellular proteins, Predicted secreted proteins, Transcription factors","Evidence at protein level","HPA018329, HPA042406","Uncertain",NA,"Approved","Nuclear bodies<br>Mitochondria",NA,"Mixed","Mixed",NA,NA,"epididymis: 6.9","Mixed",NA,NA
"ZNF433",66,"H8","IOH28825",1917,"0",NA,"zinc finger protein 433, mRNA (cDNA clone MGC:48500 IMAGE:5295132), complete cds","BC047412.1","AAH47412.1",163059,"Hs.667776","FLJ40981","ENSG00000197647","Zinc finger protein 433","19","12014732-12035741","Predicted intracellular proteins, Predicted secreted proteins, Transcription factors","Evidence at protein level","HPA073724","Uncertain",NA,"Approved","Nuclear bodies","Renal cancer:8.33e-15 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 51.5","Mixed",NA,NA
"ZNF691",62,"B4","IOH2943",855,"0",NA,"zinc finger protein 691 (ZNF691), mRNA.","NM_015911.2","NP_056995.1",51058,"Hs.20879","Zfp691","ENSG00000164011","Zinc finger protein 691","1","42846573-42852477","Predicted intracellular proteins, Predicted secreted proteins, Transcription factors","Evidence at protein level","HPA062527","Approved",NA,"Approved","Nucleus<br>Nucleoli<br>Vesicles","Liver cancer:7.33e-6 (unfavourable), Pancreatic cancer:6.25e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 21.5","Expressed in all",NA,NA
"ZNF85",127,"F5","IOH3392",168,"0",NA,"zinc finger protein 85, mRNA (cDNA clone IMAGE:3873712), complete cds.","BC008688.1","AAH08688.1",7639,"Hs.37138","HPF4, HTF1","ENSG00000105750","Zinc finger protein 85","19","20923222-20950697","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA044760","Uncertain",NA,"Supported","Nucleus","Ovarian cancer:6.45e-6 (favourable), Endometrial cancer:5.20e-5 (unfavourable)","Mixed","Tissue enhanced",NA,"testis: 28.0","thyroid gland: 12.0","Mixed",NA,NA
"ZNF85",156,"B2","IOH62364",1611,"0",NA,"zinc finger protein 85, mRNA (cDNA clone MGC:51131 IMAGE:4828290), complete cds","BC047646.1","AAH47646.1",7639,"Hs.37138","HPF4, HTF1","ENSG00000105750","Zinc finger protein 85","19","20923222-20950697","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA044760","Uncertain",NA,"Supported","Nucleus","Ovarian cancer:6.45e-6 (favourable), Endometrial cancer:5.20e-5 (unfavourable)","Mixed","Tissue enhanced",NA,"testis: 28.0","thyroid gland: 12.0","Mixed",NA,NA
